U.S. patent application number 17/173613 was filed with the patent office on 2021-06-17 for primary carboxamides as btk inhibitors.
The applicant listed for this patent is AbbVie Inc.. Invention is credited to Dominique Bonafoux, Heather Michele Davis, Kristine E. Frank, Michael M. Friedman, J. Martin Herold, Michael Z. Hoemann, Raymond Huntley, Augustine Osuma, George Sheppard, Gagandeep Kaur Somal, Jennifer Van Camp, Stacy Anne Van Epps, Anil Vasudevan, Grier Allan Wallace, Lu Wang, Lu Wang, Zhi Wang, Noel S. Wilson, Xiangdong Xu.
Application Number | 20210179556 17/173613 |
Document ID | / |
Family ID | 1000005417469 |
Filed Date | 2021-06-17 |
United States Patent
Application |
20210179556 |
Kind Code |
A1 |
Bonafoux; Dominique ; et
al. |
June 17, 2021 |
PRIMARY CARBOXAMIDES AS BTK INHIBITORS
Abstract
The invention provides compounds of Formula (I) ##STR00001##
pharmaceutically acceptable salts, pro-drugs, biologically active
metabolites, stereoisomers and isomers thereof wherein the variable
are defined herein. The compounds of the invention are useful for
treating immunological and oncological conditions.
Inventors: |
Bonafoux; Dominique;
(Winthrop, MA) ; Davis; Heather Michele; (Oxford,
MA) ; Frank; Kristine E.; (Grayslake, IL) ;
Friedman; Michael M.; (Brookline, MA) ; Herold; J.
Martin; (Cambridge, MA) ; Hoemann; Michael Z.;
(Shrewsbury, MA) ; Huntley; Raymond; (Millbury,
MA) ; Osuma; Augustine; (Lindenhurst, IL) ;
Sheppard; George; (Wilmette, IL) ; Somal; Gagandeep
Kaur; (Ashland, MA) ; Van Camp; Jennifer;
(Lake Forest, IL) ; Van Epps; Stacy Anne;
(Ashland, MA) ; Vasudevan; Anil; (Union Grove,
WI) ; Wallace; Grier Allan; (Sterling, MA) ;
Wang; Lu; (Westborough, MA) ; Wang; Lu;
(Northborough, MA) ; Wang; Zhi; (Libertyville,
IL) ; Wilson; Noel S.; (Kenosha, WI) ; Xu;
Xiangdong; (Buffalo Grove, IL) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
AbbVie Inc. |
North Chicago |
IL |
US |
|
|
Family ID: |
1000005417469 |
Appl. No.: |
17/173613 |
Filed: |
February 11, 2021 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
16421006 |
May 23, 2019 |
|
|
|
17173613 |
|
|
|
|
15398978 |
Jan 5, 2017 |
|
|
|
16421006 |
|
|
|
|
14315504 |
Jun 26, 2014 |
9567339 |
|
|
15398978 |
|
|
|
|
61897577 |
Oct 30, 2013 |
|
|
|
61839729 |
Jun 26, 2013 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07D 417/14 20130101;
C07D 401/12 20130101; C07D 417/12 20130101; C07D 487/04 20130101;
C07D 413/04 20130101; C07D 403/10 20130101; A61P 35/00 20180101;
C07D 405/14 20130101; C07D 409/04 20130101; C07D 401/14 20130101;
C07D 403/04 20130101; C07D 513/04 20130101; C07D 231/56 20130101;
C07D 209/12 20130101; C07D 409/12 20130101; C07D 409/14 20130101;
C07D 209/08 20130101; C07D 405/04 20130101; C07D 403/14 20130101;
C07D 209/14 20130101; C07D 401/04 20130101; C07D 209/10 20130101;
C07D 471/04 20130101; C07D 209/18 20130101 |
International
Class: |
C07D 209/08 20060101
C07D209/08; C07D 487/04 20060101 C07D487/04; C07D 417/12 20060101
C07D417/12; C07D 471/04 20060101 C07D471/04; C07D 417/14 20060101
C07D417/14; C07D 401/14 20060101 C07D401/14; C07D 403/14 20060101
C07D403/14; C07D 231/56 20060101 C07D231/56; C07D 401/12 20060101
C07D401/12; A61P 35/00 20060101 A61P035/00; C07D 513/04 20060101
C07D513/04; C07D 209/10 20060101 C07D209/10; C07D 209/12 20060101
C07D209/12; C07D 209/14 20060101 C07D209/14; C07D 209/18 20060101
C07D209/18; C07D 401/04 20060101 C07D401/04; C07D 403/04 20060101
C07D403/04; C07D 403/10 20060101 C07D403/10; C07D 405/04 20060101
C07D405/04; C07D 405/14 20060101 C07D405/14; C07D 409/04 20060101
C07D409/04; C07D 409/12 20060101 C07D409/12; C07D 409/14 20060101
C07D409/14; C07D 413/04 20060101 C07D413/04 |
Claims
1. A compound of Formula (I): ##STR00744## or a pharmaceutically
acceptable salt, pro-drug, biologically active metabolite, isomer,
or stereoisomer thereof, wherein: X is NR.sup.2 or S; Y is N or
CR.sup.1, and Z is N or CR.sup.1; or, Y is CR.sup.1R.sup.2 and Z is
CR.sup.1R.sup.2; A is N or CR.sup.4; E is N or CR.sup.5; R' is
independently H, deuterium, CN, halogen, CF.sub.3,
--NR.sup.cR.sup.c, --N(R.sup.a)C(O)R.sup.b, optionally substituted
(C.sub.1-C.sub.6)alkyl, optionally substituted
(C.sub.2-C.sub.6)alkenyl, optionally substituted aryl, optionally
substituted (C.sub.3-C.sub.6)cycloalkyl, optionally substituted
(C.sub.3-C.sub.6)cycloalkenyl, optionally substituted heteroaryl,
or optionally substituted saturated or partially saturated
heterocyclyl; R.sup.2 is independently H, deuterium, or optionally
substituted (C.sub.1-C.sub.3)alkyl; R.sup.3 is halogen,
--N(R.sup.a).sub.2, optionally substituted aryl, optionally
substituted (C.sub.3-C.sub.7)cycloalkyl, optionally substituted
saturated or partially saturated heterocyclyl, or optionally
substituted heteroaryl; or R.sup.3 is --R.sup.301-L-R.sup.302
wherein R.sup.301 is a bond, --O--, --OCH.sub.2--, --NR.sup.d--, or
optionally substituted (C.sub.1-C.sub.3)alkylene, and L is
optionally substituted phenyl, optionally substituted
(C.sub.3-C.sub.6)cycloalkyl, optionally substituted heteroaryl or a
saturated or partially saturated heterocyclyl containing one or
more heteroatoms, at least one of which is nitrogen; or L is
-L.sup.1-L.sup.2 wherein L.sup.1 is attached to R.sup.301 and
L.sup.1 is optionally substituted phenyl, optionally substituted
heteroaryl or optionally substituted saturated or partially
saturated carbocycle or a saturated or partially saturated
heterocyclyl; and L.sup.2 is a bond, CH.sub.2, NR.sup.d,
CH.sub.2N(H), S(O).sub.2N(H), or --O--; R.sup.302 is CN,
--CH.sub.2CN, optionally substituted --C(.dbd.O)R.sup.302a,
(CH.sub.2).sub.n-optionally substituted saturated or partly
saturated heterocyclyl or optionally substituted
--S(O).sub.2(C.sub.2)alkenyl; wherein R.sup.302a is optionally
substituted (C.sub.1-C.sub.4)alkyl, optionally substituted
(C.sub.2-C.sub.4)alkenyl, (C.sub.2-C.sub.4)alkynyl,
--C(O)--(C.sub.1-C.sub.4)alkyl, optionally substituted saturated or
partially unsaturated (C.sub.3-C.sub.6)cycloalkyl, optionally
substituted aryl, optionally substituted heteroaryl, --N(H)--
optionally substituted heteroaryl or --(CH.sub.2).sub.n optionally
substituted unsaturated or partly saturated heterocyclyl; R.sup.4
is H, deuterium, CN, optionally substituted (C.sub.1-C.sub.3)alkyl,
optionally substituted (C.sub.3-C.sub.6) cycloalkyl or optionally
substituted saturated or partially saturated heterocyclyl, or
optionally substituted heteroaryl; wherein the optionally
substituted saturated or partially saturated heterocyclyl; and
optionally substituted heteroaryl contain at least one nitrogen
atom; or R.sup.3 and R.sup.4, together with the carbon atoms to
which they are attached, form an optionally substituted, saturated,
unsaturated or partially unsaturated 5 or 6 membered carbocyclic
ring or an optionally substituted, saturated, or partially
unsaturated 5 or 6 membered heterocyclic ring containing one or
more heteroatoms selected from N, S and O; R.sup.5 is H, deuterium,
halogen, or optionally substituted (C.sub.1-C.sub.3)alkyl; R.sup.a
is independently selected from H, --C(O)-optionally substituted
(C.sub.2-C.sub.6)alkenyl, optionally substituted
(C.sub.1-C.sub.6)alkyl, --(CH.sub.2).sub.n-optionally substituted
(C.sub.3-C.sub.6)cycloalkyl, --(CH.sub.2).sub.n-optionally
substituted heterocyclyl, or --(CH.sub.2).sub.n-optionally
substituted heteroaryl; R.sup.b is H, optionally substituted
(C.sub.1-C.sub.6)alkyl, optionally substituted
(C.sub.2-C.sub.6)alkenyl, optionally substituted
(C.sub.2-C.sub.6)alkynyl, --CH.sub.2--O-optionally substituted
aryl, or --CH.sub.2--O-optionally substituted heteroaryl; R.sup.c
is independently H, optionally substituted (C.sub.1-C.sub.6)alkyl,
optionally substituted (C.sub.3-C.sub.6)cycloalkyl, optionally
substituted saturated or partially saturated heterocyclyl,
optionally substituted aryl or optionally substituted heteroaryl;
R.sup.d is H, optionally substituted heterocyclyl,
--(CH.sub.2)-optionally substituted (C.sub.3-C.sub.6)cycloalkyl,
--(CH.sub.2)-optionally substituted heteroaryl or optionally
substituted (C.sub.1-C.sub.3)alkyl; R.sup.f is optionally
substituted (C.sub.1-C.sub.3)alkyl, optionally substituted
(C.sub.2-C.sub.4)alkenyl or optionally substituted
(C.sub.2-C.sub.4)alkynyl; and n is independently 0 or 1.
2. The compound according to claim 1, wherein Y is CR' and R' of Y
is H, optionally substituted ethenyl, optionally substituted ethyl,
optionally substituted methyl, optionally substituted
2,3-dihydrobenzofuranyl, optionally substituted 1,4-dioxanyl,
optionally substituted 3,4-dihydro-2H-benzo[b][1,4]oxazinyl,
optionally substituted 6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazinyl,
optionally substituted chromanyl, optionally substituted
cyclohexenyl, optionally substituted cyclopropyl, optionally
substituted tetrahydrofuranyl, optionally substituted isochromanyl,
optionally substituted 1,2,3,4-tetrahydro-isoquinolinyl, optionally
substituted isoxazolyl, optionally substituted morpholinyl,
optionally substituted oxetanyl, optionally substituted phenyl,
optionally substituted piperidinyl, optionally substituted
piperazinyl, optionally substituted 3,6-dihydro-2H-pyranyl,
optionally substituted pyrano[4,3-b]pyridinyl, optionally
substituted pyrazolyl, optionally substituted pyridinyl, optionally
substituted 3H-pyridin-1-one, optionally substituted
1,2,3,6-tetrahydropyridinyl, optionally substituted pyrimidinyl,
optionally substituted pyrrolidinyl, optionally substituted
2,5-dihydropyrrolyl, optionally substituted tetrahydropyranyl or
optionally substituted tetrahydro-2H-thiopyranyl.
3. The compound according to claim 2 wherein R' is H or R' is
optionally substituted by one or more substituents independently
selected from the group consisting of CN, OH, .dbd.O, halogen,
(C.sub.1-C.sub.4)alkyl, (C.sub.1-C.sub.4)alkoxy,
--CH.sub.2CH.sub.2OH,
--CH.sub.2C(CH.sub.3).sub.20H,--CH.sub.2CH(OH)CH.sub.2OH,
--CH.dbd.CH.sub.2, --CH.sub.2NH.sub.2, --CH.sub.2N(H)C(O)R.sup.e,
--C(O)(C.sub.1-C.sub.4)alkyl, --C(O)(C.sub.1-C.sub.4)alkoxy,
--C(O)NH.sub.2, --C(O)N(CH.sub.3).sub.2,--C(O)-optionally
substituted heterocyclyl, --N(H)C(O)CH.sub.3, N(CH.sub.3).sub.2,
--S(O).sub.2(C.sub.1-C.sub.4)alkyl, --S(O).sub.2-pyrrolidinyl,
(C.sub.1-C.sub.4)alkoxy, --CH.sub.2-morpholinyl,
--CH.sub.2CH.sub.2-morpholinyl, morpholinyl, tetrahydropyranyl;
wherein R.sup.e is (C.sub.1-C.sub.3)alkyl, --CH.sub.2Cl,
--C.ident.CH, --C.ident.CCH.sub.3, --CH.dbd.CH.sub.2,
--CH.dbd.CHCH.sub.3, --C(.dbd.CH.sub.2)CH.sub.3, --CH.sub.2CN,
--CH.sub.2CH.sub.2N(CH.sub.3).sub.2,
--CH.sub.2CH.sub.2-piperidinyl, --CH.sub.2O-optionally substituted
phenyl.
4. The compound according to claim 3, wherein R.sup.3 is
--N(H)C(O)CH.dbd.CH.sub.2, optionally substituted isoxazolyl,
optionally substituted phenyl, optionally substituted pyrazolyl,
optionally substituted pyridinyl, optionally substituted
pyrimidinyl, optionally substituted thiazolyl, or optionally
substituted thienyl.
5. The compound according to claim 4, wherein R.sup.3 is optionally
substituted by one or more substituents independently selected from
--NH.sub.2, --NHCH.sub.3, (C.sub.1-C.sub.4)alkyl and
--C(O)(C.sub.2-C.sub.4)alkenyl.
6. The compound according to claim 5, wherein X is NR.sup.2 and
R.sup.2 is H.
7. The compound according to claim 6, wherein Y is CR' and R' of Y
is H, optionally substituted phenyl, optionally substituted
piperazinyl, optionally substituted pyrazolyl, or optionally
substituted 1,2,3,6-tetrahydropyridinyl.
8. The compound according to claim 7, wherein Y is CR' and R' of Y
is optionally substituted by one or more substituents independently
selected from halogen, (C.sub.1-C.sub.4)alkyl,
--C(O)(C.sub.1-C.sub.4)alkyl, and
--S(O).sub.2(C.sub.1-C.sub.4)alkyl.
9. The compound according to claim 8, wherein Z is N or Z is CR'
and R' of Z is H; and A is CR.sup.4 and R.sup.4 is H or azetidinyl
substituted with --C(O)CH.dbd.CH.sub.2.
10. The compound according to claim 9, wherein the compound is
4-(3-amino-2-methylphenyl)-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridi-
n-4-yl)-1H-indole-7-carboxamide;
2-(4-fluorophenyl)-4-(pyridin-3-yl)-1H-indole-7-carboxamide;
4-(pyridin-3-yl)-2-p-tolyl-1H-indole-7-carboxamide;
2-(4-fluorophenyl)-4-(pyridin-4-yl)-1H-indole-7-carboxamide;
2-(4-fluorophenyl)-4-(1H-pyrazol-5-yl)-1H-indole-7-carboxamide;
4-(3,5-dimethylisoxazol-4-yl)-2-p-tolyl-1H-indole-7-carboxamide;
2-(1-acetylpiperidin-4-yl)-4-(3-amino-2-methylphenyl)-1H-indole-7-carboxa-
mide; 4-(pyridin-4-yl)-2-p-tolyl-1H-indole-7-carboxamide;
4-(thiophen-2-yl)-2-p-tolyl-1H-indole-7-carboxamide;
4-(2-aminophenyl)-1H-indole-7-carboxamide;
4-(3-amino-2-methylphenyl)-1H-indole-7-carboxamide;
4-(5-aminopyridin-3-yl)-1H-indole-7-carboxamide;
4-(2-aminopyridin-4-yl)-1H-indole-7-carboxamide;
4-(2-aminoethylamino)-2-(4-fluorophenyl)-1H-indole-7-carboxamide;
4-(2-aminoethylamino)-2-p-tolyl-1H-indole-7-carboxamide;
4-(pyrimidin-5-yl)-2-p-tolyl-1H-indole-7-carboxamide;
4-(1H-pyrazol-4-yl)-2-p-tolyl-1H-indole-7-carboxamide;
4-(1H-pyrazol-5-yl)-2-p-tolyl-1H-indole-7-carboxamide;
2-(4-fluorophenyl)-4-(pyrimidin-5-yl)-1H-indole-7-carboxamide;
4-(thiazol-2-yl)-2-p-tolyl-1H-indole-7-carboxamide;
4-(pyridin-2-yl)-2-p-tolyl-1H-indole-7-carboxamid;
4-(thiophen-3-yl)-2-p-tolyl-1H-indole-7-carboxamide;
4-(1-methyl-1H-pyrazol-4-yl)-2-p-tolyl-1H-indole-7-carboxamide;
4-(1H-pyrazol-3-yl)-2-p-tolyl-1H-indole-7-carboxamide;
4-(2-aminophenyl)-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-1-
H-indole-7-carboxamide;
2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-4-phenyl-1H-indole--
7-carboxamide;
4-(3-amino-2-methylphenyl)-2-(4,4-difluorocyclohex-1-enyl)1H-indole-7-car-
boxamide;
4-(3-amino-2-methylphenyl)-1H-pyrrolo[2,3-c]pyridine-7-carboxami-
de; 4-(1-acryloylpiperidin-3-yl)-1H-indole-7-carboxamide;
4-(1-acryloylpiperidin
3-yl)-2-(1-methyl-1H-pyrazol-4-yl)-1H-indole-7-carboxamide;
4-(2-aminoethylamino)-2-p-tolyl-1H-indole-7-carboxamide;
4-((1R,2R)-2-aminocyclohexylamino)-2-(4-fluorophenyl)-1H-indole-7-carboxa-
mide*;
4-(1-methyl-1H-pyrazol-5-ylamino)-2-p-tolyl-1H-indole-7-carboxamide-
; 4-iodo-2-(pyridin-3-yl)-1H-indole-7-carboxamide;
4-(3-amino-2-methylphenyl)-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridi-
n-4-yl)-1H-indole-7-carboxamide;
4-(3,5-dimethylisoxazol-4-yl)-2-(4-fluorophenyl)-1H-indole-7-carboxamide;
4-(2-aminophenyl)-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-1-
H-indole-7-carboxamide; or
2-(1-Acetylpiperidin-4-yl)-4-(3-amino-2-methylphenyl)-1H-indole-7-carboxa-
mide.
11. The compound according to claim 3, wherein R is
--R.sup.301-L-R.sup.302, and R.sup.301 is a bond, N(H),
N(CH.sub.3), CH.sub.2, C(H)(optionally substituted
(C.sub.1-C.sub.3)alkyl), O, or OCH.sub.2.
12. The compound according to claim 11 wherein L is optionally
substituted azetidinyl, optionally substituted cyclopentyl,
optionally substituted 3,6-diazabicyclo[3.2.0]heptanyl, optionally
substituted 1,4-dioxanyl, optionally substituted morpholinyl,
optionally substituted [1,4]oxepanyl, optionally substituted
phenyl, optionally substituted piperidinyl, or optionally
substituted pyrrolidinyl; or L is L.sup.1-L.sup.2 wherein L.sup.1
is optionally substituted cyclohexyl, optionally substituted
cyclopentyl optionally substituted phenyl, optionally substituted
piperidinyl, optionally substituted pyridinyl; L.sup.2 is N(H),
N(CH.sub.3), N(CH.sub.2CH.sub.2OH), N(CH.sub.2CH(CH.sub.3).sub.2),
N(oxetanyl), N(CH.sub.2-cyclopentyl), N(CH.sub.2-thiazolyl), O,
S(O).sub.2N(H), or CH.sub.2N(H).
13. The compound according to claim 12, wherein L or L.sup.1 is
optionally substituted with one or more substituents independently
selected from halogen, CN, OH, (C.sub.1-C.sub.4)alkoxy,
(C.sub.1-C.sub.4)alkyl, --CH.sub.2OH, --N(H)CH.sub.2-heteroaryl,
benzyloxy, and --OCH.sub.2-heteroaryl.
14. The compound according to claim 13, wherein R.sup.302 is
--C(O)CH.sub.3, --C(O)C(O)CH.sub.3, --C(O)CF.sub.2(Cl),
--CH(CH.sub.3).sub.2, --CH.sub.2Cl, --CH.sub.2CN, --C(O)CH.sub.2CN,
--C(O)CH.sub.2CH.sub.3, --C(O)CH.sub.2F, --C(O)CH(CH.sub.3).sub.2,
--C(O)--CH.sub.2CH(CH.sub.3).sub.2, --C(O)CH(CH.sub.3)(Cl),
--C(O)CH.sub.2CH(CH.sub.3)CH.sub.3, --C(O)CH(Cl)CH.sub.2CH.sub.3,
--CH.sub.2CH.sub.2OH, --C(O)CH.sub.2CH.sub.2N(CH.sub.3).sub.2,
--C(O)CH.dbd.CH.sub.2, --C(O)C.ident.CH, --C(O)CH.dbd.CHCl,
--C(O)CH.dbd.CHCH.sub.3, --C(O)C(.dbd.CH.sub.2)CH.sub.3,
--C(O)C(CH.sub.2CH.sub.3).dbd.CH.sub.2,
--C(O)CH.dbd.CHCH(CH.sub.3).sub.2, --C(O)CH.dbd.CHC(O)OH,
--C(O)CH.dbd.CHC(O)N(H)CH.sub.2CH.sub.3,
--C(O)CH.dbd.CHCH.sub.2N(CH.sub.3).sub.2,
--C(O)CH.dbd.CHC(O)OCH.sub.3, --C(O)CH.dbd.CHC(O)OCH.sub.2CH.sub.3,
--C(O)CH.dbd.CHC(O)N(H)CH.sub.3,
--C(O)CH.dbd.CHC(O)CH.sub.2CH.sub.2OCH.sub.3,
--C(O)CH.dbd.CHC(O)N(CH.sub.3).sub.2,
--C(O)CH.dbd.CHC(O)N(H)CH.sub.2CH.sub.3,
--C(O)CH.dbd.CHC(O)N(H)CH.sub.2CH.sub.2OCH.sub.3,
--C(O)CH.dbd.CHCH.sub.2N(H)CH.sub.2CH.sub.2OCH.sub.3,
--C(O)C(CN).dbd.C(OH)(CH.sub.3), --C(O)CH.dbd.CH-optionally
substituted pyrazolyl-C(O)CH.dbd.CHCH.sub.2N(H)-optionally
substituted cyclopropyl,
--C(O)CH.dbd.CHCH.sub.2N(H)CH.sub.2-optionally substituted
tetrahydrofuranyl,
--C(O)CH.dbd.CHC(O)NH.sub.2,--C(O)CH.dbd.CHC(O)N(H)-- optionally
substituted cyclopropyl, --C(O)C(CH.sub.3).dbd.CHCH.sub.3,
--C(O)C(CH.sub.3).dbd.CHCH.sub.2CH.sub.3,
--C(O)C(.dbd.CH.sub.2)CH.sub.2N(CH.sub.3).sub.2,
--C(O)C(.dbd.CH.sub.2)CH.sub.2NH.sub.2,
--C(O)C(.dbd.CH.sub.2)CH.sub.2N(H)(CH.sub.3),
--C(O)C(.dbd.CH.sub.2)CH.sub.3, --C(O)C(.dbd.CH.sub.2)CH.sub.2--
optionally substituted morpholinyl,
--C(O)C(.dbd.CH.sub.2)-optionally substituted phenyl, --CH.sub.2--
optionally substituted benzo[d]isothiazolyl,
--C(O)--CH.sub.2--O-optionally substituted phenyl,
--CH.sub.2-optionally substituted thiazolyl,
--CH.sub.2CH.sub.2-optionally substituted morpholinyl,
--C(O)CH.sub.2O-optionally substituted phenyl,
--C(O)CH.sub.2CH.sub.2-optionally substituted piperazinyl,
--C(O)CH.sub.2CH.sub.2-- optionally substituted piperidinyl,
--C(O)CH.sub.2O-optionally substituted pyridinyl,
--C(O)CH.sub.2CH.sub.2 optionally substituted
pyrrolidinyl,--C(O)CH.dbd.CH optionally substituted
cyclopropyl,--C(O)CH.dbd.CHCH.sub.2-- optionally substituted
morpholinyl, --C(O)CH.dbd.CHCH.sub.2-- optionally substituted pi
peridinyl,--C(O)CH.dbd.CH-- optionally substituted
pyrazolyl,--C(O)CH.dbd.CH-optionally substituted pyridinyl,
--C(O)CH.dbd.CH-optionally substituted thiazolyl, --C(O)-optionally
substituted cyclohexenyl, --C(.dbd.O)-optionally substituted
cyclohexyl, --C(O)-optionally substituted cyclopentenyl,
--C(O)-cyclopentyl, optionally substituted imidazo[1,2-a]pyrazinyl,
optionally substituted tetrahydroimidazo[1,2-a]pyrazinyl,
optionally substituted dihydr-isoindolyl, optionally substituted
1,2,3,4-tetrahydro-isoquinolinyl, optionally substituted
isoquinolinyl, --C(O)-optionally substituted isoxazolyl,
--C(O)-optionally substituted oxazolyl, optionally substituted
oxetanyl,--C(.dbd.O)-optionally substituted phenyl, optionally
substituted piperidinyl, --C(O)-optionally substituted piperidinyl,
optionally substituted pyrazolyl, --C(O)CH.sub.2O-optionally
substituted pyridazinyl, --C(O)-optionally substituted pyridinyl,
optionally substituted pyrimidinyl, optionally substituted
quinazolinyl, optionally substituted dihydroquinolinyl, optionally
substituted --C(O)-tetrahydrobenzo[b]thiophenyl, --C(O)-optionally
substituted tetrahydropyranyl, --C(O)-optionally substituted
tetrahydropyridinyl, --C(O)-thiazolyl, --C(O)N(H)-thiazolyl,
--C(O)NHCH.sub.2CN, or --S(O).sub.2CH.dbd.CH.sub.2.
15. The compound according to claim 14, wherein X is NR.sup.2 and
R.sup.2 is H.
16. The compound according to claim 15, wherein Y is CR' and R' of
Y is optionally substituted with one or more substituents
independently selected from halogen, CN, .dbd.O,
(C.sub.1-C.sub.4)alkyl, (C.sub.2-C.sub.4)alkenyl,
--CH.sub.2NH.sub.2, --CH.sub.2CH.sub.2OH,
--CH.sub.2CH(OH)CH.sub.2CH.sub.3, --CH.sub.2CH(OH)CH.sub.2OH,
--CH.sub.2CH.sub.2OCH.sub.2CH.sub.3,
--CH.sub.2C(OH)(CH.sub.3).sub.2,
--CH.sub.2NHC(O)(C.sub.1-C.sub.4)alkyl, --CH.sub.2NHC(O)CH.sub.2Cl,
--CH.sub.2NHC(O)CH.sub.2CN,
--CH.sub.2NHC(O)CH.sub.2CH.sub.2N(CH.sub.3).sub.2,
--CH.sub.2NHC(O)C(.dbd.CH.sub.2)CH.sub.3,
--CH.sub.2NHC(O)(C.sub.2-C.sub.4)alkynyl,
--CH.sub.2NHC(O)CH.sub.2CH.sub.2-piperidinyl,
--(C.sub.1-C.sub.4)alkyl-morpholinyl,
--CH.sub.2NHC(O)CH.sub.2O-phenyl wherein the phenyl is optionally
substituted with halogen, (C.sub.1-C.sub.4)alkoxy,
--C(O)(C.sub.1-C.sub.4)alkyl, --C(O)(C.sub.1-C.sub.4)alkoxy,
--C(O)N(H).sub.2, --C(O)N(CH.sub.3).sub.2, --C(O)-- morpholinyl,
--C(O)-pyrrolidinyl, --N(CH.sub.3).sub.2,
--NHC(O)(C.sub.1-C.sub.4)alkyl, --NHC(O)(C.sub.2-C.sub.4)alkenyl,
--NHC(O)CH.sub.2CN, --S(O).sub.2(C.sub.1-C.sub.4)alkyl,
--S(O).sub.2-pyrrolidinyl, morpholinyl, tetrahydropyranyl, or
4-methylpiperazinecarbonyl.
17. The compound according to claim 16, wherein Z is CR' and R of Z
is H, (C.sub.1-C.sub.4)alkyl, --NHC(O)CH.sub.2Cl,
--NHC(O)CH.sub.2CN, --NHC(O)(C.sub.2-C.sub.4)alkenyl,
--NHC(O)(C.sub.2-C.sub.4)alkynyl, --NHC(O)C(.dbd.CH.sub.2)CH.sub.3,
--NHC(O)CH.sub.2-phenyl wherein the phenyl is optionally
substituted with halogen, or pyrazolyl substituted with
CH.sub.3.
18. The compound according to claim 17, wherein R.sup.302 is
optionally substituted with one or more substituents independently
selected from halogen, CF.sub.3, OCF.sub.3, .dbd.O, CHF.sub.2, CN,
C(O)OH, OH, (C.sub.1-C.sub.4)alkyl, (C.sub.1-C.sub.4)alkoxy,
(C.sub.3-C.sub.6)cycloalkyl, --(C.sub.1-C.sub.4)alkylCN,
--(C.sub.1-C.sub.4)alkyC(O)NH.sub.2, --C(O)NH.sub.2,
--C(O)N(H)(C.sub.1-C.sub.4)alkyl,
--C(O)N(C.sub.1-C.sub.4)alkyl).sub.2, --C(O)N(H)cyclopropyl,
--C(O)(C.sub.1-C.sub.4)alkoxy, NH.sub.2, N(H)CH.sub.3,
N(CH.sub.3).sub.2, or optionally substituted benzyl.
19. The compound according to claim 1, wherein X is NR.sup.2
wherein R.sup.2 is H; Y is CR wherein R' is H, CH.sub.3,
substituted pyrazolyl, 6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazinyl
or tetrahydrofuranyl; Z is CR' wherein R' is H; E is CR.sup.5
wherein R.sup.5 is H; R.sup.3 is --R.sup.301-L-R.sup.302 wherein
R.sup.301 is a bond, --O--, --N(H)--, --N(CH.sub.3)-- or
--C(H)(CH.sub.3)--; L is azetidinyl,
3,6-diazabicyclo[3.2.0]heptanyl, morpholinyl, [1,4]oxepanyl,
piperidinyl, or pyrrolidinyl; wherein the azetidinyl is optionally
substituted with CH.sub.3; and wherein the piperidinyl is
optionally substituted with --CH.sub.2OH; and R.sup.302 is
--C(O)CH.dbd.CH.sub.2 or --C(O)C.ident.CH.
20. The compound according to claim 1, wherein the compound is:
4-((1-acryloylazetidin-3-yl)(methyl)amino)-1H-indole-7-carboxamide;
4-(5-acetylthiophen-2-yl)-2-p-tolyl-1H-indole-7-carboxamide;
4-(1-(4-methoxybenzyl)-1H-pyrazol-5-ylamino)-2-p-tolyl-1H-indole-7-carbox-
amide;
4-(3-(6-fluoro-4-oxoquinazolin-3(4H)-yl)-2-methylphenyl)-2-(pyridin-
-3-yl)-1H-indole-7-carboxamide;
4-(3-(6-fluoro-4-oxoquinazolin-3(4H)-yl)-2-methylphenyl)-2-(pyridin-3-yl)-
-1H-indole-7-carboxamide;
4-(2-methyl-3-(4-oxoquinazolin-3(4H)-yl)phenyl)-2-(pyridin-3-yl)-1H-indol-
e-7-carboxamide;
4-(2-methyl-3-(4,5,6,7-tetrahydrobenzo[b]thiophene-2-carboxamido)phenyl)--
2-(pyridin-3-yl)-1H-indole-7-carboxamide;
4-(2-methyl-3-(1-oxoisoindolin-2-yl)phenyl)-2-(pyridin-3-yl)-1H-indole-7--
carboxamide;
4-(2-methyl-3-(6-methyl-1-oxoisoindolin-2-yl)phenyl)-2-(pyridin-3-yl)-1H--
indole-7-carboxamide;
4-(3-(6-fluoro-1-oxoisoindolin-2-yl)-2-methylphenyl)-2-(pyridin-3-yl)-1H--
indole-7-carboxamide;
4-(3-(6-fluoro-1-oxoisoindolin-2-yl)-2-methylphenyl)-2-(4-fluorophenyl)-1-
H-indole-7-carboxamide;
2-(4-fluorophenyl)-4-(2-methyl-3-(4,5,6,7-tetrahydrobenzo[b]thiophene-2-c-
arboxamido)phenyl)-1H-indole-7-carboxamide;
N-(3-(7-carbamoyl-2-(pyridin-3-yl)-1H-indol-4-yl)-4-methylphenyl)thiazole-
-2-carboxamide 2,2,2-trifluoroacetate;
N-(3-(7-carbamoyl-2-(pyridin-3-yl)-1H-indol-4-yl)-2-methylphenyl)thiazole-
-2-carboxamide;
(R)-4-(3-(4-oxoquinazolin-3(4H)-yl)piperidin-1-yl)-1H-indole-7-carboxamid-
e*;
(R)-2-(4-fluorophenyl)-4-(3-(4-oxoquinazolin-3(4H)-yl)piperidin-1-yl)--
1H-indole-7-carboxamide*;
(R)-4-(3-(4-oxoquinazolin-3(4H)-yl)piperidin-1-yl)-2-(pyridin-3-yl)-1H-in-
dole-7-carboxamide*;
(R)-2-(1-methyl-1H-pyrazol-4-yl)-4-(3-(4-oxoquinazolin-3(4H)-yl)piperidin-
-1-yl)-1H-indole-7-carboxamide*;
(R)-4-(3-(6-fluoro-4-oxoquinazolin-3(4H)-yl)piperidin-1-yl)-2-(4-fluoroph-
enyl)-1H-indole-7-carboxamide*;
2-(1-methyl-1H-pyrazol-4-yl)-4-(2-methyl-3-(4-oxoquinazolin-3(4H)-yl)phen-
yl)-1H-indole-7-carboxamide;
4-(2-methyl-3-(4-oxoquinazolin-3(4H)-yl)phenyl)-1H-indole-7-carboxamide;
2-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)-4-(2-methyl-3-(4-oxoquinazoli-
n-3(4H)-yl)phenyl)-1H-indole-7-carboxamide;
(R)-4-(3-(4-tert-butylbenzamido)piperidin-1-yl)-2-(pyridin-3-yl)-1H-indol-
e-7-carboxamide*;
(R)-4-(3-(4-tert-butylbenzamido)piperidin-1-yl)-1H-indole-7-carboxamide*;
(R)--N-(1-(7-carbamoyl-1H-indol-4-yl)piperidin-3-yl)-2-methyloxazole-4-ca-
rboxamide*;
(R)-4-(3-(3-thiazol-2-ylureido)piperidin-1-yl)-1H-indole-7-carboxamide*;
4-(3-(4-tert-butylbenzamido)-2-methylphenyl)-1H-indole-7-carboxamide;
4-(3-(7-cyclopropyl-5-fluoro-4-oxoquinazolin-3(4H)-yl)piperidin-1-yl)-1H--
indole-7-carboxamide;
(R)-4-(3-(4-tert-butylbenzamido)piperidin-1-yl)-2-(1-methyl-1H-pyrazol-4--
yl)-1H-indole-7-carboxamide*;
(R)-4-(3-(4-methoxybenzamido)piperidin-1-yl)-2-(1-methyl-1H-pyrazol-4-yl)-
-1H-indole-7-carboxamide*;
(R)-5-tert-butyl-N-(1-(7-carbamoyl-1H-indol-4-yl)piperidin-3-yl)isoxazole-
-3-carboxamide*;
(R)-2-(1-methyl-1H-pyrazol-4-yl)-4-(3-(4-(trifluoromethyl)benzamido)piper-
idin-1-yl)-1H-indole-7-carboxamide*;
(R)-4-(3-(4-methoxybenzamido)piperidin-1-yl)-1H-indole-7-carboxamide*;
(R)-4-(3-(4-(trifluoromethyl)benzamido)piperidin-1-yl)-1H-indole-7-carbox-
amide*;
(R)-4-(3-(4-(difluoromethyl)benzamido)piperidin-1-yl)-2-(1-methyl--
1H-pyrazol-4-yl)-1H-indole-7-carboxamide*;
4-(3-(6-fluoro-4-oxoquinazolin-3(4H)-yl)-2-methylphenyl)-2-(1-methyl-1H-p-
yrazol-4-yl)-1H-indole-7-carboxamide;
2-(3,6-dihydro-2H-pyran-4-yl)-4-(2-methyl-3-(4-oxoquinazolin-3(4H)-yl)phe-
nyl)-1H-indole-7-carboxamide;
2-(4-fluorophenyl)-4-(2-methyl-3-(4-oxoquinazolin-3(4H)-yl)phenyl)-1H-ind-
ole-7-carboxamide;
(R)-4-(3-(4-(1-amino-2-methyl-1-oxopropan-2-yl)benzamido)piperidin-1-yl)--
2-(1-methyl-1H-pyrazol-4-yl)-1H-indole-7-carboxamide*;
(R)-2-(1-methyl-1H-pyrazol-4-yl)-4-(3-(4-(trifluoromethoxy)benzamido)pipe-
ridin-1-yl)-1H-indole-7-carboxamide*;
2-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)-4-(2-methyl-3-(4-oxoquinazolin-3(4-
H)-yl)phenyl)-1H-indole-7-carboxamide;
(R)-4-(3-(6-fluoro-1-oxoisoindolin-2-yl)piperidin-1-yl)-2-(1-methyl-1H-py-
razol-4-yl)-1H-indole-7-carboxamide*;
2-(3,6-dihydro-2H-pyran-4-yl)-4-(3-(6-fluoro-4-oxoquinazolin-3(4H)-yl)-2--
methylphenyl)-1H-indole-7-carboxamide;
2-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)-4-(3-(6-fluoro-4-oxoquinazoli-
n-3(4H)-yl)-2-methylphenyl)-1H-indole-7-carboxamide;
N-(3-(7-carbamoyl-2-(1-methyl-1H-pyrazol-4-yl)-1H-indol-4-yl)-2-methylphe-
nyl)thiazole-2-carboxamide;
4-(3-(6-fluoro-4-oxoquinazolin-3(4H)-yl)-2-(hydroxymethyl)phenyl)-2-(1-me-
thyl-1H-pyrazol-4-yl)-1H-indole-7-carboxamide;
2-(1-methyl-1H-pyrazol-4-yl)-4-(2-methyl-3-(4,5,6,7-tetrahydrobenzo[b]thi-
ophene-2-carboxamido)phenyl)-1H-indole-7-carboxamide;
(R)-4-(3-(4-cyclopropylbenzamido)piperidin-1-yl)-2-(1-methyl-1H-pyrazol-4-
-yl)-1H-indole-7-carboxamide*;
2-(2,5-dihydro-1H-pyrrol-3-yl)-4-(2-methyl-3-(4-oxoquinazolin-3(4H)-yl)ph-
enyl)-1H-indole-7-carboxamide;
4-(2-methyl-3-(4-oxoquinazolin-3(4H)-yl)phenyl)-2-(1,2,3,6-tetrahydropyri-
din-4-yl)-1H-indole-7-carboxamide;
2-(1-((R)-2,3-dihydroxypropyl)-1H-pyrazol-4-yl)-4-(2-methyl-3-(4-oxoquina-
zolin-3(4H)-yl)phenyl)-1H-indole-7-carboxamide*;
N-(3-(7-carbamoyl-2-(1-methyl-1H-pyrazol-4-yl)-1H-indol-4-yl)-2-(hydroxym-
ethyl)phenyl)thiazole-2-carboxamide;
2-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)-4-(3-(4-tert-butylbenzamido)--
2-methylphenyl)-1H-indole-7-carboxamide;
N-(3-(2-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)-7-carbamoyl-1H-indol-4--
yl)-2-methylphenyl)thiazole-2-carboxamide;
2-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)-4-(2-methyl-3-(4,5,6,7-tetrah-
ydrobenzo[b]thiophene-2-carboxamido)phenyl)-1H-indole-7-carboxamide;
2-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)-4-(3-(4-cyclopropylbenzamido)-
-2-methylphenyl)-1H-indole-7-carboxamide;
4-(2-methyl-3-(1-oxo-3,4-dihydroisoquinolin-2(1H)-yl)phenyl)-2-(1-(methyl-
sulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide;
2-(1-methyl-2,5-dihydro-1H-pyrrol-3-yl)-4-(2-methyl-3-(4-oxoquinazolin-3(-
4H)-yl)phenyl)-1H-indole-7-carboxamide;
2-(1-acetyl-2,5-dihydro-1H-pyrrol-3-yl)-4-(2-methyl-3-(4-oxoquinazolin-3(-
4H)-yl)phenyl)-1H-indole-7-carboxamide; ethyl
3-(7-carbamoyl-4-(2-methyl-3-(4-oxoquinazolin-3(4H)-yl)phenyl)-1H-indol-2-
-yl)-2,5-dihydro-1H-pyrrole-1-carboxylate;
2-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-4-(2-methyl-3-(4-oxoquinazoli-
n-3(4H)-yl)phenyl)-1H-indole-7-carboxamide;
4-(2-methyl-3-(4-oxoquinazolin-3(4H)-yl)phenyl)-2-(1-(methylsulfonyl)-1,2-
,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide;
N-(3-(7-carbamoyl-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-1-
H-indol-4-yl)-2-methylphenyl)thiazole-2-carboxamide;
N-(3-(7-carbamoyl-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-1-
H-indol-4-yl)-2-methylphenyl)thiazole-2-carboxamide;
2-(1-((S)-2,3-dihydroxypropyl)-1H-pyrazol-4-yl)-4-(2-methyl-3-(4-oxoquina-
zolin-3(4H)-yl)phenyl)-1H-indole-7-carboxamide;
N-(3-(7-carbamoyl-2-(1-methyl-1H-pyrazol-4-yl)-1H-indol-4-yl)-2-methylphe-
nyl)-N-methylthiazole-2-carboxamide;
N-(3-(7-carbamoyl-2-(1-methyl-1H-pyrazol-4-yl)-1H-indol-4-yl)-2-methylphe-
nyl)-N-(oxetan-3-yl)thiazole-2-carboxamide;
2-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)-4-(3-(4-(2-cyanopropan-2-yl)b-
enzamido)-2-methylphenyl)-1H-indole-7-carboxamide;
4-(2-methyl-3-(4-oxoquinazolin-3(4H)-yl)phenyl)-2-(pyrimidin-5-yl)-1H-ind-
ole-7-carboxamide;
4-(3-(6-fluoro-4-oxoquinazolin-3(4H)-yl)-2-methylphenyl)-2-(pyrimidin-5-y-
l)-1H-indole-7-carboxamide;
4-(3-(4-(difluoromethyl)benzamido)-2-methylphenyl)-2-(pyrimidin-5-yl)-1H--
indole-7-carboxamide;
4-(3-(4-cyclopropylbenzamido)-2-methylphenyl)-2-(pyrimidin-5-yl)-1H-indol-
e-7-carboxamide;
4-(3-(6-fluoro-4-oxoquinazolin-3(4H)-yl)-2-methylphenyl)-2-(1-(2-hydroxy--
2-methylpropyl)-1H-pyrazol-4-yl)-1H-indole-7-carboxamide;
(R)-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-4-(3-(8-oxo-5,6-
-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)piperidin-1-yl)-1H-indole-7-carboxa-
mide*;
(R)-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-4-(3-(8-o-
xoimidazo[1,2-a]pyrazin-7(8H)-yl)piperidin-1-yl)-1H-indole-7-carboxamide*;
4-(2-methyl-3-(oxetan-3-ylamino)phenyl)-2-(1-(methylsulfonyl)-1,2,3,6-tet-
rahydropyridin-4-yl)-1H-indole-7-carboxamide;
4-(2-methyl-3-(1-oxo-3,4-dihydroisoquinolin-2(1H)-yl)phenyl)-2-(1-(methyl-
sulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide;
4-(3-(4-(difluoromethyl)benzamido)-2-methylphenyl)-2-(1-(methylsulfonyl)--
1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide;
4-(3-(4-hydroxy-4-(trifluoromethyl)cyclohexanecarboxamido)-2-methylphenyl-
)-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carbox-
amide;
(R)-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-4-(3-(1-o-
xo-3,4-dihydroisoquinolin-2(1H)-yl)piperidin-1-yl)-1H-indole-7-carboxamide-
*;
2-(1-acetylpiperidin-4-yl)-4-(3-(4-cyclopropylbenzamido)-2-methylphenyl-
)-1H-indole-7-carboxamide;
(R)--N-(1-(7-carbamoyl-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4--
yl)-1H-indol-4-yl)piperidin-3-yl)-2-methyloxazole-4-carboxamide*;
(R)-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-4-(2-oxo-1,3'-b-
ipiperidin-1'-yl)-1H-indole-7-carboxamide*;
2-(1-methyl-1H-pyrazol-4-yl)-4-(2-methyl-3-(4-oxoquinazolin-3(4H)-yl)phen-
yl)-1H-benzo[d]imidazole-7-carboxamide;
4-(3-(4-(difluoromethyl)-N-(oxetan-3-yl)benzamido)-2-methylphenyl)-2-(1-(-
methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide;
4-(2-methyl-3-(oxetan-3-ylamino)phenyl)-1H-indole-7-carboxamide;
4-(3-(4-(difluoromethyl)benzamido)-2-methylphenyl)-1H-indole-7-carboxamid-
e;
4-(3-(2-hydroxyethylamino)-2-methylphenyl)-2-(1-(methylsulfonyl)-1,2,3,-
6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide;
(R)--N-(1-(7-carbamoyl-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4--
yl)-1H-indol-4-yl)piperidin-3-yl)thiazole-2-carboxamide*;
4-(3-(cyclohexanecarboxamido)-2-methylphenyl)-2-(1-(methylsulfonyl)-1,2,3-
,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide;
4-(3-(4-(difluoromethyl)-N-(2-hydroxyethyl)benzamido)-2-methylphenyl)-2-(-
1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide-
;
N-(3-(7-carbamoyl-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)--
1H-indol-4-yl)-2-methylphenyl)isothiazole-4-carboxamide;
4-(2-methyl-3-(tetrahydro-2H-pyran-4-carboxamido)phenyl)-2-(1-(methylsulf-
onyl)-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide;
4-(2-methyl-3-(1-methylpiperidine-3-carboxamido)phenyl)-2-(1-(methylsulfo-
nyl)-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide;
4-(2-methyl-3-(1-methylpiperidine-4-carboxamido)phenyl)-2-(1-(methylsulfo-
nyl)-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide;
4-(3-(cyclopentanecarboxamido)-2-methylphenyl)-2-(1-(methylsulfonyl)-1,2,-
3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide;
N-(3-(7-carbamoyl-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-1-
H-indol-4-yl)-2-methylphenyl)-2-methylthiazole-4-carboxamide;
4-(3-(3-methoxycyclohexanecarboxamido)-2-methylphenyl)-2-(1-(methylsulfon-
yl)-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide;
4-(2-methyl-3-(3-methylbutanamido)phenyl)-2-(1-(methylsulfonyl)-1,2,3,6-t-
etrahydropyridin-4-yl)-1H-indole-7-carboxamide;
4-(3-isobutyramido-2-methylphenyl)-2-(1-(methylsulfonyl)-1,2,3,6-tetrahyd-
ropyridin-4-yl)-1H-indole-7-carboxamide;
4-(2-methyl-3-(nicotinamido)phenyl)-2-(1-(methylsulfonyl)-1,2,3,6-tetrahy-
dropyridin-4-yl)-1H-indole-7-carboxamide;
4-(3-acrylamido-2-methylphenyl)-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydrop-
yridin-4-yl)-1H-indole-7-carboxamide;
N-(3-(7-carbamoyl-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-1-
H-indol-4-yl)-2-methylphenyl)-5-methylthiazole-2-carboxamide;
N-(3-(7-carbamoyl-2-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-1H-indol-4-y-
l)-2-methylphenyl)thiazole-2-carboxamide;
N-((3R,4R)-1-(7-carbamoyl-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-
-4-yl)-1H-indol-4-yl)-4-hydroxypiperidin-3-yl)thiazole-2-carboxamide;
(R)-4-(3-acrylamidopiperidin-1-yl)-2-(1-(methylsulfonyl)-1,2,3,6-tetrahyd-
ropyridin-4-yl)-1H-indole-7-carboxamide*;
4-(2-methyl-3-(thiazol-2-ylmethylamino)phenyl)-2-(1-(methylsulfonyl)-1,2,-
3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide;
4-(2-methyl-3-(N-(thiazol-2-ylmethyl)acrylamido)phenyl)-2-(1-(methylsulfo-
nyl)-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide;
(Z)-4-(2-methyl-3-(2-methylbut-2-enamido)phenyl)-2-(1-(methylsulfonyl)-1,-
2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide;
(E)-4-(3-(4-(dimethylamino)but-2-enamido)-2-methylphenyl)-2-(1-(methylsul-
fonyl)-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide;
4-(2-methyl-3-(3-(piperidin-1-yl)propanamido)phenyl)-2-(1-(methylsulfonyl-
)-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide;
4-(3-(2-cyanoacetamido)-2-methylphenyl)-2-(1-(methylsulfonyl)-1,2,3,6-tet-
rahydropyridin-4-yl)-1H-indole-7-carboxamide;
4-(2-methyl-3-propionamidophenyl)-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydr-
opyridin-4-yl)-1H-indole-7-carboxamide;
4-(3-methacrylamido-2-methylphenyl)-2-(1-(methylsulfonyl)-1,2,3,6-tetrahy-
dropyridin-4-yl)-1H-indole-7-carboxamidel;
4-(3-(2-chloro-2,2-difluoroacetamido)-2-methylphenyl)-2-(1-(methylsulfony-
l)-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide;
4-(3-(2-chloropropanamido)-2-methylphenyl)-2-(1-(methylsulfonyl)-1,2,3,6--
tetrahydropyridin-4-yl)-1H-indole-7-carboxamide;
(E)-4-(3-but-2-enamido-2-methylphenyl)-2-(1-(methylsulfonyl)-1,2,3,6-tetr-
ahydropyridin-4-yl)-1H-indole-7-carboxamide;
N1-(3-(7-carbamoyl-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)--
1H-indol-4-yl)-2-methylphenyl);
4-(3-(2-(4-fluorophenoxy)acetamido)-2-methylphenyl)-2-(1-(methylsulfonyl)-
-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide;
4-(2-methyl-3-(3-(pyrrolidin-1-yl)propanamido)phenyl)-2-(1-(methylsulfony-
l)-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide;
4-(3-(2-(4-cyanophenoxy)acetamido)-2-methylphenyl)-2-(1-(methylsulfonyl)--
1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide;
4-(2-methyl-3-(2-(pyridin-3-yloxy)acetamido)phenyl)-2-(1-(methylsulfonyl)-
-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide;
4-(3-(cyclopent-1-enecarboxamido)-2-methylphenyl)-2-(1-(methylsulfonyl)-1-
,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide;
(E)-4-(2-methyl-3-(2-methylpent-2-enamido)phenyl)-2-(1-(methylsulfonyl)-1-
,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide;
(Z)-4-(3-(3-chloroacrylamido)-2-methylphenyl)-2-(1-(methylsulfonyl)-1,2,3-
,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide; (E)-methyl
4-(3-(7-carbamoyl-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-1-
H-indol-4-yl)-2-methylphenylamino)-4-oxobut-2-enoate;
4-(3-(cyclohex-1-enecarboxamido)-2-methylphenyl)-2-(1-(methylsulfonyl)-1,-
2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide; (E)-ethyl
4-(3-(7-carbamoyl-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-1-
H-indol-4-yl)-2-methylphenylamino)-4-oxobut-2-enoate;
4-(2-methyl-3-(2-phenoxyacetamido)phenyl)-2-(1-(methylsulfonyl)-1,2,3,6-t-
etrahydropyridin-4-yl)-1H-indole-7-carboxamide;
4-(3-(2-fluoroacetamido)-2-methylphenyl)-2-(1-(methylsulfonyl)-1,2,3,6-te-
trahydropyridin-4-yl)-1H-indole-7-carboxamide;
4-(3-acrylamido-2-methylphenyl)-2-(4,4-difluorocyclohex-1-enyl)-1H-indole-
-7-carboxamide;
4-(2-(acrylamidomethyl)phenyl)-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropy-
ridin-4-yl)-1H-indole-7-carboxamide;
4-(3-(3-(dimethylamino)propanamido)-2-methylphenyl)-2-(1-(methylsulfonyl)-
-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide;
4-(2-acrylamidophenyl)-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4--
yl)-1H-indole-7-carboxamide;
4-(3-(acrylamidomethyl)phenyl)-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropy-
ridin-4-yl)-1H-indole-7-carboxamide;
4-(3-(acrylamidomethyl)phenyl)-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropy-
ridin-4-yl)-1H-indole-7-carboxamide;
4-(3-(2-cyanopyrimidin-4-ylamino)phenyl)-2-(1-(methylsulfonyl)-1,2,3,6-te-
trahydropyridin-4-yl)-1H-indole-7-carboxamide;
4-(3-(6-cyclopropyl-8-fluoro-1-oxoisoquinolin-2(1H)-yl)-2-(hydroxymethyl)-
phenyl)-2-(1-methyl-1H-pyrazol-4-yl)-1H-indole-7-carboxamide;
4-(3-acrylamidophenyl)-1H-indole-7-carboxamide;
4-(3-acrylamido-2-methylphenyl)-1H-indole-7-carboxamide;
4-(3-acrylamido-2-methylphenyl)-2-(2-methoxypyridin-3-yl)-1H-indole-7-car-
boxamide;
4-(2-methyl-3-(2-(pyridin-2-yloxy)acetamido)phenyl)-2-(1-(methyl-
sulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide;
N1-(3-(7-carbamoyl-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)--
1H-indol-4-yl)-2-methylphenyl)fumaramide;
4-(3-(2-chlorobutanamido)-2-methylphenyl)-2-(1-(methylsulfonyl)-1,2,3,6-t-
etrahydropyridin-4-yl)-1H-indole-7-carboxamide;
4-(2-methyl-3-(3-(4-methylpiperazin-1-yl)propanamido)phenyl)-2-(1-(methyl-
sulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide;
4-(2-methyl-3-(2-(pyridazin-3-yloxy)acetamido)phenyl)-2-(1-(methylsulfony-
l)-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide;
2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-4-(3-(thiazol-2-ylm-
ethoxy)phenyl)-1H-indole-7-carboxamide; methyl
3-(4-(3-acrylamido-2-methylphenyl)-7-carbamoyl-1H-indol-2-yl)benzoate;
4-(3-acrylamido-2-methylphenyl)-2-(3-methoxyphenyl)-1H-indole-7-carboxami-
de;
4-(3-acrylamido-2-methylphenyl)-2-(4-methoxyphenyl)-1H-indole-7-carbox-
amide;
4-(3-acrylamido-2-methylphenyl)-2-(6-methylpyridin-3-yl)-1H-indole--
7-carboxamide;
4-(3-acrylamido-2-methylphenyl)-2-(3-carbamoylphenyl)-1H-indole-7-carboxa-
mide;
N-(3-(7-carbamoyl-3-methyl-1H-indol-4-yl)-2-methylphenyl)thiazole-2--
carboxamide;
4-(3-acrylamido-2-methylphenyl)-2-(3,5-dimethylisoxazol-4-yl)-1H-indole-7-
-carboxamide;
4-(3-acrylamido-2-methylphenyl)-2-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazo-
l-5-yl)-1H-indole-7-carboxamide;
4-(3-acrylamido-2-methylphenyl)-2-(3,5-dimethyl-1H-pyrazol-4-yl)-1H-indol-
e-7-carboxamide;
4-(3-acrylamido-2-methylphenyl)-2-(1-isopropyl-1H-pyrazol-4-yl)-1H-indole-
-7-carboxamide;
4-(3-acrylamido-2-methylphenyl)-2-(1,3-dimethyl-1H-pyrazol-4-yl)-1H-indol-
e-7-carboxamide;
4-(3-acrylamido-2-methylphenyl)-2-(1-ethyl-1H-pyrazol-4-yl)-1H-indole-7-c-
arboxamide;
4-(3-acrylamido-2-methylphenyl)-2-(1-isobutyl-1H-pyrazol-4-yl)-1H-indole--
7-carboxamide;
(E)-N-(3-(3-but-2-enamido-7-carbamoyl-1H-indol-4-yl)-2-methylphenyl)thiaz-
ole-2-carboxamide;
N-(3-(7-carbamoyl-3-methacrylamido-1H-indol-4-yl)-2-methylphenyl)thiazole-
-2-carboxamide;
N-(3-(3-but-2-ynamido-7-carbamoyl-1H-indol-4-yl)-2-methylphenyl)thiazole--
2-carboxamide;
N-(3-(7-carbamoyl-3-(2-(4-fluorophenoxy)acetamido)-1H-indol-4-yl)-2-methy-
lphenyl)thiazole-2-carboxamide;
4-(3-acrylamido-2-methylphenyl)-2-(2-fluoropyridin-3-yl)-1H-indole-7-carb-
oxamide;
4-(3-acrylamido-2-methylphenyl)-2-(1-ethyl-1H-pyrazol-4-yl)-1H-in-
dole-7-carboxamide;
2-(3-acetamidophenyl)-4-(3-acrylamido-2-methylphenyl)-1H-indole-7-carboxa-
mide;
4-(3-acrylamido-2-methylphenyl)-2-(2-methoxypyridin-4-yl)-1H-indole--
7-carboxamide;
4-(3-acrylamido-2-methylphenyl)-2-(3-cyanophenyl)-1H-indole-7-carboxamide-
; methyl
4-(4-(3-acrylamido-2-methylphenyl)-7-carbamoyl-1H-indol-2-yl)benz-
oate;
4-(3-acrylamido-2-methylphenyl)-2-(2,3-dihydrobenzofuran-5-yl)-1H-in-
dole-7-carboxamide;
4-(3-acrylamido-2-methylphenyl)-2-(3-fluorophenyl)-1H-indole-7-carboxamid-
e;
4-(3-acrylamido-2-methylphenyl)-2-(3-(dimethylamino)phenyl)-1H-indole-7-
-carboxamide;
4-(2-(2-chloroacetamido)phenyl)-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydrop-
yridin-4-yl)-1H-indole-7-carboxamide;
4-(2-acetamidophenyl)-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-y-
l)-1H-indole-7-carboxamide;
4-(3-acrylamido-2-methylphenyl)-2-(2-methyl-5-(pyrrolidin-1-ylsulfonyl)ph-
enyl)-1H-indole-7-carboxamide;
4-(3-acrylamido-2-methylphenyl)-2-(2-fluorophenyl)-1H-indole-7-carboxamid-
e;
N-(3-(3-acrylamido-7-carbamoyl-1H-indol-4-yl)-2-methylphenyl)thiazole-2-
-carboxamide;
N-(3-(7-carbamoyl-3-(2-chloroacetamido)-1H-indol-4-yl)-2-methylphenyl)thi-
azole-2-carboxamide;
4-(3-acrylamido-2-methylphenyl)-2-(1-methyl-1H-pyrazol-5-yl)-1H-indole-7--
carboxamide;
4-(3-acrylamido-2-methylphenyl)-2-(pyridin-4-yl)-1H-indole-7-carboxamide;
4-(3-acrylamido-2-methylphenyl)-2-(1-(2-morpholinoethyl)-1H-pyrazol-4-yl)-
-1H-indole-7-carboxamide;
4-(3-acrylamido-2-methylphenyl)-2-(6-morpholinopyridin-3-yl)-1H-indole-7--
carboxamide;
4-(3-acrylamido-2-methylphenyl)-2-(3-(4-methylpiperazine-1-carbonyl)pheny-
l)-1H-indole-7-carboxamide;
N-(3-(2-(2-(acrylamidomethyl)phenyl)-7-carbamoyl-1H-indol-4-yl)-2-methylp-
henyl)thiazole-2-carboxamide;
N-(3-(2-(2-(acetamidomethyl)phenyl)-7-carbamoyl-1H-indol-4-yl)-2-methylph-
enyl)thiazole-2-carboxamide;
N-(3-(7-carbamoyl-2-(2-(propionamidomethyl)phenyl)-1H-indol-4-yl)-2-methy-
lphenyl)thiazole-2-carboxamide;
N-(3-(2-(2-(butyramidomethyl)phenyl)-7-carbamoyl-1H-indol-4-yl)-2-methylp-
henyl)thiazole-2-carboxamide;
(E)-N-(3-(2-(2-(but-2-enamidomethyl)phenyl)-7-carbamoyl-1H-indol-4-yl)-2--
methylphenyl)thiazole-2-carboxamide;
N-(3-(7-carbamoyl-2-(2-(methacrylamidomethyl)phenyl)-1H-indol-4-yl)-2-met-
hylphenyl)thiazole-2-carboxamide;
N-(3-(7-carbamoyl-2-(2-(propiolamidomethyl)phenyl)-1H-indol-4-yl)-2-methy-
lphenyl)thiazole-2-carboxamide;
N-(3-(2-(2-(but-2-ynamidomethyl)phenyl)-7-carbamoyl-1H-indol-4-yl)-2-meth-
ylphenyl)thiazole-2-carboxamide;
N-(3-(7-carbamoyl-2-(2-((2-cyanoacetamido)methyl)phenyl)-1H-indol-4-yl)-2-
-methylphenyl)thiazole-2-carboxamide;
N-(3-(7-carbamoyl-2-(2-((3-(dimethylamino)propanamido)methyl)phenyl)-1H-i-
ndol-4-yl)-2-methylphenyl)thiazole-2-carboxamide;
N-(3-(7-carbamoyl-2-(2-((3-(piperidin-1-yl)propanamido)methyl)phenyl)-1H--
indol-4-yl)-2-methylphenyl)thiazole-2-carboxamide;
N-(3-(7-carbamoyl-2-(2-((2-phenoxyacetamido)methyl)phenyl)-1H-indol-4-yl)-
-2-methylphenyl)thiazole-2-carboxamide;
N-(3-(7-carbamoyl-2-(2-((2-(4-fluorophenoxy)acetamido)methyl)phenyl)-1H-i-
ndol-4-yl)-2-methylphenyl)thiazole-2-carboxamide;
N-(3-(7-carbamoyl-2-(2-((2-chloroacetamido)methyl)phenyl)-1H-indol-4-yl)--
2-methylphenyl)thiazole-2-carboxamide;
N-(3-(2-(2-(aminomethyl)phenyl)-7-carbamoyl-1H-indol-4-yl)-2-methylphenyl-
)thiazole-2-carboxamide;
4-(3-acrylamido-2-methylphenyl)-2-(4-fluorophenyl)-1H-indole-7-carboxamid-
e;
4-(3-acrylamido-2-methylphenyl)-2-phenyl-1H-indole-7-carboxamide;
4-(3-acrylamido-2-methylphenyl)-2-(2-(methylsulfonyl)phenyl)-1H-indole-7--
carboxamide;
4-(3-acrylamido-2-methylphenyl)-2-(4-(dimethylcarbamoyl)phenyl)-1H-indole-
-7-carboxamide;
4-(3-acrylamido-2-methylphenyl)-2-(pyrimidin-5-yl)-1H-indole-7-carboxamid-
e;
4-(3-acrylamido-2-methylphenyl)-2-(pyridin-3-yl)-1H-indole-7-carboxamid-
e;
4-(3-acrylamido-2-methylphenyl)-2-(4-(morpholine-4-carbonyl)phenyl)-1H--
indole-7-carboxamide;
4-(3-acrylamido-2-methylphenyl)-2-(4-(pyrrolidine-1-carbonyl)phenyl)-1H-i-
ndole-7-carboxamide;
4-(3-acrylamido-2-methylphenyl)-2-(4-(4-methylpiperazine-1-carbonyl)pheny-
l)-1H-indole-7-carboxamide;
4-(3-acrylamido-2-methylphenyl)-2-(4-(methylsulfonyl)phenyl)-1H-indole-7--
carboxamide;
4-(3-acrylamido-2-methylphenyl)-2-(6-methoxypyridin-3-yl)-1H-indole-7-car-
boxamide;
4-(3-acrylamido-2-methylphenyl)-2-(4-cyanophenyl)-1H-indole-7-ca-
rboxamide;
4-(3-acrylamido-2-methylphenyl)-2-(2-methoxyphenyl)-1H-indole-7-
-carboxamide;
N-(3-(7-carbamoyl-3-(2-cyanoacetamido)-1H-indol-4-yl)-2-methylphenyl)thia-
zole-2-carboxamide; 4-(2-acrylamidophenyl)-1H-indole-7-carboxamide;
4-(3-acrylamido-2-methylphenyl)-2-(4-(morpholinomethyl)phenyl)-1H-indole--
7-carboxamide;
4-(3-acrylamido-2-methylphenyl)-2-(4-carbamoylphenyl)-1H-indole-7-carboxa-
mide;
4-(3-acrylamido-5-(thiazol-2-ylmethylamino)phenyl)-2-(1-(methylsulfo-
nyl)-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide;
4-(2-methyl-3-(N-methylacrylamido)phenyl)-1H-indole-7-carboxamide;
4-(3-(methylamino)phenyl)-1H-indole-7-carboxamide;
4-(3-(N-methylacrylamido)phenyl)-1H-indole-7-carboxamide;
4-(2-methyl-3-(2-methylenebutanamido)phenyl)-1H-indole-7-carboxamide;
4-(2-methyl-3-(3-(pyrrolidin-1-yl)propanamido)phenyl)-1H-indole-7-carboxa-
mide; 4-(3-methacrylamido-2-methylphenyl)-1H-indole-7-carboxamide;
(E)-4-(3-(3-cyclopropylacrylamido)-2-methylphenyl)-1H-indole-7-carboxamid-
e;
(E)-4-(2-methyl-3-(3-(pyridin-2-yl)acrylamido)phenyl)-1H-indole-7-carbo-
xamide;
(E)-4-(2-methyl-3-(3-(1-methyl-1H-pyrazol-4-yl)acrylamido)phenyl)--
1H-indole-7-carboxamide; (E)-ethyl
4-(3-(7-carbamoyl-1H-indol-4-yl)-2-methylphenylamino)-4-oxobut-2-enoate;
(E)-4-(3-(4-(dimethylamino)but-2-enamido)-2-methylphenyl)-1H-indole-7-car-
boxamide;
(E)-4-(2-methyl-3-(3-(pyridin-3-yl)acrylamido)phenyl)-1H-indole--
7-carboxamide;
(E)-4-(2-methyl-3-(4-methylpent-2-enamido)phenyl)-1H-indole-7-carboxamide-
;
N1-(3-(7-carbamoyl-1H-indol-4-yl)-2-methylphenyl)-N4-ethylmaleamide;
4-(3-acetamido-2-methylphenyl)-1H-indole-7-carboxamide;
(E)-4-(3-but-2-enamido-2-methylphenyl)-1H-indole-7-carboxamide;
4-(2-methyl-3-(3-morpholinopropanamido)phenyl)-1H-indole-7-carboxamide;
(E)-4-(2-methyl-3-(3-(thiazol-2-yl)acrylamido)phenyl)-1H-indole-7-carboxa-
mide;
4-(2-methyl-3-(2-phenylacrylamido)phenyl)-1H-indole-7-carboxamide;
(E)-4-(2-methyl-3-(4-(piperidin-1-yl)but-2-enamido)phenyl)-1H-indole-7-ca-
rboxamide;
(E)-4-(2-methyl-3-(4-((tetrahydrofuran-2-yl)methylamino)but-2-e-
namido)phenyl)-1H-indole-7-carboxamide;
(E)-4-(3-(4-(2-methoxyethylamino)but-2-enamido)-2-methylphenyl)-1H-indole-
-7-carboxamide;
(E)-4-(3-(4-(cyclopropylamino)but-2-enamido)-2-methylphenyl)-1H-indole-7--
carboxamide;
(E)-4-(2-methyl-3-(4-morpholinobut-2-enamido)phenyl)-1H-indole-7-carboxam-
ide;
(E)-4-(2-methyl-3-(4-(4-methylpiperazin-1-yl)but-2-enamido)phenyl)-1H-
-indole-7-carboxamide;
4-(3-acrylamido-4-(benzyloxy)phenyl)-1H-indole-7-carboxamide;
4-(3-acrylamido-5-(benzyloxy)phenyl)-1H-indole-7-carboxamide;
4-(3-acrylamido-4-(thiazol-2-ylmethoxy)phenyl)-1H-indole-7-carboxamide;
4-(3-acrylamido-5-(thiazol-2-ylmethoxy)phenyl)-1H-indole-7-carboxamide;
4-(2-acrylamido-4-(thiazol-2-ylmethoxy)phenyl)-1H-indole-7-carboxamide;
4-(3-acrylamido-2-methylphenyl)-1H-pyrrolo[2,3-c]pyridine-7-carboxamide;
4-(2-acrylamido-4-(benzyloxy)phenyl)-1H-indole-7-carboxamide;
4-(5-acrylamidopyridin-3-yl)-1H-indole-7-carboxamide;
4-(2-acrylamidopyridin-4-yl)-1H-indole-7-carboxamide;
N1-(3-(7-carbamoyl-1H-indol-4-yl)phenyl)-N4-(2-methoxyethyl)maleamide;
N1-(3-(7-carbamoyl-1H-indol-4-yl)phenyl)-N4-ethylmaleamide;
4-(3-(1-methyl-1,2,5,6-tetrahydropyridine-3-carboxamido)phenyl)-1H-indole-
-7-carboxamide;
4-(3-(vinylsulfonamido)phenyl)-1H-indole-7-carboxamide;
4-(3-(2-oxopropanamido)phenyl)-1H-indole-7-carboxamide; (E)-methyl
4-(3-(7-carbamoyl-1H-indol-4-yl)phenylamino)-4-oxobut-2-enoate;
4-(3-(cyanomethylcarbamoyl)phenyl)-1H-indole-7-carboxamide;
N-(3-(7-carbamoyl-1H-indol-4-yl)phenyl)-5-methylisoxazole-4-carboxamide;
N1-(3-(7-carbamoyl-1H-indol-4-yl)phenyl)-N4-methylfumaramide;
N1-(3-(7-carbamoyl-1H-indol-4-yl)phenyl)-N4,N4-dimethylfumaramide;
N1-(3-(7-carbamoyl-1H-indol-4-yl)phenyl)-N4-ethylfumaramide;
N1-(3-(7-carbamoyl-1H-indol-4-yl)phenyl)-N4-cyclopropylfumaramide;
(E)-4-(3-(7-carbamoyl-1H-indol-4-yl)phenylamino)-4-oxobut-2-enoic
acid; 4-(3-(N-isobutylacrylamido)phenyl)-1H-indole-7-carboxamide;
1-Acryloyl-1,2,3,6-tetrahydro-pyrrolo[2,3-e]indole-5-carboxylic
acid amide; 4-acrylamido-1H-indole-7-carboxamide;
4-(3-(N-(cyanomethyl)sulfamoyl)phenyl)-1H-indole-7-carboxamide;
4-(3-acrylamidophenyl)-1H-pyrrolo[3,2-c]pyridine-7-carboxamide;
4-(3-acrylamido-2-methylphenyl)-1H-pyrrolo[3,2-c]pyridine-7-carboxamide;
4-(3-((2-oxopropanamido)methyl)phenyl)-1H-indole-7-carboxamide;
4-(3-acrylamidophenyl)-1H-indazole-7-carboxamide;
4-(3-acrylamido-2-methoxyphenyl)-1H-indole-7-carboxamide;
4-(3-acrylamido-2-fluorophenyl)-1H-indole-7-carboxamide;
4-(5-acrylamido-2-fluorophenyl)-1H-indole-7-carboxamide;
4-(3-acrylamido-4-fluorophenyl)-1H-indole-7-carboxamide;
4-(5-acrylamido-2-chlorophenyl)-1H-indole-7-carboxamide;
4-(5-acrylamido-2,4-difluorophenyl)-1H-indole-7-carboxamide;
4-(3-acrylamido-4-cyanophenyl)-1H-indole-7-carboxamide;
4-(3-acrylamido-2,6-difluorophenyl)-1H-indole-7-carboxamide;
4-(3-acrylamido-5-methylphenyl)-1H-indole-7-carboxamide;
4-(3-acrylamido-4-methylphenyl)-1H-indole-7-carboxamide;
4-(3-acrylamido-4-methoxyphenyl)-1H-indole-7-carboxamide;
4-(3-acrylamido-5-methoxyphenyl)-1H-indole-7-carboxamide;
4-(3-acrylamido-4-chlorophenyl)-1H-indole-7-carboxamide;
4-(5-acrylamido-2,3-difluorophenyl)-1H-indole-7-carboxamide;
4-(3-acrylamido-5-cyanophenyl)-1H-indole-7-carboxamide;
4-(3-acrylamido-2-cyanophenyl)-1H-indole-7-carboxamide;
4-(3-acrylamidophenyl)-2-vinyl-1H-indole-7-carboxamide;
4-(3-acrylamidophenyl)-2-ethyl-1H-indole-7-carboxamide;
4-(3-(2-(morpholinomethyl)acrylamido)phenyl)-1H-indole-7-carboxamide;
4-(3-(2-((dimethylamino)methyl)acrylamido)phenyl)-1H-indole-7-carboxamide-
;
(E)-4-(3-(4-(dimethylamino)but-2-enamido)-2-methylphenyl)-1H-pyrrolo[2,3-
-c]pyridine-7-carboxamide;
4-((1R,3S)-3-acrylamidocyclohexyl)-1H-indole-7-carboxamide;
4-(cis-3-acrylamidocyclohexyl)-1H-indole-7-carboxamide;
4-((1S,3S)-3-acrylamidocyclohexyl)-1H-indole-7-carboxamide;
4-(trans-3-acrylamidocyclohexyl)-1H-indole-7-carboxamide;
4-(cis-3-acrylamidocyclohexyl)-1H-indole-7-carboxamide;
4-(3-(2-(aminomethyl)acrylamido)phenyl)-1H-indole-7-carboxamide;
4-((1R,3S)-3-acrylamidocyclopentyl)-1H-indole-7-carboxamide;
4-(3-(2-((methylamino)methyl)acrylamido)phenyl)-1H-indole-7-carboxamide;
4-(3-acrylamidophenyl)-2-methyl-1H-indole-7-carboxamide;
4-((1S,3S)-3-acrylamidocyclopentyl)-1H-indole-7-carboxamide;
4-(3-acrylamidophenyl)-2-(2-ethoxyethyl)-1H-indole-7-carboxamide;
4-(3-acrylamidophenyl)-2-(2-hydroxyethyl)-1H-indole-7-carboxamide;
4-(1-acryloylpiperidin
3-yl)-2-(1-methyl-1H-pyrazol-4-yl)-1H-indole-7-carboxamide;
4-(3-acrylamido-2-methylphenyl)-2-(1-isopropyl-1H-pyrazol-4-yl)-1H-indole-
-7-carboxamide;
4-(3-(4-cyclopropylbenzamido)-2-methylphenyl)-2-(1-(methylsulfonyl)-1,2,3-
,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide;
4-(2-methyl-3-(1-methylpiperidine-4-carboxamido)phenyl)-2-(1-(methylsulfo-
nyl)-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide;
4-(3-(N-(cyclopentylmethyl)acrylamido)phenyl)-1H-indole-7-carboxamide;
ethyl
4-(7-carbamoyl-4-(2-methyl-3-(4-oxoquinazolin-3(4H)-yl)phenyl)-1H-i-
ndol-2-yl)5,6-dihydropyridine-1(2H)-carboxylate;
(R)-4-(3-(4-oxoquinazolin-3(4H)-yl)piperidin-1-yl)-1H-indole-7-carbonitri-
le; 4-(2,6-dichlorobenzyl)-2-(p-tolyl)-1H-indole-7-carboxamide;
(E)-4-(3-(2-cyano-3-hydroxybut-2-enamido)phenyl)-1H-indole-7-carboxamide;
4-(cis-3-acrylamidocyclopentyl)-1H-indole-7-carboxamide;
4-(trans-3-acrylamidocyclopentyl)-1H-indole-7-carboxamide;
4-(trans-3-acrylamidocyclopentyl)-1H-indole-7-carboxamide;
4-((1-acryloylazetidin-3-yl)oxy)-1H-indole-7-carboxamide;
(S)-4-(1-(1-acryloylazetidin-3-yl)ethyl)-1H-indole-7-carboxamide*;
(R)-4-(1-(1-acryloylazetidin-3-yl)ethyl)-1H-indole-7-carboxamide*;
4-((1-acryloylazetidin-3-yl)(methyl)amino)-1H-pyrrolo[2,3-c]pyridine-7-ca-
rboxamide;
(R)-4-(1-acryloylpiperidin-3-yl)-1H-indole-7-carboxamide*;
(S)-4-(1-acryloylpiperidin-3-yl)-1H-indole-7-carboxamide*;
(S)-4-(1-acryloylpiperidin-3-yl)-2-methyl-1H-indole-7-carboxamide;
(R)-4-(1-acryloylpiperidin-3-yl)-2-methyl-1H-indole-7-carboxamide;
(R)-4-(4-acryloylmorpholin-2-yl)-2-(1-methyl-1H-pyrazol-4-yl)-1H-indole-7-
-carboxamide;
(S)-4-(4-acryloylmorpholin-2-yl)-2-(1-methyl-1H-pyrazol-4-yl)-1H-indole-7-
-carboxamide;
(R)-4-(1-acryloylpyrrolidin-3-yl)-2-(6,7-dihydro-4H-pyrazolo[5,1-c][1,4]o-
xazin-2-yl)-1H-indole-7-carboxamide;
2-methyl-4-(methyl(1-propioloylazetidin-3-yl)amino)-1H-indole-7-carboxami-
de;
(S)-4-(1-acryloylpyrrolidin-3-yl)-2-(6,7-dihydro-4H-pyrazolo[5,1-c][1,-
4]oxazin-2-yl)-1H-indole-7-carboxamide;
(R)-4-(4-acryloyl-1,4-oxazepan-6-yl)-1H-pyrrolo[3,2-c]pyridine-7-carboxam-
ide;
(S)-4-(4-acryloyl-1,4-oxazepan-6-yl)-1H-pyrrolo[3,2-c]pyridine-7-carb-
oxamide;
(R)-4-(1-acryloylpiperidin-3-yl)-1H-pyrrolo[3,2-c]pyridine-7-carb-
oxamide;
(S)-4-(1-acryloylpiperidin-3-yl)-1H-pyrrolo[3,2-c]pyridine-7-carb-
oxamide;
(R)-7-(1-acryloylpiperidin-3-yl)-2-(1-methyl-1H-pyrazol-4-yl)thia-
zolo[5,4-c]pyridine-4-carboxamide;
(S)-7-(1-acryloylpiperidin-3-yl)-2-(1-methyl-1H-pyrazol-4-yl)thiazolo[5,4-
-c]pyridine-4-carboxamide;
(S)-4-(4-acryloyl-1,4-oxazepan-6-yl)-1H-indole-7-carboxamide;
4-((3S,5R)-1-acryloyl-5-(hydroxymethyl)piperidin-3-yl)-1H-indole-7-carbox-
amide;
4-((3S,5S)-1-acryloyl-5-(hydroxymethyl)piperidin-3-yl)-1H-indole-7--
carboxamide;
4-((3R,5S)-1-acryloyl-5-(hydroxymethyl)piperidin-3-yl)-1H-indole-7-carbox-
amide;
4-((3R,5R)-1-acryloyl-5-(hydroxymethyl)piperidin-3-yl)-1H-indole-7--
carboxamide;
(R)-4-(1-acryloylpyrrolidin-3-yl)-2-(1-methyl-1H-pyrazol-4-yl)-1H-indole--
7-carboxamide;
(S)-4-(1-acryloylpyrrolidin-3-yl)-2-(1-methyl-1H-pyrazol-4-yl)-1H-indole--
7-carboxamide;
4-((1R,3R)-3-acrylamidocyclopentyl)-1H-indole-7-carboxamide;
(S)-4-(1-acryloylpiperidin-3-yl)-1H-pyrrolo[2,3-c]pyridine-7-carboxamide;
(R)-4-(1-acryloylpiperidin-3-yl)-1H-pyrrolo[2,3-c]pyridine-7-carboxamide;
(R)-2-methyl-4-(1-propionylpyrrolidin-3-yl)-1H-indole-7-carboxamide;
(S)-2-methyl-4-(1-propionylpyrrolidin-3-yl)-1H-indole-7-carboxamide;
4-((1-acryloylazetidin-3-yl)(methyl)amino)-2-(isochroman-7-yl)-1H-indole--
7-carboxamide;
4-((1-acryloylazetidin-3-yl)(methyl)amino)-2-(6,7-dihydro-4H-pyrazolo[5,1-
-c][1,4]oxazin-2-yl)-1H-indole-7-carboxamide;
4-((1-acryloylazetidin-3-yl)(methyl)amino)-2-(4,4-difluorocyclohex-1-en-1-
-yl)-1H-indole-7-carboxamide;
4-((1-acryloylazetidin-3-yl)(methyl)amino)-2-(4-(methylsulfonyl)cyclohex--
1-en-1-yl)-1H-indole-7-carboxamide;
4-((1-acryloylazetidin-3-yl)(methyl)amino)-2-(6-morpholinopyridin-3-yl)-1-
H-indole-7-carboxamide;
4-((1-acryloylazetidin-3-yl)(methyl)amino)-2-(7,8-dihydro-5H-pyrano[4,3-b-
]pyridin-3-yl)-1H-indole-7-carboxamide;
4-((1-acryloylazetidin-3-yl)(methyl)amino)-2-(chroman-7-yl)-1H-indole-7-c-
arboxamide;
4-((1-acryloylazetidin-3-yl)(methyl)amino)-2-(5-(morpholinomethyl)pyridin-
-2-yl)-1H-indole-7-carboxamide;
4-((1-acryloylazetidin-3-yl)(methyl)amino)-2-(1-methyl-1H-pyrazol-4-yl)-1-
H-indole-7-carboxamide;
4-((1-acryloylazetidin-3-yl)(methyl)amino)-2-(3,4-dihydro-2H-benzo[b][1,4-
]oxazin-6-yl)-1H-indole-7-carboxamide;
4-((1-acryloylazetidin-3-yl)(methyl)amino)-2-(1-methyl-1H-pyrazol-5-yl)-1-
H-indole-7-carboxamide;
4-((1-acryloylazetidin-3-yl)(methyl)amino)-2-(2-ethyl-1,2,3,4-tetrahydroi-
soquinolin-6-yl)-1H-indole-7-carboxamide;
4-((1-acryloylazetidin-3-yl)(methyl)amino)-2-(1,3-dimethyl-1H-pyrazol-4-y-
l)-1H-indole-7-carboxamide;
4-((1-acryloylazetidin-3-yl)(methyl)amino)-2-(1,1-dioxidotetrahydro-2H-th-
iopyran-4-yl)-1H-indole-7-carboxamide;
4-((1-acryloylazetidin-3-yl)(methyl)amino)-2-(1-propylpiperidin-4-yl)-1H--
indole-7-carboxamide;
4-((1-acryloylazetidin-3-yl)(methyl)amino)-2-(tetrahydrofuran-3-yl)-1H-in-
dole-7-carboxamide;
4-((1-acryloylazetidin-3-yl)(methyl)amino)-2-(3-hydroxyoxetan-3-yl)-1H-in-
dole-7-carboxamide;
4-((1-acryloylazetidin-3-yl)(methyl)amino)-2-methyl-1H-indole-7-carboxami-
de; (R)-4-(4-acryloyl-1,4-oxazepan-6-yl)-1H-indole-7-carboxamide;
(S)-4-(1-acryloylpyrrolidin-3-yl)-2-methyl-1H-indole-7-carboxamide*;
(R)-4-(1-acryloylpyrrolidin-3-yl)-2-methyl-1H-indole-7-carboxamide*;
4-((1R,5S)-6-acryloyl-3,6-diazabicyclo[3.2.0]heptan-3-yl)-1H-indole-7-car-
boxamide;
4-((1S,5R)-6-acryloyl-3,6-diazabicyclo[3.2.0]heptan-3-yl)-1H-ind-
ole-7-carboxamide;
(R)-4-(1-(1-acryloylazetidin-3-yl)ethyl)-1H-pyrrolo[3,2-c]pyridine-7-carb-
oxamide;
(S)-4-(1-(1-acryloylazetidin-3-yl)ethyl)-1H-pyrrolo[3,2-c]pyridin-
e-7-carboxamide;
4-((1-acryloylazetidin-3-yl)amino)-1H-pyrrolo[2,3-c]pyridine-7-carboxamid-
e;
4-((1-acryloyl-3-methylazetidin-3-yl)(methyl)amino)-1H-indole-7-carboxa-
mide;
4-((1-cyanoazetidin-3-yl)(methyl)amino)-2-methyl-1H-indole-7-carboxa-
mide;
4-(2-chloro-6-fluorobenzyl)-2-p-tolyl-1H-indole-7-carboxamide;
(S)-4-((1-acryloylazetidin-3-yl)(methyl)amino)-2-(tetrahydrofuran-3-yl)-1-
H-indole-7-carboxamide;
(R)-4-((1-acryloylazetidin-3-yl)(methyl)amino)-2-(tetrahydrofuran-3-yl)-1-
H-indole-7-carboxamide;
(S)-4-(4-acryloyl-1,4-oxazepan-6-yl)-1H-pyrrolo[2,3-c]pyridine-7-carboxam-
ide;
(R)-4-(4-acryloyl-1,4-oxazepan-6-yl)-1H-pyrrolo[2,3-c]pyridine-7-carb-
oxamide;
(S)-4-(1-acryloylpiperidin-3-yl)-2-(1-methyl-1H-pyrazol-4-yl)-1H--
indole-7-carboxamide; or
(R)-4-(1-acryloylpiperidin-3-yl)-2-(1-methyl-1H-pyrazol-4-yl)-1H-indole-7-
-carboxamide.
21. A method of treating a disease comprising administering a
therapeutically effective amount of a compound of claim 1 to a
patient in need thereof.
22. The method according to claim 21, wherein the disease is
rheumatoid arthritis, juvenile rheumatoid arthritis,
osteoarthritis, Crohn's disease, inflammatory bowel disease,
ulcerative colitis, psoriatic arthritis, psoriasis, ankylosing
spondylitis, interstitial cystitis, asthma, systemic lupus
erythematosus, lupus nephritis, B cell chronic lymphocytic
lymphoma, multiple sclerosis, chronic lymphocytic leukemia, small
lymphocytic lymphoma, mantle cell lymphoma, B-cell non-Hodgkin's
lymphoma, activated B-cell like diffuse large B-cell lymphoma,
multiple myeloma, diffuse large B-cell lymphoma, follicular
lymphoma, hairy cell leukemia or Lymphoblastic lymphoma.
23. A kit comprising a packaged product comprising components with
which to administer a compound of claim 1 for treatment of an
autoimmune disorder.
24. The kit according to claim 23, wherein the packaged product
comprises a compound of Formula (I) and instructions for use.
25. A pharmaceutical composition comprising a compound according to
claim 1 and one or more pharmaceutically acceptable excipients.
Description
RELATED APPLICATIONS
[0001] This application is a continuation of U.S. patent
application Ser. No. 16/421,006, filed on May 23, 2019, which is
continuation of U.S. patent application Ser. No. 15/398,978, filed
on Jan. 5, 2017, which is continuation of U.S. patent application
Ser. No. 14/315,504, filed on Jun. 26, 2014, now U.S. Pat. No.
9,567,339, which claims the benefit of the filing date, under 35
U.S.C. .sctn. 119(e), of U.S. Provisional Application No.
61/839,729, filed on Jun. 26, 2013, and of U.S. Provisional
Application No. 61/897,577, filed on Oct. 30, 2013, the entire
content of each of which is incorporated herein by reference.
BACKGROUND OF THE INVENTION
[0002] The protein kinases represent a large family of proteins
that play a central role in the regulation of a wide variety of
cellular processes and maintenance of cellular function. A partial,
non-limiting, list of these kinases include: non-receptor tyrosine
kinases such as the Tec family (BTK, ITK, Tec, ETK/BMX &
RLK/TXK), Janus kinase family (Jak1, Jak2, Jak3 and Tyk2); the
fusion kinases, such as BCR-Abl, focal adhesion kinase (FAK), Fes,
Lek and Syk; receptor tyrosine kinases such as epidermal growth
factor receptor (EGFR), the platelet-derived growth factor receptor
kinase (PDGF-R), the receptor kinase for stem cell factor, c-kit,
the hepatocyte growth factor receptor, c-Met, and the fibroblast
growth factor receptor, FGFR3; and serine/threonine kinases such as
b-RAF, mitogen-activated protein kinases (e.g., MKK6) and
SAPK2.beta.. Aberrant kinase activity has been observed in many
disease states including benign and malignant proliferative
disorders as well as diseases resulting from inappropriate
activation of the immune and nervous systems. The novel compounds
of this invention inhibit the activity of one or more protein
kinases and are, therefore, expected to be useful in the treatment
of kinase-mediated diseases.
[0003] Bruton's tyrosine kinase (BTK) is a non-receptor tyrosine
kinase with a key role in immunoreceptor signaling (BCR, FcR,
Fc.gamma.R, DAP12, Dectin-1, GPVI, etc.) in a host of hematopoietic
cells including B cells, platelets, mast cells, basophils,
eosinophils, macrophages and neutrophils as well as osteoclasts
involved in bone destruction (for reviews, see Brunner et al., 2005
Histol. Histopathol., 20:945, Mohamed et al., 2009 Immunol. Rev.,
228:58). Mutations in BTK are known to lead to X-linked
agammaglobulinemia (XLA) in humans and X-linked immunodeficiency
(Xid) in mice, which are characterized by limited B-cell production
& reduced antibody titers (Lindvall et al., 2005 Immunol. Rev.,
203:200). The combined action of BTK in multiple cell types makes
it an attractive target for autoimmune disease. BTK is related with
sequence homology to other Tec family kinases (ITK, Tec, ETK/BMX
& RLK/TXK).
[0004] In B-lymphocytes, BTK is required for B-cell development and
for Ca.sup.2+ mobilization following of B-cell receptor (BCR)
engagement (Khan et al., 1995 Immunity 3:283; Genevier et al., 1997
Clin. Exp. Immun., 110:286) where it is believed to downstream of
Src family kinases (such as Lyn), Syk & PI3K. BTK has been
shown to be important for both thymus-dependent and
thymus-independent type 2 responses to antigens (Khan et al.,
Immunity 1995, 3:283). In mast cells, studies using BTK mouse
knock-outs (Hata et al., 1998 J. Exp. Med., 187:1235; Schmidt et
al., 2009 Eur. J Immun., 39:3228) indicate a role for BTK in FcsRI
induced signaling, histamine release & production of cytokines
such as TNF, IL-2, & IL-4. In platelets, BTK is important for
signaling through the glycoprotein VI (GPVI) receptor that responds
to collagen and has been shown to promote platelet aggregation and
contribute to cytokine production from fibroblast-like synoviocytes
(Hsu et al., 2013 Immun. Letters, 150:97). In monocytes and
macrophages, the action of BTK in invoked in Fc.gamma.RI induced
signaling and may also have role in Toll-Like Receptor-induced
cytokine responses including TLR2, TLR4, TLR8 & TLR9 (Horwood
et al., 2003 J. Exp. Med., 197:1603; Horwood et al., 2006 J.
Immunol., 176:3635; Perez de Diego et al., 2006 Allerg. Clin. Imm.,
117:1462; Doyle et al., 2007 J. Biol. Chem., 282:36959, Hasan et
al., 2007 Immunology, 123:239; Sochorava et al., 2007 Blood,
109:2553; Lee et al., 2008, J. Biol. Chem., 283:11189).
[0005] Therefore, inhibition of BTK is expected to intervene at
several critical junctions of the inflammatory reactions resulting
in an effective suppression of autoimmune response. As such
diseases involving B-cell receptor activation, antibody-Fc receptor
interactions & GPVI receptor signaling may be modulated by
treatment with BTK inhibitors. BTK inhibition is likely to act on
both the initiation of autoimmune disease by blocking BCR signaling
and the effector phase by abrogation of FcR signaling on
macrophages, neutrophils, basophils, and mast cells. Furthermore,
blocking BTK would provide additional benefit via inhibition of
osteoclast maturation and therefore attenuate the bone erosions
& overall joint destruction associated with rheumatoid
arthritis. Inhibiting BTK may be useful in treating a host of
inflammatory and allergic diseases--for example (but not limited
to), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE),
multiple sclerosis (MS) and type I hypersensitivity reactions such
as allergic rhinitis, allergic conjunctivitis, atopic dermatitis,
allergic asthma and systemic anaphylaxis. For a review on targeting
BTK as a treatment for inflammatory disorders and autoimmunity as
well as leukemias and lymphomas, see Uckun & Qazi, 2010 Expert
Opin. Ther. Pat., 20:1457. Because BTK is highly expressed in
cancers of the hematopoietic system & BTK-dependent signaling
in believed to be disregulated there, BTK inhibitors are expected
to be useful treatments for B-cell lymphomas/leukemias & other
oncologic disease--for example (but not limited to) acute
lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL),
non-Hodgkin's lymphoma (NHL), small lymphocytic lymphoma (SLL), and
acute myeloid leukemia (for review, see Buggy & Elias 2012 Int.
Rev. Immunol. 31:119). Taken together, BTK inhibitors provide a
strong method to treat a host of inflammatory diseases and
immunological disorders as well as hematologic cancers.
SUMMARY OF THE INVENTION
[0006] In a first embodiment the invention provides a compound of
Formula (I):
##STR00002##
[0007] or a pharmaceutically acceptable salt, pro-drug,
biologically active metabolite, isomer, or stereoisomer thereof,
wherein: [0008] X is NR.sup.2 or S; [0009] Y is N or CR.sup.1, and
Z is N or CR.sup.1; or, Y is CR.sup.1R.sup.2 and Z is
CR.sup.1R.sup.2; [0010] A is N or CR.sup.4; [0011] E is N or
CR.sup.5; [0012] R.sup.1 is independently H, deuterium, CN,
halogen, CF.sub.3, --NR.sup.cR.sup.c, --N(R.sup.a)C(O)R.sup.b,
optionally substituted (C.sub.1-C.sub.6)alkyl, optionally
substituted (C.sub.2-C.sub.6)alkenyl, optionally substituted aryl,
optionally substituted (C.sub.3-C.sub.6)cycloalkyl, optionally
substituted (C.sub.3-C.sub.6)cycloalkenyl, optionally substituted
heteroaryl, or optionally substituted saturated or partially
saturated heterocyclyl; [0013] R.sup.2 is independently H,
deuterium, or optionally substituted (C.sub.1-C.sub.3)alkyl; [0014]
R.sup.3 is halogen, --N(R.sup.a).sub.2, optionally substituted
aryl, optionally substituted (C.sub.3-C.sub.7)cycloalkyl,
optionally substituted saturated or partially saturated
heterocyclyl, or optionally substituted heteroaryl; or [0015]
R.sup.3 is --R.sup.301-L-R.sup.302 wherein [0016] R.sup.301 is a
bond, --O--, --OCH.sub.2--, --NR.sup.d--, or optionally substituted
(C.sub.1-C.sub.3)alkylene, and [0017] L is optionally substituted
phenyl, optionally substituted (C.sub.3-C.sub.6)cycloalkyl,
optionally substituted heteroaryl or a saturated or partially
saturated heterocyclyl containing one or more heteroatoms, at least
one of which is nitrogen; or [0018] L is -L.sup.1-L.sup.2 wherein
L.sup.1 is attached to R.sup.301 and [0019] L.sup.1 is optionally
substituted phenyl, optionally substituted heteroaryl or optionally
substituted saturated or partially saturated carbocycle or a
saturated or partially saturated heterocyclyl; and [0020] L.sup.2
is a bond, CH.sub.2, NR, CH.sub.2N(H), S(O).sub.2N(H), or --O--;
[0021] R.sup.302 is CN, --CH.sub.2CN, optionally substituted
--C(.dbd.)R.sup.302a, --(CH.sub.2).sub.n-optionally substituted
saturated or partly saturated heterocyclyl or optionally
substituted --S(O).sub.2(C.sub.2)alkenyl; [0022] wherein R.sup.302a
is optionally substituted (C.sub.1-C.sub.4)alkyl, optionally
substituted (C.sub.2-C.sub.4)alkenyl, (C.sub.2-C.sub.4)alkynyl,
--C(O)--(C.sub.1-C.sub.4)alkyl, optionally substituted saturated or
partially unsaturated (C.sub.3-C.sub.6)cycloalkyl, optionally
substituted aryl, optionally substituted heteroaryl, --N(H)--
optionally substituted heteroaryl or --(CH.sub.2).sub.n-optionally
substituted unsaturated or partly saturated heterocyclyl; [0023]
R.sup.4 is H, deuterium, CN, optionally substituted
(C.sub.1-C.sub.3)alkyl, optionally substituted (C.sub.3-C.sub.6)
cycloalkyl or optionally substituted saturated or partially
saturated heterocyclyl, or optionally substituted heteroaryl;
[0024] wherein the optionally substituted saturated or partially
saturated heterocyclyl; and optionally substituted heteroaryl
contain at least one nitrogen atom; or [0025] R.sup.3 and R.sup.4,
together with the carbon atoms to which they are attached, form an
optionally substituted, saturated, unsaturated or partially
unsaturated 5 or 6 membered carbocyclic ring or an optionally
substituted, saturated, or partially unsaturated 5 or 6 membered
heterocyclic ring containing one or more heteroatoms selected from
N, S and O; [0026] R.sup.5 is H, deuterium, halogen, or optionally
substituted (C.sub.1-C.sub.3)alkyl; [0027] R.sup.a is independently
selected from H, --C(O)-optionally substituted
(C.sub.2-C.sub.6)alkenyl, optionally substituted
(C.sub.1-C.sub.6)alkyl, --(CH.sub.2).sub.n-optionally substituted
(C.sub.3-C.sub.6)cycloalkyl, --(CH.sub.2).sub.n-optionally
substituted heterocyclyl, or --(CH.sub.2).sub.n-optionally
substituted heteroaryl; [0028] R.sup.b is H, optionally substituted
(C.sub.1-C.sub.6)alkyl, optionally substituted
(C.sub.2-C.sub.6)alkenyl, optionally substituted
(C.sub.2-C.sub.6)alkynyl, --CH.sub.2--O-optionally substituted
aryl, or --CH.sub.2--O-optionally substituted heteroaryl; [0029]
R.sup.c is independently H, optionally substituted
(C.sub.1-C.sub.6)alkyl, optionally substituted
(C.sub.3-C.sub.6)cycloalkyl, optionally substituted saturated or
partially saturated heterocyclyl, optionally substituted aryl or
optionally substituted heteroaryl; [0030] R.sup.d is H, optionally
substituted heterocyclyl, --(CH.sub.2)-optionally substituted
(C.sub.3-C.sub.6)cycloalkyl, --(CH.sub.2)-optionally substituted
heteroaryl or optionally substituted (C.sub.1-C.sub.3)alkyl; [0031]
R.sup.f is optionally substituted (C.sub.1-C.sub.3)alkyl,
optionally substituted (C.sub.2-C.sub.4)alkenyl or optionally
substituted (C.sub.2-C.sub.4)alkynyl; and [0032] n is independently
0 or 1.
[0033] In a second embodiment the invention provides a compound
according to the first embodiment, wherein Y is CR.sup.1 and
R.sup.1 of Y is H, optionally substituted ethenyl, optionally
substituted ethyl, optionally substituted methyl, optionally
substituted 2,3-dihydrobenzofuranyl, optionally substituted
1,4-dioxanyl, optionally substituted
3,4-dihydro-2H-benzo[b][1,4]oxazinyl, optionally substituted
6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazinyl, optionally substituted
chromanyl, optionally substituted cyclohexenyl, optionally
substituted cyclopropyl, optionally substituted tetrahydrofuranyl,
optionally substituted isochromanyl, optionally substituted
1,2,3,4-tetrahydro-isoquinolinyl, optionally substituted
isoxazolyl, optionally substituted morpholinyl, optionally
substituted oxetanyl, optionally substituted phenyl, optionally
substituted piperidinyl, optionally substituted piperazinyl,
optionally substituted 3,6-dihydro-2H-pyranyl, optionally
substituted pyrano[4,3-b]pyridinyl, optionally substituted
pyrazolyl, optionally substituted pyridinyl, optionally substituted
3H-pyridin-1-one, optionally substituted
1,2,3,6-tetrahydropyridinyl, optionally substituted pyrimidinyl,
optionally substituted pyrrolidinyl, optionally substituted
2,5-dihydropyrrolyl, optionally substituted tetrahydropyranyl or
optionally substituted tetrahydro-2H-thiopyranyl.
[0034] In a third embodiment the invention provides a compound
according to any of the foregoing embodiments wherein R.sup.1 is H
or R.sup.1 is optionally substituted by one or more substituents
independently selected from the group consisting of CN, OH, .dbd.O,
halogen, (C.sub.1-C.sub.4)alkyl, (C.sub.1-C.sub.4)alkoxy,
--CH.sub.2CH.sub.2OH,
--CH.sub.2C(CH.sub.3).sub.2OH,--CH.sub.2CH(OH)CH.sub.2OH,
--CH.dbd.CH.sub.2, --CH.sub.2NH.sub.2, --CH.sub.2N(H)C(O)R.sup.e,
--C(O)(C.sub.1-C.sub.4)alkyl, --C(O)(C.sub.1-C.sub.4)alkoxy,
--C(O)NH.sub.2, --C(O)N(CH.sub.3).sub.2,--C(O)-optionally
substituted heterocyclyl, --N(H)C(O)CH.sub.3, N(CH.sub.3).sub.2,
--S(O).sub.2(C.sub.1-C.sub.4)alkyl, --S(O).sub.2-pyrrolidinyl,
(C.sub.1-C.sub.4)alkoxy, --CH.sub.2-morpholinyl,
--CH.sub.2CH.sub.2-morpholinyl, morpholinyl, tetrahydropyranyl;
[0035] wherein R.sup.e is (C.sub.1-C.sub.3)alkyl, --CH.sub.2Cl,
--C.ident.CH, --C.ident.CCH.sub.3, --CH.dbd.CH.sub.2,
--CH.dbd.CHCH.sub.3, --C(.dbd.CH.sub.2)CH.sub.3, --CH.sub.2CN,
--CH.sub.2CH.sub.2N(CH.sub.3).sub.2,
--CH.sub.2CH.sub.2-piperidinyl, --CH.sub.2O-optionally substituted
phenyl.
[0036] In a fourth embodiment the invention provides a compound
according to any of the foregoing embodiments wherein R.sup.3 is
--N(H)C(O)CH.dbd.CH.sub.2, optionally substituted isoxazolyl,
optionally substituted phenyl, optionally substituted pyrazolyl,
optionally substituted pyridinyl, optionally substituted
pyrimidinyl, optionally substituted thiazolyl, or optionally
substituted thienyl.
[0037] In a fifth embodiment the invention provides a compound
according to any of the foregoing embodiments according to claim 4,
wherein R.sup.3 is optionally substituted by one or more
substituents independently selected from --NH.sub.2, --NHCH.sub.3,
(C.sub.1-C.sub.4)alkyl and --C(O)(C.sub.2-C.sub.4)alkenyl.
[0038] In a sixth embodiment the invention provides a compound
according to any of the foregoing embodiments wherein X is NR.sup.2
and R.sup.2 is H.
[0039] In a seventh embodiment the invention provides a compound
according to any of the foregoing embodiments wherein Y is CR.sup.1
and R.sup.1 of Y is H, optionally substituted phenyl, optionally
substituted piperazinyl, optionally substituted pyrazolyl, or
optionally substituted 1,2,3,6-tetrahydropyridinyl.
[0040] In an eighth embodiment the invention provides a compound
according to any of the foregoing embodiments wherein Y is CR.sup.1
and R.sup.1 of Y is optionally substituted by one or more
substituents independently selected from halogen,
(C.sub.1-C.sub.4)alkyl, --C(O)(C.sub.1-C.sub.4)alkyl, and
--S(O).sub.2(C.sub.1--C.sub.4)alkyl.
[0041] In a ninth embodiment the invention provides a compound
according to any of the foregoing embodiments wherein
[0042] Z is N or Z is CR.sup.1 and R.sup.1 of Z is H; and
[0043] A is CR.sup.4 and R.sup.4 is H or azetidinyl substituted
with --C(O)CH.dbd.CH.sub.2.
[0044] In a tenth embodiment the invention provides a compound
according to any of the foregoing embodiments wherein the compound
is [0045]
4-(3-amino-2-methylphenyl)-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridi-
n-4-yl)-1H-indole-7-carboxamide; [0046]
2-(4-fluorophenyl)-4-(pyridin-3-yl)-1H-indole-7-carboxamide; [0047]
4-(pyridin-3-yl)-2-p-tolyl-1H-indole-7-carboxamide; [0048]
2-(4-fluorophenyl)-4-(pyridin-4-yl)-1H-indole-7-carboxamide; [0049]
2-(4-fluorophenyl)-4-(1H-pyrazol-5-yl)-1H-indole-7-carboxamide;
[0050]
4-(3,5-dimethylisoxazol-4-yl)-2-p-tolyl-1H-indole-7-carboxamide;
[0051]
2-(1-acetylpiperidin-4-yl)-4-(3-amino-2-methylphenyl)-1H-indole-7-carboxa-
mide; [0052] 4-(pyridin-4-yl)-2-p-tolyl-1H-indole-7-carboxamide;
[0053] 4-(thiophen-2-yl)-2-p-tolyl-1H-indole-7-carboxamide; [0054]
4-(2-aminophenyl)-1H-indole-7-carboxamide; [0055]
4-(3-amino-2-methylphenyl)-1H-indole-7-carboxamide; [0056]
4-(5-aminopyridin-3-yl)-1H-indole-7-carboxamide; [0057]
4-(2-aminopyridin-4-yl)-1H-indole-7-carboxamide; [0058]
4-(2-aminoethylamino)-2-(4-fluorophenyl)-1H-indole-7-carboxamide;
[0059] 4-(2-aminoethylamino)-2-p-tolyl-1H-indole-7-carboxamide;
[0060] 4-(pyrimidin-5-yl)-2-p-tolyl-1H-indole-7-carboxamide; [0061]
4-(1H-pyrazol-4-yl)-2-p-tolyl-1H-indole-7-carboxamide; [0062]
4-(1H-pyrazol-5-yl)-2-p-tolyl-1H-indole-7-carboxamide; [0063]
2-(4-fluorophenyl)-4-(pyrimidin-5-yl)-1H-indole-7-carboxamide;
[0064] 4-(thiazol-2-yl)-2-p-tolyl-1H-indole-7-carboxamide; [0065]
4-(pyridin-2-yl)-2-p-tolyl-1H-indole-7-carboxamide; [0066]
4-(thiophen-3-yl)-2-p-tolyl-1H-indole-7-carboxamide; [0067]
4-(1-methyl-1H-pyrazol-4-yl)-2-p-tolyl-1H-indole-7-carboxamide;
[0068] 4-(1H-pyrazol-3-yl)-2-p-tolyl-1H-indole-7-carboxamide;
[0069]
4-(2-aminophenyl)-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-1-
H-indole-7-carboxamide; [0070]
2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-4-phenyl-1H-indole--
7-carboxamide; [0071]
4-(3-amino-2-methylphenyl)-2-(4,4-difluorocyclohex-1-enyl)1H-indole-7-car-
boxamide; [0072]
4-(3-amino-2-methylphenyl)-1H-pyrrolo[2,3-c]pyridine-7-carboxamide;
[0073] 4-(1-acryloylpiperidin-3-yl)-1H-indole-7-carboxamide; [0074]
4-(1-acryloylpiperidin
3-yl)-2-(1-methyl-1H-pyrazol-4-yl)-1H-indole-7-carboxamide; [0075]
4-(2-aminoethylamino)-2-p-tolyl-1H-indole-7-carboxamide; [0076]
4-((1R,2R)-2-aminocyclohexylamino)-2-(4-fluorophenyl)-1H-indole-7-carboxa-
mide*; [0077]
4-(1-methyl-1H-pyrazol-5-ylamino)-2-p-tolyl-1H-indole-7-carboxamide;
[0078] 4-iodo-2-(pyridin-3-yl)-1H-indole-7-carboxamide; [0079]
4-(3-amino-2-methylphenyl)-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridi-
n-4-yl)-1H-indole-7-carboxamide; [0080]
4-(3,5-dimethylisoxazol-4-yl)-2-(4-fluorophenyl)-1H-indole-7-carboxamide;
[0081]
4-(2-aminophenyl)-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin--
4-yl)-1H-indole-7-carboxamide; or [0082]
2-(1-Acetylpiperidin-4-yl)-4-(3-amino-2-methylphenyl)-1H-indole-7-carboxa-
mide.
[0083] In an eleventh embodiment the invention provides a compound
according to any of the first through third embodiments wherein
R.sup.3 is --R.sup.301-L-R.sup.302, and R.sup.301 is a bond, N(H),
N(CH.sub.3), CH.sub.2, C(H)(optionally substituted
(C.sub.1-C.sub.3)alkyl), O, or OCH.sub.2.
[0084] In an twelfth embodiment the invention provides a compound
according to the any of the first through third or eleventh
embodiments wherein [0085] L is optionally substituted azetidinyl,
optionally substituted cyclopentyl, optionally substituted
3,6-diazabicyclo[3.2.0]heptanyl, optionally substituted
1,4-dioxanyl, optionally substituted morpholinyl, optionally
substituted [1,4]oxepanyl, optionally substituted phenyl,
optionally substituted piperidinyl, or optionally substituted
pyrrolidinyl; or [0086] L is L.sup.1-L.sup.2 wherein [0087] L.sup.1
is optionally substituted cyclohexyl, optionally substituted
cyclopentyl optionally substituted phenyl, optionally substituted
piperidinyl, optionally substituted pyridinyl; [0088] L.sup.2 is
N(H), N(CH.sub.3), N(CH.sub.2CH.sub.2OH),
N(CH.sub.2CH(CH.sub.3).sub.2), N(oxetanyl),
N(CH.sub.2-cyclopentyl), N(CH.sub.2-thiazolyl), O, S(O).sub.2N(H),
or CH.sub.2N(H).
[0089] In an thirteenth embodiment the invention provides a
compound according to any of the first through third and eleventh
and twelfth embodiments wherein L or L.sup.1 is optionally
substituted with one or more substituents independently selected
from halogen, CN, OH, (C.sub.1-C.sub.4)alkoxy,
(C.sub.1-C.sub.4)alkyl, --CH.sub.2OH, --N(H)CH.sub.2-heteroaryl,
benzyloxy, and --OCH.sub.2-heteroaryl.
[0090] In an fourteenth embodiment the invention provides a
compound according to any of the first through third and eleventh
through thirteenth embodiments wherein R.sup.302 is --C(O)CH.sub.3,
--C(O)C(O)CH.sub.3, --C(O)CF.sub.2(Cl), --CH(CH.sub.3).sub.2,
--CH.sub.2Cl, --CH.sub.2CN, --C(O)CH.sub.2CN,
--C(O)CH.sub.2CH.sub.3, --C(O)CH.sub.2F, --C(O)CH(CH.sub.3).sub.2,
--C(O)--CH.sub.2CH(CH.sub.3).sub.2, --C(O)CH(CH.sub.3)(C),
--C(O)CH.sub.2CH(CH.sub.3)CH.sub.3, --C(O)CH(Cl)CH.sub.2CH.sub.3,
--CH.sub.2CH.sub.2OH, --C(O)CH.sub.2CH.sub.2N(CH.sub.3).sub.2,
--C(O)CH.dbd.CH.sub.2, --C(O)C.ident.CH, --C(O)CH.dbd.CHCl,
--C(O)CH.dbd.CHCH.sub.3, --C(O)C(.dbd.CH.sub.2)CH.sub.3,
--C(O)C(CH.sub.2CH.sub.3).dbd.CH.sub.2,
--C(O)CH.dbd.CHCH(CH.sub.3).sub.2, --C(O)CH.dbd.CHC(O)OH,
--C(O)CH.dbd.CHC(O)N(H)CH.sub.2CH.sub.3,
--C(O)CH.dbd.CHCH.sub.2N(CH.sub.3).sub.2,
--C(O)CH.dbd.CHC(O)OCH.sub.3, --C(O)CH.dbd.CHC(O)OCH.sub.2CH.sub.3,
--C(O)CH.dbd.CHC(O)N(H)CH.sub.3,
--C(O)CH.dbd.CHC(O)CH.sub.2CH.sub.2OCH.sub.3,
--C(O)CH.dbd.CHC(O)N(CH.sub.3).sub.2,
--C(O)CH.dbd.CHC(O)N(H)CH.sub.2CH.sub.3,
--C(O)CH.dbd.CHC(O)N(H)CH.sub.2CH.sub.2OCH.sub.3,
--C(O)CH.dbd.CHCH.sub.2N(H)CH.sub.2CH.sub.2OCH.sub.3,
--C(O)C(CN).dbd.C(OH)(CH.sub.3), --C(O)CH.dbd.CH-optionally
substituted pyrazolyl-C(O)CH.dbd.CHCH.sub.2N(H)-optionally
substituted cyclopropyl,
--C(O)CH.dbd.CHCH.sub.2N(H)CH.sub.2-optionally substituted
tetrahydrofuranyl,
--C(O)CH.dbd.CHC(O)NH.sub.2,--C(O)CH.dbd.CHC(O)N(H)-- optionally
substituted cyclopropyl, --C(O)C(CH.sub.3).dbd.CHCH.sub.3,
--C(O)C(CH.sub.3).dbd.CHCH.sub.2CH.sub.3,
--C(O)C(.dbd.CH.sub.2)CH.sub.2N(CH.sub.3).sub.2,
--C(O)C(.dbd.CH.sub.2)CH.sub.2NH.sub.2,
--C(O)C(.dbd.CH.sub.2)CH.sub.2N(H)(CH.sub.3),
--C(O)C(.dbd.CH.sub.2)CH.sub.3, --C(O)C(.dbd.CH.sub.2)CH.sub.2--
optionally substituted morpholinyl,
--C(O)C(.dbd.CH.sub.2)-optionally substituted phenyl,
--CH.sub.2-optionally substituted benzo[d]isothiazolyl,
--C(O)--CH.sub.2--O-optionally substituted phenyl,
--CH.sub.2-optionally substituted thiazolyl,
--CH.sub.2CH.sub.2-optionally substituted morpholinyl,
--C(O)CH.sub.2O-optionally substituted phenyl,
--C(O)CH.sub.2CH.sub.2-optionally substituted piperazinyl,
--C(O)CH.sub.2CH.sub.2-- optionally substituted piperidinyl,
--C(O)CH.sub.2O-optionally substituted pyridinyl,
--C(O)CH.sub.2CH.sub.2 optionally substituted
pyrrolidinyl,--C(O)CH.dbd.CH optionally substituted
cyclopropyl,--C(O)CH.dbd.CHCH.sub.2-- optionally substituted
morpholinyl, --C(O)CH.dbd.CHCH.sub.2-- optionally substituted
piperidinyl,--C(O)CH.dbd.CH-optionally substituted
pyrazolyl,--C(O)CH.dbd.CH-optionally substituted pyridinyl,
--C(O)CH.dbd.CH-optionally substituted thiazolyl, --C(O)-optionally
substituted cyclohexenyl, --C(.dbd.O)-optionally substituted
cyclohexyl, --C(O)-optionally substituted cyclopentenyl,
--C(O)-cyclopentyl, optionally substituted imidazo[1,2-a]pyrazinyl,
optionally substituted tetrahydroimidazo[1,2-a]pyrazinyl,
optionally substituted dihydr-isoindolyl, optionally substituted
1,2,3,4-tetrahydro-isoquinolinyl, optionally substituted
isoquinolinyl, --C(O)-optionally substituted isoxazolyl,
--C(O)-optionally substituted oxazolyl, optionally substituted
oxetanyl,--C(.dbd.O)-- optionally substituted phenyl, optionally
substituted piperidinyl, --C(O)-optionally substituted piperidinyl,
optionally substituted pyrazolyl, --C(O)CH.sub.2O-optionally
substituted pyridazinyl, --C(O)-optionally substituted pyridinyl,
optionally substituted pyrimidinyl, optionally substituted
quinazolinyl, optionally substituted dihydroquinolinyl, optionally
substituted --C(O)-tetrahydrobenzo[b]thiophenyl, --C(O)-optionally
substituted tetrahydropyranyl, --C(O)-optionally substituted
tetrahydropyridinyl, --C(O)-thiazolyl, --C(O)N(H)-thiazolyl,
--C(O)NHCH.sub.2CN, or --S(O).sub.2CH.dbd.CH.sub.2.
[0091] In a fifteenth embodiment the invention provides a compound
according to any of the first through third or thirteenth through
fourteenth embodiments wherein X is NR.sup.2 and R.sup.2 is H.
[0092] In a sixteenth embodiment the invention provides a compound
according to any of the first through third or thirteenth through
fifteenth embodiments wherein Y is CR.sup.1 and R.sup.1 of Y is
optionally substituted with one or more substituents independently
selected from halogen, CN, .dbd.O, (C.sub.1-C.sub.4)alkyl,
(C.sub.2-C.sub.4)alkenyl, --CH.sub.2NH.sub.2, --CH.sub.2CH.sub.2OH,
--CH.sub.2CH(OH)CH.sub.2CH.sub.3, --CH.sub.2CH(OH)CH.sub.2OH,
--CH.sub.2CH.sub.2OCH.sub.2CH.sub.3,
--CH.sub.2C(OH)(CH.sub.3).sub.2,
--CH.sub.2NHC(O)(C.sub.1-C.sub.4)alkyl, --CH.sub.2NHC(O)CH.sub.2Cl,
--CH.sub.2NHC(O)CH.sub.2CN,
--CH.sub.2NHC(O)CH.sub.2CH.sub.2N(CH.sub.3).sub.2,
--CH.sub.2NHC(O)C(.dbd.CH.sub.2)CH.sub.3,
--CH.sub.2NHC(O)(C.sub.2-C.sub.4)alkynyl,
--CH.sub.2NHC(O)CH.sub.2CH.sub.2-piperidinyl,
--(C.sub.1-C.sub.4)alkyl-morpholinyl,
--CH.sub.2NHC(O)CH.sub.2O-phenyl wherein the phenyl is optionally
substituted with halogen, (C.sub.1-C.sub.4)alkoxy,
--C(O)(C.sub.1-C.sub.4)alkyl, --C(O)(C.sub.1-C.sub.4)alkoxy,
--C(O)N(H).sub.2, --C(O)N(CH.sub.3).sub.2, --C(O)-morpholinyl,
--C(O)-pyrrolidinyl, --N(CH.sub.3).sub.2,
--NHC(O)(C.sub.1-C.sub.4)alkyl, --NHC(O)(C.sub.2-C.sub.4)alkenyl,
--NHC(O)CH.sub.2CN, --S(O).sub.2(C.sub.1-C.sub.4)alkyl,
--S(O).sub.2-pyrrolidinyl, morpholinyl, tetrahydropyranyl, or
4-methylpiperazinecarbonyl.
[0093] In a seventeenth embodiment the invention provides a
compound according to any of the first through third or thirteenth
through sixteenth embodiments wherein Z is CR.sup.1 and R.sup.1 of
Z is H, (C.sub.1-C.sub.4)alkyl, --NHC(O)CH.sub.2Cl,
--NHC(O)CH.sub.2CN, --NHC(O)(C.sub.2-C.sub.4)alkenyl,
--NHC(O)(C.sub.2-C.sub.4)alkynyl, --NHC(O)C(.dbd.CH.sub.2)CH.sub.3,
--NHC(O)CH.sub.2-phenyl wherein the phenyl is optionally
substituted with halogen, or pyrazolyl substituted with
CH.sub.3.
[0094] In a eighteenth embodiment the invention provides a compound
according to any of the first through third or thirteenth through
seventeenth embodiments wherein R.sup.302 is optionally substituted
with one or more substituents independently selected from halogen,
CF.sub.3, OCF.sub.3, .dbd.O, CHF.sub.2, CN, C(O)OH, OH,
(C.sub.1-C.sub.4)alkyl, (C.sub.1-C.sub.4)alkoxy,
(C.sub.3-C.sub.6)cycloalkyl, --(C.sub.1-C.sub.4)alkylCN,
--(C.sub.1-C.sub.4)alkylC(O)NH.sub.2, --C(O)NH.sub.2,
--C(O)N(H)(C.sub.1-C.sub.4)alkyl,
--C(O)N(C.sub.1-C.sub.4)alkyl).sub.2, --C(O)N(H)cyclopropyl,
--C(O)(C.sub.1-C.sub.4)alkoxy, NH.sub.2, N(H)CH.sub.3,
N(CH.sub.3).sub.2, or optionally substituted benzyl.
[0095] In a nineteenth embodiment the invention provides a compound
according to any of the first through third or thirteenth through
eighteenth embodiments wherein
[0096] X is NR.sup.2 wherein R.sup.2 is H;
[0097] Y is CR wherein R.sup.1 is H, CH.sub.3, substituted
pyrazolyl, 6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazinyl or
tetrahydrofuranyl;
[0098] Z is CR wherein R is H;
[0099] E is CR wherein R is H;
[0100] R.sup.3 is --R.sup.301-L-R.sup.302 wherein [0101] R.sup.301
is a bond, --O--, --N(H)--, --N(CH.sub.3)-- or --C(H)(CH.sub.3)--;
[0102] L is azetidinyl, 3,6-diazabicyclo[3.2.0]heptanyl,
morpholinyl, [1,4]oxepanyl, piperidinyl, or pyrrolidinyl; [0103]
wherein the azetidinyl is optionally substituted with CH.sub.3; and
[0104] wherein the piperidinyl is optionally substituted with
--CH.sub.2OH; and [0105] R.sup.302 is --C(O)CH.dbd.CH.sub.2 or
--C(O)C.ident.CH.
[0106] In a twentieth embodiment the invention provides a compound
according to any of the first through third or thirteenth through
nineteenth embodiments wherein the compound is: [0107]
4-((1-acryloylazetidin-3-yl)(methyl)amino)-1H-indole-7-carboxamide;
[0108] 4-(5-acetylthiophen-2-yl)-2-p-tolyl-1H-indole-7-carboxamide;
[0109]
4-(1-(4-methoxybenzyl)-1H-pyrazol-5-ylamino)-2-p-tolyl-1H-indole-7-
-carboxamide; [0110]
4-(3-(6-fluoro-4-oxoquinazolin-3(4H)-yl)-2-methylphenyl)-2-(pyridin-3-yl)-
-1H-indole-7-carboxamide; [0111]
4-(3-(6-fluoro-4-oxoquinazolin-3(4H)-yl)-2-methylphenyl)-2-(pyridin-3-yl)-
-1H-indole-7-carboxamide; [0112]
4-(2-methyl-3-(4-oxoquinazolin-3(4H)-yl)phenyl)-2-(pyridin-3-yl)-1H-indol-
e-7-carboxamide; [0113]
4-(2-methyl-3-(4,5,6,7-tetrahydrobenzo[b]thiophene-2-carboxamido)phenyl)--
2-(pyridin-3-yl)-1H-indole-7-carboxamide; [0114]
4-(2-methyl-3-(1-oxoisoindolin-2-yl)phenyl)-2-(pyridin-3-yl)-1H-indole-7--
carboxamide; [0115]
4-(2-methyl-3-(6-methyl-1-oxoisoindolin-2-yl)phenyl)-2-(pyridin-3-yl)-1H--
indole-7-carboxamide; [0116]
4-(3-(6-fluoro-1-oxoisoindolin-2-yl)-2-methylphenyl)-2-(pyridin-3-yl)-1H--
indole-7-carboxamide; [0117]
4-(3-(6-fluoro-1-oxoisoindolin-2-yl)-2-methylphenyl)-2-(4-fluorophenyl)-1-
H-indole-7-carboxamide; [0118]
2-(4-fluorophenyl)-4-(2-methyl-3-(4,5,6,7-tetrahydrobenzo[b]thiophene-2-c-
arboxamido)phenyl)-1H-indole-7-carboxamide; [0119]
N-(3-(7-carbamoyl-2-(pyridin-3-yl)-1H-indol-4-yl)-4-methylphenyl)thiazole-
-2-carboxamide 2,2,2-trifluoroacetate; [0120]
N-(3-(7-carbamoyl-2-(pyridin-3-yl)-1H-indol-4-yl)-2-methylphenyl)thiazole-
-2-carboxamide; [0121]
(R)-4-(3-(4-oxoquinazolin-3(4H)-yl)piperidin-1-yl)-1H-indole-7-carboxamid-
e*; [0122]
(R)-2-(4-fluorophenyl)-4-(3-(4-oxoquinazolin-3(4H)-yl)piperidin-
-1-yl)-1H-indole-7-carboxamide*; [0123]
(R)-4-(3-(4-oxoquinazolin-3(4H)-yl)piperidin-1-yl)-2-(pyridin-3-yl)-1H-in-
dole-7-carboxamide*; [0124]
(R)-2-(1-methyl-1H-pyrazol-4-yl)-4-(3-(4-oxoquinazolin-3(4H)-yl)piperidin-
-1-yl)-1H-indole-7-carboxamide*; [0125]
(R)-4-(3-(6-fluoro-4-oxoquinazolin-3(4H)-yl)piperidin-1-yl)-2-(4-fluoroph-
enyl)-1H-indole-7-carboxamide*; [0126]
2-(1-methyl-1H-pyrazol-4-yl)-4-(2-methyl-3-(4-oxoquinazolin-3(4H)-yl)phen-
yl)-1H-indole-7-carboxamide; [0127]
4-(2-methyl-3-(4-oxoquinazolin-3(4H)-yl)phenyl)-1H-indole-7-carboxamide;
[0128]
2-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)-4-(2-methyl-3-(4-oxoqu-
inazolin-3(4H)-yl)phenyl)-1H-indole-7-carboxamide; [0129]
(R)-4-(3-(4-tert-butylbenzamido)piperidin-1-yl)-2-(pyridin-3-yl)-1H-indol-
e-7-carboxamide*; [0130]
(R)-4-(3-(4-tert-butylbenzamido)piperidin-1-yl)-1H-indole-7-carboxamide*;
[0131]
(R)--N-(1-(7-carbamoyl-1H-indol-4-yl)piperidin-3-yl)-2-methyloxazo-
le-4-carboxamide*; [0132]
(R)-4-(3-(3-thiazol-2-ylureido)piperidin-1-yl)-1H-indole-7-carboxamide*;
[0133]
4-(3-(4-tert-butylbenzamido)-2-methylphenyl)-1H-indole-7-carboxami-
de; [0134]
4-(3-(7-cyclopropyl-5-fluoro-4-oxoquinazolin-3(4H)-yl)piperidin-
-1-yl)-1H-indole-7-carboxamide; [0135]
(R)-4-(3-(4-tert-butylbenzamido)piperidin-1-yl)-2-(1-methyl-1H-pyrazol-4--
yl)-1H-indole-7-carboxamide*; [0136]
(R)-4-(3-(4-methoxybenzamido)piperidin-1-yl)-2-(1-methyl-1H-pyrazol-4-yl)-
-1H-indole-7-carboxamide*; [0137]
(R)-5-tert-butyl-N-(1-(7-carbamoyl-1H-indol-4-yl)piperidin-3-yl)isoxazole-
-3-carboxamide*; [0138]
(R)-2-(1-methyl-1H-pyrazol-4-yl)-4-(3-(4-(trifluoromethyl)benzamido)piper-
idin-1-yl)-1H-indole-7-carboxamide*; [0139]
(R)-4-(3-(4-methoxybenzamido)piperidin-1-yl)-1H-indole-7-carboxamide*;
[0140]
(R)-4-(3-(4-(trifluoromethyl)benzamido)piperidin-1-yl)-1H-indole-7-
-carboxamide*; [0141]
(R)-4-(3-(4-(difluoromethyl)benzamido)piperidin-1-yl)-2-(1-methyl-1H-pyra-
zol-4-yl)-1H-indole-7-carboxamide*; [0142]
4-(3-(6-fluoro-4-oxoquinazolin-3(4H)-yl)-2-methylphenyl)-2-(1-methyl-1H-p-
yrazol-4-yl)-1H-indole-7-carboxamide; [0143]
2-(3,6-dihydro-2H-pyran-4-yl)-4-(2-methyl-3-(4-oxoquinazolin-3(4H)-yl)phe-
nyl)-1H-indole-7-carboxamide; [0144]
2-(4-fluorophenyl)-4-(2-methyl-3-(4-oxoquinazolin-3(4H)-yl)phenyl)-1H-ind-
ole-7-carboxamide; [0145]
(R)-4-(3-(4-(1-amino-2-methyl-1-oxopropan-2-yl)benzamido)piperidin-1-yl)--
2-(1-methyl-1H-pyrazol-4-yl)-1H-indole-7-carboxamide*; [0146]
(R)-2-(1-methyl-1H-pyrazol-4-yl)-4-(3-(4-(trifluoromethoxy)benzamido)pipe-
ridin-1-yl)-1H-indole-7-carboxamide*; [0147]
2-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)-4-(2-methyl-3-(4-oxoquinazolin-3(4-
H)-yl)phenyl)-1H-indole-7-carboxamide; [0148]
(R)-4-(3-(6-fluoro-1-oxoisoindolin-2-yl)piperidin-1-yl)-2-(1-methyl-1H-py-
razol-4-yl)-1H-indole-7-carboxamide*; [0149]
2-(3,6-dihydro-2H-pyran-4-yl)-4-(3-(6-fluoro-4-oxoquinazolin-3(4H)-yl)-2--
methylphenyl)-1H-indole-7-carboxamide; [0150]
2-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)-4-(3-(6-fluoro-4-oxoquinazoli-
n-3(4H)-yl)-2-methylphenyl)-1H-indole-7-carboxamide; [0151]
N-(3-(7-carbamoyl-2-(1-methyl-1H-pyrazol-4-yl)-1H-indol-4-yl)-2-methylphe-
nyl)thiazole-2-carboxamide; [0152]
4-(3-(6-fluoro-4-oxoquinazolin-3(4H)-yl)-2-(hydroxymethyl)phenyl)-2-(1-me-
thyl-1H-pyrazol-4-yl)-1H-indole-7-carboxamide; [0153]
2-(1-methyl-1H-pyrazol-4-yl)-4-(2-methyl-3-(4,5,6,7-tetrahydrobenzo[b]thi-
ophene-2-carboxamido)phenyl)-1H-indole-7-carboxamide; [0154]
(R)-4-(3-(4-cyclopropylbenzamido)piperidin-1-yl)-2-(1-methyl-1H-pyrazol-4-
-yl)-1H-indole-7-carboxamide*; [0155]
2-(2,5-dihydro-1H-pyrrol-3-yl)-4-(2-methyl-3-(4-oxoquinazolin-3(4H)-yl)ph-
enyl)-1H-indole-7-carboxamide; [0156]
4-(2-methyl-3-(4-oxoquinazolin-3(4H)-yl)phenyl)-2-(1,2,3,6-tetrahydropyri-
din-4-yl)-1H-indole-7-carboxamide; [0157]
2-(1-((R)-2,3-dihydroxypropyl)-1H-pyrazol-4-yl)-4-(2-methyl-3-(4-oxoquina-
zolin-3(4H)-yl)phenyl)-1H-indole-7-carboxamide*; [0158]
N-(3-(7-carbamoyl-2-(1-methyl-1H-pyrazol-4-yl)-1H-indol-4-yl)-2-(hydroxym-
ethyl)phenyl)thiazole-2-carboxamide; [0159]
2-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)-4-(3-(4-tert-butylbenzamido)--
2-methylphenyl)-1H-indole-7-carboxamide; [0160]
N-(3-(2-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)-7-carbamoyl-1H-indol-4--
yl)-2-methylphenyl)thiazole-2-carboxamide; [0161]
2-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)-4-(2-methyl-3-(4,5,6,7-tetrah-
ydrobenzo[b]thiophene-2-carboxamido)phenyl)-1H-indole-7-carboxamide;
[0162]
2-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)-4-(3-(4-cyclopropylben-
zamido)-2-methylphenyl)-1H-indole-7-carboxamide; [0163]
4-(2-methyl-3-(1-oxo-3,4-dihydroisoquinolin-2(1H)-yl)phenyl)-2-(1-(methyl-
sulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide;
[0164]
2-(1-methyl-2,5-dihydro-1H-pyrrol-3-yl)-4-(2-methyl-3-(4-oxoquinazolin-3(-
4H)-yl)phenyl)-1H-indole-7-carboxamide; [0165]
2-(1-acetyl-2,5-dihydro-1H-pyrrol-3-yl)-4-(2-methyl-3-(4-oxoquinazolin-3(-
4H)-yl)phenyl)-1H-indole-7-carboxamide; [0166] ethyl
3-(7-carbamoyl-4-(2-methyl-3-(4-oxoquinazolin-3(4H)-yl)phenyl)-1H-indol-2-
-yl)-2,5-dihydro-1H-pyrrole-1-carboxylate; [0167]
2-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-4-(2-methyl-3-(4-oxoquinazoli-
n-3(4H)-yl)phenyl)-1H-indole-7-carboxamide; [0168]
4-(2-methyl-3-(4-oxoquinazolin-3(4H)-yl)phenyl)-2-(1-(methylsulfonyl)-1,2-
,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide; [0169]
N-(3-(7-carbamoyl-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-1-
H-indol-4-yl)-2-methylphenyl)thiazole-2-carboxamide; [0170]
N-(3-(7-carbamoyl-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-1-
H-indol-4-yl)-2-methylphenyl)thiazole-2-carboxamide; [0171]
2-(1-((S)-2,3-dihydroxypropyl)-1H-pyrazol-4-yl)-4-(2-methyl-3-(4-oxoquina-
zolin-3(4H)-yl)phenyl)-1H-indole-7-carboxamide; [0172]
N-(3-(7-carbamoyl-2-(1-methyl-1H-pyrazol-4-yl)-1H-indol-4-yl)-2-methylphe-
nyl)-N-methylthiazole-2-carboxamide; [0173]
N-(3-(7-carbamoyl-2-(1-methyl-1H-pyrazol-4-yl)-1H-indol-4-yl)-2-methylphe-
nyl)-N-(oxetan-3-yl)thiazole-2-carboxamide; [0174]
2-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)-4-(3-(4-(2-cyanopropan-2-yl)b-
enzamido)-2-methylphenyl)-1H-indole-7-carboxamide; [0175]
4-(2-methyl-3-(4-oxoquinazolin-3(4H)-yl)phenyl)-2-(pyrimidin-5-yl)-1H-ind-
ole-7-carboxamide; [0176]
4-(3-(6-fluoro-4-oxoquinazolin-3(4H)-yl)-2-methylphenyl)-2-(pyrimidin-5-y-
l)-1H-indole-7-carboxamide; [0177]
4-(3-(4-(difluoromethyl)benzamido)-2-methylphenyl)-2-(pyrimidin-5-yl)-1H--
indole-7-carboxamide; [0178]
4-(3-(4-cyclopropylbenzamido)-2-methylphenyl)-2-(pyrimidin-5-yl)-1H-indol-
e-7-carboxamide; [0179]
4-(3-(6-fluoro-4-oxoquinazolin-3(4H)-yl)-2-methylphenyl)-2-(1-(2-hydroxy--
2-methylpropyl)-1H-pyrazol-4-yl)-1H-indole-7-carboxamide; [0180]
(R)-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-4-(3-(8-oxo-5,6-
-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)piperidin-1-yl)-1H-indole-7-carboxa-
mide*; [0181]
(R)-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-4-(3-(8-oxoimid-
azo[1,2-a]pyrazin-7(8H)-yl)piperidin-1-yl)-1H-indole-7-carboxamide*;
[0182]
4-(2-methyl-3-(oxetan-3-ylamino)phenyl)-2-(1-(methylsulfonyl)-1,2,-
3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide; [0183]
4-(2-methyl-3-(1-oxo-3,4-dihydroisoquinolin-2(1H)-yl)phenyl)-2-(1-(methyl-
sulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide;
[0184]
4-(3-(4-(difluoromethyl)benzamido)-2-methylphenyl)-2-(1-(methylsulfonyl)--
1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide; [0185]
4-(3-(4-hydroxy-4-(trifluoromethyl)cyclohexanecarboxamido)-2-methylphenyl-
)-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carbox-
amide; [0186]
(R)-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-4-(3-(1-oxo-3,4-
-dihydroisoquinolin-2(1H)-yl)piperidin-1-yl)-1H-indole-7-carboxamide*;
[0187]
2-(1-acetylpiperidin-4-yl)-4-(3-(4-cyclopropylbenzamido)-2-methylp-
henyl)-1H-indole-7-carboxamide; [0188]
(R)--N-(1-(7-carbamoyl-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4--
yl)-1H-indol-4-yl)piperidin-3-yl)-2-methyloxazole-4-carboxamide*;
[0189]
(R)-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-4-(2-oxo-1,3'-b-
ipiperidin-1'-yl)-1H-indole-7-carboxamide*; [0190]
2-(1-methyl-1H-pyrazol-4-yl)-4-(2-methyl-3-(4-oxoquinazolin-3(4H)-yl)phen-
yl)-1H-benzo[d]imidazole-7-carboxamide; [0191]
4-(3-(4-(difluoromethyl)-N-(oxetan-3-yl)benzamido)-2-methylphenyl)-2-(1-(-
methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide;
[0192]
4-(2-methyl-3-(oxetan-3-ylamino)phenyl)-1H-indole-7-carboxamide;
[0193]
4-(3-(4-(difluoromethyl)benzamido)-2-methylphenyl)-1H-indole-7-car-
boxamide; [0194]
4-(3-(2-hydroxyethylamino)-2-methylphenyl)-2-(1-(methylsulfonyl)-1,2,3,6--
tetrahydropyridin-4-yl)-1H-indole-7-carboxamide; [0195]
(R)--N-(1-(7-carbamoyl-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4--
yl)-1H-indol-4-yl)piperidin-3-yl)thiazole-2-carboxamide*; [0196]
4-(3-(cyclohexanecarboxamido)-2-methylphenyl)-2-(1-(methylsulfonyl)-1,2,3-
,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide; [0197]
4-(3-(4-(difluoromethyl)-N-(2-hydroxyethyl)benzamido)-2-methylphenyl)-2-(-
1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide-
; [0198]
N-(3-(7-carbamoyl-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-
-4-yl)-1H-indol-4-yl)-2-methylphenyl)isothiazole-4-carboxamide;
[0199]
4-(2-methyl-3-(tetrahydro-2H-pyran-4-carboxamido)phenyl)-2-(1-(methylsulf-
onyl)-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide;
[0200]
4-(2-methyl-3-(1-methylpiperidine-3-carboxamido)phenyl)-2-(1-(methylsulfo-
nyl)-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide;
[0201]
4-(2-methyl-3-(1-methylpiperidine-4-carboxamido)phenyl)-2-(1-(methylsulfo-
nyl)-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide;
[0202]
4-(3-(cyclopentanecarboxamido)-2-methylphenyl)-2-(1-(methylsulfonyl)-1,2,-
3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide; [0203]
N-(3-(7-carbamoyl-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-1-
H-indol-4-yl)-2-methylphenyl)-2-methylthiazole-4-carboxamide;
[0204]
4-(3-(3-methoxycyclohexanecarboxamido)-2-methylphenyl)-2-(1-(methylsulfon-
yl)-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide; [0205]
4-(2-methyl-3-(3-methylbutanamido)phenyl)-2-(1-(methylsulfonyl)-1,2,3,6-t-
etrahydropyridin-4-yl)-1H-indole-7-carboxamide; [0206]
4-(3-isobutyramido-2-methylphenyl)-2-(1-(methylsulfonyl)-1,2,3,6-tetrahyd-
ropyridin-4-yl)-1H-indole-7-carboxamide; [0207]
4-(2-methyl-3-(nicotinamido)phenyl)-2-(1-(methylsulfonyl)-1,2,3,6-tetrahy-
dropyridin-4-yl)-1H-indole-7-carboxamide; [0208]
4-(3-acrylamido-2-methylphenyl)-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydrop-
yridin-4-yl)-1H-indole-7-carboxamide; [0209]
N-(3-(7-carbamoyl-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-1-
H-indol-4-yl)-2-methylphenyl)-5-methylthiazole-2-carboxamide;
[0210]
N-(3-(7-carbamoyl-2-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-1H-indol-4-y-
l)-2-methylphenyl)thiazole-2-carboxamide; [0211]
N-((3R,4R)-1-(7-carbamoyl-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-
-4-yl)-1H-indol-4-yl)-4-hydroxypiperidin-3-yl)thiazole-2-carboxamide;
[0212]
(R)-4-(3-acrylamidopiperidin-1-yl)-2-(1-(methylsulfonyl)-1,2,3,6-t-
etrahydropyridin-4-yl)-1H-indole-7-carboxamide*; [0213]
4-(2-methyl-3-(thiazol-2-ylmethylamino)phenyl)-2-(1-(methylsulfonyl)-1,2,-
3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide; [0214]
4-(2-methyl-3-(N-(thiazol-2-ylmethyl)acrylamido)phenyl)-2-(1-(methylsulfo-
nyl)-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide;
[0215]
(Z)-4-(2-methyl-3-(2-methylbut-2-enamido)phenyl)-2-(1-(methylsulfonyl)-1,-
2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide; [0216]
(E)-4-(3-(4-(dimethylamino)but-2-enamido)-2-methylphenyl)-2-(1-(methylsul-
fonyl)-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide;
[0217]
4-(2-methyl-3-(3-(piperidin-1-yl)propanamido)phenyl)-2-(1-(methylsulfonyl-
)-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide; [0218]
4-(3-(2-cyanoacetamido)-2-methylphenyl)-2-(1-(methylsulfonyl)-1,2,3,6-tet-
rahydropyridin-4-yl)-1H-indole-7-carboxamide; [0219]
4-(2-methyl-3-propionamidophenyl)-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydr-
opyridin-4-yl)-1H-indole-7-carboxamide; [0220]
4-(3-methacrylamido-2-methylphenyl)-2-(1-(methylsulfonyl)-1,2,3,6-tetrahy-
dropyridin-4-yl)-1H-indole-7-carboxamidel; [0221]
4-(3-(2-chloro-2,2-difluoroacetamido)-2-methylphenyl)-2-(1-(methylsulfony-
l)-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide; [0222]
4-(3-(2-chloropropanamido)-2-methylphenyl)-2-(1-(methylsulfonyl)-1,2,3,6--
tetrahydropyridin-4-yl)-1H-indole-7-carboxamide; [0223]
(E)-4-(3-but-2-enamido-2-methylphenyl)-2-(1-(methylsulfonyl)-1,2,3,6-tetr-
ahydropyridin-4-yl)-1H-indole-7-carboxamide; [0224]
N1-(3-(7-carbamoyl-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)--
1H-indol-4-yl)-2-methylphenyl); [0225]
4-(3-(2-(4-fluorophenoxy)acetamido)-2-methylphenyl)-2-(1-(methylsulfonyl)-
-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide; [0226]
4-(2-methyl-3-(3-(pyrrolidin-1-yl)propanamido)phenyl)-2-(1-(methylsulfony-
l)-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide; [0227]
4-(3-(2-(4-cyanophenoxy)acetamido)-2-methylphenyl)-2-(1-(methylsulfonyl)--
1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide; [0228]
4-(2-methyl-3-(2-(pyridin-3-yloxy)acetamido)phenyl)-2-(1-(methylsulfonyl)-
-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide; [0229]
4-(3-(cyclopent-1-enecarboxamido)-2-methylphenyl)-2-(1-(methylsulfonyl)-1-
,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide; [0230]
(E)-4-(2-methyl-3-(2-methylpent-2-enamido)phenyl)-2-(1-(methylsulfonyl)-1-
,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide;
[0231]
(Z)-4-(3-(3-chloroacrylamido)-2-methylphenyl)-2-(1-(methylsulfonyl-
)-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide; [0232]
(E)-methyl
4-(3-(7-carbamoyl-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-1-
H-indol-4-yl)-2-methylphenylamino)-4-oxobut-2-enoate; [0233]
4-(3-(cyclohex-1-enecarboxamido)-2-methylphenyl)-2-(1-(methylsulfonyl)-1,-
2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide; [0234]
(E)-ethyl
4-(3-(7-carbamoyl-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-1-
H-indol-4-yl)-2-methylphenylamino)-4-oxobut-2-enoate; [0235]
4-(2-methyl-3-(2-phenoxyacetamido)phenyl)-2-(1-(methylsulfonyl)-1,2,3,6-t-
etrahydropyridin-4-yl)-1H-indole-7-carboxamide; [0236]
4-(3-(2-fluoroacetamido)-2-methylphenyl)-2-(1-(methylsulfonyl)-1,2,3,6-te-
trahydropyridin-4-yl)-1H-indole-7-carboxamide; [0237]
4-(3-acrylamido-2-methylphenyl)-2-(4,4-difluorocyclohex-1-enyl)-1H-indole-
-7-carboxamide; [0238]
4-(2-(acrylamidomethyl)phenyl)-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropy-
ridin-4-yl)-1H-indole-7-carboxamide; [0239]
4-(3-(3-(dimethylamino)propanamido)-2-methylphenyl)-2-(1-(methylsulfonyl)-
-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide; [0240]
4-(2-acrylamidophenyl)-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4--
yl)-1H-indole-7-carboxamide; [0241]
4-(3-(acrylamidomethyl)phenyl)-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropy-
ridin-4-yl)-1H-indole-7-carboxamide; [0242]
4-(3-(acrylamidomethyl)phenyl)-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropy-
ridin-4-yl)-1H-indole-7-carboxamide; [0243]
4-(3-(2-cyanopyrimidin-4-ylamino)phenyl)-2-(1-(methylsulfonyl)-1,2,3,6-te-
trahydropyridin-4-yl)-1H-indole-7-carboxamide; [0244]
4-(3-(6-cyclopropyl-8-fluoro-1-oxoisoquinolin-2(1H)-yl)-2-(hydroxymethyl)-
phenyl)-2-(1-methyl-1H-pyrazol-4-yl)-1H-indole-7-carboxamide;
[0245] 4-(3-acrylamidophenyl)-1H-indole-7-carboxamide; [0246]
4-(3-acrylamido-2-methylphenyl)-1H-indole-7-carboxamide; [0247]
4-(3-acrylamido-2-methylphenyl)-2-(2-methoxypyridin-3-yl)-1H-indole-7-car-
boxamide; [0248]
4-(2-methyl-3-(2-(pyridin-2-yloxy)acetamido)phenyl)-2-(1-(methylsulfonyl)-
-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide; [0249]
N1-(3-(7-carbamoyl-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)--
1H-indol-4-yl)-2-methylphenyl)fumaramide; [0250]
4-(3-(2-chlorobutanamido)-2-methylphenyl)-2-(1-(methylsulfonyl)-1,2,3,6-t-
etrahydropyridin-4-yl)-1H-indole-7-carboxamide; [0251]
4-(2-methyl-3-(3-(4-methylpiperazin-1-yl)propanamido)phenyl)-2-(1-(methyl-
sulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide;
[0252]
4-(2-methyl-3-(2-(pyridazin-3-yloxy)acetamido)phenyl)-2-(1-(methylsulfony-
l)-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide; [0253]
2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-4-(3-(thiazol-2-ylm-
ethoxy)phenyl)-1H-indole-7-carboxamide; [0254] methyl
3-(4-(3-acrylamido-2-methylphenyl)-7-carbamoyl-1H-indol-2-yl)benzoate;
[0255]
4-(3-acrylamido-2-methylphenyl)-2-(3-methoxyphenyl)-1H-indole-7-ca-
rboxamide; [0256]
4-(3-acrylamido-2-methylphenyl)-2-(4-methoxyphenyl)-1H-indole-7-carboxami-
de; [0257]
4-(3-acrylamido-2-methylphenyl)-2-(6-methylpyridin-3-yl)-1H-ind-
ole-7-carboxamide; [0258]
4-(3-acrylamido-2-methylphenyl)-2-(3-carbamoylphenyl)-1H-indole-7-carboxa-
mide; [0259]
N-(3-(7-carbamoyl-3-methyl-1H-indol-4-yl)-2-methylphenyl)thiazole-2-carbo-
xamide; [0260]
4-(3-acrylamido-2-methylphenyl)-2-(3,5-dimethylisoxazol-4-yl)-1H-indole-7-
-carboxamide; [0261]
4-(3-acrylamido-2-methylphenyl)-2-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazo-
l-5-yl)-1H-indole-7-carboxamide; [0262]
4-(3-acrylamido-2-methylphenyl)-2-(3,5-dimethyl-1H-pyrazol-4-yl)-1H-indol-
e-7-carboxamide; [0263]
4-(3-acrylamido-2-methylphenyl)-2-(1-isopropyl-1H-pyrazol-4-yl)-1H-indole-
-7-carboxamide; [0264]
4-(3-acrylamido-2-methylphenyl)-2-(1,3-dimethyl-1H-pyrazol-4-yl)-1H-indol-
e-7-carboxamide; [0265]
4-(3-acrylamido-2-methylphenyl)-2-(1-ethyl-1H-pyrazol-4-yl)-1H-indole-7-c-
arboxamide; [0266]
4-(3-acrylamido-2-methylphenyl)-2-(1-isobutyl-1H-pyrazol-4-yl)-1H-indole--
7-carboxamide; [0267]
(E)-N-(3-(3-but-2-enamido-7-carbamoyl-1H-indol-4-yl)-2-methylphenyl)thiaz-
ole-2-carboxamide; [0268]
N-(3-(7-carbamoyl-3-methacrylamido-1H-indol-4-yl)-2-methylphenyl)thiazole-
-2-carboxamide; [0269]
N-(3-(3-but-2-ynamido-7-carbamoyl-1H-indol-4-yl)-2-methylphenyl)thiazole--
2-carboxamide; [0270]
N-(3-(7-carbamoyl-3-(2-(4-fluorophenoxy)acetamido)-1H-indol-4-yl)-2-methy-
lphenyl)thiazole-2-carboxamide; [0271]
4-(3-acrylamido-2-methylphenyl)-2-(2-fluoropyridin-3-yl)-1H-indole-7-carb-
oxamide; [0272]
4-(3-acrylamido-2-methylphenyl)-2-(1-ethyl-1H-pyrazol-4-yl)-1H-indole-7-c-
arboxamide; [0273]
2-(3-acetamidophenyl)-4-(3-acrylamido-2-methylphenyl)-1H-indole-7-carboxa-
mide; [0274]
4-(3-acrylamido-2-methylphenyl)-2-(2-methoxypyridin-4-yl)-1H-indole-7-car-
boxamide; [0275]
4-(3-acrylamido-2-methylphenyl)-2-(3-cyanophenyl)-1H-indole-7-carboxamide-
; [0276] methyl
4-(4-(3-acrylamido-2-methylphenyl)-7-carbamoyl-1H-indol-2-yl)benzoate;
[0277]
4-(3-acrylamido-2-methylphenyl)-2-(2,3-dihydrobenzofuran-5-yl)-1H--
indole-7-carboxamide; [0278]
4-(3-acrylamido-2-methylphenyl)-2-(3-fluorophenyl)-1H-indole-7-carboxamid-
e; [0279]
4-(3-acrylamido-2-methylphenyl)-2-(3-(dimethylamino)phenyl)-1H-i-
ndole-7-carboxamide; [0280]
4-(2-(2-chloroacetamido)phenyl)-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydrop-
yridin-4-yl)-1H-indole-7-carboxamide; [0281]
4-(2-acetamidophenyl)-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-y-
l)-1H-indole-7-carboxamide; [0282]
4-(3-acrylamido-2-methylphenyl)-2-(2-methyl-5-(pyrrolidin-1-ylsulfonyl)ph-
enyl)-1H-indole-7-carboxamide; [0283]
4-(3-acrylamido-2-methylphenyl)-2-(2-fluorophenyl)-1H-indole-7-carboxamid-
e; [0284]
N-(3-(3-acrylamido-7-carbamoyl-1H-indol-4-yl)-2-methylphenyl)thi-
azole-2-carboxamide; [0285]
N-(3-(7-carbamoyl-3-(2-chloroacetamido)-1H-indol-4-yl)-2-methylphenyl)thi-
azole-2-carboxamide; [0286]
4-(3-acrylamido-2-methylphenyl)-2-(1-methyl-1H-pyrazol-5-yl)-1H-indole-7--
carboxamide; [0287]
4-(3-acrylamido-2-methylphenyl)-2-(pyridin-4-yl)-1H-indole-7-carboxamide;
[0288]
4-(3-acrylamido-2-methylphenyl)-2-(1-(2-morpholinoethyl)-1H-pyrazo-
l-4-yl)-1H-indole-7-carboxamide; [0289]
4-(3-acrylamido-2-methylphenyl)-2-(6-morpholinopyridin-3-yl)-1H-indole-7--
carboxamide; [0290]
4-(3-acrylamido-2-methylphenyl)-2-(3-(4-methylpiperazine-1-carbonyl)pheny-
l)-1H-indole-7-carboxamide; [0291]
N-(3-(2-(2-(acrylamidomethyl)phenyl)-7-carbamoyl-1H-indol-4-yl)-2-methylp-
henyl)thiazole-2-carboxamide; [0292]
N-(3-(2-(2-(acetamidomethyl)phenyl)-7-carbamoyl-1H-indol-4-yl)-2-methylph-
enyl)thiazole-2-carboxamide; [0293]
N-(3-(7-carbamoyl-2-(2-(propionamidomethyl)phenyl)-1H-indol-4-yl)-2-methy-
lphenyl)thiazole-2-carboxamide; [0294]
N-(3-(2-(2-(butyramidomethyl)phenyl)-7-carbamoyl-1H-indol-4-yl)-2-methylp-
henyl)thiazole-2-carboxamide; [0295]
(E)-N-(3-(2-(2-(but-2-enamidomethyl)phenyl)-7-carbamoyl-1H-indol-4-yl)-2--
methylphenyl)thiazole-2-carboxamide; [0296]
N-(3-(7-carbamoyl-2-(2-(methacrylamidomethyl)phenyl)-1H-indol-4-yl)-2-met-
hylphenyl)thiazole-2-carboxamide; [0297]
N-(3-(7-carbamoyl-2-(2-(propiolamidomethyl)phenyl)-1H-indol-4-yl)-2-methy-
lphenyl)thiazole-2-carboxamide; [0298]
N-(3-(2-(2-(but-2-ynamidomethyl)phenyl)-7-carbamoyl-1H-indol-4-yl)-2-meth-
ylphenyl)thiazole-2-carboxamide; [0299]
N-(3-(7-carbamoyl-2-(2-((2-cyanoacetamido)methyl)phenyl)-1H-indol-4-yl)-2-
-methylphenyl)thiazole-2-carboxamide; [0300]
N-(3-(7-carbamoyl-2-(2-((3-(dimethylamino)propanamido)methyl)phenyl)-1H-i-
ndol-4-yl)-2-methylphenyl)thiazole-2-carboxamide; [0301]
N-(3-(7-carbamoyl-2-(2-((3-(piperidin-1-yl)propanamido)methyl)phenyl)-1H--
indol-4-yl)-2-methylphenyl)thiazole-2-carboxamide; [0302]
N-(3-(7-carbamoyl-2-(2-((2-phenoxyacetamido)methyl)phenyl)-1H-indol-4-yl)-
-2-methylphenyl)thiazole-2-carboxamide; [0303]
N-(3-(7-carbamoyl-2-(2-((2-(4-fluorophenoxy)acetamido)methyl)phenyl)-1H-i-
ndol-4-yl)-2-methylphenyl)thiazole-2-carboxamide; [0304]
N-(3-(7-carbamoyl-2-(2-((2-chloroacetamido)methyl)phenyl)-1H-indol-4-yl)--
2-methylphenyl)thiazole-2-carboxamide; [0305]
N-(3-(2-(2-(aminomethyl)phenyl)-7-carbamoyl-1H-indol-4-yl)-2-methylphenyl-
)thiazole-2-carboxamide; [0306]
4-(3-acrylamido-2-methylphenyl)-2-(4-fluorophenyl)-1H-indole-7-carboxamid-
e; [0307]
4-(3-acrylamido-2-methylphenyl)-2-phenyl-1H-indole-7-carboxamide- ;
[0308]
4-(3-acrylamido-2-methylphenyl)-2-(2-(methylsulfonyl)phenyl)-1H-i-
ndole-7-carboxamide; [0309]
4-(3-acrylamido-2-methylphenyl)-2-(4-(dimethylcarbamoyl)phenyl)-1H-indole-
-7-carboxamide; [0310]
4-(3-acrylamido-2-methylphenyl)-2-(pyrimidin-5-yl)-1H-indole-7-carboxamid-
e; [0311]
4-(3-acrylamido-2-methylphenyl)-2-(pyridin-3-yl)-1H-indole-7-car-
boxamide; [0312]
4-(3-acrylamido-2-methylphenyl)-2-(4-(morpholine-4-carbonyl)phenyl)-1H-in-
dole-7-carboxamide; [0313]
4-(3-acrylamido-2-methylphenyl)-2-(4-(pyrrolidine-1-carbonyl)phenyl)-1H-i-
ndole-7-carboxamide; [0314]
4-(3-acrylamido-2-methylphenyl)-2-(4-(4-methylpiperazine-1-carbonyl)pheny-
l)-1H-indole-7-carboxamide; [0315]
4-(3-acrylamido-2-methylphenyl)-2-(4-(methylsulfonyl)phenyl)-1H-indole-7--
carboxamide; [0316]
4-(3-acrylamido-2-methylphenyl)-2-(6-methoxypyridin-3-yl)-1H-indole-7-car-
boxamide; [0317]
4-(3-acrylamido-2-methylphenyl)-2-(4-cyanophenyl)-1H-indole-7-carboxamide-
; [0318]
4-(3-acrylamido-2-methylphenyl)-2-(2-methoxyphenyl)-1H-indole-7-c-
arboxamide; [0319]
N-(3-(7-carbamoyl-3-(2-cyanoacetamido)-1H-indol-4-yl)-2-methylphenyl)thia-
zole-2-carboxamide; [0320]
4-(2-acrylamidophenyl)-1H-indole-7-carboxamide; [0321]
4-(3-acrylamido-2-methylphenyl)-2-(4-(morpholinomethyl)phenyl)-1H--
indole-7-carboxamide; [0322]
4-(3-acrylamido-2-methylphenyl)-2-(4-carbamoylphenyl)-1H-indole-7-carboxa-
mide; [0323]
4-(3-acrylamido-5-(thiazol-2-ylmethylamino)phenyl)-2-(1-(methylsulfonyl)--
1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide; [0324]
4-(2-methyl-3-(N-methylacrylamido)phenyl)-1H-indole-7-carboxamide;
[0325] 4-(3-(methylamino)phenyl)-1H-indole-7-carboxamide; [0326]
4-(3-(N-methylacrylamido)phenyl)-1H-indole-7-carboxamide; [0327]
4-(2-methyl-3-(2-methylenebutanamido)phenyl)-1H-indole-7-carboxamide;
[0328]
4-(2-methyl-3-(3-(pyrrolidin-1-yl)propanamido)phenyl)-1H-indole-7--
carboxamide; [0329]
4-(3-methacrylamido-2-methylphenyl)-1H-indole-7-carboxamide; [0330]
(E)-4-(3-(3-cyclopropylacrylamido)-2-methylphenyl)-1H-indole-7-carboxamid-
e; [0331]
(E)-4-(2-methyl-3-(3-(pyridin-2-yl)acrylamido)phenyl)-1H-indole--
7-carboxamide; [0332]
(E)-4-(2-methyl-3-(3-(1-methyl-1H-pyrazol-4-yl)acrylamido)phenyl)-1H-indo-
le-7-carboxamide; [0333] (E)-ethyl
4-(3-(7-carbamoyl-1H-indol-4-yl)-2-methylphenylamino)-4-oxobut-2-enoate;
[0334]
(E)-4-(3-(4-(dimethylamino)but-2-enamido)-2-methylphenyl)-1H-indol-
e-7-carboxamide; [0335]
(E)-4-(2-methyl-3-(3-(pyridin-3-yl)acrylamido)phenyl)-1H-indole-7-carboxa-
mide; [0336]
(E)-4-(2-methyl-3-(4-methylpent-2-enamido)phenyl)-1H-indole-7-carboxamide-
; [0337]
N1-(3-(7-carbamoyl-1H-indol-4-yl)-2-methylphenyl)-N4-ethylmaleami-
de; [0338] 4-(3-acetamido-2-methylphenyl)-1H-indole-7-carboxamide;
[0339]
(E)-4-(3-but-2-enamido-2-methylphenyl)-1H-indole-7-carboxamide;
[0340]
4-(2-methyl-3-(3-morpholinopropanamido)phenyl)-1H-indole-7-carboxamide;
[0341]
(E)-4-(2-methyl-3-(3-(thiazol-2-yl)acrylamido)phenyl)-1H-indole-7--
carboxamide; [0342]
4-(2-methyl-3-(2-phenylacrylamido)phenyl)-1H-indole-7-carboxamide;
[0343]
(E)-4-(2-methyl-3-(4-(piperidin-1-yl)but-2-enamido)phenyl)-1H-indole-7-ca-
rboxamide; [0344]
(E)-4-(2-methyl-3-(4-((tetrahydrofuran-2-yl)methylamino)but-2-enamido)phe-
nyl)-1H-indole-7-carboxamide; [0345]
(E)-4-(3-(4-(2-methoxyethylamino)but-2-enamido)-2-methylphenyl)-1H-indole-
-7-carboxamide; [0346]
(E)-4-(3-(4-(cyclopropylamino)but-2-enamido)-2-methylphenyl)-1H-indole-7--
carboxamide; [0347]
(E)-4-(2-methyl-3-(4-morpholinobut-2-enamido)phenyl)-1H-indole-7-carboxam-
ide; [0348]
(E)-4-(2-methyl-3-(4-(4-methylpiperazin-1-yl)but-2-enamido)phenyl)-1H-ind-
ole-7-carboxamide; [0349]
4-(3-acrylamido-4-(benzyloxy)phenyl)-1H-indole-7-carboxamide;
[0350]
4-(3-acrylamido-5-(benzyloxy)phenyl)-1H-indole-7-carboxamide;
[0351]
4-(3-acrylamido-4-(thiazol-2-ylmethoxy)phenyl)-1H-indole-7-carboxamide;
[0352]
4-(3-acrylamido-5-(thiazol-2-ylmethoxy)phenyl)-1H-indole-7-carboxa-
mide; [0353]
4-(2-acrylamido-4-(thiazol-2-ylmethoxy)phenyl)-1H-indole-7-carboxamide;
[0354]
4-(3-acrylamido-2-methylphenyl)-1H-pyrrolo[2,3-c]pyridine-7-carbox-
amide; [0355]
4-(2-acrylamido-4-(benzyloxy)phenyl)-1H-indole-7-carboxamide;
[0356] 4-(5-acrylamidopyridin-3-yl)-1H-indole-7-carboxamide; [0357]
4-(2-acrylamidopyridin-4-yl)-1H-indole-7-carboxamide; [0358]
N1-(3-(7-carbamoyl-1H-indol-4-yl)phenyl)-N4-(2-methoxyethyl)maleamide;
[0359] N1-(3-(7-carbamoyl-1H-indol-4-yl)phenyl)-N4-ethylmaleamide;
[0360]
4-(3-(1-methyl-1,2,5,6-tetrahydropyridine-3-carboxamido)phenyl)-1H-indole-
-7-carboxamide; [0361]
4-(3-(vinylsulfonamido)phenyl)-1H-indole-7-carboxamide; [0362]
4-(3-(2-oxopropanamido)phenyl)-1H-indole-7-carboxamide; [0363]
(E)-methyl
4-(3-(7-carbamoyl-1H-indol-4-yl)phenylamino)-4-oxobut-2-enoate;
[0364] 4-(3-(cyanomethylcarbamoyl)phenyl)-1H-indole-7-carboxamide;
[0365]
N-(3-(7-carbamoyl-1H-indol-4-yl)phenyl)-5-methylisoxazole-4-carboxamide;
[0366]
N1-(3-(7-carbamoyl-1H-indol-4-yl)phenyl)-N4-methylfumaramide;
[0367]
N1-(3-(7-carbamoyl-1H-indol-4-yl)phenyl)-N4,N4-dimethylfumaramide;
[0368] N1-(3-(7-carbamoyl-1H-indol-4-yl)phenyl)-N4-ethylfumaramide;
[0369]
N1-(3-(7-carbamoyl-1H-indol-4-yl)phenyl)-N4-cyclopropylfumaramide;
[0370]
(E)-4-(3-(7-carbamoyl-1H-indol-4-yl)phenylamino)-4-oxobut-2-enoic
acid; [0371]
4-(3-(N-isobutylacrylamido)phenyl)-1H-indole-7-carboxamide; [0372]
1-Acryloyl-1,2,3,6-tetrahydro-pyrrolo[2,3-e]indole-5-carboxylic
acid amide; [0373] 4-acrylamido-1H-indole-7-carboxamide; [0374]
4-(3-(N-(cyanomethyl)sulfamoyl)phenyl)-1H-indole-7-carboxamide;
[0375]
4-(3-acrylamidophenyl)-1H-pyrrolo[3,2-c]pyridine-7-carboxamide;
[0376]
4-(3-acrylamido-2-methylphenyl)-1H-pyrrolo[3,2-c]pyridine-7-carboxamide;
[0377]
4-(3-((2-oxopropanamido)methyl)phenyl)-1H-indole-7-carboxamide;
[0378] 4-(3-acrylamidophenyl)-1H-indazole-7-carboxamide; [0379]
4-(3-acrylamido-2-methoxyphenyl)-1H-indole-7-carboxamide; [0380]
4-(3-acrylamido-2-fluorophenyl)-1H-indole-7-carboxamide; [0381]
4-(5-acrylamido-2-fluorophenyl)-1H-indole-7-carboxamide; [0382]
4-(3-acrylamido-4-fluorophenyl)-1H-indole-7-carboxamide; [0383]
4-(5-acrylamido-2-chlorophenyl)-1H-indole-7-carboxamide; [0384]
4-(5-acrylamido-2,4-difluorophenyl)-1H-indole-7-carboxamide; [0385]
4-(3-acrylamido-4-cyanophenyl)-1H-indole-7-carboxamide; [0386]
4-(3-acrylamido-2,6-difluorophenyl)-1H-indole-7-carboxamide;
[0387]
4-(3-acrylamido-5-methylphenyl)-1H-indole-7-carboxamide; [0388]
4-(3-acrylamido-4-methylphenyl)-1H-indole-7-carboxamide; [0389]
4-(3-acrylamido-4-methoxyphenyl)-1H-indole-7-carboxamide; [0390]
4-(3-acrylamido-5-methoxyphenyl)-1H-indole-7-carboxamide; [0391]
4-(3-acrylamido-4-chlorophenyl)-1H-indole-7-carboxamide; [0392]
4-(5-acrylamido-2,3-difluorophenyl)-1H-indole-7-carboxamide; [0393]
4-(3-acrylamido-5-cyanophenyl)-1H-indole-7-carboxamide; [0394]
4-(3-acrylamido-2-cyanophenyl)-1H-indole-7-carboxamide; [0395]
4-(3-acrylamidophenyl)-2-vinyl-1H-indole-7-carboxamide; [0396]
4-(3-acrylamidophenyl)-2-ethyl-1H-indole-7-carboxamide;
[0397]
4-(3-(2-(morpholinomethyl)acrylamido)phenyl)-1H-indole-7-carboxami-
de; [0398]
4-(3-(2-((dimethylamino)methyl)acrylamido)phenyl)-1H-indole-7-c-
arboxamide; [0399]
(E)-4-(3-(4-(dimethylamino)but-2-enamido)-2-methylphenyl)-1H-pyrrolo[2,3--
c]pyridine-7-carboxamide; [0400]
4-((1R,3S)-3-acrylamidocyclohexyl)-1H-indole-7-carboxamide; [0401]
4-(cis-3-acrylamidocyclohexyl)-1H-indole-7-carboxamide; [0402]
4-((1S,3S)-3-acrylamidocyclohexyl)-1H-indole-7-carboxamide; [0403]
4-(trans-3-acrylamidocyclohexyl)-1H-indole-7-carboxamide; [0404]
4-(cis-3-acrylamidocyclohexyl)-1H-indole-7-carboxamide; [0405]
4-(3-(2-(aminomethyl)acrylamido)phenyl)-1H-indole-7-carboxamide;
[0406] 4-((1R,3S)-3-acrylamidocyclopentyl)-1H-indole-7-carboxamide;
[0407]
4-(3-(2-((methylamino)methyl)acrylamido)phenyl)-1H-indole-7-carboxamide;
[0408] 4-(3-acrylamidophenyl)-2-methyl-1H-indole-7-carboxamide;
[0409] 4-((1S,3S)-3-acrylamidocyclopentyl)-1H-indole-7-carboxamide;
[0410]
4-(3-acrylamidophenyl)-2-(2-ethoxyethyl)-1H-indole-7-carboxamide;
[0411]
4-(3-acrylamidophenyl)-2-(2-hydroxyethyl)-1H-indole-7-carboxamide;
[0412] 4-(1-acryloylpiperidin
3-yl)-2-(1-methyl-1H-pyrazol-4-yl)-1H-indole-7-carboxamide; [0413]
4-(3-acrylamido-2-methylphenyl)-2-(1-isopropyl-1H-pyrazol-4-yl)-1H-indole-
-7-carboxamide; [0414]
4-(3-(4-cyclopropylbenzamido)-2-methylphenyl)-2-(1-(methylsulfonyl)-1,2,3-
,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide; [0415]
4-(2-methyl-3-(1-methylpiperidine-4-carboxamido)phenyl)-2-(1-(methylsulfo-
nyl)-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide;
[0416]
4-(3-(N-(cyclopentylmethyl)acrylamido)phenyl)-1H-indole-7-carboxamide;
[0417] ethyl
4-(7-carbamoyl-4-(2-methyl-3-(4-oxoquinazolin-3(4H)-yl)phenyl)-1H-indol-2-
-yl)5,6-dihydropyridine-1(2H)-carboxylate; [0418]
(R)-4-(3-(4-oxoquinazolin-3(4H)-yl)piperidin-1-yl)-1H-indole-7-carbonitri-
le; [0419]
4-(2,6-dichlorobenzyl)-2-(p-tolyl)-1H-indole-7-carboxamide; [0420]
(E)-4-(3-(2-cyano-3-hydroxybut-2-enamido)phenyl)-1H-indole-7-carbo-
xamide; [0421]
4-(cis-3-acrylamidocyclopentyl)-1H-indole-7-carboxamide; [0422]
4-(trans-3-acrylamidocyclopentyl)-1H-indole-7-carboxamide; [0423]
4-(trans-3-acrylamidocyclopentyl)-1H-indole-7-carboxamide; [0424]
4-((1-acryloylazetidin-3-yl)oxy)-1H-indole-7-carboxamide; [0425]
(S)-4-(1-(1-acryloylazetidin-3-yl)ethyl)-1H-indole-7-carboxamide;
[0426]
(R)-4-(1-(1-acryloylazetidin-3-yl)ethyl)-1H-indole-7-carboxamide*;
[0427]
4-((1-acryloylazetidin-3-yl)(methyl)amino)-1H-pyrrolo[2,3-c]pyridine-7-ca-
rboxamide; [0428]
(R)-4-(1-acryloylpiperidin-3-yl)-1H-indole-7-carboxamide*; [0429]
(S)-4-(1-acryloylpiperidin-3-yl)-1H-indole-7-carboxamide*; [0430]
(S)-4-(1-acryloylpiperidin-3-yl)-2-methyl-1H-indole-7-carboxamide;
[0431]
(R)-4-(1-acryloylpiperidin-3-yl)-2-methyl-1H-indole-7-carboxamide;
[0432]
(R)-4-(4-acryloylmorpholin-2-yl)-2-(1-methyl-1H-pyrazol-4-yl)-1H-indole-7-
-carboxamide; [0433]
(S)-4-(4-acryloylmorpholin-2-yl)-2-(1-methyl-1H-pyrazol-4-yl)-1H-indole-7-
-carboxamide; [0434]
(R)-4-(1-acryloylpyrrolidin-3-yl)-2-(6,7-dihydro-4H-pyrazolo[5,1-c][1,4]o-
xazin-2-yl)-1H-indole-7-carboxamide; [0435]
2-methyl-4-(methyl(1-propioloylazetidin-3-yl)amino)-1H-indole-7-carboxami-
de; [0436]
(S)-4-(1-acryloylpyrrolidin-3-yl)-2-(6,7-dihydro-4H-pyrazolo[5,-
1-c][1,4]oxazin-2-yl)-1H-indole-7-carboxamide; [0437]
(R)-4-(4-acryloyl-1,4-oxazepan-6-yl)-1H-pyrrolo[3,2-c]pyridine-7-carboxam-
ide; [0438]
(S)-4-(4-acryloyl-1,4-oxazepan-6-yl)-1H-pyrrolo[3,2-c]pyridine-7-carboxam-
ide; [0439]
(R)-4-(1-acryloylpiperidin-3-yl)-1H-pyrrolo[3,2-c]pyridine-7-carboxamide;
[0440]
(S)-4-(1-acryloylpiperidin-3-yl)-1H-pyrrolo[3,2-c]pyridine-7-carbo-
xamide; [0441]
(R)-7-(1-acryloylpiperidin-3-yl)-2-(1-methyl-1H-pyrazol-4-yl)thiazolo[5,4-
-c]pyridine-4-carboxamide; [0442]
(S)-7-(1-acryloylpiperidin-3-yl)-2-(1-methyl-1H-pyrazol-4-yl)thiazolo[5,4-
-c]pyridine-4-carboxamide; [0443]
(S)-4-(4-acryloyl-1,4-oxazepan-6-yl)-1H-indole-7-carboxamide;
[0444]
4-((3S,5R)-1-acryloyl-5-(hydroxymethyl)piperidin-3-yl)-1H-indole-7-carbox-
amide; [0445]
4-((3S,5S)-1-acryloyl-5-(hydroxymethyl)piperidin-3-yl)-1H-indole-7-carbox-
amide; [0446]
4-((3R,5S)-1-acryloyl-5-(hydroxymethyl)piperidin-3-yl)-1H-indole-7-carbox-
amide; [0447]
4-((3R,5R)-1-acryloyl-5-(hydroxymethyl)piperidin-3-yl)-1H-indole-7-carbox-
amide; [0448]
(R)-4-(1-acryloylpyrrolidin-3-yl)-2-(1-methyl-1H-pyrazol-4-yl)-1H-indole--
7-carboxamide; [0449]
(S)-4-(1-acryloylpyrrolidin-3-yl)-2-(1-methyl-1H-pyrazol-4-yl)-1H-indole--
7-carboxamide; [0450]
4-((1R,3R)-3-acrylamidocyclopentyl)-1H-indole-7-carboxamide; [0451]
(S)-4-(1-acryloylpiperidin-3-yl)-1H-pyrrolo[2,3-c]pyridine-7-carboxamide;
[0452]
(R)-4-(1-acryloylpiperidin-3-yl)-1H-pyrrolo[2,3-c]pyridine-7-carbo-
xamide; [0453]
(R)-2-methyl-4-(1-propionylpyrrolidin-3-yl)-1H-indole-7-carboxamide;
[0454]
(S)-2-methyl-4-(1-propionylpyrrolidin-3-yl)-1H-indole-7-carboxamid-
e; [0455]
4-((1-acryloylazetidin-3-yl)(methyl)amino)-2-(isochroman-7-yl)-1-
H-indole-7-carboxamide; [0456]
4-((1-acryloylazetidin-3-yl)(methyl)amino)-2-(6,7-dihydro-4H-pyrazolo[5,1-
-c][1,4]oxazin-2-yl)-1H-indole-7-carboxamide; [0457]
4-((1-acryloylazetidin-3-yl)(methyl)amino)-2-(4,4-difluorocyclohex-1-en-1-
-yl)-1H-indole-7-carboxamide; [0458]
4-((1-acryloylazetidin-3-yl)(methyl)amino)-2-(4-(methylsulfonyl)cyclohex--
1-en-1-yl)-1H-indole-7-carboxamide; [0459]
4-((1-acryloylazetidin-3-yl)(methyl)amino)-2-(6-morpholinopyridin-3-yl)-1-
H-indole-7-carboxamide; [0460]
4-((1-acryloylazetidin-3-yl)(methyl)amino)-2-(7,8-dihydro-5H-pyrano[4,3-b-
]pyridin-3-yl)-1H-indole-7-carboxamide; [0461]
4-((1-acryloylazetidin-3-yl)(methyl)amino)-2-(chroman-7-yl)-1H-indole-7-c-
arboxamide; [0462]
4-((1-acryloylazetidin-3-yl)(methyl)amino)-2-(5-(morpholinomethyl)pyridin-
-2-yl)-1H-indole-7-carboxamide; [0463]
4-((1-acryloylazetidin-3-yl)(methyl)amino)-2-(1-methyl-1H-pyrazol-4-yl)-1-
H-indole-7-carboxamide; [0464]
4-((1-acryloylazetidin-3-yl)(methyl)amino)-2-(3,4-dihydro-2H-benzo[b][1,4-
]oxazin-6-yl)-1H-indole-7-carboxamide; [0465]
4-((1-acryloylazetidin-3-yl)(methyl)amino)-2-(1-methyl-1H-pyrazol-5-yl)-1-
H-indole-7-carboxamide; [0466]
4-((1-acryloylazetidin-3-yl)(methyl)amino)-2-(2-ethyl-1,2,3,4-tetrahydroi-
soquinolin-6-yl)-1H-indole-7-carboxamide; [0467]
4-((1-acryloylazetidin-3-yl)(methyl)amino)-2-(1,3-dimethyl-1H-pyrazol-4-y-
l)-1H-indole-7-carboxamide; [0468]
4-((1-acryloylazetidin-3-yl)(methyl)amino)-2-(1,1-dioxidotetrahydro-2H-th-
iopyran-4-yl)-1H-indole-7-carboxamide; [0469]
4-((1-acryloylazetidin-3-yl)(methyl)amino)-2-(1-propylpiperidin-4-yl)-1H--
indole-7-carboxamide; [0470]
4-((1-acryloylazetidin-3-yl)(methyl)amino)-2-(tetrahydrofuran-3-yl)-1H-in-
dole-7-carboxamide; [0471]
4-((1-acryloylazetidin-3-yl)(methyl)amino)-2-(3-hydroxyoxetan-3-yl)-1H-in-
dole-7-carboxamide; [0472]
4-((1-acryloylazetidin-3-yl)(methyl)amino)-2-methyl-1H-indole-7-carboxami-
de; [0473]
(R)-4-(4-acryloyl-1,4-oxazepan-6-yl)-1H-indole-7-carboxamide;
[0474]
(S)-4-(1-acryloylpyrrolidin-3-yl)-2-methyl-1H-indole-7-carboxamide-
*; [0475]
(R)-4-(1-acryloylpyrrolidin-3-yl)-2-methyl-1H-indole-7-carboxami-
de*; [0476]
4-((1R,5S)-6-acryloyl-3,6-diazabicyclo[3.2.0]heptan-3-yl)-1H-indole-7-car-
boxamide; [0477]
4-((1S,5R)-6-acryloyl-3,6-diazabicyclo[3.2.0]heptan-3-yl)-1H-indole-7-car-
boxamide; [0478]
(R)-4-(1-(1-acryloylazetidin-3-yl)ethyl)-1H-pyrrolo[3,2-c]pyridine-7-carb-
oxamide; [0479]
(S)-4-(1-(1-acryloylazetidin-3-yl)ethyl)-1H-pyrrolo[3,2-c]pyridine-7-carb-
oxamide; [0480]
4-((1-acryloylazetidin-3-yl)amino)-1H-pyrrolo[2,3-c]pyridine-7-carboxamid-
e; [0481]
4-((1-acryloyl-3-methylazetidin-3-yl)(methyl)amino)-1H-indole-7--
carboxamide; [0482]
4-((1-cyanoazetidin-3-yl)(methyl)amino)-2-methyl-1H-indole-7-carboxamide;
[0483]
4-(2-chloro-6-fluorobenzyl)-2-p-tolyl-1H-indole-7-carboxamide;
[0484]
(S)-4-((1-acryloylazetidin-3-yl)(methyl)amino)-2-(tetrahydrofuran--
3-yl)-1H-indole-7-carboxamide; [0485]
(R)-4-((1-acryloylazetidin-3-yl)(methyl)amino)-2-(tetrahydrofuran-3-yl)-1-
H-indole-7-carboxamide; [0486]
(S)-4-(4-acryloyl-1,4-oxazepan-6-yl)-1H-pyrrolo[2,3-c]pyridine-7-carboxam-
ide; [0487]
(R)-4-(4-acryloyl-1,4-oxazepan-6-yl)-1H-pyrrolo[2,3-c]pyridine-7-carboxam-
ide; [0488]
(S)-4-(1-acryloylpiperidin-3-yl)-2-(1-methyl-1H-pyrazol-4-yl)-1H-indole-7-
-carboxamide; or [0489]
(R)-4-(1-acryloylpiperidin-3-yl)-2-(1-methyl-1H-pyrazol-4-yl)-1H-indole-7-
-carboxamide.
[0490] In a twenty-first embodiment the invention provides a method
of treating a disease comprising administering a therapeutically
effective amount of a compound of claim 1 to a patient in need
thereof.
[0491] In a twenty-second embodiment the invention provides a
compound according to any of foregoing embodiments, wherein the
disease is rheumatoid arthritis, juvenile rheumatoid arthritis,
osteoarthritis, Crohn's disease, inflammatory bowel disease,
ulcerative colitis, psoriatic arthritis, psoriasis, ankylosing
spondylitis, interstitial cystitis, asthma, systemic lupus
erythematosus, lupus nephritis, B cell chronic lymphocytic
lymphoma, multiple sclerosis, chronic lymphocytic leukemia, small
lymphocytic lymphoma, mantle cell lymphoma, B-cell non-Hodgkin's
lymphoma, activated B-cell like diffuse large B-cell lymphoma,
multiple myeloma, diffuse large B-cell lymphoma, follicular
lymphoma, hairy cell leukemia or Lymphoblastic lymphoma.
[0492] In a twenty-third embodiment the invention provides kit
comprising a packaged product comprising components with which to
administer a compound a compound according to any of foregoing
embodiments for treatment of an autoimmune disorder.
[0493] In a twenty-fourth embodiment the invention provides a kit
according to the twenty-third embodiment, wherein the packaged
product comprises a compound of claim 1 and instructions for
use.
[0494] In a twenty-fifth embodiment the invention provides a
pharmaceutical composition comprising a compound according to any
of ht efirst thorugh twentieth embodiments and one or more
pharmaceutically acceptable excipients.
DETAILED DESCRIPTION OF THE INVENTION
[0495] Protein kinases are a broad and diverse class, of over 500
enzymes, that include oncogenes, growth factors receptors, signal
transduction intermediates, apoptosis related kinases and cyclin
dependent kinases. They are responsible for the transfer of a
phosphate group to specific tyrosine, serine or threonine amino
acid residues, and are broadly classified as tyrosine and
serine/threonine kinases as a result of their substrate
specificity.
[0496] The protein kinases represent a large family of proteins
that play a central role in the regulation of a wide variety of
cellular processes and maintenance of cellular function. A partial,
non-limiting, list of these kinases include: non-receptor tyrosine
kinases such as the Tec family (BTK, ITK, Tec, ETK/BMX &
RLK/TXK), Janus kinase family (Jak1, Jak2, Jak3 and Tyk2); the
fusion kinases, such as BCR-Abl, focal adhesion kinase (FAK), Fes,
Lek and Syk; receptor tyrosine kinases such as epidermal growth
factor receptor (EGFR), the platelet-derived growth factor receptor
kinase (PDGF-R), the receptor kinase for stem cell factor, c-kit,
the hepatocyte growth factor receptor, c-Met, and the fibroblast
growth factor receptor, FGFR3; and serine/threonine kinases such as
b-RAF, mitogen-activated protein kinases (e.g., MKK6) and
SAPK2.beta.. Aberrant kinase activity has been observed in many
disease states including benign and malignant proliferative
disorders as well as diseases resulting from inappropriate
activation of the immune and nervous systems. The novel compounds
of this invention inhibit the activity of one or more protein
kinases and are, therefore, expected to be useful in the treatment
of kinase-mediated diseases.
[0497] Bruton's tyrosine kinase (BTK) is a non-receptor tyrosine
kinase with a key role in immunoreceptor signaling (BCR, FcR,
Fc.gamma.R, DAP12, Dectin-1, GPVI, etc.) in a host of hematopoietic
cells including B cells, platelets, mast cells, basophils,
eosinophils, macrophages and neutrophils as well as osteoclasts
involved in bone destruction (for reviews, see Brunner et al., 2005
Histol. Histopathol., 20:945; Mohamed et al., 2009 Immunol. Rev.,
228:58). Mutations in BTK are known to lead to X-linked
agammaglobulinemia (XLA) in humans and X-linked immunodeficiency
(Xid) in mice, which are characterized by limited B-cell production
& reduced antibody titers (Lindvall et al., 2005 Immunol. Rev.,
203:200). The combined action of BTK in multiple cell types makes
it an attractive target for autoimmune disease. BTK is related with
sequence homology to other Tec family kinases (ITK, Tec, ETK/BMX
& RLK/TXK).
[0498] In B-lymphocytes, BTK is required for B-cell development and
for Ca2+ mobilization following B-cell receptor (BCR) engagement
(Khan et al., 1995 Immunity 3:283; Genevier et al., 1997 Clin. Exp.
Immun., 110:286) where it is believed to be downstream of Src
family kinases (such as Lyn), Syk & PI3K. BTK has been shown to
be important for both thymus-dependent and thymus-independent type
2 responses to antigens (Khan et al., Immunity 1995; 3:283). In
mast cells, studies using BTK mouse knock-outs (Hata et al., 1998
J. Exp. Med., 187:1235; Schmidt et al., 2009 Eur. J. Immun.,
39:3228) indicate a role for BTK in FcsRI induced signaling,
histamine release & production of cytokines such as TNF, IL-2,
& IL-4. In platelets, BTK is important for signaling through
the glycoprotein VI (GPVI) receptor that responds to collagen and
has been shown to promote platelet aggregation and contribute to
cytokine production from fibroblast-like synoviocytes (Hsu et al.,
2013 Immun. Letters 150:97). In monocytes and macrophages, the
action of BTK is invoked in Fc.gamma.RI induced signaling and may
also have role in Toll-Like Receptor-induced cytokine responses
including TLR2, TLR4, TLR8 & TLR9 (Horwood et al., 2003 J. Exp.
Med., 197:1603; Horwood et al., 2006 J. Immunol., 176:3635; Perez
de Diego et al., 2006 Allerg. Clin. Imm., 117:1462; Doyle et al.,
2007 J. Biol. Chem., 282:36959, Hasan et al., 2007 Immunology,
123:239; Sochorava et al., 2007 Blood, 109:2553; Lee et al., 2008,
J. Biol. Chem., 283:11189).
[0499] Therefore, inhibition of BTK is expected to intervene at
several critical junctions of the inflammatory reactions resulting
in an effective suppression of autoimmune response. As such
diseases involving B-cell receptor activation, antibody-Fc receptor
interactions & GPVI receptor signaling may be modulated by
treatment with BTK inhibitors. BTK inhibition is likely to act on
both the initiation of autoimmune disease by blocking BCR signaling
and the effector phase by abrogation of FcR signaling on
macrophages, neutrophils, basophils, and mast cells. Furthermore,
blocking BTK would provide additional benefit via inhibition of
osteoclast maturation and therefore attenuate the bone erosions
& overall joint destruction associated with rheumatoid
arthritis. Inhibiting BTK may be useful in treating a host of
inflammatory and allergic diseases--for example (but not limited
to), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE),
multiple sclerosis (MS) and type I hypersensitivity reactions such
as allergic rhinitis, allergic conjunctivitis, atopic dermatitis,
allergic asthma and systemic anaphylaxis. For a review on targeting
BTK as a treatment for inflammatory disorders and autoimmunity as
well as leukemias and lymphomas, see Uckun & Qazi 2010 Expert
Opin Ther Pat 20:1457. Because BTK is highly expressed in cancers
of the hematopoietic system & BTK-dependent signaling in
believed to be disregulated there, BTK inhibitors are expected to
be useful treatments for B-cell lymphomas/leukemias & other
oncologic disease--for example (but not limited to) acute
lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL),
non-Hodgkin's lymphoma (NHL), small lymphocytic lymphoma (SLL), and
acute myeloid leukemia (for review, see Buggy & Elias 2012 Int
Rev Immunol. 31:119). Taken together, BTK inhibitors provide a
strong method to treat a host of inflammatory diseases and
immunological disorders as well as hematologic cancers.
[0500] All kinases bind a common molecule, ATP, and therefore have
structurally similar binding pockets. Therefore, one of the
challenges for any kinase inhibitor is that they are prone to
inhibit more than one kinase due to the homology of the binding
pocket. For example, staurosporine, a well characterized
promiscuous kinase inhibitor, has been shown to inhibit at least
253 with a k.sub.d of <3 .mu.M kinases from the human kinome
(see Nature Biotechnology, 208, 26, p. 127). Additionally, several
marketed kinase inhibitors are known to inhibit more than one
intended kinase, for example Imatinib (Gleevec.RTM.) targets ABL,
ARG, PDGFR-.alpha./.beta. and c-KIT kinases, sorafenib
(Nexavar.RTM.) targets B-RAF, VEGFRs, PDGFR-.alpha./.beta., FLT3
and c-KIT and sunitinib (Sutent.RTM.) targets VEGFR, PDGFR, CSF1R,
FLT3 and c-KIT (Nature Reviews Drug Discovery 2011, 10, 111).
[0501] Inhibition of certain kinases in the human kinome are known
to have undesired effects when used as pharmaceutical treatment.
For instance, a number of kinase targets have been implicated in
playing a role in the cardiotoxicity profiles for kinase inhibitors
that are currently on the market. These kinases can include, but
not limited to, VEGFR2, PI3K, AKT, PDGFR-.alpha./p, AMPK, GSK3,
ERKs, CDK2, Aurora, PLK, INK, CAMKII<PDK1, mTOR, LKB1, CAMKKP,
MEK1/2, PKA, PKC.alpha., RAF1, B-RAF, EGFR, ERBB2, c-Kit, ABL, ARG,
JAK2, FAK, DMPK, LTK, ROCK, LKB1, LDB3, PIM, GRK2, GRK5, ASK1, and
PTEN (see Nature Reviews Drug Discovery 2011, 10:111). One example
from a marketed kinase inhibitor is that in clinical trials with
sunitinib, patients were found to be at increased risk for
hypertension (see The Lancet 2006, 368:1329; and J. Cin. Oncol.
2009, 27:3584). Subsequent research on the mechanism for the
increased hypertension suggest that while PDGFR and VEGFR may be
playing a role, off-target kinase inhibition, such as AMPK, may
also be contributing to sunitinib's increased risk for hypertension
(Curr. Hypertens. Rep. 2011, 13:436). Additionally, there is a
patent application, US 2011/0212461, that has been filed that is a
method for the prediction of cardiotoxicity based on the activity
versus a list of kinases including CSF1R, KIT, FYN, PDGFR beta,
FGR, LCK, Ephrin Receptor B2, FRK, ABL1, PDGFR1 alpha, HCK, ABL2,
LYN, ZAK, YES1, MAP4K4, PKN1, BRAF, DDR2, MAP4K5 and STK24.
Therefore, identification of kinase inhibitors with a selective
profile Btk kinase are desirable. The compounds of this invention
are selective for the inhibition of Btk over other kinases.
[0502] Many of the kinases, whether a receptor or non-receptor
tyrosine kinase or a S/T kinase have been found to be involved in
cellular signaling pathways involved in numerous pathogenic
conditions, including immunomodulation, inflammation, or
proliferative disorders such as cancer.
[0503] Many autoimmune diseases and disease associated with chronic
inflammation, as well as acute responses, have been linked to
excessive or unregulated production or activity of one or more
cytokines.
[0504] The compounds of the invention are also useful in the
treatment of rheumatoid arthritis, asthma, allergic asthma,
osteoarthritis, juvenile arthritis, lupus, lupus nephritis,
systemic lupus erythematosus (SLE), ankylosing spondylitis, an
ocular condition, interstitial cystitis, a cancer, a solid tumor, a
sarcoma, fibrosarcoma, osteoma, melanoma, retinoblastoma, a
rhabdomyosarcoma, glioblastoma, neuroblastoma, teratocarcinoma,
hypersensitivity reactions, hyperkinetic movement disorders,
hypersensitivity pneumonitis, hypertension, hypokinetic movement
disorders, aordic and peripheral aneuryisms,
hypothalamic-pituitary-adrenal axis evaluation, aortic dissection,
arterial hypertension, arteriosclerosis, arteriovenous fistula,
ataxia, spinocerebellar degenerations, streptococcal myositis,
structural lesions of the cerebellum, Subacute sclerosing
panencephalitis, Syncope, syphilis of the cardiovascular system,
systemic anaphalaxis, systemic inflammatory response syndrome,
systemic onset juvenile rheumatoid arthritis, T-cell or FAB ALL,
Telangiectasia, thromboangitis obliterans, transplants,
trauma/hemorrhage, type III hypersensitivity reactions, type IV
hypersensitivity, unstable angina, uremia, urosepsis, urticaria,
valvular heart diseases, varicose veins, vasculitis, venous
diseases, venous thrombosis, ventricular fibrillation, viral and
fungal infections, vital encephalitis/aseptic meningitis,
vital-associated hemaphagocytic syndrome, Wernicke-Korsakoff
syndrome, Wilson's disease, xenograft rejection of any organ or
tissue, heart transplant rejection, hemachromatosis, hemodialysis,
hemolytic uremic syndrome/thrombolytic thrombocytopenic purpura,
hemorrhage, idiopathic pulmonary fibrosis, antibody mediated
cytotoxicity, Asthenia, infantile spinal muscular atrophy,
inflammation of the aorta, influenza A, ionizing radiation
exposure, iridocyclitis/uveitis/optic neuritis, juvenile spinal
muscular atrophy, lymphoma, myeloma, leukaemia, malignant ascites,
hematopoietic cancers, a diabetic condition such as
insulin-dependent diabetes mellitus glaucoma, diabetic retinopathy
or microangiopathy, sickle cell anaemia, chronic inflammation,
glomerulonephritis, graft rejection, Lyme disease, von Hippel
Lindau disease, pemphigoid, Paget's disease, fibrosis, sarcoidosis,
cirrhosis, thyroiditis, hyperviscosity syndrome, Osler-Weber-Rendu
disease, chronic occlusive pulmonary disease, asthma or edema
following burns, trauma, radiation, stroke, hypoxia, ischemia,
ovarian hyperstimulation syndrome, post perfusion syndrome, post
pump syndrome, post-MI cardiotomy syndrome, preeclampsia,
menometrorrhagia, endometriosis, pulmonary hypertension, infantile
hemangioma, or infection by Herpes simplex, Herpes Zoster, human
immunodeficiency virus, parapoxvirus, protozoa or toxoplasmosis,
progressive supranucleo palsy, primary pulmonary hypertension,
radiation therapy, Raynaud's phenomenon, Raynaud's disease,
Refsum's disease, regular narrow QRS tachycardia, renovascular
hypertension, restrictive cardiomyopathy, sarcoma, senile chorea,
senile dementia of Lewy body type, shock, skin allograft, skin
changes syndrome, ocular or macular edema, ocular neovascular
disease, scleritis, radial keratotomy, uveitis, vitritis, myopia,
optic pits, chronic retinal detachment, post-laser treatment
complications, conjunctivitis, Stargardt's disease, Eales disease,
retinopathy, macular degeneration, restenosis, ischemia/reperfusion
injury, ischemic stroke, vascular occlusion, carotid obstructive
disease, ulcerative colitis, inflammatory bowel disease, diabetes,
diabetes mellitus, insulin dependent diabetes mellitus, allergic
diseases, dermatitis scleroderma, graft versus host disease, organ
transplant rejection (including but not limited to bone marrow and
solid organ rejection), acute or chronic immune disease associated
with organ transplantation, sarcoidosis, disseminated intravascular
coagulation, Kawasaki's disease, nephrotic syndrome, chronic
fatigue syndrome, Wegener's granulomatosis, Henoch-Schoenlein
purpurea, microscopic vasculitis of the kidneys, chronic active
hepatitis, septic shock, toxic shock syndrome, sepsis syndrome,
cachexia, infectious diseases, parasitic diseases, acquired
immunodeficiency syndrome, acute transverse myelitis, Huntington's
chorea, stroke, primary biliary cirrhosis, hemolytic anemia,
malignancies, Addison's disease, idiopathic Addison's disease,
sporadic, polyglandular deficiency type I and polyglandular
deficiency type II, Schmidt's syndrome, adult (acute) respiratory
distress syndrome, alopecia, alopecia areata, seronegative
arthopathy, arthropathy, Reiter's disease, psoriatic arthropathy,
ulcerative colitic arthropathy, enteropathic synovitis, chlamydia,
yersinia and salmonella associated arthropathy, atheromatous
disease/arteriosclerosis, atopic allergy, autoimmune bullous
disease, pemphigus vulgaris, pemphigus foliaceus, pemphigoid,
linear IgA disease, autoimmune haemolytic anaemia, Coombs positive
haemolytic anaemia, acquired pernicious anaemia, juvenile
pernicious anaemia, peripheral vascular disorders, peritonitis,
pernicious anemia, myalgic encephalitis/Royal Free Disease, chronic
mucocutaneous candidiasis, giant cell arteritis, primary sclerosing
hepatitis, cryptogenic autoimmune hepatitis, Acquired
Immunodeficiency Disease Syndrome, Acquired Immunodeficiency
Related Diseases, Hepatitis A, Hepatitis B, Hepatitis C, His bundle
arrythmias, HIV infection/HIV neuropathy, common varied
immunodeficiency (common variable hypogammaglobulinaemia), dilated
cardiomyopathy, female infertility, ovarian failure, premature
ovarian failure, fibrotic lung disease, chronic wound healing,
cryptogenic fibrosing alveolitis, post-inflammatory interstitial
lung disease, interstitial pneumonitis, pneumocystis cannii
pneumonia, pneumonia, connective tissue disease associated
interstitial lung disease, mixed connective tissue disease,
associated lung disease, systemic sclerosis associated interstitial
lung disease, rheumatoid arthritis associated interstitial lung
disease, systemic lupus erythematosus associated lung disease,
dermatomyositis/polymyositis associated lung disease, Sjogren's
disease associated lung disease, ankylosing spondylitis associated
lung disease, vasculitic diffuse lung disease, haemosiderosis
associated lung disease, drug-induced interstitial lung disease,
radiation fibrosis, bronchiolitis obliterans, chronic eosinophilic
pneumonia, lymphocytic infiltrative lung disease, postinfectious
interstitial lung disease, gouty arthritis, autoimmune hepatitis,
type-1 autoimmune hepatitis (classical autoimmune or lupoid
hepatitis), type-2 autoimmune hepatitis (anti-LKM antibody
hepatitis), autoimmune mediated hypoglycaemia, type B insulin
resistance with acanthosis nigricans, hypoparathyroidism, acute
immune disease associated with organ transplantation, chronic
immune disease associated with organ transplantation,
osteoarthritis, primary sclerosing cholangitis, psoriasis type 1,
psoriasis type 2, idiopathic leucopaenia, autoimmune neutropaenia,
renal disease NOS, glomerulonephritides, microscopic vasculitis of
the kidneys, Lyme disease, discoid lupus erythematosus, male
infertility idiopathic or NOS, sperm autoimmunity, multiple
sclerosis (all subtypes), sympathetic ophthalmia, pulmonary
hypertension secondary to connective tissue disease, acute and
chronic pain (different forms of pain), Goodpasture's syndrome,
pulmonary manifestation of polyarteritis nodosa, acute rheumatic
fever, rheumatoid spondylitis, Still's disease, systemic sclerosis,
Sjogren's syndrome, Takayasu's disease/arteritis, autoimmune
thrombocytopaenia, toxicity, transplants, and diseases involving
inappropriate vascularization for example diabetic retinopathy,
retinopathy of prematurity, choroidal neovascularization due to
age-related macular degeneration, and infantile hemangiomas in
human beings. In addition, such compounds may be useful in the
treatment of disorders such as ascites, effusions, and exudates,
including for example macular edema, cerebral edema, acute lung
injury, adult respiratory distress syndrome (ARDS), proliferative
disorders such as restenosis, fibrotic disorders such as hepatic
cirrhosis and atherosclerosis, mesangial cell proliferative
disorders such as diabetic nephropathy, malignant nephrosclerosis,
thrombotic microangiopathy syndromes, and glomerulopathies,
myocardial angiogenesis, coronary and cerebral collaterals,
ischemic limb angiogenesis, ischemia/reperfusion injury, peptic
ulcer Helicobacter related diseases, virally-induced angiogenic
disorders, preeclampsia, menometrorrhagia, cat scratch fever,
rubeosis, neovascular glaucoma and retinopathies such as those
associated with diabetic retinopathy, retinopathy of prematurity,
or age-related macular degeneration. In addition, these compounds
can be used as active agents against hyperproliferative disorders
such as thyroid hyperplasia (especially Grave's disease), and cysts
(such as hypervascularity of ovarian stroma characteristic of
polycystic ovarian syndrome (Stein-Leventhal syndrome) and
polycystic kidney disease since such diseases require a
proliferation of blood vessel cells for growth and/or
metastasis.
[0505] In yet other embodiments, the compounds described herein can
be used to treat a cancer, e.g., B-cell proliferative disorders,
which include, but are not limited to diffuse large B cell
lymphoma, follicular lymphoma, chronic lymphocytic lymphoma,
chronic lymphocytic leukemia, B-cell prolymphocytic leukemia,
lymphoplamacytic lymphoma/Waldenstrom macroglobulinemia, splenic
marginal zone lymphoma, plasma cell myeloma, plasmacytoma,
extranodal marginal zone B cell lymphoma, nodal marginal zone B
cell lymphoma, mantle cell lymphoma, mediastinal (thymic) large B
cell lymphoma, intravascular large B cell lymphoma, primary
effusion lymphoma, Burkitt's lymphoma/leukemia, lymphomatoid
granulomatosis, pancreatic cancer, solid or hematological tumors, a
benign or malignant tumor, carcinoma of the brain, kidney (e.g.,
renal cell carcinoma (RCC)), squamous cell carcinoma, salivary
gland carcinoma, liver, adrenal gland, bladder, breast, stomach,
gastric tumors, ovaries, colon, rectum, prostate, pancreas, lung,
vagina, endometrium, cervix, testis, genitourinary tract,
esophagus, larynx, skin, bone or thyroid, sarcoma, glioblastomas,
neuroblastomas, multiple myeloma or gastrointestinal cancer,
especially colon carcinoma or colorectal adenoma or a tumor of the
neck and head, an epidermal hyperproliferation, psoriasis, prostate
hyperplasia, a neoplasia, a neoplasia of epithelial character,
adenoma, adenocarcinoma, keratoacanthoma, epidermoid carcinoma,
large cell carcinoma, non-small-cell lung carcinoma, lymphomas,
(including, for example, non-Hodgkin's Lymphoma (NHL) and Hodgkin's
lymphoma (also termed Hodgkin's or Hodgkin's disease)), a mammary
carcinoma, follicular carcinoma, undifferentiated carcinoma,
papillary carcinoma, seminoma, melanoma, or a leukemia.
[0506] In yet other embodiments, the compounds described herein can
be used to treat Behcet's disease, osteoporosis, bone cancer, and
bone metastasis, systemic sclerosis, contact dermatitis and other
eczematous dermatitis, seborrhoetic dermatitis, lichen planus,
epidermolysis bullosa, angiodermas, vasculitides, cutaneous
eosinophilias, or vernal conjunctivitis.
[0507] In yet other embodiments, the compounds described herein can
be used to treat those conditions characterized by inflammation of
the nasal mucus membrane, including acute rhinitis, allergic,
atrophic thinitis and chronic rhinitis including rhinitis caseosa,
hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca and
rhinitis medicamentosa; membranous rhinitis including croupous,
fibrinous and pseudomembranous rhinitis and scrofoulous rhinitis,
seasonal rhinitis including rhinitis nervosa (hay fever) and
vasomotor rhinitis, sarcoidosis, farmer's lung and related
diseases, fibroid lung, and idiopathic interstitial pneumonia.
[0508] Compounds of Formula (I) of the invention can be used alone
or in combination with an additional agent, e.g., a therapeutic
agent, said additional agent being selected by the skilled artisan
for its intended purpose. For example, the additional agent can be
a therapeutic agent art-recognized as being useful to treat the
disease or condition being treated by the compound of the present
invention. The additional agent also can be an agent that imparts a
beneficial attribute to the therapeutic composition e.g., an agent
that affects the viscosity of the composition.
[0509] It should further be understood that the combinations which
are to be included within this invention are those combinations
useful for their intended purpose. The agents set forth below are
illustrative for purposes and not intended to be limited. The
combinations, which are part of this invention, can be the
compounds of the present invention and at least one additional
agent selected from the lists below. The combination can also
include more than one additional agent, e.g., two or three
additional agents if the combination is such that the formed
composition can perform its intended function.
[0510] Preferred combinations are non-steroidal anti-inflammatory
drug(s) also referred to as NSAIDS which include drugs like
ibuprofen. Other preferred combinations are corticosteroids
including prednisolone; the well known side-effects of steroid use
can be reduced or even eliminated by tapering the steroid dose
required when treating patients in combination with the compounds
of this invention. Non-limiting examples of therapeutic agents for
rheumatoid arthritis with which a compound of Formula (I) of the
invention can be combined include the following: cytokine
suppressive anti-inflammatory drug(s) (CSAIDs); antibodies to or
antagonists of other human cytokines or growth factors, for
example, TNF, LT, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8,
IL-12, IL-15, IL-16, IL-21, IL-23, interferons, EMAP-II, GM-CSF,
FGF, MMP-13 and PDGF. Compounds of the invention can be combined
with antibodies to cell surface molecules such as CD2, CD3, CD4,
CD8, CD25, CD28, CD30, CD40, CD45, CD69, CD80 (B7.1), CD86 (B7.2),
CD90, CTLA ortheirligands including CD154 (gp39 or CD40L).
[0511] Preferred combinations of therapeutic agents may interfere
at different points in the autoimmune and subsequent inflammatory
cascade; preferred examples include TNF antagonists like chimeric,
humanized or human TNF antibodies, D2E7 (U.S. Pat. No. 6,090,382,
HUMIRA.TM.), CA2 (REMICADE.TM.), SIMPONI.TM. (golimumab),
CIMZIA.TM., ACTEMRA.TM., CDP 571, and soluble p55 or p75 TNF
receptors, derivatives, thereof, (p75TNFR1gG (ENBREL.TM.) or
p55TNFR1gG (Lenercept), and also TNF.alpha. converting enzyme
(TACE) inhibitors; similarly IL-1 inhibitors
(Interleukin-1-converting enzyme inhibitors, IL-RA etc.) may be
effective for the same reason. Other preferred combinations include
Interleukin 11. Yet other preferred combinations are the other key
players of the autoimmune response which may act parallel to,
dependent on or in concert with IL-18 function; especially
preferred are IL-12 antagonists including IL-12 antibodies or
soluble IL-12 receptors, or IL-12 binding proteins. It has been
shown that IL-12 and IL-18 have overlapping but distinct functions
and a combination of antagonists to both may be most effective. Yet
another preferred combination is non-depleting anti-CD4 inhibitors.
Yet other preferred combinations include antagonists of the
co-stimulatory pathway CD80 (B7.1) or CD86 (B7.2) including
antibodies, soluble receptors or antagonistic ligands.
[0512] A compound of Formula (I) of the invention may also be
combined with agents, such as methotrexate, 6-mercaptopurine,
azathioprine sulphasalazine, mesalazine, olsalazine
chloroquinine/hydroxychloroquine, pencillamine, aurothiomalate
(intramuscular and oral), azathioprine, cochicine, corticosteroids
(oral, inhaled and local injection), beta-2 adrenoreceptor agonists
(salbutamol, terbutaline, salmeteral), xanthines (theophylline,
aminophylline), cromoglycate, nedocromil, ketotifen, ipratropium
and oxitropium, cyclosporin, FK506, rapamycin, mycophenolate
mofetil, leflunomide, NSAIDs, for example, ibuprofen,
corticosteroids such as prednisolone, phosphodiesterase inhibitors,
adensosine agonists, antithrombotic agents, complement inhibitors,
adrenergic agents, agents which interfere with signalling by
proinflammatory cytokines such as TNF.alpha. or IL-1 (e.g., NIK,
IKK, JAK1, JAK2, JAK3, p38 or MAP kinase inhibitors), IL-1.beta.
converting enzyme inhibitors, T-cell signalling inhibitors such as
kinase inhibitors, metalloproteinase inhibitors, sulfasalazine,
6-mercaptopurines, angiotensin converting enzyme inhibitors,
soluble cytokine receptors and derivatives thereof (e.g. soluble
p55 or p75 TNF receptors and the derivatives p75TNFRIgG
(Enbrel.TM.) and p55TNFRIgG (Lenercept), sIL-1RI, sIL-1RII,
sIL-6R), antiinflammatory cytokines (e.g. IL-4, IL-10, IL-11, IL-13
and TGF.beta.), celecoxib, folic acid, hydroxychloroquine sulfate,
rofecoxib, etanercept, infliximab, naproxen, valdecoxib,
sulfasalazine, methylprednisolone, meloxicam, methylprednisolone
acetate, gold sodium thiomalate, aspirin, triamcinolone acetonide,
propoxyphene napsylate/apap, folate, nabumetone, diclofenac,
piroxicam, etodolac, diclofenac sodium, oxaprozin, oxycodone HCl,
hydrocodone bitartrate/apap, diclofenac sodium/misoprostol,
fentanyl, anakinra, tramadol HCl, salsalate, sulindac,
cyanocobalamin/fa/pyridoxine, acetaminophen, alendronate sodium,
prednisolone, morphine sulfate, lidocaine hydrochloride,
indomethacin, glucosamine sulf/chondroitin, amitriptyline HCl,
sulfadiazine, oxycodone HCl/acetaminophen, olopatadine HCl
misoprostol, naproxen sodium, omeprazole, cyclophosphamide,
rituximab, IL-1 TRAP, MRA, CTLA4-IG, IL-18 BP, anti-IL-12,
Anti-IL15, BIRB-796, SCIO-469, VX-702, AMG-548, VX-740,
Roflumilast, IC-485, CDC-801, S1P1 agonists (such as FTY720), PKC
family inhibitors (such as Ruboxistaurin or AEB-071) and Mesopram.
Preferred combinations include methotrexate or leflunomide and in
moderate or severe rheumatoid arthritis cases, cyclosporine and
anti-TNF antibodies as noted above.
[0513] Non-limiting examples of therapeutic agents for inflammatory
bowel disease with which a compound of Formula (I) of the invention
can be combined include the following: budenoside; epidermal growth
factor; corticosteroids; cyclosporin, sulfasalazine;
aminosalicylates; 6-mercaptopurine; azathioprine; metronidazole;
lipoxygenase inhibitors; mesalamine; olsalazine; balsalazide;
antioxidants; thromboxane inhibitors; IL-1 receptor antagonists;
anti-IL-1.beta. monoclonal antibodies; anti-IL-6 monoclonal
antibodies; growth factors; elastase inhibitors;
pyridinyl-imidazole compounds; antibodies to or antagonists of
other human cytokines or growth factors, for example, TNF, LT,
IL-1, IL-2, IL-6, IL-7, IL-8, IL-12, IL-15, IL-16, IL-23, EMAP-II,
GM-CSF, FGF, and PDGF; cell surface molecules such as CD2, CD3,
CD4, CD8, CD25, CD28, CD30, CD40, CD45, CD69, CD90 or their
ligands; methotrexate; cyclosporine; FK506; rapamycin;
mycophenolate mofetil; leflunomide; NSAIDs, for example, ibuprofen;
corticosteroids such as prednisolone; phosphodiesterase inhibitors;
adenosine agonists; antithrombotic agents; complement inhibitors;
adrenergic agents; agents which interfere with signalling by
proinflammatory cytokines such as TNF.alpha. or IL-1 (e.g. NIK,
IKK, p38 or MAP kinase inhibitors); IL-1.beta. converting enzyme
inhibitors; TNF.alpha. converting enzyme inhibitors; T-cell
signalling inhibitors such as kinase inhibitors; metalloproteinase
inhibitors; sulfasalazine; azathioprine; 6-mercaptopurines;
angiotensin converting enzyme inhibitors; soluble cytokine
receptors and derivatives thereof (e.g. soluble p55 or p75 TNF
receptors, sIL-1RI, sIL-1RII, sIL-6R) and antiinflammatory
cytokines (e.g. IL-4, IL-10, IL-11, IL-13 and TGF.beta.). Preferred
examples of therapeutic agents for Crohn's disease with which a
compound of Formula (I) can be combined include the following: TNF
antagonists, for example, anti-TNF antibodies, D2E7 (U.S. Pat. No.
6,090,382, HUMIRA.TM.), CA2 (REMICADE.TM.), CDP 571, TNFR-Ig
constructs, (p75TNFRIgG (ENBREL.TM.) and p55TNFRIgG (LENERCEPT.TM.)
inhibitors and PDE4 inhibitors. A compound of Formula (I) can be
combined with corticosteroids, for example, budenoside and
dexamethasone; sulfasalazine, 5-aminosalicylic acid; olsalazine;
and agents which interfere with synthesis or action of
proinflammatory cytokines such as IL-1, for example, IL-1.beta.
converting enzyme inhibitors and IL-1ra; T cell signaling
inhibitors, for example, tyrosine kinase inhibitors;
6-mercaptopurine; IL-11; mesalamine; prednisone; azathioprine;
mercaptopurine; infliximab; methylprednisolone sodium succinate;
diphenoxylate/atrop sulfate; loperamide hydrochloride;
methotrexate; omeprazole; folate; ciprofloxacin/dextrose-water;
hydrocodone bitartrate/apap; tetracycline hydrochloride;
fluocinonide; metronidazole; thimerosal/boric acid;
cholestyramine/sucrose; ciprofloxacin hydrochloride; hyoscyamine
sulfate; meperidine hydrochloride; midazolam hydrochloride;
oxycodone HCl/acetaminophen; promethazine hydrochloride; sodium
phosphate; sulfamethoxazole/trimethoprim; celecoxib; polycarbophil;
propoxyphene napsylate; hydrocortisone; multivitamins; balsalazide
disodium; codeine phosphate/apap; colesevelam HCl; cyanocobalamin;
folic acid; levofloxacin; methylprednisolone; natalizumab and
interferon-gamma.
[0514] Non-limiting examples of therapeutic agents for multiple
sclerosis with which a compound of Formula (I) can be combined
include the following: corticosteroids; prednisolone;
methylprednisolone; azathioprine; cyclophosphamide; cyclosporine;
methotrexate; 4-aminopyridine; tizanidine; interferon-.beta.1a
(AVONEX.RTM.; Biogen); interferon-.beta.1b (BETASERON.RTM.;
Chiron/Berlex); interferon .alpha.-n3) (Interferon
Sciences/Fujimoto), interferon-.alpha. (Alfa Wassermann/J&J),
interferon .beta.1A-IF (Serono/Inhale Therapeutics), Peginterferon
.alpha. 2b (Enzon/Schering-Plough), Copolymer 1 (Cop-1;
COPAXONE.RTM.; Teva Pharmaceutical Industries, Inc.); hyperbaric
oxygen; intravenous immunoglobulin; cladribine; antibodies to or
antagonists of other human cytokines or growth factors and their
receptors, for example, TNF, LT, IL-1, IL-2, IL-6, IL-7, IL-8,
IL-12, IL-23, IL-15, IL-16, EMAP-I, GM-CSF, FGF, and PDGF. A
compound of Formula (I) can be combined with antibodies to cell
surface molecules such as CD2, CD3, CD4, CD8, CD19, CD20, CD25,
CD28, CD30, CD40, CD45, CD69, CD80, CD86, CD90 or their ligands. A
compound of Formula (I) may also be combined with agents such as
methotrexate, cyclosporine, FK506, rapamycin, mycophenolate
mofetil, leflunomide, an S1P1 agonist, NSAIDs, for example,
ibuprofen, corticosteroids such as prednisolone, phosphodiesterase
inhibitors, adensosine agonists, antithrombotic agents, complement
inhibitors, adrenergic agents, agents which interfere with
signalling by proinflammatory cytokines such as TNF.alpha.l or IL-1
(e.g., NIK, IKK, p38 or MAP kinase inhibitors), IL-1.beta.
converting enzyme inhibitors, TACE inhibitors, T-cell signaling
inhibitors such as kinase inhibitors, metalloproteinase inhibitors,
sulfasalazine, azathioprine, 6-mercaptopurines, angiotensin
converting enzyme inhibitors, soluble cytokine receptors and
derivatives thereof (e.g. soluble p55 or p75 TNF receptors,
sIL-1RI, sIL-1RII, sIL-6R) and antiinflammatory cytokines (e.g.
IL-4, IL-10, IL-13 and TGF.beta.).
[0515] Preferred examples of therapeutic agents for multiple
sclerosis in which a compound of Formula (I) can be combined to
include interferon-.beta., for example, IFN.beta.1a and
IFN.beta.1b; copaxone, corticosteroids, caspase inhibitors, for
example inhibitors of caspase-1, IL-1 inhibitors, TNF inhibitors,
and antibodies to CD40 ligand and CD80.
[0516] A compound of Formula (I) may also be combined with agents,
such as alemtuzumab, dronabinol, daclizumab, mitoxantrone,
xaliproden hydrochloride, fampridine, glatiramer acetate,
natalizumab, sinnabidol, .alpha.-immunokine NNSO3, ABR-215062,
AnergiX. MS, chemokine receptor antagonists, BBR-2778, calagualine,
CPI-1189, LEM (liposome encapsulated mitoxantrone), THC. CBD
(cannabinoid agonist), MBP-8298, mesopram (PDE4 inhibitor),
MNA-715, anti-IL-6 receptor antibody, neurovax, pirfenidone
allotrap 1258 (RDP-1258), sTNF-R.sup.1, talampanel, teriflunomide,
TGF-beta2, tiplimotide, VLA-4 antagonists (for example, TR-14035,
VLA4 Ultrahaler, Antegran-ELAN/Biogen), interferon gamma
antagonists and IL-4 agonists.
[0517] Non-limiting examples of therapeutic agents for ankylosing
spondylitis with which a compound of Formula (I) can be combined
include the following: ibuprofen, diclofenac, misoprostol,
naproxen, meloxicam, indomethacin, diclofenac, celecoxib,
rofecoxib, sulfasalazine, methotrexate, azathioprine, minocyclin,
prednisone, and anti-TNF antibodies, D2E7 (U.S. Pat. No. 6,090,382;
HUMIRA.TM.), CA2 (REMICADE.TM.), CDP 571, TNFR-Ig constructs,
(p75TNFRIgG (ENBREL.TM.) and p55TNFRIgG (LENERCEPT.TM.).
[0518] Non-limiting examples of therapeutic agents for asthma with
which a compound of Formula (I) can be combined include the
following: albuterol, salmeterol/fluticasone, montelukast sodium,
fluticasone propionate, budesonide, prednisone, salmeterol
xinafoate, levalbuterol HCl, albuterol sulfate/ipratropium,
prednisolone sodium phosphate, triamcinolone acetonide,
beclomethasone dipropionate, ipratropium bromide, azithromycin,
pirbuterol acetate, prednisolone, theophylline anhydrous,
methylprednisolone sodium succinate, clarithromycin, zafirlukast,
formoterol fumarate, influenza virus vaccine, amoxicillin
trihydrate, flunisolide, allergy injection, cromolyn sodium,
fexofenadine hydrochloride, flunisolide/menthol,
amoxicillin/clavulanate, levofloxacin, inhaler assist device,
guaifenesin, dexamethasone sodium phosphate, moxifloxacin HCl,
doxycycline hyclate, guaifenesin/d-methorphan,
p-ephedrine/cod/chlorphenir, gatifloxacin, cetirizine
hydrochloride, mometasone furoate, salmeterol xinafoate,
benzonatate, cephalexin, pe/hydrocodone/chlorphenir, cetirizine
HCl/pseudoephed, phenylephrine/cod/promethazine,
codeine/promethazine, cefprozil, dexamethasone,
guaifenesin/pseudoephedrine, chlorpheniramine/hydrocodone,
nedocromil sodium, terbutaline sulfate, epinephrine,
methylprednisolone, anti-IL-13 antibody, and metaproterenol
sulfate.
[0519] Non-limiting examples of therapeutic agents for COPD with
which a compound of Formula (I) can be combined include the
following: albuterol sulfate/ipratropium, ipratropium bromide,
salmeterol/fluticasone, albuterol, salmeterol xinafoate,
fluticasone propionate, prednisone, theophylline anhydrous,
methylprednisolone sodium succinate, montelukast sodium,
budesonide, formoterol fumarate, triamcinolone acetonide,
levofloxacin, guaifenesin, azithromycin, beclomethasone
dipropionate, levalbuterol HCl, flunisolide, ceftriaxone sodium,
amoxicillin trihydrate, gatifloxacin, zafirlukast,
amoxicillin/clavulanate, flunisolide/menthol,
chlorpheniramine/hydrocodone, metaproterenol sulfate,
methylprednisolone, mometasone furoate,
p-ephedrine/cod/chlorphenir, pirbuterol acetate,
p-ephedrine/loratadine, terbutaline sulfate, tiotropium bromide,
(R,R)-formoterol, TgAAT, cilomilast and roflumilast.
[0520] Non-limiting examples of therapeutic agents for HCV with
which a compound of Formula (I) (can be combined include the
following: Interferon-alpha-2.alpha., Interferon-alpha-2.beta.,
Interferon-alpha con1, Interferon-alpha-n1, pegylated
interferon-alpha-2.alpha., pegylated interferon-alpha-2.beta.,
ribavirin, peginterferon alfa-2b+ribavirin, ursodeoxycholic acid,
glycyrrhizic acid, thymalfasin, Maxamine, VX-497 and any compounds
that are used to treat HCV through intervention with the following
targets: HCV polymerase, HCV protease, HCV helicase, and HCV IRES
(internal ribosome entry site).
[0521] Non-limiting examples of therapeutic agents for Idiopathic
Pulmonary Fibrosis with which a compound of Formula (I) (can be
combined include the following: prednisone, azathioprine,
albuterol, colchicine, albuterol sulfate, digoxin, gamma
interferon, methylprednisolone sodium succinate, lorazepam,
furosemide, lisinopril, nitroglycerin, spironolactone,
cyclophosphamide, ipratropium bromide, actinomycin d, alteplase,
fluticasone propionate, levofloxacin, metaproterenol sulfate,
morphine sulfate, oxycodone HCl, potassium chloride, triamcinolone
acetonide, tacrolimus anhydrous, calcium, interferon-alpha,
methotrexate, mycophenolate mofetil and
interferon-gamma-1.beta..
[0522] Non-limiting examples of therapeutic agents for myocardial
infarction with which a compound of Formula (I) can be combined
include the following: aspirin, nitroglycerin, metoprolol tartrate,
enoxaparin sodium, heparin sodium, clopidogrel bisulfate,
carvedilol, atenolol, morphine sulfate, metoprolol succinate,
warfarin sodium, lisinopril, isosorbide mononitrate, digoxin,
furosemide, simvastatin, ramipril, tenecteplase, enalapril maleate,
torsemide, retavase, losartan potassium, quinapril
hydrochloride/magnesium carbonate, bumetanide, alteplase,
enalaprilat, amiodarone hydrochloride, tirofiban HClI m-hydrate,
diltiazem hydrochloride, captopril, irbesartan, valsartan,
propranolol hydrochloride, fosinopril sodium, lidocaine
hydrochloride, eptifibatide, cefazolin sodium, atropine sulfate,
aminocaproic acid, spironolactone, interferon, sotalol
hydrochloride, potassium chloride, docusate sodium, dobutamine HCl,
alprazolam, pravastatin sodium, atorvastatin calcium, midazolam
hydrochloride, meperidine hydrochloride, isosorbide dinitrate,
epinephrine, dopamine hydrochloride, bivalirudin, rosuvastatin,
ezetimibe/simvastatin, avasimibe, and cariporide.
[0523] Non-limiting examples of therapeutic agents for psoriasis
with which a compound of Formula (I) can be combined include the
following: calcipotriene, clobetasol propionate, triamcinolone
acetonide, halobetasol propionate, tazarotene, methotrexate,
fluocinonide, betamethasone diprop augmented, fluocinolone
acetonide, acitretin, tar shampoo, betamethasone valerate,
mometasone furoate, ketoconazole, pramoxine/fluocinolone,
hydrocortisone valerate, flurandrenolide, urea, betamethasone,
clobetasol propionate/emoll, fluticasone propionate, azithromycin,
hydrocortisone, moisturizing formula, folic acid, desonide,
pimecrolimus, coal tar, diflorasone diacetate, etanercept folate,
lactic acid, methoxsalen, hc/bismuth subgal/znox/resor,
methylprednisolone acetate, prednisone, sunscreen, halcinonide,
salicylic acid, anthralin, clocortolone pivalate, coal extract,
coal tar/salicylic acid, coal tar/salicylic acid/sulfur,
desoximetasone, diazepam, emollient, fluocinonide/emollient,
mineral oil/castor oil/na lact, mineral oil/peanut oil,
petroleum/isopropyl myristate, psoralen, salicylic acid,
soap/tribromsalan, thimerosal/boric acid, celecoxib, infliximab,
cyclosporine, alefacept, efalizumab, tacrolimus, pimecrolimus,
PUVA, UVB, sulfasalazine, ABT-874 and ustekinamab.
[0524] Non-limiting examples of therapeutic agents for psoriatic
arthritis with which a compound of Formula (I) can be combined
include the following: methotrexate, etanercept, rofecoxib,
celecoxib, folic acid, sulfasalazine, naproxen, leflunomide,
methylprednisolone acetate, indomethacin, hydroxychloroquine
sulfate, prednisone, sulindac, betamethasone diprop augmented,
infliximab, methotrexate, folate, triamcinolone acetonide,
diclofenac, dimethylsulfoxide, piroxicam, diclofenac sodium,
ketoprofen, meloxicam, methylprednisolone, nabumetone, tolmetin
sodium, calcipotriene, cyclosporine, diclofenac sodium/misoprostol,
fluocinonide, glucosamine sulfate, gold sodium thiomalate,
hydrocodone bitartrate/apap, ibuprofen, risedronate sodium,
sulfadiazine, thioguanine, valdecoxib, alefacept, D2E7 (U.S. Pat.
No. 6,090,382, HUMIRA.TM.), and efalizumab.
[0525] Non-limiting examples of therapeutic agents for restenosis
with which a compound of Formula (I) can be combined include the
following: sirolimus, paclitaxel, everolimus, tacrolimus, ABT-578,
and acetaminophen.
[0526] Non-limiting examples of therapeutic agents for sciatica
with which a compound of Formula (I) can be combined include the
following: hydrocodone bitartrate/apap, rofecoxib, cyclobenzaprine
HCl, methylprednisolone, naproxen, ibuprofen, oxycodone
HCl/acetaminophen, celecoxib, valdecoxib, methylprednisolone
acetate, prednisone, codeine phosphate/apap, tramadol
HCl/acetaminophen, metaxalone, meloxicam, methocarbamol, lidocaine
hydrochloride, diclofenac sodium, gabapentin, dexamethasone,
carisoprodol, ketorolac tromethamine, indomethacin, acetaminophen,
diazepam, nabumetone, oxycodone HCl, tizanidine HCl, diclofenac
sodium/misoprostol, propoxyphene n-pap, asa/oxycod/oxycodone ter,
ibuprofen/hydrocodone bit, tramadol HCl, etodolac, propoxyphene
HCl, amitriptyline HCl, carisoprodol/codeine phos/asa, morphine
sulfate, multivitamins, naproxen sodium, orphenadrine citrate, and
temazepam.
[0527] Preferred examples of therapeutic agents for SLE (Lupus)
with which a compound of Formula (I) can be combined include the
following: NSAIDS, for example, diclofenac, naproxen, ibuprofen,
piroxicam, indomethacin; COX2 inhibitors, for example, celecoxib,
rofecoxib, valdecoxib; anti-malarials, for example,
hydroxychloroquine; steroids, for example, prednisone,
prednisolone, budenoside, dexamethasone; cytotoxics, for example,
azathioprine, cyclophosphamide, mycophenolate mofetil,
methotrexate; inhibitors of PDE4 or purine synthesis inhibitor, for
example Cellcept.RTM.. A compound of Formula (I) may also be
combined with agents such as sulfasalazine, 5-aminosalicylic acid,
olsalazine, Imuran.RTM. and agents which interfere with synthesis,
production or action of proinflammatory cytokines such as IL-1, for
example, caspase inhibitors like IL-1.beta. converting enzyme
inhibitors and IL-1ra. A compound of Formula (I) may also be used
with T cell signaling inhibitors, for example, tyrosine kinase
inhibitors; or molecules that target T cell activation molecules,
for example, CTLA-4-IgG or anti-B7 family antibodies, anti-PD-1
family antibodies. A compound of Formula (I) (can be combined with
IL-11 or anti-cytokine antibodies, for example, fonotolizumab
(anti-IFNg antibody), or anti-receptor receptor antibodies, for
example, anti-IL-6 receptor antibody and antibodies to B-cell
surface molecules. A compound of Formula (I) may also be used with
LJP 394 (abetimus), agents that deplete or inactivate B-cells, for
example, Rituximab (anti-CD20 antibody), lymphostat-B (anti-ByS
antibody), TNF antagonists, for example, anti-TNF antibodies, D2E7
(U.S. Pat. No. 6,090,382; HUMIRA.TM.), CA2 (REMICADE.TM.), CDP 571,
TNFR-Ig constructs, (p75TNFRIgG (ENBREL.TM.) and p55TNFRIgG
(LENERCEPT.TM.)
[0528] In this invention, the following definitions are
applicable:
[0529] A "therapeutically effective amount" is an amount of a
compound of Formula (I) or a combination of two or more such
compounds, which inhibits, totally or partially, the progression of
the condition or alleviates, at least partially, one or more
symptoms of the condition. A therapeutically effective amount can
also be an amount which is prophylactically effective. The amount
which is therapeutically effective will depend upon the patient's
size and gender, the condition to be treated, the severity of the
condition and the result sought. For a given patient, a
therapeutically effective amount can be determined by methods known
to those of skill in the art.
[0530] "Pharmaceutically acceptable salts" refers to those salts
which retain the biological effectiveness and properties of the
free bases and which are obtained by reaction with inorganic acids,
for example, hydrochloric acid, hydrobromic acid, sulfuric acid,
nitric acid, and phosphoric acid or organic acids such as sulfonic
acid, carboxylic acid, organic phosphoric acid, methanesulfonic
acid, ethanesulfonic acid, p-toluenesulfonic acid, citric acid,
fumaric acid, maleic acid, succinic acid, benzoic acid, salicylic
acid, lactic acid, tartaric acid (e.g. (+) or (-)-tartaric acid or
mixtures thereof), amino acids (e.g. (+) or (-)-amino acids or
mixtures thereof), and the like. These salts can be prepared by
methods known to those skilled in the art.
[0531] Certain compounds of Formula (I) which have acidic
substituents may exist as salts with pharmaceutically acceptable
bases. The present invention includes such salts. Examples of such
salts include sodium salts, potassium salts, lysine salts and
arginine salts. These salts may be prepared by methods known to
those skilled in the art.
[0532] Certain compounds of Formula (I) and their salts may exist
in more than one crystal form and the present invention includes
each crystal form and mixtures thereof.
[0533] Certain compounds of Formula (I) and their salts may also
exist in the form of solvates, for example hydrates, and the
present invention includes each solvate and mixtures thereof.
[0534] Certain compounds of Formula (I) may contain one or more
chiral centers, and exist in different optically active forms. When
compounds of Formula (I) contain one chiral center, the compounds
exist in two enantiomeric forms and the present invention includes
both enantiomers and mixtures of enantiomers, such as racemic
mixtures. The enantiomers may be resolved by methods known to those
skilled in the art, for example by formation of diastereoisomeric
salts which may be separated, for example, by crystallization;
formation of diastereoisomeric derivatives or complexes which may
be separated, for example, by crystallization, gas-liquid or liquid
chromatography; selective reaction of one enantiomer with an
enantiomer-specific reagent, for example enzymatic esterification;
or gas-liquid or liquid chromatography in a chiral environment, for
example on a chiral support for example silica with a bound chiral
ligand or in the presence of a chiral solvent. It will be
appreciated that where the desired enantiomer is converted into
another chemical entity by one of the separation procedures
described above, a further step is required to liberate the desired
enantiomeric form. Alternatively, specific enantiomers may be
synthesized by asymmetric synthesis using optically active
reagents, substrates, catalysts or solvents, or by converting one
enantiomer into the other by asymmetric transformation.
[0535] When a compound of Formula (I) contains more than one chiral
center, it may exist in diastereoisomeric forms. The
diastereoisomeric compounds may be separated by methods known to
those skilled in the art, for example chromatography or
crystallization and the individual enantiomers may be separated as
described above. The present invention includes each
diastereoisomer of compounds of Formula (I) (and mixtures
thereof.
[0536] Certain compounds of Formula (I) may exist in different
tautomeric forms or as different geometric isomers, and the present
invention includes each tautomer and/or geometric isomer of
compounds of Formula (I) and mixtures thereof.
[0537] Certain compounds of Formula (I) may exist in different
stable conformational forms which may be separable. Torsional
asymmetry due to restricted rotation about an asymmetric single
bond, for example because of steric hindrance or ring strain, may
permit separation of different conformers.
[0538] The present invention includes each conformational isomer of
compounds of Formula (I) and mixtures thereof.
[0539] Certain compounds of Formula (I) may exist in zwitterionic
form and the present invention includes each zwitterionic form of
compounds of Formula (I) (and mixtures thereof.
[0540] As used herein the term "pro-drug" refers to an agent which
is converted into the parent drug in vivo by some physiological
chemical process (e.g., a prodrug on being brought to the
physiological pH is converted to the desired drug form). Pro-drugs
are often useful because, in some situations, they may be easier to
administer than the parent drug. They may, for instance, be
bioavailable by oral administration whereas the parent drug is not.
The pro-drug may also have improved solubility in pharmacological
compositions over the parent drug. An example, without limitation,
of a pro-drug would be a compound of the present invention wherein
it is administered as an ester (the "pro-drug") to facilitate
transmittal across a cell membrane where water solubility is not
beneficial, but then it is metabolically hydrolyzed to the
carboxylic acid once inside the cell where water solubility is
beneficial.
[0541] Pro-drugs have many useful properties. For example, a
pro-drug may be more water soluble than the ultimate drug, thereby
facilitating intravenous administration of the drug. A pro-drug may
also have a higher level of oral bioavailability than the ultimate
drug. After administration, the prodrug is enzymatically or
chemically cleaved to deliver the ultimate drug in the blood or
tissue.
[0542] Exemplary pro-drugs upon cleavage release the corresponding
free acid, and such hydrolyzable ester-forming residues of the
compounds of this invention include but are not limited to
carboxylic acid substituents wherein the free hydrogen is replaced
by (C.sub.1-C.sub.4)alkyl, (C.sub.1-C.sub.12)alkanoyloxymethyl,
(C.sub.4-C.sub.9)1-(alkanoyloxy)ethyl,
1-methyl-1-(alkanoyloxy)-ethyl having from 5 to 10 carbon atoms,
alkoxycarbonyloxymethyl having from 3 to 6 carbon atoms,
1-(alkoxycarbonyloxy)ethyl having from 4 to 7 carbon atoms,
1-methyl-1-(alkoxycarbonyloxy)ethyl having from 5 to 8 carbon
atoms, N-(alkoxycarbonyl)aminomethyl having from 3 to 9 carbon
atoms, 1-(N-(alkoxycarbonyl)amino)ethyl having from 4 to 10 carbon
atoms, 3-phthalidyl, 4-crotonolactonyl, gamma-butyrolacton-4-yl,
di-N,N--(C.sub.1-C.sub.2)alkylamino(C.sub.2-C.sub.3)alkyl (such as
.beta.-dimethylaminoethyl), carbamoyl-(C.sub.1-C.sub.2)alkyl,
NN-di(C.sub.1-C.sub.2)-alkylcarbamoyl-(C.sub.1-C.sub.2)alkyl and
piperidino-, pyrrolidino- or morpholino(C.sub.2-C.sub.3)alkyl.
[0543] Other exemplary pro-drugs release an alcohol of Formula (I)
wherein the free hydrogen of the hydroxyl substituent (e.g.,
R.sup.1 contains hydroxyl) is replaced by
(C.sub.1-C.sub.6)alkanoyloxymethyl,
1-((C.sub.1-C.sub.6)alkanoyloxy)ethyl,
1-methyl-1-((C.sub.1-C.sub.6)alkanoyloxy)ethyl,
(C.sub.1-C.sub.12)alkoxycarbonyloxymethyl,
N--(C.sub.1-C.sub.6)alkoxycarbonylamino-methyl, succinoyl,
(C.sub.1-C.sub.6)alkanoyl, .alpha.-amino(C.sub.2-C.sub.4)alkanoyl,
arylactyl and .alpha.-aminoacyl, or
.alpha.-aminoacyl-.alpha.-aminoacyl wherein said .alpha.-aminoacyl
moieties are independently any of the naturally occurring L-amino
acids found in proteins, P(O)(OH).sub.2,
--P(O)(O(C.sub.1-C.sub.6)alkyl).sub.2 or glycosyl (the radical
resulting from detachment of the hydroxyl of the hemiacetal of a
carbohydrate).
[0544] As used herein, the term "bridged (C.sub.5-C.sub.12)
cycloalkyl group" means a saturated or unsaturated, bicyclic or
polycyclic bridged hydrocarbon group having two or three
C.sub.3-C.sub.10 cycloalkyl rings. Non bridged cycloalkyls are
excluded. Bridged cyclic hydrocarbon may include, such as
bicyclo[2.1.1]hexyl, bicyclo[2.2.I]heptyl, bicyclo[2.2.2]octyl,
bicyclo[3.2.1]octyl, bicyclo[4.3.1]decyl, bicyclo[3.3.1]nonyl,
bomyl, bornenyl, norbornyl, norbomenyl, 6,6-dimethylbicyclo
[3.1.1]heptyl, tricyclobutyl, and adamantyl.
[0545] As used herein the term "bridged (C.sub.2-C.sub.10)
heterocyclyl" means bicyclic or polycyclic aza-bridged hydrocarbon
groups and may include azanorbomyl, quinuclidinyl,
isoquinuclidinyl, tropanyl, azabicyclo[3.2.1]octanyl,
azabicyclo[2.2.1]heptanyl, 2-azabicyclo[3.2.1]octanyl,
azabicyclo[3.2.1]octanyl, azabicyclo[3.2.2]nonanyl,
azabicyclo[3.3.0]nonanyl, and azabicyclo [3.3.1]nonanyl.
[0546] The term "heterocyclic," "heterocyclyl" or
"heterocyclylene," as used herein, include non-aromatic, ring
systems, including, but not limited to, monocyclic, bicyclic,
tricyclic and spirocyclic rings, which can be completely saturated
or which can contain one or more units of unsaturation, for the
avoidance of doubt, the degree of unsaturation does not result in
an aromatic ring system) and have 5 to 12 atoms including at least
one heteroatom, such as nitrogen, oxygen, or sulfur. For purposes
of exemplification, which should not be construed as limiting the
scope of this invention, the following are examples of heterocyclic
rings: azepinyl, azetidinyl, indolinyl, isoindolinyl, morpholinyl,
piperazinyl, piperidinyl, pyrrolidinyl, quinucludinyl,
thiomorpholinyl, tetrahydropyranyl, tetrahydrofuranyl,
tetrahydroindolyl, thiomorpholinyl and tropanyl.
[0547] The term "heteroaryl" or "heteroarylene" as used herein,
include aromatic ring systems, including, but not limited to,
monocyclic, bicyclic and tricyclic rings, and have 5 to 12 atoms
including at least one heteroatom, such as nitrogen, oxygen, or
sulfur. For purposes of exemplification, which should not be
construed as limiting the scope of this invention: azaindolyl,
benzo(b)thienyl, benzimidazolyl, benzofuranyl, benzoxazolyl,
benzothiazolyl, benzothiadiazolyl, benzoxadiazolyl, furanyl,
imidazolyl, imidazopyridinyl, indolyl, indazolyl, isoxazolyl,
isothiazolyl, oxadiazolyl, oxazolyl, purinyl, pyranyl, pyrazinyl,
pyrazolyl, pyridinyl, pyrimidinyl, pyrrolyl,
pyrrolo[2,3-d]pyrimidinyl, pyrazolo[3,4-d]pyrimidinyl, quinolinyl,
quinazolinyl, triazolyl, thiazolyl, thiophenyl, tetrazolyl,
thiadiazolyl, thienyl,
6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyrazinyl,
6H-imidazo[1,5-a]pyrrolo[2,3-e]pyrazinyl,
1,6-dihydropyrazolo[3,4-d]pyrrolo[2,3-b]pyridine,
3H-3,4,6,8a-tetraaza-asindacenyl,
3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazinyl,
pyrazolo[3,4-d]pyrrolo[2,3-b]pyridinyl,
1,6-dihydro-1,2,5,6-tetraza-as-indacenyl,
3H-3,4,8a-triaza-as-indacenyl, 6H-3-oxa-2,5,6-triaza-as-indacenyl,
3,6-dihydro-2,3,6-tetraaza-as-indacenyl,
1,6-dihydro-dipyrrolo[2,3-b;2'3'-d]pyridinyl,
6H-3-thia-2,5,6-triaza-as-indacenyl or
1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine.
[0548] As used herein, "alkyl," "alkylene" or notations such as
"(C.sub.1-C.sub.8)" include straight chained or branched
hydrocarbons which are completely saturated. Examples of alkyls are
methyl, ethyl, propyl, isopropyl, butyl, pentyl, hexyl and isomers
thereof. As used herein, "alkenyl," "alkenylene," "alkynylene" and
"alkynyl" means C.sub.2-C.sub.8 and includes straight chained or
branched hydrocarbons which contain one or more units of
unsaturation, one or more double bonds for alkenyl and one or more
triple bonds for alkynyl.
[0549] As used herein, "aromatic" groups (or "aryl" or "arylene"
groups) include aromatic carbocyclic ring systems (e.g. phenyl) and
fused polycyclic aromatic ring systems (e.g. naphthyl, biphenyl and
1,2,3,4-tetrahydronaphthyl).
[0550] As used herein, "cycloalkyl" or "cycloalkylene" means
C.sub.3-C.sub.12 monocyclic or multicyclic (e.g., bicyclic,
tricyclic, spirocyclic, etc.) hydrocarbons that is completely
saturated. Examples of a cycloalkyl group are cyclopropyl,
cyclobutyl, cyclopentyl, and cyclohexyl.
[0551] As used herein, "cycloalkenyl" means C.sub.3-C.sub.12
monocyclic or multicyclic (e.g., bicyclic, tricyclic, spirocyclic,
etc.) hydrocarbons that has one or more unsaturated bonds but does
not amount to an aromatic group. Examples of a cycloalklenyl group
are cyclopentenyl and cyclohexenyl.
[0552] As used herein, many moieties or substituents are termed as
being either "substituted" or "optionally substituted". When a
moiety is modified by one of these terms, unless otherwise noted,
it denotes that any portion of the moiety that is known to one
skilled in the art as being available for substitution can be
substituted, which includes one or more substituents, where if more
than one substituent then each substituent is independently
selected. Such means for substitution are well-known in the art
and/or taught by the instant disclosure. For purposes of
exemplification, which should not be construed as limiting the
scope of this invention, some examples of groups that are
substituents are: (C.sub.1-C.sub.8)alkyl groups,
(C.sub.2-C.sub.8)alkenyl groups, (C.sub.2-C.sub.8)alkynyl groups,
(C.sub.3-C.sub.10)cycloalkyl groups, halogen (F, Cl, Br or I),
halogenated (C.sub.1-C.sub.8)alkyl groups (for example but not
limited to --CF.sub.3), --O--(C.sub.1-C.sub.8)alkyl groups, .dbd.O,
.dbd.CH.sub.2, --OH, --CH.sub.2OH, --CH.sub.2NH.sub.2,
(C.sub.2-C.sub.4)alkyl-OH, --CH.sub.2CH.sub.2OCH.sub.2CH.sub.3,
--S--(C.sub.1 --C.sub.8)alkyl groups, --SH,
--NH(C.sub.1-C.sub.8)alkyl groups,
--N((C.sub.1-C.sub.8)alkyl).sub.2 groups, --NH.sub.2,
--C(O)NH.sub.2, --CH.sub.2NHC(O)(C.sub.1-C.sub.4)alkyl,
--CH.sub.2NHC(O)CH.sub.2Cl, --CH.sub.2NHC(O)CH.sub.2CN,
--CH.sub.2NHC(O)CH.sub.2CH.sub.2N(CH.sub.3).sub.2,
--CH.sub.2NHC(O)C(.dbd.CH.sub.2)CH.sub.3,
--CH.sub.2NHC(O)(C.sub.2-C.sub.4)alkynyl,
--CH.sub.2NHC(O)CH.sub.2CH.sub.2-piperidinyl,--(C.sub.1-C.sub.4)alkyl-mor-
pholinyl,--CH.sub.2NHC(O)CH.sub.2O-phenyl wherein the phenyl is
optionally substituted with halogen, (C.sub.1-C.sub.4)alkoxy,
--C(O)(C.sub.1-C.sub.4)alkyl, --C(O)(C.sub.1-C.sub.4)alkoxy,
--C(O)N(H).sub.2, --C(O)N(CH.sub.3).sub.2,
--C(O)(C.sub.1-C.sub.6)heteroaryl, --N(CH.sub.3).sub.2,
--NHC(O)(C.sub.1-C.sub.4)alkyl, --NHC(O)(C.sub.2-C.sub.4)alkenyl,
--NHC(O)CH.sub.2CN, --S(O).sub.2(C.sub.1-C.sub.4)alkyl,
--S(O).sub.2(C.sub.1-C.sub.6)heteroaryl,
--S(O).sub.2(C.sub.1-C.sub.6) (C.sub.1-C.sub.6)heterocyclyl,
4-methylpiperazinecarbonyl, --(C.sub.1-C.sub.4)alkylC(O)NH.sub.2,
--C(O)NH(C.sub.1-C.sub.8)alkyl groups,
--C(O)N((C.sub.1-C.sub.8)alkyl).sub.2,
--C(O)N(H)(C.sub.3-C.sub.8)cycloalkyl groups,
--C(O)(C.sub.1-C.sub.4)alkoxy, --NHC(O)H,
--NHC(O)(C.sub.1-C.sub.8)alkyl groups,
--NHC(O)(C.sub.3-C.sub.8)cycloalkyl groups,
--N((C.sub.1-C.sub.8)alkyl)C(O)H,
--N((C.sub.1-C.sub.8)alkyl)C(O)(C.sub.1-C.sub.8)alkyl groups,
--NHC(O)NH.sub.2, --NHC(O)NH(C.sub.1-C.sub.8)alkyl groups,
--N((C.sub.1-C.sub.8)alkyl)C(O)NH.sub.2groups,
--NHC(O)N((C.sub.1-C.sub.8)alkyl).sub.2groups,--N((C.sub.1-C.sub.8)alkyl)-
C(O)N((C.sub.1-C.sub.8)alkyl).sub.2 groups,
--N((C.sub.1-C.sub.8)alkyl)C(O)NH((C.sub.1-C.sub.8)alkyl),
--NHCH.sub.2-heteroaryl, benzyl, --OCH.sub.2-heteroaryl, --C(O)H,
--C(O)(C.sub.1-C.sub.8)alkyl groups, --CN, --NO.sub.2,
--S(O)(C.sub.1-C.sub.8)alkyl groups,
--S(O).sub.2(C.sub.1-C.sub.8)alkyl groups,
--S(O).sub.2N((C.sub.1-C.sub.8)alkyl).sub.2 groups,
--S(O).sub.2NH(C.sub.1-C.sub.8)alkyl groups,
--S(O).sub.2NH(C.sub.3-C.sub.8)cycloalkyl groups,
--S(O).sub.2NH.sub.2 groups, --NHS(O).sub.2(C.sub.1-C.sub.8)alkyl
groups, --N((C.sub.1-C.sub.8)alkyl)S(O).sub.2(C.sub.1-C.sub.8)alkyl
groups, --(C.sub.1-C.sub.8)alkyl-O--(C.sub.1-C.sub.8)alkyl groups,
--O--(C.sub.1-C.sub.8)alkyl-O--(C.sub.1-C.sub.8)alkyl groups,
--C(O)OH, --C(O)O(C.sub.1-C.sub.8)alkyl groups, NHOH,
NHO(C.sub.1-C.sub.8)alkyl groups, --O-halogenated
(C.sub.1-C.sub.8)alkyl groups (for example but not limited to
--OCF.sub.3), --S(O).sub.2-halogenated (C.sub.1-C.sub.8)alkyl
groups (for example but not limited to --S(O).sub.2CF.sub.3),
--S-halogenated (C.sub.1-C.sub.8)alkyl groups (for example but not
limited to --SCF.sub.3), --(C.sub.1-C.sub.6)heterocyclyl (for
example but not limited to pyrrolidine, tetrahydrofuran, pyran or
morpholine), --(C.sub.1-C.sub.6)heteroaryl (for example but not
limited to tetrazole, imidazole, furan, pyrazine or pyrazole),
-phenyl, optionally substituted benzyl,
--NHC(O)O--(C.sub.1-C.sub.6)alkyl groups,
--N((C.sub.1-C.sub.6)alkyl)C(O)O--(C.sub.1-C.sub.6)alkyl groups,
--C(.dbd.NH)--(C.sub.1-C.sub.6)alkyl groups,
--C(.dbd.NOH)--(C.sub.1-C.sub.6)alkyl groups, or
--C(.dbd.N--O--(C.sub.1-C.sub.6)alkyl)-(C.sub.1-C.sub.6)alkyl
groups.
[0553] The term "kit" as used herein refers to a packaged product
comprising components with which to administer a compound of
Formula (I) of the invention for treatment of an autoimmune
disorder. The kit preferably comprises a box or container that
holds the components of the kit. The box or container is affixed
with a label or a Food and Drug Administration approved protocol.
The box or container holds components of the invention which are
preferably contained within plastic, polyethylene, polypropylene,
ethylene, or propylene vessels. The vessels can be capped-tubes or
bottles. The kit can also include instructions for administering a
compound of Formula (I).
[0554] One or more compounds of this invention can be administered
to a human patient by themselves or in pharmaceutical compositions
where they are mixed with biologically suitable carriers or
excipient(s) at doses to treat or ameliorate a disease or condition
as described herein. Mixtures of these compounds can also be
administered to the patient as a simple mixture or in suitable
formulated pharmaceutical compositions. A therapeutically effective
dose refers to that amount of the compound or compounds sufficient
to result in the prevention or attenuation of a disease or
condition as described herein. Techniques for formulation and
administration of the compounds of the instant application may be
found in references well known to one of ordinary skill in the art,
such as "Remington's Pharmaceutical Sciences," Mack Publishing Co.,
Easton, Pa., latest edition.
[0555] Suitable routes of administration may, for example, include
oral, eyedrop, rectal, transmucosal, topical, or intestinal
administration; parenteral delivery, including intramuscular,
subcutaneous, intramedullary injections, as well as intrathecal,
direct intraventricular, intravenous, intraperitoneal, intranasal,
or intraocular injections.
[0556] Alternatively, one may administer the compound in a local
rather than a systemic manner, for example, via injection of the
compound directly into an edematous site, often in a depot or
sustained release formulation.
[0557] Furthermore, one may administer the drug in a targeted drug
delivery system, for example, in a liposome coated with endothelial
cell-specific antibody.
[0558] The pharmaceutical compositions of the present invention may
be manufactured in a manner that is itself known, e.g., by means of
conventional mixing, dissolving, granulating, dragee-making,
levigating, emulsifying, encapsulating, entrapping or lyophilizing
processes.
[0559] Pharmaceutical compositions for use in accordance with the
present invention thus may be formulated in a conventional manner
using one or more physiologically acceptable carriers comprising
excipients and auxiliaries which facilitate processing of the
active compounds into preparations which can be used
pharmaceutically. Proper formulation is dependent upon the route of
administration chosen.
[0560] For injection, the agents of the invention may be formulated
in aqueous solutions, preferably in physiologically compatible
buffers such as Hanks' solution, Ringer's solution, or
physiological saline buffer. For transmucosal administration,
penetrants appropriate to the barrier to be permeated are used in
the formulation. Such penetrants are generally known in the
art.
[0561] For oral administration, the compounds can be formulated
readily by combining the active compounds with pharmaceutically
acceptable carriers well known in the art. Such carriers enable the
compounds of the invention to be formulated as tablets, pills,
dragees, capsules, liquids, gels, syrups, slurries, suspensions and
the like, for oral ingestion by a patient to be treated.
Pharmaceutical preparations for oral use can be obtained by
combining the active compound with a solid excipient, optionally
grinding a resulting mixture, and processing the mixture of
granules, after adding suitable auxiliaries, if desired, to obtain
tablets or dragee cores. Suitable excipients are, in particular,
fillers such as sugars, including lactose, sucrose, mannitol, or
sorbitol; cellulose preparations such as, for example, maize
starch, wheat starch, rice starch, potato starch, gelatin, gum
tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium
carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). If
desired, disintegrating agents may be added, such as the
cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt
thereof such as sodium alginate.
[0562] Dragee cores are provided with suitable coatings. For this
purpose, concentrated sugar solutions may be used, which may
optionally contain gum arabic, talc, polyvinyl pyrrolidone,
carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer
solutions, and suitable organic solvents or solvent mixtures.
Dyestuffs or pigments may be added to the tablets or dragee
coatings for identification or to characterize different
combinations of active compound doses.
[0563] Pharmaceutical preparations that can be used orally include
push-fit capsules made of gelatin, as well as soft, sealed capsules
made of gelatin and a plasticizer, such as glycerol or sorbitol.
The push-fit capsules can contain the active ingredients in
admixture with filler such as lactose, binders such as starches,
and/or lubricants such as talc or magnesium stearate and,
optionally, stabilizers. In soft capsules, the active compounds may
be dissolved or suspended in suitable liquids, such as fatty oils,
liquid paraffin, or liquid polyethylene glycols. In addition,
stabilizers may be added. All formulations for oral administration
should be in dosages suitable for such administration.
[0564] For buccal administration, the compositions may take the
form of tablets or lozenges formulated in conventional manner.
[0565] For administration by inhalation, the compounds for use
according to the present invention are conveniently delivered in
the form of an aerosol spray presentation from pressurized packs or
a nebuliser, with the use of a suitable propellant, e.g.,
dichlorodifluoromethane, trichlorofluoromethane,
dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In
the case of pressurized aerosol the dosage unit may be determined
by providing a valve to deliver a metered amount. Capsules and
cartridges of e.g. gelatin for use in an inhaler or insufflator may
be formulated containing a powder mix of the compound and a
suitable powder base such as lactose or starch.
[0566] The compounds can be formulated for parenteral
administration by injection, e.g. bolus injection or continuous
infusion. Formulations for injection may be presented in unit
dosage form, e.g. in ampoules or in multi-dose containers, with an
added preservative. The compositions may take such forms as
suspensions, solutions or emulsions in oily or aqueous vehicles,
and may contain formulatory agents such as suspending, stabilizing
and/or dispersing agents.
[0567] Pharmaceutical formulations for parenteral administration
include aqueous solutions of the active compounds in water-soluble
form. Additionally, suspensions of the active compounds may be
prepared as appropriate oily injection suspensions. Suitable
lipophilic solvents or vehicles include fatty oils such as sesame
oil, or synthetic fatty acid esters, such as ethyl oleate or
triglycerides, or liposomes. Aqueous injection suspensions may
contain substances which increase the viscosity of the suspension,
such as sodium carboxymethyl cellulose, sorbitol, or dextran.
Optionally, the suspension may also contain suitable stabilizers or
agents which increase the solubility of the compounds to allow for
the preparation of highly concentrated solutions.
[0568] Alternatively, the active ingredient may be in powder form
for constitution with a suitable vehicle, e.g., sterile
pyrogen-free water, before use.
[0569] The compounds may also be formulated in rectal compositions
such as suppositories or retention enemas, e.g., containing
conventional suppository bases such as cocoa butter or other
glycerides.
[0570] In addition to the formulations described previously, the
compounds may also be formulated as a depot preparation. Such long
acting formulations may be administered by implantation (for
example subcutaneously or intramuscularly or by intramuscular
injection). Thus, for example, the compounds may be formulated with
suitable polymeric or hydrophobic materials (for example as an
emulsion in an acceptable oil) or ion exchange resins, or as
sparingly soluble derivatives, for example, as a sparingly soluble
salt.
[0571] An example of a pharmaceutical carrier for the hydrophobic
compounds of the invention is a cosolvent system comprising benzyl
alcohol, a nonpolar surfactant, a water-miscible organic polymer,
and an aqueous phase. The cosolvent system may be the VPD
co-solvent system. VPD is a solution of 3% w/v benzyl alcohol, 8%
w/v of the nonpolar surfactant polysorbate 80, and 65% w/v
polyethylene glycol 300, made up to volume in absolute ethanol. The
VPD co-solvent system (VPD:5W) consists of VPD diluted 1:1 with a
5% dextrose in water solution. This co-solvent system dissolves
hydrophobic compounds well, and itself produces low toxicity upon
systemic administration. Naturally, the proportions of a co-solvent
system may be varied considerably without destroying its solubility
and toxicity characteristics. Furthermore, the identity of the
co-solvent components may be varied: for example, other
low-toxicity nonpolar surfactants may be used instead of
polysorbate 80; the fraction size of polyethylene glycol may be
varied; other biocompatible polymers may replace polyethylene
glycol, e.g. polyvinyl pyrrolidone; and other sugars or
polysaccharides may substitute for dextrose.
[0572] Alternatively, other delivery systems for hydrophobic
pharmaceutical compounds may be employed. Liposomes and emulsions
are well known examples of delivery vehicles or carriers for
hydrophobic drugs. Certain organic solvents such as
dimethysulfoxide also may be employed, although usually at the cost
of greater toxicity. Additionally, the compounds may be delivered
using a sustained-release system, such as semipermeable matrices of
solid hydrophobic polymers containing the therapeutic agent.
Various sustained-release materials have been established and are
well known by those skilled in the art. Sustained-release capsules
may, depending on their chemical nature, release the compounds for
a few weeks up to over 100 days. Depending on the chemical nature
and the biological stability of the therapeutic reagent, additional
strategies for protein stabilization may be employed.
[0573] The pharmaceutical compositions also may comprise suitable
solid or gel phase carriers or excipients. Examples of such
carriers or excipients include but are not limited to calcium
carbonate, calcium phosphate, various sugars, starches, cellulose
derivatives, gelatin, and polymers such as polyethylene
glycols.
[0574] Many of the compounds of the invention may be provided as
salts with pharmaceutically compatible counter ions.
Pharmaceutically compatible salts may be formed with many acids,
including but not limited to hydrochloric, sulfuric, acetic,
lactic, tartaric, malic, succinic, etc. Salts tend to be more
soluble in aqueous or other protonic solvents than are the
corresponding free base forms.
[0575] Pharmaceutical compositions suitable for use in the present
invention include compositions wherein the active ingredients are
contained in an effective amount to achieve its intended purpose.
More specifically, a therapeutically effective amount means an
amount effective to prevent development of or to alleviate the
existing symptoms of the subject being treated. Determination of
the effective amounts is well within the capability of those
skilled in the art.
[0576] For any compound used in a method of the present invention,
the therapeutically effective dose can be estimated initially from
cellular assays. For example, a dose can be formulated in cellular
and animal models to achieve a circulating concentration range that
includes the IC.sub.50 as determined in cellular assays (e.g., the
concentration of the test compound which achieves a half-maximal
inhibition of a given protein kinase activity). In some cases it is
appropriate to determine the IC.sub.50 in the presence of 3 to 5%
serum albumin since such a determination approximates the binding
effects of plasma protein on the compound. Such information can be
used to more accurately determine useful doses in humans. Further,
the most preferred compounds for systemic administration
effectively inhibit protein kinase signaling in intact cells at
levels that are safely achievable in plasma.
[0577] A therapeutically effective dose refers to that amount of
the compound that results in amelioration of symptoms in a patient.
Toxicity and therapeutic efficacy of such compounds can be
determined by standard pharmaceutical procedures in cell cultures
or experimental animals, e.g., for determining the maximum
tolerated dose (MTD) and the EDo (effective dose for 50% maximal
response). The dose ratio between toxic and therapeutic effects is
the therapeutic index and it can be expressed as the ratio between
MTD and ED.sub.50. Compounds which exhibit high therapeutic indices
are preferred. The data obtained from these cell culture assays and
animal studies can be used in formulating a range of dosage for use
in humans. The dosage of such compounds lies preferably within a
range of circulating concentrations that include the EDo with
little or no toxicity. The dosage may vary within this range
depending upon the dosage form employed and the route of
administration utilized. The exact formulation, route of
administration and dosage can be chosen by the individual physician
in view of the patient's condition (see, e.g., Fingl et al., 1975,
in The Pharmacological Basis of Therapeutics, Ch. 1, p. 1). In the
treatment of crises, the administration of an acute bolus or an
infusion approaching the MTD may be required to obtain a rapid
response.
[0578] Dosage amount and interval may be adjusted individually to
provide plasma levels of the active moiety which are sufficient to
maintain the kinase modulating effects, or minimal effective
concentration (MEC). The MEC will vary for each compound but can be
estimated from in vitro data; e.g. the concentration necessary to
achieve 50-90% inhibition of protein kinase using the assays
described herein. Dosages necessary to achieve the MEC will depend
on individual characteristics and route of administration. However,
HPLC assays or bioassays can be used to determine plasma
concentrations.
[0579] Dosage intervals can also be determined using the MEC value.
Compounds should be administered using a regimen which maintains
plasma levels above the MEC for 10-90% of the time, preferably
between 30-90% and most preferably between 50-90% until the desired
amelioration of symptoms is achieved. In cases of local
administration or selective uptake, the effective local
concentration of the drug may not be related to plasma
concentration.
[0580] The amount of composition administered will, of course, be
dependent on the subject being treated, on the subject's weight,
the severity of the affliction, the manner of administration and
the judgment of the prescribing physician.
[0581] The compositions may, if desired, be presented in a pack or
dispenser device which may contain one or more unit dosage forms
containing the active ingredient. The pack may for example comprise
metal or plastic foil, such as a blister pack. The pack or
dispenser device may be accompanied by instructions for
administration. Compositions comprising a compound of the invention
formulated in a compatible pharmaceutical carrier may also be
prepared, placed in an appropriate container, and labelled for
treatment of an indicated condition.
[0582] In some formulations it may be beneficial to use the
compounds of the present invention in the form of particles of very
small size, for example as obtained by fluid energy milling.
[0583] The use of compounds of the present invention in the
manufacture of pharmaceutical compositions is illustrated by the
following description. In this description the term "active
compound" denotes any compound of the invention but particularly
any compound which is the final product of one of the following
Examples.
a) Capsules
[0584] In the preparation of capsules, 10 parts by weight of active
compound and 240 parts by weight of lactose can be de-aggregated
and blended. The mixture can be filled into hard gelatin capsules,
each capsule containing a unit dose or part of a unit dose of
active compound.
b) Tablets
[0585] Tablets can be prepared, for example, from the following
ingredients.
[0586] Parts by weight
TABLE-US-00001 Active compound 10 Lactose 190 Maize starch 22
Polyvinylpyrrolidone 10 Magnesium stearate 3
[0587] The active compound, the lactose and some of the starch can
be de-aggregated, blended and the resulting mixture can be
granulated with a solution of the polyvinylpyrrolidone in ethanol.
The dry granulate can be blended with the magnesium stearate and
the rest of the starch. The mixture is then compressed in a
tabletting machine to give tablets each containing a unit dose or a
part of a unit dose of active compound.
c) Enteric Coated Tablets
[0588] Tablets can be prepared by the method described in (b)
above. The tablets can be enteric coated in a conventional manner
using a solution of 20% cellulose acetate phthalate and 3% diethyl
phthalate in ethanol:dichloromethane (1:1).
d) Suppositories
[0589] In the preparation of suppositories, for example, 100 parts
by weight of active compound can be incorporated in 1300 parts by
weight of triglyceride suppository base and the mixture formed into
suppositories each containing a therapeutically effective amount of
active ingredient.
[0590] In the compositions of the present invention the active
compound may, if desired, be associated with other compatible
pharmacologically active ingredients. For example, the compounds of
this invention can be administered in combination with another
therapeutic agent that is known to treat a disease or condition
described herein. For example, with one or more additional
pharmaceutical agents that inhibit or prevent the production of
VEGF or angiopoietins, attenuate intracellular responses to VEGF or
angiopoietins, block intracellular signal transduction, inhibit
vascular hyperpermeability, reduce inflammation, or inhibit or
prevent the formation of edema or neovascularization. The compounds
of the invention can be administered prior to, subsequent to or
simultaneously with the additional pharmaceutical agent, whichever
course of administration is appropriate. The additional
pharmaceutical agents include, but are not limited to, anti-edemic
steroids, NSAIDS, ras inhibitors, anti-TNF agents, anti-IL1 agents,
antihistamines, PAF-antagonists, COX-1 inhibitors, COX-2
inhibitors, NO synthase inhibitors, Akt/PTB inhibitors, IGF-1R
inhibitors, PKC inhibitors, PI3 kinase inhibitors, calcineurin
inhibitors and immunosuppressants. The compounds of the invention
and the additional pharmaceutical agents act either additively or
synergistically. Thus, the administration of such a combination of
substances that inhibit angiogenesis, vascular hyperpermeability
and/or inhibit the formation of edema can provide greater relief
from the deletrious effects of a hyperproliferative disorder,
angiogenesis, vascular hyperpermeability or edema than the
administration of either substance alone. In the treatment of
malignant disorders combinations with antiproliferative or
cytotoxic chemotherapies or radiation are included in the scope of
the present invention.
[0591] The present invention also comprises the use of a compound
of Formula (I) as a medicament.
[0592] A further aspect of the present invention provides the use
of a compound of Formula (I) or a salt thereof in the manufacture
of a medicament for treating vascular hyperpermeability,
angiogenesis-dependent disorders, proliferative diseases and/or
disorders of the immune system in mammals, particularly human
beings.
[0593] The present invention also provides a method of treating
vascular hyperpermeability, inappropriate neovascularization,
proliferative diseases and/or disorders of the immune system which
comprises the administration of a therapeutically effective amount
of a compound of Formula (I) to a mammal, particularly a human
being, in need thereof.
Abbreviations
[0594] Ac Acetyl [0595] AcOH Glacial acetic acid [0596] Bn Benzyl
[0597] BnBr Benzyl bromide [0598] Boc t-Butoxycarbonyl [0599]
Boc.sub.2O Di-tert-butyl dicarbonate [0600] BPO Benzoyl peroxide
[0601] br broad [0602] t-BuOH tert-Butanol [0603] (CH.sub.2O).sub.n
paraformaldehyde [0604] d Doublet [0605] dba Dibenzylideneacetone
[0606] DCAD (E)-Bis(4-chlorobenzyl) diazene-1,2-dicarboxylate
[0607] DCE 1,2-Dichloroethane [0608] DCM Dichloromethane (methylene
chloride) [0609] dd Doublet of doublets [0610] DIEA
N,N-Diisopropylethylamine [0611] DMA Dimethylacetamide [0612] DMAP
4-Dimethylaminopyridine [0613] DME 1,2-Dimethoxyethane [0614] DMF
N,N-Dimethylformamide [0615] DMSO Dimethyl sulfoxide [0616] dppf
1,1'-Bis(diphenylphosphino)ferrocene [0617] EDC
1-(3-dimethylaminopropyl)-3-ethylcarbodiimide [0618] EDC.HCl
N1-((ethylimino)methylene)-N3,N3-dimethylpropane-1,3-diamine
hydrochloride [0619] equiv Equivalent(s) [0620] EtOAc Ethyl acetate
[0621] Et.sub.2O Diethyl ether [0622] EtOH Ethanol [0623] Fmoc
Fluorenylmethyloxycarbonyl [0624] g Gram(s) [0625] h Hour(s) [0626]
HATU 4-(3-Acrylamidophenyl)-2-ethyl-1H-indole-7-carboxamide [0627]
HOBt 1H-Benzo[d][1,2,3]triazol-1-ol hydrate [0628] HPLC
High-pressure liquid chromatography [0629] IPA Isopropyl alcohol
[0630] KHMDS Potassium bis(trimethylsilyl)amide [0631] KOAc
Potassium acetate [0632] KOt-Bu Potassium tert-butoxide [0633]
LC/MS Liquid chromatography/mass spectrometry [0634] LDA Lithium
diisopropylamide [0635] LiHMDS Lithium bis(trimethylsilyl)amide
[0636] m Multiplet [0637] M Molar [0638] MeCN Acetonitrile [0639]
MeOH Methyl alcohol [0640] min Minute(s) [0641] mmol Millimole
[0642] MS Mass spectrometry [0643] MsCl Methanesulfonyl chloride
[0644] MTBE tert-Butyl methyl ether [0645] n-Normal (nonbranched)
[0646] N Normal [0647] NaBH(OAc).sub.3 Sodium triacetoxyhydroborate
[0648] NaHMDS Sodium bis(trimethylsilyl)amide [0649] n-BuLi n-Butyl
lithium [0650] NaOt-Bu Sodium tert-butoxide [0651] NBS
N-bromosuccinimide [0652] NCS N-chlorosuccinimide [0653]
NH.sub.4OAc Ammonium acetate [0654] NMP N-Methylpyrolidinone [0655]
NMR Nuclear magnetic resonance [0656] Pd.sub.2dba.sub.3
Tris(dibenzylideneacetone)dipalladium(O) [0657] Pd(OAc).sub.2
Palladium(II) acetate [0658] Pet ether petroleum ether [0659] pH
-log[H.sup.+] [0660] Pd(PPh.sub.3).sub.4
Tetrakis(triphenylphosphine)palladium(0) [0661]
Pd(PPh.sub.3).sub.2Cl.sub.2 Bis(triphenylphosphine)palladium(II)
chloride [0662] PMB para-Methoxybenzyl [0663] PPh.sub.3
Triphenylphosphine [0664] ppm Parts per million [0665] PrOH
Propanol [0666] psi Pounds per square inch [0667] PyBOP
((1H-benzo[d][1,2,3]triazol-1-yl)oxy)tri(pyrrolidin-1-yl)phosphonium
hexafluorophosphate(V) [0668] R.sub.t Retention time [0669] rt Room
temperature [0670] s Singlet [0671] SEM
2-(Trimethylsilyl)ethoxymethyl [0672] SEMCl
2-(Trimethylsilyl)ethoxymethyl chloride [0673] SFC Supercritical
fluid chromatography [0674] SPE Solid phase extraction [0675] t
Triplet [0676] t-Tertiary [0677] TBAF tetrabutylammonium fluoride
[0678] TBME tert-Butyl methyl ether [0679] TBDMS
tert-Butyldimethylsilane [0680] TBSCl tert-Butyldimethylsilyl
chloride [0681] TBTU
2-(1H-Benzo[d][1,2,3]triazol-1-yl)-1,1,3,3-tetramethylisouronium
tetrafluoroborate [0682] TEA Triethylamine [0683] tert-Tertiary
[0684] tert-Butyl X-Phos
2-Di-tert-butylphosphino-2',4',6'-triisopropylbiphenyl [0685] TFA
Trifluoroacetic acid [0686] THF Tetrahydrofuran [0687] TLC Thin
layer chromatography [0688] TMS Trimethylsilyl [0689] TMSCl
Trimethylsilyl chloride [0690] TMSI Trimethylsilyl iodide [0691]
TsCl p-Toluenesulfonyl chloride [0692] UV Ultraviolet [0693] wt %
Weight percent [0694] X-Phos
2-Dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl
General Synthetic Schemes
[0695] Compounds of the invention may be prepared using the
synthetic transformations illustrated in Schemes I-XVIII. Starting
materials are commercially available, may be prepared by the
procedures described herein, by literature procedures, or by
procedures that would be well known to one skilled in the art of
organic chemistry.
[0696] Methods for preparing 1H-indole-7-carboxamide compounds 9 of
the invention are illustrated in Scheme I. In Scheme I, step a,
commercially available 4-bromo-2-nitrobenzoic acid 1 is reacted
with vinylmagnesium bromide via a Bartoli indole synthesis using
methods known to one skilled in the art (for example Preparation
#1, step A) to give indole 2. Indole 2 can be alkylated with methyl
iodide (Scheme I, step b) to provide methyl 1H-indole-7-carboxylate
3 using methods known to one skilled in the art (for example
Preparation #1, step B). The resulting indole 3 may be tosyl (Ts)
protected (Scheme I, step c) using conditions such as those
described in Preparation #1, step C or those described in Greene,
T. W. and Wuts, P. G. M. "Protective Groups in Organic Synthesis,
3rd Edition", 1999, Wiley-Interscience; Larock, R. C.
"Comprehensive Organic Transformations: A Guide to Functional Group
Preparations, 2.sup.nd edition", 1999, Wiley-VCH. In step d,
directed lithiation of methyl
4-bromo-1-tosyl-1H-indole-7-carboxylate 4 followed by trapping of
the anion with iodine yields methyl
4-bromo-2-iodo-1H-indole-7-carboxylates 5 using conditions such as
those described in Preparation #1 step D. Tosyl protected methyl
4-bromo-2-iodo-1H-indole-7-carboxylates 5 may be hydrolyzed and
deprotected under aqueous base conditions in one step e to give
4-bromo-2-iodo-1H-indole-7-carboxylic acid 6 using conditions such
as those described in Preparation #1, step E or known to one
skilled in the art (for example, the books from Larock, R. C. or
Greene, T. W. and Wuts, P. G. M. referenced above). In step f,
4-bromo-2-iodo-1H-indole-7-carboxylic acid 6 may be converted to a
primary amide 7 as shown using conditions such as those described
in General Procedure D. The 4-bromo-2-iodo-1H-indole-7-carboxamide
7 may undergo a variety of reactions known to one skilled in the
art (for example, Larock, R. C. referenced above) including, but
not limited to, Suzuki or Stille coupling reactions such as those
described in General Procedure A and Example #22, step A.
Alternatively, in step i, the tosyl protected indoles 5 may undergo
a variety of reactions known to one skilled in the art (for
example, Larock, R. C. referenced above) including, but not limited
to, Suzuki or Stille coupling reactions described by General
Procedure A (for example Preparation #15 step A). Hydrolysis of
esters 10 gives acids 11 (Scheme I, step j) using well known
conditions such as those described in Preparation #15, step B or
General Procedure C. In step k, carboxylic acid 11 may be coverted
to primary amides 12 as shown using conditions such as those
described in General Procedure D. Removal of the sulfonamide
protecting group of indoles 12 may be accomplished using conditions
such as those described in General Procedure N, or by methods known
to one skilled in the art (for example, Larock, R. C. or Greene, T.
W. and Wuts, P. G. M. referenced above) to give indoles 8 (Scheme
I, step 1). Indoles 8 are reacted with a boronate ester or boronic
acid, either commercially available or prepared by methods known to
one skilled in the art (see, for example, Larock, R. C.
"Comprehensive Organic Transformations: A Guide to Functional Group
Preparations, 2.sup.nd edition", 1999, Wiley-VCH or General
Procedure P), using Suzuki coupling conditions, such as those
described by General Procedure A, to give 1H-indole-7-carboxamide
compounds 9. Alternatively, in step h, indoles 8 may undergo a
variety of reactions known to one skilled in the art (for example,
Larock, R. C. referenced above) including, but not limited to,
Buchwald or Negishi coupling conditions as described by General
Procedures T and U. Further functionalization of the R'' group in
indoles 9 can be performed, if desired, using reactions known to
one skilled in the art (for example, Larock, R. C. referenced
above). For example, indoles 9 containing a double bond may be
reduced to saturated systems using hydrogenation conditions such as
those described in General Procedure L. Ethers can be prepared from
indoles 9 containing an alcohol using condition such as those
described in General Procedure Q. In addition amides, ureas,
sulfonamides, aryl amines, heteroaryl amines, or sulfonyl ureas can
be prepared from indoles 9 containing a primary or secondary amine
(for example General Procedures D, E, I, H, and J). Also,
deprotection of indoles 9 containing a protecting group in either
R' or R'' can be performed using conditions such as those described
in Greene, T. W. and Wuts, P. G. M. referenced above or in General
Procedures G, M, or N. For example, for R'' containing a
TBDMS-protected alcohol, the protecting group can be removed to
yield an unprotected alcohol (for example General Procedure M) and
the deprotected compounds 9 may then be reacted further as
described above. Alternatively, compound 4 may first undergo a
coupling reaction in step m, including but not limited to, such as
Suzuki, Buchwald, or Negishi using conditions as described b
General Procedures A, T and U to give compounds 107 followed by an
iodination reaction as illustrated in General Procedure Y to give
compounds 108 (step n). Indoles 108 may undergo a variety of
reactions known to one skilled in the art (for example, Larock, R.
C. referenced above) including, but not limited to, Suzuki or
Stille coupling reactions such as those described in General
Procedure A to give compounds 109. One can then envisage that
compounds 109 can undergo hydrolysis, amidation and de-tosylation
reactions similar to steps j, k and l to arrive at compounds 9.
##STR00003##
[0697] An alternative method preparing 1H-indole-7-carboxamide
compounds 9 of the invention are illustrated in Scheme II. In step
a, indole 3 from Scheme I may be protected with a SEM group using
conditions known in the literature such as those found in Greene,
T. W. and Wuts, P. G. M. referenced above or as those described in
Preparation #10, step A. The resulting SEM protected indole 13 can
undergo directed lithiation followed by trapping of the anion with
an electrophile (for example iodomethane) yielding indole 14 as
shown in step b using conditions described in Example #19, step A
or trapping the anion with iodine as shown in step g yielding
methyl
4-bromo-2-iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-7-carboxyla-
te 17 using conditions such as those described in Preparation #10,
step B). In step h, indole 14 may undergo a variety of reactions
known to one skilled in the art including, but not limited to,
Suzuki or Stille coupling reactions such as those described in
Larock, R. C. referenced above, General Procedure A, and
Preparation #10, step C. Hydrolysis of esters 14 gives acids 15
(step c) using well known conditions such as those described in
Preparation #10, step D, or General Procedure C. Indole carboxylic
acids 15 may be converted to primary amides 16 as shown using
conditions such as those described in General Procedure D. The SEM
protecting group of 1H-indole-7-carboxamide compounds 16 may be
removed by methods such as those described in Preparation #10, step
E or using conditions such as described in Greene, T. W. and Wuts,
P. G. M. referenced above to give 1H-indole-7-carboxamides 8.
Indoles 8 may then be reacted further as described above (Scheme I)
to give the targeted 1H-indole-7-carboxamide compounds 9.
##STR00004##
[0698] An additional method preparing indole-7-carboxamide
compounds 9 of the invention is illustrated in Scheme III.
Hydrolysis of ester 17 gives acid 18 (step a) using well known
conditions such as those described in Preparation #10, step D or
General Procedure C. Acid 18 may be coverted to a primary amide 19
as shown using conditions such as those described in General
Procedure D. The SEM protecting group of indole 19 may be removed
by methods such as those described in Example #19, step D or using
conditions such as described in Greene, T. W. and Wuts, P. G. M.
referenced above to give 1H-indole-7-carboxamides 7. Indoles 7 may
then be reacted further as described above above to give the
targeted 1H-indole-7-carboxamide compounds 9.
##STR00005##
[0699] An alternative method preparing 1H-indole-7-carboxamide
compounds 9 of the invention is illustrated in Scheme IV. Indole 19
may undergo a variety of reactions known to one skilled in the art
(for example, Larock, R. C. referenced above) including, but not
limited to, Stille coupling reactions such as those described in
Example #22, step A or Suzuki coupling reaction as those described
in General Procedure A. In step b, indole-7-carboxamides 16 are
reacted with a boronate ester or boronic acid either commercially
available or can be prepared by methods known to one skilled in the
art (see, for example, Example #22, step B; Larock, R. C.
"Comprehensive Organic Transformations: A Guide to Functional Group
Preparations, 2.sup.nd edition", 1999, Wiley-VCH; or General
Procedure A) using Suzuki coupling conditions (for example, Example
#19 or General Procedure A). The SEM protecting group of indoles 20
may be removed by methods such as those described in Example #22,
step D or using conditions such as described in Greene, T. W. and
Wuts, P. G. M. referenced above to give 1H-indole-7-carboxamides 9.
Indoles 9 may then be reacted further as described above.
##STR00006##
[0700] Indole-7-carboxamide compounds 9 of the invention can also
be prepared using the route illustrated in Scheme V. In step a,
methyl ester 21 is prepared using standard condition such as those
described in General Procedure F, or Larock, R. C. referenced
above. Enolizable ketones 23 react with m-nitroaniline 22 to give
4-nitroindoles 24 (step b) using standard conditions such as those
described in General Procedure F, or Tetrahedron, 2004, 60(2), 347.
In step c, acids 24 may be converted to primary amides 25 as shown
using conditions such as those described in General Procedure D or
F. Amino indoles 26 are prepared by reduction of the nitro group of
primary amides 25 using methods known to one skilled in the art
(for example, General Procedure F, or Larock, R. C. referenced
above). Diazotization of 26 followed by iodination gives 27 using
standard condition such as those described in General Procedure F,
or Larock, R. C. referenced above. In step f, indoles 27 may
undergo a variety of reactions known to one skilled in the art (for
example, Larock, R. C. referenced above) including, but not limited
to, Suzuki, Buchwald, or Negishi coupling conditions as described
by General Procedures A, T and U. Indoles 9 may then be reacted
further as described above.
##STR00007##
[0701] Methods for preparing 1H-indole-7-carboxamide compounds 30
of the invention are illustrated in Scheme VI. In Scheme VI, step
a, commercially available 4-bromo-1H-indole-7-carbonitrile [Sinova]
28 is hydrolyzed to give primary amide 29 using conditions such as
those described in Preparation #2 or known to one skilled in the
art (for example, the books from Larock, R. C. or Greene, T. W. and
Wuts, P. G. M. referenced above). In step b, indole 29 may undergo
a variety of reactions known to one skilled in the art (for
example, Larock, R. C. referenced above) including, but not limited
to, Suzuki, Buchwald, or Negishi coupling conditions as described
by General Procedures A, T and U. Alternatively, indole 29 can be
converted to the boronate ester 31 using reactions such as those
described in General Procedure P. Indole 31 may undergo a Suzuki
coupling using conditions such as those described in General
Procedure A or known to one skilled in the art (for example,
Larock, R. C. referenced above). Further functionalization of the
R' group in indoles 30 can be performed, if desired, using
reactions known to one skilled in the art (for example, Larock, R.
C. referenced above). For example, indoles 30 containing a double
bond may be reduced to saturated systems using hydrogenation
conditions such as those described in General Procedure L. Ethers
can be prepared from indoles 30 containing an alcohol using
condition such as those described in General Procedure Q. In
addition amides, ureas, sulfonamides, aryl amines, heteroaryl
amines, or sulfonyl ureas can be prepared from indoles 30 with an
R' containing a primary or secondary amine (for example General
Procedures D, E, I, H, and J). Also, deprotection of the R' group
in 1H-indole-7-carboxamide compounds 30 to yield an unprotected
compound can be performed using conditions such as those described
in Greene, T. W. and Wuts, P. G. M. referenced above or in General
Procedures G, M, or N. For example, a protecting group such as a
Boc group can be removed from a protected amine to yield the
unprotected amine (for example General Procedure G) and the
deprotected compounds 30 may then be reacted further as described
above.
##STR00008##
[0702] Methods for preparing 1H-indole-7-carboxamide compounds 35
of the invention are illustrated in Scheme VII. Nitration of indole
29 (Scheme VII step a) can be performed using conditions such as
those described in Preparation #7, step C or known to one skilled
in the art (for example, Larock, R. C. referenced above). In step
b, indole 32 may undergo a variety of reactions known to one
skilled in the art (for example, Larock, R. C. referenced above)
including, but not limited to, Suzuki, Buchwald, or Negishi
coupling conditions as described by General Procedures A, T and U.
Amino indoles 34 are prepared from the reduction of nitroindoles 33
using methods known to one skilled in the art (for example,
Preparation #7, step E, or Larock, R. C. referenced above). The
amino indoles 34 may be coverted to give amides 35 as shown in step
d using conditions such as those described in General Procedure D
or E.
##STR00009##
[0703] Methods for preparing
1H-pyrrolo[3,2-c]pyridine-7-carboxamides 39 of the invention are
illustrated in Scheme VIII. In Scheme VIII, step a,
6-bromo-4-nitronicotinic acid [European Journal of Medicinal
Chemistry 1977, 12(6), 541] 36 is reacted with vinylmagnesium
bromide via a Bartoli indole synthesis using methods known to one
skilled in the art (for example Preparation #9, step A) to give
pyrrolo[3,2-c]pyridine 37. In step b, the acid of compounds 37 may
be converted to primary amides 38 as shown using conditions such as
those described in General Procedure D. Pyrrolo[3,2-c]pyridine 38
may undergo a variety of reactions known to one skilled in the art
(for example, Larock, R. C. referenced above) including, but not
limited to, Suzuki, Buchwald, or Negishi coupling conditions as
described by General Procedures A, T and U. Further
functionalization of the R' group in pyrrolo[3,2-c]pyridines 39 can
be performed, if desired, using reactions known to one skilled in
the art (for example, Larock, R. C. referenced above). For example,
indoles 39 containing a double bond may be reduced to saturated
systems using hydrogenation conditions such as those described in
General Procedure L. Ethers can be prepared from indoles 39
containing an alcohol using condition such as those described in
General Procedure Q. In addition amides, ureas, sulfonamides, aryl
amines, heteroaryl amines, or sulfonyl ureas can be prepared from
indoles 39 containing a primary or secondary amine (for example
General Procedures D, E, I, H, and J). Also, deprotection of
indoles 39 containing a protecting group in R' can be performed
using conditions such as those described in Greene, T. W. and Wuts,
P. G. M. referenced above or in General Procedures G, M, or N. For
example, for R'' containing a TBDMS-protected alcohol, the
protecting group can be removed to yield an unprotected alcohol
(for example General Procedure M) and the deprotected compounds 39
may then be reacted further as described above.
##STR00010##
[0704] Methods for preparing
1H-pyrrolo[2,3-c]pyridine-7-carboxamides 44 of the invention are
illustrated in Scheme IX. In Scheme IX, step a,
5-bromo-2-chloro-3-nitropyridine 40 is reacted with vinylmagnesium
bromide via a Bartoli indole synthesis using methods known to one
skilled in the art (for example, Example #2, step A) to give
pyrrolo[2,3-c]pyridine 41. In step b, pyrrolo[2,3-c]pyridine 41 may
undergo a variety of reactions known to one skilled in the art (for
example, Larock, R. C. referenced above) including, but not limited
to, Suzuki, Buchwald, or Negishi coupling conditions as described
by General Procedures A, T and U to give pyrrolo[2,3-c]pyridines
42. In step c, Pd-mediated carbonylation of pyrrolo[2,3-c]pyridines
42 gives esters 43 using methods known to one skilled in the art
such as those described in Example #2, step C. Esters 43 may
undergo ammonolosis such as those described in Example #2, step D
or known to one skilled in the art (for example, Larock, R. C.
referenced above) give compounds 44. Further functionalization of
the R' group in pyrrolo[2,3-c]pyridines 44 can be performed, if
desired, using reactions known to one skilled in the art (for
example, Larock, R. C. referenced above). For example, indoles 44
containing a double bond may be reduced to saturated systems using
hydrogenation conditions such as those described in General
Procedure L. Ethers can be prepared from indoles 44 containing an
alcohol using condition such as those described in General
Procedure Q. Also, deprotection of indoles 44 containing a
protected alcohol can be performed using conditions such as those
described in Greene, T. W. and Wuts, P. G. M. referenced above or
in General Procedures M. In addition amides, ureas, sulfonamides,
aryl amines, heteroaryl amines, or sulfonyl ureas can be prepared
from indoles 44 with an R' containing a primary or secondary amine
(for example General Procedures D, E, I, H, and J). Also,
deprotection of the R' group in 1H-indole-7-carboxamide compounds
44 to yield an unprotected compound can be performed using
conditions such as those described in Greene, T. W. and Wuts, P. G.
M. referenced above or in General Procedures G, M, or N. For
example, a protecting group such as a Boc group can be removed from
a protected amine to yield the unprotected amine (for example
General Procedure G) and the deprotected compounds 44 may then be
reacted further as described above.
##STR00011##
[0705] Methods for preparing 1H-indole-7-carboxamides 51 of the
invention are illustrated in Scheme X. In Scheme X, step a, indole
45 under goes a Vilsmeier-Haack reaction using methods known to one
skilled in the art (for example, Example #3, step A) to give
aldehyde 46. The reductive amination of aldehyde 46 with
4-methoxybenzylamine (PMB) using conditions such as those described
in General Procedure H gives amine 47 (Scheme X, step b).
Hydrolysis of ester 47 gives acid 48 (step c) using well known
conditions such as those described in Example #3, step C or General
Procedure C. Acid 48 may be converted to a primary amide 49 as
shown using conditions such as those described in General Procedure
D. Indole 49 may undergo a variety of reactions known to one
skilled in the art (for example, Larock, R. C. referenced above)
including, but not limited to, Suzuki, Buchwald, or Negishi
coupling conditions as described by General Procedures A, T and U.
Indoles 50 may be converted to give methyl indoles 51 using
conditions such as those described in Example #3, step F.
##STR00012##
[0706] Methods for preparing
1,2,3,6-tetrahydropyrrolo[2,3-e]indole-5-carboxamides 58 of the
invention are illustrated in Scheme XI. Nitration of
5-bromoindoline 52 (Scheme XI, step a) can be performed using
conditions such as those described in Example #4, step A or known
to one skilled in the art (for example, Larock, R. C. referenced
above). The resulting indoline 53 may be protected (Scheme XI, step
b) using conditions described in Greene, T. W. and Wuts, P. G. M.
referenced above (for example, a Boc protecting group using
conditions such as those described in Example #4, step B or those
described in Greene, T. W. and Wuts, P. G. M. referenced above). In
Scheme XI, step c, indoline 54 is reacted with vinylmagnesium
bromide via a Bartoli indole synthesis using methods known to one
skilled in the art to give indole 55 using conditions described in
Example #4, step C. In step d, Pd-mediated cyanation of bromide 55
gives the corresponding nitrile 56 (for example Example #4, step D
or Tetrahedron Letters 1999, 40(47), 8193-8195). Subsequent
hydrolysis of nitrile 56 gives a primary amide 57 (Scheme XI, step
e) using methods known to one skilled in the art (for example,
General Procedure O). The primary amide 57 may be converted to give
amides 58 as shown in step f using conditions such as those
described in General Procedure D or E.
##STR00013##
[0707] Methods for preparing benzimidazoles 64 of the invention are
illustrated in Scheme XII. In step a,
4,7-dibromobenzo[c][1,2,5]thiadiazole 59 may undergo a variety of
reactions known to one skilled in the art (for example, Larock, R.
C. referenced above) including, but not limited to, Suzuki,
Buchwald, or Negishi coupling conditions as described by General
Procedures A, T and U. In step b, Pd-mediated cyanation of bromide
60 gives the corresponding nitriles 61 (for example Tetrahedron
Letters 1999, 40(47), 8193-8195). Nitriles 61 can undergo ring
opening to give diamine 62 using conditions such as those described
in Example #14, step C. As shown in Scheme XII, step d, the
cyclization of the diamine 62 can be accomplished by reacting with
aldehydes (for example, Example #14, step D). Hydrolysis of nitrile
63 gives benzimidazoles 64 (Scheme XII, step e) using methods known
to one skilled in the art such as those described in General
Procedure O.
##STR00014##
[0708] Methods for preparing indazoles 70 of the invention are
illustrated in Scheme XIII. In Scheme XIII, step a,
2-amino-4-chloro-3-methylbenzoic acid [Enamine] 65 is esterified
using standard conditions such as those described in General
Procedure F or Larock, R. C. referenced above. In step b, the
cyclization of ester 66 gives indazole 67 using methods known to
one skilled in the art (for example, Example #18, step B or
WO2007/113596). Hydrolysis of ester 67 gives acid 68 (Scheme XIII,
step c) using well known conditions such as those described in
General Procedure C. The acid 68 may be coverted to amide 69 as
shown in step d using conditions such as those described in General
Procedure D. Indole 69 may undergo a variety of reactions known to
one skilled in the art (for example, Larock, R. C. referenced
above) including, but not limited to, Suzuki, Buchwald, or Negishi
coupling conditions as described by General Procedures A, T and U.
Further functionalization of the R' group in indoles 70 can be
performed, if desired, using reactions known to one skilled in the
art (for example, Larock, R. C. referenced above). For example,
indoles 70 containing a double bond may be reduced to saturated
systems using hydrogenation conditions such as those described in
General Procedure L. Ethers can be prepared from indoles 70
containing an alcohol using conditions such as those described in
General Procedure Q. In addition amides, ureas, sulfonamides, aryl
amines, heteroaryl amines, or sulfonyl ureas can be prepared from
indoles 70 with an R' containing a primary or secondary amine (for
example General Procedures D, E, I, H, and J). Also, deprotection
of the R' group in 1H-indole-7-carboxamide compounds 70 to yield an
unprotected compound can be performed using conditions such as
those described in Greene, T. W. and Wuts, P. G. M. referenced
above or in General Procedures G, M, or N. For example, a
protecting group such as a Boc group can be removed from a
protected amine to yield the unprotected amine (for example General
Procedure G) and the deprotected compounds 70 may then be reacted
further as described above.
##STR00015##
[0709] Methods for preparing 1H-indole-7-carboxamide compounds 77
of the invention are illustrated in Scheme XIV. In Scheme XIV, step
a, indole 71 may be tosyl (Ts) protected (Scheme I, step c) using
conditions such as those described in Preparation #1 step C or
those described in Greene, T. W. and Wuts, P. G. M. or Larock, R.
C. referenced above). In step b, directed lithiation of
4-fluoro-1-tosyl-1H-indole-7-carbonitrile 72 followed by trapping
of the anion with iodine yields indole 73 using conditions such as
those described in Preparation #1, step D. The
4-fluoro-2-iodo-1-tosyl-1H-indole-7-carbonitrile 73 may undergo a
variety of reactions known to one skilled in the art (for example,
Larock, R. C. referenced above) including, but not limited to,
Suzuki coupling reactions such as those described in General
Procedure A. Further functionalization of the R' group in tosyl
protected carbonitriles 74 can be performed, if desired, using
reactions known to one skilled in the art (for example, Larock, R.
C. referenced above). For example, formation of amides, ethers,
ureas, sulfonamides, aryl amines, heteroaryl amines, or sulfonyl
ureas can be prepared from compounds 74 with an R' containing a
primary or secondary amine (for example General Procedures D, E, I,
H, and J). Also, deprotection of the R' group in compounds 74 to
yield an unprotected compound can be performed using conditions
such as those described in Greene, T. W. and Wuts, P. G. M.
referenced above or in General Procedures G, M, or N. For example,
a protecting group such as a Boc group can be removed from a
protected amine to yield the unprotected amine (for example
Preparation #27, Step D or General Procedure G) and the deprotected
compounds 74 may then be reacted further as described above amine.
Indole carbonitriles 74 shown in step d can be reacted with amines
via displacement chemistry using conditions known to one skilled in
the art such as those described in General Procedure B to give
compounds 75. Tosyl protected 1H-indole-7-carbonitriles 75 may be
deprotected under aqueous base conditions in one step to give
compound 76 using conditions such as those described in Example
#12, step B or known to one skilled in the art (for example, the
books from Larock, R. C. or Greene, T. W. and Wuts, P. G. M.
referenced above). In step f, 1H-indole-7-carbonitriles 76
hydrolyzed to give primary amide 77 using conditions such as those
described in Preparation #2 or known to one skilled in the art (for
example, the books from Larock, R. C. or Greene, T. W. and Wuts, P.
G. M. referenced above). In addition, amides, carbamates, ureas, or
substituted amines can be prepared from 1H-indole-7-carboxamide
compounds 77 containing a primary or secondary amine (for example
General Procedures). Also, deprotection of 1H-indole-7-carboxamide
compounds 77 containing a protected primary or secondary amine can
be performed using conditions such as those described in Greene, T.
W. and Wuts, P. G. M. referenced above or in General Procedures.
For example, for R'' or R''' containing a protecting group (for
example a Boc group), the protecting group can be removed to yield
the unprotected amine (for example General Procedure G) and the
deprotected compounds 3 may then be reacted further as described
above.
##STR00016##
[0710] Methods for preparing
7-chlorothiazolo[5,4-c]pyridine-4-carboxamides 87 of the invention
are illustrated in Scheme XV. Wittig reaction of an aldehyde 78
(step a) is performed with a triphenyl phosphonium ylide using
standard conditions known to on skilled in the art, such as those
described in Preparation #46, step A or Larock, R. C. referenced
above, to give .alpha., .beta. unsaturated methyl ester 79. This
intermediate is reacted with a boronate or boronic acid via a
Suzuki reaction in step b, using conditions such as those
illustrated in Preparation #46, step B. Intermediate 80 is
hydrolyzed to give an acid as shown in Preparation #46, step B
(step c). In step d, the acid is converted to an acyl azide via in
situ formation of an acyl chloride using standard conditions such
as those described Preparation #46, step D or WO 2012/035039. The
acyl azide intermediate can then undergo a Curtius rearrangement
and cyclize to give a pyridone 83 in step e, under high
temperatures (For example, Preparation #46, step E or WO
2012/035039). On treatment with POCl.sub.3, in step f,
pyridine-2-chloride is formed (for example, Preparation #46, step F
or WO 2012/035039), which can subsequently be treated with NCS in
step g, to afford a 4-bromo-7-chlorothiazolo[5,4-c]pyridine
intermediate 85, as illustrated in Preparation #46, step G.
Conversion of the bromo group in 85 to a cyano functionality is
performed via Pd-catalyzed cyanation reaction and subsequent
hydrolysis of the cyano group yields a
7-chlorothiazolo[5,4-c]pyridine-4-carboxamide as illustrated in
Preparation #46, step H. In step j,
thiazolo[5,4-c]pyridine-4-carboxamide 87 may undergo a variety of
reactions known to one skilled in the art (for example, Larock, R.
C. referenced above) including, but not limited to, Suzuki,
Buchwald, or Negishi coupling conditions as described by General
Procedures A, T and U to give
thiazolo[5,4-c]pyridine-4-carboxamides 88.
##STR00017##
[0711] A second alternative for the preparation of
1H-pyrrolo[3,2-c]pyridine-7-carboxamides 39 to the route shown in
scheme VIII is shown in scheme XVI, wherein
1H-pyrrolo[3,2-c]pyridine-7-carboxamides 39 can also be prepared
from commercially available methyl
1H-pyrrolo[3,2-c]pyridine-7-carboxylate 89, which is first
tosylated in step a, using standard conditions known to one skilled
in the art, as shown in General Procedure AH. The tosylated
intermediate 90 is then oxidized (step b) using conditions such as
those described in General Procedure AC to give an N-oxide
intermediate 91. In step c the material is halogenated as
illustrated in Preparation #45, step C, followed by hydrolysis
using a base, to both remove the tosyl group and hydrolyze the
ester to an acid using conditions such as those described in
General Procedure X. The acid can then undergo a standard amine
coupling reaction as illustrated in General Procedure D, to give
the amide in step e. The pyrrolo[3,2-c]pyridine 94 may undergo a
variety of reactions known to one skilled in the art (for example,
Larock, R. C. referenced above) including, but not limited to,
Suzuki, Buchwald, or Negishi coupling conditions as described by
General Procedures A, T and U to give compounds 39. Further
functionalization of the R' group in pyrrolo[3,2-c]pyridines 39 can
be performed, if desired, using reactions known to one skilled in
the art (for example, Larock, R. C. referenced above). For example,
pyrrolo[3,2-c]pyridines 39 containing a double bond may be reduced
to saturated systems using hydrogenation conditions such as those
described in General Procedure L. Ethers can be prepared from
indoles 39 containing an alcohol using condition such as those
described in General Procedure Q. In addition amides, ureas,
sulfonamides, aryl amines, heteroaryl amines, or sulfonyl ureas can
be prepared from indoles 39 containing a primary or secondary amine
(for example General Procedures D, E, I, H, and J). Also,
deprotection of indoles 39 containing a protecting group in R' can
be performed using conditions such as those described in Greene, T.
W. and Wuts, P. G. M. referenced above or in General Procedures G,
M, or N. For example, for R'' containing a TBDMS-protected alcohol,
the protecting group can be removed to yield an unprotected alcohol
(for example General Procedure M) and the deprotected compounds 39
may then be reacted further as described above.
##STR00018##
[0712] A third alternative to routes shown in schemes VIII and XVI
for the preparation of 1H-pyrrolo[3,2-c]pyridine-7-carboxamides 39
is shown in scheme XVII. In step a, (4-methoxyphenyl)methanamine is
treated with dimethyl 3-oxopentanedioate to give intermediate 96,
which is not isolated. In step b, it is cyclized in situ via
treatment with chloroacetaldehyde using conditions such as those
illustrated in Preparation #37, step A or WO2005121140.
De-protonation of the acidic hydrogen of 97 and reaction with
methylformate, in step c, is accomplished using methods known to
one skilled in the art (for example Preparation #37, step B, or WO
2005121140) to give intermediate 98. In step d, cyclization of
intermediate 98 is performed using conditions such as those
illustrated in Preparation #37, step C or WO 2005121140 to give the
pyridinone intermediate 99. Subsequent aromatization and
halogenation of pyridinone intermediate 99 in step e is done using
well known conditions (for example Preparation #37, step D or WO
2005121140) to give pyrrolo[3,2-c]pyridine 100. Hydrolysis of the
ester functionality in 100 gives acid 93 (step f) using standard
conditions such as those described in General Procedure C. The acid
can then undergo an amine coupling reaction as illustrated in
General Procedure D, to give the amide in step e. The
pyrrolo[3,2-c]pyridine 94 may undergo a variety of reactions known
to one skilled in the art (for example, Larock, R. C. referenced
above) including, but not limited to, Suzuki, Buchwald, or Negishi
coupling conditions as described by General Procedures A, T and U
to give compounds 39. Further functionalization of the R' group in
pyrrolo[3,2-c]pyridines 39 can be performed, if desired, using
reactions known to one skilled in the art (for example, Larock, R.
C. referenced above). For example, pyrrolo[3,2-c]pyridines 39
containing a double bond may be reduced to saturated systems using
hydrogenation conditions such as those described in General
Procedure L. Ethers can be prepared from indoles 39 containing an
alcohol using condition such as those described in General
Procedure Q. In addition amides, ureas, sulfonamides, aryl amines,
heteroaryl amines, or sulfonyl ureas can be prepared from indoles
39 containing a primary or secondary amine (for example General
Procedures D, E, I, H, and J). Also, deprotection of indoles 39
containing a protecting group in R' can be performed using
conditions such as those described in Greene, T. W. and Wuts, P. G.
M. referenced above or in General Procedures G, M, or N. For
example, for R'' containing a TBDMS-protected alcohol, the
protecting group can be removed to yield an unprotected alcohol
(for example General Procedure M) and the deprotected compounds 39
may then be reacted further as described above.
##STR00019##
[0713] Alternative methods for preparing
1H-pyrrolo[2,3-c]pyridine-7-carboxamides 44 of the invention are
illustrated in Scheme XVIII. 4-Bromo-1H-pyrrolo[2,3-c]pyridine 101
is oxidized to the N-oxide intermediate using methods known to one
skilled in the art (for example General Procedure AC). Cyanation of
the N-oxide 102 in step b is accomplished using conditions such as
those illustrated in General Procedure AD to give the carbonitrile
103. The carbonitrile 103 may undergo a variety of reactions known
to one skilled in the art (for example, Larock, R. C. referenced
above) including, but not limited to, Suzuki, Buchwald, or Negishi
coupling conditions as described by General Procedures A, T and U
to give pyrrolo[2,3-c]pyridines 106. Subsequent hydrolysis of
pyrrolo[2,3-c]pyridines 106 in step f, using standard conditions
(for example General Procedure O) will yield compounds 44.
Alternatively the carbonitrile 103 may first be hydrolyzed as shown
in in step c to give the amide 104 when subjected to known
conditions (for example General Procedure O). The amide 104 may
then undergo a variety of reactions known to one skilled in the art
(for example, Larock, R. C. referenced above) including, but not
limited to, Suzuki, Buchwald, or Negishi coupling conditions as
described by General Procedures A, T and U to give compounds 44.
Further functionalization of the R' group in
pyrrolo[2,3-c]pyridines 44 can be performed, if desired, using
reactions known to one skilled in the art (for example, Larock, R.
C. referenced above). For example, pyrrolo[2,3-c]pyridines 44
containing a double bond may be reduced to saturated systems using
hydrogenation conditions such as those described in General
Procedure L. Ethers can be prepared from pyrrolo[2,3-c]pyridines 44
containing an alcohol using condition such as those described in
General Procedure Q. In addition amides, ureas, sulfonamides, aryl
amines, heteroaryl amines, or sulfonyl ureas can be prepared from
pyrrolo[2,3-c]pyridines 44 containing a primary or secondary amine
(for example General Procedures D, E, I, H, and J). Also,
deprotection of pyrrolo[2,3-c]pyridines 44 containing a protecting
group in R' can be performed using conditions such as those
described in Greene, T. W. and Wuts, P. G. M. referenced above or
in General Procedures G, M, or N. For example, for R'' containing a
TBDMS-protected alcohol, the protecting group can be removed to
yield an unprotected alcohol (for example General Procedure M) and
the deprotected compounds 44 may then be reacted further as
described above.
##STR00020##
[0714] If desired, chiral separation of any of the chiral compounds
in Schemes I-XVIII may be done using methods known to one skilled
in the art such as chiral preparative HPLC, chiral SFC or
crystallization of diastereomeric salts.
GENERAL PROCEDURES AND EXAMPLES
[0715] The general synthetic schemes that were utilized to
construct the majority of compounds disclosed in this application
are described below in Schemes 1-34. These schemes are provided for
illustrative purposes only and are not to be construed as limiting
the scope of the invention.
##STR00021##
##STR00022##
##STR00023##
##STR00024##
##STR00025##
##STR00026##
##STR00027##
##STR00028##
##STR00029##
##STR00030##
##STR00031##
##STR00032##
##STR00033##
##STR00034##
##STR00035##
##STR00036##
##STR00037##
##STR00038##
##STR00039##
##STR00040##
##STR00041##
##STR00042##
##STR00043##
##STR00044##
##STR00045##
##STR00046##
##STR00047##
##STR00048##
##STR00049##
##STR00050##
##STR00051##
##STR00052##
##STR00053##
##STR00054##
LIST OF GENERAL PROCEDURES
[0716] General Procedure A Suzuki Reaction of an aryl or heteroaryl
halide with an aryl or heteroaryl boronic acid or boronate [0717]
General Procedure B Nucleophilic displacement of an aryl halide
with an amine [0718] General Procedure C Hydrolysis of an ester to
a carboxylic acid [0719] General Procedure D Formation of an amide
from an amine and a carboxylic acid [0720] General Procedure E
Formation of an amide from an amine and an acid halide or anhydride
[0721] General Procedure F Formation of a
4-iodoindole-7-carboxamide [0722] General Procedure G Acidic
cleavage of a Boc-protected amine [0723] General Procedure H
Reductive amination of an aldehyde or ketone with a primary or
secondary amine [0724] General Procedure I Formation of a
sulfonamide from an amine and a sulfonyl chloride [0725] General
Procedure J. Substitution of an alkyl halide with an amine
nucleophile [0726] General Procedure K Hydrolysis of an acetonide
[0727] General Procedure L Hydrogenation of an alkene [0728]
General Procedure M Removal of a silyl group from an O-silyl ether
[0729] General Procedure N Hydrolysis of a sulfonamide [0730]
General Procedure O Hydrolysis of a nitrile to a primary amide
[0731] General Procedure P Formation of a boronate from an aryl
halide or heteroaryl halide [0732] General Procedure Q Mitsunobu
reaction of an alcohol [0733] General Procedure R Reduction of a
nitro group to an amine using Fe [0734] General Procedure S
Demethylation of aryl methyl ether [0735] General Procedure T
Buchwald reaction of an aryl halide or an heteroaryl halide with an
amine [0736] General Procedure U Negishi cross-coupling reaction of
an aryl halide or a heteroaryl halide with an organozinc [0737]
General Procedure V Formation of an amide from a Boc-protected
amine and a carboxylic acid [0738] General Procedure W Conversion
of a vinyl triflate to a vinyl boronate or boronic acid [0739]
General Procedure X Hydrolysis of an ester to a carboxylic acid
under basic conditions and removal of a tosyl group from an N-tosyl
protected heteroaryl ring [0740] General Procedure Y Iodination of
a 1H-indole or a 1H-aza indole ring to give a 2-iodo-1H-indole or a
2-iodo-1H-azaindole ring [0741] General Procedure Z Formation of an
N-Boc protected amine [0742] General Procedure AA Conversion of a
ketone to a vinyl triflate [0743] General Procedure AB Reduction of
a double bond and removal of a CBZ group from a CBZ protected amine
[0744] General Procedure AC N-Oxidation of an N containing hetero
aromatic ring [0745] General Procedure AD Cyanation of an N-oxide
containing heteroaryl ring [0746] General Procedure AE Reduction of
an ester to form an alcohol [0747] General Procedure AF Reduction
of a pyridine ring to a piperidine ring [0748] General Procedure AG
Borylation of a vinyl triflate and Suzuki reaction of the newly
formed boronate with an aryl halide [0749] General Procedure AH
Formation of an N-tosyl protected heteroaromatic ring
[0750] The following examples are ordered according to the final
general procedure used in their Preparation. The synthetic routes
to any novel intermediates are detailed by sequentially listing the
general procedure (letter codes) in parentheses after their name
with additional reactants or reagents as appropriate. A worked
example of this protocol is given below using Example #A.3.7 as a
non-limiting illustration. Example #A.3.7 is
2-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)-4-(3-(4-(difluoromethyl)be-
nzamido)-2-methylphenyl)-1H-indole-7-carboxamide, which was
prepared from
2-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)-4-bromo-1H-indole-7-carboxami-
de using General Procedure A with
4-(difluoromethyl)-N-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan--
2-yl)phenyl)benzamide as represented in Scheme A.
##STR00055##
[0751] The precursor to Example #A.3.7,
2-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)-4-bromo-1H-indole-7-carboxami-
de, was prepared (as shown in Scheme B) by reacting
4-bromo-2-iodo-1H-indole-7-carboxamide (Preparation #1) with
1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridin-1(2-
H)-yl)ethanone, commercially available Combi-Blocks, following the
conditions given in General Procedure A. Hence the Example #A.3.7
would be written as: Example #A.3.7 was prepared from
4-(difluoromethyl)-N-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan--
2-yl)phenyl)benzamide (Preparation #29) and
2-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)-4-bromo-1H-indole-7-carboxami-
de (prepared using A with 4-bromo-2-iodo-1H-indole-7-carboxamide
[Preparation #1] and
1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridin-1(2-
H)-yl)ethanone [Combi-Blocks]) using General Procedure A. In the
tables after a General Procedure, this is represented by having one
reactant in the title of the table and one in a separate column in
the same row as the product.
##STR00056##
[0752] In Vitro BTK Kinase Activity Measured by Time-Resolved
Fluorescence Resonance Energy Transfer
[0753] (trFRET) The in-house BTK corresponds to recombinant human
catalytic domain (aa 393-659), which was expressed in SF9 cells
with an N-terminal his tag and purified by immobilized metal
affinity chromatography. BTK was mixed with peptide substrate
(biotin-TYRI, Sequence: Biotin-(Ahx)-GAEEEIYAAFFA-COOH, 0.2 .mu.M
final) at varying inhibitor concentrations in reaction buffer: 50
mM MOPSO pH 6.5, 10 mM MgCl.sub.2, 2 mM MnCl.sub.2, 2.5 mM DTT,
0.01% BSA, 0.1 mM Na.sub.3VO.sub.4 and 0.001 mM ATP. After about 60
min incubation at room temperature, the reaction was quenched by
addition of EDTA (final concentration: 100 mM) and developed by
addition of detection reagents (final approximate concentrations:
30 mM HEPES pH 7.0, 0.06% BSA, 0.006% Tween-20, 0.24 M KF, 80 ng/mL
PT66K (europium labeled anti-phosphotyrosine antibody cat #61T66KLB
Cisbio, Bedford, Mass.) and 0.6 g/mL SAXL (Phycolink
streptavidin-allophycocyanin acceptor, cat #PJ25S, Prozyme, San
Leandro, Calif.). The developed reaction was incubated in the dark
for about 60 min at room temperature, then read via a time-resolved
fluorescence detector (Rubystar, BMG) using a 337 nm laser for
excitation and monitoring emission wavelength at 665 nm. Within the
linear range of the assay, the observed signal at 665 nm was
directly related to phosphorylated product and can be used to
calculate the IC.sub.50 values.
[0754] For the purpose of the Tables and Examples below, the Btk
IC.sub.50 of each compound is expressed as follows: A=a compound
with IC.sub.50 less than 0.1 .mu.M, B=a compound with IC.sub.50
within the range of 0.1 .mu.M to 1 .mu.M, and C=a compound with a
Btk IC.sub.50 within the range of 1 .mu.M to 10 M.
[0755] Analytical Methods
[0756] Analytical data was included within the procedures below, in
the illustrations of the general procedures, or in the tables of
examples. Unless otherwise stated, all .sup.1H NMR data were
collected on a Varian 400 MHz Mercury Plus, Inova, or 400-MR
instrument and chemical shifts are quoted in parts per million
(ppm). LC/MS and HPLC data are referenced to the table of LC/MS and
HPLC conditions using the lower case method letter provided in
Table 1.
TABLE-US-00002 TABLE 1 LC/MS and HPLC methods Method Conditions a
LC/MS: The gradient was 5-60% B in 1.5 min then 60-95% B to 2.5 min
with a hold at 95% B for 1.2 min (1.3 mL/min flow rate). Mobile
phase A was 10 mM NH.sub.4OAc, mobile phase B was HPLC grade MeCN.
The column used for the chromatography is a 4.6 .times. 50 mm
MAC-MOD Halo C18 column (2.7 .mu.m particles). Detection methods
are diode array (DAD) and evaporative light scattering (ELSD)
detection as well as positive/negative electrospray ionization. b
LC/MS: The gradient was 30-60% B in 1.50 min then 60-95% B to 2.5
min with a hold at 95% B for 1.2 min (1.3 mL/min flow rate). Mobile
phase A was 10 mM NH.sub.4OAc, mobile phase B was HPLC grade MeCN.
The column used for the chromatography was a 4.6 .times. 50 mm
MAC-MOD Halo C8 column (2.7 .mu.m particles). Detection methods
were diode array (DAD) and evaporative light scattering (ELSD)
detection as well as positive/negative electrospray ionization. c
LC/MS: The gradient was 5% B for 0.1 min, 5-100% B in 5.1 min with
a hold at 100% B for 0.5 min then 100-5% B in 0.3 min (2.0 mL/min
flow rate). Mobile phase A was 0.1% TFA in water, mobile phase B
was HPLC grade MeCN. The column used for the chromatography was a
2.1 .times. 50 mm Phenomenex Luna Combi-HTS C8(2) column (5 .mu.m
particles) at a temperature of 55.degree. C. Detection methods are
diode array (DAD) and evaporative light scattering (ELSD) detection
under positive APCI ionization conditions. d LC/MS: The gradient
was 1-90% B in 3.4 min, 90-100% B in 0.45 min, 100-1% B in 0.01
min, and then held at 1% B for 0.65 min (0.8 mL/min flow rate).
Mobile phase A was 0.0375% TFA in water, mobile phase B was 0.018%
TFA in MeCN. The column used for the chromatography was a 2.1
.times. 50 mm Venusil XBP-C18 column (5 .mu.m particles). Detection
methods are diode array (DAD) and evaporative light scattering
(ELSD) detection as well as positive/negative electrospray
ionization. e LC/MS: The gradient was 10% B for 0.1 min, 10-100% B
in 1.0 min with a hold at 100% B for 0.2 min then 100-10% B in 0.1
min (1.0 mL/min flow rate). Mobile phase A was 0.1% TFA in water,
mobile phase B was HPLC grade MeOH. The column used for the
chromatography was a 2.1 .times. 30 mm Waters BEH C8 column (1.7
.mu.m particles) at a temperature of 55.degree. C. Detection
methods are diode array (DAD) and evaporative light scattering
(ELSD) detection under positive APCI ionization conditions. f
LC/MS: The gradient was 5% B for 0.1 min, 5-100% B in 2.5 min with
a hold at 100% B for 0.3 min then 100-5% B in 0.1 min (2.0 mL/min
flow rate). Mobile phase A was 0.1% TFA in water, mobile phase B
was HPLC grade MeCN. The column used for the chromatography was a
2.1 mm .times. 50 mm Phenomenex Luna Combi-HTS C8(2) column (5
.mu.m particles) at a temperature of 55.degree. C. Detection
methods are diode array (DAD) and evaporative light scattering
(ELSD) detection under positive APCI ionization conditions. g
LC/MS: The gradient was 5% B for 0.1 min, 5-100% B in 2.5 min with
a hold at 100% B for 0.3 min then 100-5% B in 0.1 min (2.0 mL/min
flow rate). Mobile phase A was 0.1% TFA in water, mobile phase B
was HPLC grade MeCN. The column used for the chromatography was a
2.1 .times. 50 mm Phenomenex Luna Combi-HTS C8(2) column (5 .mu.m
particles) at a temperature of 65.degree. C. Detection methods are
diode array (DAD) and evaporative light scattering (ELSD) detection
under positive APCI ionization conditions. h LC/MS: The gradient
was 10-100% MeCN (A) and 10 mM ammonium acetate in water (B) was
used, at a flow rate of 1.0 mL/min (0-0.1 min 10% A, 0.1-1.1 min
10-100% A, 1.1-1.3 min 100% A, 1.3-1.4 min 100-10% A). The column
used for the chromatography was a 2.1 .times. 30 mm Waters BEH C8
column (1.7 .mu.m particles) at a temperature of 55.degree. C.
Detection methods are diode array (DAD) and evaporative light
scattering (ELSD) detection under positive APCI ionization
conditions. i HPLC: The gradient was 5-95% B over about 10 min (25
mL/min flow rate). Mobile phase A was 0.1% TFA in water, mobile
phase B was HPLC grade MeCN. The column used for the chromatography
was a 250 .times. 21.2 mm Phenomenex Luna C18(2) 100 .ANG. AXIA
column (10 .mu.m particles). Detection method is UV at wavelengths
of 220 nM and 254 nM. j LC/MS: The gradient was 5-100% B in 3.4 min
with a hold at 100% B for 0.45 min, 100-5% B in 0.01 min, and then
held at 5% B for 0.65 min (0.8 mL/min flow rate). Mobile phase A
was 10 mM NH.sub.4HCO.sub.3, mobile phase B was HPLC grade MeCN.
The column used for the chromatography is a 2.1 .times. 50 mm
Xbridge Shield RPC18 column (5 .mu.m particles). Detection methods
are diode array (DAD) and evaporative light scattering (ELSD)
detection as well as positive/negative electrospray ionization. k
LC/MS: The gradient was 0-60% B in 2.1 min then 60-100% B to 2.5
min, finally changed to 0% B in 0.02 min under this condition for
0.5 min (1 mL/min flow rate). Mobile phase A was H.sub.2O
containing 0.0375% TFA, mobile phase B was MeCN containing 0.018%
TFA. The column used for the chromatography is a 2.1 .times. 30 mm
Halo C18 column (2.7 .mu.m particles). Detection methods are diode
array (DAD) and evaporative light scattering (ELSD) detection as
well as positive/negative electrospray ionization.) l LC/MS: The
gradient was 10-90% B in 1.15 min with a hold at 90% B for 0.4 min,
90-10% B in 0.01 min and then held at 10% B for 0.54 min (1 mL/min
flow rate). Mobile phase A 0.0375% TFA in water, mobile phase B was
0.018% TFA in MeCN. The column used for the chromatography is a 2.1
.times. 30 mm Halo C18 column (2.7 .mu.m particles). Detection
methods are diode array (DAD) and positive/negative electrospray
ionization. m LC/MS: The gradient was 10-80% B in 2.0 min then
80-80% B in 0.48 min, finally changed to 10% B in 0.02 min under
this condition for 0.5 min (1.0 mL/min flow rate). Mobile phase A
was H.sub.2O containing 0.0375% TFA, mobile phase B was MeCN
containing 0.018% TFA. The column used for the chromatography is a
2.1 .times. 30 mm Halo C18 column (2.7 .mu.m particles). Detection
methods are diode array (DAD) and positive/negative electrospray
ionization. n HPLC: The gradient was 0-30% B over 25 min (80 mL/min
flow rate). Mobile phase A was 0.09% TFA in water, mobile phase B
was MeCN. The column used for the chromatography was a 50 .times.
250 mm Luna(2) C18 column (10 .mu.m particles). Detection method is
UV. o LC/MS: The gradient was 10-100% B in 3.4 min with a hold at
100% B for 0.45 min, 100-10% B in 0.01 min, and then held at 10% B
for 0.65 min (0.8 mL/min flow rate). Mobile phase A was 0.0375% TFA
in water, mobile phase B was 0.018% TFA in MeCN. The column used
for the chromatography was a 2.1 .times. 50 mm Venusil XBP-C18
column (5 .mu.m particles). Detection methods are diode array (DAD)
and evaporative light scattering (ELSD) detection as well as
positive/negative electrospray ionization. p LC/MS: The gradient
was 5-100% B in 3.4 min with a hold at 100% B for 0.45 min, 100-5%
B in 0.01 min, and then held at 5% B for 0.65 min (0.8 mL/min flow
rate). Mobile phase A was 10 mM NH.sub.4HCO.sub.3, mobile phase B
was HPLC grade MeCN. The column used for the chromatography was a
2.1 .times. 50 mm Xbridge Shield RPC18 column (5 .mu.m particles).
Detection methods are diode array (DAD) and evaporative light
scattering (ELSD) detection as well as positive/negative
electrospray ionization. q HPLC: The gradient was a hold at 21% B
for 1 min and then 21-51% B over 7 min with a hold at 51% for 4 min
(25.0 mL/min flow rate). Mobile phase A was 0.075% TFA in water,
mobile phase B was 0.075% TFA in MeCN. The column used for the
chromatography was a 30 .times. 100 mm Luna C18 column (5 .mu.m
particles). Detection method is UV at wavelengths of 220 nm and 254
nm. r HPLC: The gradient was a hold at 25% B for 2 min and then
25-55% B over 12 min (25.0 mL/min flow rate). Mobile phase A was
0.075% TFA in water, mobile phase B was 0.075% TFA in MeCN. The
column used for the chromatography was a 30 .times. 100 mm Luna C18
column (5 .mu.m particles). Detection method is UV at wavelengths
of 220 nm and 254 nm. s HPLC: The gradient was 10-38% B over 20 min
(80 mL/min flow rate). Mobile phase A was 0.09% TFA in water,
mobile phase B was MeCN. The column used for the chromatography was
a 50 .times. 250 mm Luna(2) C18 column (10 .mu.m particles).
Detection method is UV. t HPLC: The gradient was a hold at 5% B for
1 min and then 5-35% B over 12 min (25.0 mL/min flow rate). Mobile
phase A was 0.075% TFA in water, mobile phase B was MeCN. The
column used for the chromatography was a 30 .times. 100 mm Luna C18
column (5 .mu.m particles). Detection method is UV at wavelengths
of 220 nm and 254 nm. u HPLC: The gradient was 7-37% B over 8 min
with a hold at 37% B for 2 min (25.0 mL/min flow rate). Mobile
phase A was 0.04% NH.sub.3.cndot.H.sub.2O in water, mobile phase B
was MeCN. The column used for the chromatography was a 25 .times.
150 mm Waters Xbridge column (5 .mu.m particles). Detection method
is UV at wavelengths of 220 nm and 254 nm. v LC/MS: The gradient
was 0-80% B in 3.4 min, 80-100% B in 0.45 min, 100-0% B in 0.01
min, and then held at 0% B for 0.65 min (0.8 mL/min flow rate).
Mobile phase A was 0.0375% TFA in water, mobile phase B was 0.018%
TFA in MeCN. The column used for the chromatography was a 2.1
.times. 50 mm Venusil XBP-C18 column (5 .mu.m particles). Detection
methods are diode array (DAD) and evaporative light scattering
(ELSD) detection as well as positive/negative electrospray
ionization. w HPLC: The gradient was a hold at 18% B for 1 min and
then 18-48% B over 12 min (25.0 mL/min flow rate). Mobile phase A
was 0.075% TFA in water, mobile phase B was MeCN. The column used
for the chromatography was a 30 .times. 100 mm Luna C18 column (5
.mu.m particles). Detection method is UV at wavelengths of 220 nm
and 254 nm. x HPLC: The gradient was a hold at 23% B for 1 min and
then 23-53% B over 12 min (25.0 mL/min flow rate). Mobile phase A
was 0.075% TFA in water, mobile phase B was MeCN. The column used
for the chromatography was a 30 .times. 100 mm Luna C18 column (5
.mu.m particles). Detection method is UV at wavelengths of 220 nm
and 254 nm. y HPLC: The gradient was a hold at 20% B for 1 min and
then 20-35% B over 12 min (25.0 mL/min flow rate). Mobile phase A
was 0.075% TFA in water, mobile
phase B was MeCN. The column used for the chromatography was a 30
.times. 100 mm Luna C18 column (5 .mu.m particles). Detection
method is UV at wavelengths of 220 nm and 254 nm. z HPLC: The
gradient was a hold at 15% B for 1 min and then 15-45% B over 12
min (25.0 mL/min flow rate). Mobile phase A was 0.075% TFA in
water, mobile phase B was MeCN. The column used for the
chromatography was a 30 .times. 100 mm Luna C18 column (5 .mu.m
particles). Detection method is UV at wavelengths of 220 nm and 254
nm. aa HPLC: The gradient was a hold at 5% B for 0.2 min, 5-95% B
over 1.7 min with a hold at 95% B for 1.3 min (2.5 mL/min flow
rate). Mobile phase A was 0.01% TFA in water, mobile phase B was
0.01% TFA in MeCN. The column used for the chromatography was a 4.6
.times. 50 mm SunFire C18 column (3.5 .mu.m particles) at a
temperature of 50.degree. C. Detection method is UV. ab HPLC: The
gradient was a hold at 5% B for 0.2 min, 5-95% B over 1.7 min with
a hold at 95% B for 1.4 min (2.1 mL/min flow rate). Mobile phase A
was 0.01% TFA in water, mobile phase B was 0.01% TFA in MeCN. The
column used for the chromatography was a 4.6 .times. 50 mm XBridge
C18 column (3.5 .mu.m particles) at a temperature of 50.degree. C.
Detection method is UV. ac HPLC: The gradient was a hold at 5% B
for 0.2 min, 5-95% B over 1.7 min with a hold at 95% B for 1.4 min
(2.1 mL/min flow rate). Mobile phase A was 10 mM NH.sub.4HCO.sub.3,
mobile phase B was MeCN. The column used for the chromatography was
a 4.6 .times. 50 mm XBridge C18 column (3.5 .mu.m particles) at
50.degree. C. Detection method is UV. ad HPLC: The gradient was
37-67% B over 23 min (80 mL/min flow rate). Mobile phase A was
0.04% NH.sub.3.cndot.H.sub.2O in water, mobile phase B was MeCN.
The column used for the chromatography was a 50 .times. 300 mm
Gemini column (10 .mu.m particles). Detection method is UV at
wavelengths of 220 nm and 254 nm. ae LC/MS: The gradient was 10% B
for 0.1 min, 10-100% B in 1.0 min with a hold at 100% B for 0.2 min
then 100-10% B in 0.1 min (1.0 mL/min flow rate). Mobile phase A
was 0.1% TFA in water, mobile phase B was HPLC grade MeCN. The
column used for the chromatography was a 2.1 .times. 30 mm Waters
BEH C8 column (1.7 .mu.m particles) at a temperature of 55.degree.
C. Detection methods are diode array (DAD) and evaporative light
scattering (ELSD) detection under positive APCI ionization
conditions. af HPLC: The gradient was a hold at 10% B for 0.5 min,
20-100% B over 6.5 min, 95% B for 3 min, and then 95-10% B over 2
min (50.0 mL/min flow rate). Mobile phase A was 0.1% TFA in water
and mobile phase B was HPLC grade MeCN. The column used for the
chromatography was a 30 .times. 75 mm Phenomenex Luna C8(2) 100
.ANG. AXIA column (5 .mu.m particle). Detection methods were Waters
996 diode-array detector and Alltech Varex III evaporative
light-scattering detector. ag HPLC: The gradient was a hold at 10%
B for 0.5 min, 40-75% B over 6.5 min, 95% B for 3 min, and then
95-10% B over 2 min (50.0 mL/min flow rate). Mobile phase A was
0.1% TFA in water and mobile phase B was HPLC grade MeCN. The
column used for the chromatography was a 30 .times. 75 mm
Phenomenex Luna C8(2) 100 .ANG. AXIA column (5 .mu.m particle).
Detection methods were Waters 996 diode-array detector and Alltech
Varex III evaporative light-scattering detector. ah Instrument:
Gilson 281 semi-preparative HPLC system Mobile phase: A: 15 mL TFA
in 20 L H.sub.2O; B: MeCN Column: Luna 100 .times. 30.0 mm, 5.mu.;
Flow rate: 25 mL/min; Monitor wavelength: 220 & 254 nm
Gradient: an initial hold at 21% B for 1 min, a gradient of 21% to
51% B in 12 min ai Instrument: Shimadzu LC-20AP preparative HPLC
Column: Synergi Max-RP C18 250 .times. 80 mm i.d. 10 u Mobile
phase: A for H.sub.2O(0.09% TFA) and B for CH.sub.3CN Gradient: B
from 15% to 43% in 25 min Flow rate: 40 mL/min Injection amount: 50
mg per injection aj Instrument: Gilson 281 semi-preparative HPLC
system Mobile phase: A: TFA/H.sub.2O = 0.075% v/v; B: MECN Column:
Luna C18 100 .times. 30.0 mm, 5.mu. Flow rate: 25 mL/min Monitor
wavelength: 220 & 254 nm Gradient: Time B% 0.00 10 12.0 40 14.0
40 14.2 100 16.2 100 16.4 10 18.0 10 ak Instrument: Gilson 281
semi-preparative HPLC system Mobile phase: A: TFA/H.sub.2O = 0.075%
v/v; B: MeCN Column: Luna C18 200 .times. 21.2 mm, 5.mu. Flow rate:
25 mL/min Monitor wavelength: 220 & 254 nm Gradient: Time B%
0.00 1 12.0 8 14.0 8 14.2 100 16.2 100 16.4 1 18.0 1 al Instrument:
Gilson 281 semi-preparative HPLC system Mobile phase: A: 15 mL TFA
in 20 L H.sub.2O; B: MeCN Column: Luna 100 .times. 30.0 mm, 5.mu.
Flow rate: 25 mL/min Monitor wavelength: 220 & 254 nm Gradient:
an initial hold at 8% B for 1 min, a gradient of 8% to 38% B in 12
min am Instrument: Gilson 281 semi-preparative HPLC system Mobile
phase: A: TFA/H.sub.2O = 0.075% v/v; B: MeCN Column: Luna C18 100
.times. 30.0 mm, 5.mu. Flow rate: 25 mL/min Monitor wavelength: 220
& 254 nm Gradient: Time B% 0.00 18 8.00 48 12.0 48 12.1 100
13.6 100 13.7 18 14.7 18 an Instrument: Gilson 281 semi-preparative
HPLC system Mobile phase: A: 8 mL NH.sub.3.cndot.H.sub.2O in 20 L
H.sub.2O; B: MeCN Column: waters Xbridge 130 .times. 21.2 mm, 5.mu.
Flow rate: 25 mL/min Monitor wavelength: 220 & 254 nm Gradient:
an initial hold at 27% B for 1 min, a gradient of 27% to 57% B in
12 min ao Instrument: Shimadzu LC-8A preparative HPLC Column:
Luna(2) C18 250 .times. 50 mm i.d. 10 u Mobile phase: A for
H.sub.2O (0.09% TFA) and B for CH.sub.3CN Gradient: B from 82% to
82% Flow rate: 100 mL/min Injection amount: 0.7 g per injection ap
HPLC: The gradient was a hold at 10% B for 0.5 min, 10-50% B over
6.5 min, 50-80% over 5 min, 80-100% over 0.5 min, with a hold at
100% B for 0.5 min (40 mL/min flow rate). Mobile phase A was 0.01%
TFA in water, mobile phase B was MeCN. The column used for the
chromatography was a 30 .times. 75 mm SunFire C8 column (5 .mu.m
particles) at ambient temperature. Detection method is UV. aq HPLC:
The gradient was a hold at 10% B for 0.5 min, 10-50% B over 3.5
min, 50-80% over 4 min, 80-100% over 1.0 min, with a hold at 100% B
for 2.0 min (40 mL/min flow rate). Mobile phase A was 0.01% TFA in
water, mobile phase B was MeCN. The column used for the
chromatography was a 30 .times. 75 mm SunFire C8 column (5 .mu.m
particles) at ambient temperature. Detection method is UV. ar
LC/MS: The gradient was a hold at 5% B for 0.2 min, 5-95% B over
1.7 min with a hold at 95% B for 1.3 min (2.3 mL/min flow rate).
Mobile phase A was 0.01% TFA in water, mobile phase B was 0.01% TFA
in MeCN. The column used for the chromatography was a 4.6 .times.
50 mm XBridge C18 column (3.5 .mu.m particles) at a temperature of
50.degree. C. Detection methods are diode array (DAD) under
positive APCI ionization conditions. as LC/MS: The gradient was
5-60% B in 1.50 min then 60-95% B to 2.5 min with a hold at 95% B
for 1.2 min (1.3 mL/min flow rate). Mobile phase A was 10 mM
NH.sub.4OAc, mobile phase B was HPLC grade MeCN. The column used
for the chromatography was a 4.6 .times. 50 mm MAC-MOD Halo C8
column (2.7 .mu.m particles). Detection methods were diode array
(DAD) and evaporative light scattering (ELSD) detection as well as
positive/negative electrospray ionization. at LC/MS: The gradient
was 5-95% B over 1.2 min, with a hold at 95% for 1.3 min, back to
5% over 0.01 min (2.0 mL/min flow rate). Mobile phase A was 0.01%
TFA in water, mobile phase B was 0.01% TFA in MeCN. The column used
for the chromatography was a 4.6 .times. 50 mm SunFire C18 column
(3.5 .mu.m particles) at 50 C. Detection method is UV au LC/MS: The
gradient was 5-95% B over 1.3 min, with a hold at 95% for 1.5 min,
back to 5% over 0.01 min (1.8 mL/min flow rate). Mobile phase A was
0.01% ammonium acetate in water, mobile phase B was MeCN. The
column used for the chromatography was a 4.6 .times. 50 mm Xbridge
C18 column (3.5 .mu.m particles) at 50 C. Detection method is UV av
LC/MS: The gradient was 5-100% B over 1.2 min, with a hold at 100%
for 1.3 min (2.0 mL/min flow rate). Mobile phase A was 0.01% TFA in
water, mobile phase B was 0.01% TFA in MeCN. The column used for
the chromatography was a 4.6 .times. 50 mm Sunfire C18 column (3.5
.mu.m particles) at 50 C. Detection method is UV and MS aw LC/MS:
The gradient was 5-95 % B over 1.3 min, with a hold at 95% for 1.5
min (1.8 mL/min flow rate). Mobile phase A was 0.01% ammonium
acetate in water, mobile phase B was MeCN. The column used for the
chromatography was a 4.6 .times. 50 mm Xbridge C18 column (3.5
.mu.m particles) at 50 C. Detection method is UV and MS ax LC/MS:
The gradient was 5-100% B over 1.3 min (2.0 mL/min flow rate).
Mobile phase A was 0.01% TFA in water, mobile phase B was 0.01% TFA
in MeCN. The column used for the chromatography was a 4.6 .times.
50 mm Sunfire C18 column (3.5 .mu.m particles) at 45 C. Detection
method is UV and MS ay LC/MS: The gradient was 5-100% B over 1.2
min, with a hold at 95% for 1.3 min (2.0 mL/min flow rate). Mobile
phase A was 0.01% TFA in water, mobile phase B was 0.01% TFA in
MeCN. The column used for the chromatography was a 4.6 .times. 50
mm Sunfire C18 column (3.5 .mu.m particles) at 50 C. Detection
method is UV and MS az LC/MS: The gradient was 5-100% B over 1.2
min, with a hold at 100% for 1.3 min (2.0 mL/min flow rate), then
down to 95% over 0.01 min. Mobile phase A was 0.01% TFA in water,
mobile phase B was 0.01% TFA in MeCN. The column used for the
chromatography was a 4.6 .times. 50 mm Sunfire C18 column (3.5
.mu.m particles) at 50 C. Detection method is UV and MS ba LC/MS:
The gradient was 5-60% B in 1.50 min then 60-95% B to 2.5 min with
a hold at 95% B for 1.2 min (1.3 mL/min flow rate). Mobile phase A
was 0.1%
formic acid in water, mobile phase B was HPLC grade MeCN. The
column used for the chromatography was a 4.6 .times. 50 mm MAC-MOD
Halo C18 column (2.7 .mu.m particles). Detection methods were diode
array (DAD) and evaporative light scattering (ELSD) detection as
well as positive/negative electrospray ionization. bb LC/MS: The
gradient was 5-60% B in 0.60 min then 60-95% B to 1.00 min with a
hold at 95% B for 0.30 min (1.3 mL/min flow rate). Mobile phase A
was 10 mM ammonium acetate, mobile phase B was HPLC grade MeCN. The
column used for the chromatography was a 2.1 .times. 50 mm ACE
Excel 2 UHPLC C18 column (2.0 .mu.m particles). Detection methods
were diode array (DAD) and evaporative light scattering (ELSD)
detection as well as positive/negative electrospray ionization. bc
Instrument Gilson 281(PHG008) Column: waters X-bridge ODS C 18 19
.times. 250 mm, 10 .mu.m Mobile Phase: A: water (l0 ppM
NH.sub.4HC0.sub.3); B: ACN Flow Rate: 30 mL/min Monitor wavelength:
220 & 254 nm Gradient: 10-60% B in 8 min, stop at 15 min bd
HPLC: The column used for the chromatography was a 21.2 .times. 250
mm Hypersil C18 HS column (8 mm particles). The gradient was 40% B
for 4 min, 40-65 % B over 30 min (21 mL/min flow rate). Mobile
phase A was 0.05N aqueous NH.sub.4OAc buffer (pH 4.5) and mobile
phase B was HPLC grade MeCN. Detection method is UV, 1 = 254 nm be
LC/MS: The gradient was 5-100% B over 1.2 min, with a hold at 100%
for 1.3 min, then back down to 5% over 0.01 min (2.0 mL/min flow
rate). Mobile phase A was 0.01% TFA in water, mobile phase B was
0.01% TFA in MeCN. The column used for the chromatography was a 4.6
.times. 50 mm Sunfire C18 column (3.5 .mu.m particles) at 50 C.
Detection method is UV and MS
TABLE-US-00003 TABLE 2 Chiral HPLC methods Method Conditions 1 The
gradient was 20% B in 15.25 min then 20-65% B in 0.05 min and held
at 65% B for 6.70 min. Then equilibrated back down to 20% and held
for 4 min. (20 mL/min flow rate). Mobile phase B was 1:1 EtOH/MeOH
and mobile phase A was HPLC grade heptane with 0.12% diethylamine
added. The column used for the chromatography was a Daicel IA, 20
.times. 250 mm column (5 .mu.m particles). Detection method was UV
(.lamda. = 264 nm) 2 The method was isocratic 25% B for 25 min (20
mL/min flow rate). Mobile phase B was EtOH and Mobile phase A was
HPLC grade heptane with no modifier added. The column used for the
chromatography was a Daicel IA, 20 .times. 250 mm column (5 .mu.m
particles). Detection methods were evaporative light scattering
(ELSD) detection and UV (.lamda. = 312 nm) 3 (LC) The gradient was
40-65% B in 14.75 min then step to 98% B and hold for 5.2 min (20
mL/min flow rate). Mobile phase B was EtOH (200 proof), mobile
phase A was HPLC grade heptane with 0.2% diethylamine added. The
column used for the chromatography was a WhelkO1 R,R 21 .times. 250
mm column from Regis Technologies (5 .mu.m particles). 4 (SFC)
Isocratic, 50% co-solvent B (80 mL/min, 100 bar system pressure,
40.degree. C.). Co-solvent B was 1:1 HPLC grade EtOh:MeCN with 0.1%
triethylamine added. Solvent A was SFC grade CO.sub.2. The column
used for the chromatography was a 30 .times. 250 mm Daicel
Chiralpak AS-H (5 .mu.m particles). 5 (LC) Isocratic 18% B for 20
min then 18-30% B in 7 min and hold at 30% B for 6 min (20 mL/min
flow rate). Mobile phase B was EtOH (200 proof), mobile phase A was
HPLC grade heptane with 0.2% diethylamine added. The column used
for the chromatography was a WhelkO1 R,R 21 .times. 250 mm column
from Regis Technologies (5 .mu.m particles). 6 (LC) Isocratic 9% B
for 37.5 min then step to 40% B to elute second stereoisomer (20
mL/min flow rate). Mobile phase B was EtOH (200 proof), mobile
phase A was HPLC grade heptane with 0.2% diethylamine added. The
chromatography used a Daicel IA, 21 .times. 250 mm column (5 .mu.m
particles). 7 (LC) Isocratic 22% B for 19 min then step to 35% B
and hold for 3 min (20 mL/min flow rate). Mobile phase B was EtOH
(200 proof), mobile phase A was HPLC grade heptane with 0.2%
diethylamine added. The chromatography used a Daicel IE, 20 .times.
250 mm column (5 .mu.m particles). 8 (LC) Isocratic 30% B for 15
min then 30-33% B in 9 min then step to 45% B and hold for 4 min
(20 mL/min flow rate). Mobile phase B was EtOH (200 proof), mobile
phase A was HPLC grade heptane with 0.2% diethylamine added. The
chromatography used a Daicel IE, 20 .times. 250 mm column (5 .mu.m
particles). 9 (LC) Isocratic 15% B for 17 min then step to 55% B
and hold for 11 min (20 mL/min flow rate). Mobile phase B was EtOH
(200 proof), mobile phase A was HPLC grade heptane with 0.2%
diethylamine added. The chromatography used a Daicel IC, 20 .times.
250 mm column (5 .mu.m particles). 10 (LC) Isocratic 20% B for 42
min (20 mL/min flow rate). Mobile phase B was EtOH (200 proof),
mobile phase A was HPLC grade heptane with 0.2% diethylamine added.
The chromatography used a Daicel IC, 20 .times. 250 mm column (5
.mu.m particles). 11 (LC) Isocratic 25% B for 18.5 min then step to
60% B and hold for 4 min (20 mL/min flow rate). Mobile phase B was
200 proof EtOH, mobile phase A was HPLC grade heptane with 0.2%
diethylamine added. The column used for the chromatography was a
WhelkO1 S,S 21 .times. 250 mm column from Regis Technologies (5
.mu.m particles). 12 LC) Isocratic 25% B for 15 min then step to
45% B and hold for 12 min (20 mL/min flow rate). Mobile phase B was
HPLC grade IPA, mobile phase A was HPLC grade heptane with 0.2%
diethylamine added. The column used for the chromatography was a
Daciel IC 20 .times. 250 mm column (5 .mu.m particles). 13 LC)
Isocratic 30% B for 15.5 min then step to 35% B and hold for 20 min
(20 mL/min flow rate). Mobile phase B was HPLC grade IPA, mobile
phase A was HPLC grade heptane with 0.2% diethylamine added. The
column used for the chromatography was a Daciel IF 20 .times. 250
mm column (5 .mu.m particles). 14 (LC) Isocratic 25% B for 25 min
(20 mL/min flow rate). Mobile phase B was EtOH (200 proof), mobile
phase A was HPLC grade heptane with 0.2% diethylamine added. The
chromatography used a Daicel IB, 20 .times. 250 mm column (5 .mu.m
particles). 15 (LC) 40-45% B in 5 min, hold at 45% B for 23 min
then step to 65% B and hold for 10 min (20 mL/min flow rate).
Mobile phase B was EtOH (200 proof), mobile phase A was HPLC grade
heptane with no modifier added. The column used for the
chromatography was a WhelkO1 S,S 21 .times. 250 mm column from
Regis Technologies (5.mu.m particles). 16 (LC) Isocratic 19% B for
35 min (25 mL/min flow rate). Mobile phase B was HPLC grade MeCN,
mobile phase A was HPLC grade water with no modifier added. The
chromatography used an Astec, Chirobiotic T 21.2 .times. 250 mm
column (5 .mu.m particles). 17 (LC) Isocratic 25% B for 18.5 min
then step to 50% B and hold for 5.5 min (20 mL/min flow rate).
Mobile phase B was 200 proof EtOH, mobile phase A was HPLC grade
heptane with 0.2% diethylamine added. The column used for the
chromatography was a Daicel IF, 20 .times. 250 mm column (5 .mu.m
particles). 18 (LC) Isocratic 5% B for 37.5 min (20 mL/min flow
rate). Mobile phase B was 200 proof EtOH, mobile phase A was HPLC
grade heptane with 0.2% diethylamine added. The column used for the
chromatography was a Daicel IB, 20 .times. 250 mm column (5 .mu.m
particles). 19 (LC) Isocratic 20% B for 30 min (20 mL/min flow
rate). Mobile phase B was 200 proof EtOH, mobile phase A was HPLC
grade heptane with 0.2% diethylamine added. The column used for the
chromatography was a Daicel IF, 20 .times. 250 mm column (5 .mu.m
particles).
[0757] General Purification Methods
[0758] For the general procedures, the final compounds may be
purified by any technique or combination of techniques known to one
skilled in the art. Some examples that are not limiting include
column chromatography with a solid phase (i.e. silica gel, alumina,
etc.) and a solvent (or combination of solvents) that elutes the
desired compounds (i.e. hexanes, heptane, EtOAc, DCM, MeOH, EtOH,
MeCN, water, etc.); preparatory TLC with a solid phase (i.e. silica
gel, alumina etc.) and a solvent (or combination of solvents) that
elutes the desired compounds (i.e. hexanes, heptane, EtOAc, DCM,
MeOH, EtOH, MeCN, water, etc.); reverse phase HPLC (see Table 1 for
some non-limiting conditions); recrystalization from an appropriate
solvent (i.e. MeOH, EtOH, IPA, EtOAc, toluene, etc.) or combination
of solvents (i.e. EtOAc/heptane, EtOAc/MeOH, etc.); chiral LC with
a solid phase and an appropriate solvent (i.e. EtOH/heptane,
MeOH/heptane, IPA/heptane, etc. with or without a modifier such as
diethylamine, TFA, etc.) to elute the desired compound; chiral SFC
with a solid phase and CO.sub.2 with an appropriate modifier (i.e.
MeOH, EtOH, IPA with or without additional modifier such as
diethylamine, TFA, etc.); precipitation from a combination of
solvents (i.e. DMF/water, DMSO/DCM, EtOAc/heptane, etc.);
trituration with an appropriate solvent (i.e. EtOAc, DCM, MeCN,
MeOH, EtOH, IPA, n-PrOH, etc.); extractions by dissolving a
compound in a liquid and washing with an appropriately immiscible
liquid (i.e. DCM/water, EtOAc/water, DCM/saturated NaHCO.sub.3,
EtOAc/saturated NaHCO.sub.3, DCM/10% aqueous HCl, EtOAc/10% aqueous
HCl, etc.); distillation (i.e. simple, fractional, Kugelrohr,
etc.); gas chromatography using an appropriate temperature, carrier
gas and flow rate; sublimation at an appropriate temperature and
pressure; filtration through a media (i.e. Florosil.RTM., alumina,
Celite.RTM., silica gel, etc.) with a solvent (i.e. heptane,
hexanes, EtOAc, DCM, MeOH, etc.) or combination of solvents; salt
formation with solid support (resin based, i.e. ion exchange) or
without. Some descriptions of these techniques can be found in the
following references, Gordon, A. J. and Ford, R. A. "The Chemist's
Companion", 1972; Palleros, D. R. "Experimental Organic Chemistry",
2000; Still, W. C., Kahn, M. and Mitra, A. J. Org. Chem. 1978, 43,
2923; Yan, B. "Analysis and Purification Methods in Combinatorial
Chemistry" 2003; Harwood, L. M., Moody, C. J. and Percy, J. M.
"Experimental Organic Chemistry: Standard and Microscale, 2.sup.nd
Edition", 1999; Stichlmair, J. G. and Fair, J. R. "Distillation;
Principles and Practices" 1998; Beesley T. E. and Scott, R. P. W.
"Chiral Chromatography", 1999; Landgrebe, J. A. "Theory and
Practice in the Organic Laboratory, 4.sup.th Edition", 1993; Skoog,
D. A. and Leary, J. J. "Principles of Instrumental Analysis,
4.sup.th Edition" 1992; Subramanian, G. "Chiral Separation
Techniques 3.sup.rd Edition" 2007; Kazakevich, Y. and Lobrutto, R.
"HPLC for Pharmaceutical Scientists" 2007. Final or intermediate
compounds prepared via any of the following General Procedures can
be optionally purified using one or more of the purification
methods described above.
PREPARATIONS AND EXAMPLES
[0759] The general synthetic methods used in each General Procedure
follow and include an illustration of a compound that was
synthesized using the designated General Procedure. None of the
specific conditions and reagents noted herein are to be construed
as limiting the scope of the invention and are provided for
illustrative purposes only. All starting materials are commercially
available from Sigma-Aldrich (including Fluka and Discovery CPR)
unless otherwise noted after the chemical name. Reagent/reactant
names given are as named on the commercial bottle or as generated
by IUPAC conventions, CambridgeSoft.RTM. ChemDraw Ultra 9.0.7,
CambridgeSoft.RTM. Chemistry E-Notebook v9.0.127 or v11.0.3.68, or
AutoNom 2000. Compounds designated as salts (e.g. hydrochloride,
acetate) may contain more than one molar equivalent of the salt.
Compounds of the invention where the absolute stereochemistry has
been determined by the use of a commercially available
enantiomerically pure starting material or a stereochemically
defined intermediate, or by X-ray diffraction are denoted by an
asterisk after the example number.
Preparation #1. 4-Bromo-2-iodo-1H-indole-7-carboxamide
##STR00057##
[0760] Step A: 4-Bromo-1H-indole-7-carboxylic acid
##STR00058##
[0762] To a solution of 4-bromo-2-nitrobenzoic acid (30 g, 122
mmol) in anhydrous THF (500 mL), a solution of vinylmagnesium
bromide (51.2 mL, 512 mmol, 1 N) in THF was added dropwise at about
-30 to -50.degree. C. The reaction mixture was stirred at about -30
to -40.degree. C. for about 2 h. Then the reaction mixture was
poured into saturated aqueous NH.sub.4Cl solution and the mixture
was extracted with EtOAc (200 mL.times.2). The combined organic
layers were washed with brine, dried over andydrous
Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure
to provide 4-bromo-1H-indole-7-carboxylic acid (33 g crude), which
was used directly for next step without further purification.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.42 (m, 1H), 8.11
(bs, 1H), 7.63 (dd, J=17.4, 8.0 Hz, 1H), 7.45 (dt, J=14.2, 2.8 Hz,
1H), 7.32 (dd, J=21.9, 8.0 Hz, 1H), 6.47 (ddd, J=25.5, 3.1, 2.1 Hz,
1H).
Step B: Methyl 4-bromo-1H-indole-7-carboxylate
##STR00059##
[0764] To a solution of 4-bromo-1H-indole-7-carboxylic acid (33 g,
137 mmol) in DMF (300 mL), Cs.sub.2CO.sub.3 (90 g, 276 mmol) was
added and stirred at rt for 1 h. Then iodomethane (29.3 g, 206
mmol) was added dropwise at about 0.degree. C. The reaction mixture
was warmed to rt for about 3 h. The mixture was poured into water
and extracted with EtOAc (200 mL.times.2). The combined organic
layers were washed with brine, dried over anhydrous
Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure
and the residue was purified by silica gel column chromatography to
provide methyl 4-bromo-1H-indole-7-carboxylate (13.8 g, 20%):
.sup.1H NMR (CDCl.sub.3) .delta. 9.98 (s, 1H), 7.76-7.74 (d, J=8,
1H), 7.39-7.34 (m, 2H), 6.68-6.66 (m, 1H), 4.00 (s, 3H).
Step C: Methyl 4-bromo-1-tosyl-1H-indole-7-carboxylate
##STR00060##
[0766] To a solution of methyl 4-bromo-1H-indole-7-carboxylate (130
g, 512 mmol) in anhydrous THF (1500 mL) was added NaH (18.4 g, 767
mmol) in portions at about 0.degree. C. and stirred for about 1 h
at 0.degree. C. Then TsCl (117 g, 614 mmol) was added in portions
at about 0.degree. C. The reaction mixture was warmed to rt for
about 2 h. The reaction mixture was poured into ice water and
extracted with EtOAc (1000 mL.times.2). The combined organic layers
were washed with brine, dried over anhydrous Na.sub.2SO.sub.4,
filtered and concentrated under reduced pressure and the residue
was purified by silica gel column chromatography to provide methyl
4-bromo-1-tosyl-1H-indole-7-carboxylate (150 g, 72%): .sup.1H NMR
(CDCl.sub.3) .delta. 7.60-7.58 (d, J=8.4, 2H), 7.54-7.53 (d, J=3.6,
1H), 7.46-7.44 (d, J=8, 1H), 7.37-7.35 (d, J=8.4, 1H), 7.21-7.18
(d, J=8.4, 2H), 6.77-6.76 (m, 1H), 3.93 (s, 3H), 2.35 (s, 3H).
Step D: Methyl 4-bromo-2-iodo-1-tosyl-1H-indole-7-carboxylate
##STR00061##
[0768] To a solution of diisopropylamine (6.2 g, 61.2 mmol) in
anhydrous THF (100 mL), stirred in t-BuLi (3.92 g, 61.2 mmol) in
pentane was added at about 0.degree. C. under N.sub.2 atmosphere,
and the mixture was stirred for about 10 min. The solution of
methyl 4-bromo-1-tosyl-1H-indole-7-carboxylate (10 g, 24.49 mmol)
in anhydrous THF (100 mL) was added at about -70.degree. C. under
N.sub.2 atmosphere. After about 30 min, a solution of I.sub.2 (9.33
g, 36.7 mmol) in anhydrous THF (50 mL) was added. After about 30
min, the cooling bath was removed and the mixture was stirred for
about another hour. The mixture was quenched with saturated aqueous
Na.sub.2S.sub.2O.sub.3. Water and EtOAc were added to the mixture.
The layers were separated and the aqueous layer was extracted with
EtOAc (300 mL.times.2). The combined organic layers were washed
with brine, dried with anhydrous Na.sub.2SO.sub.4, filtered,
concentrated under reduced pressure and the residue was purified by
silica gel column chromatography to provide methyl
4-bromo-2-iodo-1-tosyl-1H-indole-7-carboxylate (7.5 g, 38%):
.sup.1H NMR (CDCl.sub.3): .delta. 7.64-7.59 (m, 2H), 7.55-7.53 (m,
2H), 7.30-7.27 (m, 2H), 7.17-7.17 (m, 1H), 4.06-4.05 (d, J=1.2,
3H), 2.49 (s, 3H).
Step E: 4-Bromo-2-iodo-1H-indole-7-carboxylic acid
##STR00062##
[0770] To a solution of methyl
4-bromo-2-iodo-1-tosyl-1H-indole-7-carboxylate (75 g, 23.4 mmol) in
MeOH (750 mL), THF (1500 mL) and water (750 mL), LiOH (67 g, 280
mmol) was added the the reaction mixture was heated at about
45.degree. C. for about 3 h. The resulting solution was
concentrated under reduced pressure to remove MeOH and THF, then
the solution was adjusted to pH=6 to 7 with HCl (1 N), the
precipitate was filtered and dried by high vacuum to provide
4-bromo-2-iodo-1H-indole-7-carboxylic acid (45 g, 88%): .sup.1H NMR
(DMSO-d6) .delta. 11.60 (s, 1H), 7.56 (d, J=8.0, 1H), 7.31 (m,
J=8.0, 1H), 6.72 (s, 1H).
Step F: 4-bromo-2-iodo-1H-indole-7-carboxamide
##STR00063##
[0772] To a solution of 4-bromo-2-iodo-1H-indole-7-carboxylic acid
(45 g, 123 mmol) in DMF (450 mL) was added HOBt (28.2 g, 184 mmol),
PyBOP (96 g, 184 mmol), NH.sub.4Cl (10 g, 184.5 mmol) and DIEA
(63.6 g, 492 mmol). The reaction mixture was stirred at rt for
about 2 h. Water was added, the reaction mixture was extracted with
EtOAc (1000 mL.times.2), the organic phase was dried with anhydrous
Na.sub.2SO.sub.4 and concentrated under reduced pressure and the
residue was purified by column chromatography with Pet ether:EtOAc
(20:1 to 1:1) to provide 4-bromo-2-iodo-1H-indole-7-carboxamide (25
g, 56%): .sup.1H NMR (DMSO-d6) .delta. 11.62 (s, 1H), 8.24 (s, 1H),
7.62-7.60 (d, J=8, 2H), 7.38-7.36 (d, J=8, 1H), 6.77 (s, 1H): LC/MS
(Table 1, Method d) 14=3.07 min; MS m/z: 366 (M-H).sup.-.
Preparation #2. 4-Bromo-1H-indole-7-carboxamide
##STR00064##
[0774] To a solution of 4-bromo-1H-indole-7-carbonitrile (3 g,
13.57 mmol, Sinova) in EtOH (36.2 mL)/DMSO (9.05 mL) was slowly
added added hydrogen peroxide (28.0 mL, 274 mmol) and NaOH (28.0
mL, 28.0 mmol). The reaction mixture was stirred at rt for about 1
h. Water was added and the precipitate was collected by filtration,
washed with water, and dried under vacuum to provide
4-bromo-1H-indole-7-carboxamide (2.85 g, 88%). LC/MS (Table 1,
Method f).sub.14=1.42 min; MS m/z: 280 (M+MeCN).sup.+.
Preparation #3.
2-(2-Methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3,4-di-
hydroisoquinolin-1(2H)-one
##STR00065##
[0775] Step A: 3,4-Dihydroisoquinolin-1(2H)-one
##STR00066##
[0777] To a solution of 2,3-dihydro-1H-inden-1-one (30 g, 227 mmol)
in DCM (300 mL) was added methanesulfonic acid (300 mL) and the
solution was cooled to about 0.degree. C. Sodium azide (30 g, 461
mmol) was added to the solution in portions at about 0.degree. C.
and the reaction mixture was stirred overnight at rt. The reaction
mixture was neutralized with 20% aqueous NaOH and extracted with
DCM (2.times.1 L). The organic phase was dried with anhydrous
Na.sub.2SO.sub.4 and concentrated to give a residue, which was
purified by column chromatography on silica gel to provide
3,4-dihydroisoquinolin-1(2H)-one (5 g, 15%): .sup.1H NMR (MeOD)
.delta. 7.93-7.91 (m, 1H), 7.49-7.45 (m, 1H), 7.36-7.45 (m, 1H),
7.28-7.26 (d, 1H), 3.50-3.46 (t, 2H), 2.97-2.94 (t, 2H).
Step B:
2-(3-Bromo-2-methylphenyl)-3,4-dihydroisoquinolin-1(2H)-one
##STR00067##
[0779] A mixture of 3,4-dihydroisoquinolin-1(2H)-one (3.5 g, 13.6
mmol), 1,3-dibromo-2-methylbenzene (17.5 g, 70.5 mmol) and
K.sub.2CO.sub.3 (9.85 g, 71.3 mmol) in DMSO (40 mL) was purged with
N.sub.2, treated with CuI (1.75 g, 9 mmol) and heated to about
160.degree. C. for about 4 h. The reaction mixture was diluted with
DCM and filtered through Celite.RTM.. The filtrate was washed with
5% ammonia hydroxide, dried and concentrated. The residue was
purified by column chromatography on silica gel to provide
2-(3-bromo-2-methylphenyl)-3,4-dihydroisoquinolin-1(2H)-one (6 g,
80%): .sup.1H NMR (CDCl.sub.3) .delta.8.16-8.14 (d, 1H), 7.56-7.54
(d, 2H), 7.49-7.41 (t, 1H), 7.26 (d, 1H), 7.25-7.18 (d, 1H),
7.15-7.13 (d, 1H), 3.98-3.92 (m, 1H), 3.76-3.70 (m, 1H), 3.30-3.22
(m, 1H), 3.13-3.07 (m, 1H) 2.36 (s, 3H).
Step C:
2-(2-Methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-
-3,4-dihydroisoquinolin-1(2H)-one
##STR00068##
[0781] To a mixture of
2-(3-bromo-2-methylphenyl)-3,4-dihydroisoquinolin-1(2H)-one (4.6 g,
14.6 mmol), bis(pinacolato)diboron (8.8 g, 34.6 mmol) and
CH.sub.3COOK (9 g, 91.8 mmol) in 1, 4-dioxane (100 mL) and DMSO (20
mL), PdCl.sub.2 (dppf) (1 g, 1.4 mmol) was added. The reaction
mixture was heated at about 120.degree. C. overnight under N.sub.2
protection. After cooling to ambient temperature, the reaction
mixture was filtered through Celite.RTM. the solid was washed with
EtOAc, and the filtrate was washed with water and brine, dried over
Na.sub.2SO.sub.4, concentrated and the residue was purified by
column chromatography on silica gel to provide
2-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3,4-di-
hydroisoquinolin-1(2H)-one (1.5 g, 28%): .sup.1H NMR (CDCl.sub.3)
.delta. 8.19-8.17 (dd, 1H), 7.80-7.78 (dd, 1H), 7.51-7.47 (t, 1H),
7.42-7.38 (t, 1H), 7.32-7.25 (m, 3H), 3.96-3.89 (m, 1H), 3.77-3.71
(m, 1H), 3.27-3.23 m, 1H), 3.14-3.08 (m, 1H), 2.50 (s, 3H), 1.36
(s, 12H); LC/MS (Table 1, Method o) R.sub.t=3.34 min; MS m/z: 364
(M+H).sup.+.
Preparation #4.
N-(2-Methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)thiazol-
e-2-carboxamide
##STR00069##
[0783] To a solution of
2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline
(1.9 g, 8.15 mmol, CombiBlocks) in DCM (50 mL), DIEA (2.1 g, 16.3
mmol) and HATU (4.03 g, 10.6 mmol) were added at rt. After about 5
min, thiazole-2-carboxylic acid (1.9 g, 8.15 mmol) was added and
the solution was stirred for about 3 h at rt. The reaction mixture
was poured into water, extracted with DCM (100 mL.times.2) and the
organic phase was washed with brine, dried with anhydrous
Na.sub.2SO.sub.4 and concentrated under reduced pressure and the
residue was purified by column chromatography on silica gel (eluted
with Pet ether:EtOAc=10:1 to 3:1) to provide
N-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl-
)thiazole-2-carboxamide (1 g, 36%): .sup.1H NMR (CDCl.sub.3)
.delta. 9.07 (s, 1H), 8.16-8.14 (d, J=8 Hz, 1H), 7.87-7.86 (t,
J=3.2 Hz, 1H), 7.57-7.55 (m, 2H), 7.20-7.18 (m, 1H), 2.53 (s, 3H),
1.29 (s, 12H).
Preparation #5.
1-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one
##STR00070##
[0784] Step A: 5-Bromo-1-methylpyridin-2(H)-one
##STR00071##
[0786] To a solution of 5-bromopyridin-2-ol (4 g, 23 mmol) in THF
(200 mL) at about 0.degree. C. was added NaH (0.83 g, 34.7 mmol) in
portions. The reaction mixture was stirred at rt for about 15 min
followed by addition of iodomethane (9.8 g, 69 mmol). The mixture
was stirred overnight at rt. After the completion of the reaction
(TLC monitoring), the reaction mixture was cooled to about
0.degree. C., water was added, extracted with EtOAc (100
mL.times.2). The organic layer was washed with brine, dried with
anhydrous Na.sub.2SO.sub.4, filtered and concentrated under reduced
pressure to provide 5-bromo-1-methylpyridin-2-(1H)-one (3 g, 69%):
.sup.1H NMR (MeOD) .delta. 7.87 (s, 1H), 7.58-7.55 (m, 1H), 6.47
(d, J=9.6 Hz, 1H), 3.53 (s, 3H).
Step B:
1-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(-
1H)-one
##STR00072##
[0788] To a mixture of 5-bromo-1-methylpyridin-2(1H)-one (1.0 g,
5.32 mmol), KOH (0.78 g, 7.98 mmol) and bis(pinacolato)diboron
(0.162 g, 6.38 mmol) in 1,4-dioxane (20 mL), tricyclohexylphosphine
(149 mg, 0.532 mmol), Pd.sub.2dba.sub.3 (487 mg, 0.532 mmol) were
added under N.sub.2 atmosphere. The mixture was stirred at about
80.degree. C. for about 5 h. Then water was added, the aqueous
layer was extracted with EtOAc (50 mL.times.2), and the organic
layer was dried over anhydrous Na.sub.2SO.sub.4, concentrated under
reduced pressure and the residue was purified by column
chromatograph on silica gel to provide
1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(H)-one
(0.80 g, 64%): .sup.1H NMR (CDCl.sub.3) .delta. 7.70 (s, 1H), 7.54
(d, J=8.8 Hz, 1H), 6.47 (d, J=8.8 Hz, 1H), 3.49 (s, 3H), 1.24 (s,
12H).
Preparation #6.
4-(3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenylamino)pyrimidine--
2-carbonitrile
##STR00073##
[0790] To a microwave vial was added
4-chloropyrimidine-2-carbonitrile (100 mg, 0.717 mmol, CombiPhos),
3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (314 mg,
1.433 mmol), and N-ethyl-N-isopropylpropan-2-amine (0.250 mL, 1.433
mmol) in MeCN (7 mL). The vial was sealed and heated in a microwave
at about 150.degree. C. for about 20 min with stirring. The
reaction mixture was cooled to rt and the solvent removed under a
warm stream of nitrogen. The residue was dissolved in DCM (10 mL)
and washed with water (10 mL). The mixture was separated using a
Biotage phase separator and the organics were concentrated in vacuo
to afford the crude product. The crude product was added to a
silica gel column and was eluted with 10-60% EtAcO/heptane to
provide
4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenylamino)pyrimidine--
2-carbonitrile (0.11 g, 48%): LC/MS (Table 1, Method f)
R.sub.t=1.89 min; MS m/z: 323 (M+H).sup.+.
Preparation #7.
N-(3-(3-amino-7-carbamoyl-1H-indol-4-yl)-2-methylphenyl)thiazole-2-carbox-
amide
##STR00074##
[0791] Step A: 4-Bromo-1H-indole-7-carboxylic acid
##STR00075##
[0793] To a solution of methyl 4-bromo-1H-indole-7-carboxylate (6
g, 23 mmol, Preparation #1 step B) in THF (300 mL), water (60 mL)
and MeOH (60 mL) was added lithium hydroxide (2.83 g, 118 mmol).
Then the mixture was heated to reflux overnight. After cooling to
rt, the solvent was removed under reduced pressure, the aqueous
layer was acidified by addition of 4 N HCl to about pH 6. The
precipitate was filtered, and the solid was dried to provide
4-bromo-1H-indole-7-carboxylic acid (5.5 g, 97%): .sup.1H NMR
(DMSO-d6) .delta. 11.39 (br, 1H), 7.65-7.63 (d, J=8.0 Hz, 1H),
7.46-7.44 (m, 1H), 7.33-7.31 (d, J=8.0 Hz, 1H), 6.49-6.48 (m,
1H).
Step B: 4-Bromo-1H-indole-7-carboxamide
##STR00076##
[0795] A solution of 4-bromo-1H-indole-7-carboxylic acid (5.5 g,
22.91 mmol) EDC (6.59 g, 34.4 mmol) and HOBt (5.26 g, 34.4 mmol) in
THF (150 mL) and DCM (180 mL) was stirred at rt for 1 h. The
mixture was then bubbled with NH.sub.3 gas for about 15 min and the
resulting mixture was stirred at rt overnight. The mixture was
diluted by addition of water and extracted with DCM. The organic
phase was washed with brine, dried and concentrated to give a
residue, which was suspended in ether and filtered to provide
4-bromo-1H-indole-7-carboxamide (5.3 g, 97%): .sup.1H NMR (DMSO-d6)
.delta. 11.40 (br, 1H), 8.08 (br, 1H), 7.29-7.57 (d, J=7.6 Hz, 1H),
7.43-7.42 (m, 2H), 7.28-7.26 (d, J=7.6 Hz, 1H), 6.43-6.42 (m,
1H).
Step C: 4-Bromo-3-nitro-1H-indole-7-carboxamide
##STR00077##
[0797] To a solution of 4-bromo-1H-indole-7-carboxamide (5.3 g,
22.17 mmol) and AgNO.sub.3 (11.30 g, 66.5 mmol) in CH.sub.3CN (100
mL) was added benzoyl chloride (9.35 g, 66.5 mmol) in CH.sub.3CN
(20 mL) at about 0.degree. C. and the mixture was stirred at about
0.degree. C. for 1 h in the dark. Water and EtOAc was added. The
organic phase was concentrated to give a residue which was washed
with DCM to provide 4-bromo-3-nitro-1H-indole-7-carboxamide (2.6 g,
41%): .sup.1H NMR (DMSO-d6) .delta. 12.46 (br, 1H), 8.39-8.38 (d,
J=3.6 Hz, 1H), 8.33 (br, 1H), 7.77-7.73 (m, 2H), 7.67-7.62 (m, 1H).
LC/MS (Table 1, Method 1) R.sub.t=2.41 min; MS m/z: 285
(M+H).sup.+.
Step D:
N-(3-(7-Carbamoyl-3-nitro-1H-indol-4-yl)-2-methylphenyl)thiazole-2-
-carboxamide
##STR00078##
[0799] To a solution of 4-bromo-3-nitro-1H-indole-7-carboxamide (4
g, 14 mmol),
N-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-
thiazole-2-carboxamide (5.8 g, 16.9 mmol, Preparation #4) in
1,4-dioxane (100 mL) and water (25 mL) was added
Pd(PPh.sub.3).sub.4 (0.81 g, 0.7 mmol) and CsF (6.4 g, 42 mmol) and
the mixture was stirred at about 120.degree. C. overnight under
N.sub.2. After cooling to rt, the mixture was diluted by addition
of water and extracted with EtOAc. The organic phase was dried and
concentrated under reduced pressure to give a residue, which was
purified by prep-HPLC (Table 1, Method ah) to provide crude
N-(3-(7-carbamoyl-3-nitro-1H-indol-4-yl)-2-methylphenyl)thiazole-2--
carboxamide (2 g, 33%): LC/MS (Table 1, Method 1) R.sub.t=1.44 min;
MS m/z: 422 (M+H).sup.+.
Step E:
N-(3-(3-Amino-7-carbamoyl-1H-indol-4-yl)-2-methylphenyl)thiazole-2-
-carboxamide
##STR00079##
[0801] To a solution of
N-(3-(7-carbamoyl-3-nitro-1H-indol-4-yl)-2-methylphenyl)thiazole-2-carbox-
amide (0.20 g, 0.48 mmol) in EtOH (20 mL) was added Raney Ni (0.10
g) and the mixture was stirred at rt under H.sub.2 50 psi for about
6 h. The mixture was filtered and the filtrate was concentrated
under reduced pressure to provide crude
N-(3-(3-amino-7-carbamoyl-1H-indol-4-yl)-2-methylphenyl)thiazole-2-carbox-
amide (0.11 g, 59%) which was used without further purification:
LC/MS (Table 1, Method 1) R.sub.t=1.54 min; MS m/z: 392
(M+H).sup.+.
Preparation #8.
4-Hydroxy-N-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phen-
yl)-4-(trifluoromethyl)cyclohexanecarboxamide
##STR00080##
[0802] Step A: Ethyl
4-hydroxy-4-(trifluoromethyl)cyclohexanecarboxylate
##STR00081##
[0804] A round bottom flask was charged with ethyl
4-oxocyclohexanecarboxylate (10.0 g, 58.8 mmol) and CsF (8.92 g,
58.8 mmol) in DME (100 mL) at about 23.degree. C. The reaction was
cooled in an ice bath to about 5.degree. C., then
trimethyl(trifluoromethyl)silane (8.35 g, 58.8 mmol) was added
dropwise at such a rate as to maintain reaction temperature below
8.degree. C. The reaction was stirred about 18 h at about
23.degree. C. TBAF (19.4 mL, 1M solution in THF, 19.39 mmol) was
added drop wise and the mixture was stirred about 20 min. The
mixture was diluted with EtOAc (200 mL) and washed with water
(3.times.200 mL). The organic layer was dried over
Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure.
The residue was purified on silica gel using a gradient 10 to 50%
EtOAc in heptaneto give ethyl
4-hydroxy-4-(trifluoromethyl)cyclohexanecarboxylate (9.27 g, 67%).
The product was taken as a mixture of isomers to the next step
without further purification: .sup.1H NMR (DMSO-d6) .delta. 5.73
(s, 0.5H), 5.72 (s, 0.5H), 4.13-4.01 (m, 2H), 2.70-2.64 (m, 0.55H),
2.37-2.27 (m, 0.45H), 1.90-1.45 (m, 8H), 1.21-1.14 (m, 3H).
Step B: (1s,4s)-4-Hydroxy-4-(trifluoromethyl)cyclohexanecarboxylic
acid
##STR00082##
[0806] Dry EtOH (90 mL) was treated with sodium (1.03 g, 45.0 mmol)
at rt and the mixture was stirred until the sodium dissolved. A
solution of ethyl
4-hydroxy-4-(trifluoromethyl)cyclohexanecarboxylate (9.00 g, 37.5
mmol) in EtOH (90 mL) was added and the mixture was heated at about
70.degree. C. under nitrogen for about 18 h. To the mixture was
added 2N aqueous NaOH (18.7 mL, 37.5 mmol) and the mixture was
stirred with heating at about 70.degree. C. for about 4 h. The
reaction was cooled to rt and concentrated to remove most of the
EtOH. The resulting suspension was diluted with water (50 mL) to
give a clear solution. The solution was acidified with conc. HCl to
pH=2. The solution was concentrated to a volume of about 50 mL and
the precipitated product was collected by filtration. The
precipitate was rinsed with water (2.times.8 mL) and dried for
about 18 h under reduced pressure to give
(1s,4s)-4-hydroxy-4-(trifluoromethyl)cyclohexanecarboxylic acid as
a white solid (5.99 g, 75%): LC/MS (Table 1, Method a) R.sub.t=1.35
min; MS m/z 211 (M-H).sup.-, .sup.1H NMR (DMSO-d6) .delta. 12.10
(s, 1H), 5.69 (s, 1H), 2.26-2.16 (m, 1H), 1.79-1.69 (m, 4H),
1.69-1.56 (m, 2H), 1.55-1.44 (m, 2H).
Step C:
(1s,4s)-4-Hydroxy-N-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxabo-
rolan-2-yl)phenyl)-4-(trifluoromethyl)cyclohexanecarboxamide
##STR00083##
[0808] A solution containing
(1s,4s)-4-hydroxy-4-(trifluoromethyl)cyclohexanecarboxylic acid
(100 mg, 0.471 mmol) and
2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline
(110 mg, 0.471 mmol, CombiBlocks) in DMF (2.0 mL) was treated with
DIEA (0.082 mL, 0.471 mmol) and
2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-1,1,3,3-tetramethylisouronium
hexafluorophosphate(V) (179 mg, 0.471 mmol) and the mixture was
stirred at rt for about 1 h. The mixture was diluted with water (5
mL), triturated and the supernatant decanted. The residue was
dissolved in EtOAc (10 mL), dried over Na.sub.2SO.sub.4, filtered
and concentrated. The residue was purified on silica gel using a
gradient of 25-75% EtOAc in heptane. Product fractions were
combined, concentrated and dried to solids under reduced pressure
to give
(1s,4s)-4-hydroxy-N-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
-yl)phenyl)-4-(trifluoromethyl)cyclohexanecarboxamide as a solid
(135 mg, 67%): LC/MS (Table 1, Method b) R.sub.t=1.56 min; MS m/z
428 (M+H).sup.+, .sup.1H NMR (DMSO-d6) .delta. 9.23 (s, 1H), 7.46
(dd, J=7.4, 1.4 Hz, 1H), 7.35 (dd, J=7.9, 1.4 Hz, 1H), 7.14 (t,
J=7.6 Hz, 1H), 5.74 (s, 1H), 2.44-2.34 (m, 1H), 2.32 (s, 3H),
1.90-1.67 (m, 6H), 1.60-1.42 (m, 2H), 1.30 (s, 12H).
Preparation #9: 4-Bromo-1H-pyrrolo[3,2-c]pyridine-7-carboxamide
##STR00084##
[0809] Step A: 4-Bromo-1H-pyrrolo[3,2-c]pyridine-7-carboxylic
acid
##STR00085##
[0811] A solution of 6-bromo-4-nitronicotinic acid (3.8 g, 15.4
mmol, Eur. J. Med. Chem. 1977, 12(6), 541) in anhydrous THF (100
mL) was stirred between about -40 and -50.degree. C. for about 5
min. Then vinylmagnesium bromide (1N in THF, 69.2 mL, 69.2 mmol)
was added dropwise. The mixture was stirred between about -40 and
-50.degree. C. for about 4 h. The mixture was quenched with
saturated aqueous NH.sub.4Cl (2 mL). The solvent was removed under
reduced pressure to get a residue, which was purified by prep-HPLC
(Table 1, Method w) to provide
4-bromo-1H-pyrrolo[3,2-c]pyridine-7-carboxylic acid (1 g, 27%):
.sup.1H NMR (DMSO-d6) .delta. 11.90 (br. s, 1H), 8.46 (s, 1H), 7.54
(t, J=2.65 Hz, 1H), 6.56 (br, 1H).
Step B: 4-Bromo-1H-pyrrolo[3,2-c]pyridine-7-carboxamide
##STR00086##
[0813] To a solution of
4-bromo-1H-pyrrolo[3,2-c]pyridine-7-carboxylic acid (100 mg, 0.42
mmol) in DMF (2 mL) was added HOBt (95 mg, 0.62 mmol) and EDCI (119
mg, 0.62 mmol). After the reaction mixture was stirred at rt for
about 1 h, NH.sub.3/THF (10 mL) was added and the resulting mixture
was stirred at rt overnight. Then the suspension was filtered and
the filtrate was concentrated under reduced pressure. Water was
added and extracted with EtOAc. The combined organic phase was
washed with brine, dried over Na.sub.2SO.sub.4, filtered and
concentrated under reduced pressure to provide
4-bromo-1H-pyrrolo[3,2-c]pyridine-7-carboxamide (60 mg, 42%). The
product was used without further purification: .sup.1H NMR
(DMSO-d6) .delta. 11.89 (br, 1H), 8.51 (s, 1H), 8.27 (br, 1H), 7.68
(br, 1H), 7.52-7.51 (d, J=2.8 Hz, 1H), 6.52-6.51 (d, J=3.2 Hz,
1H).
Preparation #10.
4-Bromo-2-(1-methyl-1H-pyrazol-4-yl)-1H-indole-7-carboxamide
##STR00087##
[0814] Step A: Methyl
4-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-7-carboxylate
##STR00088##
[0816] To a solution of methyl 4-bromo-1H-indole-7-carboxylate (35
g, 138 mmol, Preparation #1 step B) in anhydrous THF (1500 mL) was
added NaH (10 g, 250 mmol) in portions at about 0.degree. C. and
stirred for 1 h at about 0.degree. C. Then SEMCl (31.9 mL, 180
mmol) was added in portions at about 0.degree. C. The reaction
mixture was allowed to warm up to rt and stirred for about 12 h.
Then to the reaction mixture was added saturated aqueous NH.sub.4Cl
and extracted with EtOAc. The combined organic layers were washed
with brine, dried over anhydrous Na.sub.2SO.sub.4, filtered and
concentrated under reduced pressure to give the residue, which was
purified by column chromatography on silica gel to give methyl
4-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-7-carboxylate
(32 g, 60%): .sup.1H NMR (CDCl.sub.3) .delta. 7.62-7.60 (d, J=8.4
Hz, 1H), 7.46-7.44 (d, J=8.0 Hz, 1H), 7.36-7.35 (d, J=3.2 Hz, 1H),
6.77-6.76 (d, J=3.6 Hz, 1H), 5.80 (s, 2H), 4.06 (s, 3H), 3.32-3.28
(t, J=8.0 Hz, 2H), 0.89-0.85 (t, J=8.0 Hz, 2H), 0.00 (s, 9H).
Step B: Methyl
4-bromo-2-iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-7-carboxyla-
te
##STR00089##
[0818] To a solution of methyl
4-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-7-carboxylate
(10 g, 26 mmol, Preparation #1 step B) in anhydrous THF (200 mL)
was added lithium diisopropylamide (18 mL, 36 mmol) at about
-70.degree. C. and stirred for about 2 h. Then a solution of 12 (10
g, 39 mmol) in anhydrous THF (50 mL) was added to above solution
dropwise at about -70.degree. C. and then stirred for about 2 h.
The mixture was poured into aqueous Na.sub.2S.sub.2O.sub.3 solution
and extracted with EtOAc. The combined organic phases were washed
with brine, dried over Na.sub.2SO.sub.4, filtered and concentrated
under pressure to get a residue, which was purified by column
chromatography (eluted with Pet ether:EtOAc=200:1) to provide
methyl
4-bromo-2-iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-7-carboxyla-
te (6.2 g, 47%): .sup.1H NMR (CDCl.sub.3) .delta. 7.50-7.48 (d,
J=8.0 Hz, 1H), 7.42-7.40 (d, J=8.0 Hz, 1H), 7.10 (s, 1H), 5.90 (s,
2H), 4.06 (s, 3H), 3.29-3.25 (t, J=8.0 Hz, 2H), 0.87-0.83 (t, J=8.0
Hz, 2H), 0.00 (s, 9H).
Step C: Methyl
4-bromo-2-iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-7-carboxyla-
te
##STR00090##
[0820] To a solution of methyl
4-bromo-2-iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-7-carboxyla-
te (1.1 g, 2.2 mmol) in DME (20 mL) and water (5 mL) was added
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
(0.49 g, 2.37 mmol), PdCl.sub.2(dppf) (0.176 g, 0.216 mmol) and
Na.sub.2CO.sub.3 (0.894 g, 6.47 mmol). The mixture was heated to
reflux for about 3 h. After cooling to rt, water (20 mL) was added
to the solution and extracted with EtOAc (50 mL). The organic phase
was dried over Na.sub.2SO.sub.4 and concentrated in vacuo to get a
crude product, which was purified by column chromatography on
silica gel (eluted with Pet ether:EtOAc=10:1) to provide methyl
4-bromo-2-iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-7-carboxyla-
te (0.65 g, 65%): H NMR (CDCl.sub.3) .delta. 7.84 (s, 1H), 7.77 (s,
1H), 7.61-7.59 (d, J=7.2 Hz, 1H), 7.49-7.40 (d, J=8.0 Hz, 1H), 6.79
(s 1H), 5.84 (s, 2H), 4.14 (s, 3H), 4.11 (s, 3H), 3.20-3.16 (t,
J=8.4 Hz, 2H), 0.82-0.78 (t, J=8.4 Hz, 2H), 0.00 (s, 9H).
Step D:
4-Bromo-2-(1-methyl-1H-pyrazol-4-yl)-1-((2-(trimethysilyl)ethoxy)m-
ethyl)-1H-indole-7-carboxylic acid
##STR00091##
[0822] To a solution of methyl
4-bromo-2-iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-7-carboxyla-
te (0.65 mg, 1.41 mmol) in THF (10 mL), MeOH (2 mL) and water (2
mL) was added LiOH (0.17 mg, 7.04 mmol). The mixture was heated to
reflux for about 4 h. After cooling to rt, the solvent was removed
under reduced pressure and the aqueous layer was acidified with
aqueous HCl (1N) to pH=4, extracted with EtOAc (10 mL), dried over
Na.sub.2SO.sub.4, and concentrated under reduced pressure to
provide
4-bromo-2-(1-methyl-1H-pyrazol-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-
-1H-indole-7-carboxylic acid (0.63 g, 99%): .sup.1H NMR
(CDCl.sub.3) .delta. 7.90 (s, 1H), 7.81 (s, 1H), 7.80-7.79 (d,
J=2.4 Hz, 1H), 7.54-7.52 (d, J=8.0 Hz, 1H), 6.84 (s, 1H), 5.95 (s,
2H), 4.18 (s, 3H), 3.25-3.20 (t, J=7.2 Hz, 2H), 0.82-0.78 (t, J=7.2
Hz, 2H), 0.00 (s, 9H).
Step E:
4-Bromo-2-(1-methyl-1H-pyrazol-4-yl)-1-((2-(trimethylsilyl)ethoxy)-
methyl)-1H-indole-7-carboxamide
##STR00092##
[0823] To a solution of
4-bromo-2-(1-methyl-1H-pyrazol-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-
-1H-indole-7-carboxylic acid (0.63 g, 1.4 mmol) in DMF (10 mL) was
added PyBOP (1.46 g, 2.80 mmol), HOBt (0.43 g, 2.80 mmol),
NH.sub.4Cl (0.11 g, 2.10 mmol) and DIEA (0.72 g, 5.60 mmol). The
mixture was stirred at rt for about 2 h. Water (20 mL) was added to
the mixture and extracted with EtOAc (30 mL). The organic phase was
dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure
to get a crude product, which was purified by column chromatography
on silica gel (eluted with Pet ether:EtOAc=3:1) to provide crude
4-bromo-2-(1-methyl-1H-pyrazol-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-
-1H-indole-7-carboxamide. It was dissolved in in anhydrous THF (10
mL) was added (2.02 g, 12.2 mmol) and ethane-1,2-diamine (2.20 g,
36.7 mmol) and heated to about 100.degree. C. for about 2 h. After
cooling to rt, water was added to dilute the mixture, extracted
with EtOAc, the organic phase was dried over Na.sub.2SO.sub.4, and
concentrated under reduced pressure to give a residue, which was
purified by column chromatography on silica gel (eluted with Pet
ether:EtOAc=3:1) to provide
4-bromo-2-(1-methyl-1H-pyrazol-4-yl)-1H-indole-7-carboxamide (0.20
g, 51%): .sup.1H NMR (CDCl.sub.3) .delta. 10.40 (br, 1H), 7.87 (s,
1H), 7.75 (s, 1H), 7.30-7.28 (d, J=8, 1H), 7.20-7.18 (d, J=8, 1H),
6.64 (s, 1H), 6.05 (br, 2H), 3.99 (s, 3H).
Preparation #11.
3-(2-(((tert-Butyldimethylsilyl)oxy)methyl)-3-(4,4,5,5-tetramethyl-1,3,2--
dioxaborolan-2-yl)phenyl)-6-fluoroquinazolin-4(3H)-one
##STR00093##
[0824] Step A: (2-Amino-6-bromophenyl)methanol
##STR00094##
[0826] The solution of 2-amino-6-bromobenzoic acid (19.8 g, 91.7
mmol) in THF (190 mL) was added to the suspension of LiAlH.sub.4
(7.00 g, 183 mmol) in THF (190 mL) dropwise at about 0.degree. C.
After the addition was complete, the mixture was stirred at rt for
about 4 h. Then the mixture was quenched with EtOAc (180 mL). The
mixture was poured into H.sub.2O (1.1 L) and filtered. The filtrate
was extracted with EtOAc (3.times.900 mL). The combined organic
layer was dried over Na.sub.2SO.sub.4, filtered and concentrated.
The residue was purified by column chromatography on silica gel
(eluted with Pet ether:EtOAc=50:1-5:1) to provide
(2-amino-6-bromophenyl)methanol (10 g, 54%): .sup.1H NMR
(CDCl.sub.3) .delta. 1.77 (s, 1H), 4.34 (s, 2H), 4.92 (s, 2H), 6.64
(m, 1H), 6.95 (m, 2H).
Step B:3-Bromo-2-(((tert-butyldimethylsilyl)oxy)methyl)aniline
##STR00095##
[0828] To the solution of (2-amino-6-bromophenyl)methanol (3.02 g,
15 mmol) and imidazole (1.83 g, 27 mmol) in DMF (40 mL) was added
TBSCl (3.39 g, 22.5 mmol) in portions at about 0.degree. C. Then
the resulting mixture was stirred at rt overnight. The mixture was
poured into H.sub.2O (80 mL), extracted with MTBE (3.times.80 mL).
The combined organic phase was washed with brine, dried over
Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure.
The residue was purified by column chromatography on silica gel
(eluted with Pet ether:EtOAc=15:1) to give
3-bromo-2-(((tert-butyldimethylsilyl)oxy)methyl)aniline (4.2 g,
89%): .sup.1H NMR (CDCl.sub.3) .delta. 0.00 (s, 6H), 0.80 (s, 9H),
4.38 (s, 2H), 4.85 (s, 2H), 6.48 (m, 1H), 6.79 (m, 2H).
Step C:
3-(3-Bromo-2-(((tert-butyldimethylsilyl)oxy)methyl)phenyl)-6-fluor-
oquinazolin-4(3)-one
##STR00096##
[0830] The mixture of
3-bromo-2-(((tert-butyldimethylsilyl)oxy)methyl)aniline (3.5 g, 11
mmol), 2-amino-5-fluoro-benzoic acid (1.7 g, 11 mmol) and
CH(OMe).sub.3 (1.8 g, 16.5 mmol) in THF (30 mL) was heated at about
120.degree. C. in a sealed tube overnight. The mixture was cooled
to rt and concentrated under reduced pressure. The residue was
washed with EtOAc to afford
3-(3-bromo-2-(((tert-butyldimethylsilyl)oxy)methyl)phenyl)-6-fluoroquinaz-
olin-4(3H)-one (1.3 g, 25%): .sup.1H NMR (CDCl.sub.3) .delta. 0.00
(d, J=8 Hz, 6H), 0.85 (s, 9H), 4.57 (d, J=11.6 Hz, 1H), 4.98 (d,
J=11.6 Hz, 1H), 7.35 (m, 1H), 7.43 (t, J=8 Hz, 1H), 7.62 (m, 1H),
7.83 (m, 2H), 8.06 (m, 2H).
Step D:
3-(2-(((tert-Butyldimethylsilyl)oxy)methyl)-3-(4,4,5,5-tetramethyl-
-1,3,2-dioxaborolan-2-yl)phenyl)-6-fluoroquinazolin-4(3H)-one
##STR00097##
[0832] The mixture of
3-(3-bromo-2-tert-butyldimethylsilyloxy)methyl)phenyl-6-fluoroquinazolin--
4(3H)-one (4 g, 8.6 mmol),
4,4,5,5,4',4',5',5'-octamethyl-[2,2']b[1,3,2]dioxaborolanyl (2.6 g,
10.4 mmol), KOAc (1.7 g, 17.2 mmol) and Pd(dppf)Cl.sub.2 (0.8 g) in
DMSO/1,4-dioxane (8 mL: 40 mL) was heated to about 110.degree. C.
under N.sub.2 atmosphere for about 2 h. The mixture was cooled to
rt, diluted with EtOAc (100 mL), filtered and the filtrate was
washed with H.sub.2O (30 mL) and brine (30 mL) successively. The
organic phase was dried over Na.sub.2SO.sub.4, filtered and
concentrated to afford the crude product which was purified by
column chromatography on silica gel (Pet ether/EtOAc, 30:1 to 5:1)
to provide
3-(2-(((tert-butyldimethylsilyl)oxy)methyl)-3-(4,4,5,5-tetramethyl-1,3,2--
dioxaborolan-2-yl)phenyl)-6-fluoroquinazolin-4(3H)-one (1.7 g,
38%): .sup.1H NMR (CDCl.sub.3) .delta. 0.00 (d, J=2 Hz, 6H), 0.92
(s, 9H), 1.52 (s, 12H), 4.70 (d, J=1.6 Hz, 1H), 5.43 (d, J=1.6 Hz,
1H), 7.63 (m, 1H), 7.70 (m, 2H), 7.93 (m, 1H), 8.16 (m, 3H).
Preparation #12:
(R)-7-(Piperidin-3-yl)imidazo[1,2-a]pyrazin-8(7H)-one
hydrochloride
##STR00098##
[0834] Step A: (R)-tert-Butyl (1-benzylpiperidin-3-yl)carbamate
##STR00099##
[0835] To a solution of (R)-tert-butyl piperidin-3-ylcarbamate
(40.0 g, 0.2 mol, 1.0 equiv) and TEA (22.22 g, 0.22 mol, 1.1 equiv)
in DCM (500 mL) was added dropwise bromomethyl-benzene (37.62 g,
0.22 mol, 1.1 equiv) at 0.degree. C. After stirring overnight at
about 25.degree. C., the solution was diluted with DCM and washed
with water. The organic layer was dried and evaporated to afford
(R)-tert-butyl (1-benzylpiperidin-3-yl)carbamate (58.0 g, 100%),
which was used to the next step without further purification:
.sup.1H NMR (CDCl.sub.3) 7.15-7.26 (m, 5H), 4.92 (s, 1H), 3.67 (s,
1H), 3.39 (s, 2H), 2.16-2.45 (m, 4H), 1.41-1.61 (m, 4H), 1.37 (s,
9H)
Step B: (R)-1-Benzylpiperidin-3-amine hydrochloride
##STR00100##
[0837] To a solution of (R)-tert-butyl
(1-benzylpiperidin-3-yl)carbamate (58.0 g, 0.2 mol, 1.0 equiv) in
MeOH (200 mL) was added HCl/MeOH (4.0 M, 200 mL) and the mixture
was stirred for about 2 h. The solvent was removed by vacuum to
provide (R)-1-benzylpiperidin-3-amine hydrochloride (50 g): .sup.1H
NMR (MeOD) .delta. 7.64 (d, J=2.4 Hz, 2H), 7.50 (s, 3H), 4.42-4.52
(q, 2H), 3.64-3.66 (d, J=10.8 Hz, 2H), 3.51-3.54 (d, J=12 Hz, 1H),
3.01-3.16 (m, 2H), 2.20-2.22 (d, J=11.2 Hz, 1H), 2.00-2.11 (m, 2H),
1.66-1.74 (m, 1H)
Step C:
(R)--N-(1-Benzylpiperidin-3-yl)-1H-imidazole-2-carboxamide
##STR00101##
[0839] To a solution of 1H-imidazole-2-carboxylic acid (16.8 g,
0.15 mol) in DMF (500 mL) was added HATU (57 g, 0.15 mol) and the
mixture was stirred for about 2 h at rt. Then (R)-tert-butyl
(1-benzylpiperidin-3-yl)carbamate (39.45 g, 0.15 mol) was added to
the solution and the mixture was stirred overnight. Additional
1H-imidazole-2-carboxylic acid (5.2 g, 46 mmol) and HATU (17.6 g,
46 mmol, 0.3 equiv) was added and the mixture was stirred at rt for
3 days. The solvent was removed and the residue was dissolved in
EtOAc, washed with water, dried and concentrated. The residue was
purified by column chromatograph on silica gel to provide crude
(R)--N-(1-benzylpiperidin-3-yl)-1H-imidazole-2-carboxamide (50 g):
LC/MS (Table 1, Method k) R.sub.t=1.15 min; MS m/z: 285
(M+H).sup.+.
Step D:
(R)--N-(1-Benzylpiperidin-3-yl)-1-(2,2-diethoxyethyl)-1H-imidazole-
-2-carboxamide
##STR00102##
[0841] A mixture of
(R)-7-(1-benzylpiperidin-3-yl)imidazo[1,2-a]pyrazin-8(7H)-one (73.0
g, 150 mmol, crude), 2-bromo-1,1-diethoxy-ethane (30 g, 150 mmol),
K.sub.2CO.sub.3 (41.4 g, 300 mmol) and KI (1 g) in DMF (500 mL) was
heated to about 120.degree. C. for 3 days. The solvent was removed.
The residue was dissolved in DCM, washed with water, dried and
evaporated to afford
(R)--N-(1-benzylpiperidin-3-yl)-1-(2,2-diethoxyethyl)-1H-imidazole-
-2-carboxamide (30 g, 75 mmol) as an oil: LC/MS (Table 1, Method k)
R.sub.t=1.81 min; MS m/z: 401 (M+H).sup.+.
Step E:
(R)-7-(1-Benzylpiperidin-3-yl)imidazo[1,2-a]pyrazin-8(7H)-one
##STR00103##
[0843] A mixture of
(R)--N-(1-benzylpiperidin-3-yl)-1-(2,2-diethoxyethyl)-1H-imidazole-2-carb-
oxamide (30.0 g, 75 mmol, crude) in 2N HCl (200 mL) was heated to
reflux overnight. The solvent was removed and the residue was
diluted with water (50 mL) which was basified by saturated
Na.sub.2CO.sub.3 to pH 10. The aqueous phase was extracted with
DCM, dried and evaporated. The residue was purified by column
chromatograph on silica gel to afford
(R)-7-(1-benzylpiperidin-3-yl)imidazo[1,2-a]pyrazin-8(7H)-one (3.0
g, 9.7 mmol): .sup.1H NMR (CDCl.sub.3) .delta. 7.44 (s, 1H),
7.17-7.24 (m, 7H), 7.01-7.02 (d, J=6 Hz, 1H), 5.00-5.05 (m, 1H),
3.45-3.47 (d, J=5.6 Hz, 2H), 2.78-2.80 (m, 1H), 2.55-2.58 (m, 1H),
2.31-2.36 (m, 1H), 2.25 (s, 1H), 1.81 (s, 1H), 1.16-1.69 (m,
3H)
Step F: (R)-tert-Butyl
3-(8-oxoimidazo[1,2-a]pyrazin-7(8H)-yl)piperidine-1-carboxylate
##STR00104##
[0845] To a solution of
(R)-7-(1-benzylpiperidin-3-yl)imidazo[1,2-a]pyrazin-8(7H)-one (2.13
g, 6.9 mmol) in MeOH (40 mL) was added (Boc).sub.2O (3.09 g, 13.8
mmol) and Pd/C (1.5 g). The mixture was hydrogenated under H.sub.2
balloon overnight and then filtrated. The filtrate was concentrated
and purified by column chromatograph on silica gel to afford
(R)-tert-butyl
3-(8-oxoimidazo[1,2-a]pyrazin-7(8H)-yl)piperidine-1-carboxylate
(1.4 g, 64%): .sup.1H NMR (MeOD) .delta. 7.69-7.70 (d, J=1.2 Hz,
1H), 7.52-7.54 (d, J=6.4 Hz, 1H), 7.50 (s, 1H), 7.12-7.14 (d, J=6
Hz, 1H), 4.74-4.82 (m, 1H), 4.12-4.15 (d, J=11.6 Hz, 1H), 4.04-4.05
(m, 1H), 3.05-3.11 (m, 1H), 2.83 (s, 1H), 1.91-2.02 (m, 2H),
1.86-1.90 (m, 1H), 1.60-1.71 (m, 1H), 1.46 (s, 9H)
Step G: (R)-7-(Piperidin-3-yl)imidazo[1,2-a]pyrazin-8(7H)-one
hydrochloride
##STR00105##
[0847] To a solution of (R)-tert-butyl
3-(8-oxoimidazo[1,2-a]pyrazin-7(8H)-yl)piperidine-1-carboxylate
(1.4 g, 4.4 mmol) in MeOH (10 mL) was added HCl/MeOH (4 M, 10 mL)
and the mixture was stirred for about 1 h at rt. The solvent was
removed to afford
(R)-7-(piperidin-3-yl)imidazo[1,2-a]pyrazin-8(7H)-one hydrochloride
(1.35 g, 100%): .sup.1H NMR (DMSO-d6) .delta. 10.06 (s, 1H), 9.67
(s, 1H), 8.18-8.21 (m, 1H), 8.00-8.03 (m, 1H), 7.89-7.93 (m, 1H),
7.69-7.74 (m, 1H), 5.12-5.18 (m, 1H), 3.20-3.34 (m, 3H), 2.82-2.90
(m, 1H), 2.02-2.08 (m, 1H), 1.84-1.93 (m, 3H)
Preparation #13:
(R)-7-(Piperidin-3-yl)-6,7-dihydroimidazo[1,2-a]pyrazin-8(5H-one
hydrochloride
##STR00106##
[0848] Step A: (R)-tert-Butyl
3-(8-oxo-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)piperidine-1-carboxyla-
te
##STR00107##
[0850] To a solution of
(R)-7-(1-benzylpiperidin-3-yl)imidazo[1,2-a]pyrazin-8(7H)-one (0.77
g, 2.5 mmol) in MeOH (20 mL) was added (Boc).sub.2O (1.09 g, 5.0
mmol) and Pd(OH).sub.2 (0.5 g). The mixture was hydrogenated under
H.sub.2 balloon overnight and then filtrated. The filtrate was
evaporated and purified by column chromatograph on silica gel to
afford (R)-tert-butyl
3-(8-oxo-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)piperidine-1-carboxyla-
te (0.5 g, 60%): .sup.1H NMR (MeOD) .delta. 7.16 (s, 1H), 7.06 (s,
1H), 4.22-4.33 (m, 1H), 4.19-4.20 (m, 2H), 3.93-3.96 (m, 2H),
3.64-3.78 (m, 2H), 2.86-2.89 (m, 1H), 2.61 (s, 1H), 168-1.79 (m,
3H), 1.47-1.53 (m, 1H), 1.46 (s, 9H).
Step B:
(R)-7-(Piperidin-3-yl)-6,7-dihydroimidazo[1,2-a]pyrazin-8(5H)-one
hydrochloride
##STR00108##
[0852] To a solution of (R)-tert-butyl
3-(8-oxo-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)piperidine-1-carboxyla-
te (0.5 g, 1.5 mmol, 1 equiv) in MeOH (5 mL) was added HCl/MeOH
(4.0 M, 5 mL) and the mixture was stirred for 1 h at rt. The
solvent was removed to afford
(R)-7-(piperidin-3-yl)-6,7-dihydroimidazo[1,2-a]pyrazin-8(5H)-one
hydrochloride (0.45 g, 100%): .sup.1H NMR (MeOD) .delta. 7.75-7.78
(q, J=9.6 Hz, 2H), 4.66-4.74 (m, 1H), 4.56-4.59 (q, J=7.2 Hz, 2H),
3.99-4.03 (t, J=6 Hz, 2H), 3.32-3.45 (m, 3H), 2.96-3.03 (m, 1H),
1.85-2.14 (m, 4H).
Preparation #14:
(Z)-4-((3-(7-carbamoyl-1H-indol-4-yl)phenyl)amino)-4-oxobut-2-enoic
acid
##STR00109##
[0854] To a solution of 4-(3-aminophenyl)-1H-indole-7-carboxamide
(0.25 g, 0.995 mmol, Preparation #A.1), furan-2,5-dione (0.117 g,
1.19 mmol), and N-ethyl-N-isopropylpropan-2-amine (0.521 mL, 2.98
mmol) in DMF (10.0 mL) was added. The mixture is stirred at rt
overnight. Solvent was removed under high vacuum and the residue
was purified by prep HPLC (Table 2, Method y) to provide
(Z)-4-((3-(7-carbamoyl-1H-indol-4-yl)phenyl)amino)-4-oxobut-2-enoic
acid (0.32 g, 92%) as a solid. LC/MS (Table 1, Method g)
R.sub.t=1.37 min; MS m/z 350 (M+H).sup.+.
Preparation #15. tert-Butyl
3-(7-carbamoyl-4-(2-methyl-3-(4-oxoquinazolin-3(4H)-yl)phenyl)-1H-indol-2-
-yl)-2,5-dihydro-1H-pyrrole-1-carboxylate
##STR00110##
[0855] Step A. Methyl
4-bromo-2-(1-(tert-butoxycarbonyl)-2,5-dihydro-1H-pyrrol-3-yl)-1-tosyl-1H-
-indole-7-carboxylate
##STR00111##
[0857] To a mixture of methyl
4-bromo-2-iodo-1-tosyl-1H-indole-7-carboxylate (1 g, 1.9 mmol,
Preparation #1, Step D) in DME (20 mL)/water (5 mL) was added
tert-butyl
3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,5-dihydro-1H-pyrrole-1--
carboxylate (0.72 g, 2.4 mmol), Na.sub.2CO.sub.3 (0.6 g, 5.6 mmol)
and Pd(dppf)Cl.sub.2 (0.2 g, 0.28 mmol). The reaction mixture was
stirred at rt for 10 h under N.sub.2 atmosphere. After filtering,
the filtrate was concentrated under reduced pressure to give a
residue, which was purified by column chromatography on silica gel
(eluted with hexanes:EtOAc=5:1) to give methyl
4-bromo-2-(1-(tert-butoxycarbonyl)-2,5-dihydro-1H-pyrrol-3-yl)-1-tosyl-1H-
-indole-7-carboxylate (0.6 g, 56%) as yellow solid: .sup.1H NMR
(CDCl.sub.3) .delta. 7.68-7.56 (d, J=8.22 Hz, 1H), 7.55-7.54 (m,
1H), 7.14-7.05 (m, 4H), 6.45-6.37 (m, 2H), 4.37-4.31 (m, 2H), 4.05
(s, 3H), 3.89-3.84 (m, 2H), 2.38-2.34 (m, 3H), 1.53 (m, 9H).
Step B:
4-Bromo-2-(1-(tert-butoxycarbonyl)-2,5-dihydro-1H-pyrrol-3-yl)-1H--
indole-7-carboxylic acid
##STR00112##
[0859] To a solution of methyl
4-bromo-2-(1-(tert-butoxycarbonyl)-2,5-dihydro-1H-pyrrol-3-yl)-1-tosyl-1H-
-indole-7-carboxylate (2.5 g, 4.34 mmol) in THF (20 mL)/MeOH (5
mL)/water (5 mL) was added LiOH.H.sub.2O (2.5 g, 59.5 mmol) at rt.
The reaction mixture was stirred at rt for about 3 h. The reaction
was concentrated and residue was acidified by addition of 2N HCl to
about pH 5 and extracted with EtOAc (3.times.50 mL). The combined
organic layer was dried and concentrated to give a solid, which was
washed with EtOAc and MTBE to give
4-bromo-2-(1-(tert-butoxycarbonyl)-2,5-dihydro-1H-pyrrol-3-yl)-1H-indole--
7-carboxylic acid (1 g, 56.5%) as white solid: .sup.1H NMR
(CDCl.sub.3) .delta. 9.84 (m, 1H), 7.77-7.75 (t, J=5.6 Hz, 1H),
7.34-7.32 (d, J=8 Hz, 1H), 6.54-6.49 (d, J=16.8 Hz, 1H), 6.18-6.14
(d, J=18 Hz, 1H), 4.58-4.51 (d, J=30.4 Hz, 2H), 4.38-4.32 (d, J=22
Hz, 2H), 1.54 (s, 9H).
Step C: tert-Butyl
3-(4-bromo-7-carbamoyl-1H-indol-2-yl)-2,5-dihydro-1H-pyrrole-1-carboxylat-
e
##STR00113##
[0861] To a solution of
4-bromo-2-(1-(tert-butoxycarbonyl)-2,5-dihydro-1H-pyrrol-3-yl)-1H-indole--
7-carboxylic acid (1 g, 2. 5 mmol) in DMF (6 mL) was added PyBOP
(2.6 g, 4.9 mmol), HOBt (0.75 g, 4.91 mmol), DIEA (1.7 mL, 9.82
mmol) and NH.sub.4Cl (0.2 g, 3.7 mmol). The reaction mixture was
stirred at rt overnight. After quenching with water, the aqueous
layer was extracted with EtOAc (3.times.25 mL). The combined
organic layers were dried and concentrated under reduced pressure
to give a residue, which was purified by prep-HPLC (Table 1, Method
ad) to give tert-butyl
3-(4-bromo-7-carbamoyl-1H-indol-2-yl)-2,5-dihydro-1H-pyrrole-1-carboxylat-
e (0.6 g, 54%) as white solid: .sup.1H NMR (CDCl.sub.3) .delta.
10.42 (s, 1H), 7.26-7.25 (m, 2H), 6.48 (s, 1H), 6.19-6.13 (d,
J=22.4 Hz, 1H), 4.55-4.51 (d, J=16 Hz, 2H), 4.37-4.32 (d, J=18 Hz,
2H), 1.54 (s, 9H).
Step D: tert-Butyl
3-(7-carbamoyl-4-(2-methyl-3-(4-oxoquinazolin-3(4H)-yl)phenyl)-1H-indol-2-
-yl)-2,5-dihydro-1H-pyrrole-1-carboxylate
##STR00114##
[0863] A solution of tert-butyl
3-(4-bromo-7-carbamoyl-1H-indol-2-yl)-2,5-dihydro-1H-pyrrole-1-carboxylat-
e (0.6 g, 1.48 mmol),
3-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)quinazo-
lin-4(3H)-one (1 g, 2.95 mmol, WO 2011159857), K.sub.2CO.sub.3
(0.816 g, 5.91 mmol) and Pd(dppf)Cl.sub.2 (0.22 g, 0.3 mmol) in THF
(20 mL)/MeOH (5 mL)/water (5 mL) was stirred at about 60.degree. C.
for about 2 h under N.sub.2 atmosphere. The solvent was removed to
give a residue, which was purified by column chromatography on
silica gel (eluted with hexanes:EtOAc=2:1) to give tert-butyl
3-(7-carbamoyl-4-(2-methyl-3-(4-oxoquinazolin-3(4H)-yl)phenyl)-1H-indol-2-
-yl)-2,5-dihydro-1H-pyrrole-1-carboxylate (0.6 g, 72%) as a solid:
.sup.1H NMR (MeOD) .delta. 10.44 (s, 1H), 8.40-8.38 (d, J=8 Hz,
1H), 8.15-8.10 (s, J=21.6 Hz, 1H), 7.83-7.81 (m, 2H), 7.59-7.35 (m,
5H), 7.09-6.98 (m, 1H), 6.31-6.11 (m, 4H), 4.49-4.36 (m, 4H), 2.04
(s, 3H), 1.51 (s, 9H).
Preparation #16. tert-Butyl
4-(7-carbamoyl-4-(2-methyl-3-(4-oxoquinazolin-3(4H)-yl)phenyl)-1H-indol-2-
-yl)-5,6-dihydropyridine-1(2H)-carboxylate
##STR00115##
[0864] Step A: tert-Butyl
2-(4-bromo-7-carbamoyl-1H-indol-2-yl)benzylcarbamate
##STR00116##
[0866] To a solution of compound methyl
4-bromo-2-iodo-1-tosyl-1H-indole-7-carboxylate (2.4 g, 6.58 mmol,
Preparation #1) and tert-butyl
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-
-carboxylate (2.0 g, 6.58 mmol) in THF (50 mL), MeOH (10 mL) and
water (10 mL) were added Na.sub.2CO.sub.3 (2.1 g, 19.73 mmol) and
Pd(dppf)Cl.sub.2 (0.481 g, 0.658 mmol), the mixture was heated to
about 80.degree. C. for about 3 h. The resulting solution was
diluted with EtOAc (100 mL), and washed with water (30 mL). The
organic phase was dried over Na.sub.2SO.sub.4, and concentrated
under reduced pressure to give a crude product, which was purified
by column chromatography on silica gel (eluted with Pet
ether:EtOAc=1:1) to give tert-butyl
4-(4-bromo-7-carbamoyl-1H-indol-2-yl)-5,6-dihydropyridine-1(2H)-carboxyla-
te (2 g, 72%) as a solid: .sup.1H NMR (DMSO-d6) .delta. 10.87 (s,
1H), 8.15 (s, 1H), 7.59-7.57 (d, J=8.0 Hz, 1H), 7.52 (s, 1H),
7.27-7.25 (d, J=8.0 Hz, 1H), 6.47 (s, 1H), 6.42 (s, 1H), 4.03 (s,
2H), 3.55 (s, 2H), 2.52 (s, 2H), 1.41 (s, 9H).
Step B: tert-Butyl
4-(7-carbamoyl-4-(2-methyl-3-(4-oxoquinazolin-3(4H)-yl)phenyl)-1H-indol-2-
-yl)-5,6-dihydropyridine-1(2H)-carboxylate
##STR00117##
[0868] To a solution of tert-butyl
4-(4-bromo-7-carbamoyl-1H-indol-2-yl)-5,6-dihydropyridine-1(2H)-carboxyla-
te (2 g, 4.76 mmol) and
3-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)quinazo-
lin-4(3H)-one (2.59 g, 7.14 mmol, WO 2011159857) in THF (40 mL),
MeOH (10 mL) and water (10 mL) were added Na.sub.2CO.sub.3 (1.513
g, 14.28 mmol) and Pd(dppf)Cl.sub.2 (0.348 g, 0.476 mmol). The
mixture was heated to about 80.degree. C. for about 4 h. The
resulting solution was diluted with EtOAc (100 mL), and washed with
water and brine (30 mL each). The organic phase was dried over
Na.sub.2SO.sub.4, and concentrated to give a crude product, which
was purified by column chromatography on silica gel (eluted with
Pet ether:EtOAc=1:1) to give tert-butyl
4-(7-carbamoyl-4-(2-methyl-3-(4-oxoquinazolin-3(4H)-yl)phenyl)-1H-indol-2-
-yl)-5,6-dihydropyridine-1(2H)-carboxylate (1.4 g, 51%) as a solid:
.sup.1H NMR (CDCl.sub.3) 10.43 (s, 1H), 8.42-8.40 (d, J=7.6 Hz,
1H), 8.15 (s, 1H), 7.85-7.83 (m, 2H), 7.61-7.59 (m, 1H), 7.49-7.45
(m, 3H), 7.37-7.34 (m, 1H), 7.04-7.01 (m, 1H), 6.20 (s, 2H), 3.65
(s, 2H), 2.55 (s, 2H), 2.00 (s, 3H), 1.76 (s, 2H), 1.50 (s,
9H).
Preparation #17:
1-(Methylsulfonyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,-
6-tetrahydropyridine
##STR00118##
[0870] A solution of tert-butyl
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-
-carboxylate (4.03 g, 13.03 mmol, Carbocore) in HCl (4 M in
dioxane, 19.55 mL, 78 mmol) was stirred at ambient temperature for
about 2 h. The solution was concentrated under reduced pressure
then dissolved in DCM (20.05 mL) and TEA added (12.72 mL, 91 mmol).
The mixture was cooled to about 0.degree. C. and methanesulfonyl
chloride (1.83 mL, 23.5 mmol) added dropwise. The mixture was
stirred at ambient temperature for about 2 h. To the mixture was
added 1N HCl (60 mL) and the organic layer was extracted. The
organic layer was with saturated aqueous sodium bicarbonate (60
mL), dried over MgSO.sub.4, filtered, and concentrated under
reduced pressure. The residue was trituated with a mixture of EtOAc
and heptanes, filtered and dried (1.477 g). The filtrate was
concentrated and residue was trituated with a mixture of EtOAc and
heptanes, filtered and dried to get second lot (0.940 g). Lots were
combined to obtain
1-(methylsulfonyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,-
6-tetrahydropyridine (2.41 g, 64%). LC/MS (Table 1, Method a)
R.sub.t=2.18 min: MS m/z: 288 (M+H).sup.+.
Preparation #18:
4-Bromo-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-
-carboxamide
##STR00119##
[0872] A flask containing
1-(methylsulfonyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,-
6-tetrahydropyridine (0.446 g, 1.55 mmol, Preparation #17),
4-bromo-2-iodo-1H-indole-7-carboxamide (0.54 g, 1.48 mmol,
Preparation #1), sodium carbonate (0.470 g, 4.44 mmol) and
1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.108
g, 0.148 mmol) was purged with nitrogen. A mixture of THF (15.0
mL), MeOH (2.10 mL), and water (2.10 mL) was added. The mixture was
stirred for about 2 h at about 70.degree. C. The mixture was
filtered through Celite.COPYRGT. rinsing with EtOAc and
concentrated under reduced pressure. The residue was trituated with
DCM, filtered, washed with DCM and EtOAc to afford a solid (0.315
g). The filtrate was concentrated and purified by column
chromatography on silica gel (40-100% EtOAc/heptane). The resulting
residue was triturated with DCM, filtered and dried to afford a
solid (0.125 g). The solids were combined to obtain
4-bromo-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-
-carboxamide (0.44 g, 75%). LC/MS (Table 1, Method a) R.sub.t=1.92
min: MS m/z: 400 (M+H).sup.+.
Preparation #19:
N-Methyl-N-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pheny-
l)thiazole-2-carboxamide
##STR00120##
[0874] To
N-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pheny-
l)thiazole-2-carboxamide (502 mg, 1.46 mmol, Preparation #4) in THF
(10 mL) was added sodium hydride (70.0 mg, 1.75 mmol) at about
0.degree. C. and stirred for about 25 min. To the mixture was added
iodomethane (0.363 mL, 5.83 mmol) at about 0.degree. C. The
reaction mixture was brought to rt and then stirred at rt for about
18 h. To mixture was added water, extracted twice with DCM and
layers separated. Combined organic layers were evaporated and the
residue was purified using normal phase chromatography to provide
N-methyl-N-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pheny-
l)thiazole-2-carboxamide (0.406 g, 59%). LC/MS (Table 1, Method f)
R.sub.t=1.97 min: MS m/z: 359 (M+H).sup.+.
Preparation #20.
(R)-1-((2,2-Dimethyl-1,3-dioxolan-4-yl)methyl)-4-(4,4,5,5-tetramethyl-1,3-
,2-dioxaborolan-2-yl)-1H-pyrazole
##STR00121##
[0876] To a mixture of
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (1 g,
5.15 mmol) in DMF (25.8 mL) was added sodium hydride (0.206 g, 5.15
mmol). The mixture was stirred at rt for about 10 min under
nitrogen. (S)-(+)-2,2-dimethyl-1,3-dioxolan-4-ylmethyl
p-toluenesulfonate (1.62 g, 5.67 mmol) was added and the mixture
was stirred at about 90.degree. C. overnight under an nitrogen
atmosphere. The reaction was cooled to rt, and partitioned between
EtOAc and water. The aqueous layer was re-extracted with EtOAc
(2.times.) and the organics were combined, washed with water,
brine, dried over anhydrous MgSO.sub.4, filtered and concentrated
under reduced pressure. The residue was purified by column
chromatography on silica gel with EtOAc/hexanes (30-75%) to provide
(R)-1-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)-4-(4,4,5,5-tetramethyl-1,3-
,2-dioxaborolan-2-yl)-1H-pyrazole (0.66 g, 42%): LC/MS (Table 1,
Method f) R.sub.t=1.41 min; MS m/z: 309 (M+H).sup.+.
Preparation #21.
(S)-1-((2,2-Dimethyl-1,3-dioxolan-4-yl)methyl)-4-(4,4,5,5-tetramethyl-1,3-
,2-dioxaborolan-2-yl)-1H-pyrazole
##STR00122##
[0878] To a mixture of
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (1.0 g,
5.2 mmol) in DMF (25.8 mL) was added sodium hydride (0.206 g, 5.15
mmol). The mixture was stirred at rt for about 10 min under
nitrogen. (R)-(2,2-dimethyl-1,3-dioxolan-4-yl)methyl
4-methylbenzenesulfonate (1.62 g, 5.67 mmol) was added and the
mixture was stirred at about 90.degree. C. overnight under an
nitrogen atmosphere. The reaction was cooled to rt, partitioned
between EtOAc and water. The aqueous layer was re-extracted with
EtOAc (2.times.) and the organics were combined, washed with water,
brine, dried over anhydrous MgSO.sub.4, filtered and concentrated
under reduced pressure. The residue was purified by was column
chromatography on silica gel with EtOAc/hexanes (30-75%) to provide
(S)-1-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)-4-(4,4,5,5-tetramethyl-1,3-
,2-dioxaborolan-2-yl)-1H-pyrazole (0.83 g, 52%): LC/MS (Table 1,
Method f) R.sub.t=1.35 min; MS m/z: 251
(M-(CH.sub.3).sub.2CHO+H).sup.+.
Preparation #22:
N-(3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acrylamide
##STR00123##
[0880] To a vial was added
3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (0.30 g,
1.37 mmol) in DCM (10 mL), and DIEA (0.72 mL, 4.11 mmol). The
mixture was cooled to about 0.degree. C. and acryloyl chloride
(0.122 mL, 1.51 mmol) was added while stirring. The mixture was
stirred for about 20 min while warming to rt. The mixture was
diluted with and additional DCM (10 mL) washed with water
(2.times.10 mL), filtered through a Biotage phase separator and
concentrated under a warm stream of nitrogen to provide
N-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acrylamide
(0.375 g, 100%): LC/MS (Table 1, Method f) R.sub.t=1.70 min; MS
m/z: 274 (M+H).sup.+.
Preparation #23:
N-(trans-4-Hydroxypiperidin-3-yl)thiazole-2-carboxamide
##STR00124##
[0881] Step A. Benzyl 4-(hydroxyimino)piperidine-1-carboxylate
##STR00125##
[0883] A mixture of benzyl 4-oxopiperidine-1-carboxylate (10 g,
42.9 mmol), NH.sub.2OH HCl (5.9 g, 86 mmol) and K.sub.2CO.sub.3
(11.8 g, 86 mmol) in EtOH (45 mL) was heated at about 50.degree. C.
for about 0.5 h. Then the solvent was removed under reduced
pressure. Water and EtOAc were added to the residue. The aqueous
phase was extracted with EtOAc (3.times.75 mL). The organic layer
was washed with brine and dried over Na.sub.2SO.sub.4, filtered and
concentrated to provide benzyl
4-(hydroxyimino)piperidine-1-carboxylate (10 g, 94%). .sup.1H NMR
(CDCl.sub.3) .delta. 2.36 (br, 2H), 2.63 (br, 2H), 3.63-3.58 (m,
4H), 5.15 (s, 2H), 7.36-7.35 (m, 5H), 9.05 (br, 1H).
Step B. Benzyl 4-((tosyloxy)imino)piperidine-1-carboxylate
##STR00126##
[0885] To a solution of benzyl
4-(hydroxyimino)piperidine-1-carboxylate (12.2 g, 49.1 mmol) in
pyridine (75 mL) was added TsCl (12.2 g, 64 mmol) slowly at about
0.degree. C. The reaction mixture was stirred at this temperature
for about 0.5 h and stirred at rt for another 2 h. Then the solvent
was removed under reduced pressure. Water and EtOAc were added to
the residue. The aqueous phase was extracted with EtOAc
(3.times.125 mL). The organic layer was washed with brine and dried
over Na.sub.2SO.sub.4. The solvent was concentrated to give the
crude product which was purified by column chromatography on silica
gel (Pet ether:EtOAc=15:1) to provide benzyl
4-((tosyloxy)imino)piperidine-1-carboxylate (5 g, 25.3%): .sup.1H
NMR (CDCl.sub.3) .delta. 2.37 (br, 2H), 2.44 (s, 3H), 2.63 (br,
2H), 3.62-3.55 (m, 4H), 5.13 (s, 2H), 7.35-7.32 (m, 7H), 7.85 (d,
J=8.0 Hz, 2H).
Step C. Benzyl 3-amino-4-oxopiperidine-1-carboxylate
hydrochloride
##STR00127##
[0887] Na (28.6 mg, 1.243 mmol) was added to EtOH (6.5 mL) and the
mixture was stirred until the Na was completely dissolved.
MgSO.sub.4 (0.98 g) was added to the solution, then benzyl
4-((tosyloxy)imino)piperidine-1-carboxylate (0.5 g, 1.242 mmol) was
added to the solution at about 0.degree. C. After the reaction
mixture was heated at about 30.degree. C. for about 2 h, the
mixture was filtered and 1 N HCl (6.5 mL) was added to the
filtration. The filtration was stirred at rt for about 0.5 h and
concentrated. The residue was mixed with EtOH (3 mL) and filtered.
The filtration was concentrated to give crude benzyl
3-amino-4-oxopiperidine-1-carboxylate hydrochloride (200 mg, 0.702
mmol): 1H NMR (MeOD) .delta.=7.33 (m, 5H), 5.12 (br. s., 2H),
3.75-3.95 (m, 1H), 3.6-3.7 (m, 1H), 3.5 (m, 2H), 3.1-3.2 (m, 1H),
1.95-2.10 (m, 1H), 1.7-1.8 (m, 1H).
Step D. Benzyl
4-oxo-3-(thiazole-2-carboxamido)piperidine-1-carboxylate
##STR00128##
[0889] A solution of thiazole-2-carboxyic acid mg, 14.6 mmol) and
HATU (723 mg, 1.9 mmol) in DMF (20 mL) was stirred at rt for 0.5 h,
then DIEA (945 mg, 7.31 mmol) and benzyl
3-amino-4-oxopiperidine-1-carboxylate hydrochloride (500 mg, 1.76
mmol) was added to the mixture. The reaction solution was stirred
at rt for about 4 h. Water was added to the mixture, extracted with
EtOAc (3.times.45 mL). The combined organic layer was washed with
brine several times, dried over Na.sub.2SO.sub.4, filtered and
concentrated to give the crude product which was purified by
Prep-HPLC (Table 1, Method ai) to provide benzyl
4-oxo-3-(thiazole-2-carboxamido)piperidine-1-carboxylate (82 mg,
12%). .sup.1H NMR (CDCl.sub.3) .delta. 2.68-2.62 (br, 2H),
2.93-2.86 (m, 1H), 3.16 (br, 1H), 4.7-5.9 (br, 2H), 5.08-5.05 (m,
1H), 5.31-5.22 (m, 2H), 7.43-7.38 (m, 5H), 7.60 (q, J=1.2 Hz, 1H),
7.92-7.90 (m, 1H), 8.08 (s, 1H).
Step E. trans-Benzyl
4-hydroxy-3-(thiazole-2-carboxamido)piperidine-1-carboxylate
##STR00129##
[0891] To a solution of benzyl
4-oxo-3-(thiazole-2-carboxamido)piperidine-1-carboxylate (6.9 g,
19.2 mmol) in MeOH (50 mL) was added NaBH.sub.4 (0.726 g, 0.019
mmol) in batches and the mixture was stirred at rt for about 0.5 h.
Then water (50 mL) was added to the reaction mixture and extracted
with DCM (3.times.60 mL). The organic layer was washed with brine
and dried over Na.sub.2SO.sub.4, filtered and concentrated under
reduced pressure to give the crude product which was purified by
column chromatography on silica gel to provide trans-benzyl
4-hydroxy-3-(thiazole-2-carboxamido)piperidine-1-carboxylate (3 g,
43%). .sup.1H NMR (MeOD) .delta. 1.56-1.51 (m, 1H), 2.00 (t, J=5.2
Hz, 1H), 3.10-2.97 (m, 2H), 3.85-3.75 (m, 2H), 4.16-3.99 (m, 1H),
4.21-4.20 (m, 1H), 5.12 (s, 2H), 7.34-7.31 (m, 5H), 7.85 (q, J=3.2
Hz, 1H), 7.94 (t, J=3.2 Hz, 1H).
Step F. N-(trans-4-Hydroxypiperidin-3-yl)thiazole-2-carboxamide
##STR00130##
[0893] To a stirred solution of trans-benzyl
4-hydroxy-3-(thiazole-2-carboxamido)piperidine-1-carboxylate (0.7
g, 1.937 mmol) in MeCN (15 mL) was added TMSI (1.55 g, 775 mmol)
slowly at about 0.degree. C., then the mixture was stirred at rt
for about 1 h. Water was poured into the mixture and MeCN was
removed under reduced pressure. 1 N HCl was added to the residue
and the mixture was extracted with MTBE (3.times.30 mL). Then the
aqueous phase was basified with NaOH (3 N) to about pH=12 and
extracted with DCM (6.times.45 mL). The organic phase was washed
with brine and dried over Na.sub.2SO.sub.4, filtered and
concentrated to give the crude product which was purified by
Prep-TLC (1:1 MeOH/DCM) to provide
N-(trans-4-hydroxypiperidin-3-yl)thiazole-2-carboxamide (50 mg,
11%): .sup.1H NMR (MeOD) .delta. 1.86-1.77 (m, 1H), 2.28-2.22 (m,
1H), 3.29-309 (m, 2H), 3.56-3.44 (m, 2H), 4.84-3.90 (m, 2H), 7.88
(q, J=3.2 Hz, 1H), 7.97 (q, J=3.2 Hz, 1H).
Preparation #24:
4-Bromo-2-iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-7-carboxami-
de
##STR00131##
[0894] Step A.
4-Bromo-2-iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-7-carboxyli-
c acid
##STR00132##
[0896] To a solution of methyl
4-bromo-2-iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-7-carboxyla-
te (10 g, 19.6 mmol, Preparation #10, step B) in MeOH (150 mL), THF
(300 mL) and water (150 mL) was added lithium hydroxide hydrate (12
g, 286 mmol). The resulting mixture was heated at about 45.degree.
C. for about 3 h. Then the mixture was concentrated under reduced
pressure to remove most solvent, the residue was dissolved in
water. The aqueous mixture was acidified by addition of aqueous HCl
(1N) to about pH 6. The precipitate was filtered, and the solid was
dried to give
4-bromo-2-iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-7-carboxyli-
c acid (9.1 g, 94%) as a solid: .sup.1H NMR (CDCl.sub.3) .delta.
13.44 (br, 1H), 7.57-7.51 (m, 2H), 7.09 (s, 1H), 5.95 (s, 2H),
3.35-3.11 (t, J=8.0 Hz, 2H), 0.87-0.83 (t, J=8.0 Hz, 2H), 0.00 (s,
9H).
Step B.
4-Bromo-2-iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-7-ca-
rboxamide
##STR00133##
[0898] A solution of
4-bromo-2-iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-7-carboxyli-
c acid (8 g, 16 mmol), EDCI (4.6 g, 24 mmol) and HOBt (3.7 g, 24
mmol) in THF (240 mL) and DCM (280 mL) was stirred at rt for about
1 h. The reaction mixture was then bubbled with NH.sub.3 gas for 15
min and stirred at rt overnight. Then the mixture was concentrated
and partitioned between aqueous NaHCO.sub.3 and EtOAc. The organic
phase was washed with brine, dried and concentrated to give a
residue, which was suspended in Pet ether and the solid was
collected by filtration to provide
4-bromo-2-iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-7-c-
arboxamide (7.2 g, 90%) as a white solid: .sup.1H NMR (CDCl.sub.3)
.delta. 7.36-7.33 (m, 1H), 7.26-7.24 (d, J=8.0 Hz, 1H), 7.05 (s,
1H), 6.08 (br, 1H), 5.82 (br, 1H) 5.82 (s, 2H), 3.48-3.41 (m, 2H),
0.90-0.86 (m, 2H), 0.00 (s, 9H).
Preparation #25:
4-(Difluoromethyl)-N-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan--
2-yl)phenyl)-N-(oxetan-3-yl)benzamide
##STR00134##
[0900] A solution of 4-(difluoromethyl)benzoic acid (0.089 g, 0.519
mmol, Oakwood) in DCM (3.46 mL) under nitrogen was treated with
sulfurous dichloride (0.075 mL, 1.037 mmol) and 1 drop DMF. The
mixture was stirred at about 35.degree. C. for about 16 h. The
reaction was concentrated under reduced pressure, triturated
residue with heptane, and concentrated. The residue was dissolved
in DCM (3.46 mL) and added
N-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)oxetan--
3-amine (0.100 g, 0.346 mmol, prepared using H from
2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline
[Combi-Blocks] and 3-oxetanone[(Molbridge]) and TEA (0.193 mL,
1.383 mmol). The mixture was stirred at ambient temperature for
about 4 h then diluted with DCM (10 mL) and quenched with saturated
aqueous sodium bicarbonate (10 mL). The organics were combined and
washed with 30 mL saturated aqueous sodium bicarbonate. The organic
layer was dried over MgSO.sub.4, filtered and concentrated under
reduced pressure to give the crude product which was purified by
column chromatography on silica gel (0-40% EtOAc/heptane) to
provide a yellow oil that solidified upon standing to afford
4-(difluoromethyl)-N-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan--
2-yl)phenyl)-N-(oxetan-3-yl)benzamide (0.092 g, 60%). LCMS (Table
1, Method a) R.sub.t=2.51 min: MS m/z: 444 (M+H).sup.+.
Preparation #26:
2-Methyl-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1--
yl)propan-2-ol
##STR00135##
[0902] To a solution of
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (2.0 g,
10.31 mmol) in 2,2-dimethyloxirane (11.96 mL, 134 mmol) in a 30 mL
microwave vial was added cesium carbonate (0.521 g, 1.60 mmol). The
mixture was heated in a microwave oven at about 120.degree. C. for
about 30 min. The reaction was cooled and filtered. The resulting
solution was evaporated to dryness to give
2-methyl-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1--
yl)propan-2-ol as a white solid. (2.7 g, 99%); (Table 1, Method g)
R.sub.t=1.34 min.; MS m/z: 267 (M+H).sup.+
Preparation #27:
4-Fluoro-2-iodo-1-tosyl-1H-indole-7-carbonitrile
##STR00136##
[0903] Step A. 4-Fluoro-1-tosyl-1H-indole-7-carbonitrile
##STR00137##
[0905] To a solution of 4-fluoro-1H-indole-7-carbonitrile (5.3 g,
33.1 mmol, Sinova) in DMF (92 mL) was added NaH (2.0 g, 49.6 mmol)
at 0.degree. C. under N.sub.2 atmosphere and stirred for about 30
min. Then TsCl (9.46 g, 49.6 mmol) was added to the above mixture
and stirred at rt for about 5 h. The mixture was poured into
saturated aqueous NH.sub.4Cl solution (200 mL), extracted with
EtOAc (100 mL.times.3). The combined organic phase was washed with
brine, dried over Na.sub.2SO.sub.4, filtered and concentrated to
afford the crude product which was washed with MTBE to provide
4-fluoro-1-tosyl-1H-indole-7-carbonitrile (7 g, 67.3%) as a solid:
.sup.1H NMR (CDCl.sub.3) .delta. 2.39 (s, 3H), 6.86 (d, J=4 Hz,
1H), 6.99 (t, J=8.4 Hz, 1H), 7.33 (d, J=8.4 Hz, 2H), 7.62 (m, 1H),
7.84 (d, J=3.6 Hz, 1H), 7.92 (d, J=8.4 Hz, 2H).
Step B. 4-Fluoro-2-iodo-1-tosyl-1H-indole-7-carbonitrile
##STR00138##
[0907] Freshly prepared LDA (67 mL, 38.2 mmol) was added dropwise
to a solution of 4-fluoro-1-tosyl-1H-indole-7-carbonitrile (10 g,
31.8 mmol) in THF (50 mL) at about -78.degree. C. After the
addition was complete, the mixture was stirred for another 45 min.
Then a solution of I.sub.2 (9.69 g, 38.2 mmol) in THF (50 mL) was
added dropwise to the mixture at about -78.degree. C. After the
addition, the mixture was stirred for about another 1 h. The
solution was poured into saturated aqueous Na.sub.2S.sub.2O.sub.3
(400 mL), extracted with EtOAc (100 mL.times.3). The combined
organic phase was washed with brine, dried over Na.sub.2SO.sub.4,
filtered and concentrated to afford the crude product which was
washed with EtOAc to give
4-fluoro-2-iodo-1-tosyl-1H-indole-7-carbonitrile (8.5 g, 61%) as a
solid: .sup.1H NMR (CDCl.sub.3) .delta.2.45 (s, 3H), 7.01 (t, J=8.4
Hz, 1H), 7.20 (s, 1H), 7.33 (d, J=8.4 Hz, 2H), 7.64 (m, 1H), 8.05
(d, J=8.4 Hz, 2H).
Step C. tert-Butyl
4-(7-cyano-4-fluoro-1-tosyl-1H-indol-2-yl)-5,6-dihydropyridine-1(2H)-carb-
oxylate
##STR00139##
[0909] To a solution of
4-fluoro-2-iodo-1-tosyl-1H-indole-7-carbonitrile (0.2 g, 6.3 mol)
and tert-butyl
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-
-carboxylate (2.05 g, 6.63 mmol) in the mixture of THF (20 mL),
MeOH (4 mL) and water (4 mL) was added Na.sub.2CO.sub.3 (2.108 g,
19.89 mmol) and PdCl.sub.2(dppf) DCM (0.541 g, 0.663 mmol). The
mixture was heated at about 80.degree. C. for about 3 h. Then the
reaction was cooled and diluted with EtOAc (30 mL) and washed with
water (3.times.10 mL). The organic phase was dried over
Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure
to give crude product which was purified by column chromatography
on silica gel (eluted with Pet ether:EtOAc=10:1) to give tert-butyl
4-(7-cyano-4-fluoro-1-tosyl-1H-indol-2-yl)-5,6-dihydropyridine-1(2H)-carb-
oxylate (2.5 g, 76%): .sup.1H NMR (CDCl.sub.3) .delta. 1.25 (s,
2H), 1.52 (s, 9H), 2.38 (s, 3H), 3.63 (t, J=5.6 Hz, 2H), 4.09 (d,
J=2.8 Hz, 2H), 5.83 (d, J=2.8 Hz, 1H), 6.56 (s, 1H), 7.04 (t, J=8.4
Hz, 1H), 7.20 (d, J=8.0 Hz, 2H), 7.48 (s, 2H), 7.68 (q, J=5.2 Hz,
1H).
Step D.
4-Fluoro-2-(1,2,3,6-tetrahydropyridin-4-yl)-1-tosyl-1H-indole-7-ca-
rbonitrile hydrochloride
##STR00140##
[0911] To a solution of tert-butyl
4-(7-cyano-4-fluoro-1-tosyl-1H-indol-2-yl)-5,6-dihydropyridine-1(2H)-carb-
oxylate (2.7 g, 5.45 mmol) in EtOAc (30 mL) was added dropwise
HCl/EtOAc (30 mL) at about 0.degree. C., then the reaction was
stirred at rt for about 3 h. The mixture was filtered and the
filter cake was washed with EtOAc to give
4-fluoro-2-(1,2,3,6-tetrahydropyridin-4-yl)-1-tosyl-1H-indole-7-carbonitr-
ile hydrochloride (1.96 g, 83%): .sup.1H NMR (MeOD) .delta. 2.35
(s, 3H), 2.78 (s, 2H), 3.48 (t, J=5.6 Hz, 2H), 3.94 (s, 2H), 6.04
(s, 1H), 6.86 (s, 1H), 7.23-7.29 (m, 3H), 7.43 (d, J=8.0 Hz, 2H),
7.84 (t, J=5.2 Hz, 1H).
Step E.
4-Fluoro-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-1-t-
osyl-1H-indole-7-carbonitrile
##STR00141##
[0913] To a solution of tert-butyl
4-(7-cyano-4-fluoro-1-tosyl-1H-indol-2-yl)-5,6-dihydropyridine-1(2H)-carb-
oxylate (1.96 g, 4.54 mmol) and TEA (1.84 g, 18.2 mmol) in DCM (30
mL) was added MsCl (0.623 g, 5.44 mmol), then the mixture was
stirred at rt for about 24 h. Then water was added to the mixture
and the reaction mixture was extracted with DCM (3.times.30 mL).
The combined organic layer was washed with brine and dried over
Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure
to give
4-fluoro-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-1-tosyl-1H-
-indole-7-carbonitrile (1.35 g, 63%) which was used in the next
step without any further purification. LC/MS (Table 1, Method f)
R.sub.t=2.15 min; MS m/z: 474 (M+H).sup.+.
Preparation #28: 3-Bromo-N-(cyanomethyl)benzenesulfonamide
##STR00142##
[0915] To a cooled (0.degree. C.) solution of 2-aminoacetonitrile
hydrochloride (0.50 g, 5.40 mmol) in pyridine (27.0 mL) was slowly
added 3-bromobenzene-1-sulfonyl chloride (0.779 mL, 5.40 mmol). The
mixture was slowly warmed to rt and stirred for about 16 h. The
mixture was concentrated under reduced pressure and the residue was
dissolved in DCM and washed with 1N HCl, saturated sodium
bicarbonate, brine and filtered through a Biotage Phase separator
after each wash step. The organics were concentrated under reduced
pressure afford the crude product. The crude product was purified
by column chromatography on silica gel eluted EtOAc/heptane (0-40%)
to provide 3-bromo-N-(cyanomethyl)benzenesulfonamide (0.61 g, 41%):
.sup.1H NMR (DMSO-d6): .delta. 8.73 (br, 1H), 7.98 (t, J=1.79, 1H),
7.91 (d, J=8.02, 1H), 7.84 (d, J=8.02, 1H), 7.60 (t, J=7.92, 1H),
4.18 (s, 2H).
Preparation #29:
4-Cyclopropyl-N-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-
phenyl)benzamide
##STR00143##
[0917] To a solution of
2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline
(0.350 g, 1.501 mmol) and HATU (0.856 g, 2.252 mmol) in DCM (2 mL)
was added TEA (0.628 mL, 4.50 mmol) and 4-(difluoromethyl)benzoic
acid (0.336 g, 1.952 mmol). The mixture was stirred at about rt for
about 18 h. The mixture was evaporated and the resulting residue
was purified by silica gel chromatography eluting with a gradient
of 30-50% EtOAc in hexane to give
4-cyclopropyl-N-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-
phenyl)benzamide (0.52, 89%); LC/MS (Table 1, Method c)
R.sub.t=2.10 min.; MS m/z: 388 (M+H).sup.+
Preparation #30: (R)-6-Fluoro-2-(piperidin-3-yl)isoindolin-1-one
hydrochloride
##STR00144##
[0918] Step A: Methyl 5-fluoro-2-methylbenzoate
##STR00145##
[0920] To a solution of 5-fluoro-2-methylbenzoic acid (20 g, 0.13
mol) in anhydrous MeOH (200 mL) was added SOCl.sub.2 (38.9 g, 0.33
mol) dropwise. The resulting mixture was stirred at rt overnight.
The solvent was evaporated to dryness to give methyl
5-fluoro-2-methylbenzoate (24 g, 99%) as an oil. .sup.1H NMR
(CDCl.sub.3): .delta. 7.62-7.59 (d, J=9.6 Hz, 1H), 7.21-7.18 (d,
J=8.4 Hz, 1H), 7.12-7.09 (d, J=8.0 Hz, 1H), 3.89 (s, 3H), 2.55 (s,
3H).
Step B: Methyl 2-(bromomethyl)-5-fluorobenzoate
##STR00146##
[0922] To a solution of methyl 5-fluoro-2-methylbenzoate (24 g,
0.14 mol) in CCl.sub.4 (250 mL) was added NBS (28 g, 0.16 mol) and
BPO (1.7 g, 7.2 mmol). The reaction mixture was heated to reflux
for about 18 h. The hot reaction mixture was filtered and the
filtrate was concentrated in vacuo to give methyl
2-(bromomethyl)-5-fluorobenzoate (35 g, crude), which was used in
next step reaction directly without further purification. H NMR
(DMSO-d6): .delta. 7.67-7.60 (m, 2H), 7.48-7.45 (d, J=8.4 Hz, 1H),
4.98 (s, 2H), 3.86 (s, 3H).
Step C: (R)-tert-Butyl
3-(6-fluoro-1-oxoisoindolin-2-yl)piperidine-1-carboxylate
##STR00147##
[0924] To a solution of methyl 2-(bromomethyl)-5-fluorobenzoate (35
g) in MeCN (400 mL) was added K.sub.2CO.sub.3 (39 g, 0.29 mol) and
3-(R)-amino-piperidine-1-carboxylic acid tert-butyl ester (20 g,
0.10 mol). The reaction mixture was heated to reflux for about 3 h
and then stirred at rt overnight. The resulting suspension was
filtered and the filtrate was concentrated under vacuum to give the
residue which was dissolved in EtOAc (300 mL) and washed with brine
(2.times.100 mL). The organic phase was dried over Na.sub.2SO.sub.4
and concentrated. The resulting residue was purified by column
chromatography on silica gel (eluting with 15:1 petroleum
ether:EtOAc) to give (R)-tert-butyl
3-(6-fluoro-1-oxoisoindolin-2-yl)piperidine-1-carboxylate (12 g,
25%) as a solid: .sup.1H NMR (CDCl.sub.3): .delta. 7.46-7.43 (d,
J=7.6 Hz, 1H), 7.35-7.32 (d, J=8.0 Hz, 1H), 7.20-7.14 (m, 1H),
4.36-4.26 (m, 2H), 4.18 (m, 1H), 4.06-3.89 (m, 2H), 2.99-2.93 (m,
1H), 2.75 (s, 1H), 1.95-1.92 (m, 1H), 1.74-1.65 (m, 2H), 1.56-1.54
(m, 1H), 1.39 (s, 9H).
Step D: (R)-6-Fluoro-2-(piperidin-3-yl)isoindolin-1-one
hydrochloride
##STR00148##
[0926] To a solution of (R)-tert-butyl
3-(6-fluoro-1-oxoisoindolin-2-yl)piperidine-1-carboxylate (12 g,
0.036 mol) in DCM (100 mL) was added 1M HCl in MeOH (150 mL). The
resulting mixture was stirred at rt overnight. The reaction mixture
was concentrated under vacuum to give
(R)-6-fluoro-2-(piperidin-3-yl)isoindolin-1-one hydrochloride B
(9.0 g, 100%) as a solid. LCMS (ESI+): m/z 235 (M+H).sup.+,
R.sub.t: 1.90 min.; .sup.1H NMR (D.sub.2O): .delta. 7.43-7.40 (m,
1H), 7.28-7.21 (m, 2H), 4.39-4.37 (d, J=5.6 Hz, 2H), 4.33-4.31 (m,
1H), 3.38-3.34 (m, 2H), 3.12-3.06 (t, J=12.0 Hz, 1H), 2.88-2.85 (m,
1H), 2.00-1.95 (m, 2H), 1.87-1.77 (m, 2H).
Preparation #31: (R)-3-(Piperidin-3-yl)quinazolin-4(3H)-one
##STR00149##
[0927] Step A: (R)-tert-Butyl
3-(4-oxoquinazolin-3(4H)-yl)piperidine-1-carboxylate
##STR00150##
[0929] To a solution of 2-aminobenzoic acid (7.5 g, 54.7 mmol) and
3-(R)-amino-piperidine-1-carboxylic acid tert-butyl ester (10.9 g,
54.7 mmol) in THF (20 mL) was added triethyl orthoformate (8.1 g,
54.7 mmol). The reaction mixture was heated to about 110.degree. C.
in a sealed tube overnight. After cooling to rt, the mixture was
diluted with water and extracted with EtOAc. The combined organic
phase was washed with brine, dried over anhydrous Na.sub.2SO.sub.4
and concentrated under reduced pressure to give a residue, which
was purified by column chromatography on silica gel (eluting with
10:1 petroleum ether:EtOAc) to give (R)-tert-butyl
3-(4-oxoquinazolin-3(4H)-yl)piperidine-1-carboxylate (7.5 g, 42%)
as a yellow solid. .sup.1H NMR (CDCl.sub.3): .delta. 8.34-8.32 (m,
1H), 8.11 (s, 1H), 7.80-7.71 (m, 2H), 7.55-7.51 (m, 1H), 4.75 (br,
1H), 4.23-4.11 (br, 2H), 3.24-3.18 (t, 1H), 2.87 (br, 1H),
2.18-1.98 (m, 2H), 1.91-1.87 (br, 1H), 1.77-1.71 (m, 1H), 1.48 (s,
9H).
Step B: (R)-3-(Piperidin-3-yl)quinazolin-4(3H)-one
##STR00151##
[0931] The reaction solution of (R)-tert-butyl
3-(4-oxoquinazolin-3(4H)-yl)piperidine-1-carboxylate (12.5 g, 36
mmol) in 1M HCl/MeOH (150 mL) was stirred at about rt for about 2.5
h. The mixture was filtered. The solid was washed with EtOAc and
dried to give (R)-3-(piperidin-3-yl)quinazolin-4(3H)-one (10 g,
98%) as a white solid. LCMS (ESI+): m/z 248 (M+H).sup.+, RT: 1.90
min. .sup.1H NMR (D.sub.2O): .delta. 8.55-8.54 (d, J=2.8 Hz, 1H),
7.80-7.77 (dd, J=3.2 Hz, J=2.8 Hz, 1H), 7.68-7.60 (m, 2H),
4.95-4.89 (m, 1H), 3.61-3.57 (m, 1H), 3.46-3.43 (d, J=12.4 Hz, 1H),
3.37-3.31 (t, 1H), 3.04-2.97 (m, 1H), 2.24-2.14 (m, 3H), 1.94-1.87
(m, 1H).
Preparation #32:
(R)-6-Fluoro-3-(piperidin-3-yl)quinazolin-4(3H)-one
hydrochloride
##STR00152##
[0932] Step A: (R)-tert-Butyl
3-(6-fluoro-4-oxoquinazolin-3(4H)-yl)piperidine-1-carboxylate
##STR00153##
[0934] The reaction solution of 2-amino-5-fluorobenzoic acid (7.5
g, 48.4 mmol), 3-(R)-1-amino-piperidine-1-carboxylic acid
tert-butyl ester (9.68 g, 48.4 mmol) and triethyl orthoformate (7.2
g, 48.4 mmol) in THF (20 mL) was heated to about 110.degree. C. in
a sealed tube overnight. After cooling to rt, the mixture was
diluted with water. The aqueous layer was extracted with EtOAc. The
combined organic phase was washed with brine, dried over anhydrous
Na.sub.2SO.sub.4 and concentrated under reduced pressure to give a
residue, which was purified by column chromatography on silica gel
(eluting with 10:1 petroleum ether:EtOAc) to give (R)-tert-butyl
3-(6-fluoro-4-oxoquinazolin-3(4H)-yl)piperidine-1-carboxylate (6.25
g, 37%) as a solid. .sup.1H NMR (CDCl.sub.3): .delta. 8.08 (s, 1H),
7.97-7.95 (m, 1H), 7.76-7.72 (m, 1H), 7.53-7.48 (m, 1H), 4.74 (br,
1H), 4.24-4.12 (br, 2H), 3.24-3.19 (t, 1H), 2.89 (br, 1H),
2.14-2.10 (m, 2H), 2.04-2.01 (m, 1H), 1.91-1.71 (m, 1H), 1.49 (s,
9H).
Step B: (R)-6-Fluoro-3-(piperidin-3-yl)quinazolin-4(3H)-one
hydrochloride
##STR00154##
[0936] A solution of (R)-tert-butyl
3-(6-fluoro-4-oxoquinazolin-3(4H)-yl)piperidine-1-carboxylate (12.5
g, 36 mmol) in 1M HCl/MeOH (150 mL) was stirred at about rt about
for about 2.5 h. The mixture was filtered and the solid was washed
with EtOAc and dried to give
(R)-6-fluoro-3-(piperidin-3-yl)quinazolin-4(3H)-one hydrochloride
(10 g, 98%) as a solid. LC/MS (ESI+): m/z 248 (M+H).sup.+, RT: 1.90
min. .sup.1H NMR (D.sub.2O): .delta. 8.55-8.54 (d, J=2.8 Hz, 1H),
7.80-7.77 (dd, J=3.2 Hz, J=2.8 Hz, 1H), 7.68-7.60 (m, 2H),
4.95-4.89 (m, 1H), 3.61-3.57 (m, 1H), 3.46-3.43 (d, J=12.4 Hz, 1H),
3.37-3.31 (t, 1H), 3.04-2.97 (m, 1H), 2.24-2.14 (m, 3H), 1.94-1.87
(m, 1H).
Preparation #33:
7-Cyclopropyl-5-fluoro-3-(piperidin-3-yl)quinazolin-4(3H)-one
hydrochloride
##STR00155##
[0937] Step A: tert-Butyl
3-(7-bromo-5-fluoro-4-oxoquinazolin-3(4H)-yl)piperidine-1-carboxylate
##STR00156##
[0939] To a solution of 2-amino-4-bromo-6-fluorobenzoic acid (7 g 3
mol, prepare according to WO 2011075699) and
3-amino-piperidine-1-carboxylic acid tert-butyl ester (6.6 g, 0.033
mol) in THF (50 mL) was added triethyl orthoformate (6.6 g, 0.044
mol). The reaction mixture was heated at about 110.degree. C. in a
sealed tube overnight. After cooling to about rt, the mixture was
diluted with water. The aqueous was extracted with EtOAc. The
combined organic phase was washed with brine, dried over anhydrous
Na.sub.2SO.sub.4 and concentrated under reduced pressure to give a
residue, which was purified by column chromatography on silica gel
(eluting with 50:1 petroleum ether:EtOAc) to give tert-butyl
3-(7-bromo-5-fluoro-4-oxoquinazolin-3(4H)-yl)piperidine-1-carboxylate
(6.4 g, 50%) as a solid. .sup.1H NMR (CDCl.sub.3): .delta. 8.1 (s,
1H), 7.54-7.52 (dd, J=2.4 Hz, 1H), 7.35-7.32 (dd, J=2.8 Hz, 1H),
4.7 (br, 1H), 4.2-4.16 (br, 1H), 4.07-4.03 (br, 1H), 3.24-3.18 (t,
1H), 2.92-2.89 (br, 1H), 2.11-2.09 (br, 1H), 1.98-1.96 (br, 1H),
1.89-1.85 (br, 1H), 1.74-1.64 (br, 1H), 1.45 (s, 9H).
Step B: tert-Butyl
3-(7-cyclopropyl-5-fluoro-4-oxoquinazolin-3(4H)-yl)piperidine-1-carboxyla-
te
##STR00157##
[0941] To a mixture of tert-butyl
3-(7-bromo-5-fluoro-4-oxoquinazolin-3(4H)-yl)piperidine-1-carboxylate
(20 g, 0.047 mol), Pd(OAc).sub.2 (0.526 g, 0.002 mol),
tricyclohexylphosphine (1.31 g, 0.005 mol), anhydrous
K.sub.3PO.sub.4 (50 g, 0.236 mol) and water (40 mL) in toluene (200
mL) was added cyclopropylboronic acid (6.06 g, 0.07 mol). The
reaction mixture was heated to reflux overnight under N.sub.2.
After cooling to rt, the mixture was diluted with water. The
aqueous layer was extracted with EtOAc. The combined organic phase
was washed with brine, dried over anhydrous Na.sub.2SO.sub.4 and
concentrated under reduced pressure to give a residue, which was
purified by column chromatography on silica gel (eluting with 50:1
petroleum ether:EtOAc) to give tert-butyl
3-(7-cyclopropyl-5-fluoro-4-oxoquinazolin-3(4H)-yl)piperidine-1-carboxyla-
te (15 g, 83%) as a solid. .sup.1H NMR (CDCl.sub.3): .delta. 7.96
(s, 1H), 7.07-7.04 (dd, J=2.4 Hz, 1H), 6.71-6.67 (dd, J=2.4 Hz,
1H), 4.68-4.65 (br, 1H), 4.16 (br, 1H), 4.06-4.02 (br, 1H),
3.37-3.33 (m, 1H), 3.08-3.02 (m, 1H), 2.82-2.76 (br, 1H), 2.06-2.01
(m, 1H), 1.90-1.69 (m, 2H), 1.64-1.60 (m, 1H), 1.40 (s, 9H),
1.20-1.06 (m, 2H), 0.712-0.608 (m, 2H).
Step C:
7-Cyclopropyl-5-fluoro-3-(piperidin-3-yl)quinazolin-4-(3H)-one
hydrochloride
##STR00158##
[0943] A solution of tert-butyl
3-(7-cyclopropyl-5-fluoro-4-oxoquinazolin-3(4H)-yl)piperidine-1-carboxyla-
te (15 g, 0.039 mmol) in 1M HCl/MeOH (150 mL) was stirred at about
rt for about 2.5 h. The mixture was filtered, the solid was washed
with EtOAc and dried to give
7-cyclopropyl-5-fluoro-3-(piperidin-3-yl)quinazolin-4(3H)-one
hydrochloride (10 g, 91%) as a solid. LCMS (ESI+): m/z 288
(M+H).sup.+, R.sub.t: 2.916 min. .sup.1H NMR (D.sub.2O): .delta.
8.56 (s, 1H), 6.99-6.96 (m, 1H), 6.85-6.82 (dd, J=1.6 Hz, 1H),
4.87-4.83 (m, 1H), 3.54-3.51 (m, 1H), 3.41-3.38 (d, 1H), 3.24-3.18
(t, 1H), 2.96-2.89 (t, 1H), 2.84-2.81 (m, 1H), 2.13-2.09 (m, 3H),
1.89-1.82 (m, 1H), 0.96-094 (br, 2H), 0.61 (br, 2H).
Preparation #34:
2-(Benzyloxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline
##STR00159##
[0944] Step A: 1-(Benzyloxy)-4-bromo-2-nitrobenzene
##STR00160##
[0946] To a solution of 4-bromo-2-nitrophenol (5 g, 22.9 mmol) in
acetone (100 mL) was added (bromomethyl)benzene (4.7 g, 27.5 mmol)
and K.sub.2CO.sub.3 (6.3 g, 45.9 mmol). The mixture was refluxed
overnight. After cooling to rt, the mixture was filtered. The
filtrate was concentrated under reduced pressure to give a residue,
which was washed with TBME to give
1-(benzyloxy)-4-bromo-2-nitrobenzene (6.3 g, 89%): .sup.1H NMR
(CDCl.sub.3) .delta. 8.00 (d, J=2.2 Hz, 1H), 7.60 (dd, J=2.6, 8.8
Hz, 1H), 7.49-7.31 (m, 5H), 7.03 (d, J=8.8 Hz, 1H), 5.24 (s,
2H).
Step B: 2-(Benzyloxy)-bromoaniline
##STR00161##
[0948] To a solution of 1-(benzyloxy)-4-bromo-2-nitrobenzene (2 g,
6.5 mmol) in EtOH (80 mL) and water (20 mL) was added iron (1.8 g,
32.5 mmol) and NH.sub.4Cl (1.7 g, 32.5 mmol). The resulting mixture
was refluxed for 3 h. The mixture was filtered. The filtrate was
diluted with water and extracted with EtOAc. The organic layer was
concentrated to give 2-(benzyloxy)-5-bromoaniline (1.6 g, 89%):
.sup.1H NMR (CDCl.sub.3) .delta. 7.51-7.30 (m, 5H), 6.86 (d, J=2.2
Hz, 1H), 6.83-6.76 (m, 1H), 6.74-6.66 (m, 1H), 5.07 (s, 2H), 3.91
(br, 2H)
Step C:
2-(Benzyloxy-5-(4,4,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline
##STR00162##
[0950] To a solution of 2-(benzyloxy)-5-bromoaniline (2.0 g, 7.19
mmol) in DMSO (30 mL) was added
4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (2.2 g,
8.6 mmol), Pd(dppf)Cl.sub.2 (0.53 g, 0.72 mmol) and potassium
acetate (2.1 g, 21.6 mmol). The mixture was stirred at 80.degree.
C. overnight under N.sub.2. After cooling to rt, the mixture was
diluted with water and extracted with EtOAc. The organic layer was
concentrated and purified by column to give
2-(benzyloxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline
(1.5 g, 64%): .sup.1H NMR (CDCl.sub.3) .delta. 7.55-7.29 (m, 5H),
7.23-7.12 (m, 2H), 6.86 (d, J=7.9 Hz, 1H), 5.11 (s, 2H), 3.80 (br,
2H), 1.32 (s, 12H).
Preparation #35:
3-(Benzyloxy)-5-(4,4,5,5-tetramethyl-13,2-dioxaborolan-2-yl)aniline
##STR00163##
[0951] Step A: 3-Bromo-5-nitrophenol
##STR00164##
[0953] To a solution of 1-bromo-3-methoxy-5-nitrobenzene (19 g, 82
mmol) in DCM (800 mL) was added dropwise BBr.sub.3 (27.9 mL, 295
mmol) in DCM (120 mL). The resulting mixture was heated to reflux
overnight. After cooling in ice-water, the mixture was diluted by
addition of water. Then the mixture was washed with brine. The
organic phase was dried over Na.sub.2SO.sub.4, concentrated under
reduced pressure to give a residue, which was purified by column
chromatography on silica gel to give 3-bromo-5-nitrophenol (8 g,
44%) as a solid: H NMR (CDCl.sub.3) .delta. 7.89 (s, 1H), 7.57 (s,
1H), 7.27 (s, 1H), 5.27 (s, 1H).
Step B: 1-(Benzyloxy)-3-bromo-5-nitrobenzene
##STR00165##
[0955] To a solution of 3-bromo-5-nitrophenol in acetone (50 mL)
was added (bromomethyl)benzene (2.4 g, 13.8 mmol) and
K.sub.2CO.sub.3 (3.2 g, 22.9 mmol). The resulting mixture was
heated to reflux overnight. The mixture was filtered. The filtrate
was concentrated under reduced pressure to give a residue, which
was washed with TBME to give 1-(benzyloxy)-3-bromo-5-nitrobenzene
(1.3 g, 37%) as a solid: .sup.1H NMR (CDCl.sub.3) .delta. 8.00 (s,
1H), 7.78-7.77 (m, 1H), 7.64-7.40 (m, 6H), 5.15 (s, 2H).
Step C: 3-(Benzyloxy)-5-bromoaniline
##STR00166##
[0957] To a solution of 1-(benzyloxy)-3-bromo-5-nitrobenzene (1.3
g, 4.2 mmol) in EtOH (30 mL) and water (7.5 mL) was added iron (1.2
g, 21.1 mmol) and NH.sub.4Cl (1.1 g, 21.1 mmol). The mixture was
heated to reflux overnight. The mixture was filtered. The filtrate
was concentrated under reduced pressure to give a residue, which
was diluted by addition of water and extracted by EtOAc. The
organic layer was concentrated under reduced pressure to give
3-(benzyloxy)-5-bromoaniline (1 g, 85%): .sup.1H NMR (CDCl.sub.3)
.delta. 7.33-7.31 (m, 5H), 6.48 (s, 1H), 6.39 (s, 1H), 6.14 (s,
1H), 4.92 (s, 2H), 3.63 (br, 2H).
Step
D:3-(Benzyloxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)anilin-
e
##STR00167##
[0959] To a solution of 3-(benzyloxy)-5-bromoaniline (1 g, 3.6
mmol) and
4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (1.1 g,
4.3 mmol) in DMSO (1 mL) was added Pd(dppf)Cl.sub.2 (0.26 g, 0.36
mmol) and potassium acetate (1.1 g, 10.8 mmol). The mixture was
heated to about 80.degree. C. overnight under N.sub.2. After
cooling to rt, the mixture was diluted by addition of water and
extracted by EtOAc. The organic layer was concentrated under
reduced pressure to give a residue, which was purified by column
chromatography on silica gel to give
3-(benzyloxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline
(1 g, 86%) as a solid: .sup.1H NMR (CDCl.sub.3) .delta. 7.43-7.31
(m, 5H), 6.87 (s, 1H), 6.77 (s, 1H), 6.43-6.42 (m, 1H), 5.05 (s,
2H), 3.64 (br, 2H), 1.34 (s, 12H).
Preparation #36: 4-(Benzyloxy)-1-bromo-2-nitrobenzene
##STR00168##
[0961] To a solution of 4-bromo-3-nitrophenol (2 g, 9.17 mmol,
Preparation #S.1) in acetone (50 mL) was added BnBr (1.9 g, 11.0
mmol) and K.sub.2CO.sub.3 (2.5 g, 18.4 mmol). The mixture was
filtered. The filtrate was concentrated under reduced pressure to
give a residue, which was washed with TBME to give
4-(benzyloxy)-1-bromo-2-nitrobenzene (2.6 g, 92%): .sup.1H NMR
(CDCl.sub.3) .delta. 7.62 (d, J=8.8 Hz, 1H), 7.48 (d, J=2.6 Hz,
1H), 7.45-7.35 (m, 5H), 7.07 (dd, J=2.9, 9.0 Hz, 1H), 5.12 (s,
2H).
Preparation #37: 4-(Benzyloxy)-1-bromo-2-nitrobenzene
##STR00169##
[0962] Step A: Methyl
2-(2-methoxy-2-oxoethyl)-1-(4-methoxybenzyl)-1H-pyrrole-3-carboxylate
##STR00170##
[0964] A flask was charged with dimethyl 3-oxopentanedioate (77.0
g, 442 mmol), (4-methoxyphenyl)methanamine (60.1 mL, 460 mmol) and
anhydrous NaOAc (72.5 g, 884 mmol) in dioxane (100 mL). The
reaction mixture was stirred at about rt for about 30 min, then
heated to about 50.degree. C. and stirred for about 16 h. The
reaction mixture was cooled to rt and dioxane (250 mL) was added.
2-chloroacetaldehyde (51.9 mL, 442 mmol) was added via a dropping
funnel. After about 7 h additional 2-chloroacetaldehyde (17.4 g,
221 mmol) was added and stirred for about 16 h. Additional
2-chloroacetaldehyde (17.4 g, 221 mmol) was added and stirred for
about 5 h, more 2-chloroacetaldehyde was added (25.9 mL, 221 mmol),
the final portion of 2-chloroacetaldehyde (25.9 mL, 221 mmol) was
added after about 2 h and left to stir for about 72 h. NaOAc (36.3
g, 442 mmol) was added and the solution and stirred for about 16 h.
The reaction mixture was cooled under an ice bath and ice-water
added to it (about 500 mL). The mixture was extracted with DCM (850
mL). The organic layer was washed with water (4.times.700 mL). The
organic layer was dried over MgSO.sub.4, filtered and concentrated
to give a viscous oil. The crude material was purified via flash
chromatography (using heptane for 3 column volumes, 0-25%
EtOAc/heptane over 4 column volumes, 20-35% over 4 column volumes).
The pure fractions were combined and concentrated and minimal
Et.sub.2O added to precipitate out a first batch of product which
was collected via filtration. The filtrate was combined with the
impure fractions, concentrated under vacuum and recrystallized from
isopropanol to give a solid which was collected via filtration and
combined with the first batch of product. The material was dried in
a vacuum oven at about 70.degree. C. for about 16 h to give methyl
2-(2-methoxy-2-oxoethyl)-1-(4-methoxybenzyl)-1H-pyrrole-3-carboxylate
(28.5 g, 20%): LC/MS (Table 1, Method as) R.sub.t=2.20 min; MS m/z:
318 (M+H).sup.+.
Step B: Methyl
2-(1-amino-3-methoxy-3-oxoprop-1-en-2-yl)-1-(4-methoxybenzyl)-1H-pyrrole--
3-carboxylate
##STR00171##
[0966] A flask was charged with NaH (23.3 g, 582 mmol) and THF (500
mL). The mixture was cooled to about 0.degree. C. and methyl
2-(2-methoxy-2-oxoethyl)-1-(4-methoxybenzyl)-1H-pyrrole-3-carboxylate
(28 g, 88 mmol) was added portion wise. The internal temperature
measured below 10.degree. C. during the addition. The suspension
was stirred at about 0.degree. C. for about 1 h. Methyl formate
(7.62 mL, 124 mmol) was added. The reaction mixture was allowed to
warm to rt and was stirred for about 16 h. Additional methyl
formate (1.09 mL, 17.6 mmol) was added and the mixture stirred at
rt for about 4 to 5 h, at which point all the starting material was
consumed. The reaction was cooled on ice and quenched by the
addition of MeOH (5 mL), and water was added carefully until
effervescence stopped. The mixture was then acidified to pH of
about 1 with aqueous 6N HCl, while keeping the flask on an ice
bath. The reaction mixture was diluted with EtOAc (100 mL) and
water (100 mL). The aqueous layer was separated and extracted with
EtOAc (3.times.50 mL). The combined organic layers were then dried
over MgSO.sub.4 and filtered. The solvent was evaporated to yield
an oil consisting of two layers. The thinner top layer was clear
and was separated using a pipette and discarded. The remaining
bottom layer was the crude intermediate, methyl
2-(1-hydroxy-3-methoxy-3-oxoprop-1-en-2-yl)-1-(4-methoxybenzyl)-1H-pyrrol-
e-3-carboxylate. A flask was charged with this crude methyl
2-(1-hydroxy-3-methoxy-3-oxoprop-1-en-2-yl)-1-(4-methoxybenzyl)-1H-pyrrol-
e-3-carboxylate (30 g, 87 mmol) and MeOH (300 mL). Ammonium acetate
(33.5 g, 434 mmol) was added and the reaction mixture was refluxed
for about 4 h and stirred at about 60.degree. C. for about 72 h.
The reaction mixture was concentrated under vacuum and diluted with
water (200 mL) and EtOAc (200 mL). Part of the product precipitated
out and was collected by filtration. The organic layer was
separated. The aqueous layer was extracted again with EtOAc
(2.times.80 mL). The combined organic layers were dried over
MgSO.sub.4, filtered, and concentrated. The residue was suspended
in Et.sub.2O (200 mL) and stirred for about 10 min and filtered to
collect the product. This batch was combined with the previous
precipitate and dried in a vacuum oven at about 70.degree. C. for
about 4 h to give methyl
2-(1-amino-3-methoxy-3-oxoprop-1-en-2-yl)-1-(4-methoxybenzyl)-1H-pyrrole--
3-carboxylate (25.7 g, 82%): LC/MS (Table 1, Method as)
R.sub.t=1.88 min; MS m/z: 345 (M+H).sup.+.
Step C: Methyl
1-(4-methoxybenzyl)-4-oxo-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-7-carboxy-
late
##STR00172##
[0968] A flask was charged with methyl
2-(1-amino-3-methoxy-3-oxoprop-1-en-2-yl)-1-(4-methoxybenzyl)-1H-pyrrole--
3-carboxylate (24.6 g, 71.4 mmol) and t-BuONa (6.87 g, 71.4 mmol)
in DMA (100 mL). The solution was heated at about 150.degree. C.
for about 10 min, and cooled to rt. The solution was then poured
onto ice-water (250 mL) and diluted with EtOAc (200 mL). The
mixture was stirred at rt for about 45 min. The precipitate that
formed was filtered and washed with water, then dried in a vacuum
oven at about 70.degree. C. for about 16 h to yield methyl
1-(4-methoxybenzyl)-4-oxo-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-7-carboxy-
late (18.9 g, 85%): LC/MS (Table 1, Method as) R.sub.t=1.76 min; MS
m/z: 313 (M+H).sup.+.
Step D: Methyl 4-chloro-1H-pyrrolo[3,2-c]pyridine-7-carboxylate
##STR00173##
[0970] A mixture of methyl
1-(4-methoxybenzyl)-4-oxo-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-7-carboxy-
late (24 g, 76 mmol) in phenyl phosphorodichloridate (30.8 mL, 206
mmol) was heated at about 150.degree. C. for about 30 min. LCMS
showed complete conversion to mixture of ester and acid. The
reaction mixture was cooled to about 0.degree. C. and 50% aqueous
NaOH was added slowly until pH of about 7. The reaction mixture was
extracted with DCM (3.times.100 mL). The organic layers were
combined and concentrated under reduced pressure. The residue was
suspended in Et.sub.2O (100 mL), stirred at about 30.degree. C. for
about 1 h, cooled to rt and filtered. The filtrate was concentrated
to give crude methyl 4-chloro-1-(4-methoxybenzyl)-1H-pyrrolo
[3,2-c]pyridine-7-carboxylate (22.5 g, 75%) as a black oil. A
mixture of this crude methyl
4-chloro-1-(4-methoxybenzyl)-1H-pyrrolo[3,2-c]pyridine-7-carboxylate
(21.76 g, 65.8 mmol) and triflic anhydride (7.50 mL, 44.4 mmol) in
TFA (50 mL) was stirred at about 50.degree. C. for about 16 h. The
reaction mixture was cooled to rt and added to ice cold NaHCO.sub.3
solution. Aqueous NaOH was slowly added to adjust the pH to about
9. The solid was filtered and sonicated in Et.sub.2O. The
precipitate was filtered of and the filtrate was concentrated to
give methyl 4-chloro-1H-pyrrolo[3,2-c]pyridine-7-carboxylate (9.4
g, 68%): LCMS (Table 1, Method a) R.sub.t=1.83 min; MS m/z: 211
(M+H).sup.+.
Preparation #38: Methyl
4-(1-(tert-butoxycarbonyl)pyrrolidin-3-yl)-2-methyl-1H-indole-7-carboxyla-
te
##STR00174##
[0971] Step A: 1-tert-Butyl 7-methyl
4-(1-(tert-butoxycarbonyl)pyrrolidin-3-yl)-2-methyl-1H-indole-1,7-dicarbo-
xylate
##STR00175##
[0973] To a solution of 1-tert-butyl 7-methyl
4-(1-(tert-butoxycarbonyl)pyrrolidin-3-yl)-2-iodo-1H-indole-1,7-dicarboxy-
late (2.0 g, 3.5 mmol, Preparation #Y.1) in THF (35 mL) was added
Zn (Me).sub.2 (1 Min hexane, 21.04 mL, 21.04 mmol). The mixture was
degassed using nitrogen and Pd(dppf)Cl.sub.2(0.257 g, 0.351 mmol)
was added in one portion and stirred at rt for about 19 h. The
reaction was warmed to about 45.degree. C. and stirred for about 22
h. The reaction mixture was carefully quenched by the addition of
saturated aqueous NaHCO.sub.3 (50 mL) and diluted with EtOAc (50
mL) and brine (20 mL). The layers were separated and the aqueous
phase was extracted with EtOAc (2.times.50 mL). The combined
organic extracts were washed with brine, dried over MgSO.sub.4,
filtered, concentrated under reduced pressure and purified by
column chromatography on silica gel (0-50% EtOAc/heptane) to
provide 1-tert-butyl 7-methyl
4-(1-(tert-butoxycarbonyl)pyrrolidin-3-yl)-2-methyl-1H-indole-1,7-dicarbo-
xylate (1.45 g, 79%): LCMS (Table 1, Method ba) R.sub.t=3.02 min;
MS m/z: 476 (M+H).sup.+.
Step B: Methyl
4-(1-(tert-butoxycarbonyl)pyrrolidin-3-yl)-2-methyl-1H-indole-7-carboxyla-
te
##STR00176##
[0975] A solution of 1-tert-butyl 7-methyl
4-(1-(tert-butoxycarbonyl)pyrrolidin-3-yl)-2-methyl-1H-indole-1,7-dicarbo-
xylate (1.40 g, 3.05 mmol) in MeOH (7 mL) was added to a microwave
reaction vial and the solution was heated to about 120.degree. C.
for about 30 min. The reaction mixture was adsorbed onto silica gel
and purified using silica gel chromatography (0-50% EtOAc/heptane)
to give methyl
4-(1-(tert-butoxycarbonyl)pyrrolidin-3-yl)-2-methyl-1H-indole-7-ca-
rboxylate (1 g, 86%): LCMS (Table 1, Method as) R.sub.t=2.58 min;
MS m/z: 359 (M+NH.sub.4).
Preparation #39: Methyl
4-(1-(tert-butoxycarbonyl)-1,2,5,6-tetrahydropyridin-3-yl)-1-tosyl-1H-ind-
ole-7-carboxylate
##STR00177##
[0977] A flask was charged with methyl
4-(1-(tert-butoxycarbonyl)-1,2,5,6-tetrahydropyridin-3-yl)-1-tosyl-1H-ind-
ole-7-carboxylate (2.00 g, 3.92 mmol, prepared using A from
Preparation #1, step B with tert-butyl
3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-
-carboxylate) in THF (39.2 mL). The solution was cooled to about
-71.degree. C. LDA (1M solution in hexanes/THF, 5.88 mL, 5.88 mmol)
was added drop wise over about 5 min while maintaining the
temperature below -65.degree. C. The solution was stirred at about
-72.degree. C. for about 45 min. CH.sub.3I (0.367 mL, 5.88 mmol)
was added. The mixture was stirred at about -70.degree. C. for a
further 2.5 hours, and then quenched with a saturated aqueous
Na.sub.2CO.sub.3 solution (150 mL). The mixture was extracted with
EtOAc (2.times.200 mL) and DCM (1.times.100 mL). The combined
organic layers were dried over Na.sub.2SO.sub.4, filtered,
concentrated under reduced pressure and purified by column
chromatography on silica gel (25-75% EtOAc/heptane) to provide
methyl
4-(1-(tert-butoxycarbonyl)-1,2,5,6-tetrahydropyridin-3-yl)-1-tosyl-1H-ind-
ole-7-carboxylate (1.67 g, 57%, 70% purity): LCMS (Table 1, Method
as) R.sub.t=2.88 min; MS m/z: 542 (M+NH.sub.4).
Preparation #40: tert-butyl
3-((7-carbamoyl-2-iodo-1H-indol-4-yl)(methyl)amino)azetidine-1-carboxylat-
e
##STR00178##
[0978] Step A: Methyl
4-((1-(tert-butoxycarbonyl)azetidin-3-yl)(methyl)amino)-2-iodo-1-tosyl-1H-
-indole-7-carboxylate
##STR00179##
[0980] To a solution of methyl
4-((1-(tert-butoxycarbonyl)azetidin-3-yl)(methyl)amino)-1-tosyl-1H-indole-
-7-carboxylate (4.00 g, 7.79 mmol, prepared using T from
Preparation #1, step C with
tert-butyl-3-aminoazetidine-1-carboxylate and J. with CH.sub.3I) in
THF (60 mL) at about -78.degree. C. was added slowly LDA (2M
solution in THF, 5.84 mL, 11.7 mmol). The reaction was stirred at
about -78.degree. C. for about 1 h and a solution of 12 (2.97 g,
11.7 mmol) in THF (10 mL) was added slowly and the reaction stirred
at about -78.degree. C. for about 4 h. The cooling bath was removed
to warm the reaction to rt and the reaction was quenched by the
addition of saturated aqueous Na.sub.2S.sub.2O.sub.3 (120 mL),
extracted with additional EtOAc (2.times.150 mL) and washed with
brine (2.times.150 mL). The combined organics were dried with
anhydrous Na.sub.2SO.sub.4, filtered and concentrated under reduced
pressure to give the crude product, methyl
4-((1-(tert-butoxycarbonyl)azetidin-3-yl)(methyl)amino)-2-iodo-1-tosyl-1H-
-indole-7-carboxylate (4.1 g, 80%): LC/MS (Table 1, Method aa)
R.sub.t=1.87 min; MS m/z: 640 (M+H).sup.+.
Step
B:4-((1-(tert-Butoxycarbonyl)azetidin-3-yl)(methyl)amino)-2-iodo-1H-i-
ndole-7-carboxylic acid
##STR00180##
[0982] To a solution of methyl
4-((1-(tert-butoxycarbonyl)azetidin-3-yl)(methyl)amino)-2-iodo-1-tosyl-1H-
-indole-7-carboxylate (15.5 g, 24.2 mmol) in MeOH (75 mL):THF (75
mL):water (30 mL) was added KOH (9.52 g, 170 mmol). The mixture was
stirred at about 60.degree. C. for about 16 h, cooled, and
acidified with aqueous 2N HCl. It was extracted with EtOAc
(2.times.350 mL) and washed with brine (2.times.300 mL). The
combined organics were dried with anhydrous Na.sub.2SO.sub.4,
filtered and concentrated under reduced pressure to give the crude
product
4-((1-(tert-butoxycarbonyl)azetidin-3-yl)(methyl)amino)-2-iodo-1H-indole--
7-carboxylic acid (11.4 g, 99%): LC/MS (Table 1, Method aa)
R.sub.t=1.86 min; MS m/z: 416 (M+H-tBu).sup.+.
Step C: tert-Butyl
3-((7-carbamoyl-2-iodo-1H-indol-4-yl)(methyl)amino)azetidine-1-carboxylat-
e
##STR00181##
[0984]
4-((1-(tert-Butoxycarbonyl)azetidin-3-yl)(methyl)amino)-2-iodo-1H-i-
ndole-7-carboxylic acid (13.7 g, 29.1 mmol), HOBt (8.90 g, 58.1
mmol) and EDC (11.2 g, 58.1 mmol) were dissolved in DMF (260 mL)
and DIEA (25.4 mL, 145 mmol) was added. The mixture was stirred at
rt for about 10 min and NH.sub.4Cl (12.4 g, 233 mmol) was added.
The mixture was stirred at rt for about 16 h and saturated aqueous
NH.sub.4Cl (1 L) was added. The solid was collected by filtration,
washed with water, and dried to give the crude product tert-butyl
3-((7-carbamoyl-2-iodo-1H-indol-4-yl)(methyl)amino)azetidine-1-carboxylat-
e (13.4 g, 97%): LC/MS (Table 1, Method aa) R.sub.t=1.81 min; MS
m/z: 471 (M+H).sup.+.
Preparation #41:
4-(Azetidin-3-yl(methyl)amino)-2-(tetrahydrofuran-3-yl)-1H-indole-7-carbo-
xamide
##STR00182##
[0986] A reaction vial was charged with tert-butyl
3-((7-carbamoyl-2-iodo-1H-indol-4-yl)(methyl)amino)azetidine-1-carboxylat-
e (0.050 g, 0.11 mmol, Preparation #40), (Z)-but-2-ene-1,4-diol
(0.014 g, 0.16 mmol), NaHCO.sub.3 (10.7 mg, 0.128 mmol) and
PdCl.sub.2 (1.885 mg, 10.63 .mu.mol) in NMP (1.2 mL). The mixture
was purged with nitrogen and heated at about 130.degree. C. for
about 1 h. It was extracted with EtOAc (2.times.20 mL) and washed
with brine (2.times.20 mL). The combined organics were dried over
anhydrous Na.sub.2SO.sub.4, filtered, concentrated under reduced
pressure and purified by Prep TLC (EtOAc) to give crude tert-butyl
3-((7-carbamoyl-2-(2,3-dihydrofuran-3-yl)-1H-indol-4-yl)(methyl)amino)aze-
tidine-1-carboxylate (0.028 g, 39%). A mixture of tert-butyl
3-((7-carbamoyl-2-(2,3-dihydrofuran-3-yl)-1H-indol-4-yl)(methyl)amino)aze-
tidine-1-carboxylate (0.055 g, 0.081 mmol) in DCM (1.5 mL) was
stirred at about 0.degree. C. in an ice bath. Triethylsilane (0.014
g, 0.12 mmol) was added and then BF.sub.3.OEt.sub.2 (0.015 mL,
0.122 mmol) was added drop wise. The mixture was stirred at about
0.degree. C. for about 1 h and quenched with a saturated aqueous
solution of Na.sub.2CO.sub.3 to a pH of about 8 then filtered. The
filtrate was purified by Prep HPLC (Table 1, method bc) to give
4-(azetidin-3-yl(methyl)amino)-2-(tetrahydrofuran-3-yl)-1H-indole-7-carbo-
xamide (0.008 mg, 28%): LC/MS (Table 1, Method av) R.sub.t=1.03
min; MS m/z: 315 (M+H).sup.+.
Preparation #42: Methyl
4-((1-(tert-butoxycarbonyl)azetidin-3-yl)(methyl)amino)-2-(3-hydroxyoxeta-
n-3-yl)-1-tosyl-1H-indole-7-carboxylate
##STR00183##
[0988] To a cold solution of methyl
4-((1-(tert-butoxycarbonyl)azetidin-3-yl)(methyl)amino)-1-tosyl-1H-indole-
-7-carboxylate (0.80 g, 1.56 mmol, prepared using T from
Preparation #1, step C with
tert-butyl-3-aminoazetidine-1-carboxylate and J. with CH.sub.3I) in
THF (12 mL) at about -78.degree. C. was added slowly LDA (2M
solution in THF, 1.168 mL, 2.336 mmol). The reaction was stirred at
about -78.degree. C. for about 1 h, then a solution of oxetan-3-one
(0.168 g, 2.34 mmol) in THF (1 mL) was added slowly and the
reaction mixture was stirred at about -78.degree. C. for about 4 h.
The cooling bath was removed and the reaction was quenched with
saturated aqueous NH.sub.4Cl solution. The mixture was extracted
with EtOAc (2.times.50 mL) and washed with brine (2.times.50 mL).
The combined organics were dried over anhydrous Na.sub.2SO.sub.4,
filtered, concentrated under reduced pressure and purified by
Prep-TLC (1:1 EtOAc/pet. Et.sub.2O) to give methyl
4-((1-(tert-butoxycarbonyl)azetidin-3-yl)(methyl)amino)-2-(3-hydro-
xyoxetan-3-yl)-1-tosyl-1H-indole-7-carboxylate (0.55 g, 59%): LC/MS
(Table 1, Method av) R.sub.t=1.67 min; MS m/z: 586 (M+H).sup.+.
Preparation #43: tert-Butyl
2-(7-cyano-1-tosyl-1H-indol-4-yl)morpholine-4-carboxylate
##STR00184##
[0989] Step A: 4-Bromo-1-tosyl-1H-indole-7-carbonitrile
##STR00185##
[0991] A round bottom flask was charged with
4-bromo-1H-indole-7-carbonitrile (4.50 g, 20.4 mmol) and THF (75
mL). The solution was cooled to about 0.degree. C. followed by the
addition of NaH (60% dispersion in mineral oil, 1.22 g, 30.5 mmol).
The solution was stirred at about 0.degree. C. for about 40 min
followed by the addition of 4-methylbenzene-1-sulfonyl chloride
(4.66 g, 24.4 mmol). The ice bath was removed and the mixture was
stirred at rt for about 15 h. The mixture was poured onto ice water
(.about.150 mL) and the product was extracted with EtOAc
(4.times.75 mL). The combined extracts were washed with water (75
mL), dried over MgSO.sub.4, filtered and concentrated under reduced
pressure to give 4-bromo-1-tosyl-1H-indole-7-carbonitrile (5.74 g,
75%): .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 8.21 (d, J=3.9
Hz, 1H), 7.97-7.89 (m, 2H), 7.80-7.64 (m, 2H), 7.56-7.42 (m, 2H),
7.00 (d, J=3.8 Hz, 1H), 2.38 (s, 3H).
Step B: 1-Tosyl-4-vinyl-1H-indole-7-carbonitrile
##STR00186##
[0993] A round bottom flask was charged with
4-bromo-1-tosyl-1H-indole-7-carbonitrile (8.54 g, 22.8 mmol),
Na.sub.2CO.sub.3 (7.24 g, 68.3 mmol) and PdCl.sub.2(dppf) (1.665 g,
2.276 mmol) followed by the addition of THF (70.2 mL): MeOH (10.03
mL): water (10.03 mL). The reaction mixture was purged with N.sub.2
for about 15 min, 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane
(4.63 mL, 27.3 mmol) was added and the mixture was heated to about
70.degree. C. for about 5 h. The mixture was cooled to rt and DCM
(75 mL) and water (50 mL) were added. The layers were separated and
the aqueous layer was extracted with DCM (50 mL). The combined
extracts were dried over MgSO.sub.4, filtered, concentrated under
reduced pressure and passed through a plug of silica gel, eluting
with DCM, and concentrated under vacuum. The residue was suspended
in a mixture of Et.sub.2O/EtOAc, filtered and then washed the
precipitate with a small amount of EtOAc/Et.sub.2O. The material
thus obtained was dried in vacuum oven to give
1-tosyl-4-vinyl-1H-indole-7-carbonitrile (5.62 g, 77%): LC/MS
(Table 1, Method as) R.sub.t=2.57 min; MS m/z: 323 (M+H).sup.+.
Step C: 4-(Oxiran-2-yl)-1-tosyl-1H-indole-7-carbonitrile
##STR00187##
[0995] To a suspension of 1-tosyl-4-vinyl-1H-indole-7-carbonitrile
(0.40 g, 1.241 mmol) in dioxane (16 mL) and water (8 mL) was added
AcOH (0.0710 mL, 1.24 mmol). The mixture was cooled to about
0.degree. C. NBS (0.243 g, 1.36 mmol) was added in one portion. The
reaction was allowed to warm to rt and stirred for about 2 h. NaOH
(2M aqueous solution, 8.0 mL, 16 mmol) was added in one portion.
The solid formed was collected by filtration, washed with water and
dried in a vacuum oven at about 60.degree. C. for about 16 h to
give 4-(oxiran-2-yl)-1-tosyl-1H-indole-7-carbonitrile (0.29 g,
68%): LC/MS (Table 1, Method as) R.sub.t=2.36 min; MS m/z: 339
(M+H).sup.+.
Step C:
4-(1-Hydroxy-2-((2-hydroxyethyl)amino)ethyl)-1-tosyl-1H-indole-7-c-
arbonitrile
##STR00188##
[0997] To a suspension of
4-(oxiran-2-yl)-1-tosyl-1H-indole-7-carbonitrile (0.285 g, 0.841
mmol) in IPA (8 mL) was added TEA (0.586 mL, 4.21 mmol) followed by
2-aminoethanol (0.253 mL, 4.21 mmol). The mixture was heated at
about 75.degree. C. for about 3 h and concentrated under reduced
pressure. The residue was partitioned between EtOAc and water. The
mixture was extracted with EtOAc (2.times.10 mL). The combined
organic layers were dried over Na.sub.2SO.sub.4, filtered,
concentrated and dried under a vacuum pump to give
4-(1-hydroxy-2-((2-hydroxyethyl)amino)ethyl)-1-tosyl-1H-indole-7-carbonit-
rile (0.39 g, 94%): LC/MS (Table 1, Method as) R.sub.t=1.53 min; MS
m/z: 400 (M+H).sup.+.
Step D: tert-Butyl
(2-(7-cyano-1-tosyl-1H-indol-4-yl)-2-hydroxyethyl)(2-hydroxyethyl)carbama-
te
##STR00189##
[0999] To a solution of
4-(1-hydroxy-2-((2-hydroxyethyl)amino)ethyl)-1-tosyl-1H-indole-7-carbonit-
rile (0.336 g, 0.673 mmol) in EtOAc (3 mL) was added DIEA (0.176
mL, 1.01 mmol) followed by drop wise addition of a solution of
di-tert-butyl dicarbonate (0.220 g, 1.01 mmol) in EtOAc (1 mL) at
rt. THF (1 mL) was added to help solubilize the mixture and stirred
at rt for about 2 h. Additional DIEA (0.060 mL, 0.34 mmol) and
di-tert-butyl dicarbonate (0.073 g, 0.34 mmol) were added. The
mixture was stirred at rt for about another 2 h. The solvent was
removed under reduced pressure and purified by flash chromatography
(25-50% EtOAc/heptane) then by HPLC (Table 1, Method bd) to give
tert-butyl
(2-(7-cyano-1-tosyl-1H-indol-4-yl)-2-hydroxyethyl)(2-hydroxyethyl)carbama-
te (0.25 g, 74%): LC/MS (Table 1, Method as) R.sub.t=2.22 min; MS
m/z: 500 (M+H).sup.+.
Step E: tert-Butyl
2-(7-cyano-1-tosyl-1H-indol-4-yl)morpholine-4-carboxylate
##STR00190##
[1001] To a vial charged with
tert-butyl-(2-(7-cyano-1-tosyl-1H-indol-4-yl)-2-hydroxyethyl)(2-hydroxyet-
hyl)carbamate (0.50 g, 1.0 mmol) and PPh.sub.3 (0.315 g, 1.20 mmol)
in toluene (10 mL) at about 0.degree. C. was added TEA (0.367 mL,
2.63 mmol) followed by addition of DCAD (0.441 g, 1.20 mmol). The
solution was stirred at about 0.degree. C. for about 5 min and then
stirred at about rt for about 16 h. Additional PPh.sub.3 (0.131 g,
0.500 mmol) and DCAD (0.184 g, 0.500 mmol) were added at rt and the
mixture was stirred at about rt for about 6 h. The reaction mixture
was filtered and the filtrate was concentrated and purified by
flash chromatography (0-30% EtOAc/heptane) to give tert-butyl
2-(7-cyano-1-tosyl-1H-indol-4-yl)morpholine-4-carboxylate (0.41 g,
84%): LC/MS (Table 1, Method as) R.sub.t=2.72 min; MS m/z: 499
(M+H.sub.2O).sup.+.
Preparation #44:
2-Iodo-6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazine
##STR00191##
[1002] Step A:
2-Nitro-6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazine
##STR00192##
[1004] A mixture of
(1-(2-bromoethyl)-3-nitro-1H-pyrazol-5-yl)methanol (4.0 g, 12 mmol)
[Princeton] in NMP (7.7 mL) was heated at about 130.degree. C. for
about 16 h. The mixture was diluted with DCM and washed with water
and brine. The organic layer was dried, concentrated and purified
by chromatography on silica gel (0-5% MeOH/DCM) to give
2-nitro-6,7-dihydro-4H-pyrazolo[5,1-c][1, 4]oxazine (1 g, 49%):
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 6.88 (s, 1H), 4.83 (s,
2H), 4.24 (t, J=5.2 Hz, 2H), 4.13 (dd, J=5.9, 4.6 Hz, 2H).
Step B: 6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazin-2-amine
##STR00193##
[1006] A flask was charged with Pd/C (10 wt %, 0.755 g, 0.709 mmol)
under nitrogen before the addition of a solution of
2-nitro-6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazine (4.0 g, 24 mmol)
in EtOAc (59.1 mL) and MeOH (59.1 mL). The reaction stirred at rt
for about 16 h. The reaction mixture was filtered through a plug of
Celite.RTM. and the filtrate was concentrated under reduced
pressure to afford
6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazin-2-amine (3.2 g, 97%):
LC/MS (Table 1, Method as) R.sub.t=0.61 min; MS m/z: 140
(M+H).sup.+.
Step C: 2-Iodo-6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazine
##STR00194##
[1008] A 50 mL round-bottom flask was charged with
6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazin-2-amine (1.5 g, 11 mmol)
and concentrated HCl (2.43 mL, 29.6 mmol). The mixture was cooled
to about 0.degree. C. A solution of NaNO.sub.2 (0.707 g, 10.2 mmol)
in water (10 mL) was added and the reaction stirred for about 15
min. A solution of KI (2.86 g, 17.3 mmol) in water (10 mL) was
added carefully and the reaction was stirred at about 0.degree. C.
for about 1 h and stirred at rt for about 30 min. The reaction
mixture was diluted with EtOAc (20 mL) and water (20 mL) and then
separated from the aqueous layer. The solution was purified via
chromatography on silica gel (0-50% EtOAc/heptane) to give
2-iodo-6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazine (0.996 g, 37%):
LC/MS (Table 1, Method as) R.sub.t=1.58 min; MS m/z: 251
(M+H).sup.+.
Preparation #45: Methyl
4-chloro-1-tosyl-1H-pyrrolo[3,2-c]pyridine-7-carboxylate
##STR00195##
[1009] Step A: Methyl
1-tosyl-1H-pyrrolo[3,2-c]pyridine-7-carboxylate
##STR00196##
[1011] A round bottom flask was charged with methyl
1H-pyrrolo[3,2-c]pyridine-7-carboxylate (14 g, 79 mmol) and THF
(225 mL) [Pharmablock] and the solution was cooled to about
5.degree. C. followed by the addition of KHMDS (1M in THF, 79 mL,
79 mmol). The solution was then stirred for about 1 h followed by
the addition of a solution of 4-methylbenzene-1-sulfonyl chloride
(15.2 g, 79.0 mmol) in THF (25 mL). The mixture was stirred for
about 2 h at about 0 to 5.degree. C. followed by the addition of
saturated aqueous NH.sub.4Cl and DCM. The layers were separated and
the organic solution was dried over MgSO.sub.4, filtered,
concentrated under reduced pressure and purified by silica gel
chromatography (0-50% EtOAc/DCM) to give methyl
1-tosyl-1H-pyrrolo[3,2-c]pyridine-7-carboxylate (18.8 g, 72%):
LC/MS (Table 1, Method as) R.sub.t=2.10 min; MS m/z: 331
(M+H).sup.+.
Step B: 7-(Methoxycarbonyl)-1-tosyl-1H-pyrrolo[3,2-c]pyridine
5-oxide
##STR00197##
[1013] A round bottom flask was charged with methyl
1-tosyl-1H-pyrrolo[3,2-c]pyridine-7-carboxylate (16.0 g, 48.4 mmol)
and EtOAc (150 mL). To the reaction solution was added a solution
of 3-chlorobenzoperoxoic acid (14.2 g, 82 mmol) in EtOAc (80 mL)
and stirred at rt for about 16 h. To the reaction mixture was added
saturated aqueous Na.sub.2CO.sub.3 (50 mL) and the layers were
separated. The aqueous layer was extracted with EtOAc (2.times.30
mL) and DCM (2.times.30 mL). The combined extracts were dried over
Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure
to give a thick oil that was dried on a vacuum pump to give
7-(methoxycarbonyl)-1-tosyl-1H-pyrrolo[3,2-c]pyridine 5-oxide (11.6
g, 69%): LC/MS (Table 1, Method as) R.sub.t=1.73 min; MS m/z: 347
(M+H).sup.+.
Step C: Methyl
4-chloro-1-tosyl-1H-pyrrolo[3,2-c]pyridine-7-carboxylate
##STR00198##
[1015] A round bottom flask was charged with
7-(methoxycarbonyl)-1-tosyl-1H-pyrrolo[3,2-c]pyridine 5-oxide (11.6
g, 33.5 mmol) and PCl3 (26.5 mL, 285 mmol) and heated to about
60.degree. C. for about 2 h. The solution was cooled to rt and
slowly poured into ice water with stirring and the resulting
mixture was neutralized with the addition of saturated aqueous
Na.sub.2CO.sub.3. The aqueous mixture was extracted with EtOAc
(3.times.40 mL) and the combined extracts were dried over
Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure
to give methyl
4-chloro-1-tosyl-1H-pyrrolo[3,2-c]pyridine-7-carboxylate (8.47 g,
69%): LC/MS (Table 1, Method as) R.sub.t=2.46 min; MS m/z: 365
(M+H).sup.+.
Preparation #46:
7-Chloro-2-(1-methyl-1H-pyrazol-4-yl)thiazolo[5,4-c]pyridine-4-carboxamid-
e
##STR00199##
[1016] Step A: (E)-Ethyl 3-(2-bromothiazol-4-yl)acrylate
##STR00200##
[1018] A 1 L round-bottom flask was charged with ethyl
2-(triphenylphosphoranylidene)acetate (37.2 g, 107 mmol) in DCM
(130 mL) to give a colorless solution. The solution was cooled to
about 0.degree. C. and a solution of 2-bromothiazole-4-carbaldehyde
(20.5 g, 107 mmol) [ArkPharm] in DCM (500 mL) was added drop wise
via a dropping funnel. The reaction mixture was slowly warmed to rt
and stirred for about 2 h then concentrated under reduced pressure.
The mixture was taken up in Et.sub.2O (300 mL) and stirred at about
40.degree. C. for about 30 min. It was then cooled, filtered and
washed with Et.sub.2O (50 mL). The precipitate was discarded and
the filtrate was concentrated to half the volume. The precipitate
formed was collected via filtration to give the first batch of
product. The filtrate was concentrated and Et.sub.2O was added (60
mL), the mixture was stirred at rt for about 20 min and the newly
formed precipitate was filtered again to collect a second batch of
product. The filtrate from this batch was concentrated under
reduced pressure and purified silica gel chromatography (0-10%
EtOAc/heptane). The material thus obtained was recrystallized from
Et.sub.2O to give a third and final batch of product. All the
batches were combined to give white crystalline material, (E)-ethyl
3-(2-bromothiazol-4-yl)acrylate (20.1 g, 72%): LC/MS (Table 1,
Method as) R.sub.t=2.26 min; MS m/z: 262, 264 (M+H).sup.+.
Step B: (E)-Ethyl
3-(2-(1-methyl-1H-pyrazol-3-yl)thiazol-4-yl)acrylate
##STR00201##
[1020] A 500 mL round bottom flask was charged with
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
(20.7 g, 100 mmol), (E)-ethyl 3-(2-bromothiazol-4-yl)acrylate (20.1
g, 77.0 mmol), Na.sub.2CO.sub.3 (24.4 g, 230 mmol),
PdCl.sub.2(dppf) (5.61 g, 7.67 mmol) and (E)-ethyl
3-(2-bromothiazol-4-yl)acrylate (20.1 g, 77.0 mmol). To the solid
mixture was added THF (150 mL): MeOH (21.00 mL): water (21 mL) and
the suspension was degassed and purged with N.sub.2 for about 20
min. The reaction mixture was heated at about 75.degree. C. for
about 15 h. The reaction was filtered and washed with EtOAc (100
mL) and the filtrate was washed with water (70 mL). The aqueous
layer was extracted with EtOAc (2.times.70 mL) and the combined
organics were dried over MgSO.sub.4, filtered and concentrated. To
the residue was added DCM (50 mL) and heptane (150 mL). The entire
suspension was filtered, washed with acetone and isopropanol and
dried in a vacuum oven to give the first batch of product. The
filtrate was concentrated, dissolved in DCM (40 mL) and passed
through a silica gel plug (eluent: 50% EtOAc/heptane). The filtrate
was concentrated and refluxed in acetone (35 mL) and cooled. The
precipitate was filtered, washed with isopropanol, combined with
the first batch and dried in a vacuum oven at about 70.degree. C.
for about 16 h to give (E)-ethyl
3-(2-(1-methyl-1H-pyrazol-3-yl)thiazol-4-yl)acrylate (15.2 g, 75%):
LC/MS (Table 1, Method as) R.sub.t=1.94 min; MS m/z: 264
(M+H).sup.+.
Step C: (E)-3-(2-(1-Methyl-1H-pyrazol-4-yl)thiazol-4-yl)acrylic
acid
##STR00202##
[1022] In a 20 mL reaction vial, (E)-ethyl
3-(2-(1-methyl-1H-pyrazol-4-yl)thiazol-4-yl)acrylate (15.2 g, 57.7
mmol) and LiOH (4.15 g, 173 mmol) in MeOH (60 mL): water (12 mL)
were added. The reaction mixture was stirred at about 40.degree. C.
for about 2 h. The reaction mixture was concentrated, diluted with
water (50 mL) and washed with DCM (50.times.3 mL). The aqueous
layer was acidified with 1N HCl until no more precipitate formed.
The precipitate was collected via filtration and dried in a vacuum
oven at about 60.degree. C. for about 16 h to give
(E)-3-(2-(1-methyl-1H-pyrazol-4-yl)thiazol-4-yl)acrylic acid (12.3
g, 91%): .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 12.42 (s, 1H),
8.38 (s, 1H), 7.94 (s, 2H), 7.56 (s, 1H), 6.56 (s, 1H), 3.90 (s,
3H).
Step D: (E)-3-(2-(1-Methyl-1H-pyrazol-4-yl)thiazol-4-yl)acryloyl
azide
##STR00203##
[1024] To a suspension of
(E)-3-(2-(1-methyl-1H-pyrazol-4-yl)thiazol-4-yl)acrylic acid (11.2
g, 47.4 mmol) in acetone (170 mL) was added TEA (6.61 mL, 47.4
mmol) and the mixture was cooled in an ice bath. Isobutyl
chloroformate (6.22 mL, 47.4 mmol) was added drop wise. After about
3.5 h a solution of NaN.sub.3 (3.85 g, 59.2 mmol) in water (15 mL)
was added carefully and the reaction was stirred for about 3 h at
about 0.degree. C. The reaction mixture was poured over ice and
stirred for about 5 min, filtered and washed with water (50 mL).
The precipitate was dried in a vacuum oven at about 60.degree. C.
for about 16 h to give
(E)-3-(2-(1-methyl-1H-pyrazol-4-yl)thiazol-4-yl)acryloyl azide (9.6
g, 78%): LC/MS (Table 1, Method as) R.sub.t=1.91 min; MS m/z: 261
(M+H).sup.+.
Step E:
2-(1-methyl-1H-pyrazol-4-yl)thiazolo[5,4-c]pyridin-4(5H)-one
##STR00204##
[1026] A 250 mL 3-neck round-bottomed flask was charged with
tributylamine (6.10 mL, 25.6 mmol) in diphenylether (30 mL). The
reaction mixture was heated to about 190.degree. C. and a solution
of (E)-3-(2-(1-methyl-1H-pyrazol-4-yl)thiazol-4-yl)acryloyl azide
(5.60 g, 21.5 mmol) in diphenylether (80 mL) was added carefully
and the reaction was stirred for about 5 h at about 190.degree. C.
The reaction mixture was cooled and poured onto petroleum ether
(300 mL) and stirred for about 5 min and filtered. The precipitate
was dried in a vacuum oven at about 70.degree. C. for about 30 min.
The material was suspended in Et.sub.2O (100 mL) and heated at
about 50.degree. C. for about 20 min. It was then filtered and
washed with cold Et.sub.2O. The precipitate was dried in a vacuum
oven at about 70.degree. C. for about 10 h to give
2-(1-methyl-1H-pyrazol-4-yl)thiazolo[5,4-c]pyridin-4(5H)-one (3.8
g, 76%): LC/MS (Table 1, Method as) R.sub.t=1.13 min; MS m/z: 233
(M+H).sup.+.
Step F:
7-Chloro-2-(1-methyl-1H-pyrazol-4-yl)thiazolo[5,4-c]pyridin-4(5H)--
one
##STR00205##
[1028] In a 250 mL round-bottom flask
2-(1-methyl-1H-pyrazol-4-yl)thiazolo[5,4-c]pyridin-4(5H)-one (3.7
g, 16 mmol) in MeCN (80 mL) was added to give a suspension. The
reaction mixture was heated with stirring to about 80.degree. C. A
solution of NCS (3.19 g, 23.9 mmol)) in MeCN (25 mL) was added drop
wise via a dropping funnel, and the reaction was stirred for about
5 h at about 80.degree. C. The mixture was diluted with water (100
mL), filtered and washed with water (40 mL). The precipitate was
dried in a vacuum oven at about 70.degree. C. for about 16 h to
give
7-chloro-2-(1-methyl-1H-pyrazol-4-yl)thiazolo[5,4-c]pyridin-4(5H)-one
(3.55 g, 84%): LC/MS (Table 1, Method as) R.sub.t=1.27 min; MS m/z:
267 (M+H).sup.+.
Step G:
4-Bromo-7-chloro-2-(1-methyl-1H-pyrazol-4-yl)thiazolo[5,4-c]pyridi-
ne
##STR00206##
[1030] In a 100 mL 3-neck round-bottom flask a mixture of
7-chloro-2-(1-methyl-1H-pyrazol-4-yl)thiazolo[5,4-c]pyridin-4(5H)-one
(1.30 g, 4.87 mmol) and POBr.sub.3 (3.91 g, 13.6 mmol) was heated
to about 70.degree. C. for about 10 min then heated to to about
120.degree. C. for about 45 min. Additional POBr.sub.3 (1.40 g,
4.87 mmol) was added and heated for about 50 min. The mixture was
cooled on an ice bath and to it was added carefully a mixture of
crushed ice and water (40 mL). The mixture was stirred at rt for
about 16 h. To the suspension was added DCM (60 mL) and stirred for
about 30 min, then filtered to remove some black solids. The DCM
layer was separated and aqueous layer was extracted with DCM
(2.times.20 mL). The combined organic layers were dried over
MgSO.sub.4, filtered and adsorbed on silica gel (4-6 g). The
material was purified by silica gel chromatography (1-3%
EtOAc/heptane) to give
4-bromo-7-chloro-2-(1-methyl-1H-pyrazol-4-yl)thiazolo[5,4-c]pyridine
(0.85 g, 53%): LC/MS (Table 1, Method as) R.sub.t=2.20 min; MS m/z:
331 (M+H).sup.+.
Step
H:7-Chloro-2-(1-methyl-1H-pyrazol-4-yl)thiazolo[5,4-c]pyridine-4-carb-
onitrile
##STR00207##
[1032] In a 50 mL round-bottom flask,
4-bromo-7-chloro-2-(1-methyl-1H-pyrazol-4-yl)thiazolo[5,4-c]pyridine
(0.770 g, 2.13 mmol), Zn (CN).sub.2 (0.168 g, 1.44 mmol) and
Pd(PPh.sub.3).sub.4 (0.174 g, 0.151 mmol) in DMF (10 mL) were
added. The flask was degassed and purged with nitrogen then heated
thermally under nitrogen at about 110.degree. C. to 120.degree. C.
for about 50 min. The reaction mixture was diluted with water (25
mL) and stirred for about 5 min, filtered and washed with water (6
mL). The precipitate was dried in a vacuum oven at about 70.degree.
C. for about 16 h to give crude
7-chloro-2-(1-methyl-1H-pyrazol-4-yl)thiazolo[5,4-c]pyridine-4-carbonitri-
le (0.67 g, 98%). To a flask charged with NaOH (1M aqueous
solution, 7.29 mL, 7.29 mmol) in MeOH (12 mL) was added
H.sub.2O.sub.2 (30% aqueous solution, 1.24 mL, 12.2 mmol). This
solution was added to a flask containing
7-chloro-2-(1-methyl-1H-pyrazol-4-yl)thiazolo[5,4-c]pyridine-4-carbonitri-
le (0.670 g, 2.43 mmol) and stirred at about 30.degree. C. for
about 5 min. The reaction mixture was diluted with water (51 mL)
and stirred at rt for about 5 min and filtered. The precipitate was
triturated with Et.sub.2O, filtered and dried in a vacuum oven for
about 16 h to give
7-chloro-2-(1-methyl-1H-pyrazol-4-yl)thiazolo[5,4-c]pyridine-4-carboxamid-
e (0.597 g, 84%): LC/MS (Table 1, Method as) R.sub.t=1.58 min; MS
m/z: 294 (M+H).sup.+.
Preparation #47: Methyl
4-((1R,3R)-3-((tert-butoxycarbonyl)amino)cyclopentyl)-1-tosyl-1H-indole-7-
-carboxylate
##STR00208##
[1033] Step A: Methyl
4-(3-oxocyclopent-1-en-1-yl)-1-tosyl-1H-indole-7-carboxylate
##STR00209##
[1035] A flask was charged with methyl
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-tosyl-1H-indole-7-carbo-
xylate (1.74 g, 3.82 mmol, prepared using A from Preparation #1,
step C with bis(pinacolato)diboron) in 2-methyl-THF(18.64 mL) and
water (12.43 mL). The mixture was cooled to about 10.degree. C. in
a cold water bath. NaIO.sub.4 (1.23 g, 5.73 mmol) was added, the
reaction was stirred for about 30 min and aqueous 1M HCl (8.41 mL,
8.41 mmol) was added drop wise. The mixture was stirred at rt for
about 16 h. Additional 2-methyl-THF (50 mL) was added, the aqueous
layer was separated and the organic layer was washed with 10%
aqueous Na.sub.2S.sub.2O.sub.3 (2.times.30 mL), saturated aqueous
NaHCO.sub.3 (30 mL) and brine (20 mL). The organic layer was then
dried over Na.sub.2SO.sub.4, filtered and concentrated to afford
crude (7-(methoxycarbonyl)-1-tosyl-1H-indol-4-yl)boronic acid. In a
100 mL round-bottom flask the crude
(7-(methoxycarbonyl)-1-tosyl-1H-indol-4-yl)boronic acid (1.59 g,
4.26 mmol) in dioxane (17 mL) was added. A solution of
Cs.sub.2CO.sub.3 (3.47 g, 10.7 mmol) in water (4.26 mL) was added,
the mixture was degassed with nitrogen followed by the addition of
PdCl.sub.2(PPh.sub.3).sub.2 (0.209 g, 0.298 mmol) and
3-bromocyclopent-2-enone (1.4 mL, 12.8 mmol) under inert
atmosphere. The mixture was heated at about 80.degree. C. for about
3 h then cooled to rt and added DCM (100 mL) and water (50 mL). The
layers were separated and the aqueous layer was extracted with DCM
(2.times.50 mL). The combined organics were dried over MgSO.sub.4.
The solvent was removed in vacuo and the residue was purified using
silica gel chromatography (0-60% EtOAc/heptane) to afford methyl
4-(3-oxocyclopent-1-en-1-yl)-1-tosyl-1H-indole-7-carboxylate (1.2
g, 69%): .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 7.92 (d, J=3.9
Hz, 1H), 7.71 (d, J=7.9 Hz, 1H), 7.67-7.62 (m, 2H), 7.58 (d, J=7.9
Hz, 1H), 7.39-7.31 (m, 2H), 7.23 (d, J=3.9 Hz, 1H), 6.67 (t, J=1.8
Hz, 1H), 3.83 (s, 3H), 3.12 (dt, J=6.9, 1.9 Hz, 2H), 2.47 (dd,
J=4.9, 2.5 Hz, 2H), 2.33 (s, 3H).
Step B: (R)-methyl
4-(3-oxocyclopentyl)-1-tosyl-1H-indole-7-carboxylate
##STR00210##
[1037] In a 40 mL reaction vial,
(2S,5S)-5-benzyl-3-methyl-2-(5-methylfuran-2-yl)imidazolidin-4-one
(0.190 g, 0.703 mmol) and methyl
4-(3-oxocyclopent-1-en-1-yl)-1-tosyl-1H-indole-7-carboxylate (3.05
g, 7.45 mmol) in THF (5.67 mL) were added. The mixture was cooled
to about 0.degree. C. and degassed with nitrogen. Di-tert-butyl
2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate (1.05 g, 3.40
mmol) and trichloroacetic acid (0.071 mL, 0.70 mmol) were added
under inert atmosphere. The reaction mixture was stirred at about
4.degree. C. for about 16 h. Additional di-tert-butyl
2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate (0.420 g, 1.36
mmol) was added, and reaction was stirred with cooling for about 72
h. The crude material was adsorbed onto silica gel and purified via
silica gel chromatography (0-45% EtAOc/heptane) to afford
(R)-methyl 4-(3-oxocyclopentyl)-1-tosyl-1H-indole-7-carboxylate (1
g, 79%). .sup.1H NMR (400 MHz, CDCl.sub.3-d) .delta. 7.67-7.58 (m,
2H), 7.58-7.45 (m, 2H), 7.23-7.10 (m, 3H), 6.75 (d, J=4.2 Hz, 1H),
3.91 (s, 3H), 3.73 (tdd, J=10.1, 7.6, 6.0 Hz, 1H), 2.73-2.61 (m,
1H), 2.51-2.24 (m, 7H), 2.16-1.98 (m, 1H).
Step C: Methyl
4-((1R,3S)-3-hydroxycyclopentyl)-1-tosyl-1H-indole-7-carboxylate
##STR00211##
[1039] In a 200 mL round-bottom flask, (R)-methyl
4-(3-oxocyclopentyl)-1-tosyl-1H-indole-7-carboxylate (1.60 g, 3.89
mmol) in THF (32.4 mL) was added. The solution was cooled to about
-78.degree. C. L-Selectride (7.78 mL, 7.78 mmol) was added drop
wise over about 20 min and the mixture was stirred for about 16 h.
The reaction mixture was cooled on an ice bath, saturated aqueous
NH.sub.4Cl (60 mL) was added drop wise then EtOAc (100 mL) and
water (20 mL) were added. The organic layer was separated, washed
with brine, dried over Na.sub.2SO.sub.4, filtered, concentrated and
purified via silica gel chromatography (0-65% EtOAc/heptane). The
residue obtained was purified using chiral chromatography (Table 2,
Method 19) to give methyl
4-((1R,3S)-3-hydroxycyclopentyl)-1-tosyl-1H-indole-7-carboxylate
(0.36 g, 22%): LC/MS (Table 1, Method a) R.sub.t=2.21 min; MS m/z:
431 (M+H.sub.2O).sup.+.
Step D: Methyl
4-((1R,3R)-3-((tert-butoxycarbonyl)amino)cyclopentyl)-1-tosyl-1H-indole-7-
-carboxylate
##STR00212##
[1041] In a 40 mL reaction vial, methyl
4-((1R,3S)-3-hydroxycyclopentyl)-1-tosyl-1H-indole-7-carboxylate
(0.35 g, 0.85 mmol) and PPh.sub.3 (0.266 g, 1.02 mmol) in THF (3.4
mL) were added. The solution was cooled to about 10.degree. C.,
DIEA (0.148 mL, 0.846 mmol) was added followed by drop wise
addition of DIAD (0.197 mL, 1.02 mmol) and the reaction mixture was
stirred for about 30 min. Diphenyl phosphorazidate (0.219 mL, 1.02
mmol) was added drop wise and stirred at rt for about 3 h. A
solution of PPh.sub.3 (0.289 g, 1.10 mmol) in THF (0.6 mL) was
added drop wise and the mixture was stirred for about 18 h. Water
(0.183 mL, 10.2 mmol) was added and the mixture was heated at about
45.degree. C. for about 72 h. To the reaction mixture was added DCM
(10.7 mL, 166 mmol) and a solution of potassium hydrogenphosphate
(0.737 g, 4.23 mmol) in water (2.14 mL, 119 mmol). A solution of
di-tert-butyl dicarbonate (0.393 mL, 1.69 mmol) in DCM (2.14 mL,
33.2 mmol) was added drop wise and stirred at rt for about 1 h.
Brine (2 mL) was added, the organic layer was separated and washed
with brine (3 mL), dried over Na.sub.2SO.sub.4, filtered,
concentrated and purified via silica gel chromatography (0-40%
EtOAc/heptane) to afford methyl
4-((1R,3R)-3-((tert-butoxycarbonyl)amino)cyclopentyl)-1-tosyl-1H-indole-7-
-carboxylate (0.396 g, 59%): LC/MS (Table 1, Method a) R.sub.t=2.72
min; MS m/z: 530 (M+H.sub.2O).sup.+.
Preparation #48: tert-Butyl
3-((7-carbamoyl-2-(5-(morpholinomethyl)pyridin-2-yl)-1H-indol-4-yl)(methy-
l)amino)azetidine-1-carboxylate
##STR00213##
[1043] To a mixture of 4-((6-bromopyridin-3-yl)methyl)morpholine
(0.300 g, 1.17 mmol) in THF (5 mL) was added n-BuLi (1.17 mL, 2.92
mmol). The mixture was stirred at about -78.degree. C. for about 1
h, and then tributylchlorostannane (0.949 g, 2.92 mmol) was slowly
added. The mixture was allowed to warm to rt over about 1 h, and a
saturated solution of NH.sub.4Cl was added. The mixture was
extracted with EtOAc and the combined organic layers were dried
over Na.sub.2SO.sub.4, filtered and concentrated in vacuo to yield
crude 4-((6-(tributylstannyl)pyridin-3-yl)methyl)morpholine. A
solution containing the tert-butyl
3-((7-carbamoyl-2-iodo-1H-indol-4-yl)(methyl)amino)azetidine-1-carboxylat-
e (0.300 g, 0.638 mmol, preparation #40) in DMF (2 mL) was treated
with LiCl (0.270 g, 6.38 mmol), PdCl.sub.2(dppf)-CH.sub.2Cl.sub.2
adduct (0.156 g, 0.191 mmol) and
4-((6-(tributylstannyl)pyridin-3-yl)methyl)morpholine (0.894 g,
1.91 mmol). The mixture was heated at about 100.degree. C. for
about 16 h, cooled, filtered through Celite.RTM. and partitioned
between EtOAc and water. The organic phase was washed with brine,
dried over Na.sub.2SO.sub.4, filtered and concentrated. The residue
was purified by silica gel chromatography (0-5% MeOH/DCM) to afford
tert-butyl
3-((7-carbamoyl-2-(5-(morpholinomethyl)pyridin-2-yl)-1H-indol-4-yl)(methy-
l)amino)azetidine-1-carboxylate (0.172 g, 11%): LCMS (Table 1,
Method av) R.sub.t=1.24 min; MS m/z: 521 (M+H).sup.+.
Preparation #49: tert-Butyl
6-(7-carbamoyl-1H-pyrrolo[2,3-c]pyridin-4-yl)-2,3-dihydro-1,4-oxazepine-4-
(7H)-carboxylate
##STR00214##
[1045] To a solution of tert-butyl
6-(7-cyano-1-tosyl-1H-pyrrolo[2,3-c]pyridin-4-yl)-2,3-dihydro-1,4-oxazepi-
ne-4(7H)-carboxylate (0.973 g, 1.97 mmol, prepared using AG from
tert-butyl
6-(((trifluoromethyl)sulfonyl)oxy)-2,3-dihydro-1,4-oxazepine-4(7H)-carbox-
ylate (Preparation #W.1) with
4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) and
Preparation #AH.1) in EtOH (3.93 mL) at about 0.degree. C. was
added NaOH (1N aqueous solution, 7.87 mL, 7.87 mmol) followed by
H.sub.2O.sub.2 (30% aqueous solution, 1.12 mL, 9.84 mmol). After
about 10 min the ice bath was removed. After about 1 h additional
NaOH (1N aqueous solution, 7 mL, 7 mmol) and H.sub.2O.sub.2 (30%
aqueous solution, 1.00 mL, 8.82 mmol) and DCM (3 mL) were added.
The reaction mixture was allowed to stir for about 1 h and
concentrated down to about 15 mL and diluted with water (10 mL) and
DCM (20 mL). The suspension was filtered to remove any solids. The
DCM layer was separated, dried over MgSO.sub.4, filtered,
concentrated and purified via silica gel chromatography to give
tert-butyl
6-(7-carbamoyl-1H-pyrrolo[2,3-c]pyridin-4-yl)-2,3-dihydro-,4-oxazepine-4(-
7H)-carboxylate (0.138 g, 20%): LC/MS (Table 1, Method as)
R.sub.t=1.90 min; MS m/z: 359 (M+H).sup.+.
General Procedure A: Suzuki Reaction of an Aryl or Heteroaryl
Halide with an Aryl or Heteroaryl Boronic Acid or Boronate
[1046] To a mixture of an aryl halide (preferably 1 equiv), a
boronic acid or boronate ester (1 to 2 equiv, preferably 1.1
equiv), and an inorganic base (such as, KF, Na.sub.2CO.sub.3,
K.sub.2CO.sub.3 or Cs.sub.2CO.sub.3, preferably Na.sub.2CO.sub.3 or
Cs.sub.2CO.sub.3) (1.1 to 16 equiv, preferably 2 equiv) in a
solvent (such as THF, DME, DMF, 1,4-dioxane, 1,4-dioxane/water,
DME/water, 1,4-dioxane/water, toluene/EtOH/water,
1,4-dioxane/EtOH/water or THF/MeOH/water preferably THF/MeOH/water,
1,4-dioxane/water, DME/water or 1,4-dioxane/EtOH/water) is added a
palladium catalyst (for example Pd(OAc).sub.2, Pd.sub.2dba.sub.3,
Pd(PPh.sub.3).sub.4, bis(acetato)triphenylphosphinepalladium(II),
polymer-bound FibreCat.TM. 1032, SiliaCat DPP-Pd, PdCl.sub.2(dppf),
(1,1'-bis(diphenylphosphino)ferrocene)dichloropalladium(II), or
Pd(PPh.sub.3).sub.2C.sub.2; preferably PdCl.sub.2(dppf),
(1,1'-bis(diphenylphosphino)ferrocene)dichloropalladium(II), or
SiliaCat DPP-Pd 0.01 to 0.20 equiv, preferably 0.1 equiv) and a
ligand (for example tricyclohexylphosphine,
tri-tert-butyl-phosphine; preferably none or
tricyclohexylphosphine; 0.01-1.0 equiv, preferably 0.16 equiv) is
added optionally. The mixture is heated at about 40 to 120.degree.
C. (preferably about 70-85.degree. C.) for about 1 to 48 h
(preferably about 24 h) thermally, or at about 100 to 200.degree.
C. (preferably about 120 to 150.degree. C.) for about 5 to 60 min
(preferably about 20 to 45 min) in a microwave (preferably 5 min
ramp time, 300 Watts max power, 250 psi max pressure). The mixture
is allowed to cool to rt and is worked up using one of the
following methods. Method 1. For reactions containing water, the
mixture may be diluted with an organic solvent (such as DCM or
EtOAc). The layers are separated, the organic solution is
optionally washed with water and/or brine, dried over anhydrous
MgSO.sub.4 or Na.sub.2SO.sub.4, filtered, and the solvent is
removed under reduced pressure to give the desired compound. Method
2. The mixture is concentrated under reduced pressure. Method 3.
The catalyst is removed by filtration and the filtrate is
concentrated under reduced pressure.
[1047] Illustration of General Procedure A
Preparation #A.1: 4-(3-Aminophenyl)-1H-indole-7-carboxamide
##STR00215##
[1049] A vessel was charged with 4-bromo-1H-indole-7-carboxamide
(2.08 g, 8.70 mmol, Preparation #2),
3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (2.10 g,
9.57 mmol), sodium carbonate (2.77 g, 26.1 mmol),
[1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.637
g, 0.870 mmol) and purged with nitrogen. A mixture of THF (71.4
mL), MeOH (10 mL), and water (10 mL) was added and the reaction was
stirred at about 70.degree. C. for about 24 h. The mixture was
filtered through Celite.RTM., the solvent was removed under reduced
pressure and the residue was purified by column chromatograph on
silica gel eluted with MeOH/DCM (0-10%) to provide a solid. The
solid was triturated with ether to provide
4-(3-aminophenyl)-1H-indole-7-carboxamide (1.37 g, 63): LC/MS
(Table 1, Method f) R.sub.t=0.76 min; MS m/z: 293
(M+MeCN+H).sup.+.
TABLE-US-00004 TABLE A.1 Examples prepared from
N-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)
acrylamide (prepared using E from 2-methyl-3-
(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline and acryloyl
chloride) using General Procedure A R.sub.t min m/z Exam- (Table 1,
ESI+ Aryl Bromide Product ple # Method) (M + H).sup.+ Btk IC.sub.50
4-bromo-2-(3,5- dimethylisoxazol-4-yl)- 1H-indole-7-carboxamide
(prepared using A from Preparation #1 and 3,5- dimethylisoxazole-4-
boronic acid pinacol ester) ##STR00216## A.1.1 2.84 (d) 415 B
4-bromo-2-(1-(tetrahydro- 2H-pyran-2-yl)-1H-
pyrazol-5-yl)-1H-indole- 7-carboxamide (prepared using A from
Preparation #1 and 1-(2- tetrahydropyranl)-1H- pyrazole-5-boronic
acid pinacol ester) ##STR00217## A.1.2 2.87 (p) 470 A
4-bromo-2-(3,5-dimethyl- 1H-pyrazol-4-yl)-1H- indole-7-carboxamide
(prepared using A from Preparation #1 and 3,5- dimethylpyrazole-4-
boronic acid, pinacol ester) ##STR00218## A.1.3 2.51 (d) 414 B
4-bromo-2-(1-isopropyl- 1H-pyrazol-4-yl)-1H- indole-7-carboxamide
(prepared using A from Preparation #1 and 1-
isopropyl-1H-pyrazole-4- boronic acid pinacol ester) ##STR00219##
A.1.4 2.85 (d) 428 A 4-bromo-2-(1,3-dimethyl- 1H-pyrazol-4-yl)-1H-
indole-7-carboxamide (prepared using A from Preparation #1 and 1,3-
dimethyl-1H-pyrazole-4- boronic acid, pinacol ester) ##STR00220##
A.1.5 2.66 (d) 414 A 4-bromo-2-(1-ethyl-1H-
pyrazol-4-yl)-1H-indole- 7-carboxamide (prepared using A from
Preparation #1 and 1-ethyl-1H- pyrazole-4-boronic acid, pinacol
ester) ##STR00221## A.1.6 2.74 (d) 414 A 4-bromo-2-(1-isobutyl-
1H-pyrazol-4-yl)-1H- indole-7-carboxamide (prepared using A from
Preparation #1 and 1- isobutyl-4-(4,4,5,5- tetramethyl-1,3,2-
dioxaborolan-2-yl)-1H- pyrazole) ##STR00222## A.1.7 2.98 (d) 442 A
4-bromo-2-(1-(2- morpholinoethyl)-1H- pyrazol-4-yl)-1H-indole-
7-carboxamide (prepared using A from Preparation #1 and 1-(2-
morpholinoethyl)-1H - pyrazole-4-boronic acid, pinacol ester)
##STR00223## A.1.8 2.28 (d) 499 A 4-bromo-1H-indole-7 - carboxamide
(Preparation #2) ##STR00224## A.1.9 1.31 (f) 320 B
4-bromo-2-(pyrimidin-5- yl)-1H-indole-7- carboxamide (prepared
using A from Preparation #1 and Pyrimidine-5- boronic acid pinacol
ester) ##STR00225## A.1.10 2.56 (d) 398 A 4-bromo-2-(1-methyl-1H-
pyrazol-5-yl)-1H-indole- 7-carboxamide (prepared using A from
Preparation #1 and 1-methyl-1H- pyrazole-5-boronic acid pinacol
ester) ##STR00226## A.1.11 2.66 (d) 400 A 4-bromo-2-(pyridin-4-yl)-
1H-indole-7-carboxamide (prepared using A from Preparation #1 and
4- pyridineboronic acid pinacol ester) ##STR00227## A.1.12 2.22 (d)
397 A 4-bromo-2-(2- methoxypyridin-4-yl)-1H- indole-7-carboxamide
(prepared using A from Preparation #1 and 2- methoxy-pyridine-4-
boronicacid) ##STR00228## A.1.13 2.70 (d) 427 A 4-bromo-2-(3-
cyanophenyl)-1H-indole- 7-carboxamide (prepared using A from
Preparation #1 and 3-cyanophenyl- boronic acid) ##STR00229## A.1.14
3.03 (d) 421 A 2-(3-acetamidophenyl)-4- bromo-1H-indole-7-
carboxamide (prepared using A from Preparation #1 and 3-acetamido-
phenylboronic acid) ##STR00230## A.1.15 2.79 (d) 453 A
4-bromo-2-(6- fluoropyridin-3-yl)-1H- indole-7-carboxaimide
(prepared using A from Preparation #1 and 2-
fluoropyridine-5-boronic acid) ##STR00231## A.1.16 2.87 (d) 415 A
4-bromo-2-(2- fluoropyridin-3-yl)-1H- indole-7-carboxamide
(prepared using A from Preparation #1 and 2-
fluoropyridine-3-boronic acid) ##STR00232## A.1.17 2.86 (d) 415 A
4-bromo-2-(2- methoxypyridin-3-yl)-1H- indole-7-carboxamide
(prepared using A from Preparation #1 and 2- methoxy-pyridine-3-
boronic acid pinacol ester) ##STR00233## A.1.18 2.97 (d) 427 A
methyl 3-(4-bromo-7- carbamoyl-1H-indol-2- yl)benzoate (prepared
using A from Preparation #1 and 3-methoxy- carbonylphenylboronic
acid) ##STR00234## A.1.19 2.77 (o) 454 A methyl 4-(4-bromo-7-
carbamoyl-1H-indol-2- yl)benzoate (prepared using A from
Preparation #1 and 4- methoxy- carbonylphenylboronic acid)
##STR00235## A.1.20 2.77 (o) 454 A 4-bromo-2-(2,3-
dihydrobenzofuran-5-yl)- 1H-indole-7-carboxamide (prepared using A
from Preparation #1 and 2,3- dihydrobenzofuran-5- boronic acid)
##STR00236## A.1.21 2.75 (o) 438 A 4-bromo-2-(3- methoxyphenyl)-1H-
indole-7-carboxamide (prepared using A from Preparation #1 and 3-
methoxy-phenylboronic acid) ##STR00237## A.1.22 2.78 (o) 426 A
4-bromo-2-(4- methoxyphenyl)-1H- indole-7-carboxamide (prepared
using A from Preparation #1 and 4- methoxy-phenylboronic acid)
##STR00238## A.1.23 2.76 (o) 426 A 4-bromo-2-(6-
methylpyridin-3-yl)-1H- indole-7-carboxamide (prepared using A from
Preparation #1 and 6- methylpyridine-3-boronic acid) ##STR00239##
A.1.24 2.36 (d) 411 A 4-bromo-2-(3- carbamoylphenyl)-1H-
indole-7-carboxamide (prepared using A from Preparation #1 and 3-
amino- carbonylphenylboronic acid) ##STR00240## A.1.25 2.68 (d) 439
A 4-bromo-2-(3- fluorophenyl)-1H-indole- 7-carboxamide (prepared
using A from Preparation #1 and 3- fluorophenylboronic acid)
##STR00241## A.1.26 2.82 (o) 414 A 4-bromo-2-(3-
(dimethylamino)phenyl)- 1H-indole-7-carboxamide (prepared using A
from Preparation #1 and 3- (N,N- dimethylamino) phenylboronic acid)
##STR00242## A.1.27 2.24 (o) 439 A 4-bromo-2-(2-methyl-5-
(pyrrolidin-1- ylsulfonly)phenyl)-1H- indole-7-carboxamide
(prepared using A from Preparation #1 and 2-
methyl-5-(pyrrolidin-1- ylsulfonyl)phenylboronic acid) ##STR00243##
A.1.28 2.76 (o) 543 B 4-bromo-2-(2- fluorophenyl)-1H-indole-
7-carboxamide (prepared using A from Preparation #1 and 2-
fluorophenylboronic acid) ##STR00244## A.1.29 2.80 (o) 414 A
4-bromo-2-(6- morpholinopyridin-3-yl)- 1H-indole-7-carboxamide
(prepared using A from Preparation #1 and 6-
(morpholin-4-yl)pyridine- 3-boronic acid pinacol ester)
##STR00245## A.1.30 2.64 (d) 482 A 4-bromo-2-(4-(4-
methylpiperazine-1- carbonyl)phenyl)-1H- indole-7-carboxamide
(prepared using A from Preparation #1 and 3-(4- methyl-1-
piperazinylcarbonyl) benzeneboronic acid pinacol ester)
##STR00246## A.1.31 2.34 (d) 522 A 4-bromo-2-(4-
fluorophenyl)-1H-indole- 7-carboxamidc (prepared using A from
Preparation #1 and 4- fluorophenylboronic acid) ##STR00247## A.1.32
2.80 (o) 414 A 4-bromo-2-phenyl-1H- indole-7-carboxamide (prepared
using A from Preparation #1 and phenylboronic acid pinacol ester)
##STR00248## A.1.33 2.77 (o) 396 A 4-bromo-2-(2-
(methylsulfonyl)phenyl)- 1H-indole-7-carboxamide (prepared using A
from Preparation #1 and 2- (methylsulfonyl) phenylboronic acid)
##STR00249## A.1.34 2.85 (d) 474 B 4-bromo-2-(4-
(dimethylcarbamoyl) phenyl)-1H-indole-7- carboxamide (prepared
using A from Preparation #1 and 4-(N,N- dimethylaminocarbonyl)
phenylboronic acid) ##STR00250## A.1.35 2.76 (d) 467 A
4-bromo-2-(pyridin-3-yl)- 1H-indole-7-carboxamide (prepared using A
from Preparation #1 and 3- pyridineboronic acid pinacol ester)
##STR00251## A.1.36 1.71 (a) 397 A 4-bromo-2-(4- (morpholine-4-
carbonyl)phenyl)-1H- indole-7-carboxamide (prepared using A from
Preparation #1 and 4- (morpholine-4- carbonyl)phenylboronic acid
pinacol ester) ##STR00252## A.1.37 2.74 (d) 509 A 4-bromo-2-(4-
(pyrrolidine-1- carbonyl)phenyl)-1H- indole-7-carboxamide (prepared
using A from Preparation #1 and 4-(1- pyrrolidinylcarbonyl)
benzeneboronic acid pinacol ester) ##STR00253## A.1.38 2.87 (d) 493
A 4-bromo-2-(4-(4- methylpiperazine-1- carbonyl)phenyl)-1H-
indole-7-carboxamide (prepared using A from Preparation #1 and
4-(4- methyl-1- piperazinylcarbonyl) benzeneboronic acid pinacol
ester) ##STR00254## A.1.39 2.31 (d) 522 A 4-bromo-2-(4-
(methylsulfonyl)phenyl)- 1H-indole-7-carboxamide (prepared using A
from Preparation #1 and 4- (methylsulfonyl) phenylboronic acid)
##STR00255## A.1.40 2.49 (o) 474 A 4-bromo-2-(6-
methoxypyridin-3-yl)-1H- indole-7-carboxamide (prepared using A
from Preparation #1 and 2-methoxy-5- pyridineboronic acid)
##STR00256## A.1.41 2.89 (d) 427 A 4-bromo-2-(4-
cyanophenyl)-1H-indole- 7-carboxamide (prepared using A from
Preparation #1 and 4- cyanophenylboronic acid) ##STR00257## A.1.42
3.01 (d) 421 A 4-bromo-2-(2- methoxyphenyl)-1H-
indole-7-carboxamide (prepared using A from Preparation #1 and 2-
methoxy-phenylboronic acid) ##STR00258## A.1.43 3.10 (d) 426 A
4-bromo-2-(4- (morpholinomethyl) phenyl)-1H-indole-7- carboxamide
(prepared using A from Preparation #1 and 4-(4- morpholinylmethyl)-
benzeneboronic acid pinacol ester) ##STR00259## A.1.44 2.37 (d) 495
A 4-bromo-2-(4- carbamoylphenyl)-1H- indole-7-carboxamide (prepared
using A from Preparation #1 and 4- aminocarbonyl- phenylboronic
acid) ##STR00260## A.1.45 2.61 (d) 439 A
TABLE-US-00005 TABLE A.2 Examples prepared from
N-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)phenyl)thiazole-2-carboxamide (Preparation #4) using General
Procedure A R.sub.t min (Table 1, m/z ESI+ Aryl Bromide Product
Example # Method) (M + H).sup.+ Btk IC.sub.50
4-bromo-2-(1-methy1-6- oxo-1,6-dihydropyridin-3- yl)-1H-indole-7-
carboxamide (prepared using A from Preparation #1 and 1-methyl-5-
(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2- yl)pyridin-2(1H)-one
(Preparation #5) ##STR00261## A.2.1 2.90 (d) 484 A
4-bromo-2-(1-methyl-1H- pyrazol-4-yl)-1H-indole- 7-carboxamide
(Preparation #10) ##STR00262## A.2.2 2.87 (d) 457 A
TABLE-US-00006 TABLE A.3 Examples prepared from
2-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)-4-bromo-1H-
indole-7-carboxamide (prepared using A with
4-bromo-2-iodo-1H-indole-7-carboxamide (Preparation #1) and
1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridin-
1(2H)-yl)ethanone [Combi-Blocks]) using General Procedure A R.sub.t
min (Table 1, m/z ESI+ Btk Boronate Product Example # Method) (M +
H).sup.+ IC.sub.50 3-(2-methyl-3-(4,4,5,5- tetramethyl-1,3,2-
dioxaborolan-2- yl)phenyl)quinazolin- 4(3H)-one [WO 2011159857]
##STR00263## A.3.1 1.89 (g) 518 A 6-fluoro-3-(2-methyl-3- (4,4,5,5-
tetramethyl-1,3,2- dioxaborolan-2- yl)phenyl)quinazolin- 4(3H)-one
[WO 2011159857] ##STR00264## A.3.2 1.52 (g) 536 A 4-tert-butyl-N-
(2-methyl-3- (4,4,5,5- tetramethyl-1,3,2- dioxaborolan-2-
yl)phenyl)benzamide [WO 2006/099075] ##STR00265## A.3.3 1.84 (g)
549 A N-(2-methyl-3-(4,4,5,5- tetramethyl-1,3,2- dioxaborolan-2-
yl)phenyl)thiazole-2- carboxamide (Preparation #4) ##STR00266##
A.3.4 1.51 (g) 500 A N-(2-methyl-3-(4,4,5,5- tetramethyl-1,3,2-
dioxaborolan- 2-yl)phenyl)- 4,5,6,7- tetrahydrobenzo [b]thiophene-
2-carboxamide [WO 2006/099075] ##STR00267## A.3.5 1.76 (g) 553 A
4-cyclopropyl-N-(2-methyl- 3-(4,4,5,5-tetramethyl-
1,3,2-dioxaborolan-2- yl)phenyl)benzamide [US 20090105209]
##STR00268## A.3.6 1.68 (g) 533 A 4-(difluoromethyl)-N-(2-
methyl-3-(4,4,5,5- tetramethyl-1,3,2- dioxaborolan-2-
yl)phenyl)benzamide (Preparation #29) ##STR00269## A.3.7 1.59 (g)
543 A 4-(2-cyanopropan- 2-yl)-N- (2-methyl-3-(4,4,5,5-
tetramethyl-1,3,2- dioxaborolan-2- yl)phenyl)benzamide (prepared
using D from 2- methyl-3-(4,4,5,5- tetramethyl-1,3,2-
dioxaborolan-2-yl)aniline [Combi-Block] and 4-(2-
cyanopropan-2-yl)benzoic acid) ##STR00270## A.3.8 1.69 (g) 560
A
TABLE-US-00007 TABLE A.4 Examples prepared from
4-bromo-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-
yl)-1H-indole-7-carboxamide (Preparation #18) using General
Procedure A R.sub.t min m/z (Table 1, ESI+ Btk Boronate Product
Example # Method) (M + H).sup.+ IC.sub.50
N-(3-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-
yl)benzyl)acrylamide (prepared using E from (3-(4,4,5,5-
tetramethyl-1,3,2- dioxaborolan-2- yl)phenyl)methanamine
[ChemMaker] and acryloyl chloride) ##STR00271## A.4.1 1.59 (g) 479
A 2-(4,4,5,5- tetramethyl-1,3,2- dioxaborolan-2-yl)aniline
##STR00272## A.4.2 1.27 (f) 411 A N-(2-(4,4,5,5-tetramethyl-
1,3,2-dioxaborolan-2- yl)phenyl)acrylamide (prepared using E from
2- aminophenylboronic acid pinacol ester and acryloyl chloride)
##STR00273## A.4.3 1.62 (g) 465 A 2-((3-(4,4,5,5-tetramethyl-
1,3,2-dioxaborolan-2- yl)phenoxy) methyl)thiazole (prepared using Q
from 3-(4,4,5,5- tetramethyl-1,3,2- dioxaborolan-2-yl) phenol and
thiazol-2-ylmethanol) ##STR00274## A.4.4 1.83 (g) 509 A
2-methyl-3-(4,4,5,5- tetramethyl-1,3,2- dioxaborolan-2-yl)aniline
[CombiBlocks] ##STR00275## A.4.5 1.15 (f) 425 A
2-(2-methyl-3-(4,4,5,5- tetramethyl-1,3,2- dioxaborolan-
2-yl)phenyl)- 3,4-dihydroisoquinolin- 1(2H)-one (Preparation #3)
##STR00276## A.4.6 1.79 (f) 555 A phenylboronic acid ##STR00277##
A.4.7 1.72 (f) 396 A 4-(3-(4,4,5,5-tetramethyl-
1,3,2-dioxaborolan-2- yl)phenylamino) pyrimidine-2- carbonitrile
(Preparation #6) ##STR00278## A.4.8 1.60 (f) 514 A
(1s,4s)-4-hydroxy-N-(2- methyl-3-(4,4,5,5- tetramethyl-1,3,2-
dioxaborolan-2- yl)phenyl)-4- (trifluoromethyl) cyclohexane-
carboxamide (Preparation #8) ##STR00279## A.4.9 1.56 (a) 619 A
4-(difluoromethyl)-N-(2- methyl-3-(4,4,5,5- tetramethyl-1,3,2-
dioxaborolan-2- yl)phenyl)benzamide (prepared using D from 4-
(difluoromethyl) benzoic acid [Oakwood] and 2-methyl-3- (4,4,5,5-
tetramethyl-1,3,2- dioxaborolan-2-yl) aniline [Combi-Blocks])
##STR00280## A.4.10 2.06 (a) 579 A N-(2-methyl-3-(4,4,5,5-
tetramethyl-1,3,2- dioxaborolan-2- yl)phenyl)oxetan-3-amine
(prepared using H from 2- methyl-3-(4,4,5,5- tetramethyl-1,3,2-
dioxaborolan-2-yl)aniline [Combi-Blocks] and 3- oxetanone
[Molbridge]) ##STR00281## A.4.11 1.84 (a) 481 A
4-(difluoromethyl)-N-(2- methyl-3-(4,4,5,5- tetramethyl-1,3,2-
dioxaborolan-2-yl) phenyl)-N- (oxetan-3-yl)benzamide (Preparation
#25) ##STR00282## A.4.12 1.94 (a) 635 A 2-(2-methyl-3-(4,4,5,5-
tetramethyl-1,3,2- dioxaborolan-2- yl)phenylamino)ethanol (prepared
using J from 2- methyl-3-(4,4,5,5- tetramethyl-1,3,2-
dioxaborolan-2-yl)aniline [Combi-Blocks] and 2-iodo- ethanol)
##STR00283## A.4.13 1.72 (a) 469 A 4-(difluoromethyl)-N-(2-
hydroxyethyl)- N-(2-methyl-3- (4,4,5,5- tetramethyl-1,3,2-
dioxaborolan-2- yl)phenyl)benzamide (prepared using J from 2-
methyl-3-(4,4,5,5- tetramethyl-1,3,2- dioxaborolan-2-yl)aniline
[Combi-Blocks] and 2-iodo- ethanol, D from 4- (difluoromethyl)
benzoic acid [Oakwood]) ##STR00284## A.4.14 1.82 (a) 623 A
N-(3-(4,4,5,5- tetramethyl- 1,3,2-dioxaborolan-2-
yl)phenyl)acrylamide (Preparation #22) ##STR00285## A.4.15 1.63 (g)
465 A 4-cyclopropyl- N-(2-methyl-3- (4,4,5,5- tetramethyl-1,3,2-
dioxaborolan-2- yl)phenyl)benzamide [US 20090105209] ##STR00286##
A.4.16 1.85 (g) 569 A N-(2-methyl-3-(4,4,5,5- tetramethyl-1,3,2-
dioxaborolan-2- yl)phenyl)thiazole-2- carboxamide (Preparation #4)
##STR00287## A.4.17 1.68 (g) 536 A 3-(2-methyl-3-(4,4,5,5-
tetramethyl-1,3,2- dioxaborolan-2- yl)phenyl) quinazolin-4(3H)- one
[WO 2011159857] ##STR00288## A.4.18 1.66 (g) 554 A
6-fluoro-3-(2-methyl-3- (4,4,5,5- tetramethyl-1,3,2-
dioxaborolan-2- yl)phenyl) quinazolin-4(3H)- one [WO 2011159857]
##STR00289## A.4.19 1.71 (g) 572 A
TABLE-US-00008 TABLE A.5 Examples prepared from
4-bromo-1H-indole-7-carboxamide (Preparation #2) using General
Procedure A R.sub.t min m/z (Table 1, ESI+ Boronate Product Example
# Method) (M + H).sup.+ Btk IC.sub.50 2-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)aniline ##STR00290## A.5.1 1.04 (f) 252 C
N-(3-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-
yl)phenyl)acrylamide (Preparation #22) ##STR00291## A.5.2 1.36 (f)
306 B 4-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)pyridin-2-
arnine ##STR00292## A.5.3 0.45 (f) 253 C
5-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)pyridin-3- amine
[Maybridge] ##STR00293## A.5.4 0.31 (f) 253 C
3-(2-methyl-3-(4,4,5,5- tetramethyl-1,3,2- dioxaborolan-2-
yl)phenyl)quinazolin-4(3H)- one [US 20100160303] ##STR00294## A.5.5
1.82 (a) 395 B 4-(tert-butyl)-N-(2-methyl-3-
(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2- yl)phenyl)benzamide [WO
2006/099075] ##STR00295## A.5.6 2.28 (a) 426 C
TABLE-US-00009 TABLE A.6 Examples prepared from
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-
7-carboxamide (Preparation #P.1) using General Procedure A m/z
R.sub.t min ESI+ (Table 1, (M + Me Arylbromide Product Example #
Method) CN + H).sup.+ Btk IC.sub.50 3-bromo-N- (cyanomethyl)
benzenesulfonamide (Preparation #29) ##STR00296## A.6.1 1.32 (f)
396 C 3-bromo-N-methylaniline ##STR00297## A.6.2 0.95 (f) 307 C
TABLE-US-00010 TABLE A.7 Examples prepared from
4-iodo-2-(pyridin-3-yl)-1H-indole-7-carboxamide (Example #F.1)
using General Procedure A R.sub.t min m/z (Table 1, APCI+ Boronate
Product Example # Method) (M + H).sup.+ Btk IC.sub.50
4-(tert-butyl)-N-(2-methyl-3- (4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2- yl)phenyl)benzamide [WO 2006/099075] ##STR00298##
A.7.1 1.93 (aa) 503 A 3-(2-methyl-3-(4,4,5,5- tetramethyl-1,3,2-
dioxaborolan-2- yl)phenyl)quinazolin-4(3H)- one [WO 2011159857]
##STR00299## A.7.2 1.88 (ac) 472 A N-(2-methyl-3-(4,4,5,5-
tetramethyl-1,3,2- dioxaborolan-2-yl)phenyl)- 4,5,6,7-
tetrahydrobenzo[b]thiophene- 2-carboxamide [WO 2006/099075]
##STR00300## A.7.3 1.85 (ab) 507 A 2-(2-methyl-3-(4,4,5,5-
tetramethyl-1,3,2- dioxaborolan-2- yl)phenyl)isoindolin-1-one [U.S.
20100160303] ##STR00301## A.7.4 1.90 (ac) 459 A
6-methyl-2-(2-methyl-3- (4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-
yl)phenyl)isoindolin-1-one [U.S. 2010/0160303] ##STR00302## A.7.5
1.99 (ac) 473 A 6-fluoro-2-(2-methyl-3- (4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2- yl)phenyl)isoindolin-1-one [WO 2011/159857 A1]
##STR00303## A.7.6 1.98 (a) 477 A N-(4-methyl-3-(4,4,5,5-
tetramethyl-1,3,2- dioxaborolan-2- yl)phenyl)thiazole-2-
carboxamide (prepared using E from 5-amino-2- methylphenylboronic
acid, pinacol ester and 1,3-thiazole-2-carbonyl chloride
[Maybridge-International]) ##STR00304## A.7.7 1.65 (f) 454 C
N-(2-methyl-3-(4,4,5,5- tetramethyl-1,3,2- dioxaborolan-2-
yl)phenyl)thiazole-2- carboxamide (Preparation #4) ##STR00305##
A.7.8 1.87 (a) 454 A
TABLE-US-00011 TABLE A.8 Examples prepared from
4-iodo-2-(p-tolyl)-1H-indole-7-carboxamide (prepared using F from
1-(p-tolyl)ethanone) using General Procedure A R.sub.t min m/z
(Table 1, APCI+ Btk Boronic Acid or Boronate Product Example #
Method) (M + H).sup.+ IC.sub.50 pyrazole-3-boronic acid
##STR00306## A.8.1 1.93 (a) 317 B 3,5-dimethylisoxazole-4- boronic
acid pinacol ester ##STR00307## A.8.2 2.27 (a) 346 B
pyridine-3-boronic acid ##STR00308## A.8.3 2.15 (a) 328 B
pyridine-4-boronic acid ##STR00309## A.8.4 2.27 (a) 328 B
5-acetylthiophen-2-ylboronic acid ##STR00310## A.8.5 0.92 (e) 375 B
4,4,5,5-tetramethyl-2- (thiophen-3-yl)-1,3,2- dioxaborolane
##STR00311## A.8.6 0.97 (e) 333 B 1-methyl-4-(4,4,5,5-
tetramethyl-1,3,2- dioxaborolan-2-yl)-1H- pyrazole ##STR00312##
A.8.7 0.83 (e) 331 B 1H-pyrazol-3-ylboronic acid ##STR00313## A.8.8
0.81 (e) 317 B thiophen-2-ylboronic acid ##STR00314## A.8.9 0.97
(e) 333 B thiophen-3-ylboronic acid ##STR00315## A.8.10 0.97 (e)
333 B
TABLE-US-00012 TABLE A.9 Examples prepared from
4-iodo-2-(p-tolyl)-1H-indole-7-carboxamide (prepared with F using
1-(4-fluorophenyl)ethanone) using General Procedure A R.sub.t min
m/z (Table 1, APCI+ Btk Boronic Acid or Boronate Product Example #
Method) (M + H).sup.+ IC.sub.50 pyrimidine-5-boronic acid
##STR00316## A.9.1 1.82 (a) 333 B pyridine-3-boronic acid
##STR00317## A.9.2 2.05 (a) 332 A 3,5-dimethylisoxazole-4- boronic
acid pinacol ester ##STR00318## A.9.3 2.18 (a) 350 B
pyridine-4-boronic acid ##STR00319## A.9.4 2.15 (a) 332 B
pyrazole-3-boronic acid ##STR00320## A.9.5 1.87 (a) 321 B
6-fluoro-2-(2-methyl-3- (4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-
yl)phenyl)isoindolin-1-one [WO 2011/159857] ##STR00321## A.9.6 2.37
(a) 494 A N-(2-methyl-3-(4,4,5,5- tetramethyl-1,3,2-
dioxaborolan-2-yl)phenyl)- 4,5,6,7- tetrahydrobenzo[b]thiophene-
2-carboxamide [WO 2006/099075] ##STR00322## A.9.7 2.66 (a) 524
C
TABLE-US-00013 TABLE A.10 Examples prepared from
4-bromo-2-(1-methyl-1H-pyrazol-4-yl)-1H-indole-7- carboxamide
(prepared using A from 4-bromo-2-iodo-1H-indole-7-carboxamide
(Preparation #1) with
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyraz-
ole) using General Procedure A R.sub.t min m/z (Table 1, APCI+ Btk
Boronate Product Example # Method) (M + H).sup.+ IC.sub.50
3-(2-methyl-3-(4,4,5,5- tetramethyl-1,3,2- dioxaborolan-2-
yl)phenyl)quinazolin-4(3H)- one [WO 2011159857] ##STR00323## A.10.1
2.11 (c) 475 A 6-fluoro-3-(2-methyl-3- (4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2- yl)phenyl)quinazolin-4(3H)- one [US 2010/0160303]
##STR00324## A.10.2 1.90 (a) 493 A N-(3-(7-carbamoyl-2-(1-
methyl-1H-pyrazol-4-yl)-1H- indol-4-yl)-2-methylphenyl)-
N-(oxetan-3-yl)thiazole-2- carboxamide (prepared using H from 2-
methyl-3-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2- yl)aniline
[Combi-Blocks] and 3-oxetanone [Molbridge]), E with thiazole-
2-carbonyl chloride [Maybridge]) ##STR00325## A.10.3 1.48 (g) 513 A
N-methyl-N-(2-methyl-3- (4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-
yl)phenyl)thiazole-2- carboxamide (Preparation #19) ##STR00326##
A.10.4 1.52 (f) 471 B N-(2-methyl-3-(4,4,5,5- tetramethyl-1,3,2-
dioxaborolan-2-yl)phenyl)- 4,5,6,7- tetrahydrobenzo[b]thiophene-
2-carboxamide [WO 2006/099075] ##STR00327## A.10.5 1.84 (g) 510
A
TABLE-US-00014 TABLE A.11 Examples prepared from
4-bromo-2-(3,6-dihydro-2H-pyran-4-yl)-1H-indole-7- carboxamide
(prepared using A from 4-bromo-2-iodo-1H-indole-7-carboxamide
(Preparation #1) and
2-(3,6-dihydro-2H-pyran-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborol-
ane) using General Procedure A R.sub.t min (Table 1, m/z ESI+ Btk
Boronate Product Example # Method) (M + H).sup.+ IC.sub.50
3-(2-methyl-3-(4,4,5,5- tetramethyl-1,3,2- dioxaborolan-2-
yl)phenyl)quinazolin-4(3H)- one [WO 2011159857] ##STR00328## A.11.1
1.51 (g) 477 A 6-fluoro-3-(2-methyl-3- (4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2- yl)phenyl)quinazolin-4(3H)- one [WO 2011159857]
##STR00329## A.11.2 1.55 (g) 495 A
TABLE-US-00015 TABLE A.12 Examples prepared from
4-bromo-2-(4-fluorophenyl)-1H-indole-7-carboxamide (prepared using
A from 4-bromo-2-iodo-1H-indole-7-carboxamide (Preparation #1) and
2-(4- fluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane) using
General Proecedure A R.sub.t min (Table 1, m/z ESI+ Btk Boronate
Product Example # Method) (M + H).sup.+ IC.sub.50
3-(2-methyl-3-(4,4,5,5- tetramethyl-1,3,2- dioxaborolan-2-
yl)phenyl)quinazolin- 4(3H)-one [WO 2011159857] ##STR00330## A.12.1
1.78 (g) 489 A
TABLE-US-00016 TABLE A.13 Examples prepared from
4-bromo-2-(pyrimidin-5-yl)-1H-indole-7-carboxamide (prepared using
A from 4-bromo-2-iodo-1H-indole-7-carboxamide (Preparation #1) and
5- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine) using
General Procedure A R.sub.t min (Table 1, m/z ESI+ Btk Boronate
Product Example # Method) (M + H).sup.+ IC.sub.50
3-(2-methyl-3-(4,4,5,5- tetramethyl-1,3,2- dioxaborolan-2-
yl)phenyl)quinazolin-4(3H)- one [WO 2011159857] ##STR00331## A.13.1
1.52 (g) 473 B 6-fluoro-3-(2-methyl-3- (4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2- yl)phenyl)quinazolin-4(3H)- one [WO 2011159857]
##STR00332## A.13.2 1.59 (g) 491 B 4-(difluoromethyl)-N-(2-
methyl-3-(4,4,5,5- tetramethyl-1,3,2- dioxaborolan-2-
yl)phenyl)benzamide (Preparation #29) ##STR00333## A.13.3 1.64 (g)
498 B 4-cyclopropyl-N-(2-methyl-3- (4,4,5,5-tetramethyl-
1,3,2-dioxaborolan-2- yl)phenyl)benzamide (prepared using B with 2-
methyl-3-(4,4,5,5- tetramethyl-1,3,2- dioxaborolan-2-yl)aniline and
4-(2-cyanopropan-2- yl)benzoic acid) ##STR00334## A.13.4 1.73 (g)
488 B
TABLE-US-00017 TABLE A.14 Examples prepared from
4-bromo-2-(1-(2-hydroxy-2-methylpropyl)-1H-pyrazol-4-
yl)-1H-indole-7-carboxamide (prepared using A from
4-bromo-2-iodo-1H-indole-7-carboxamide (Preparation #1) and
2-methyl-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-
yl)propan-2-ol (Preparation #26) using General Procedure A R.sub.t
min (Table 1, m/z ESI+ Btk Boronate Product Example # Method) (M +
H).sup.+ IC.sub.50 6-fluoro-3-(2-methyl-3- (4,4,5,5-tetramethyl-
1,3,2-dioxaborolan-2- yl)phenyl)quinazolin- 4(3H)-one [WO
2011159857] ##STR00335## A.14.1 1.65 (g) 551 A
TABLE-US-00018 TABLE A.15 Examples prepared from
2-(3-chloro-2-(hydroxymethyl)phenyl)-6-cyclopropyl-8-
fluoroisoquinolin-1(2H)-one [U.S. 20100222325] using General
Procedure A R.sub.t min (Table 1, m/z ESI+ Btk Boronate Product
Example # Method) (M + H).sup.+ IC.sub.50 2-(1-methyl-1H-pyrazol-4-
yl)-4-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-yl)-1H-
indole-7-carboxamide (prepared using A from Preparation #1 with 1-
methyl-4-(4,4,5,5- tetramethyl-1,3,2- dioxaborolan-
2-yl)-1H-pyrazole, and P with 4,4,4',4',5,5,5',5'-
octamethyl-2,2'-bi(1,3,2- dioxaborolane)) ##STR00336## A.15.1 2.77
(o) 548 A
General Procedure B: Nucleophilic Displacement of an Aryl Halide
with an Amine
[1050] To a solution of an aryl halide or heteraryl halide and an
appropriate organic solvent (such as DMSO, 1,4-dioxane, n-butanol,
THF, pyridine, preferably DMSO or pyridine) was added an amine (1
to 10 equiv, preferably 1equiv) and abase (such as TEA, pyridine,
DIEA, K.sub.2CO.sub.3, preferably TEA; 1 to 5 equiv, preferably
1equiv.). The resulting solution is stirred at about 20 to
150.degree. C. (preferably about 130-150.degree. C.) thermally for
a period of about 1 h to 72 h (preferably about 24 h) or in a
microwave for about 5 min to 2 h (preferably about 30 mi). The
mixture is optionally concentrated in vacuo or under a warm
nitrogen stream to give the intermediates or targeted compound or
optionally filtered through a media (such as SiCO.sub.3 or
Celite.RTM.) which is rinsed with an appropriate solvent (such as
EtOAc, 1,4-dioxane, THF, MeCN, DCM, Et.sub.2O, MeOH, EtOH, DMSO,
1:1 MeOH/DMSO, 2:1 MeOH/DMSO) and then optionally concentrated in
vacuo or under a warm nitrogen stream to give the targeted
compound.
Illustration of General Procedure B
Preparation #B.1: (R)-tert-Butyl 1-(7-cyano-1H-in
dol-4-yl)piperidin-3-ylcarbamate
##STR00337##
[1052] A mixture of (R)-tert-butyl piperidin-3-ylcarbamate (1.501
g, 7.49 mmol) and 4-fluoro-1H-indole-7-carbonitrile (0.6 g, 3.75
mmol) in pyridine (3.02 mL, 37.5 mmol) were heated at about
150.degree. C. for about 30 min in a microwave oven. The mixture
was evaporated to dryness and the resulting residue was purified by
silica gel chromatography eluting with a gradient 30 to 100% of
EtOAc in hexanes to give (R)-tert-butyl
1-(7-cyano-1H-indol-4-yl)piperidin-3-ylcarbamate (0.4 g, 31%);
LC/MS (Table 1, Method g) R.sub.t=1.69 min.; MS m/z: 341
(M+H).sup.+
General Procedure C: Hydrolysis of an Ester to a Carboxylic
Acid
[1053] To a flask containing an ester (preferably 1 equiv) either
neat or in an organic solvent (such as 1,4-dioxane, MeOH, or
THF/MeOH, preferably 1,4-dioxane) is added an aqueous base (such as
aqueous NaOH or LiOH; 1-10 equiv, preferably 2-6 equiv). The
mixture is stirred at about 0 to 100.degree. C. (preferably about
25 to 60.degree. C.) for about 1 to 48 h (preferably about 4 to 24
h). The organic solvent is optionally be concentrated in vacuo. The
mixture is then acidified by the addition of a suitable aqueous
acid (such as aqueous HCl). If a precipitate forms, it may be
collected via filtration to give product. The mixture or the
filtrate if the solid is not product may optionally be concentrated
in vacuo to give the target compound as a carboxylate salt.
Alternatively, the mixture is optionally filtered through a media
(such as silica gel or Celite.RTM.) which is rinsed with an
appropriate solvent (such as EtOAc, 1,4-dioxane, THF, MeCN, DCM,
Et.sub.2O, MeOH, EtOH) and then optionally concentrated in vacuo to
give a residue as the target compound. Either the residue or the
solution may be optionally partitioned between water and an organic
solvent (such as EtOAc, Et.sub.2O or DCM). The organic layer is
isolated and may optionally be washed in no particular order with
water and/or aqueous solutions containing an acid (such as HCl,
AcOH or NH.sub.4Cl) and/or aqueous solutions containing a base
(such as NaHCO.sub.3, Na.sub.2CO.sub.3, NaOH, KOH or NH.sub.4OH)
and/or aqueous solutions containing an inorganic salt (such as
NaCl, Na.sub.2SO.sub.3 or Na.sub.2S.sub.2O.sub.3). The organic
solution may then be optionally dried with a drying agent (such as
anhydrous MgSO.sub.4 or Na.sub.2SO.sub.4), filtered and
concentrated in vacuo to give the target compound.
Illustration of General Procedure C
Example #C.1:
(E)-4-((3-(7-Carbamoyl-1H-indol-4-yl)phenyl)amino)-4-oxobut-2-enoic
acid
##STR00338##
[1055] (E)-Methyl
4-((3-(7-carbamoyl-1H-indol-4-yl)phenyl)amino)-4-oxobut-2-enoate
(0.610 g, 1.68 mmol, Example #D.1) was suspended in 1,4-dioxane
(8.39 mL). Lithium hydroxide (1M in water, 8.39 mL, 8.39 mmol) was
added and the mixture was stirred at about 60.degree. C. for about
1 h. The reaction was concentrated to about 8 mL and diluted with
water (10 mL). The pH was adjusted to about 4 using 1N HCl. The
solids were collected, washed with water, and dried under vacuum to
provide
(E)-4-((3-(7-carbamoyl-1H-indol-4-yl)phenyl)amino)-4-oxobut-2-enoic
acid (0.45 g, 77%) as a solid. 50 mg of the crude product was
further purified by preparative-HPLC (Table 1, Method af) to afford
30.9 mg to provide analytically pure
(E)-4-((3-(7-carbamoyl-1H-indol-4-yl)phenyl)amino)-4-oxobut-2-enoic
acid: LC/MS (Table 1, Method f) R.sub.t=1.64 min; MS m/z: 350
(M+H).sup.+ (Btk IC.sub.50=C)
General Procedure D: Formation of an Amide from an Amine and a
Carboxylic Acid
[1056] To a flask is added in no particular order, a carboxylic
acid or carboxylate salt (1 to 5 equiv, preferably 1.1 to 1.5
equiv), an amine (1 to 5 equiv, preferably 1 to 1.5 equiv), an
organic solvent (such as DCM, DCE, THF, or 1,4-dioxane, DMF,
DMF/pyridine preferably DCM or DMF/pyridine), a peptide coupling
reagent (such as BOP-Cl, HATU, EDC, DCI, PyBOP, or EDC.HCl,
preferably HATU or EDC; 1 to 10 equiv, preferably 1 to 2.5 equiv),
a base (such as TEA, DIEA, pyridine or DIEA, preferably DIEA; 1 to
20 equiv, preferably 1 to 5 equiv) and optionally HOBt (0 to 5
equiv, preferably 0 to 1 equiv). The mixture is then stirred at
about 10 to 60.degree. C. (preferably about 25 to 50.degree. C.)
for about 5 min to 48 h (preferably about 5 min to 24 h).
Optionally, additional amounts of the reagents above can be added
to drive the reaction to completion. The mixture is optionally
concentrated in vacuo to give the targeted compound. The mixture is
optionally filtered through a media (such as silica gel or
Celite.RTM.) which is rinsed with an appropriate solvent (such as
EtOAc, 1,4-dioxane, THF, MeCN, DCM, Et.sub.2O, MeOH, EtOH) and then
optionally concentrated in vacuo to give a residue. Either the
residue or the solution may be optionally partitioned between water
and an organic solvent (such as EtOAc, Et.sub.2O or DCM). If the
product does not partition, the mixture may be stirred for 5 min to
1 h (preferably 30 min) and the solid may be collected via vacuum
filtration. Alternatively, the organic layer is isolated and may be
optionally washed in no particular order with water and/or aqueous
solutions containing an acid (such as HCl, AcOH or NH.sub.4Cl)
and/or aqueous solutions containing a base (such as NaHCO.sub.3,
Na.sub.2CO.sub.3, NaOH, KOH or NH.sub.4OH) and/or aqueous solutions
containing an inorganic salt (such as NaCl, Na.sub.2SO.sub.3 or
Na.sub.2S.sub.2O.sub.3). The organic solution may then be
optionally dried with a drying agent (such as anhydrous MgSO.sub.4
or Na.sub.2SO.sub.4), filtered and concentrated in vacuo to give
the targeted compound.
Illustration of General Procedure D
Example #D.1: (E)-Methyl
4-((3-(7-carbamoyl-1H-indol-4-yl)phenyl)amino)-4-oxobut-2-enoate
##STR00339##
[1058] To a solution of (E)-4-methoxy-4-oxobut-2-enoic acid (0.43
g, 3.28 mmol) in DCM (40 mL) and DIEA (0.59 mL, 3.58 mmol) was
added HATU (1.362 g, 3.58 mmol). The mixture was stirred at rt for
5 min then 4-(3-aminophenyl)-1H-indole-7-carboxamide (0.75 g, 2.98
mmol, Preparation #A.1) was added. The mixture was stirred at rt
for about 3 h. The mixture was concentrated and the residue was
suspended between water and EtOAc. The mixture was stirred at rt
for about 30 min, filtered to collect the solid, which was washed
with water and EtOAc, and dried under vacuum to provided (E)-methyl
4-((3-(7-carbamoyl-1H-indol-4-yl)phenyl)amino)-4-oxobut-2-enoate
(0.64 g, 59%): LC/MS (Table 1, Method f) R.sub.t=1.45 min; MS m/z:
364 (M+H).sup.+ (Btk IC.sub.50=A)
TABLE-US-00019 TABLE D.1 Examples prepared from
N-(3-(2-(2-(aminomethyl)phenyl)-7-carbamoyl-1H-indol-4-
yl)-2-methylphenyl)thiazole-2-carboxamide (Example #1) using
General Procedure D R.sub.t min (Table 1, m/z ESI+ Acid Product
Example # Method) (M + H).sup.+ Btk IC.sub.50 but-2-ynoic acid
##STR00340## D.1.1 3.13 (d) 548 C acrylic acid ##STR00341## D.1.2
3.10 (d) 536 C 2-cyanoacetic acid ##STR00342## D.1.3 3.05 (d) 549 B
3-(dimethyl- amino)ropanoic acid HCl ##STR00343## D.1.4 2.64 (d)
581 B 3-(piperidin-1- yl)propanoic acid ##STR00344## D.1.5 2.38 (o)
621 C 2-phenoxyacetic acid ##STR00345## D.1.6 3.06 (o) 616 C
2-(4-fluoro- phenoxy)acetic acid ##STR00346## D.1.7 3.08 (o) 634 C
butyric acid ##STR00347## D.1.8 2.87 (o) 552 C (E)-but-2-enoic acid
##STR00348## D.1.9 2.84 (o) 550 C methacrylic acid ##STR00349##
D.1.10 3.20 (d) 550 C propiolic acid ##STR00350## D.1.11 3.10 (d)
534 B
TABLE-US-00020 TABLE D.2 Examples prepared from an amine and
2-(3-oxobenzo[d]isothiazol-2(3H)-yl)acetic acid [Matrix] using
General Procedure D R.sub.t min (Table 1, m/z ESI+ Amine Product
Example # Method) (M + H).sup.+ Btk IC.sub.50 4-(2-aminophenyl)-1H-
indole-7-carboxamide (prepared using A from 4 -bromo-1H-indole-7-
carboxamide (Preparation #2) and 2-(4,4,5,5-tetramethyl-
1,3,2-dioxaborolan-2- yl)aniline) ##STR00351## D.2.1 1.42 (f) 443
C
TABLE-US-00021 TABLE D.3 Examples prepared from
N-(3-(3-amino-7-carbamoyl-1H-indol-4-yl)-2-
methylphenyl)thiazole-2-carboxamide (Preparation #7) using General
Procedure D R.sub.t min (Table 1, m/z ESI+ Acid Product Example #
Method) (M + H).sup.+ Btk IC.sub.50 2-cyanoacetic acid ##STR00352##
D.3.1 2.58 (d) 459 C acrylic acid ##STR00353## D.3.2 2.69 (d) 446 C
(E)-but-2-enoic acid ##STR00354## D.3.3 2.82 (d) 460 C methacrylic
acid ##STR00355## D.3.4 2.89 (d) 460 C but-2-ynoic acid
##STR00356## D.3.5 2.52 (d) 458 C 2-(4-fluorophenoxy)acetic acid
##STR00357## D.3.6 3.09 (d) 544 C
TABLE-US-00022 TABLE D.4 Examples prepared from an
(E)-4-((3-(7-carbamoyl-1H-indol-4-yl)phenyl)amino)-4-
oxobut-2-enoic acid (Example #C.1) using General Procedure D
R.sub.t min (Table 1, m/z ESI+ Amine Product Example # Method) (M +
H).sup.+ Btk IC.sub.50 Methylamine ##STR00358## D.4.1 1.60 (f) 363
C Dimethylamine ##STR00359## D.4.2 1.66 (f) 377 C ethanamine
##STR00360## D.4.3 1.68 (f) 377 C cyclopropanamine ##STR00361##
D.4.4 1.70 (f) 389 C
TABLE-US-00023 TABLE D.5 Examples prepared from an acid and
2-(1-acetylpiperidin-4-yl)-4-(3-amino-2-
methylphenyl)-1H-indole-7-carboxamide (Example #L.1) using General
Procedure D R.sub.t min (Table 1, m/z ESI+ Acid Product Example #
Method) (M + H).sup.+ Btk IC.sub.50 4-cyclopropylbenzoic acid
[Astra tech] ##STR00362## D.5.1 1.77 (f) 535 B
TABLE-US-00024 TABLE D.6 Examples prepared from
4-(3-aminophenyl)-1H-indole-7-carboxamide (Preparation #A.1) using
General Procedure B R.sub.t min (Table 1, m/z ESI+ Acid Product
Example # Method) (M + H).sup.+ Btk IC.sub.50 2-
((dimethylamino)methyl)a- crylic acid (prepared using J from 2-
(bromomethyl)acrylic acid and dimethylamine hydrochloride)
##STR00363## D.6.1 2.24 (d) 363 A 2- ((dimethylamino)methyl)a-
crylic acid (prepared using J from 2- (bromomethyl)acrylic acid and
morpholine) ##STR00364## D.6.2 2.27 (d) 405 A
TABLE-US-00025 TABLE D.7 Examples prepared from
4-(3-amino-2-methylphenyl)-2-(1-(methylsulfonyl)-1,2,3,6-
tetrahydropyridin-4-yl)-1H-indole-7-carboxamide (Example #A.4.5)
using General Procedure D. Example m/z ESI+ Btk Acid Product #
R.sub.t min (M + H).sup.+ IC.sub.50 (Z)-2-methylbut-2-enoic acid
##STR00365## D.7.1 0.73 (e) 507 A (E)-4-(dimethyl-
amino)but-2-enoic acid hydrochloride ##STR00366## D.7.2 0.57 (e)
536 A 3-(piperidin-1- yl)propanoic acid ##STR00367## D.7.3 0.59 (e)
564 B 2-cyanoacetic acid ##STR00368## D.7.4 0.66 (e) 492 A
methacrylic acid ##STR00369## D.7.5 0.71 (e) 493 A acrylic acid
##STR00370## D.7.6 0.68 (e) 479 A 2-chloro-2,2- difluoroacetic acid
##STR00371## D.7.7 0.77 (e) 537 A 2-chloropropanoic acid
##STR00372## D.7.8 0.72 (e) 515 A (E)-but-2-enoic acid ##STR00373##
D.7.9 0.71 (e) 493 A (Z)-4-amino-4-oxobut-2- enoic acid
##STR00374## D.7.10 0.62 (e) 522 A 2-(4-fluoro- phenoxy)acetic acid
##STR00375## D.7.11 0.78 (e) 577 A 3-(pyrrolidin-1- yl)propanoic
acid ##STR00376## D.7.12 0.58 (e) 550 A 2-(4-cyano- phenoxy)acetic
acid ##STR00377## D.7.13 0.75 (e) 584 A 2-(pyridin-3-yloxy)acetic
acid ##STR00378## D.7.14 0.58 (e) 560 A cyclopent-1- enecarboxylic
acid ##STR00379## D.7.15 0.75 (e) 519 A (E)-2-methylpent-2- enoic
acid ##STR00380## D.7.16 0.78 (e) 521 A (Z)-3-chloroacrylic acid
##STR00381## D.7.17 0.70 (e) 513 A (E)-4-methoxy-4-oxobut- 2-enoic
acid ##STR00382## D.7.18 0.72 (e) 537 A cyclohex-1- enecarboxylic
acid ##STR00383## D.7.19 0.78 (e) 533 A (E)-4-ethoxy-4-oxobut-
2-enoic acid ##STR00384## D.7.20 0.75 (e) 551 A 2-phenoxyacetic
acid ##STR00385## D.7.21 0.79 (e) 559 A 2-fluoroacetic acid
##STR00386## D.7.22 0.66 (e) 485 A 3-(dimethyl- amino)propanoic
acid ##STR00387## D.7.23 0.58 (h) 524 A 2-(pyridin-2- yloxy)acetic
acid ##STR00388## D.7.24 0.69 (e) 560 A (E)-4-amino-4-oxobut-
2-enoic acid ##STR00389## D.7.25 0.59 (e) 522 A 2-chlorobutanoic
acid ##STR00390## D.7.26 0.74 (e) 529 A 3-(4-methylpiperazin-1-
yl)propanoic acid ##STR00391## D.7.27 0.52 (e) 579 A
2-(pyridazin-3- yloxy)acetic acid ##STR00392## D.7.28 0.61 (e) 561
A cyclohexanecarboxylic acid ##STR00393## D.7.29 1.75 (e) 535 A
2-methylthiazole-4- carboxylic acid ##STR00394## D.7.30 0.75 (ae)
550 A cyclopentanecarboxylic acid ##STR00395## D.7.31 0.75 (ae) 521
A 5-methylthiazole-2- carboxylic acid ##STR00396## D.7.32 0.77 (ae)
550 A tetrahydro-2H-pyran-4- carboxylic acid ##STR00397## D.7.33
0.65 (ae) 537 A 3- methoxycyclohexane- carboxylic acid ##STR00398##
D.7.34 0.71 (ae) 565 A 3-methylbutanoic acid ##STR00399## D.7.35
0.73 (ae) 509 A 1-methylpiperidine-4- carboxylic acid ##STR00400##
D.7.36 0.56 (ae) 550 A 1-methylpiperidine-3- carboxylic acid
##STR00401## D.7.37 0.57 (ae) 550 B isothiazole-4-carboxylic acid
##STR00402## D.7.38 0.67 (ae) 536 A nicotinic acid ##STR00403##
D.7.39 0.59 (ae) 530 A isobutyric acid ##STR00404## D.7.40 0.69
(ae) 495 A propionic acid ##STR00405## D.7.41 0.67 (e) 481 A
TABLE-US-00026 TABLE D.8 Compounds made from
4-(3-amino-2-methylphenyl)-1H-indole-7-carboxamide (Example #16)
using General Procedure D. m/z ESI+ Acid Product Example # R.sub.t
min (M + H).sup.+ Btk IC.sub.50 (E)-4-ethoxy-4-oxobut-2- enoic acid
##STR00406## D.8.1 0.69 (ae) 392 A (E)-3-(1-methyl-1H-
pyrazol-4-yl)acrylic acid ##STR00407## D.8.2 0.62 (ae) 400 B
(E)-3-(pyridin-2-yl)acrylic acid ##STR00408## D.8.3 0.55 (ae) 397 B
(E)-3-(pyridin-3-yl)acrylic acid ##STR00409## D.8.4 0.53 (ae) 397 B
(E)-3-(thiazol-2-yl)acrylic acid ##STR00410## D.8.5 0.65 (ae) 403 B
(E)-3-cyclopropylacrylic acid ##STR00411## D.8.6 0.69 (ae) 360 B
2-phenylacrylic acid ##STR00412## D.8.7 0.75 (ae) 396 B
(E)-4-methylpent-2-enoic acid ##STR00413## D.8.8 0.74 (ae) 362 B
(E)-but-2-enoic acid ##STR00414## D.8.9 0.64 (ae) 334 B methacrylic
acid ##STR00415## D.8.10 0.65 (ae) 334 C 2-methylenebutanoic acid
##STR00416## D.8.11 0.69 (ae) 348 C acetic acid ##STR00417## D.8.12
0.56 (ae) 308 C 3-morpholinopropanoic acid ##STR00418## D.8.13 0.50
(ae) 407 C 3-(pyrrolidin-1- yl)propanoic acid ##STR00419## D.8.14
0.51 (ae) 391 C (Z)-4-(ethylamino)-4- oxobut-2-enoic acid
##STR00420## D.8.15 0.62 (ae) 391 A
TABLE-US-00027 TABLE D.9 Examples prepared from
(Z)-4-((3-(7-carbamoyl-1H-indol-4-yl)phenyl)amino)-4-
oxobut-2-enoic acid (Preparation #14) using General Procedure D
R.sub.t min (Table 1, m/z ESI+ Amine Product Example # Method) (M +
H).sup.+ Btk IC.sub.50 2-methoxyethylamine ##STR00421## D.9.1 1.42
(g) 407 B Ethanamine ##STR00422## D.9.2 1.41 (g) 377 A
TABLE-US-00028 TABLE D.10 Examples prepared from propiolic acid
with an amine using General Procedure D R.sub.t min (Table 1, m/z
ESI+ Amine Product Example # Method) (M + H).sup.+ Btk IC.sub.50
4-(Azetidin-3- yl(methyl)amino)-2- methyl-1H-indole-7- carboxamide
hydrochloride (Prepared using A from Preparation #40 with
methylboronic acid and G with HCl) ##STR00423## D.10.1 1.35 (at)
311 A
General Procedure E: Formation of an Amide from an Amine and an
Acid Halide or Anhydride
[1059] To a solution of an amine (1 to 3 equiv, preferably 1 to 3
equiv), optionally as a hydrochloride salt, in an organic solvent
(such as DCM, DCE, DMF, DMA, NMP, THF, Et.sub.2O or 1,4-dioxane,
preferably DMF, DMA, or DCM) is added a base (such as TEA, DIEA or
pyridine; 1 to 4 equiv, preferably TEA or DIEA 1 to 3 equiv) and an
acid halide or anhydride (1 to 4 equiv, preferably 1 to 4 equiv).
The mixture is optionally cooled to about 0.degree. C. prior to
addition of an acid halide or anhydride. The mixture is allowed to
stir at about 0 to 60.degree. C. (preferably about 0 to 50.degree.
C.) for about 5 min to 20 h (preferably about 20 min to 2 h). The
mixture is optionally neutralized with AcOH. The mixture is
optionally concentrated in vacuo to give the final compound. The
mixture is optionally filtered through a media (such as silica gel
or Celite.RTM.) which is rinsed with an appropriate solvent (such
as EtOAc, 1,4-dioxane, THF, MeCN, DCM, Et.sub.2O, MeOH, EtOH) and
then optionally concentrated in vacuo to give a residue. Either the
residue or the solution may be optionally partitioned between water
and an organic solvent (such as EtOAc, Et.sub.2O or DCM). The
organic layer is isolated and may be optionally washed in no
particular order with water and/or aqueous solutions containing an
acid (such as HCl, AcOH or NH.sub.4Cl) and/or aqueous solutions
containing a base (such as NaHCO.sub.3, Na.sub.2CO.sub.3, NaOH, KOH
or NH.sub.4OH) and/or aqueous solutions containing an inorganic
salt (such as NaCl Na.sub.2SO.sub.3 or Na.sub.2S.sub.2O.sub.3). The
organic solution may then be optionally dried with a drying agent
(such as anhydrous MgSO.sub.4 or Na.sub.2SO.sub.4), filtered and
concentrated in vacuo to give the targeted compound. Alternatively,
the residue from concentration of the reaction is suspended in
water, sonicated, and collected via vacuum filtration.
Illustration of General Procedure E
Example #E.1.
4-(3-Acrylamido-2-methylphenyl)-2-(4,4-difluorocyclohex-1-en-1-yl)-1H-ind-
ole-7-carboxamide
##STR00424##
[1061] To a vial was added
4-(3-amino-2-methylphenyl)-2-(4,4-difluorocyclohex-1-en-1-yl)-1H-indole-7-
-carboxamide (0.189 g, 0.496 mmol, Example #21) in DCM (5 mL), and
DIEA (0.129 mL, 0.743 mmol). The mixture was cooled to about
0.degree. C. and acryloyl chloride (0.044 mL, 0.545 mmol) was added
while stirring. The mixture was warmed to rt over about 20 min,
then concentrated and the residue was suspended in water (30 mL).
The suspension was sonicated for about 5 min, filtered, washed with
water, ether, and dried under vacuum. The crude product was added
to a silica gel column and eluted with heptane/EtOAc (0-100%) to
provide
4-(3-acrylamido-2-methylphenyl)-2-(4,4-difluorocyclohex-1-en-1-yl)-1H-ind-
ole-7-carboxamide (0.16 g, 74%): LC/MS (Table 1, Method g)
R.sub.t=3.02 min; MS m/z: 436 (M+H).sup.+. (BTK IC.sub.50=A)
TABLE-US-00029 TABLE E.1 Examples prepared from acryloyl chloride
using General Procedure E R.sub.t min (Table 1, m/z ESI+ Amine
Product Example # Method) (M + H).sup.+ Btk IC.sub.50 4-(2-
(aminomethyl)phenyl)-2- (1-(methylsulfonyl)-
1,2,3,6-tetrahydropyridin- 4-yl)-1H-indole-7- carboxamide
hydrochloride (prepared using A from Preparation #18 and tert-butyl
2-(4,4,5,5- tetramethyl-1,3,2- dioxaborolan-2- yl)benzylcarbamate
[JW] and G with HCl ##STR00425## E.1.1 1.47 (f) 479 A
4-(2-aminophenyl)-1H- indole-7-carboxamide (Example #A.5.1)
##STR00426## E.1.2 1.32 (f) 306 C 4-(2-aminopyridin-4-yl)-
1H-indole-7-carboxamide (Example #A.5.3) ##STR00427## E.1.3 0.96
(f) 307 A 4-(5-aminopyridin-3-yl)- 1H-indole-7-carboxamide (Example
#A.5.4) ##STR00428## E.1.4 0.90 (f) 307 A 4-(3-
(methylamino)phenyl)-1H- indole-7-carboxamide (prepared using A
from Preparation #P.1 and 3-bromo-N-methylaniline) ##STR00429##
E.1.5 1.41 (f) 320 A 4-(2-methyl-3- (methylamino)phenyl)-1H-
indole-7-carboxamide (prepared using A from Preparation #P.1 and
3-bromo-N,2- dimethylaniline [Beta Pharm]) ##STR00430## E.1.6 1.45
(f) 334 B 4-(2-methyl-3-(thiazol-2- ylmethylamino)phenyl)-2-
(1-(methylsulfonyl)- 1,2,3,6-tetrahydropyridin- 4-yl)-1H-indole-7-
carboxamide (Example #H.2.1) ##STR00431## E.1.7 1.75 (g) 576 A
4-(3-amino-4- methoxyphenyl)-1H- indole-7-carboxamide (prepared
using A from Preparation #P.1 and 5- bromo-2-methoxyaniline)
##STR00432## E.1.8 0.63 (ae) 336 B 4-(3-amino-2- methylphenyl)-1H-
pyrrolo[3,2-c]pyridine-7- carboxamide (prepared using A from
Preparation #9 and 2-methyl-3-(4,4,5,5- tetramethyl-1,3,2-
dioxaborolan-2-yl)aniline [CombiBlocks]) ##STR00433## E.1.9 1.94
(d) 321 A 4-(3-amino-2- methylphenyl)-1H- pyrrolo[3,2-c]pyridine-7-
carboxamide (prepared using A from Preparation #9 and
3-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2- yl)aniline)
##STR00434## E.1.10 2.04 (d) 307 A (R)-4-(3-aminopiperidin-1-
yl)-2-(1-(methylsulfonyl)- 1,2,3,6-tetrahydropyridin-
4-yl)-1H-indole-7- carboxamide (prepared using B from Preparation
#27 and (R)-tert-butyl piperidin- 3-ylcarbamate, N with
Cs.sub.2CO.sub.3, G with HCl, and O) ##STR00435## E.1.11* 1.27 (F)
472 A 4-(3-amino-4- (benzyloxy)phenyl)-1H- indole-7-carboxamide
(prepared using A Preparation #2 and Preparation #34) ##STR00436##
E.1.12 3.18 (d) 412 C 4-(3-amino-4-(thiazol-2-
ylmethoxy)phenyl)-1H- indole-7-carboxamide (prepared using R from
Preparation #Q.1, A from Preparation #P.1) ##STR00437## E.1.13 2.79
(D) 419 B 4-(3-amino-5-(thiazol-2- ylmethoxy)phenyl)-1H-
indole-7-carboxamide (prepared using A Preparation #2 and
Preparation #35) ##STR00438## E.1.14 2.80 (o) 412 C
4-(3-amino-5-(thiazol-2- ylmethoxy)phenyl)-1H- indole-7-carboxamide
(prepared using S from 1-bromo-3-methoxy-5- nitrobenzene with
BBr.sub.3, Q from thiazol-2-ylmethanol, R with Fe, P with
4,4,4',4',5,5,5',5'- octamethyl-2,2'-bi(1,3,2- dioxaborolane), and
A from Preparation #2 ##STR00439## E.1.14 2.77 (d) 419 B
4-(2-amino-4-(thiazol-2- ylmethoxy)phenyl)-1H- indole-7-carboxamide
(prepared using A from Preparation #P.1 and Preparation #R.1)
##STR00440## E.1.16 2.77 (d) 419 C 4-(2-amino-4-
(benzyloxy)phenyl)-1H- indole-7-carboxamide (prepared using R from
Preparation #36 with Fe, and A from Preparation #P.1) ##STR00441##
E.1.17 3.29 (d) 412 C 4-(3-aminophenyl)-2- ethyl-1H-indole-7-
carboxamide (Example #20, Step C) ##STR00442## E.1.18 2.93 (d) 332
A 4-(3-amino-4- chlorophenyl)-1H-indole- 7-carboxamide (prepared
using A from Preparation #P.1 and 5-bromo-2- chloroaniline)
##STR00443## E.1.19 0.67 (ae) 340 A 4-(3-amino-2,6-
difluorophenyl)-1H-indole- 7-carboxamide (prepared using A from
Preparation #P.1 and 3-bromo-2,4- difluoroaniline) ##STR00444##
E.1.20 0.62 (ae) 342 A 4-(5-amino-2,3- difluorophenyl)-1H-indole-
7-carboxamide (prepared using A from Preparation #P.1 and
3-bromo-4,5- difluoroaniline) ##STR00445## E.1.21 0.66 (ae) 342 A
4-(5-amino-2,4- difluorophenyl)-1H-indole- 7-carboxamide (prepared
using A from Preparation #P.1 and 5-bromo-2,4- difluoroaniline)
##STR00446## E.1.22 0.62 (ae) 342 A 4-(3-amino-4-
fluorophenyyl)-1H-indole- 7-carboxamide (prepared using A from
Preparation #P.1 and 5-bromo-2- fluoroaniline) ##STR00447## E.1.23
0.62 (ae) 324 A 4-(5-amino-2- chlorophenyl)-1H-indole-
7-carboxamide (prepared using A from Preparation #P.1 and
3-bromo-4-chloroaniline) ##STR00448## E.1.24 0.65 (ae) 340 A
4-(3-amino-4- methylphenyl)-1H-indole- 7-carboxamide (prepared
using A from Preparation #P.1 and 5-bromo-2- methylaniline)
##STR00449## E.1.25 0.63 (ae) 320 A 4-(3-amino-5-
cyanophenyl)-1H-indole-7- carboxamide (prepared using A from
Preparation #P.1 and 3-bromo-3-cyano aniline) ##STR00450## E.1.26
0.63 (ae) 331 B 4-(3-amino-2-cyano- phenyl)-1H-indole-7-
carboxamide (prepared using A from Preparation #P.1 and
3-bromo-2cyano aniline) ##STR00451## E.1.27 0.58 (ae) 331 B
4-(3-amino-5- methoxyphenyl)-1H- indole-7- carboxamide (prepared
using A from Preparation #P.1 and 3-bromo-5- methoxyaniline)
##STR00452## E.1.28 0.63 (ae) 336 B 4-(3-amino-5-
methylphenyl)-1H-indole- 7-carboxamide (prepared using A from
Preparation #P.1 and 3-bromo-5- methylaniline) ##STR00453## E.1.29
0.65 (ae) 320 B 4-(3-amino-2- methoxyphenyl)-1H-
indole-7-carboxamide 2- (prepared using A from Preparation #P. 1
and 3- bromo-2-methoxyaniline) ##STR00454## E.1.30 0.63 (ae) 336 B
4-(3-amino-4- cyanophenyl)-1H-indole-7- carboxamide (prepared using
A from Preparation #P.1 and 2-amino-4- bromobenzonitrile)
##STR00455## E.1.31 0.59 (ae) 331 A 4-(5-amino-2-
fluorophenyl)-1H-indole- 7-carboxamide (prepared using A from
Preparation #P.1 and 3-bromo-4- fluoroaniline) ##STR00456## E.1.32
0.63 (ae) 324 B 4-(3-amino-2- fluorophenyl)-1H-indole-
7-carboxamide (prepared using A from Preparation #P.1 and
3-bromo-2- fluoroaniline) ##STR00457## E.1.33 0.62 (ae) 324 A
4-(3-amino-2- fluorophenyl)-1H-indole- 7-carboxamide (prepared
using A from Preparation #P.1 and 3-bromo-2- fluoroaniline)
##STR00458## E.1.33 0.62 (ae) 324 A 4-(3-(N-
(cyclopentylmethyl)acryla- mido)phenyl)-1H-indole-7- carboxamide
(prepared using H from Preparation #A.1 and
cyclopentanecarbaldehyde) ##STR00459## E.1.34 0.79 (ae) 388 C
4-(3-(N-iso- butylacrylamido)phenyl)- 1H-indole-7- carboxamide
(prepared using H from Preparation #A.1 and isobutyraldehyde)
##STR00460## E.1.35 0.75 (ae) 362 B
TABLE-US-00030 TABLE E.2 Examples prepared from
4-(3-aminophenyl)-1H-indole-7-carboxamide (Preparation #A.1) using
General Procedure E Exam- R.sub.t min m/z ple (Table 1, ESI+ Btk
Acid Chloride Product # Method) (M + H).sup.+ IC.sub.50
5-methylisoxazole-4- carbonyl chloride ##STR00461## E.2.1 2.61 (c)
361 C 1-methyl-1,2,5,6- tetrahydropyridine-3- carbonyl chloride
hydrochloride [J. Med. Chem., 1980, 23 (8) 865] ##STR00462## E.2.2
1.36 (f) 375 C
TABLE-US-00031 TABLE E.3 Examples prepared from
4-(2-aminophenyl)-2-(1-(methylsulfonyl)-1,2,3,6-
tetrahydropyridin-4-yl)-1H-indole-7-carboxamide (Example #A.4.2)
using General Procedure E Exam- R.sub.t min m/z Acid ple (Table 1,
ESI+ Btk Chloride Product # Method) (M + H).sup.+ IC.sub.50 acetyl
chloride ##STR00463## E.3.1 1.41 (f) 453 B
TABLE-US-00032 TABLE E.4 Examples prepared from
N-(3-(2-(2-(aminomethyl)phenyl)-7-carbamoyl-1H-indol-4-
yl)-2-methylphenyl)thiazole-2-carboxamide (Example #1) using
General Procedure E Acid Chloride Exam- R.sub.t min m/z or ple
(Table 1, ESI+ Btk Anhydride Product # Method) (M + H).sup.+
IC.sub.50 2-chloroacetyl chloride ##STR00464## E.4.1 3.17 (d) 558 B
propionyl chloride ##STR00465## E.4.2 3.10 (d) 538 C acetic
anhydride ##STR00466## E.4.3 3.01 (d) 524 B
TABLE-US-00033 TABLE E.5 Examples prepared from
N-(3-(3-amino-7-carbamoyl-1H-indol-4-yl)-2-
methylphenyl)thiazole-2-carboxamide (Preparation #7) using General
Procedure E Acid Exam- R.sub.t min m/z Chloride or ple (Table 1,
ESI+ Btk Anhydride Product # Method) (M + H).sup.+ IC.sub.50
2-chloro- acetyl chloride ##STR00467## E.5.1 2.79 (d) 468 C
TABLE-US-00034 TABLE E.6 Examples prepared from ethyl
carbono-chloridate using General Procedure E Exam- R.sub.t min m/z
ple (Table 1, ESI+ Btk Amine Product # Method) (M + H).sup.+
IC.sub.50 2-(2,5- dihydro- 1H- pyrrol- 3-yl)-4- (2-methyl-
3-(4-oxo- quinazolin- 3(4H)- yl)phenyl)- 1H-indole- 7-carbox- amide
(Example #G.1) ##STR00468## E.6.1 2.74 (o) 534 A 4-(2- methyl-3-
(4-oxo- quinazo- lin-3(4H)- yl)phenyl)- 2-(1,2,3,6- tetrahydro-
pyridin-4- yl)-1H- indole-7- carbox- amide (Example #G.1.1)
##STR00469## E.6.2 2.82 (o) 548 A
TABLE-US-00035 TABLE E.7 Examples prepared from 2-oxopropanoyl
chloride (prepared from pyruvic aicd and 1,1-dichlorodimethyl ether
[Synthesis, 1975, 3 163-164]) using General Procedure E Exam-
R.sub.t min m/z ple (Table 1, ESI+ Btk Amine Product # Method) (M +
H).sup.+ IC.sub.50 4-(3-aminophenyl)-1H- indole-7-carboxamide
(Preparation #A.1) ##STR00470## E.7.1 1.47 (g) 322 B 4-(3-
(aminomethyl)phenyl)- 1H-indole-7-carboxamide (prepared using A
from (3-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-
yl)phenyl)methanamine hydrochloride with 4- bromo-1H-indole-7-
carboxamide [Preparation #2]) ##STR00471## E.7.2 1.41 (g) 336 B
TABLE-US-00036 TABLE E.8 Examples prepared from acetyl chloride
using General Procedure E Exam- R.sub.t min m/z ple (Table 1, ESI+
Btk Acid Chloride Product # Method) (M + H).sup.+ IC.sub.50
2-(2,5-dihydro-1H-pyrrol- 3-yl)-4-(2-methyl-3-(4-
oxoquinazolin-3(4H)- yl)phenyl)-1H-indole-7- carboxamide (Example
#G.1) ##STR00472## E.8.1 2.72 (d) 504 A 4-(2-methyl-3-(4-
oxoquinazolin-3(4H)- yl)phenyl)-2-(1,2,3,6-
tetrahydropyridin-4-yl)- 1H-indole-7-carboxamide (Example #G.1.1)
##STR00473## E.8.2 1.78 (a) 518 A
TABLE-US-00037 TABLE E.9 Examples prepared from acryloyl chloride
with an amine using General Procedure E Exam- R.sub.t min m/z ple
(Table 1, ESI+ Btk Amine Product # Method) (M + H).sup.+ IC.sub.50
4-(2- (Aminomethyl)phenyl)- 2-(1-(methylsulfonyl)-
1,2,3,6-tetrahydropyridin- 4-yl)-1H-indole-7- carboxamide
hydrochloride (prepared using A from Preparation #18 with
tert-butyl 2-(4,4,5,5- tetramethyl-1,3,2- dioxaborolan-2-
yl)benzylcarbamate [JW] and G with HCl) ##STR00474## E.9.1 1.47 (f)
479 A 4-(Azetidin-3- yl(methyl)amino)-2- cyclopropyl-1H-indole-
7-carboxamide (prepared using A from Preparation #40 with
Cyclopropylboronic acid [SCRC] and G with HCl) ##STR00475## E.9.2
1.38 (aa) 339 A 4-(Azetidin-3- yl(methyl)amino)-2-
(isochroman-7-yl)-1H- indole-7-carboxamide (prepared using A from
Preparation #40 with 2-(isochroman-7-yl)-
4,4,5,5-tetramethyl-1,3,2- dioxaborolane [prepared using P and
7-bromoisochroman] and G with HCl) ##STR00476## E.9.3 1.44 (aa) 431
A 4-(Azetidin-3- yl(methyl)amino)-2-(6,7- dihydro-4H-pyrazolo[5,1-
c][1,4]oxazin-2-yl)-1H- indole-7-carboxamide (Prepared using P from
preparation #40, Step A with 4,4,5,5-tetramethyl-1,3,2-
dioxaborolane, A with Preparation #44, C with LiOH, D with
NH.sub.4Cl and G with HCl) ##STR00477## E.9.4 1.46 (a) 421 A
4-(Azetidin-3- yl(methyl)amino)-2-(4,4- difluorocyclohex-1-en-1-
yl)-1H-indole-7- carboxamide (prepared using A from Preparation #40
with 2-(4,4-difluorocyclohex- 1-en-1-yl)-4,4,5,5-
tetramethyl-1,3,2- dioxaborolane [Syngene] and G with HCl)
##STR00478## E.9.5 1.53 (aa) 415 A 4-(Azetidin-3-
yl(methyl)amino)-2-(4- (methylsulfonyl)cyclohex-
1-en-1-yl)-1H-indole-7- carboxamide hydrochloride (prepared using A
from Preparation #40 with 4,4,5,5-tetramethyl-2-(4-
(methylsulfonyl)cyclohex- 1-en-1-yl)-1,3,2- dioxaborolane
(WO2005/73206 A1) and G with HCl ##STR00479## E.9.6 1.44 (ab) 457 A
(S)-2-Methyl-4-(piperidin- 3-yl)-1H-indole-7- carboxamide
hydrochloride (prepared using X from Preparation #39 with LiOH, D
with NH.sub.4Cl, L with Pd/C, chiral separation (Table 2, Method 5)
and G with HCl) ##STR00480## E.9.7 1.58 (a) 312 A
(R)-2-Methyl-4-(piperidin- 3-yl)-1H-indole-7- carboxamide
hydrochloride (prepared using X from Preparation #39 with LiOH, D
with NH.sub.4Cl, L with Pd/C, chiral separation (Table 2, Method 5)
and G with HCl) ##STR00481## E.9.8 1.64 (a) 312 A 4-(Azetidin-3-
yl)(methyl)amino)-2-(6- morpholinopyridin-3-yl)-
1H-indole-7-carboxamide (Prepared using A from Preparation #40 with
4-(5-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-
yl)pyridin-2-yl)morpholine and G with HCl) ##STR00482## E.9.10 1.22
(at) 461 A 4-(Azetidin-3- yl(methyl)amino)-2-(7,8-
dihydro-5H-pyrano[4,3- b]pyridin-3-yl)-1H-indole- 7-carboxamide
hydrochloride (Prepared using A from Preparation #40 with
(7,8-dihydro-5H- pyrano[4,3-b]pyridin-3- yl)boronic acid [Anichem])
and G with HCl) ##STR00483## E.9.11 1.48 (au) 432 A 4-(Azetidin-3-
yl(methyl)amino)-2- (chroman-7-yl)-1H- indole-7-carboxamide
hydrochloride (Prepared using P from 7-bromochroman [Arkpharm] with
bis(pinacolato)diboron, A with Preparation #40 and G with HCl)
##STR00484## E.9.12 1.51 (av) 431 A 4-(Azetidin-3-
yl)(methyl)amino)-2-(5- (morpholinomethyl)
pyridin-2-yl)-1H-indole-7- carboxamide (Prepared using G from
Preparation #48 with HCl) ##STR00485## E.9.13 1.60 (aw) 475 A
4-(Azetidin-3- yl(methyl)amino)-2-(1- methyl-1H-pyrazol-4-yl)-
1H-indole-7-carboxamide hydrochloride (Prepared using A from
Preparation #40 with 1-methyl-4- (4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)-1H- pyrazole and G with HCl) ##STR00486## E.9.14
1.51 (aw) 379 A 4-(Azetidin-3- yl(methyl)amino)-2-(3,4-
dihydro-2H-benzo[b] [1,4]oxazin-6-yl)- 1H-indole-7-carboxamide
dihydrochloride (Prepared using A from Preparation #40 with tert-
butyl 3-((7-carbamoyl-2- iodo-1H-indol-4-yl)
(methyl)amino)azetidine- 1-carboxylate [Arkpharminc] and G with
HCl) ##STR00487## E.9.15 1.37 (av) 432 A 4-(Azetidin-3-
yl(methyl)amino)-2-(1- methyl-1H-pyrazol-5-yl)-
1H-indole-7-carboxamide hydrochloride (Prepared using A from
Preparation #40 with 1-methyl-5- (4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)-1H- pyrazole and G with HCl) ##STR00488## E.9.16
1.28 (be) 379 A 4-(Azetidin-3- yl(methyl)amino)-2-(2-
ethyl-1,2,3,4- tetrahydroisoquinolin-6- yl)-1H-indole-7-
carboxamide hydrochloride (Prepared using A from Preparation #40
with 1- methyl-5-(4,4,5,5- tetramethyl-1,3,2-
dioxaborolan-2-yl)-1H- pyrazole and G with HCl) ##STR00489## E.9.17
1.12 (av) 458 A 4-(Azetidin-3- yl(methyl)amino)-2-(1,3-
dimethyl-1H-pyrazol-4- yl)-1H-indole-7- carboxamide hydrochloride
(Prepared using A from Preparation #40 with 1,3-
dimethyl-4-(4,4,5,5- tetramethyl-1,3,2- dioxaborolan-2-yl)-1H-
pyrazole and G with HCl) ##STR00490## E.9.18 1.29 (av) 393 A
4-(Azetidin-3- yl(methyl)amino)-2-(1,1- dioxidotetrahydro-2H-
thiopyran-4-yl)-1H-indole- 7-carboxamide hydrochloride (Prepared
using A from Preparation #40 with 4- (4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)-3,6- dihydro-2H-thiopyran 1,1-dioxide
[JWpharmlab], L with Pd/C and G with HCl) ##STR00491## E.9.19 1.41
(aw) 431 A 4-(Azetidin-3- yl)(methyl)amino)-2-(1-
propylpiperidin-4-yl)-1H- indole-7-carboxamide (Prepared using J
from 1- iodopropane with 4- (4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)- 1,2,3,6-tetrahydropyridine [Arkpharminc], A
with Preparation #40, L with Pd/C and G with HCl) ##STR00492##
E.9.20 1.10 (av) 424 A 4-(Azetidin-3- yl)(methyl)amino)-2-
(tetrahydrofuran-3-yl)-1H- indole-7-carboxamide (Preparation #41)
##STR00493## E.9.21 1.28 (av) 369 A 4-(Azetidin-3-
yl(methyl)amino)-2-(3- hydroxyoxetan-3-yl)-1H- indole-7-carboxamide
2,2,2-trifluoroacetate (Prepared using X from Preparation # 42 with
KOH, D with NH.sub.4Cl and G with TFA) ##STR00494## E.9.22 1.18
(ay) 372 B (R)-2-(1-Methyl-1H- pyrazol-4-yl)-4-
(morpholin-2-yl)-1H- indole-7-carboxamide hydrochloride (Prepared
using Y from Preparation #43, A with 1- methyl-4-(4,4,5,5-
tetramethyl-1,3,2- dioxaborolan-2-yl)-1H- pyrazole [Arkpharm], O,
chiral separation (Table 2, Method 4) and G with HCl) ##STR00495##
E.9.23 1.40 (a) 380 A (S)-2-(1-Methyl-1H- pyrazol-4-yl)-4-
(morpholin-2-yl)-1H- indole-7-carboxamide hydrochloride (Prepared
using Y from Preparation #43, A with 1-methyl-4-(4,4,5,5-
tetramethyl-1,3,2- dioxaborolan-2-yl)-1H- pyrazole [Arkpharm], O,
chiral separation (Table 2, Method 4) and G with HCl)) ##STR00496##
E.9.24 1.36 (a) 380 A 4-(Azetidin-3- yl(methyl)amino)-2-
methyl-1H-indole-7- carboxamide hydrochloride (Prepared using A
from Preparation #40 with methylboronic acid and G with HCl)
##STR00497## E.9.25 1.30 (az) 313 A (R)-2-(6,7-Dihydro-4H-
pyrazolo[5,1- c][1,4]oxazin-2-yl)-4- (pyrrolidin-3-yl)-1H-
indole-7-carboxamide (Prepared using P from Preparation #Y.1 with
4,4,5,5-tetramethyl-1,3,2- dioxaborolane, A with Preparation #44,
chiral separation (Table 2, Method 6), C with LiOH, D with NH.sub.3
and G with HCl) ##STR00498## E.9.26 1.58 (ba) 406 A
(S)-2-(6,7-Dihydro-4H- pyrazolo[5,1- c][1,4]oxazin-2-yl)-4-
(pyrrolidin-3-yl)-1H- indole-7-carboxamide (Prepared using P from
Preparation #Y.1 with 4,4,5,5-tetramethyl-1,3,2- dioxaborolane, A
with Preparation #44, chiral separation (Table 2, Method 6), C with
LiOH, D with NH.sub.3 and G with HCl) ##STR00499## E.9.27 1.58 (ba)
406 A (R)-4-(1-(Azetidin-3- yl)ethyl)-1H-pyrrolo[3,2-
c]pyridine-7-carboxamide (prepared using AA from tert-butyl 3-
acetylazetidine-1- carboxylate [JWpharm] with
N-(5-chloropyridin-2-yl)- 1,1,1-trifluoro-N-
((trifluoromethyl)sulfonyl) methane sulfonamide, W with
4,4,4',4',5,5,5',5'- octamethyl-2,2'-bi(1,3,2- dioxaborolane)], A
with Preparation #37, L with Pd/C, C with LiOH, D ##STR00500##
E.9.28 1.03 (a) 299 A with NH.sub.4Cl, chiral separation (Table 2,
Method 7) and G with HCl) (S)-4-(1-(Azetidin-3-
yl)ethyl)-1H-pyrrolo[3,2- c]pyridine-7-carboxamide (prepared using
AA from tert-butyl 3- acetylazetidine-1- carboxylate [JWpharm] with
N-(5- chloropyridin-2-yl)- 1,1,1-trifluoro-N-
((trifluoromethyl)sulfonyl) methane sulfonamide, W with
4,4,4',4',5,5,5',5'- octamethyl-2,2'-bi(1,3,2- dioxaborolane)], A
with Preparation #37, L with Pd/C, C with LiOH, D ##STR00501##
E.9.29 0.99 (a) 299 B with NH.sub.4Cl, chiral separation (Table 2,
Method 7) and G with HCl) 4-((R)-1,4-Oxazepan-6-
yl)-7,7a-dihydro-1H- pyrrolo[3,2-c]pyridine-7- carboxamide
(prepared using C from Preparation #AH.1 with LiOH, D with
NH.sub.4Cl, L with Pd(OH).sub.2, chiral separation (Table 2, Method
8) and G with HCl) ##STR00502## E.9.30 0.97 315 (a) A
4-((S)-1,4-Oxazepan-6- yl)-7,7a-dihydro-1H-
pyrrolo[3,2-c]pyridine-7- carboxamide (prepared using C from
Preparation #AH.1 with LiOH, D with NH.sub.4Cl, L with
Pd(OH).sub.2, chiral separation (Table 2, Method 8) and G with HCl)
##STR00503## E.9.31 0.97 (as) 315 C (R)-4-(Piperidin-3-yl)-1H-
pyrrolo[3,2-c]pyridine-7- carboxamide hydrochloride (prepared using
Z from Preparation #AB.1, chiral separation (Table 2, Method 9) and
G with HCl) ##STR00504## E.9.32 1.04 (as) 299 A
(S)-4-(Piperidin-3-yl)-1H- pyrrolo[3,2-c]pyridine-7- carboxamide
hydrochloride (prepared using Z from Preparation #AB.1, chiral
separation (Table 2, Method 9) and G with HCl) ##STR00505## E.9.33
1.04 (a) 299 B 4-(Azetidin-3-ylamino)- 1H-pyrrolo[2,3-c]pyridine-
7-carboxamide (prepared using O from Preparation #AD.1, T with
tert-butyl 3- aminoazetidine-1- carboxylate[arkpharm] and G with
HCl) ##STR00506## E.9.34 1.10 (ba) 286 A tert-Butyl 3-((7-
carbamoyl-1H-indol-4- yl)(methyl)amino)-3- methylazetidine-1-
carboxylate (Prepared using T from Preparation #1, Step C and
tert-butyl 3-amino-3- methylazetidine-1- carboxylate [AKSCI], J
withCH.sub.3I, X with LiOH, D with NH.sub.4Cl and G with HCl)
##STR00507## E.9.35 1.47 (a) 313 A (R)-2-(1-Methyl-1H-
pyrazol-4-yl)-7-(piperidin- 3-yl)thiazolo[5,4-
c]pyridine-4-carboxamide (Prepared using A from Preparation #46
with tert-butyl 3-(4,4,5,5- tetramethyl-1,3,2-
dioxaborolan-2-yl)-5,6- dihydropyridine-1(2H)- carboxylate, L with
Pd/C, chiral separation (Table 2, Method 10) and G with HCl)
##STR00508## E.9.36 1.62 (as) 397 A (S)-2-(1-Methyl-1H-
pyrazol-4-yl)-7-(piperidin- 3-yl)thiazolo[5,4-
c]pyridine-4-carboxamide (Prepared using A from Preparation #46
with tert-butyl 3-(4,4,5,5- tetramethyl-1,3,2-
dioxaborolan-2-yl)-5,6- dihydropyridine-1(2H)- carboxylate, L with
Pd/C, chiral separation (Table 2, Method 10) and G with HCl)
##STR00509## E.9.37 1.60 (as) 397 A (S)-4-(1,4-Oxazepan-6-yl)-
1H-indole-7-carboxamide (prepared using AA with tert-butyl
6-oxo-1,4- oxazepane-4- carboxylate[Arkpharm] and
1,1,1-trifluoro-N- phenyl-N- ((trifluoromethyl)sulfonyl) methane
sulfonamide, A with Preparation #P.1, L with Pd/C, chiral
separation (Table 2, Method 11) and G with HCl) ##STR00510## E.9.38
1.34 (a) 314 A (R)-4-(1,4-Oxazepan-6-yl)- 1H-indole-7-carboxamide
(prepared using AA with tert-butyl 6-oxo-1,4- oxazepane-4-
carboxylate[Arkpharm] and 1,1,1-trifluoro-N- phenyl-N-
((trifluoromethyl)sulfonyl) methane sulfonamide, A with Preparation
#P.1, L with Pd/C, chiral separation (Table 2, Method 11) and G
with HCl) ##STR00511## E.9.39 1.33 (a) 314 C (S)-2-Methyl-4-
(pyrrolidin-3-yl)-1H- indole-7-carboxamide (Prepared using chiral
separation (Table 2, Method 3) from Preparation #38, C with LiOH, D
with NH.sub.3 and G with HCl) ##STR00512## E.9.40* 1.52 (ba) 298 B
(R)-2-Methyl-4- (pyrrolidin-3-yl)-1H- indole-7-carboxamide
(Prepared using chiral separation (Table 2, Method 3) from
Preparation #38, C with LiOH, D with NH.sub.3 and G with HCl)
##STR00513## E.9.41* 1.60 (ba) 298 B 4-((1S,5S)-3,6-
Diazabicyclo[3.2.0] heptan-3-yl)-1H-indole- 7-carboxamide (Prepared
using A from 4-bromo- 1H-indole-7- carboxamide[Anthem] with
tert-butyl 3,6- diazabicyclo[3.2.0] heptane-6-carboxylate
[Arkpharm], chiral separation (Table 2, Method 13) and G with HCl)
##STR00514## E.9.42 1.39 (ba) 311 B 4-((1R,5R)-3,6-
Diazabicyclo[3.2.0] heptan-3-yl)-1H-indole- 7-carboxamide (Prepared
using A from 4-bromo- 1H-indole-7- carboxamide[Anthem] with
tert-butyl 3,6- diazabicyclo[3.2.0] heptane-6-carboxylate
[Arkpharm], chiral separation (Table 2, Method 13) and G with HCl)
##STR00515## E.9.43 1.40 (ba) 311 B
4-((3S,5R)-5- (Hydroxymethyl) piperidin-3-yl)-1H-
indole-7-carboxamide (Prepared using chiral separation (Table 2,
Method 14) from Preparation #AE.1 and G with HCl) ##STR00516##
E.9.44 1.31 (ba) 328 B 4-((3S,5S)-5- (Hydroxymethyl)
piperidin-3-yl)-1H- indole-7-carboxamide (Prepared using chiral
separation (Table 2, Method 14) from Preparation #AE.1 and G with
HCl) ##STR00517## E.9.45 1.29 (ba) 328 C 4-(5- (Hydroxymethyl)
piperidin-3-yl)-1H- indole-7-carboxamide (Prepared using chiral
separation (Table 2, Method 14) from Preparation #AE.1 and G with
HCl) ##STR00518## E.9.46 1.34 (ba) 328 C 4-(5- (Hydroxymethyl)
piperidin-3-yl)-1H- indole-7-carboxamide (Prepared using chiral
separation (Table 2, Method 14) from Preparation #AE.1 and G with
HCl) ##STR00519## E.9.47 1.30 (ba) 328 B (R)-2-(1-Methyl-1H-
pyrazol-4-yl)-4- (pyrrolidin-3-yl)-1H- indole-7-carboxamide
hydrochloride (Prepared using A from Preparation #Y.1 with
1-methyl-4-(4,4,5,5- tetramethyl-1,3,2- dioxaborolan-2-yl)-1H-
pyrazole[arkpharm], chiral separation (Table 2, Method 17), C with
LiOH, D with NH.sub.3 and G with HCl) ##STR00520## E.9.48 1.39 (a)
364 A (S)-2-(1-Methyl-1H- pyrazol-4-yl)-4- (pyrrolidin-3-yl)-1H-
indole-7-carboxamide (Prepared using A from Preparation #Y.1 with
1-methyl-4-(4,4,5,5- tetramethyl-1,3,2- dioxaborolan-2-yl)-1H-
pyrazole[arkpharm], chiral separation (Table 2, Method 17), C with
LiOH, D with NH.sub.3 and G with HCl) ##STR00521## E.9.49 1.50 (ba)
364 B 4-((1R,3R)-3- Aminocyclopentyl)-1H- indole-7-carboxamide
hydrochloride (Prepared using C from Preparation #47 with LiOH, D
with NH.sub.4Cl and G with HCl) ##STR00522## E.9.50 1.43 (a) 298 A
(S)-4-(Piperidin-3-yl)-1H- pyrrolo[2,3-c]pyridine-7- carboxamide
(Prepared using A from Example #29, Step A with tert-butyl
3-(4,4,5,5- tetramethyl-1,3,2- dioxaborolan-2-yl)-5,6-
dihydropyridine-1(2H)- carboxylate, O, L with Pd/C, chiral
separation (Table 2, Method 18) and G with acetyl chloride)
##STR00523## E.9.51 1.42 (ba) 299 B (R)-4-(Piperidin-3-yl)-1H-
pyrrolo[2,3-c]pyridine-7- carboxamide (Prepared using A from
Example #29, Step A with tert-butyl 3-(4,4,5,5- tetramethyl-1,3,2-
dioxaborolan-2-yl)-5,6- dihydropyridine-1(2H)- carboxylate, O, L
with Pd/C, chiral separation (Table 2, Method 18) and G with acetyl
chloride) ##STR00524## E.9.52 1.43 (ba) 299 B
TABLE-US-00038 TABLE E.9.1 Examples prepared from acryloyl chloride
with an amine using General Procedure E Exam- R.sub.t min m/z ple
(Table 1, (M + H.sub.2O + Btk Amine Product # Method) H).sup.+
IC.sub.50 4-(Azetidin-3- yl(methyl)amino)-2-(3-
hydroxyoxetan-3-yl)-1H- indole-7-carboxamide 2,2,2-trifluoroacetate
(Prepared using X from Preparation # 42 with KOH, D with NH.sub.4Cl
and G with TFA) ##STR00525## E.9.1.1 1.18 (ay) 353 B
TABLE-US-00039 TABLE E.10 Examples prepared from propionyl chloride
with an amine using General Procedure E R.sub.t min (Table 1, m/z
ESI+ Btk Amine Product Example # Method) (M + H).sup.+ IC.sub.50
(R)-2-Methyl-4- (pyrrolidin-3-yl)-1H- indole-7-carboxamide
(Prepared using chiral separation (Table 2, Method 12) from
Preparation #38, C with LiOH, D with NH.sub.3 and G with HCl)
##STR00526## E.10.1 1.64 (ba) 300 B (S)-2-Methyl-4-
(pyrrolidin-3-yl)-1H- indole-7-carboxamide (Prepared using chiral
separation (Table 2, Method 12) from Preparation #38, C with LiOH,
D with NH.sub.3 and G with HCl) ##STR00527## E.10.2 1.63 (ba) 300
B
General Procedure F: Formation of a4-iodoindole-7-carboxamide
[1062] To a solution of 2-amino-4-nitrobenzoic acid (preferably
1equiv) in MeOH is added slowly concentrated sulfuric acid
(preferably 1equiv). The resulting solution is heated at about
75.degree. C. for about 3 days. After cooling, the reaction is
neutralized by addition of aqueous NaOH solution until pH-10. The
reaction is extracted with EtOAc, dried over anhydrous sodium
sulfate, filtered and concentrated. To this intermediate
(preferably 1equiv) is added a methyl ketone (1-2 equiv, preferably
2 equiv) and an organic solvent (preferably dimethyl sulfoxide).
The reaction is cooled to about -15.degree. C. A base (preferably
potassium tert-butoxide 2 equiv) is added. After stirring for about
2.5 h at rt, the reaction is quenched with saturated aqueous
ammonium chloride solution and then stirred for about 1 h at rt.
The resulting suspension was filtered, washed with water and the
solid is dried under high vacuum. To this intermediate (preferably
1 equiv) is added
((1H-benzo[d][1,2,3]triazol-1-yl)oxy)tri(pyrrolidin-1-yl)phosphonium
hexafluorophosphate(V) (preferably 2 equiv), hydroxybenzotriazole
hydrate (preferably 2 equiv) and ammonium chloride (preferably 1.5
equiv) and an organic solvent (preferably DMF). An organic base
(preferably diisopropylethylamine, 4 equiv) is added. The reaction
mixture is stirred at rt overnight. The mixture is poured into
water and the resulting precipitate is filtered, washed with water
and EtOAc, and collected. To this intermediate (preferably 1 equiv)
is added an organic solvent (preferably MeOH), and the solution is
purged with nitrogen. To this solution is added 10% palladium on
carbon (preferably 0.1 equiv). The resulting suspension is treated
with hydrogen (30 psi). After stirring overnight at rt, the
reaction is filtered, and the solids are rinsed with MeOH. The
filtrate is concentrated. A solution of sodium nitrite (preferably
2.2 equiv) in water is added to an ice cold suspension of this
intermediate (preferably 1 equiv) in an organic solvent (preferably
MeCN) and 2N HCl (preferably 5.4 equiv) with stirring, maintaining
the temperature below about -5.degree. C. After stirring for about
30 min, a cold solution of aqueous potassium iodide (preferably 2.5
equiv) is added to the reaction and the resulting mixture was
stirred at rt for about 30 min. The reaction is heated to about
85.degree. C. for about 5 min. The reaction is cooled to rt and
neutralized with saturated aqueous sodium bicarbonate to pH 8. The
mixture is extracted with DCM. The organic layer is washed with
brine, dried over sodium sulfate, filtered and concentrated. The
residue is purified by flash chromatography (preferably silica gel,
petroleum ether) to give the target compound.
Illustration of General Procedure F
Example #F.1: 4-Iodo-2-(pyridin-3-yl)-1H-indole-7-carboxamide
##STR00528##
[1064] To a solution of 2-amino-4-nitrobenzoic acid (102 g, 560
mmol) in MeOH (1.5 L) was added slowly concentrated sulfuric acid
(0.030 L, 560 mmol). The resulting solution was heated at about
75.degree. C. for about 3 days. After cooling, the product was
neutralized by addition of aqueous NaOH solution until pH.about.10.
The crude product was extracted with EtOAc, dried over anhydrous
sodium sulfate, filtered and concentrated to provide methyl
2-amino-4-nitrobenzoate (100 g, 91%). LC/MS (Table 1, Method ar)
R.sub.t=1.85 min; MS m/z 197.1 (M+H).sup.+. To a portion of this
material (25 g, 127 mmol) and 1-(pyridin-3-yl)ethanone (30.9 g, 255
mmol) in dimethyl sulfoxide (150 mL) at about -15.degree. C. was
added potassium tert-butoxide (28.6 g, 255 mmol). After stirring
for about 2.5 h at rt, the reaction was quenched with saturated
aqueous ammonium chloride solution (100 mL) and then stirred for
about 1 hr at rt. The resulting suspension was filtered, washed
with water and dried under high vacuum to provide
4-nitro-2-(pyridin-3-yl)-1H-indole-7-carboxylic acid (22.4 g, 34%).
LC/MS (Table 1, Method ab) R.sub.t=1.50 min; MS m/z 284.1
(M+H).sup.+. To a mixture of this material (26.9 g, 95 mmol),
((1H-benzo[d][1,2,3]triazol-1-yl)oxy)tri(pyrrolidin-1-yl)phosphonium
hexafluorophosphate(V) (99 g, 190 mmol), hydroxybenzotriazole
hydrate (29.1 g, 190 mmol) and ammonium chloride (7.62 g, 142 mmol)
in DMF (150 mL) was added diisopropylethylamine (66.3 mL, 380
mmol). The reaction mixture was stirred at rt overnight. The
mixture was poured into 1000 mL water and the precipitate was
filtered, washed with water and EtOAc, and collected to provide
4-nitro-2-(pyridin-3-yl)-1H-indole-7-carboxamide (17.48 g, 56%).
LC/MS (Table 1, Method ar) R.sub.t=1.44 min; MS m/z 283.1
(M+H).sup.+. To a nitrogen-purged stirred solution of this material
(17.5 g, 52.6 mmol) in MeOH (1.5 L) was added 10% palladium on
carbon (5.60 g, 5.26 mmol). The resulting suspension was treated
with hydrogen (30 psi). After stirring overnight at rt, the
reaction was filtered, and the solids were rinsed with MeOH. The
filtrate was concentrated to provide
4-amino-2-(pyridin-3-yl)-1H-indole-7-carboxamide (10 g, 75%). LC/MS
(Table 1, Method ar) R.sub.t=1.10 min; MS m/z 253.1 (M+H).sup.+. A
solution of sodium nitrite (7.82 g, 113 mmol) in water (20 mL) was
added to an ice cold suspension of this material (13 g, 51.5 mmol)
in MeCN (150 mL) and 2N hydrogen chloride (188 mL, 376 mmol) with
stirring, maintaining the temperature below about -5.degree. C.
After stirring for about 30 min, a cold solution of aqueous
potassium iodide (21.4 g, 129 mmol) was added to the reaction and
the resulting mixture was stirred at rt for about 30 min. The
reaction was heated on a water bath (85.degree. C.) for 5 min. The
reaction was cooled to rt and neutralized with saturated aqueous
sodium bicarbonate to pH 8. The mixture was extracted with DCM. The
organic layer was washed with brine, dried over sodium sulfate,
filtered and concentrated. The residue was purified by flash
chromatography (silica gel, petroleum ether) to provide
4-iodo-2-(pyridin-3-yl)-1H-indole-7-carboxamide (2.0 g, 9%). LC/MS
(Table 1, Method ab) R.sub.t=1.88 min; MS m/z 364.0 (M+H).sup.+.
(Btk IC.sub.50=B)
General Procedure G: Acidic Cleavage of a Boc-Protected Amine
[1065] To a solution of an N-Boc amine (1 equiv) in an organic
solvent (such as DCM, DCE, 1,4-dioxane, EtOAc, or MeOH, preferably
DCM, EtOAc, or 1,4-dioxane) is added an acid (such as TFA or HCl,
preferably TFA; 2 to 35 equiv, preferably 15 to 25 equiv). The
mixture is stirred at about 0 to 100.degree. C. (preferably about
20 to 60.degree. C.) for about 1 to 24 h (preferably about 1 to 6
h). Optionally, additional acid (2 to 35 equiv, preferably 20 to 25
equiv) may be added and the mixture stirred at about 0 to
100.degree. C. (preferably about 15 to 60.degree. C.) for about 1
to 24 h (preferably about 1 to 6 h). If a solid is present in the
mixture, the mixture may be optionally filtered and the solid
washed with an organic solvent such as 1,4-dioxane or Et.sub.2O.
The resulting solid is then optionally dried under reduced pressure
to give the targeted compound. Alternatively, the mixture may be
optionally concentrated in vacuo to give final compound.
Alternatively, the mixture is optionally filtered through a media
(such as silica gel or Celite.RTM.) which is rinsed with an
appropriate solvent (such as EtOAc, 1,4-dioxane, THF, MeCN, DCM,
Et.sub.2O, MeOH, EtOH) and then optionally concentrated in vacuo to
give a residue. Either the residue or the solution may be
optionally partitioned between water and an organic solvent (such
as EtOAc, Et.sub.2O or DCM). The organic layer is isolated and may
be optionally washed in no particular order with water and/or
aqueous solutions containing an acid (such as HCl, AcOH or
NH.sub.4Cl) and/or aqueous solutions containing a base (such as
NaHCO.sub.3, Na.sub.2CO.sub.3, NaOH, KOH or NH.sub.4OH) and/or
aqueous solutions containing an inorganic salt (such as NaCl
Na.sub.2SO.sub.3 or Na.sub.2S.sub.2O.sub.3). The organic solution
may then be optionally dried with a drying agent (such as anhydrous
MgSO.sub.4 or Na.sub.2SO.sub.4), filtered and concentrated in vacuo
to give the targeted compound.
Illustration of General Procedure G
Example #G.1.
2-(2,5-Dihydro-1H-pyrrol-3-yl)-4-(2-methyl-3-(4-oxoquinazolin-3(4H)-yl)ph-
enyl)-1H-indole-7-carboxamide
##STR00529##
[1067] To a solution of tert-butyl
3-(7-carbamoyl-4-(2-methyl-3-(4-oxoquinazolin-3(4H)-yl)phenyl)-1H-indol-2-
-yl)-2,5-dihydro-1H-pyrrole-1-carboxylate (0.6 g, 1 mmol,
Preparation #15) in EtOAc (20 mL) was added HC/EtOAc at rt. The
reaction mixture was stirred at rt for 1 h. The solid was collected
as a salt via filtration and dried to give
2-(2,5-dihydro-1H-pyrrol-3-yl)-4-(2-methyl-3-(4-oxoquinazolin-3(4H)-yl)ph-
enyl)-1H-indole-7-carboxamide hydrochloride (0.5 g, 94%): LC/MS
(Table 1, Method d) R.sub.t=2.39 min; MS m/z: 462 (M+H).sup.+ (Btk
IC.sub.50=A).
TABLE-US-00040 TABLE G.1 Examples prepared using General Procedure
G R.sub.t min (Table 1, m/z ESI+ Btk N-Boc Amine Product Example #
Method) (M + H).sup.+ IC.sub.50 tert-butyl 4-(7-carbamoyl-
4-(2-methyl-3-(4- oxoquinazolin-3(4H)- yl)phenyl)-1H-indol-2-yl)-
5,6-dihydropyridine- 1(2H)-carboxylate (Preparation #2)
##STR00530## G.1.1 2.13 (o) 476 A di-tert-butyl (2-((3-(7-
carbamoyl-1H-indol-4- yl)phenyl)carbamoyl)allyl) carbamate
(prepared using J from 2- (bromomethyl)acrylic acid and
di-tert-butyl iminodicarboxylate, D from Preparation #A.1)
##STR00531## G.1.2 2.17 (d) 335 A tert-butyl (2-((3-(7-
carbamoyl-1H-indol-4- yl)phenyl)carbamoyl)allyl)- (methyl)carbamate
(prepared using J from 2- (bromomethyl)acrylic acid and tert-butyl
methylcarbamate, D from Preparation #A.1) ##STR00532## G.1.3 2.20
(d) 349 A
General Procedure H: Reductive Amination of an Aldehyde or Ketone
with a Primary or Secondary Amine
[1068] An aldehyde or ketone (preferably 1.0 equiv to 1.3 equiv)
and an amine or amine salt (preferably 1.0 to 2.2 equiv) are added
in an organic solvent or mixture of organic solvents (such as DCM,
DCE or MeOH, or a mixture of DCE and MeOH, preferably DCE, MeOH, or
1:1MeOH/DCM) at about rt to about 80.degree. C. (preferably about
rt). If an amine salt is used, then an amine base (such as TEA or
DIEA, 1.0 to 2.2 equiv) is optionally added. AcOH (0.1 equiv to 5.0
equiv) is optionally added. The mixture is stirred at rt for about
1 to 90 min (preferably 5 to 30 min). A reducing agent (such as
NaBH(OAc).sub.3, Na(CN)BH.sub.3, NaBH.sub.4, MP-Cyanoborohydride
from Biotage.TM., 0.5 to 5.0 equiv, preferably 2.5-3.0 equiv of
NaBH(OAc).sub.3), is added as a solid or as a solution in an
organic solvent (as DCM, DCE or MeOH, or a mixture of DCE and MOH).
The mixture is stirred at rt for about 30 min to 72 h (preferably 1
to 24 h). The crude mixture may be concentrated under reduced
pressure or optionally partitioned between water and an organic
solvent (such as EtOAc, Et.sub.2O or DCM). The organic layer is
isolated and may be optionally washed with water and/or aqueous
solutions containing an acid (such as HCl, AcOH or NH.sub.4Cl)
and/or aqueous solutions containing a base (such as NaHCO.sub.3,
Na.sub.2CO.sub.3, NaOH, KOH or NH.sub.4OH) and/or aqueous solutions
containing an inorganic salt (such as NaCl or Na.sub.2SO.sub.3).
The organic solution may then be optionally dried with a drying
agent (such as MgSO.sub.4 or Na.sub.2SO.sub.4), filtered and
concentrated in vacuo to give the target compound.
Illustration of General Procedure H
Example #H.1.
2-(1-Methyl-2,5-dihydro-1H-pyrrol-3-yl)-4-(2-methyl-3-(4-oxoquinazolin-3(-
4H)-yl)phenyl)-1H-indole-7-carboxamide
##STR00533##
[1070] To a solution of
2-(2,5-dihydro-1H-pyrrol-3-yl)-4-(2-methyl-3-(4-oxoquinazolin-3(4H)-yl)ph-
enyl)-1H-indole-7-carboxamide (50 mg, 0.1 mmol, Example #G.1) in
MeOH (1 mL) was added (CH.sub.2O) (1.6 mg, 0.054 mmol) at rt. After
stirring at rt for 1 h under N.sub.2 atmosphere, NaBH(OAc).sub.3
(60 mg, 0.27 mmol) was added. The resulting mixture was stirred at
rt for 2 h. The solvent was removed under reduced pressure to give
a residue, which was purified by prep-HPLC to give
2-(1-methyl-2,5-dihydro-1H-pyrrol-3-yl)-4-(2-methyl-3-(4-oxoquinazolin-3(-
4H)-yl)phenyl)-1H-indole-7-carboxamide (15 mg, 32%): LC/MS (Table
1, Method o) R.sub.t=2.05 min; MS m/z: 476 (M+H).sup.+ (Btk
IC.sub.50 A).
TABLE-US-00041 TABLE H.1 Examples prepared from
4-(2-methyl-3-(4-oxoquinazolin-3(4H)-yl)phenyl)-2-(1,2,3,6-
tetrahydropyridin-4-yl)-1H-indole-7-carboxamide (Example #G.1.1)
using General Procedure H R.sub.t min (Table 1, m/z ESI+ Btk
Aldehyde Product Example # Method) (M + H).sup.+ IC.sub.50
paraformaldehyde ##STR00534## H.1.1 2.08 (o) 490 A
TABLE-US-00042 TABLE H.2 Examples prepared from
4-(3-amino-2-methylphenyl)-2-(1-(methylsulfonyl)-1,2,3,6-
tetrahydropyridin-4-yl)-1H-indole-7-carboxamide (Example #A.4.5)
using General Procedure H R.sub.t min (Table 1, m/z ESI+ Btk
Aldehyde Product Example # Method) (M + H).sup.+ IC.sub.50
thiazole-2- carbaldehyde ##STR00535## H.2.1 1.74 (g) 522 A
General Procedure I: Formation of a Sulfonamide from an Amine and a
Sulfonyl Chloride
[1071] To a flask is added an amine (1.0 equiv), optionally as a
hydrochloride salt, a solvent or mixture of solvents (such as DCM,
DCE, EtOAc, THF, 1,4-dioxane, pyridine, DME, or pyridine/DCM,
preferably THF, optionally with a base (such as TEA, DIEA,
preferably DIEA; 1 to 5 equiv, preferably 1-2 equiv) and a sulfonyl
chloride (0.9 to 2.0 equiv, preferably 1.0 to 1.25 equiv). The
mixture is stirred at about 0 to 80.degree. C. (preferably about 0
to 35.degree. C.) for about 1 h to 24 h (preferably 5 to 16 h). The
mixture may optionally be concentrated in vacuo to give a residue
as the target compound. Either the residue or the solution may be
optionally partitioned between water and an organic solvent (such
as EtOAc, Et.sub.2O or DCM). The organic layer is isolated and may
optionally be washed in no particular order with water and/or
aqueous solutions containing an acid (such as HCl, AcOH or
NH.sub.4Cl) and/or aqueous solutions containing a base (such as
NaHCO.sub.3, Na.sub.2CO.sub.3, NaOH, KOH or NH.sub.4OH) and/or
aqueous solutions containing an inorganic salt (such as NaCl
Na.sub.2SO.sub.3 or Na.sub.2S.sub.2O.sub.3). The organic solution
may then be optionally dried with a drying agent (such as anhydrous
MgSO.sub.4 or Na.sub.2SO.sub.4), filtered and concentrated in vacuo
to give the target compound.
Illustration of General Procedure I
Example #I.1:
4-(3-(Vinylsulfonamido)phenyl)-1H-indole-7-carboxamide
##STR00536##
[1073] To a mixture of 4-(3-aminophenyl)-1H-indole-7-carboxamide
(0.11 g, 0.438 mmol, Preparation #A.1), THF (4 mL) and DIEA (0.152
mL, 0.876 mmol) at about 0.degree. C. (ice bath) was added
ethenesulfonyl chloride (0.058 g, 0.460 mmol, FCH Group). The ice
bath was removed and mixture was stirred for about 6 h at rt. The
reaction mixture was concentrated under reduced pressure and the
residue was dissolved in DCM and washed water (2.times.), brine,
and passed through a Biotage Phase separator. The mixture was
concentrated under reduced pressure and the residue was purified on
silica gel using a gradient of 0-10% MeOH in DCM to provide a
solid. The solid was triturated with ether (3.times., sonicating
after each addition of ether). The solid was dried over night under
reduced pressure at 75.degree. C. to provide
4-(3-(vinylsulfonamido)phenyl)-1H-indole-7-carboxamide (29 mg,
19%): LC/MS (Table 1, Method c) R.sub.t=2.34 min; MS m/z 342
(M+H).sup.+. (Btk IC.sub.50=A)
General Procedure J: Substitution of an Alkyl Halide with an Amine
Nucleophile
[1074] A flask is charged with an alkyl halide (preferably 1 equiv)
and an organic solvent (such as THF, MeCN, DMF, DMA, NMP or DMSO;
preferably THF or MeCN). To the flask are added in no particular
order the amine nucleophile (1 to 25 equiv, preferably 1.2-20
equiv) and an optionally a base (such as LiHMDS, NaH,
K.sub.2CO.sub.3, NaHMDS, NaOt-Bu, KHMDS or KOt-Bu, preferably none,
NaH or K.sub.2CO.sub.3; 1 to 5 equiv, preferably 1-3 equiv). The
mixture is stirred at about 0 to 100.degree. C. (preferably about
0-40.degree. C.) for about 1 to 24 h (preferably about 3 to 20 h).
The mixture may optionally be concentrated in vacuo to give a
residue as the target compound. Either the residue or the solution
may be optionally partitioned between water and an organic solvent
(such as EtOAc, Et.sub.2O or DCM). The organic layer is isolated
and may optionally be washed in no particular order with water
and/or aqueous solutions containing an acid (such as HCl, AcOH or
NH.sub.4Cl) and/or aqueous solutions containing a base (such as
NaHCO.sub.3, Na.sub.2CO.sub.3, NaOH, KOH or NH.sub.4OH) and/or
aqueous solutions containing an inorganic salt (such as NaCl
Na.sub.2SO.sub.3 or Na.sub.2S.sub.2O.sub.3). The organic solution
may then be optionally dried with a drying agent (such as anhydrous
MgSO.sub.4 or Na.sub.2SO.sub.4), filtered and concentrated in vacuo
to give the target compound. Alternatively, the residue from
concentrating the reaction mixture may be suspended in water,
sonicated and collected via vacuum filtration.
Illustration of General Procedure J
Example #J.1:
(E)-4-(3-(4-(Dimethylamino)but-2-enamido)-2-methylphenyl)-1H-indole-7-car-
boxamide
##STR00537##
[1076] To a solution of
(E)-4-(3-(4-bromobut-2-enamido)-2-methylphenyl)-1H-indole-7-carboxamide
(1.4 g, 3.40 mmol, prepared using E from
4-(3-amino-2-methylphenyl)-1H-indole-7-carboxamide (Example #16)
and (E)-4-bromobut-2-enoyl chloride [J. Org. Chem. 2011, 76, 4467])
in THF (24 mL) at 0.degree. C. was added 2 M dimethylamine in THF
(34.0 mL, 67.9 mmol). The mixture was stirred for 3 h while warming
to rt. The mixture was concentrated under reduced pressure and
water (15 mL) was added to the residue. The mixture was sonicated
for about 20 min at rt, filtered, washed with water and dried under
reduced pressure. The residue was added to a silica gel column and
was eluted with MeOH/DCM (0-15%) to provide the crude product
(0.650 g). The crude product was dissolved in DMA (5 mL) and water
(100 mL) added while stirring for 20 min at rt. The mixture was
filtered, washed with water (50 mL.times.3), and dried under
reduced pressure to provide
(E)-4-(3-(4-(dimethylamino)but-2-enamido)-2-methylphenyl)-1H-indole-7-car-
boxamide (0.40 g, 31%): LC/MS (Table 1, Method f) R.sub.t=1.05 min;
MS m/z 377 (M+H).sup.+. (Btk IC.sub.50 B)
TABLE-US-00043 TABLE J.1 Examples prepared from an
(E)-4-(3-(4-bromobut-2-enamido)-2-methylphenyl)-1H-
indole-7-carboxamide (prepared using E from
4-(3-amino-2-methylphenyl)-1H-indole-7- carboxamide (Example #16)
and (E)-4-bromobut-2-enoyl chloride [J.Org.Chem. 2011, 76, 4467])
using General Procedure J R.sub.t min (Table 1, m/z ESI+ Btk Amine
Product Example # Method) (M + H).sup.+ IC.sub.50 piperidine
##STR00538## J.1.1 1.13 (f) 417 B (tetrahydrofuran-2-yl)
methanamine ##STR00539## J.1.2 1.13 (f) 433 B 2-methoxyethanamine
##STR00540## J.1.3 1.09 (f) 407 C cyclopropanamine ##STR00541##
J.1.4 1.09 (f) 389 B morpholine ##STR00542## J.1.5 1.06 (f) 419 C
1-methylpiperazine ##STR00543## J.1.6 1.14 (f) 432 C
TABLE-US-00044 TABLE J.2 Example prepared from
(E)-4-(3-(4-bromobut-2-enamido)-2-methylphenyl)-1H-
pyrrolo[2,3-c]pyridine-7-carboxamide (prepared using E from
4-(3-amino-2-methylphenyl)-1H- pyrrolo[2,3-c]pyridine-7-carboxamide
(Example #2) and (E)-4-bromobut-2-enoyl chloride [J.Org.Chem. 2011,
76, 4467]) using General Procedure J R.sub.t min (Table 1, m/z ESI+
Btk Amine Product Example # Method) (M + H).sup.+ IC.sub.50
Dimethyl amine ##STR00544## J.2.1 0.70 (g) 378 B
TABLE-US-00045 TABLE J.3 Example prepared from cyanic bromide with
an amine using General Procedure J R.sub.t min (Table 1, m/z ESI+
Btk Amine Product Example # Method) (M + H).sup.+ IC.sub.50
4-(Azetidin-3- yl(methyl)amino)-2- methyl-1H-indole-7- carboxamide
hydrochloride (Prepared using A from Preparation #40 with
methylboronic acid and G with HCl) ##STR00545## J.3.1 1.39 (at) 284
B
General Procedure K: Hydrolysis of an acetonide
[1077] To a solution of an acetonide (preferably 1equiv) in an
organic solvent (such as 1,4-dioxane and THF, preferably THF) is
added an acid, such as 4MHCl inl,4-dioxane (3-100 equiv, preferably
30-40 equiv). The reaction mixture is heated at about
20-120.degree. C. (preferably about rt using conventional heating;
about 120.degree. C. using microwave irradiation) for about 0.25-24
h (preferably about 4 h using conventional heating; about 20 min
using microwave irradiation). The reaction mixture is allowed to
cool to ambient temperature before it is optionally partitioned
between an organic solvent (such as EtOAc or DCM) and aqueous base
(such as NaHCO.sub.3, Na.sub.2CO.sub.3 or NaOH, preferably
NaHCO.sub.3) and the aqueous layer is optionally extracted with
additional organic solvent (such as EtOAc or DCM). The organic
layer is dried over anhydrous MgSO.sub.4 or Na.sub.2SO.sub.4,
filtered, and cond under reduced pressure. Alternatively the
solvent is removed under reduced pressure to give the desired
compound.
Illustration of General Procedure K
Example
#K.1*:2-(1-((R)-2,3-Dihydroxypropyl)-1H-pyrazol-4-yl)-4-(2-methyl--
3-(4-oxoquinazolin-3(4H)-yl)phenyl)-1H-indole-7-carboxamide
##STR00546##
[1079] To a solution of
2-(1-(((R)-2,2-dimethyl-1,3-dioxolan-4-yl)methyl)-1H-pyrazol-4-yl)-4-(2-m-
ethyl-3-(4-oxoquinazolin-3(4H)-yl)phenyl)-1H-indole-7-carboxamide
(0.047 g, 0.082 mmol, prepared using A from
4-bromo-2-iodo-1H-indole-7-carboxamide and
(R)-1-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)-4-(4,4,5,5-tetramethyl-1,3-
,2-dioxaborolan-2-yl)-1H-pyrazole (Preparation #20), A from
3-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)quinazo-
lin-4(3H)-one [PCT Int. Appl., WO 2011159857]) in THF (5 mL) was
added 4 M HCl in 1,4-dioxane (0.5 mL). The mixture was stirred at
rt for about 4 h. The reaction mixture was concentrated under
reduced pressure and the residue was purified by prep-HPLC (Table
1, Method af) to provide
2-(1-((R)-2,3-dihydroxypropyl)-1H-pyrazol-4-yl)-4-(2-methyl-3-(4-oxoquina-
zolin-3(4H)-yl)phenyl)-1H-indole-7-carboxamide (0.035 g, 80%):
LC/MS (Table 1, Method a) R.sub.t=1.65 min; MS m/z 535. (Btk
IC.sub.50=A)
TABLE-US-00046 TABLE K.1 Examples prepared from an acetonide using
General Procedure K R.sub.t min m/z Example (Table 1, ESI+ Btk
Acetonide Product # Method) (M + H).sup.+ IC.sub.50
2-(1-(((S)-2,2-dimethyl-1,3- dioxolan-4-yl)methyl)-1H-
pyrazol-4-yl)-4-(2-methyl-3- (4-oxoquinazolin-3(4H)-
yl)phenyl)-1H-indole-7- carboxamide (prepared using A from
4-bromo-2-iodo-1H- indole-7-carboxamide and Preparation #21, A from
3- (2-methyl-3-(4,4,5,5- tetramethyl-1,3,2- dioxaborolan-2-
yl)phenyl)quinazolin-4(3H)- one [WO 2011159857]) ##STR00547## K.1.1
1.64 (a) 535 A
General Procedure L: Hydrogenation of an Alkene
[1080] A round bottom flask is charged with a palladium catalyst,
such as Pd/C or Pd(OH).sub.2 (10 or 20 wt %, about 0.005 to 1.0
equiv, preferably 0.5 to 1.0 equiv). The flask is evacuated then
flushed with nitrogen 2 to 5 times (preferably 3 times) prior to
addition of an organic solvent or mixture of solvents (such as
EtOAc, MeOH, EtOH or MeOH/AcOH, preferably MeOH/AcOH) under a
nitrogen atmosphere. To the mixture is added an alkene (preferably
1 equiv), neat or optionally as a solution in an organic solvent or
mixture of solvents (such as EtOAc, MeOH, EtOH or MeOH/AcOH,
preferably MeOH). The mixture is stirred under a hydrogen
atmosphere (about 30 to 50 psi) for about 1 to 60 h (preferably
about 4 to 5 h). Optionally the reaction may be performed using an
H-cube instrument with either Pd/C or Pd(OH).sub.2 cartridges (10
or 20 wt %) and the starting material is passed through the system
as a solution in the preferred solvent/s. In cases where the
reaction does not proceed to completion as monitored by TLC, LC/MS,
or HPLC, the mixture can be optionally heated to about 30 to
80.degree. C. (preferably about 50.degree. C.) for about 1 to 24 h
(preferably about 16 h) and in cases where the H-cube is used to
perform the reaction, the pressure may be increased (25 to 50 bar,
preferably 40 to 50 bar). The mixture is then filtered and the
filter cake is rinsed with an organic solvent (such as EtOAc, MeOH
or EtOH, preferably the reaction solvent) and the filtrate is
concentrated under reduced pressure to give the crude product.
Illustration of General Procedure L
Example #L.1:
2-(1-Acetylpiperidin-4-yl)-4-(3-amino-2-methylphenyl)-1H-indole-7-carboxa-
mide
##STR00548##
[1082]
2-(1-Acetyl-1,2,3,6-tetrahydropyridin-4-yl)-4-(3-amino-2-methylphen-
yl)-1H-indole-7-carboxamide (300 mg, 0.772 mmol, prepared using A
with 4-bromo-2-iodo-1H-indole-7-carboxamide (Preparation #1) and
1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridin-1(2-
H)-yl)ethanone [Combi-Blocks], A with 3-amino-2-methylphenylboronic
acid, pinacol ester [Combi-Blocks]) and solvent MeOH (72 mL) were
added to 20 wt % Pd/C (60.0 mg, 0.564 mmol) in a 250 mL stainless
steel pressure bottle and stirred for about 4.5 h at 30 psi then at
about 50.degree. C. for about 16 h. The reaction was filtered,
concentrated in vacuo and the residue was purified on silica gel
using a gradient of 0-10% MeOH in DCM to provide
2-(1-acetylpiperidin-4-yl)-4-(3-amino-2-methylphenyl)-1H-indole-7-carboxa-
mide (77.1 mg, 0.197 mmol): LC/MS (Table 1, Method f) R.sub.t=1.06
min; MS m/z 391. (Btk IC.sub.50=B)
General Procedure M: Removal of a Silyl Group from an O-Silyl
Ether
[1083] Method 1:
[1084] To a solution of an O-silyl-ether (1 equiv) in an organic
solvent (such as DMF, 1,4-dioxane, or DCM, preferably DCM) is added
an acid (such as TFA or HCl, 5 to 50 equiv, preferably 30 equiv)
and the mixture is stirred at about 0 to 50.degree. C. (preferably
about 15 to 25.degree. C.) for about 1 to 48 h (preferably about 4
to 16 h). Alternatively, additional acid (5 to 20 equiv, preferably
10 equiv) may be added and the mixture is heated to about 30 to
100.degree. C. (preferably about 50 to 80.degree. C.) for about 0.5
to 10 h (preferably about 1 to 5 h).
[1085] Method 2:
[1086] To a solution of an O-silyl ether (1 equiv) in an organic
solvent (such as DMF, 1,4-dioxane, or DCM, preferably DMF) is added
a fluoride source such as HF, TBAF (1 to 10 equiv, preferably 4
equiv), and the mixture is stirred at about 20 to 110.degree. C.
(preferably about 25 to 60.degree. C.) for about 1 to 20 h
(preferably about 2 to 8 h).
[1087] For either method, the targeted compound may optionally be
isolated by cooling the mixture and filtering the precipitate.
Alternatively, the mixture is optionally concentrated in vacuo to
give the targeted compound. Alternatively, the mixture is
optionally filtered through a media (such as silica gel or
Celite.RTM.) which is rinsed with an appropriate solvent (such as
EtOAc, 1,4-dioxane, THF, MeCN, DCM, Et.sub.2O, MeOH, or EtOH) and
then optionally concentrated in vacuo to give a residue. Either the
residue or the solution may be optionally partitioned between water
and an organic solvent (such as EtOAc, Et.sub.2O or DCM). The
organic layer is isolated and may be optionally washed in no
particular order with water and/or aqueous solutions containing an
acid (such as HCl, AcOH or NH.sub.4Cl) and/or aqueous solutions
containing a base (such as NaHCO.sub.3, Na.sub.2CO.sub.3, NaOH, KOH
or NH.sub.4OH) and/or aqueous solutions containing an inorganic
salt (such as NaCl, Na.sub.2SO.sub.3 or Na.sub.2S.sub.2O.sub.3).
The organic solution may then be optionally dried with a drying
agent (such as anhydrous MgSO.sub.4 or Na.sub.2SO.sub.4), filtered
and concentrated in vacuo to give the targeted compound.
Illustration of General Procedure M
Example #M.1:
N-(3-(7-carbamoyl-2-(1-methyl-1H-pyrazol-4-yl)-1H-indol-4-yl)-2-(hydroxym-
ethyl)phenyl)thiazole-2-carboxamide
##STR00549##
[1089] To a solution of
N-(2-(((tert-butyldimethylsilyl)oxy)methyl)-3-(7-carbamoyl-2-(1-methyl-1H-
-pyrazol-4-yl)-1H-indol-4-yl)phenyl)thiazole-2-carboxamide (100 mg,
0.170 mmol, prepared using D from thiazole-2-carboxylic acid and
2-((tert-butyldimethylsilyloxy)methyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxa-
borolan-2-yl)aniline [Matrix], and Preparation #10) in 1,4-dioxane
(2 mL) was added 3N aqueous HCl (2 mL, 6.00 mmol) and the mixture
was stirred at about 25.degree. C. for about 3 h. The resulting
solution was diluted with EtOAc (5 mL) and washed with water (3
mL). The organic phase was dried over Na.sub.2SO.sub.4 and
concentrated to give a crude product, which was purified by
Prep-TLC (DCM:MeOH=20:1) to provide
N-(3-(7-carbamoyl-2-(1-methyl-1H-pyrazol-4yl)-1H-indol-4-yl)-2-(hydroxyme-
thyl)phenyl)thiazole-2-carboxamide (36 mg, 45): .sup.1H NMR
(DMSO-d6) .delta.11.16 (s, 1H), 10.92 (s, 1H), 8.32 (s, 1H),
8.27-8.25 (d, J=8.4 Hz, 1H), 8.14-8.07 (m, 3H), 7.94 (s, 1H),
7.67-7.65 (d, J=6.4 Hz, 1H), 7.46-7.43 (m, 2H), 7.14-7.12 (d, J=7.6
Hz, 1H), 6.96-6.94 (d, J=7.6 Hz, 1H), 6.31 (s, 1H), 5.78 (s, 1H),
4.54-4.47 (m, 2H), 3.82 (s, 3H). LC/MS (Table 1, Method o)
R.sub.t=2.73 min; MS m/z: 473 (M-H).sup.+. (Btk IC.sub.50=A)
TABLE-US-00047 TABLE M.1 Examples prepared from an O-silyl ether
using General Procedure M R.sub.t min m/z (Table 1, ESI+ Btk
O-silyl ether Product Example # Method) (M + H).sup.+ IC.sub.50
4-(2-(((tert- butyldimethylsilyl)oxy) methyl)-3-(6-fluoro-4-
oxoquinazolin-3(4H)- yl)phenyl)-2-(1-methyl- 1H-pyrazol-4-yl)-1H-
indole-7-carboxamide (prepared using A from Preparation #10 and
Preparation #11) ##STR00550## M.1.1 3.22 (v) 509 A
4-bromo-2-(1-(2-(tert- butyldimethylsilyloxy)
ethyl)-1H-pyrazol-4-yl)-1H- indole-7-carboxamide (prepared using J
from 4-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-yl)- 1H-pyrazole
with A with (2-bromoethoxy)-tert- butyldimethylsilane,
4-bromo-2-iodo-1H- indole-7-carboxamide, A with
3-(2-methyl-3-(4,4,5,5- tetramethyl-1,3,2- dioxaborolan-2-
yl)phenyl)quinazolin- 4(3H)-one [WO 2011159857]) ##STR00551## M.1.2
1.70 (a) 505 A
General Procedure N: Hydrolysis of a Sulfonamide
[1090] To a flask containing a sulfonamide, for example, a
sulfonyl-protected indole, (preferably 1 equiv) in an organic
solvent (such as 1,4-dioxane, MeOH, or THF/MeOH, preferably
1,4-dioxane) is added an base (such as K.sub.2CO.sub.3,
Cs.sub.2CO.sub.3, aqueous Na.sub.2CO.sub.3 or aqueous NaOH, 1-30
equiv; preferably 1-5 equiv for Cs.sub.2CO.sub.3). The mixture is
stirred at about 25-100.degree. C. (preferably about 60.degree. C.)
for about 1-72 h (preferably about 1-18 h). In cases where the
reaction does not proceed to completion as monitored by TLC, LC/MS,
or HPLC, additional base (such as K.sub.2CO.sub.3,
Cs.sub.2CO.sub.3, aqueous Na.sub.2CO.sub.3 or aqueous NaOH,
preferably 1-5 equiv for Cs.sub.2CO.sub.3) and/or a cosolvent (such
as EtOH) is added. The reaction is continued at about
25-100.degree. C. (preferably about 60.degree. C.) for about 0.25-3
h (preferably about 1-2 h). In any case where an additional base
labile group is present (for example, an ester or a cyano group),
this group may also be hydrolyzed. The reaction is worked up using
one of the following methods. Method 1. The organic solvent is
optionally removed under reduced pressure and the aqueous solution
is neutralized with the addition of a suitable aqueous acid (such
as aqueous HCl). A suitable organic solvent (such as EtOAc or DCM)
and water are added, the layers are separated, and the organic
solution is dried over anhydrous Na.sub.2SO.sub.4 or MgSO.sub.4,
filtered, and concentrated to dryness under reduced pressure to
give the target compound. Method 2. The organic solvent is
optionally removed under reduced pressure a suitable organic
solvent (such as EtOAc or DCM) and water are added, the layers are
separated, and the organic solution is dried over anhydrous
Na.sub.2SO.sub.4 or MgSO.sub.4, filtered, and concentrated to
dryness under reduced pressure to give the target compound. Method
3. The reaction mixture is concentrated under reduced pressure and
directly purified by one of the subsequent methods.
Illustration of General Procedure N
Preparation #N.1:
(R)-4-(3-(4-Oxoquinazolin-3(4H)-yl)piperidin-1-yl)-1H-indole-7-carbonitri-
le
##STR00552##
[1092] To a mixture of
(R)-4-(3-(4-oxoquinazolin-3(4H)-yl)piperidin-1-yl)-1-tosyl-1H-indole-7-ca-
rbonitrile (0.12 g, 0.229 mmol, prepared using B from
4-fluoro-1-tosyl-1H-indole-7-carbonitrile (Preparation #27, step A)
and (R)-3-(piperidin-3-yl)quinazolin-4(3H)-one (Preparation #31) in
THF (2 mL) and MeOH (1 mL) was added cesium carbonate (0.128 mL,
1.60 mmol) and stirred at rt for about 18 h. The reaction was
diluted with water (60 mL) and stirred for another 20 min. The
mixture was extracted into DCM, dried by passing through a Biotage
phase separator to remove residual water and evaporated to dryness
to give
(R)-4-(3-(4-oxoquinazolin-3(4H)-yl)piperidin-1-yl)-1H-indole-7-carbonitri-
le (0.044 g, 52%); LC/MS (Table 1, Method g) R.sub.t=1.50 min.; MS
m/z: 370 (M+H).sup.+
General Procedure O: Hydrolysis of a Nitrile to a Primary Amide
[1093] To a flask containing a nitrile, (preferably 1 equiv) in an
organic solvent (such as MeOH, EtOH, DMSO, DMSO/MeOH, or DMSO/EtOH,
preferably DMSO/EtOH) is added a base (such as KOH, aqueous KOH or
aqueous NaOH, 1-30 equiv, preferably 3-5 equiv for KOH, preferably
10-15 equiv for aqueous NaOH). The mixture is stirred at about rt
for about 1-30 min (preferably about 1-10 min) then 30%
H.sub.2O.sub.2 (5-30 equiv preferably 9-27 equiv) was added to the
mixture slowly and the reaction mixture was stirred at rt for about
10-30 min. In cases where the reaction does not proceed to
completion as monitored by TLC, LC/MS, or HPLC, the reaction is
continued at rt for about 0.25-1 h (preferably about 0.25-0.5 h).
The reaction is worked up using one of the following methods.
Method 1. The mixture is diluted with saturated NH.sub.4Cl and
water, stirred at about rt for about 1-30 min. The resulting
suspension is collected by filtration, washed with a suitable
solvent (such as MeOH, EtOH, or water), and the filtercake is dried
under vacuum to give the target compound. Method 2. The organic
solvent is optionally removed under reduced pressure a suitable
organic solvent (such as EtOAc or DCM) and water are added, the
layers are separated, and the organic solution is dried over
anhydrous Na.sub.2SO.sub.4 or MgSO.sub.4, filtered, and
concentrated to dryness under reduced pressure to give the target
compound. Method 3. The reaction mixture is concentrated under
reduced pressure and directly purified by one of the subsequent
methods
Illustration of General Procedure O
Example #O.1:
N-(trans-1-(7-carbamoyl-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-
-yl)-1H-indol-4-yl)-4-hydroxypiperidin-3-yl)thiazole-2-carboxamide
##STR00553##
[1095] To a stirred solution of
N-(trans-1-(7-cyano-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-
-1H-indol-4-yl)-4-hydroxypiperidin-3-yl)thiazole-2-carboxamide (36
mg, 0.068 mmol, prepared using B Preparation #27 and Preparation
#23, N with Cs.sub.2CO.sub.3) in DMSO (0.8 mL) was added EtOH (4.8
mL) and KOH (12.81 mg, 0.228 mmol). The mixture was stirred at rt
for about 10 min, then 30% H.sub.2O.sub.2 (0.070 mg, 0.615 .mu.mol)
was added to the mixture slowly and the reaction mixture was
stirred at rt for about 15 min. Then water (6 mL) was added to the
mixture and the solution was extracted with EtOAc (3.times.20 mL).
The organic layer was washed with brine, dried over
Na.sub.2SO.sub.4, filtered and concentrated to give the crude
product which was purified by flash chromatography to provide
N-(trans-1-(7-carbamoyl-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-
-yl)-1H-indol-4-yl)-4-hydroxypiperidin-3-yl)thiazole-2-carboxamide
(15 mg, 40%): LC/MS (Table 1, Method d) R.sub.t=2.52 min.; MS m/z:
545 (M+H).sup.+. (Btk IC.sub.50=A)
TABLE-US-00048 TABLE O.1 Examples prepared using General Procedure
O R.sub.t min m/z Example (Table 1, ESI+ Btk Nitrile Product #
Method) (M + H).sup.+ IC.sub.50 N-(3-(7-cyano-1H-indol-4-
yl)-2-methylphenyl)-4- (difluoromethyl)benzamide (prepared using A
from 4-bromo-1H-indole-7- carbonitrile and 2-methyl-3-(4,4,5,5-
tetramethyl-1,3,2- dioxaborolan-2-yl)aniline [Combi-Blocks]), N
with Cs.sub.2CO.sub.3 ##STR00554## O.1.1 1.69 (f) 420 B
4-(2-methyl-3-(oxetan-3- ylamino)phenyl)-1H-indole- 7-carbonitrile
(prepared using A from 4-bromo-1H-indole-7- carbonitrile and
2-methyl-3-(4,4,5,5- tetramethyl-1,3,2- dioxaborolan-2-yl)aniline
[CombiBlocks]), H from oxetan-3-one, N with Cs.sub.2CO.sub.3
##STR00555## O.1.2 1.72 (f) 322 C (R)-2-(1-(methylsulfonyl)-
1,2,3,6-tetrahydropyridin-4- yl)-4-(3-(8-oxo-5,6-
dihydroimidazo[1,2- a]pyrazin-7(8H)- yl)piperidin-1-yl)-1H-indole-
7-carbonitrile (prepared using B from Preparation #27 and
Preparation #13, N with Cs.sub.2CO.sub.3 ##STR00556## O.1.3* 0.99
(f) 538 A (R)-2-(1-(methylsulfonyl)- 1,2,3,6-tetrahydropyridin-4-
yl)-4-(3-(8-oxoimidazo[1,2- a]pyrazin-7(8H)-
yl)piperidin-1-yl)-1H-indole- 7-carbonitrile (prepared using B from
Preparation #27 and Preparation #12, N with Cs.sub.2CO.sub.3
##STR00557## O.1.4* 1.18 (f) 536 A (R)-N-(1-(7-cyano-2-(1-
(methylsulfonyl)-1,2,3,6- tetrahydropyridin-4-yl)-1H-
indol-4-yl)piperidin-3-yl)-2- methyloxazole-4- carboxamide
(prepared using B from Preparation #27 and (R)-tert-butyl
piperidin-3- ylcarbamate, G with HCl, and D with 2-methyloxazole-4-
carboxylic acid, N with Cs.sub.2CO.sub.3 ##STR00558## O.1.5* 1.43
(f) 527 A (R)-N-(1-(7-cyano-1H-indol- 4-yl)piperidin-3-yl)-2-
methyloxazole-4- carboxamide (Preparation #V.1), N with
Cs.sub.2CO.sub.3 ##STR00559## O.1.6* 1.08 (g) 368
(R)-1-(1-(7-cyano-1H-indol- 4-yl)piperidin-3-yl)-3-
(thiazol-2-yl)urea (prepared using V with thiazol-2- ylcarbamic
acid and Preparation #B.1, N with Cs.sub.2CO.sub.3 ##STR00560##
O.1.7* 0.72 (g) 385 C (R)-N-(1-(7-cyano-1H-indol-
4-yl)piperidin-3-yl)-4- (trifluoromethyl)benzamide (prepared using
V with 4- (trifluoromethyl)benzoic acid and Preparation #B.1, N
with Cs.sub.2CO.sub.3 ##STR00561## O.1.8* 1.62 (g) 431 C
(R)-N-(1-(7-cyano-1H-indol- 4-yl)piperidin-3-yl)-4-
methoxybenzamide (prepared using V with 4- methoxybenzoic acid and
Preparation #B.1, N with Cs.sub.2CO.sub.3 ##STR00562## O.1.9* 1.30
(g) 393 C (R)-5-tert-butyl-N-(1-(7- cyano-1H-indol-4-
yl)piperidin-3-yl)isoxazole- 3-carboxamide (prepared using V with
5-tert- butylisoxazole-3-carboxylic acid and Preparation #B.1, N
with Cs.sub.2CO.sub.3 ##STR00563## O.1.10* 1.70 (g) 410 C
(R)-4-(3-aminopiperidin-1- yl)-1H-indole-7-carboxamide (prepared
using V with 4-tert-butylbenzoic acid and Preparation #B.1, N with
Cs.sub.2CO.sub.3 ##STR00564## O.1.11* 1.55 (g) 419 C
(R)-4-(3-(4-oxoquinazolin- 3(4H)-yl)piperidin-1-yl)-1H-
indole-7-carbonitrile (Preparation #N.1) ##STR00565## O.1.12* 1.28
(g) 388 C 4-(3-(7-cyclopropyl-5- fluoro-4-oxoquinazolin-
3(4H)-yl)piperidin-l-yl)-1H- indole-7-carbonitrile (prepared using
B from Preparation #27, step A and Preparation #33, N with
Cs.sub.2CO.sub.3 ##STR00566## O.1.13 1.63 (g) 446 C
(R)-2-(4-fluorophenyl)-4-(3- (4-oxoquinazolin-3(4H)-
yl)piperidin-1-yl)-1H-indole- 7-carbonitrile (prepared using A from
Preparation #27, step B and 2-(4- fluorophenyl)-4,4,5,5-
tetramethyl-1,3,2- dioxaborolane, B from Preparation #31, N with
Cs.sub.2CO.sub.3 ##STR00567## O.1.14* 1.69 (g) 482 B
(R)-4-(3-(6-fluoro-4- oxoquinazolin-3(4H)- yl)piperidin-1-yl)-2-(4-
fluorophenyl)-1H-indole-7- carbonitrile (prepared using A from
Preparation #27, step B and 2-(4-fluorophenyl)-
4,4,5,5-tetramethyl-1,3,2- dioxaborolane, B from Preparation #32, N
with Cs.sub.2CO.sub.3 ##STR00568## O.1.15* 1.75 (g) 500 C
(R)-2-(1-methyl-1H-pyrazol- 4-yl)-4-(3-(4-oxoquinazolin-
3(4H)-yl)piperidin-1-yl)-1H- indole-7-carbonitrile (prepared using
A from Preparation #27, step B and 1-methyl-4-(4,4,5,5-
tetramethyl-1,3,2- dioxaborolan-2-yl)-1H- pyrazole, B from
Preparation #31, N with Cs.sub.2CO.sub.3 ##STR00569## O.1.16* 1.39
(g) 468 B (R)-4-(3-(6-fluoro-1- oxoisoindolin-2-yl)piperidin-
1-yl)-2-(1-methyl-1H- pyrazol-4-yl)-1H-indole-7- carbonitrile
(prepared using A from Preparation #27, step B and
1-methyl-4-(4,4,5,5- tetramethyl-1,3,2- dioxaborolan-2-yl)-1H-
pyrazole, B from Preparation #30, N with Cs.sub.2CO.sub.3
##STR00570## O.1.18* 1.48 (g) 473 C (R)-4-tert-butyl-N-(1-(7-
cyano-2-(1-methyl-1H- pyrazol-4-yl)-1H-indol-4-
yl)piperidin-3-yl)benzamide (prepared using A from Preparation #27,
step B and 1-methyl-4-(4,4,5,5- tetramethyl-1,3,2-
dioxaborolan-2-yl)-1H- pyrazole, B from (R)-tert- butyl
piperidin-3- ylcarbamate, V with 4-tert- butylbenzoic acid, N with
Cs.sub.2CO.sub.3 ##STR00571## O.1.19* 1.73 (g) 499 A
(R)-N-(1-(7-cyano-2-(1- methyl-1H-pyrazol-4-yl)-1H-
indol-4-yl)piperidin-3-yl)-4- methoxybenzamide (prepared using A
from Preparation #27, step B and 1-methyl-4-(4,4,5,5-
tetramethyl-1,3,2- dioxaborolan-2-yl)-1H- pyrazole, B with
(R)-tert- butyl piperidin-3- ylcarbamate, V with 4- methoxybenzoic
acid, N with Cs.sub.2CO.sub.3 ##STR00572## O.1.20* 1.32 (g) 473 B
(R)-N-(1-(7-cyano-2-(1- methyl-1H-pyrazol-4-yl)-1H-
indol-4-yl)piperidin-3-yl)-4- (trifluoromethyl)benzamide
methoxybenzamide (prepared using A from Preparation #27, step B and
1-methyl-4-(4,4,5,5- tetramethyl-1,3,2- dioxaborolan-2-yl)-1H-
pyrazole, B with (R)-tert- butyl piperidin-3- ylcarbamate, V with
4- (trifluoromethyl)benzoic acid, N with Cs.sub.2CO.sub.3
##STR00573## O.1.21* 1.65 (g) 511 B (R)-N-(1-(7-cyano-2-(1-
methyl-1H-pyrazol-4-yl)-1H- indol-4-yl)piperidin-3-yl)-4-
(difluoromethyl)benzamide (prepared using A from Preparation #27,
step B and 1-methyl-4-(4,4,5,5- tetramethyl-1,3,2-
dioxaborolan-2-yl)-1H- pyrazole, B with (R)-tert- butyl
piperidin-3- ylcarbamate, V with 4- (difluoromethyl)benzoic acid, N
with Cs.sub.2CO.sub.3 ##STR00574## O.1.22* 1.51 (g) 493 B
(R)-N-(1-(7-cyano-2-(1- methyl-1H-pyrazol-4-yl)-1H-
indol-4-yl)piperidin-3-yl)-4- (2-cyanopropan-2- yl)benzamide
(prepared using A from Preparation #27, step B and
1-methyl-4-(4,4,5,5- tetramethyl-1,3,2- dioxaborolan-2-yl)-1H-
pyrazole, B with (R)-tert- butyl piperidin-3- ylcarbamate, V with
4-(1- amino-2-methyl-1- oxopropan-2-yl)benzoic acid, N with
Cs.sub.2CO.sub.3 ##STR00575## O.1.23* 1.28 (g) 528 B
(R)-N-(1-(7-cyano-2-(1- methyl-1H-pyrazol-4-yl)-1H-
indol-4-yl)piperidin-3-yl)-4- (trifluoromethoxy)benzamide (prepared
using A from Preparation #27, step B and 1-methyl-4-(4,4,5,5-
tetramethyl-1,3,2- dioxaborolan-2-yl)-1H- pyrazole, B with
(R)-tert- butyl piperidin-3- ylcarbamate, V with 4-
(trifluoromethoxy)benzoic acid, N with Cs.sub.2CO.sub.3
##STR00576## O.1.24* 1.68 (g) 527 B (R)-N-(1-(7-cyano-2-(1-
methyl-1H-pyrazol-4-yl)-1H- indol-4-yl)piperidin-3-yl)-4-
cyclopropylbenzamide (prepared using A from Preparation #27, step B
and 1-methyl-4-(4,4,5,5- tetramethyl-1,3,2- dioxaborolan-2-yl)-1H-
pyrazole, B with (R)-tert- butyl piperidin-3- ylcarbamate, V with
4- cyclopropylbenzoic acid, N with Cs.sub.2CO.sub.3 ##STR00577##
O.1.25* 1.40 (g) 483 A (R)-4-tert-butyl-N-(1-(7-
cyano-2-(pyridin-3-yl)-1H- indol-4-yl)piperidin-3- yl)benzamide
(prepared using A from Preparation #27, step B and pyridin-3-
ylboronic acid, B with (R)- tert-butyl piperidin-3- ylcarbamate, V
with 4-tert- butylbenzoic acid, N with Cs.sub.2CO.sub.3
##STR00578## O.1.26 1.56 (g) 496 A (R)-4-(3-(4-oxoquinazolin-
3(4H)-yl)piperidin-1-yl)-2- (pyridin-3-yl)-1H-indole-7-
carbonitrile (prepared using A from Preparation #27, step B and
pyridin-3-ylboronic acid with Cs.sub.2CO.sub.3, B from Preparation
#31, N with Cs.sub.2CO.sub.3 ##STR00579## O.1.27* 1.22 465 B
General Procedure P: Formation of a Boronate from an Aryl Halide or
Heteroaryl Halide
[1096] To a mixture of an halide, for example, a bromo indole
(preferably 1 equiv),
4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (1 to 3
equiv, preferably 1.2 equiv), potassium acetate (2 to 5 equiv,
preferably 3 equiv), and in a solvent (such as THF or 1,4-dioxane;
preferably 1,4-dioxane) is added a palladium catalyst (for example
Pd.sub.2dba.sub.3 or
(1,1'-bis(diphenylphosphino)ferrocene)dichloropalladium(II) complex
with DCM; preferably
1,1'-bis(diphenylphosphino)ferrocene)dichloropalladium(II) complex
with DCM, 0.01 to 0.20 equiv, preferably 0.1 equiv). The mixture is
heated at about 40 to 120.degree. C. (preferably about 80.degree.
C.) for about 1 to 24 h (preferably about 16 h). The mixture is
allowed to cool to rt and is worked up using one of the following
methods. Method 1. The mixture may be diluted with an organic
solvent (such as DCM or EtOAc) and the organic solution is
optionally washed with water and/or brine, dried over anhydrous
MgSO.sub.4 or Na.sub.2SO.sub.4, filtered, and the solvent is
removed under reduced pressure to give the desired compound. Method
2. The mixture is concentrated under reduced pressure and
optionally purified using one or more of the Purification Methods
described above to give the desired compound. Method 3. The
catalyst is removed by filtration and the filtrate is concentrated
under reduced pressure.
Illustration of General Procedure P
Preparation #P.1:
4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-7-carboxamide
##STR00580##
[1098] A mixture of 4-bromo-1H-indole-7-carboxamide (5 g, 20.9
mmol, Preparation #2),
4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (6.37
g, 25.1 mmol), potassium acetate (6.16 g, 62.7 mmol) and
Pd(dppf)Cl.sub.2-DCM (0.85 g, 1.05 mmol) in 1,4-dioxane (2 mL) was
heated at about 80.degree. C. under N.sub.2 overnight. The solvent
was removed under reduced pressure to get a residue, which was
purified by column chromatography on silica gel to afford
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-7-carboxamide
(3 g, 50%): .sup.1H NMR (CDCl.sub.3) .delta. 10.30 (br, 1H),
7.64-7.62 (d, J=8 Hz, 1H), 7.40-7.38 (m, 2H), 7.08-7.07 (m, 1H),
1.42 (s, 12H).
General Procedure Q: Mitsunobu Reaction of an Alcohol
[1099] To an alcohol (preferably 1 equiv) in an organic solvent
(such as THF, benzene, toluene, or 1,4-dioxane, preferably toluene
or 1,4-dioxane) is added a suitably acidic reactant (such as a
carboxylic acid, a phenol or a heteroaryl alcohol, 1-3 equiv,
preferably 1 equiv), followed by tri-n-butylphosphine,
triphenylphosphine or polymer bound triphenylphosphine (preferably
triphenylphosphine, 1-3 equiv, preferably 1.2 equiv), and TMAD,
1,1'-(azodicarbonyl)dipiperidine, DIAD or DEAD (preferably DEAD,
1-3 equiv, preferably 1.2 equiv) is added dropwise at about
0-120.degree. C. (preferably 0-25.degree. C.). The reaction mixture
is stirred at about 25-120.degree. C. for about 5-48 h (preferably
about 16 h). Alternatively, after about 0.1-24 h additional
phosphine reagent (0.2-2 equiv) and TMAD,
1,1'-(azodicarbonyl)dipiperidine, DIAD or DEAD (0.2-1 equiv) are
added to drive the reaction to completion. Method 1. When polymer
bound reagent is used, the reaction mixture is filtered and washed
with a mixture of solvents such as DCM, EtOAc and MeOH (preferably
DCM then MeOH). The filtrate is concentrated under reduced
pressure. Method 2. When no polymer bound reagent is used, the
reaction mixture is optionally diluted with an organic solvent such
as DCM or EtOAc and then washed with water, saturated aqueous
NaHCO.sub.3, brine and dried over anhydrous Na.sub.2SO.sub.4 or
MgSO.sub.4, filtered, and concentrated under reduced pressure.
Alternatively, the reaction mixture is directly concentrated under
reduced pressure.
Illustration of General Procedure Q
Preparation #Q.1: 2-((4-Bromo-3-nitrophenoxy)methyl)thiazole
##STR00581##
[1101] To a solution of 4-bromo-3-nitrophenol (2 g, 9.17 mmol,
Preparation #S.1), thiazol-2-ylmethanol (1.01 g, 9.17 mmol) and
triphenylphosphine (2.9 g, 11.01 mmol) in anhydrous toluene (50 mL)
was added DEAD (1.7 mL, 11.01 mmol) at about 0.degree. C. under
N.sub.2. Then the mixture was heated to reflux overnight. After
cooling to rt, the mixture was concentrated under reduced pressure
to give a residue, which was purified by column chromatography on
silica gel to give 2-((4-bromo-3-nitrophenoxy)methyl)thiazole (2 g,
69%): .sup.1H NMR (CDCl.sub.3) .delta. 7.83 (d, J=3.1 Hz, 1H), 7.63
(d, J=8.8 Hz, 1H), 7.53 (d, J=3.1 Hz, 1H), 7.42 (d, J=3.1 Hz, 1H),
7.12 (dd, J=3.1, 8.8 Hz, 1H), 5.43 (s, 2H).
General Procedure R: Reduction of a Nitro Group to an Amine Using
Fe
[1102] To a mixture of a nitro-containing compound in a solvent
(such as MeOH, EtOH, MeOH/water or EtOH/water, preferably
EtOH/water) is added Fe (3 to 5 equiv, preferably 5 equiv) and
NH.sub.4Cl (3 to 5 equiv, preferably 5 equiv). The mixture is
heated at about 40 to 100.degree. C. (preferably about 80.degree.
C.) for about 2 to 24 h (preferably about 16 h). The mixture is
allowed to cool to rt and is worked up using one of the following
methods. Method 1. The mixture may be diluted with an organic
solvent (such as DCM or EtOAc) and the organic solution is
optionally washed with water and/or brine, dried over anhydrous
MgSO.sub.4 or Na.sub.2SO.sub.4, filtered, and the solvent is
removed under reduced pressure to give the desired compound. Method
2. The mixture is concentrated under reduced pressure and
optionally purified using one or more of the Purification Methods
described above to give the desired compound. Method 3. The
catalyst is removed by filtration and the filtrate is concentrated
under reduced pressure. Intermediates and final compounds prepared
via this General Procedure can be optionally purified using one or
more of the Purification Methods described above.
Illustration of General Procedure R
Preparation #R.1: 2-Bromo-5-(thiazol-2-ylmethoxy)aniline
##STR00582##
[1104] To a solution of 2-((4-bromo-3-nitrophenoxy)methyl)thiazole
(1 g, 3.2 mmol) in EtOH (40 mL) and water (20 mL) was added iron
(0.88 g, 15.8 mmol) and NH.sub.4Cl (0.85 g, 15.8 mmol). The mixture
was heated to reflux overnight. The mixture was filtered and the
filtrate was concentrated under reduced pressure to get a residue,
which was diluted by addition of water and extracted by EtOAc. The
organic layer was concentrated under reduced pressure to provide
2-bromo-5-(thiazol-2-ylmethoxy)aniline (0.7 g, 77%): LC/MS (Table
1, Method 1) R.sub.t=1.46 min; MS m/z 285 (M+H).sup.+.
General Procedure S: Demethylation of aryl methyl ether
[1105] To a mixture of a methoxy compound in a solvent (such as
DCM, DCE, THF, benzene, toluene, or 1,4-dioxane, preferably DCM) is
slowly added BBr.sub.3 (2 to 24 equiv, preferably 2.5 equiv). The
mixture is heated at about 30 to 110.degree. C. (preferably about
45.degree. C.) for about 2 to 24 h (preferably about 4-24 h). The
mixture is allowed to cool to 0-10.degree. C. (preferably about
0.degree. C.) and is diluted with water. The mixture may be diluted
with an organic solvent (such as DCM or EtOAc) and the organic
solution is optionally washed with water and/or saturated
NaHCO.sub.3 and/or brine, dried over anhydrous MgSO.sub.4 or
Na.sub.2SO.sub.4, filtered, and the solvent is removed under
reduced pressure to give the desired compound.
Illustration of General Procedure S
Preparation #S.1: 4-Bromo-3-nitrophenol
##STR00583##
[1107] To a solution of 1-bromo-4-methoxy-2-nitrobenzene (20 g, 82
mmol) in DCM (800 mL) was added dropwise BBr.sub.3 (19 mL, 207
mmol) in DCM (120 mL). The resulting mixture was heated to reflux
overnight. The mixture was cooled in ice-water and was diluted by
addition of water. Then the mixture was washed with saturated
NaHCO.sub.3 and brine. The organic phase was dried over
Na.sub.2SO.sub.4, concentrated under reduced pressure to give a
residue, which was purified by column chromatography on silica gel
to provide 4-bromo-3-nitrophenol (6 g, 31%) as a solid: .sup.1H NMR
(CDCl.sub.3): .delta. 7.57 (d, J=8.8 Hz, 1H), 7.35 (d, J=2.6 Hz,
1H), 6.94 (dd, J=2.9, 8.6 Hz, 1H), 5.90 (br., 1H).
General Procedure T: Buchwald Reaction of an Aryl Halide or a
Heteroaryl Halide with an Amine
[1108] A mixture of an aryl halide or heteroaryl halide (1.0
equiv), an amine (1 to 2.2 equiv, preferably 1 to 1.2 equiv), a
palladium catalyst (such as Pd.sub.2dba.sub.3 or Pd(OAc).sub.2,
preferably Pd.sub.2dba.sub.3; 0.01 to 1.0 equiv, preferably 0.04 to
0.1 equiv), a ligand (such as X-phos, Xanthphos or
tert-butyl-X-phos, preferably tert-butyl-X-phos or X-Phos, 0.01 to
2.0 equiv, preferably 0.04 to 0.1 equiv) and a base (such as
K.sub.2CO.sub.3, Na.sub.2CO.sub.3, Cs.sub.2CO.sub.3,
K.sub.3PO.sub.4, NaOt-Bu, KOt-Bu, KOAc, KOH, preferably
K.sub.2CO.sub.3; 1 to 5 equiv, preferably 1 to 3 equiv) are added
to a solvent (such as 1,4-dioxane, t-BuOH, preferably t-BuOH). The
mixture is degassed under an inert atmosphere (such as nitrogen or
argon, preferably nitrogen) and heated with conventional heating at
about 80 to 100.degree. C. (preferably about 85 to 95.degree. C.)
for about 2 to 24 h (preferably about 18 h) or with microwave
heating at about 100-150.degree. C. for about 30 min to 2 h. The
mixture is cooled to rt. The mixture is optionally filtered through
a media (such as silica gel or Celite.RTM.) which is rinsed with an
appropriate solvent (such as EtOAc, 1,4-dioxane, THF, MeCN, DCM,
Et.sub.2O, MeOH, EtOH, DMSO, 1:1 MeOH/DMSO or 2:1 MeOH/DMSO,
preferably MeOH/DMSO) and then the filtrate is optionally
concentrated in vacuo or under a warm nitrogen stream to give a
residue.
Illustration of General Procedure T
Preparation #T.1:
4-(1-Methyl-1H-pyrazol-5-ylamino)-2-p-tolyl-1H-indole-7-carboxamide
##STR00584##
[1110] 4-Iodo-2-(p-tolyl)-1H-indole-7-carboxamide (99 mg, 0.26
mmol, prepared using F with 1-(p-tolyl)ethanone),
1-methyl-1H-pyrazol-5-ylamine (27 mg, 0.26 mmol, Maybridge-Int),
X-Phos (7.53 mg, 0.016 mmol), K.sub.2CO.sub.3 (44 mg, 0.316 mmol),
and Pd.sub.2dba.sub.3 (14 mg, 0.016 mmol) were combined in t-BuOH
(1.32 mL) in a sealed microwaved tube. The tube was degassed and
purged with N.sub.2 and heated at about 85.degree. C. for 18 h. The
reaction was cooled to rt and filtered through Celite.RTM.. The
filtrate was extracted twice with DCM. The combined organic layers
were concentrated. The residue product was purified on a normal
phase column (18 mg, 20%): LC/MS (Table 1, Method f) R.sub.t=1.48
min; MS m/z 346 (M+H).sup.+. (Btk IC.sub.50=B)
TABLE-US-00049 TABLE T.1 Examples prepared from
4-iodo-2-(p-tolyl)-1H-indole-7-carboxamide (prepared using F with
1-(p-tolyl)ethanone) using General Procedure T R.sub.t min (Table
1, m/z ESI+ Btk Amine Product Example # Method) (M + H).sup.+
IC.sub.50 1-(4-methoxybenzyl)-1H- pyrazo1-5-amine ##STR00585##
T.1.1 1.77 (f) 452 B
General Procedure U: Negishi Cross-Coupling Reaction of an Aryl
Halide or a Heteroaryl Halide
[1111] with an Organozinc A mixture of an aryl halide or heteroaryl
halide (preferably 1.0 equiv) an organic solvent or mixture of
solvents (such as THF, Et.sub.2O or 1,4-dioxane, preferably THF),
an organozinc compound (0.67 to 1.5 equiv, preferably 0.9 to 1.2
equiv), a palladium catalyst (such as Pd(PPh.sub.3).sub.4, 0.01 to
1.0 equiv, preferably 0.025 to 0.10 equiv) is stirred at about rt
to 90.degree. C. (preferably about 85.degree. C.) for about 1 to 24
h (preferably about 18 h). The mixture is cooled to rt. The mixture
is optionally filtered through a media (such as silica gel or
Celite.RTM.) which is rinsed with an appropriate solvent (such as
EtOAc, 1,4-dioxane, THF, MeCN, DCM, Et.sub.2O, MeOH, EtOH) and then
optionally concentrated in vacuo to give a residue. Either the
residue or the solution may be optionally partitioned between water
and an organic solvent (such as EtOAc, Et.sub.2O or DCM). The
organic layer is isolated and may be optionally washed in no
particular order with water and/or aqueous solutions containing an
acid (such as HCl, AcOH or NH.sub.4Cl) and/or aqueous solutions
containing a base (such as NaHCO.sub.3, Na.sub.2CO.sub.3, NaOH, KOH
or NH.sub.4OH) and/or aqueous solutions containing an inorganic
salt (such as NaCl, Na.sub.2SO.sub.3 or Na.sub.2S.sub.2O.sub.3).
The organic solution may then be optionally dried with a drying
agent (such as anhydrous MgSO.sub.4 or Na.sub.2SO.sub.4), filtered
and concentrated in vacuo to give the targeted compound.
Illustration of General Procedure U
Preparation #U.1:
4-(2-Chloro-6-fluorobenzyl)-2-p-tolyl-1H-indole-7-carboxamide
##STR00586##
[1113] 4-Iodo-2-(p-tolyl)-1H-indole-7-carboxamide (97 mg, 0.258
mmol, prepared using F from 1-(p-tolyl)ethanone),
(2-chloro-6-fluorobenzyl)zinc(II) bromide (0.77 mL, 0.387 mmol) and
tetrakis(triphenylphosphine)palladium(0) (15 mg, 0.013 mmol) were
dissolved in THF (0.82 mL) in a sealed microwave tube and heated
thermally at 85.degree. C. for about 18 h. The reaction was cooled
to rt and filtered through Celite.RTM.. The filtrate was
concentrated to give a residue. The residue was purified on a
normal phase column eluting with EtOAc in hexane to give
4-(2-chloro-6-fluorobenzyl)-2-p-tolyl-1H-indole-7-carboxamide (30
mg, 30%): LC/MS (Table 1, Method f) R.sub.t=2.09 min; MS m/z 393
(M+H).sup.+.
TABLE-US-00050 TABLE U.1 Examples prepared from
4-iodo-2-(p-tolyl)-1H-indole-7-carboxamide (prepared using F with
1-(p-tolyl)ethanone) using General Procedure U R.sub.t min (Table
1, m/z ESI+ Organozinc Product Example # Method) (M + H).sup.+ Btk
IC.sub.50 (2,6-dichlorobenzyl)zinc(II) bromide ##STR00587## U.1.1
2.13 (f) 409 C 2-Thiazolylzinc bromide ##STR00588## U.1.2 1.76 (f)
334 A 2-Pyridylzinc bromide ##STR00589## U.1.3 1.34 (g) 328 B
General Procedure V: Formation of an Amide from a Boc-Protected
Amine and a Carboxylic Acid
[1114] To a solution of an N-Boc amine (1 equiv) in an organic
solvent (such as DCM, DCE, 1,4-dioxane or MeOH, preferably DCM or
1,4-dioxane) is added an acid (such as TFA or HCl, preferably TFA;
2 to 100 equiv, preferably 25 to 50 equiv). The mixture is stirred
at about 0 to 100.degree. C. (preferably about 20 to 60.degree. C.)
for about 0.5 to 24 h (preferably about 0.5 to 6 h). Optionally,
additional acid (2 to 35 equiv, preferably 20 to 25 equiv) may be
added and the mixture stirred at about 0 to 100.degree. C.
(preferably about 20 to 60.degree. C.) for about 1 to 24 h
(preferably about 1 to 6 h). If a solid is present in the mixture,
the mixture may be optionally filtered and the solid washed with an
organic solvent such as 1,4-dioxane or Et.sub.2O. The resulting
solid is then optionally dried under reduced pressure.
Alternatively, the reaction miture is concentrated under reduced
pressure. To the residue in a flask is added in no particular
order, a carboxylic acid or carboxylate salt (1 to 5 equiv,
preferably 1.1 to 1.5 equiv) an organic solvent (such as DCM, DCE,
DMF, THF, or 1,4-dioxane, preferably DCM or DMF), a peptide
coupling reagent (such as BOP-Cl, IBCF, HATU, DCI, PyBOP, or
EDCHCl, preferably HATU; 1 to 10 equiv, preferably 1 to 2 equiv), a
base (such as TEA, DIEA, pyridine or DIEA, preferably DIEA; 1 to 20
equiv, preferably 1 to 5 equiv) and optionally HOBt (0 to 5 equiv,
preferably 0 to 1 equiv). The mixture is then stirred at about 10
to 60.degree. C. (preferably about 25 to 50.degree. C.) for about
15 min to 48 h (preferably about 15 min to 24 h). Optionally,
additional amounts of the reagents above can be added to drive the
reaction to completion. The mixture is optionally concentrated in
vacuo to give the targeted compound. The mixture is optionally
filtered through a media (such as silica gel or Celite.COPYRGT.)
which is rinsed with an appropriate solvent (such as EtOAc,
1,4-dioxane, THF, MeCN, DCM, Et.sub.2O, MeOH, EtOH) and then
optionally concentrated in vacuo to give a residue. Either the
residue or the solution may be optionally partitioned between water
and an organic solvent (such as EtOAc, Et.sub.2O or DCM). The
organic layer is isolated and may be optionally washed in no
particular order with water and/or aqueous solutions containing an
acid (such as HCl, AcOH or NH.sub.4Cl) and/or aqueous solutions
containing a base (such as NaHCO.sub.3, Na.sub.2CO.sub.3, NaOH, KOH
or NH.sub.4OH) and/or aqueous solutions containing an inorganic
salt (such as NaCl, Na.sub.2SO.sub.3 or Na.sub.2S.sub.2O.sub.3).
The organic solution may then be optionally dried with a drying
agent (such as anhydrous MgSO.sub.4 or Na.sub.2SO.sub.4), filtered
and concentrated in vacuo to give the targeted compound.
Illustration of General Procedure V
Preparation #V.1:
(R)--N-(1-(7-cyano-1H-indol-4-yl)piperidin-3-yl)-2-methyloxazole-4-carbox-
amide
##STR00590##
[1116] To a solution of (R)-tert-butyl
1-(7-cyano-1H-indol-4-yl)piperidin-3-ylcarbamate (0.11 g, 0.333
mmol, Preparation #B.1) in DCM (1 mL) was added TFA (1 mL) and the
solution stirred at about 25.degree. C. for about 30 min. The
mixture was evaporated to dryness followed by the addition of DMF
(2 mL), TEA (0.139 mL, 0.999 mmol), HATU (190 mg, 0.499 mmol) and
2-methyloxazole-4-carboxylic acid (0.055 g, 0.433 mmol) The mixture
was stirred at about rt for about 18 h. The reaction was evaporated
and the resulting residue was purified by silica gel chromatography
eluting with a gradient of 30-100% EtOAc in hexane to
(R)--N-(1-(7-cyano-1H-indol-4-yl)piperidin-3-yl)-2-methyloxazole-4-carbox-
amide (0.092 g, 79%); LC/MS (Table 1, Method g).sub.14=1.35 min.;
MS m/z: 350 (M+H).sup.+
General Procedure W: Conversion of a Vinyl Triflate to a Vinyl
Boronate or Boronic Acid
[1117] To a mixture of a boronic acid or boronate (1 to 2 equiv,
preferably 1.1 equiv) a palladium catalyst (for example
Pd(OAc).sub.2, Pd.sub.2dba.sub.3, Pd(PPh.sub.3).sub.4,
bis(acetato)triphenylphosphinepalladium(II), PdCl2 (dppf),
(1,1'-bis(diphenylphosphino)ferrocene)dichloropalladium(II), or
Pd(PPh.sub.3).sub.2Cl.sub.2; preferably PdCl.sub.2(dppf) or
Pd(PPh.sub.3).sub.2Cl.sub.2; 0.01 to 0.20 equiv, preferably 0.05 to
0.1 equiv), abase (such as KF, KOAc, Na.sub.2CO.sub.3,
K.sub.2CO.sub.3 or Cs.sub.2CO.sub.3, preferably K.sub.2CO.sub.3 or
KOAc) (1.1 to 16 equiv, preferably 1.5 to 2 equiv) and optionally a
phosphine additive (preferably PPh.sub.3; 0.01 to 0.1 equiv,
preferable 0.06 equiv) in an organic solvent (such as dioxane, DME
or DCE, preferably dioxane) is added a vinyl triflate (1 equiv).
The mixture is heated under inert atmosphere at about 60 to
90.degree. C. (preferably 70 to 80.degree. C.) for about 1 to 20 h
(preferably 8 to 16 h). The mixture is optionally concentrated in
vacuo to give the targeted compound. Alternatively, the mixture is
optionally filtered through a media (such as silica gel or
Celite.RTM.) which is rinsed with an appropriate solvent (such as
EtOAc, 1,4-dioxane, THF, ACN, DCM, Et.sub.2O, MeOH, or EtOH) and
then optionally concentrated in vacuo to give a residue. Either the
residue or the solution may be optionally partitioned between water
and an organic solvent (such as EtOAc, Et.sub.2O or DCM). The
organic layer is isolated and may be optionally washed in no
particular order with water and/or aqueous solutions containing an
acid (such as HCl, AcOH or NH.sub.4Cl) and/or aqueous solutions
containing a base (such as NaHCO.sub.3, Na.sub.2CO.sub.3, NaOH, KOH
or NH.sub.4OH) and/or aqueous solutions containing an inorganic
salt (such as NaCl, Na.sub.2SO.sub.3 or Na.sub.2S.sub.2O.sub.3).
The organic solution may then be optionally dried with a drying
agent (such as anhydrous MgSO.sub.4 or Na.sub.2SO.sub.4), filtered
and concentrated in vacuo to give the targeted compound.
Illustration of General Procedure W
Preparation #W.1: tert-Butyl
6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1,4-oxazepine-
-4(7H)-carboxylate
##STR00591##
[1119] A 100 mL 3 neck round-bottomed flask was charged with
4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (1.10
g, 4.34 mmol, Preparation #AA.1), PPh.sub.3 (0.062 g, 0.24 mmol),
Pd(PPh.sub.3).sub.2Cl.sub.2 (0.138 g, 0.197 mmol) and
K.sub.2CO.sub.3 (0.818 g, 5.92 mmol). To this mixture was added a
solution of tert-butyl
6-(((trifluoromethyl)sulfonyl)oxy)-2,3-dihydro-1,4-oxazepine-4(7H)-carbox-
ylate (1.37 g, 3.94 mmol) in dioxane (30 mL). The entire mixture
was degassed for about 5 min and purged with nitrogen. The mixture
was heated at about 75.degree. C. for about 15 h. The mixture was
diluted with EtOAc (30 mL) and water (30 mL). The organic layer was
separated, dried over MgSO.sub.4, filtered and concentrated. The
resulting mixture was purified silica gel chromatography (10-40%
EtOAc/heptane) to give tert-butyl
6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1,4-oxazepine-
-4(7H)-carboxylate (0.57 g, 44%): LC/MS (Table 1, Method as)
R.sub.t=2.65 min; MS m/z: 226 (M+H-Boc)+
General Procedure X: Hydrolysis of an Ester to a Carboxylic Acid
Under Basic Conditions and Removal of a Tosyl Group from an N-Tosyl
Protected Heteroaryl Ring
[1120] To a flask containing a compound with and ester
functionality and a tosyl-protected heteroaromatic ring (1 equiv)
either neat or in an organic solvent (such as 1,4-dioxane, MeOH, or
THF/MeOH, THF/water/MeOH preferably THF/water/MeOH) is added a base
or combination of bases (such as aqueous or solid Na.sub.2CO.sub.3,
KOH, Cs.sub.2CO.sub.3, K.sub.2CO.sub.3, NaOH or LiOH, preferably
LiOH, or KOH; 1 to 10 equiv, preferably 5 to 10 equiv). The mixture
is stirred at about 0 to 100.degree. C. (preferably about 40 to
85.degree. C.) for about 1 to 48 h (preferably about 1 to 24 h).
Optionally, more base is added (such as aqueous or solid
Na.sub.2CO.sub.3, KOH, Cs.sub.2CO.sub.3, K.sub.2CO.sub.3, NaOH or
LiOH, preferably LiOH or NaOH, 1 to 10 equiv, preferably 2 to 6
equiv) and the mixture is stirred at about 0 to 100.degree. C.
(preferably about 10 to 100.degree. C.) for about 1 to 48 h
(preferably about 4 to 24 h). The mixture is then acidified with
the addition of a suitable aqueous acid (such as aqueous HCl, AcOH
or citric acid, preferably citric acid). The mixture is optionally
concentrated in vacuo to give the targeted compound. Alternatively,
the mixture is optionally filtered through a media (such as silica
gel or Celite.RTM.) which is rinsed with an appropriate solvent
(such as EtOAc, 1,4-dioxane, THF, ACN, DCM, Et.sub.2O, MeOH, or
EtOH) and then optionally concentrated in vacuo to give a residue.
Either the residue or the solution may be optionally partitioned
between water and an organic solvent (such as EtOAc, Et.sub.2O or
DCM). The organic layer is isolated and may be optionally washed in
no particular order with water and/or aqueous solutions containing
an acid (such as HCl, AcOH or NH.sub.4Cl) and/or aqueous solutions
containing a base (such as NaHCO.sub.3, Na.sub.2CO.sub.3, NaOH, KOH
or NH.sub.4OH) and/or aqueous solutions containing an inorganic
salt (such as NaCl, Na.sub.2SO.sub.3 or Na.sub.2S.sub.2O.sub.3).
The organic solution may then be optionally dried with a drying
agent (such as anhydrous MgSO.sub.4 or Na.sub.2SO.sub.4), filtered
and concentrated in vacuo to give the targeted compound.
Illustration of General Procedure X
Preparation #X.1:
4-(1-(tert-Butoxycarbonyl)-1,2,5,6-tetrahydropyridin-3-yl)-2-methyl-1H-in-
dole-7-carboxylic acid
##STR00592##
[1122] A round bottom flask was charged with methyl
4-(1-(tert-butoxycarbonyl)-1,2,5,6-tetrahydropyridin-3-yl)-2-methyl-1-tos-
yl-1H-indole-7-carboxylate (1.67 g, 2.30 mmol, Preparation #39) in
THF (12 mL), water (4 mL) and MeOH (4 mL). LiOH (monohydrate, 0.468
g, 11.1 mmol) was added. The mixture was stirred at about
60.degree. C. After about 7 h additional LiOH (monohydrate, 0. 234
g, 5.57 mmol) was added and the mixture was allowed to stir for
about 24 h at about 60.degree. C. The mixture was diluted with 5%
citric acid (200 mL) and extracted with DCM (2.times.100 mL) and
3:1, CHCl.sub.3: isopropanol (100 mL). The combined organic layers
were washed with water (50 mL) and dried over Na.sub.2SO.sub.4,
filtered and concentrated under reduced pressure to give
4-(1-(tert-butoxycarbonyl)-1,2,5,6-tetrahydropyridin-3-yl)-2-methyl--
1H-indole-7-carboxylic acid (1.16 g, 93%): LC/MS (Table 1, Method
as) R.sub.t=2.33 min; MS m/z: 355 (M-H).sup.-.
General Procedure Y: Iodination of a 1H-indole or a 1H-aza indole
ring to give a 2-iodo-1H-indole or a 2-iodo-1H-azaindole ring
[1123] To a solution of an indole or azaindole (1 equiv) in an
organic solvent (such as THF or Et.sub.2O, preferably THF) at about
-60 to -78.degree. C. (preferably about -70 to -78.degree. C.) is
added a base (such as BuLi or LDA, preferably LDA; 1 to 2 equiv,
preferably 1.1 to 1.5 equiv). The reaction mixture is then stirred
for about 30 to 45 min and iodine (1 to 2 equiv, preferably 1.4 to
1.6 equiv) is then added. The reaction mixture is stirred for about
10 to 60 min (preferably about 10 to 30 min). The mixture is
optionally quenched with Na.sub.2S.sub.2O.sub.3. The mixture is
optionally concentrated in vacuo to give the targeted compound.
Either the residue or the solution may be optionally partitioned
between water and an organic solvent (such as EtOAc, Et.sub.2O or
DCM). The organic layer is isolated and may be optionally washed in
no particular order with water and/or aqueous solutions containing
an acid (such as HCl, AcOH or NH.sub.4Cl) and/or aqueous solutions
containing a base (such as NaHCO.sub.3, Na.sub.2CO.sub.3, NaOH, KOH
or NH.sub.4OH) and/or aqueous solutions containing an inorganic
salt (such as NaCl, Na.sub.2SO.sub.3 or Na.sub.2S.sub.2O.sub.3).
The organic solution may then be optionally dried with a drying
agent (such as anhydrous MgSO.sub.4 or Na.sub.2SO.sub.4), filtered
and concentrated in vacuo to give the targeted compound.
Illustration of General Procedure Y
Preparation #Y.1: 1-tert-Butyl 7-methyl
4-(1-(tert-butoxycarbonyl)pyrrolidin-3-yl)-2-iodo-1H-indole-1,7-dicarboxy-
late
##STR00593##
[1125] A solution of anhydrous 1-tert-butyl 7-methyl
4-(1-(tert-butoxycarbonyl)pyrrolidin-3-yl)-1H-indole-1,7-dicarboxylate
(10.0 g, 22.5 mmol, (Preparation #Z.1) in THF (136 mL) was cooled
to about -78.degree. C. and LDA (1M in THF, 33.7 mL, 33.7 mmol) was
added drop wise. After about 45 min, a solution of iodine (7.99 g,
31.5 mmol) in THF (15 mL) was added drop wise while maintaining the
temperature at about -71.degree. C. The reaction mixture was then
quenched by pouring into an aqueous solution of
Na.sub.2S.sub.2O.sub.3 and NaHCO.sub.3 (10:1, 150 mL). The mixture
was diluted with EtOAc and the layers were separated. The aqueous
phase was extracted with EtOAc (3.times.50 mL). The combined
organic layers were washed with brine, dried over MgSO4 and
filtered. The solvent was removed under reduced pressure to give
methyl
4-(1-(tert-butoxycarbonyl)-2,5-dihydro-1H-pyrrol-3-yl)-1H-indole-7-carbox-
ylate (10.4 g, 97%): LC/MS (Table 1, Method as) R.sub.t=2.90 min;
MS m/z: 588 (M+NH.sub.4).sup.+.
General Procedure Z: Formation of an N-Boc Protected Amine
[1126] To a solution of an amine or amine salt (preferably 1 equiv)
in an organic solvent (such as ACN, 1,4-dioxane, DCM, DMF or THF,
preferably DCM) is added an aqueous base such as Na.sub.2CO.sub.3,
NaOH, K.sub.2CO.sub.3 or NaHCO.sub.3, preferably Na.sub.2CO.sub.3
(2 to 20 equiv, preferably 2 to 10 equiv) or an organic base such
as TEA or DIEA, preferably TEA (1 to 5 equiv, preferably 1 to 2
equiv) followed by addition of a Boc transfer reagent such as
BoC.sub.2O, Boc ON, Boc-azide or Boc-OSu preferably Boc.sub.2O (1
to 4 equiv, preferably 1 to 2 equiv). Optionally, an additive, such
as DMAP (0.01 to 0.1 equiv, preferable 0.05 equiv) may be added.
The addition of base is optional if an amine salt is not used. The
mixture is stirred at about 0 to 40.degree. C. (preferably about 0
to 25.degree. C.) for about 2 to 24 h (preferably about 2 to 16 h).
The mixture may optionally be concentrated in vacuo to give the
target compound. Alternatively, the mixture is optionally filtered
through a media (such as silica gel or Celite.RTM.) which is rinsed
with an appropriate solvent (such as EtOAc, 1,4-dioxane, THF, ACN,
DCM, Et.sub.2O, MeOH, EtOH) and then optionally concentrated in
vacuo to give a residue as the target compound. Either the residue
or the solution may be optionally partitioned between water and an
organic solvent (such as EtOAc, Et.sub.2O or DCM). The organic
layer is isolated and may optionally be washed in no particular
order with water and/or aqueous solutions containing an acid (such
as HCl, AcOH or NH.sub.4Cl) and/or aqueous solutions containing a
base (such as NaHCO.sub.3, Na.sub.2CO.sub.3, NaOH, KOH or
NH.sub.4OH) and/or aqueous solutions containing an inorganic salt
(such as NaCl Na.sub.2SO.sub.3 or Na.sub.2S.sub.2O.sub.3). The
organic solution may then be optionally dried with a drying agent
(such as anhydrous MgSO.sub.4 or Na.sub.2SO.sub.4), filtered and
concentrated in vacuo to give the target compound.
Illustration of General Procedure Z
Preparation #Z.1: 1-tert-Butyl 7-methyl
4-(1-(tert-butoxycarbonyl)pyrrolidin-3-yl)-1H-indole-1,7-dicarboxylate
##STR00594##
[1128] In a 200 mL round-bottomed flask, methyl
4-(1-(tert-butoxycarbonyl)pyrrolidin-3-yl)-1H-indole-7-carboxylate
(12.4 g, 36.0 mmol, prepared using A from methyl
4-bromo-1H-indole-7-carboxylate [Anthem] with tert-butyl
3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,5-dihydro-1H-pyrrole-1--
carboxylate [AKSCI] and L with Pd/C) and di-tert-butyl dicarbonate
(9.43 g, 43.2 mmol)) in ACN (100 mL) were added. DMAP (0.22 g, 1.8
mmol) was added, the reaction mixture was stirred at rt for about
18 h, TEA (10 mL, 72 mmol) and di-tert-butyl dicarbonate (1.60 mL,
6.87 mmol) were added. The reaction mixture was stirred at rt for
about 16 h. The mixture was extracted with dilute acetic acid and
EtOAc. The combined organic layers were dried over MgSO4,
concentrated under reduced pressure and purified using silica gel
chromatography (0-25% EtOAC/heptane) to give 1-tert-butyl 7-methyl
4-(1-(tert-butoxycarbonyl)pyrrolidin-3-yl)-1H-indole-,7-dicarboxylate
(12.5 g, 70%, 89% purity): LC/MS (Table 1, Method as) R.sub.t=2.79
min; MS m/z: 462 (M+NH.sub.4).
General Procedure AA: Conversion of a Cyclic Ketone to a Cyclic
Vinyl Triflate
[1129] A solution of a ketone (1 equiv) in an organic solvent (such
as THF, dioxane or ether preferably THF) is cooled to about -60 to
-78.degree. C. (preferably about -65 to -75.degree. C.). A base is
then added slowly (such as LiHMDS, KHMDS or NaHMDS preferably
KHMDS). After about 20 to 60 min (preferably 60 min) a solution of
a triflating reagent is added, such as,
N-(5-Chloro-2-pyridyl)bis(trifluoromethanesulfonimide)) or
1,1,1-trifluoro-N-phenyl-N-((trifluoromethyl)sulfonyl)methanesulfonamide
in THF. The reaction mixture is then allowed to warm to rt over
about 1 to 1.5 h. The reaction mixture may then be quenched with a
saturated solution of NH.sub.4Cl or water and diluted with an
organic solvent (such as DCM or EtOAc). The layers are separated,
the organic solution is optionally washed with water and/or brine,
dried over anhydrous MgSO.sub.4 or Na.sub.2SO.sub.4, filtered, and
the solvent is removed under reduced pressure to give the desired
compound.
Illustration of General Procedure AA
Preparation #AA.1: tert-Butyl
6-(((trifluoromethyl)sulfonyl)oxy)-2,3-dihydro-1,4-oxazepine-4(7H)-carbox-
ylate
##STR00595##
[1131] To a solution of tert-butyl
6-oxo-1,4-oxazepane-4-carboxylate (5.00 g, 23.2 mmol) [Arkpharm] in
THF (51.6 mL) at about -78.degree. C. was added KHMDS (1M in THF,
30.2 mL, 30.2 mmol) drop wise maintaining internal temperature of
about -72 to -74.degree. C. The mixture was then stirred at about
-77.degree. C. for about 1 h. A solution of
1,1,1-trifluoro-N-phenyl-N-((trifluoromethyl)sulfonyl)methanesulfonamide
(7.88 g, 22.1 mmol) in THF (25.8 mL) was added drop wise. The
mixture was gradually warmed to about 0.degree. C. over about 1 to
2 h. The reaction mixture was quenched with a saturated aqueous
solution of NH.sub.4Cl and extracted with EtOAc (2.times.75 mL).
The combined organic layers were washed with brine, dried over
MgSO.sub.4, filtered, concentrated under reduced pressure and
passed through a plug of neutral alumina (EtOAc/heptane as eluent)
to yield
(((trifluoromethyl)sulfonyl)oxy)-2,3-dihydro-1,4-oxazepine-4(7H)-carboxyl-
ate (5.1 g, 63.2%); .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
7.17 (s, 1H), 4.41 (s, 2H), 3.77 (q, J=2.3 Hz, 4H), 1.45 (s,
9H).
General Procedure AB: Reduction of a Double Bond and Removal of a
CBZ Group from a CBZ Protected Amine
[1132] A round bottom flask is charged with a palladium catalyst,
such as Pd/C or Pd(OH).sub.2 (10 or 20 wt %, about 0.005 to 1.0
equiv, preferably 0.5 to 1.0 equiv). The flask is evacuated then
flushed with nitrogen 2 to 5 times (preferably 3 times) prior to
addition of an organic solvent or mixture of solvents (such as
EtOAc, MeOH, EtOH or MeOH/AcOH, preferably MeOH/AcOH) under a
nitrogen atmosphere. To the mixture is added a compound with an
alkene functionality and an N-CBZ protected amine (preferably 1
equiv), neat or optionally as a solution in an organic solvent or
mixture of solvents (such as EtOAc, MeOH, EtOH or MeOH/AcOH,
preferably MeOH). The mixture is stirred under a hydrogen
atmosphere (about 30 to 50 psi) for about 1 to 60 h (preferably
about 4 to 5 h). Optionally the reaction may be performed using an
H-cube instrument with either Pd/C or Pd(OH).sub.2 cartridges (10
or 20 wt %) and the starting material is passed through the system
as a solution in the preferred solvent/s. In cases where the
reaction does not proceed to completion as monitored by TLC, LC/MS,
or HPLC, the mixture can be optionally heated to about 30 to
80.degree. C. (preferably about 50.degree. C.) for about 1 to 24 h
(preferably about 16 h) and in cases where the H-cube is used to
perform the reaction, the pressure may be increased (25 to 50 bar,
preferably 40 to 50 bar). The mixture is then filtered and the
filter cake is rinsed with an organic solvent (such as EtOAc, MeOH
or EtOH, preferably the reaction solvent) and the filtrate is
concentrated under reduced pressure to give the crude product.
Illustration of General Procedure AB
Preparation
#AB.1:4-(Piperidin-3-yl)-1H-pyrrolo[3,2-c]pyridine-7-carboxamide
##STR00596##
[1134] A round bottom flask was charged with Pd(OH).sub.2 (20 wt %,
0.336 g, 0.478 mmol) followed by the slow addition of a solution of
benzyl
3-(7-carbamoyl-1H-pyrrolo[3,2-c]pyridin-4-yl)-5,6-dihydropyridine-1(2H)-c-
arboxylate (1.8 g, 4.8 mmol, prepared using A from Preparation #45
and benzyl
3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridin-
e-1(2H)-carboxylate [Arkpharm], Y with LiOH and D with NH.sub.4Cl)
in MeOH (30 mL) and AcOH (10 mL). The flask was purged with
N.sub.2, then filled with H.sub.2 using a balloon. The reaction
mixture was then heated at about 45.degree. C. for about 3 h. The
reaction mixture was cooled to rt and filtered through a pad of
Celite.COPYRGT., washing with MeOH. The filtrate was concentrated
under reduced pressure, dissolved in MeOH and then treated with
MP-carbonate beads by stirring at rt for about 2 h. The beads were
filtered off and the filtrate was concentrated under reduced
pressure to give
4-(piperidin-3-yl)-1H-pyrrolo[3,2-c]pyridine-7-carboxamide (0.84 g,
72%): LC/MS (Table 1, Method as) R.sub.t=0.58 min.; MS m/z: 245
(M+H).sup.+.
General Procedure AC: N-Oxidation of an N Containing Hetero
Aromatic Ring
[1135] A solution of an N-containing hetero aromatic compound (1
equiv) in an organic solvent (such as DCE, DME, DCM or EtOAc,
preferably DCM) is cooled to about 0.degree. C. and an oxidizing
reagent such as 3-chlorobenzoperoxoic acid or magnesium
monoperoxyphthalate hexahydrate (1 to 3 equiv, preferably 2 equiv).
The solution is stirred at rt for about 2 to 24 h (preferably about
10 to 16 h). The mixture is optionally filtered to give the desired
product or optionally concentrated in vacuo to give a residue,
either the residue or the solution may be optionally partitioned
between water and an organic solvent (such as EtOAc, Et.sub.2O or
DCM). The organic layer is isolated and may optionally be washed in
no particular order with water and/or aqueous solutions containing
an acid (such as HCl, AcOH or NH.sub.4Cl) and/or aqueous solutions
containing a base (such as NaHCO.sub.3, Na.sub.2CO.sub.3, NaOH, KOH
or NH.sub.4OH) and/or aqueous solutions containing an inorganic
salt (such as NaCl Na.sub.2SO.sub.3 or Na.sub.2S.sub.2O.sub.3). The
organic solution may then be optionally dried with a drying agent
(such as anhydrous MgSO.sub.4 or Na.sub.2SO.sub.4), filtered and
concentrated in vacuo to give the target compound.
Illustration of General Procedure AC
Preparation #AC.1: 4-Bromo-1H-pyrrolo[2,3-c]pyridine 6-oxide
##STR00597##
[1137] A flask was charged with 4-bromo-1H-pyrrolo[2,3-c]pyridine
(10.0 g, 50.8 mmol) [Combiblocks] and dissolved in EtOAc (254 mL).
The flask was cooled to about 0.degree. C. and a solution of
3-chlorobenzoperoxoic acid (10.5 g, 60.9 mmol) in EtOAc (254 mL)
was slowly added. The reaction was stirred warming to rt for about
16 h. The precipitate that had formed was collected via filtration
and dried in vacuum oven to afford 4-bromo-1H-pyrrolo[2,
3-c]pyridine 6-oxide (0.85 g, 79%): LC/MS (Table 1, Method as)
R.sub.t=1.18 min; MS m/z: 213, 215 (M+H).sup.+.
General Procedure AD: Cyanation of an N-Oxide Containing Heteroaryl
Ring
[1138] A flask is charged with an N-oxide heteroaromatic compound
(1 equiv) in an appropriate organic solvent, such as ACN. TEA is
added (1 to 2 equiv, preferably 1.5 equiv). TMSCN (2 to 5 equiv,
preferable 3 to 4 equiv) is then added using a syringe. The
reaction mixture is refluxed until complete consumption of starting
material is observed either via TLC or LC/MS. The reaction mixture
is cooled to rt and quenched appropriately, preferable with an
aqueous solution of NaOH and extracted with an organic solvent,
such as DCM or EtOAC. The organic layer is isolated and may
optionally be washed in no particular order with water and/or
aqueous solutions containing an acid (such as HCl, AcOH or
NH.sub.4Cl) and/or aqueous solutions containing a base (such as
NaHCO.sub.3, Na.sub.2CO.sub.3, NaOH, KOH or NH.sub.4OH) and/or
aqueous solutions containing an inorganic salt (such as NaCl
Na.sub.2SO.sub.3 or Na.sub.2S.sub.2O.sub.3). The organic solution
may then be optionally dried with a drying agent (such as anhydrous
MgSO.sub.4 or Na.sub.2SO.sub.4), filtered and concentrated in vacuo
to give the target compound.
Illustration of General Procedure AD
Preparation #AD.1:
4-Bromo-1H-pyrrolo[2,3-c]pyridine-7-carbonitrile
##STR00598##
[1140] A flask was charged with
4-bromo-1H-pyrrolo[2,3-c]pyridine-6-oxide 3-chlorobenzoate (6.25 g,
16.91 mmol, Preparation #AC.1) in ACN (97 mL) and TEA (3.56 mL,
25.4 mmol). TMSCN (9.02 mL, 67.6 mmol) was added in one portion via
syringe the mixture was refluxed for about 45 min. The reaction was
quenched by careful addition of 50 mL of aqueous 1 M NaOH solution,
transferred to a separatory funnel and diluted with aqueous 1M NaOH
solution (200 mL) and EtOAc (200 mL). The layers were separated and
the organic phase was washed again with 50 mL of aqueous 1 M NaOH
solution. The combined aqueous extracts were washed with EtOAc
(4.times.75 mL) and then with 1 M NaOH (2.times.20 mL) and brine
(1.times.50 mL), dried over Na.sub.2SO.sub.4, filtered and the
solvent was removed to afford
4-bromo-1H-pyrrolo[2,3-c]pyridine-7-carbonitrile (3.84 g, 93%):
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 8.27 (s, 1H), 7.90 (d,
J=2.8 Hz, 1H), 6.60 (d, J=2.8 Hz, 1H).
General Procedure AE: Reduction of an Ester to Form an Alcohol
[1141] To a solution of an ester in an appropriate organic solvent
(such as THF, dioxane, DCM or EtOAc, preferably THF) is optionally
added water (1 to 4 equiv, preferably 2 equiv). The mixture is then
cooled to about 0.degree. C. and a reducing agent is added (such as
LiBH.sub.4 or LAH, preferably LiBH.sub.4; 2 to 12 equiv, preferably
6 equiv). The reaction mixture is stirred for about 5 to 24 h until
complete consumption of the ester. Additional reducing agent may be
optionally added as required. The reaction mixture is then quenched
with an aqueous solution of NH.sub.4C. The organic layer is
isolated and may optionally be washed in no particular order with
water and/or aqueous solutions containing an acid (such as HCl,
AcOH or NH.sub.4Cl) and/or aqueous solutions containing a base
(such as NaHCO.sub.3, Na.sub.2CO.sub.3, NaOH, KOH or NH.sub.4OH)
and/or aqueous solutions containing an inorganic salt (such as NaCl
Na.sub.2SO.sub.3 or Na.sub.2S.sub.2O.sub.3). The organic solution
may then be optionally dried with a drying agent (such as anhydrous
MgSO.sub.4 or Na.sub.2SO.sub.4), filtered and concentrated in vacuo
to give the target compound.
Illustration of General Procedure AE
Preparation #AE.1: tert-Butyl
3-(7-carbamoyl-1H-indol-4-yl)-5-(hydroxymethyl)piperidine-1-carboxylate
##STR00599##
[1143] In a 500 mL round-bottomed flask, 1-tert-butyl 3-methyl
5-(7-carbamoyl-1H-indol-4-yl)piperidine-1,3-dicarboxylate (6.75 g,
16.8 mmol, prepared using Z from Preparation #AF.1) in THF (150 mL)
was added. The reaction mixture was cooled to about 0.degree. C.
and water (0.606 mL, 33.6 mmol) was added. LiBH.sub.4 (2.93 g, 135
mmol) was added and reaction mixture stirred at rt for about 12 h.
Additional LiBH.sub.4 (2.93 g, 135 mmol) was added and reaction
mixture was stirred for about 3 h. The reaction mixture was
carefully added to a saturated aqueous solution of NH.sub.4Cl (800
mL) at about -10.degree. C. The mixture was extracted with DCM (500
mL). The DCM layer was dried over MgSO.sub.4, filtered and
concentrated to give crude tert-butyl
3-(7-carbamoyl-1H-indol-4-yl)-5-(hydroxymethyl)piperidine-1-carboxylate
(6.35 g, 101%): LC/MS (Table 1, Method as) R.sub.t=1.74 min; MS
m/z: 374 (M+H).sup.+.
General Procedure AF: Reduction of a Pyridine Ring to a Piperiding
Ring
[1144] To a solution of the pyridine (1 equiv) in acetic acid is
added a reducing reagent (such as PtO.sub.2, Pd(OH).sub.2 or Pd/C,
preferably PtO.sub.2; 0.05 to 0.5 equiv, preferable 0.1 to 0.2
equiv). The reaction mixture is heated at about 50.degree. C. at
about 20 to 50 psi (preferably about 30 psi) for about 6 to 12 h
(preferably about 10 h). The reaction mixture is concentrated under
reduced pressure to give the desired compound.
Illustration of General Procedure AF
Preparation #AF.1: Methyl
5-(7-carbamoyl-1H-indol-4-yl)piperidine-3-carboxylate
##STR00600##
[1146] Methyl 5-(7-carbamoyl-1H-indol-4-yl)nicotinate (6.25 g, 23.7
mmol, prepared using A from Preparation #P.1 with methyl
5-bromonicotinate) and AcOH (70 mL) were added to PtO.sub.2 (1.26
g, 5.55 mmol) in a 50 mL pressure bottle and shaken for about 10 h
at about 50.degree. C. at about 30 psi. The resulting black
solution was concentrated under reduced pressure and filtered
through a plug of Celite.RTM. and washed with DCM. The filtrate was
then concentrated to a thick viscous black oily residue. This
material was dissolved in 15% MeOH/EtOAc and passed through a large
silica gel plug. The plug was flushed with 10% MeOH/EtOAc (250 mL),
then 35-40% MeOH/EtOAc (1.5 L) to afford methyl
5-(7-carbamoyl-1H-indol-4-yl)piperidine-3-carboxylate (6.3 g, 79%):
LC/MS (Table 1, Method a) R.sub.t=0.96 min; MS m/z: 302
(M+H).sup.+.
General Procedure AG: One Pot Borylation of a Triflate and Suzuki
Reaction of the In Situ Formed Boronate with an Aryl Halide
[1147] To a mixture of a vinyl triflate (preferably 1 equiv), a
boronic acid or boronate ester (1 to 2 equiv, preferably 1.1
equiv), and an inorganic base (such as KF, Na.sub.2CO.sub.3,
K.sub.2CO.sub.3 or Cs.sub.2CO.sub.3, preferably Na.sub.2CO.sub.3 or
Cs.sub.2CO.sub.3; 1.1 to 16 equiv, preferably 2 equiv) in a solvent
(such as THF, DME, DMF, 1,4-dioxane, 1,4-dioxane, preferably
dioxane) is added a palladium catalyst (for example Pd(OAc).sub.2,
Pd.sub.2dba.sub.3, Pd(PPh.sub.3).sub.4,
bis(acetato)triphenylphosphinepalladium(II), polymer-bound
FibreCat.TM. 1032, SiliaCat DPP-Pd, PdCl.sub.2(dppf) or
Pd(PPh.sub.3).sub.2Cl.sub.2; preferably PdCl.sub.2(dppf) or
Pd(PPh.sub.3).sub.2Cl.sub.2; 0.01 to 0.20 equiv, preferably 0.05 to
0.1 equiv) and a ligand (for example tricyclohexylphosphine,
tri-tert-butyl-phosphine; preferably none or PPh.sub.3; 0.01 to 1.0
equiv, preferably 0.01 to 0.03 equiv) is added optionally. The
mixture is heated at about 40 to 120.degree. C. (preferably about
70 to 85.degree. C.) for about 1 to 48 h (preferably about 2 to 4
h) thermally, or at about 100 to 200.degree. C. (preferably about
120 to 150.degree. C.) for about 5 to 60 min (preferably about 20
to 45 min) in a microwave (preferably 5 min ramp time, 300 Watts
max power, 250 psi max pressure). The mixture is optionally allowed
to cool to rt and filtered. To the reaction mixture is added the
aryl halide (1 to 2 equiv), water (about 1/3 to 1/4 the volume of
the original organic solvent used) and optionally additional
catalyst, base and ligand is added (preferably the same ones used
in the first reaction) and heated at the same temperature for about
3 to 24 h (preferably about 8 to 10 h) and is worked up using one
of the following methods. Method 1. For reactions containing water,
the mixture may be diluted with an organic solvent (such as DCM or
EtOAc). The layers are separated, the organic solution is
optionally washed with water and/or brine, dried over anhydrous
MgSO.sub.4 or Na.sub.2SO.sub.4, filtered, and the solvent is
removed under reduced pressure to give the desired compound. Method
2. The mixture is concentrated under reduced pressure. Method 3.
The catalyst is removed by filtration and the filtrate is
concentrated under reduced pressure
Illustration of General Procedure AG
Preparation #AG.1: tert-Butyl
6-(7-(methoxycarbonyl)-1H-pyrrolo[3,2-c]pyridin-4-yl)-2,3-dihydro-1,4-oxa-
zepine-4(7H)-carboxylate
##STR00601##
[1149] A 40 mL microwave reaction vial was charged with
4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (0.995
g, 3.92 mmol), PPh.sub.3(0.056 g, 0.214 mmol),
Pd(PPh.sub.3).sub.2Cl.sub.2 (0.125 g, 0.178 mmol) and
K.sub.2CO.sub.3 (0.738 g, 5.34 mmol). To this mixture was added a
solution of tert-butyl
6-(((trifluoromethyl)sulfonyl)oxy)-2,3-dihydro-1,4-oxazepine-4(7H)-carbox-
ylate (1.24 g, 3.56 mmol, Preparation #AA.1) in dioxane (13 mL).
The entire mixture was degassed for about 5 min and purged with
nitrogen. The mixture was heated at about 75.degree. C. for about 2
h. To the reaction mixture was added methyl
4-chloro-1H-pyrrolo[3,2-c]pyridine-7-carboxylate (0.600 g, 2.85
mmol), Pd(PPh.sub.3).sub.2Cl.sub.2 (125 mg, 0.178 mmol),
K.sub.2CO.sub.3 (0.492 g, 3.56 mmol) and water (3.25 mL). The
entire suspension was degassed with nitrogen for about 10 min and
heated at about 75.degree. C. for about 8 h. The reaction mixture
was cooled, filtered over a plug of Celite.RTM. and MgSO.sub.4,
concentrated and purified via silica gel chromatography (0-40%
EtOAc/heptane) to give tert-butyl
6-(7-(methoxycarbonyl)-1H-pyrrolo[3,2-c]pyridin-4-yl)-2,3-dihydro-1,4-oxa-
zepine-4(7H)-carboxylate (0.3 g, 23%): LC/MS (Table 1, Method as)
R.sub.t=2.04 min; MS m/z: 374 (M+H).sup.+.
General Procedure AH: Formation of an N-Tosyl Protected
Heteroaromatic Ring
[1150] A solution of a compound with an N-heteroaromatic ring, such
as an indole or azaindole (1 equiv) in an appropriate organic
solvent (such as THF, DMF, DCE, toluene or dioxane, preferably THF)
is optionally cooled to about 0.degree. C. and a base (such as NaH,
KOH or NaOH, preferable NaH; 1 to 2 equiv, preferable 1.1 to 1.3
equiv) is added. The reaction mixture is stirred for about 10 to 30
min and 4-methyl-benzenesulfonyl chloride (1 to 3 equiv, preferable
1 to 1.5 equiv) is added. The reaction mixture is optionally
allowed to warm to rt if cooled or optionally heated at about 30 to
90.degree. C. until complete consumption of the starting
N-heteroaromatic compound. Additional base and tosylating reagent
may be optionally added as required. The reaction mixture is
quenched by the addition of water and extracted with an organic
solvent (such as EtOAc or DCM). The organic layer is isolated and
may optionally be washed in no particular order with water and/or
aqueous solutions containing an acid (such as HCl, AcOH or
NH.sub.4Cl) and/or aqueous solutions containing a base (such as
NaHCO.sub.3, Na.sub.2CO.sub.3, NaOH, KOH or NH.sub.4OH) and/or
aqueous solutions containing an inorganic salt (such as NaCl
Na.sub.2SO.sub.3 or Na.sub.2S.sub.2O.sub.3). The organic solution
may then be optionally dried with a drying agent (such as anhydrous
MgSO.sub.4 or Na.sub.2SO.sub.4), filtered and concentrated in vacuo
to give the target compound.
Illustration of General Procedure AH
Preparation #AH.1:
4-Bromo-1-tosyl-1H-pyrrolo[2,3-c]pyridine-7-carbonitrile
##STR00602##
[1152] A flask is charged with
4-bromo-1H-pyrrolo[2,3-c]pyridine-7-carbonitrile (0.985 g, 4.44
mmol, Preparation #AD.1) in THF (30 mL). NaH (60% dispersion in
mineral oil, 0.213 g, 5.32 mmol) was added portion wise at about
0.degree. C. The mixture was allowed to stir for about 15 min, then
4-methyl-benzenesulfonyl chloride (0.930 g, 4.88 mmol) was added in
one portion and the reaction was allowed to warm to room
temperature and stirred or about 16 h. Additional NaH (60%
dispersion in mineral oil, 0.355 g, 0.89 mmol) and
4-methylbenzene-1-sulfonyl chloride (0.254 g, 1.33 mmol) were added
in sequence and stirred at rt for about 1 h. The reaction mixture
was diluted with water (30 mL) and extracted with EtOAc (60 mL).
The organic layer was dried over MgSO.sub.4, filtered, concentrated
and purified using silica gel chromatography (0-35% EtOAc/heptane)
to give 4-bromo-1-tosyl-1H-pyrrolo[2, 3-c]pyridine-7-carbonitrile
(1.35 g, 81%): LC/MS (Table 1, Method as) R.sub.t=2.51 min; MS m/z:
376, 378 (M+H).sup.+.
Example #1: tert-Butyl
2-(4-bromo-7-carbamoyl-1H-indol-2-yl)benzylcarbamate
methylphenyl)thiazole-2-carboxamide
##STR00603##
[1153] Step A: tert-Butyl
2-(4-bromo-7-carbamoyl-1H-indo-2-yl)benzylcarbamate
##STR00604##
[1155] To a solution of 4-bromo-2-iodo-1H-indole-7-carboxamide (2.5
g, 6.8 mmol, Preparation #1) in THF (185 mL), MeOH (25 mL) and
water (25 mL) was added tert-butyl
2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzylcarbamate (2.7
g, 8.2 mmol, JW), Pd(dppf)Cl.sub.2 (0.5 g, 0.7 mmol) and
Na.sub.2CO.sub.3 (2.2 g, 20.6 mmol). The mixture was stirred at
about 80.degree. C. overnight under nitrogen. The solvent was
removed under reduced pressure to give a residue, which was
purified by column chromatography on silica gel to provide crude
tert-butyl 2-(4-bromo-7-carbamoyl-1H-indol-2-yl)benzylcarbamate
(2.5 g, 5.6 mmol).
Step B:
tert-Butyl2-(7-carbamoyl-4-(2-methyl-3-(thiazole-2-carboxamido)phe-
nyl)-1H-indol-2-yl)benzylcarbamate
##STR00605##
[1157] To a solution of
2-(4-bromo-7-carbamoyl-1H-indol-2-yl)benzylcarbamate (2.5 g, 5.6
mmol) in THF (185 mL), MeOH (25 mL) and water (25 mL) was added
N-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)thiazol-
e-2-carboxamide (2.3 g, 6.8 mmol, Preparation #4), Pd(dppf)Cl.sub.2
(0.4 g, 0.6 mmol) and Na.sub.2CO.sub.3 (1.8 g, 16.9 mmol). The
mixture was stirred at about 80.degree. C. overnight under
nitrogen. The solvent was removed under reduced pressure to give a
residue, which was purified by column chromatograph on silica gel
to provide tert-butyl
2-(7-carbamoyl-4-(2-methyl-3-(2-oxo-2-(thiazol-2-yl)ethyl)phenyl)-1H-indo-
l-2-yl)benzylcarbamate (3 g, 92%): .sup.1H NMR (CDCl.sub.3) .delta.
10.57 (s, 1H), 9.25 (s, 1H), 8.22-8.20 (d, J=7.6 Hz, 1H), 7.92-7.91
(d, J=3.2 Hz, 1H), 7.64-7.63 (d, J=3.2 Hz, 1H), 7.50-7.45 (m, 3H),
7.37-7.35 (m, 3H), 7.26-7.24 (m, 2H), 7.04-7.02 (d, J=3.6 Hz, 1H),
6.32 (s, 1H), 4.43 (s, 2H), 2.25 (s, 3H), 1.38 (s, 9H).
Step C:
N-(3-(2-(2-(aminomethyl)phenyl)-7-carbamoyl-1H-indol-4-yl)-2-methy-
lphenyl)thiazole-2-carboxamide
##STR00606##
[1159] A solution of tert-butyl
2-(7-carbamoyl-4-(2-methyl-3-(2-oxo-2-(thiazol-2-yl)ethyl)phenyl)-1H-indo-
l-2-yl)benzylcarbamate (3 g, 5.2 mmol) in DCM (50 mL) and TFA (10
mL) was stirred at about 25.degree. C. for about 6 h. The solvent
was removed by reduced pressure. Water was added and the solution
was basified by addition of saturated aqueous NaHCO.sub.3 to pH 9.
The mixture was extracted with EtOAc. The organic phase was
concentrated to provide
N-(3-(2-(2-(aminomethyl)phenyl)-7-carbamoyl-1H-indol-4-yl)-2-methylphenyl-
)thiazole-2-carboxamide (2.2 g, 89%): LC/MS (Table 1, Method b)
R.sub.t=2.53 min; MS m/z: 482 (M+H).sup.+. (Btk IC.sub.50=B)
Example #2:
4-(3-Amino-2-methylphenyl)-1H-pyrrolo[2,3-c]pyridine-7-carboxamide
##STR00607##
[1160] Step A: 4-Bromo-7-chloro-1H-pyrrolo[2,3-c]pyridine
##STR00608##
[1162] To a solution of 5-bromo-2-chloro-3-nitropyridine (10 g,
0.042 mol) in anhydrous THF (150 mL), a solution of vinylmagnesium
bromide (17 g, 0.127 mol) in THF was added dropwise at -30 to
-50.degree. C. The reaction mixture was stirred at -30 to
-40.degree. C. for 2 h. Then the reaction mixture was poured into
saturated aqueous NH.sub.4Cl solution and the mixture was extracted
with EtOAc (50 mL.times.3). The combined organic layers were washed
with brine, dried over anhydrous Na.sub.2SO.sub.4, filtered and
concentrated under reduced pressure and the residue was purified by
column chromatography to provide
4-bromo-7-chloro-1H-pyrrolo[2,3-c]pyridine (3 g, 31%): .sup.1H NMR:
(DMSO-d6) .delta. 12.45 (s, 1H), 8.04 (s, 1H), 7.79-7.78 (m, 1H),
6.59-6.58 (d, J=2.0, 1H).
Step B:
3-(7-Chloro-1H-pyrrolo[2,3-c]pyridin-4-yl)-2-methylaniline
##STR00609##
[1164] To a mixture of 4-bromo-7-chloro-1H-pyrrolo[2,3-c]pyridine
[Matrix] (5 g, 21.6 mmol),
2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline
(7.55 g, 32.4 mmol, CombiBlocks) and sodium carbonate (1.6 g, 64.8
mmol) in THF (80 mL), MeOH (80 mL) and water (20 mL),
Pd(dppf)Cl.sub.2 (1.6 g, 2.16 mmol) was added and the mixture was
degassed several times and heated to about 70.degree. C. overnight
under N.sub.2. The reaction mixture was filtered through
Celite.COPYRGT. and concentrated under reduced pressure and the
residue was purified by column chromatography to provide
3-(7-chloro-1H-pyrrolo[2, 3-c]pyridin-4-yl)-2-methylaniline (2.2 g,
40%): .sup.1H NMR (DMSO-d6) .delta. 12.05 (s, 1H), 7.71 (s, 1H),
7.64 (d, J=2.4, 1H), 6.99-6.96 (m, 1H), 6.72-6.70 (d, J=8.0, 1H),
6.48 (d, J=6.8, 1H), 6.2 (d, J=2.8, 1H), 4.95 (s, 2H), 1.82 (s,
3H).
Step C: Methyl
4-(3-amino-2-methylphenyl)-1H-pyrrolo[2,3-c]pyridine-7-carboxylate
##STR00610##
[1166] To a solution of
3-(7-chloro-1H-pyrrolo[2,3-c]pyridin-4-yl)-2-methylaniline (800 mg,
3.1 mmol) in anhydrous MeOH (80 mL), Et.sub.3N (3.1 g, 31 mmol) and
Pd(dppf)Cl.sub.2 (0.45 g, 0.62 mmol) were added and the reaction
mixture was heated to about 130.degree. C. for about 24 h under CO.
The reaction mixture was concentrated under reduced pressure and
the residue was purified by silica gel column to provide methyl
4-(3-amino-2-methylphenyl)-1H-pyrrolo[2,3-c]pyridine-7-carboxylate
(0.60 g, 69%): .sup.1H NMR (DMSO-d6): .delta. 11.65 (br. s., 1H),
8.09 (s, 1H) 7.65 (s, 1H) 7.02 (t, J=7.72 Hz, 1H), 6.74 (d, J=7.94
Hz, 1H), 6.52 (d, J=7.50 Hz, 1H) 6.26 (d, J=2.65 Hz, 1H), 5.02 (s,
2H), 4.0 (s, 3H), 1.83 (s, 3H)
Step D:
4-(3-Amino-2-methylphenyl)-1H-pyrrolo[2,3-c]pyridine-7-carboxamide
##STR00611##
[1168] To a solution of methyl
4-(3-amino-2-methylphenyl)-1H-pyrrolo[2,3-c]pyridine-7-carboxylate
(600 mg, 2.13 mmol) in MeOH (10 mL), ammonia (2 mL) was added and
the reaction mixture was stirred overnight at rt. The mixture was
concentrated and the residue was purified by prep-TLC (30:1
DCM/MeOH) to provide
4-(3-amino-2-methylphenyl)-1H-pyrrolo[2,3-c]pyridine-7-carboxamide
(320 mg, 56%): .sup.1H NMR (DMSO-d6): .delta. 11.56 (s, 1H), 8.2
(s, 1H), 7.97 (s, 1H), 7.64 (s, 1H), 7.55 (s, 1H), 7.0-6.97 (m,
1H), 6.71 (d, J=7.6, 1H), 6.50 (d, J=4.4, 1H), 6.17 (s, 1H), 4.97
(s, 2H), 1.82 (s, 3H); (Table 1, Method d) R.sub.t4=1.95 min; MS
m/z: 267 (M+H).sup.+. (BtkIC.sub.50=C)
Example #3:
N-(3-(7-carbamoyl-3-methyl-1H-indol-4-yl)-2-methylphenyl)thiazole-2-carbo-
xamide
##STR00612##
[1169] Step A: Methyl 4-bromo-3-formyl-1H-indole-7-carboxylate
##STR00613##
[1171] POCl.sub.3 (2.4 mL, 26 mmol) was added into DMF (60 mL)
solution dropwise at 0.degree. C. and stirred for about 30 min.
Then a solution of methyl 4-bromo-1H-indole-7-carboxylate (5 g, 13
mmol, Preparation #1, step B) in DMF (60 mL) was added dropwise
into the above reaction mixture at about 0.degree. C. and stirred
for about 20 min. The resulting reaction mixture was heated to
about 90.degree. C. for about 3 h. After cooling to rt, the mixture
was poured into ice water and basified by addition of aqueous NaOH
solution to pH=8 to 9. The aqueous mixture was extracted with
EtOAc. The combined organic phase was washed with brine, dried over
Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure
to get a residue, which was purified by column chromatography on
silica gel to provide methyl
4-bromo-3-formyl-1H-indole-7-carboxylate (3.5 g, 95%): .sup.1H NMR
(DMSO-d6): .delta. 12.33 (br, 1H), 10.69 (s, 1H), 8.20 (d, J=2.0
Hz, 1H), 7.76-7.74 (d, J=8.0 Hz, 1H), 7.61-7.59 (d, J=8.4 Hz, 1H),
3.94 (s, 3H).
Step B: Methyl
4-bromo-3-(((4-methoxybenzyl)amino)methyl)-1H-indole-7-carboxylate
##STR00614##
[1173] To a solution of methyl
4-bromo-3-formyl-1H-indole-7-carboxylate (3.5 g, 12.4 mmol) in
anhydrous DCE (50 mL) was added (4-methoxyphenyl)methanamine (2.6
g, 18.6 mmol) and a catalyst amount of AcOH. The reaction mixture
was stirred at rt for about 1 h. Then NaBH(OAc).sub.3 (13.2 g, 62
mmol) was added in portions and stirred at rt overnight. When the
reaction was completed, water was added to quench the reaction. The
aqueous phase was extracted with DCM. The combined organic phase
was concentrated under reduced pressure to get a residue, which was
purified by column chromatography on silica gel to provide methyl
4-bromo-3-(((4-methoxybenzyl)amino)methyl)-1H-indole-7-carboxylate
(4 g, 80%): .sup.1H NMR (DMSO-d6): .delta. 11.25 (br, 1H),
7.61-7.59 (d, J=8.4 Hz, 1H), 7.41 (s, 1H), 7.30-7.23 (m, 3H),
6.85-6.83 (d, J=8.4 Hz, 2H), 4.02 (s, 2H), 3.90 (s, 3H), 3.70-3.69
(m, 5H), 1.88 (s, 1H).
Step C:
4-Bromo-3-(((4-methoxybenzyl)amino)methyl)-1H-indole-7-carboxylica-
cid
##STR00615##
[1175] To a solution of methyl
4-bromo-3-(((4-methoxybenzyl)amino)methyl)-1H-indole-7-carboxylate
(5.4 g, 13.4 mmol) in THF (250 mL), MeOH (50 mL) and water (50 mL)
was added LiOH (1.6 g, 67.0 mmol) and heated to reflux for about 6
h. After cooling to rt, the organic solvent was removed under
reduced pressure. The aqueous phase was acidified with 1 N HCl to
pH=5 to 6. Then the suspension was filtered and the filter cake was
washed with water and dried to afford
4-bromo-3-(((4-methoxybenzyl)amino)methyl)-1H-indole-7-carboxylic
acid (4 g, 77%): .sup.1H NMR (DMSO-d6) .delta. 11.40 (br, 1H),
7.58-7.56 (d, J=8.0 Hz, 1H), 7.53 (s, 1H), 7.40-7.38 (d, J=8.4 Hz,
2H), 7.27-7.25 (d, J 8.0 Hz, 1H), 6.94-6.92 (d, J=8.4 Hz, 2H), 4.31
(s, 2H), 3.98 (s, 2H), 3.74 (s, 3H).
Step D:
4-Bromo-3-(((4-methoxybenzyl)amino)methyl)-1H-indole-7-carboxamide
##STR00616##
[1177] A mixture of
4-bromo-3-(((4-methoxybenzyl)amino)methyl)-1H-indole-7-carboxylic
acid (9.3 g, 23.9 mmol), EDCI (5.5 g, 28.7 mmol) and HOBt (4.4 g,
28.7 mmol) in THF (350 mL) and DCM (420 mL) was stirred at rt for
about 1 h. Then the reaction mixture was bubbled with ammonia gas
for about 15 min at about -60.degree. C., then warmed to rt and
stirred overnight. The solvent was removed under reduced pressure
and MeOH was added. The suspension was filtered and the filtrated
was concentrated under reduced pressure to get a residue, which was
purified by Prep-HPLC (Table 1, Method s) to provide
4-bromo-3-(((4-methoxybenzyl)amino)methyl)-1H-indole-7-carboxamide
(2.1 g, 23%): LC/MS (Table 1, Method d) R.sub.t4=2.31 min; MS m/z:
388 (M+H).sup.+
Step E:
N-(3-(7-carbamoyl-3-(((4-methoxybenzyl)amino)methyl)-1H-indol-4-yl-
)-2-methylphenyl)thiazole-2-carboxamide
##STR00617##
[1179] To a solution of
4-bromo-3-(((4-methoxybenzyl)amino)methyl)-1H-indole-7-carboxamide
(100 mg, 0.26 mmol),
N-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)thiazol-
e-2-carboxamide (116 mg, 0.39 mmol, Preparation #4) and CsF (39 mg,
0.26 mmol) in 1,4-dioxane (2 mL) and water (0.4 mL) was added
Pd(PPh.sub.3).sub.4 (29.8 mg, 0.03 mmol). Then the reaction mixture
was heated to about 100.degree. C. under nitrogen for about 12 h.
After cooling to rt, water was added and extracted with EtOAc. The
combined organic phase was washed with brine, dried over
Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure
to get a crude product, which was purified by Prep-HPLC (Table 1,
Method r) to provide
N-(3-(7-carbamoyl-3-(((4-methoxybenzyl)amino)methyl)-1H-indol-4-yl)-2-met-
hylphenyl)thiazole-2-carboxamide (10 mg, 8%): .sup.1H NMR
(DMSO-d6): .delta. 11.05 (br, 1H), 10.23 (br, 1H), 8.14-8.10 (m,
3H), 7.72-7.65 (m, 2H), 7.27 (br, 1H), 7.26-7.24 (m, 2H), 7.11-7.09
(m, 1H), 7.02-7.00 (d, J=8.8 Hz, 2H), 6.77-6.71 (m, 3H), 3.63 (s,
3H), 3.24-3.21 (m, 4H), 1.88 (s, 3H), 1.83 (s, 1H)
Step F:
N-(3-(7-carbamoyl-3-methyl-1H-indol-4-yl)-2-methylphenyl)thiazole--
2-carboxamide
##STR00618##
[1181] To a solution of
N-(3-(7-carbamoyl-3-(((4-methoxybenzyl)amino)methyl)-1H-indol-4-yl)-2-met-
hylphenyl)thiazole-2-carboxamide (10 mg, 0.02 mmol) in anhydrous
MeOH (5 mL) was added dry Pd/C (5 mg) and stirred at rt under
hydrogen (50 Psi) overnight. Then the reaction mixture was filtered
and the filtrated was concentrated under reduced pressure to get a
residue, which was purified by Prep-HPLC (Table 1, Method q) to
provide
N-(3-(7-carbamoyl-3-methyl-1H-indol-4-yl)-2-methylphenyl)thiazole-2-carbo-
xamide (1.1 mg, 15%): LC/MS (Table 1, Method j) R.sub.t=3.05 min;
MS m/z: 391 (M+H).sup.+. (Btk IC.sub.50=B)
Example #4:
N-(3-(7-carbamoyl-3-methyl-1H-indol-4-yl)-2-methylphenyl)thiazole-2-carbo-
xamide
##STR00619##
[1182] Step A: 5-Bromo-6-nitroindoline
##STR00620##
[1184] To a solution of 5-bromoindoline (12.33 g, 83 mmol) in
H.sub.2SO.sub.4 (60 mL) was added KNO.sub.3 (7.55 mL, 74.7 mmol) at
about 0.degree. C. The solution was stirred at 0-10.degree. C. for
about 1 h, and then the mixture was stirred overnight at rt. The
mixture was poured into ice water, basified with NaCO.sub.3 to
about pH 8. The mixture was extracted with EtOAc (300 mL.times.3),
the organic phase was dried with NaSO.sub.4, concentrated under
reduced pressure and the residue was purified by column
chromatography on silica gel (Pet ether:EtOAc=20:1) to provide
5-bromo-6-nitroindoline (12.3 g, 81%): .sup.1H NMR (CDCl.sub.3)
.delta. 7.25 (s, 1H), 6.91 (s, 1H), 3.98 (s, 1H), 3.66-3.56 (m,
2H), 3.08-2.96 (m, 2H).
Step B: tert-Butyl 5-bromo-6-nitroindoline-1-carboxylate
##STR00621##
[1186] To a solution of 5-bromo-6-nitroindoline (7.5 g, 30.9 mmol)
in DCM (750 mL) was added (Boc).sub.2O (13.47 g, 61.7 mmol) at
0.degree. C. Then Et.sub.3N (9.37 g, 93 mmol) and DMAP (0.337 g,
3.09 mmol) were added to the mixture. The mixture was stirred
overnight at rt. The reaction mixture was poured into water,
extracted with DCM (300 mL.times.3) and the organic phase was dried
with NaSO.sub.4, concentrated under reduced pressure and the
residue was purified by silica gel column (Pet ether:EtOAc=30:1) to
provide tert-butyl 5-bromo-6-nitroindoline-1-carboxylate (6.7 g,
63%): .sup.1H NMR (CDCl.sub.3) .delta. 8.29 (s, 1H), 7.42 (s, 1H),
4.06 (s, 2H), 3.18-3.13 (m, 2H) 1.57 (s, 9H).
Step C: tert-Butyl
5-bromo-2,3-dihydropyrrolo[2,3-e]indole-1(6H)-carboxylate
##STR00622##
[1188] To a mixture of tert-butyl
5-bromo-6-nitroindoline-1-carboxylate (4 g, 11.66 mmol) in THF (60
mL) was added vinylmagnesium bromide (6.43 g, 49.0 mmol) at -40 to
50.degree. C., then the resulting mixture was stirred at -20 to
-30.degree. C. for about 2 h, and then overnight at rt. The mixture
was poured into saturated NH.sub.4Cl solution and extracted with
EtOAc (100 mL.times.3). The organic phase was dried with
NaSO.sub.4, concentrated under reduced pressure and the residue was
purified by gel chromatography silica (Pet ether:EtOAc=50:1) to
provide tert-butyl
5-bromo-2,3-dihydropyrrolo[2,3-e]indole-1(6H)-carboxylate (0.7 g,
18%): .sup.1H NMR (CDCl.sub.3) .delta. 8.17 (s, 1H), 7.13-7.10 (m,
2H), 7.07 (m, 1H), 4.05-4.00 (t, J=8.4 Hz, 2H), 3.07-3.03 (t, J=8.4
Hz, 2H), 1.5 (s, 9H).
Step D: 1,2,3,6-Tetrahydropyrrolo[2,3-e]indole-5-carbonitrile
##STR00623##
[1190] To the solution of tert-butyl
5-bromo-2,3-dihydropyrrolo[2,3-e]indole-1(6H)-carboxylate (60 mg,
0.178 mmol) in DMF (2 mL) was added Zn (CN).sub.2 (12.53 mg, 0.107
mmol) and Pd(PPh.sub.3).sub.4 (20.56 mg, 0.018 mmol). The solution
was heated at about 145.degree. C. for about 50 min by microwave
under N.sub.2. The mixture was concentrated under reduced pressure
and the residue was purified by prep-HPLC (Table 1, Method aj) to
provide 1,2,3,6-tetrahydropyrrolo[2,3-e]indole-5-carbonitrile (20
mg, 61%): H NMR (MeOD): .delta. 7.34 (s, 1H), 7.30 (d, J=3.2, 1H),
6.51 (d, J=3.2, 1H), 3.82-3.78 (t, J=8 Hz, 2H), 3.23-3.18 (t, J=8.4
Hz, 2H).
Step E: 1,2,3,6-Tetrahydropyrrolo[2,3-e]indole-5-carboxamide
##STR00624##
[1192] To a solution of
1,2,3,6-tetrahydropyrrolo[2,3-e]indole-5-carbonitrile (160 mg,
0.873 mmol) in DMSO (4 mL), K.sub.2CO.sub.3 (300 mg, 2.171 mmol)
was added, then H.sub.2O.sub.2 (4 mL, 39.2 mmol) was added dropwise
at rt. And the reaction mixture was stirred overnight at rt. The
mixture was poured into water, extracted with EtOAc (20 mL.times.3)
and the organic phase was washed by saturated aqueous
Na.sub.2S.sub.2O.sub.3, dried and concentrated and the residue was
purified by prep-HPLC (Table 1, Method ak) to provide
1,2,3,6-tetrahydropyrrolo[2,3-e]indole-5-carboxamide (70 mg, 40%):
LC/MS (Table 1, Method d) R.sub.t=1.43 min; MS m/z: 202
(M+H).sup.+.
Step F:
1-Acryloyl-1,2,3,6-tetrahydropyrrolo[2,3-e]indole-5-carboxamide
##STR00625##
[1194] To a solution of
1,2,3,6-tetrahydropyrrolo[2,3-e]indole-5-carboxamide (15 mg, 0.075
mmol) in DCM (10 mL), Et.sub.3N (1 mL, 7.17 mmol) was added, and
then a solution of acryloyl chloride (10 mg, 0.11 mmol) in DCM (0.5
mL) was added dropwise at 0.degree. C. The reaction mixture was
stirred overnight ar rt. The reaction solution was concentrated
under reduced pressure and the residue was purified by prep-HPLC
(Table 1, Method t) to provide
1-acryloyl-1,2,3,6-tetrahydropyrrolo[2,3-e]indole-5-carboxamide (12
mg, 63%): .sup.1H NMR: (DMSO-d6) .delta. 11.13 (s, 1H), 7.93 (s,
1H), 7.61 (s, 1H), 7.21 (s, 2H), 6.8-6.73 (m, 2H), 6.34-6.30 (m,
1H), 5.84-5.82 (d, J=10.4, 1H), 4.25-4.21 (t, J=8.0, 2H), 3.21-3.13
(m, 2H); LC/MS (Table 1, Method d) R.sub.t=2.39 min; MS m/z: 256
(M+H).sup.+. (Btk IC.sub.50=B)
Example #5: 4-Acrylamido-1H-indole-7-carboxamide
##STR00626##
[1195] Step A: 4-Amino-1-tosyl-1H-indole-7-carbonitrile
##STR00627##
[1197] To a solution of 4-fluoro-1-tosyl-1H-indole-7-carbonitrile
(500 mg, 1.59 mmol, Preparation #27, step A) in 1,4-dioxane (5 mL),
ammonia (2.5 mL, 116 mmol) was added. The mixture was stirred at
about 120.degree. C. overnight. The reaction mixture was
concentrated under reduced pressure and the residue was purified by
silica gel column to provide
4-amino-1-tosyl-1H-indole-7-carbonitrile (100 mg, 20%): .sup.1H NMR
(DMSO-d6): .delta. 7.86-7.84 (m, 2H), 7.77-7.76 (d, J=4, 1H),
7.46-7.44 (d, J=8, 2H), 7.37-7.35 (d, J=8, 1H), 7.12 (s, 1H), 6.70
(s, 2H), 6.46-6.44 (d, J=8, 1H), 2.37 (s, 3H).
Step B: 4-Amino-1H-indole-7-carbonitrile
##STR00628##
[1199] To a solution of 4-amino-1-tosyl-1H-indole-7-carbonitrile
(90 mg, 0.289 mmol) in THF (2 mL), MeOH (1 mL) and water (1 mL) was
added LiOH (69 mg, 2.89 mmol). The mixture was stirred at about
40.degree. C. overnight. The reaction mixture was concentrated
under reduced pressure, water was added, and extracted with EtOAc
(20 mL.times.3) The combined organics were dried over
Na.sub.2SO.sub.4, filtered, and concentrated under reduced pressure
to provide 4-amino-1H-indole-7-carbonitrile (40 mg, 88%): .sup.1H
NMR (DMSO-d6): .delta. 11.43 (s, 1H), 7.21-7.19 (d, J=8, 1H),
7.13-7.12 (m, 1H), 6.67-6.62 (m, 1H), 6.20-6.18 (d, J=8, 1H).
Step C: 4-Amino-1H-indole-7-carboxamide
##STR00629##
[1201] To a solution of 4-amino-1H-indole-7-carbonitrile (40 mg,
0.254 mmol) in DMSO (2 mL), K.sub.2CO.sub.3 (52.8 mg, 0.382 mmol)
and 30% H.sub.2O.sub.2 (2 mL) were added at rt. The reaction
mixture was stirred at rt for 5 h. Water was added to the reaction
mixture and the mixture was extracted with EtOAc (20 mL.times.3)
and the organic phase was dried over Na.sub.2SO.sub.4, concentrated
under reduced pressure and the residue was purified by prep-TLC
(DCM:MeOH=15:1) to provide 4-amino-1H-indole-7-carboxamide (30 mg,
67%): .sup.1H NMR (DMSO-d6) .delta. 10.79 (s, 1H), 7.43-7.41 (d,
J=8, 1H), 7.04 (s, 1H), 6.52 (s, 1H), 6.10-6.08 (d, J=8, 1H), 5.83
(s, 2H).
Step D: 4-Acrylamido-1H-indole-7-carboxamide
##STR00630##
[1203] To a solution of 4-amino-1H-indole-7-carboxamide (30 mg,
0.171 mmol) in DCM (3 mL), DIEA (0.060 mL, 0.342 mmol) and acryloyl
chloride (18.60 mg, 0.205 mmol) were added and the reaction mixture
was stirred overnight at rt. Then the reaction mixture was
concentrated under reduced pressure and the residue was purified by
prep-HPLC (Table 1, Method u) to provide
4-acrylamido-1H-indole-7-carboxamide (17 mg, 43%): LC/MS (Table 1,
Method d) R.sub.t=2.10 min; MS m/z: 230 (M+H).sup.+. (Btk
IC.sub.50=C)
Example #6: 4-Acrylamido-1H-indole-7-carboxamide
##STR00631##
[1204] Step A:
4-(3-Acrylamido-5-aminophenyl)-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropy-
ridin-4-yl)-1H-indole-7-carboxamide
##STR00632##
[1206] To a round bottom flask was added
4-(3-acrylamido-5-nitrophenyl)-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropy-
ridin-4-yl)-1H-indole-7-carboxamide (0.175 g, 0.343 mmol, prepared
using A from
4-bromo-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-1H-ind-
ole-7-carboxamide (Preparation #18) and
3-amino-5-nitrophenylboronic acid hydrochloride [CombiBlocks], E
and acryloyl chloride) in NMP (2 mL) and HCl, 37% (0.222 mL) to
give a red suspension. The reaction was heated to about 85.degree.
C. and tin (II) chloride (0.600 g, 0.316 mmol) was added. The
reaction was stirred at about 85.degree. C. for about 1.5 h.
Additional tin (II) chloride (2.39 g, 1.26 mmol) was added and the
reaction was further stirred at about 85.degree. C. for about 2 h.
The reaction was cooled to rt and DCM (30 mL), MeOH (10 mL), and 1N
NaOH (15 mL) were added. The mixture was stirred vigorously for
about 2 h, filtered, and the filtrate extracted with DCM
(3.times.). The organic layers were combined and the solvent
removed under vacuum. Water and EtOAc was added to the residue and
extracted with EtOAc (4.times.). The organic layers were combined
and washed with water and brine. The organic layers were combined
and solvent removed under vacuum. The crude product was added to a
silica gel column and was eluted with 0-10% MeOH in DCM. The
material was further purified by prep-HPLC (Table 1, Method ag) to
provide
4-(3-acrylamido-5-aminophenyl)-2-(1-(methylsulfonyl)-1,2,3,6-tetr-
ahydropyridin-4-yl)-1H-indole-7-carboxamide (20 mg, 12%): LC/MS
(Table 1, Method g) R.sub.t=1.12 min.; MS m/z: 480 (M+H).sup.+.
Step B:
4-(3-Acrylamido-5-(thiazol-2-ylmethylamino)phenyl)-2-(1-(methylsul-
fonyl)-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide
##STR00633##
[1208] To a stirring solution of
4-(3-acrylamido-5-aminophenyl)-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropy-
ridin-4-yl)-1H-indole-7-carboxamide (20 mg, 0.042 mmol) and
thiazole-2-carbaldehyde (4.03 .mu.L, 0.046 mmol) in MeOH (1 mL) was
added MP-Cyanoborohydride (88 mg, 0.167 mmol) and acetic acid (9.55
.mu.L, 0.167 mmol). The slurry was stirred at about 40.degree. C.
for about 40 h. The suspension was filtered and the resin washed
with DCM and MeOH. The filtrate was passed through a plug of
Si-carbonate. The filtrate was concentrated under reduced pressure
and the residue was purified by Prep-TLC (10% MeOH/DCM) follow by a
second purification by Prep-TLC (5% MeOH/DCM) to provide
4-(3-acrylamido-5-(thiazol-2-ylmethylamino)phenyl)-2-(1-(methylsulfonyl)--
1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-7-carboxamide (7.2 mg,
25%): LC/MS (Table 1, Method g) R.sub.t=1.56 min.; MS m/z: 577
(M+H).sup.+. (Btk IC.sub.50=A)
Example #7:
(E)-4-(3-(2-Cyano-3-hydroxybut-2-enamido)phenyl)-1H-indole-7-carboxamide
##STR00634##
[1210] A mixture of
N-(3-(7-carbamoyl-1H-indol-4-yl)phenyl)-5-methylisoxazole-4-carboxamide
(0.060 g, 0.166 mmol, Example #E.2.1) and NaOH (0.008 g, 0.200
mmol) in MeOH (1.9 mL) was heated in a vial at about 60.degree. C.
After about 2 h, the reaction was cooled to rt and 1N aqueous HCl
was added to acidify. The resulting precipitate was collected via
vacuum filtration to provide
(E)-4-(3-(2-cyano-3-hydroxybut-2-enamido)phenyl)-1H-indole-7-carboxamide
(0.047 g, 78%) as a solid after drying under vacuum at about
55.degree. C.: LC/MS (Table 1, Method c) R.sub.t=2.79 min.; MS m/z:
361 (M+H).sup.+. (Btk IC.sub.50=C)
Example #8: 4-(cis-3-Acrylamidocyclohexyl)-1H-indole-7-carboxamide
and Example #9.
4-(trans-3-Acrylamidocyclohexyl)-1H-indole-7-carboxamide
##STR00635##
[1211] Step A: tert-Butyl
(3-(7-carbamoyl-1H-indol-4-yl)cyclohex-2-en-1-yl)carbamate and
tert-Butyl
(3-(7-carbamoyl-1H-indol-4-yl)cyclohex-3-en-1-yl)carbamate
##STR00636##
[1213] To a solution of 4-bromo-1H-indole-7-carboxamide (296 mg,
1.237 mmol, Preparation #2), a mixture of
[3-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)-cyclohex-3-enyl]-carbami-
c acid tert-butyl ester and
[3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-cyclohex-2-enyl]-carbam-
ic acid tert-butyl ester (400 mg, 1.237 mmol, U.S. 2009/0197864),
Na.sub.2CO.sub.3 (328 mg, 3.09 mmol), PdCl.sub.2(dppf)-DCM Adduct
(101 mg, 0.124 mmol) in THF:MeOH:H.sub.2O (Ratio: 4:2:2, 20 mL)
under N.sub.2 atmosphere, the mixture was heated at about
100.degree. C. overnight. The reaction mixture was filtered through
a pad of Celite.COPYRGT.. The resulting mixture was diluted with
EtOAc (30 mL), washed with H.sub.2O (20 mL.times.2), dried with
Na.sub.2SO.sub.4, concentrated under reduced pressure and the
residue was purified by prep-HPLC (Table 1, Method x) to provide a
mixture of tert-butyl
(3-(7-carbamoyl-1H-indol-4-yl)cyclohex-2-en-1-yl)carbamate and
tert-butyl
(3-(7-carbamoyl-1H-indol-4-yl)cyclohex-3-en-1-yl)carbamate (300 mg,
68%): LC/MS (Table 1, Method 1) R.sub.t=1.67 min; MS m/z: 356
(M+H).sup.+.
Step B: tert-Butyl
(3-(7-carbamoyl-1H-indo-4-yl)cyclohexyl)carbamate
##STR00637##
[1215] To a solution of tert-butyl
(3-(7-carbamoyl-1H-indol-4-yl)cyclohex-2-en-1-yl)carbamate and
tert-butyl
(3-(7-carbamoyl-1H-indol-4-yl)cyclohex-3-en-1-yl)carbamate (300 mg,
0.844 mmol) in THF (20 mL), Pd/C (44.9 mg, 0.422 mmol) was added
and the reaction mixture was stirred at rt for about 3 h under
H.sub.2 atmosphere. The mixture was filtered and concentrated under
reduced pressure to give crude product tert-butyl
(3-(7-carbamoyl-1H-indol-4-yl)cyclohexyl)carbamate (290 mg, 96%),
which was used to next step directly. LC/MS (Table 1, Method 1)
R.sub.t=1.53 min; MS m/z: 358 (M+H).sup.+.
Step C: 4-(3-Aminocyclohexyl)-1H-indole-7-carboxamide
##STR00638##
[1217] To a solution of tert-butyl
(3-(7-carbamoyl-1H-indol-4-yl)cyclohexyl)carbamate (220 mg, 0.615
mmol) in MeOH (10 mL), MeOH/HCl (10 mL) was added at about
0.degree. C., then the reaction mixture was stirred at rt for about
3 h. The reaction mixture was concentrated under reduced pressure
to give crude product 4-(3-aminocyclohexyl)-1H-indole-7-carboxamide
(100 mg, 63%), which was used to next step directly. LC/MS (Table
1, Method 1) R.sub.t=0.54 min; MS m/z: 258 (M+H).sup.+.
Step D: 4-(cis-3-Acrylamidocyclohexyl)-1H-indole-7-carboxamide and
4-(trans-3-Acrylamidocyclohexyl)-1H-indole-7-carboxamide
##STR00639##
[1219] To a solution of
4-(3-aminocyclohexyl)-1H-indole-7-carboxamide (120 mg, 0.466 mmol)
in DCM (3 mL), DIEA (120 mg, 0.933 mmol) was added, acryloyl
chloride (42.2 mg, 0.466 mmol) was added at about 0.degree. C.
dropwise and the mixture was stirred at about 0.degree. C. for
about 10 min, then concentrated under reduced pressure and the
residue was purified by prep-HPLC (Table 1, Method y) to provide
4-(cis-3-acrylamidocyclohexyl)-1H-indole-7-carboxamide (27 mg, 19%)
1H NMR: (MeOD) .delta. 7.59 (d, J=8, 1H), 7.33 (d, J=3.2, 1H), 6.95
(d, J=8, 1H), 6.64 (d, J=4, 1H), 6.26-6.17 (m, 2H), 5.67-5.58 (m,
1H), 4.01-3.96 (m, 1H), 3.22-3.13 (m, 1H), 2.19-1.97 (m, 4H),
1.65-1.59 (m, 3H), 1.37-1.34 (m, 1H); LC/MS (Table 1, Method d)
R.sub.t=2.56 min; MS m/z: 312 (M+H).sup.+. (Btk IC.sub.50=A) and
4-(trans-3-acrylamidocyclohexyl)-1H-indole-7-carboxamide (33 mg,
23%): .sup.1H NMR (MeOD) .delta. 7.58 (d, J=8, 1H), 7.31 (d, J=3.2,
1H), 6.98 (d, J=8, 1H), 6.59 (d, J=2.8, 1H), 6.52-6.46 (m, 1H),
6.28-6.24 (m, 1H), 5.69-5.64 (m, 1H), 4.35 (s, 1H), 3.42-3.36 (m,
1H), 2.13-1.72 (m, 8H); LC/MS (Table 1, Method d) R.sub.t=2.56 min;
MS m/z: 312 (M+H).sup.+. (Btk IC.sub.50=B)
Examples #10 and #11:
4-(cis-3-Acrylamidocyclopentyl)-1H-indole-7-carboxamide and
4-(trans-3-Acrylamidocyclopentyl)-1H-indole-7-carboxamide
##STR00640##
[1220] Step A: 3-((tert-Butoxycarbonyl)amino)cyclopent-1-en-1-yl
trifluoromethanesulfonate and
4-((tert-butoxycarbonyl)amino)cyclopent-1-en-1-yl
trifluoromethanesulfonate
##STR00641##
[1222] To a freshly prepared LDA solution (2M in THF, 9.38 mL) was
added tert-butyl (3-oxocyclopentyl)carbamate (2.00 g, 10.0 mmol) in
THF (4 mL) at about -78.degree. C. dropwise. The mixture was warmed
to rt for about 30 min and then cooled to about -78.degree. C.
again. A solution of
1,1,1-trifluoro-N-phenyl-N-((trifluoromethyl)sulfonyl)methanesulfonamide
(5.38 g, 15.1 mmol) in THF (10 mL) was added dropwise to the
reaction mixture at about -78.degree. C. The resulting mixture was
warmed to rt and stirred for another 3 h. Treated with EtOAc (30
mL), the mixture was washed with H.sub.2O (20 mL.times.3) and brine
(10 mL), dried with Na.sub.2SO.sub.4, concentrated under reduced
pressure and the residue was purified by chromatography on silica
gel to provide a mixture of
3-((tert-butoxycarbonyl)amino)cyclopent-1-en-1-yl
trifluoromethanesulfonate and
4-((tert-butoxycarbonyl)amino)cyclopent-1-en-1-yl
trifluoromethanesulfonate (0.82 g, 25%), which was used in next
step without further purification.
Step B: tert-Butyl
(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclopent-2-en-1-yl)carba-
mate and tert-butyl
(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclopent-3-en-1-yl)carba-
mate
##STR00642##
[1224] A mixture of
3-((tert-butoxycarbonyl)amino)cyclopent-1-en-1-yl
trifluoromethanesulfonate and
4-((tert-butoxycarbonyl)amino)cyclopent-1-en-1-yl
trifluoromethanesulfonate (720 mg, 2.173 mmol),
4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (662
mg, 2.61 mmol), PdCl.sub.2(dppf)-DCM adduct (177 mg, 0.217 mmol)
and KOAc (427 mg, 4.35 mmol) in 1,4-dioxane (20 mL) under N.sub.2
atmosphere was heated at about 100.degree. C. overnight. The
resulting mixture was diluted with DCM (30 mL), washed with
H.sub.2O (20 mL.times.2), concentrated under reduced pressure and
the residue was purified by silica gel to give crude mixture of
tert-butyl
(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclopent-2-en-1-yl)carba-
mate and tert-butyl
(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclopent-3-en-1-yl)carba-
mate (0.42 g, 63%), which was used directly in the next step
without further purification.
Step C: tert-Butyl
(3-(7-carbamoyl-1H-indol-4-yl)cyclopent-2-en-1-yl)carbamate and
tert-butyl
(3-(7-carbamoyl-1H-indol-4-yl)cyclopent-3-en-1-yl)carbamate
##STR00643##
[1226] To a solution of 4-bromo-1H-indole-7-carboxamide (325 mg,
1.36 mmol, Preparation #2), tert-butyl
(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclopent-2-en-1-yl)carba-
mate and tert-butyl
(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclopent-3-en-1-yl)carba-
mate (420 mg, 1.36 mmol), Na.sub.2CO.sub.3 (360 mg, 3.4 mmol),
PdCl.sub.2(dppf)-DCM Adduct (111 mg, 0.136 mmol) in
THF:MeOH:H.sub.2O (Ratio: 4:2:2, 15 mL) under N.sub.2 atmosphere,
the mixture was stirred at about 100.degree. C. overnight. The
reaction mixture was filtered to remove Pd complex. The resulting
mixture was diluted with EtOAc (30 mL), washed with H.sub.2O (20
mL.times.2), dried with Na.sub.2SO.sub.4, concentrated and purified
by prep-HPLC (Table 1, Method y) to provide a mixture of tert-butyl
(3-(7-carbamoyl-1H-indol-4-yl)cyclopent-2-en-1-yl)carbamate and
tert-butyl
(3-(7-carbamoyl-1H-indol-4-yl)cyclopent-3-en-1-yl)carbamate (0.32
g, 69%): LC/MS (Table 1, Method 1) R.sub.t=1.65 min; MS m/z: 342
(M+H).sup.+.
Step D: tert-Butyl
(3-(7-carbamoyl-1H-indol-4-yl)cyclopentyl)carbamate
##STR00644##
[1228] To a solution of tert-butyl
(3-(7-carbamoyl-1H-indol-4-yl)cyclopent-2-en-1-yl)carbamate and
tert-butyl
(3-(7-carbamoyl-1H-indol-4-yl)cyclopent-3-en-1-yl)carbamate (300
mg, 0.844 mmol) in THF (20 mL), Pd/C (44.9 mg, 0.422 mmol) was
added and the the mixture was stirred for about 3 h at rt under
H.sub.2. The mixture was filtered and concentrated under reduced
pressure to provide crude tert-butyl
(3-(7-carbamoyl-1H-indol-4-yl)cyclopentyl)carbamate (0.29 g, 96%),
which was used to next step directly without further purification.
LC/MS (Table 1, Method 1) R.sub.t=1.50 min; MS m/z: 344
(M+H).sup.+.
Step E: 4-(cis-3-Aminocyclopentyl)-1H-indole-7-carboxamide and
4-(trans-3-aminocyclopentyl)-1H-indole-7-carboxamide
##STR00645##
[1230] To a solution of tert-butyl
(3-(7-carbamoyl-1H-indol-4-yl)cyclopentyl)carbamate (250 mg, 0.728
mmol) in MeOH (10 mL), MeOH/HCl (10 mL) was added at about
0.degree. C. and the mixture was stirred for about 3 h at rt. The
mixture was concentrated under reduced pressure and the residue was
purified by prep-HPLC (Table 1, Method t) to provide
4-(trans-3-aminocyclopentyl)-1H-indole-7-carboxamide (10 mg, 6%)
and 4-(cis-3-aminocyclopentyl)-1H-indole-7-carboxamide (50 mg,
28%). To a solution of
4-(cis-3-aminocyclopentyl)-1H-indole-7-carboxamide (50 mg, 0.206
mmol) in DCM (3 mL), DIEA (53 mg, 0.411 mmol) was added, then
acryloyl chloride (18.60 mg, 0.206 mmol) was added dropwise at
about 0.degree. C., the mixture was stirred at about 0.degree. C.
for about 10 min, then concentrated under reduced pressure and the
residue was purified by prep-HPLC (Table 1, Method z) to give
4-(cis-3-acrylamidocyclopentyl)-1H-indole-7-carboxamide (20 mg,
33%): .sup.1H NMR (MeOD) .delta. 7.59 (d, J=7.2, 1H), 7.33 (s, 1H),
7.02 (d, J=8, 1H), 6.64 (s, 1H), 6.30-6.20 (m, 2H), 5.64 (d, J=8.8,
1H), 4.51-4.40 (m, 1H), 3.60-3.58 (m, 1H), 2.56-2.51 (m, 1H),
2.26-2.21 (m, 2H), 2.07-2.02 (m, 1H), 1.86-1.78 (m, 2H): LC/MS
(Table 1, Method d) R.sub.t=2.48 min; MS m/z: 298 (M+H).sup.+. (Btk
IC.sub.50=A) To a solution of
4-(trans-3-aminocyclopentyl)-1H-indole-7-carboxamide (10 mg, 0.041
mmol) in DCM (1 mL), DIEA (11 mg, 0.082 mmol) was added, then
acryloyl chloride (3.72 mg, 0.041 mmol) was dropwise added, the
mixture was stirred at about 0.degree. C. for about 10 min,
concentrated and purified by prep-HPLC (Table 1, Method z) to give
4-(trans-3-acrylamidocyclopentyl)-1H-indole-7-carboxamide (1.1 mg,
9%): .sup.1H NMR (MeOD) .delta. 7.60 (d, J=7.6, 1H), 7.33 (d,
J=2.8, 1H), 7.00 (d, J=7.6, 1H), 6.62 (d, J=3.2, 1H), 6.33-6.20 (m,
2H), 5.67-5.64 (m, 1H), 4.50-4.49 (m, 1H), 3.81-3.72 (m, 1H),
2.34-2.28 (m, 3H), 2.26-2.23 (m, 1H), 2.07-1.89 (m, 1H), 1.88-1.74
(m, 1H); LC/MS (Table 1, Method d) R.sub.t=2.47 min; MS m/z: 298
(M+H).sup.+. (BtkIC.sub.50=A)
Example #12*:
(R)-2-(1-(Methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-4-(2-oxo-1,3'-b-
ipiperidin-1'-yl)-1H-indole-7-carboxamide
##STR00646##
[1231] Step A:
(R)-2-(1-(Methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-4-(2-oxo-1,3'-b-
ipiperidin-1'-yl)-1-tosyl-1H-indole-7-carbonitrile
##STR00647##
[1233] To a solution of (R)-tert-butyl
2-oxo-1,3`-bipiperidine-1`-carboxylate (100 mg, 0.354 mmol, WO
2011/029046) in DCM (4 mL) was added TFA (1.000 mL). The reaction
was stirred for about 4 h at rt. The solvent was stripped off and a
mixture of
4-fluoro-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-1-tosyl-
-1H-indole-7-carbonitrile (168 mg, 0.354 mmol, Preparation #27) and
TEA (0.197 mL, 1.417 mmol) in DMSO (2 mL) was added. The vial was
sealed and the reaction was heated in a microwave at about
120.degree. C. for about 30 min. Water (20 mL) was added and
extracted into DCM then washed with brine and passed through a
phase separatore to remove residual water. Evaporated and
chromatographed on silica to eluting with a gradent of 0-100%
EtOAc/hexane to provide crude
(R)-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-4-(2-oxo-1,3'-b-
ipiperidin-1'-yl)-1-tosyl-1H-indole-7-carbonitrile (0.041 g,
18.21%).
Step B:
(R)-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-4-(2-oxo-
-1,3'-bipiperidin-1'-yl)-1H-indole-7-carboxamide
##STR00648##
[1235] A mixture of Cs.sub.2CO.sub.3 (20.50 mg, 0.063 mmol) and
(R)-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-4-(2-oxo-1,3'-b-
ipiperidin-1'-yl)-1-tosyl-1H-indole-7-carbonitrile (40 mg, 0.063
mmol) in THF (2 mL) and MeOH (1.000 mL) were stirred at rt
overnight. The solution was diluted with water (15 mL) and stirred
for about 20 min. DCM was added to dissolve the suspension and the
mixture was filtered through a Biotage phase separator. The
organics were collected and concentrated. The intermediate was
dissolved in t-butanol (1 mL) and DMSO (0.500 mL) and NaOH (0.377
mL, 0.755 mmol) and hydrogen peroxide (0.175 mL, 1.699 mmol) were
added. The mixture was stirred for about 20 min at rt and saturated
NH.sub.4Cl (1 mL) was added. The mixture was diluted with water (15
mL) and stirred for about 15 min. The solids were collected by
filtration washing several times with water and dried under vacuum
and purified by prep-HPLC (Table 1, Method aq). The samples were
returned and dissolved in DCM. The organics were combined and
washed with saturated sodium bicarbonate, filtered through a
Biotage phase separator, and concentrated to provide
(R)-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-4-(2-oxo-1,3'-b-
ipiperidin-'-yl)-1H-indole-7-carboxamide (3 mg, 9.54%): LC/MS
(Table 1, Method f) R.sub.t=1.37 min; MS m/z: 500 (M+H).sup.+. (Btk
IC.sub.50=B)
Example #13*:
(R)-2-(1-(Methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-4-(3-(1-oxo-3,4-
-dihydroisoquinolin-2(1H)-yl)piperidin-1-yl)-1H-indole-7-carboxamide
##STR00649##
[1236] Step A: (R)-2-Methyl-N-(piperidin-3-yl)benzamide
##STR00650##
[1238] A mixture of (R)-tert-butyl
3-(2-methylbenzamido)piperidine-1-carboxylate (19.0 g, 59.7 mmol,
prepared using D from (R)-tert-butyl
3-aminopiperidine-1-carboxylate and 2-methylbenzoic acid) in HCl (2
N in MeOH, 300 mL, 600 mmol) was stirred at rt for about 4 h, then
concentrated under reduced pressure to provide crude
(R)-2-methyl-N-(piperidin-3-yl)benzamide (20.0 g), which was used
directly for the next step without further purification.
Step B: (R)--N-(1-Benzylpiperidin-3-yl)-2-methylbenzamide
##STR00651##
[1240] To a solution of (R)-2-methyl-N-(piperidin-3-yl)benzamide
(20.0 g, crude) and TEA (30.1 g, 298.5 mmol) in DCM (260 mL) was
added dropwise BnBr (11.2 g, 65.7 mmol) at rt over about 30 min.
Then the mixture was stirred at rt overnight. After completion, DCM
(1 L) was added, and the mixture was washed with H.sub.2O
(3.times.100 mL). The organic phase was dried over anhydrous
Na.sub.2SO.sub.4 and concentrated under reduced pressure to provide
(R)--N-(1-benzylpiperidin-3-yl)-2-methylbenzamide (12.0 g, 65% over
two steps): LC/MS (Table 1, Method 1) R.sub.t=0.91 min; MS m/z: 309
(M+H).sup.+.
Step C: (R)-2-(1-Benzylpiperidin-3-yl)isoquinolin-1(2H)-one
##STR00652##
[1242] To the solution of
(R)--N-(1-benzylpiperidin-3-yl)-2-methylbenzamide (12.0 g, 38.9
mmol) in THF was added dropwise n-BuLi (2.5 M, 32.7 mL) between -22
and -14.degree. C., over about 30 min. The resulting deep red
solution was stirred at about -22.degree. C. for about 30 min and
DMF was added below about -14.degree. C. (internal). After the
addition was completed, the solution was stirred at about
-22.degree. C. for about 30 min. Then HCl (6 N aqueous, 25 mL, 150
mmol) was slowly added, keeping the temperature below 5.degree. C.
The mixture was basified by addition of saturated NaOH at about
0.degree. C. to pH 14 and extracted with DCM (3.times.500 mL). The
organic phase was dried over Na.sub.2SO.sub.4 and concentrated
under reduced pressure to provide
(R)-2-(1-benzylpiperidin-3-yl)isoquinolin-1(2H)-one (12.0 g, 97%)
as a solid: LC/MS (Table 1, Method 1) R.sub.t=1.35 min; MS m/z: 319
(M+H).sup.+.
Step D: (R)-2-(Piperidin-3-yl)-3,4-dihydroisoquinolin-1(2H)-one
##STR00653##
[1244] A mixture of
(R)-2-(1-benzylpiperidin-3-yl)isoquinolin-1(2H)-one (12 g, 37.7
mmol) and Pd(OH).sub.2 (0.5 g) in MeOH was stirred at about
50.degree. C. under H.sub.2 atmosphere (50 psi) overnight. Then the
mixture was filtrated through Celite.COPYRGT., and the filtrate was
concentrated. The crude product was purified by flash
chromatography to afford 6.3 g of the crude product which was
recrystallized in a mixture of MTBE (15 mL) and HCl/MeOH (5 mL) to
provide (R)-2-(piperidin-3-yl)-3,4-dihydroisoquinolin-1(2H)-one
(HCl salt) as a solid (2.1 g, 21%): .sup.1H NMR (MeOD) 7.95 (d,
J=8, 1H), 7.51-7.47 (m, 1H), 7.38-7.34 (m, 1H), 7.29 (d, J=7.6,
1H), 4.86-4.80 (m, 1H), 3.61-3.58 (m, 2H), 3.39-3.35 (m, 2H),
3.28-3.22 (m, 1H), 3.03-2.95 (m, 3H), 2.12-1.87 (m, 4H); LC/MS
(Table 1, Method d) R.sub.t=2.05 min; MS m/z: 231 (M+H).sup.+.
Step E:
(R)-2-(1-(Methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-4-(3-(1--
oxo-3,4-dihydroisoquinolin-2(1H)-yl)piperidin-1-yl)-1-tosyl-1H-indole-7-ca-
rbonitrile
##STR00654##
[1246] A mixture of
4-fluoro-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-1-tosyl-1H-
-indole-7-carbonitrile (318 mg, 0.672 mmol, Preparation #27),
(R)-2-(piperidin-3-yl)-3,4-dihydroisoquinolin-1(2H)-one
hydrochloride (179 mg, 0.672 mmol) and TEA (0.374 mL, 2.69 mmol) in
DMSO (4 mL) were heated in a microwave at about 120.degree. C. for
about 20 min. The reaction was heated in a microwave at about
120.degree. C. for an additional 30 min. Water (50 mL) was added
and extracted into DCM. The solution was washed with brine and
passed through a phase separator to remove residual water. The
organics were concentrated and chromatographed on silica to eluting
with a gradient of 0-100% EtOAc/hexane to provide crude
(R)-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-4-(3-(1-o-
xo-3,4-dihydroisoquinolin-2(1H)-yl)piperidin-1-yl)-1-tosyl-1-indole-7-carb-
onitrile (110 mg, 24%). The material was used without further
purification.
Step F:
(R)-2-(1-(Methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-4-(3-(1--
oxo-3,4-dihydroisoquinolin-2(1H)-yl)piperidin-1-yl)-1H-indole-7-carboxamid-
e
##STR00655##
[1248] A mixture of Cs.sub.2CO.sub.3 (51.9 mg, 0.159 mmol) and
(R)-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-4-(3-(1-oxo-3,4-
-dihydroisoquinolin-2(1H)-yl)piperidin-1-yl)-1-tosyl-1H-indole-7-carbonitr-
ile (109 mg, 0.159 mmol) in THF (2 mL) and MeOH (1.000 mL) were
stirred at rt overnight. The mixture was diluted with water (15 mL)
and stirred for about 20 min. The precipitate was collected by
filtration and the filter cake was washed with water. The filter
cake was dissolved in t-butanol (1 mL) and DMSO (0.500 mL) was
added NaOH (0.956 mL, 1.91 mmol) and hydrogen peroxide (0.444 mL,
4.30 mmol). The mixture was stirred for about 20 min at rt and
saturated NH.sub.4Cl (1 mL) was added. The mixture was diluted with
water (15 mL) and stirred for about 15 min. The solids were
collected by filtration washing several times with water and dried
under vacuum. The resulting solids were purified by prep-HPLC
(Table 1, Method ap). The samples were returned and dissolved in
DCM. The organics were combined and washed with saturated sodium
bicarbonate, filtered through a Biotage phase separator, and
concentrated. The residue was further dried in a vacuum oven at
about 50.degree. C. for about 48 h to afford
(R)-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-4-(3-(1-oxo-3,4-
-dihydroisoquinolin-2(1H)-yl)piperidin-1-yl)-1H-indole-7-carboxamide
(30 mg, 34%): LC/MS (Table 1, Method f) R.sub.t=1.63 min; MS m/z:
548 (M+H).sup.+. (Btk IC.sub.50=A)
Example #13A*:
(R)--N-(1-(7-Carbamoyl-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4--
yl)-1H-indol-4-yl)piperidin-3-yl)thiazole-2-carboxamide
##STR00656##
[1249] Step A: (R)-tert-Butyl
3-(thiazole-2-carboxamido)piperidine-1-carboxylate
##STR00657##
[1251] To a solution of (R)-tert-butyl
3-aminopiperidine-1-carboxylate (2 g, 9.99 mmol) and
thiazole-2-carboxylic acid (1.29 g, 9.99 mmol) in DCM (40 mL) was
added HATU (4.85, 12.5 mmol) and DIEA (3.87 g, 29.9 mmol) and the
mixture was stirred at rt overnight. Then the mixture was poured
into water and extracted with DCM (3.times.80 mL). The combined
organic layers were washed with saturated aqueous NaHCO.sub.3 (80
mL) and brine (80 mL), and dried over Na.sub.2SO.sub.4. The solvent
was concentrated under reduced pressure to afford the crude
product, which was purified by column chromatography on silica gel
to provide (R)-tert-butyl
3-(thiazole-2-carboxamido)piperidine-1-carboxylate (2.2 g, 71%):
.sup.1H NMR (CDCl3) .delta. 1.45 (s, 9H), 1.78-1.73 (m, 2H),
1.94-1.91 (m, 1H), 2.80 (s, 2H), 3.42 (br, 2H), 3.66 (d, J=13.2 Hz,
1H), 4.11 (s, 1H), 7.36 (br, 1H), 7.57 (t, J=3.2 Hz, 1H), 7.84 (t,
J=3.2 Hz, 1H).
Step B: (R)--N-(Piperidin-3-yl)thiazole-2-carboxamide
##STR00658##
[1253] To a solution of (R)-tert-butyl
3-(thiazole-2-carboxamido)piperidine-1-carboxylate (1.9 g, 6.1
mmol) in EtOAc (20 mL) was added HCl/EtOAc (20 mL) dropwise at
about 0.degree. C., then the reaction was stirred at rt for about 3
h. The mixture was filtered and the filter cake was hygroscopic.
The filter cake was dissolved into water and saturated aqueous
NaHCO.sub.3 solution. The mixture was extracted with DCM
(3.times.50 mL) and the combined organic layers were washed with
brine, dried over Na.sub.2SO.sub.4, filtered and concentrated to
provide (R)--N-(piperidin-3-yl)thiazole-2-carboxamide (1.2 g, 5.68
mmol, 93%): .sup.1H NMR (CDCl3) .delta. 1.79-1.66 (m, 3H),
1.92-1.86 (m, 1H), 2.04 (s, 1H), 2.87-2.70 (m, 3H), 3.15-2.88 (m,
1H), 4.12-4.06 (m, 1H), 7.54-7.53 (m, 2H), 7.84 (t, J=2.8 Hz,
1H).
Step C:
(R)--N-(1-(7-Cyano-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-
-4-yl)-1-tosyl-1H-indol-4-yl)piperidin-3-yl)thiazole-2-carboxamide
##STR00659##
[1255] A mixture of
4-fluoro-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-1-tosyl-1H-
-indole-7-carbonitrile (200 mg, 0.422 mmol, Preparation #27),
(R)--N-(piperidin-3-yl) thiazole-2-carboxamide (178 mg, 0.842 mmol)
and TEA (170 mg, 1.680 mmol) in DMSO (2 mL) was heated under
microwave condition at about 120.degree. C. for about 1 h. Water
(10 mL) was added to the mixture and extracted with DCM (3.times.20
mL). The organic layer was washed with brine, dried over
Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure
to give the crude product which was purified by Prep-TLC
(DCM:MeOH=75:1) to provide
(R)--N-(1-(7-cyano-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)--
1-tosyl-1H-indol-4-yl)piperidin-3-yl)thiazole-2-carboxamide (20 mg,
7%): LC/MS (Table 1, Method m) R.sub.t=2.24 min; MS m/z: 665
(M+H).sup.+.
Step D:
(R)--N-(1-(7-Carbamoyl-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyr-
idin-4-yl)-1H-indol-4-yl)piperidin-3-yl)thiazole-2-carboxamide
##STR00660##
[1257] A mixture of
(R)--N-(1-(7-cyano-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)--
1-tosyl-1H-indol-4-yl)piperidin-3-yl)thiazole-2-carboxamide (76 mg,
0.114 mmol), NaOH (54.9 mg, 1.37 mmol) and 30% H.sub.2O.sub.2 (350
mg, 3.09 mmol) in the mixture of DMSO (1 mL) and n-butanol (2 mL)
was stirred at rt for about 24 h. Then saturated aqueous NH.sub.4Cl
(2 mL) was added and diluted with water (30 mL) and stirred for 30
min. The solid was collected by filtration and washed several times
with water and the crude product was purified by Prep-TLC (50:1
DCM/MeOH) to provide
(R)--N-(1-(7-carbamoyl-2-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4--
yl)-1H-indol-4-yl)piperidin-3-yl)thiazole-2-carboxamide (32 mg,
53%): LC/MS (Table 1, Method d) R.sub.t=2.90 min; MS m/z: 529
(M+H).sup.+. (Btk IC.sub.50=A)
Example #14:
2-(1-Methyl-1H-pyrazol-4-yl)-4-(2-methyl-3-(4-oxoquinazolin-3(4H)-yl)phen-
yl)-1H-benzo[d]imidazole-7-carboxamide
##STR00661##
[1258] Step A:
3-(3-(7-Bromobenzo[c][1,2,5]thiadiazol-4-yl)-2-methylphenyl)quinazolin-4(-
3H)-one
##STR00662##
[1260] To a solution of 4,7-dibromobenzo[c][1,2,5]thiadiazole
(1.029 g, 3.5 mmol) and
3-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)quinazo-
lin-4(3H)-one (1.141 g, 3.15 mmol, WO 2011159857) in the mixture of
toluene (40 mL), MeOH (10 mL) and water (10 mL) were added
Na.sub.2CO.sub.3 (0.742 g, 7.00 mmol) and Pd(PPh.sub.3).sub.4
(0.081 g, 0.070 mmol). The mixture was heated to about 100.degree.
C. for 24 h. The resulting solution was cooled to rt and diluted
with EtOAc, washed with water and brine, dried over
Na.sub.2SO.sub.4, filtered and concentrated to give a crude
product, which was purified by column chromatography on silica gel
(eluted with Pet ether:EtOAc=5:1 to 1:1) to afford
3-(3-(7-bromobenzo[c][1,2,5]thiadiazol-4-yl)-2-methylphenyl)quinazolin-4(-
3H)-one (1.0 g, 64%): .sup.1H NMR (CDCl.sub.3) .delta. 8.40-8.38
(d, J=8.0 Hz, 1H), 8.13 (s, 1H), 7.95-7.93 (d, J=7.6 Hz, 1H),
7.82-7.80 (m, 2H), 7.58-7.56 (m, 1H), 7.51-7.46 (m, 3H), 7.41-7.39
(t, J=4.8 Hz, 1H), 1.95 (s, 3H).
Step B:
7-(2-Methyl-3-(4-oxoquinazolin-3(4H)-yl)phenyl)benzo[c][1,2,5]thia-
diazole-4-carbonitrile
##STR00663##
[1262] To a solution of
3-(3-(7-bromobenzo[c][1,2,5]thiadiazol-4-yl)-2-methylphenyl)quinazolin-4(-
3H)-one (0.449 g, 1 mmol) in DMF (12 mL) were added Zn (CN).sub.2
(0.076 g, 0.650 mmol) and Pd(PPh.sub.3).sub.4 (0.046 g, 0.040
mmol). The mixture was heated to about 160.degree. C. for about 15
min under N.sub.2 atmosphere in a microwave reactor. The resulting
solution was diluted with EtOAc, and washed with brine (4.times.).
The organic phase was dried over Na.sub.2SO.sub.4, filtered and
concentrated to give a crude product, which was purified by column
chromatography on silica gel (eluted with Pet ether:EtOAc=5:1 to
1:1) to provide
7-(2-methyl-3-(4-oxoquinazolin-3(4H)-yl)phenyl)benzo[c][1,2,5]thiadiazole-
-4-carbonitrile (0.3 g, 76%): .sup.1H NMR (CDCl.sub.3) .delta.
8.33-8.03 (d, J=8.0 Hz, 1H), 8.10-8.06 (t, J=7.2 Hz, 2H), 7.77-7.74
(m, 2H), 7.63-7.61 (t, J=7.2 Hz, 1H), 7.53-7.45 (m, 3H), 7.39-7.37
(d, J=7.2 Hz, 1H), 1.90 (s, 3H).
Step C:
2,3-Diamino-2'-methyl-3'-(4-oxoquinazolin-3(4H)-yl)-[1,1'-biphenyl-
]-4-carbonitrile
##STR00664##
[1264] To a solution of
2,3-diamino-2'-methyl-3'-(4-oxoquinazolin-3(4H)-yl)-[1,1'-biphenyl]-4-car-
bonitrile (0.53 mg, 1.34 mmol) in AcOH (50 mL) was added zinc (1.75
g, 26.8 mmol), the mixture was heated to about 120.degree. C. for
about 2 h. The solvent was concentrated and the residue was taken
up into EtOAc, washed with saturated aqueous NaHCO.sub.3 solution
and brine. The organic phase was dried over Na.sub.2SO.sub.4,
filtered and concentrated to give a crude product, which was
purified by column chromatography on silica gel (eluted with Pet
ether:EtOAc=1:1 to 0:1) to provide
2,3-diamino-2'-methyl-3'-(4-oxoquinazolin-3(4H)-yl)-[1,1'-biphenyl]-4-car-
bonitrile (0.4 g, 81%): LC/MS (Table 1, Method 1) R.sub.t=1.33 min;
MS m/z: 368 (M+H).sup.+.
Step D:
2-(1-Methyl-1H-pyrazol-4-yl)-4-(2-methyl-3-(4-oxoquinazolin-3(4H)--
yl)phenyl)-1H-benzo[d]imidazole-7-carbonitrile
##STR00665##
[1266] To a solution of
2,3-diamino-2'-methyl-3'-(4-oxoquinazolin-3(4H)-yl)-[1,1'-biphenyl]-4-car-
bonitrile (400 mg, 1.09 mmol) in DMF (15 mL) were added
1-methyl-1H-pyrazole-4-carbaldehyde (240 mg, 2.18 mmol) and TMSCl
(0.417 mL, 3.27 mmol). The mixture was heated to about 100.degree.
C. for about 30 min in a microwave reactor. The resulting solution
was diluted with EtOAc, and washed with brine (4.times.). The
organic phase was dried over Na.sub.2SO.sub.4, filtered and
concentrated to give a crude product, which was purified by column
chromatography on silica gel (eluted with Pet ether:EtOAc=1:1 then
EtOAc:MeOH=50:1) to provide
2-(1-methyl-1H-pyrazol-4-yl)-4-(2-methyl-3-(4-oxoquinazolin-3(4H)-yl)phen-
yl)-1H-benzo[d]imidazole-7-carbonitrile (200 mg, 40%): LC/MS (Table
1, Method m) R.sub.t=1.78 min; MS m/z: 458 (M+H).sup.+.
Step E:
2-(1-Methyl-1H-pyrazol-4-yl)-4-(2-methyl-3-(4-oxoquinazolin-3(4H)--
yl)phenyl)-1H-benzo[d]imidazole-7-carboxamide
##STR00666##
[1268] To a solution of
2-(1-methyl-1H-pyrazol-4-yl)-4-(2-methyl-3-(4-oxoquinazolin-3(4H)-yl)phen-
yl)-1H-benzo[d]imidazole-7-carbonitrile (278 mg, 0.608 mmol) in the
mixture of butanol (6 mL) and DMSO (3 mL) were added NaOH (292 mg,
7.29 mmol) and H.sub.2O.sub.2 (1.68 mL, 16.4 mmol). The mixture was
stirred for about 24 h at about 25.degree. C. The resulting
solution was quenched with saturated aqueous NH.sub.4Cl solution,
extracted with EtOAc. The organic phase was dried over
Na.sub.2SO.sub.4, filtered and concentrated to give a crude
product, which was purified by prep-HPLC (Table 1, Method n) to
provide
2-(1-methyl-1H-pyrazol-4-yl)-4-(2-methyl-3-(4-oxoquinazolin-3(4H)-yl)phen-
yl)-1H-benzo[d]imidazole-7-carboxamide (140 mg, 48%): LCMS (Table
1, Method d) R.sub.t=2.53 min; MS m/z: 476 (M+H).sup.+. (Btk
IC.sub.50=B)
Example #15: 4-(3-Acrylamidophenyl)-1H-indazole-7-carboxamide
##STR00667##
[1269] Step A: 3-(7-Carbamoyl-1H-indol-4-yl)benzoic acid
##STR00668##
[1271] A mixture of 4-bromo-1H-indole-7-carboxamide (0.5 g, 2.091
mmol, Preparation #2), (3-(methoxycarbonyl)phenyl)boronic acid
(0.565 g, 3.14 mmol), sodium carbonate (2.61 mL, 5.23 mmol) in DME
(10.00 mL) was degassed and purged with nitrogen for about 5 min,
then tetrakis(triphenylphosphine)palladium(0) (0.121 g, 0.105 mmol)
was added. The reaction vessel was sealed and heated with microwave
(Biotage Initiator) at about 110.degree. C. for about 45 min. The
mixture was cooled to rt, followed by addition of about 50 mL of
water. The precipitate is filtered, air-dried and used without
further purification. This crude was then dissolved in THF (25 mL)
and treated with lithium hydroxide (0.250 g, 10.46 mmol) solution
in water (25 mL). The reaction mixture was stirred at rt overnight.
THF was removed and the aqueous layer was extracted with DCM to
remove triphenylphosphine oxide. The aqueous phase was then
acidified with 1N HCl solution to about pH 2. The precipitate was
filtered and dried to give 0.58 g of crude
3-(7-carbamoyl-1H-indol-4-yl)benzoic acid as a solid. LC/MS (Table
1, Method g) R.sub.t=1.37 min; MS m/z 281 (M+H).sup.+.
Step B:
4-(3-((Cyanomethyl)carbamoyl)phenyl)-1H-indole-7-carboxamide
##STR00669##
[1273] A mixture of 3-(7-carbamoyl-1H-indol-4-yl)benzoic acid (0.1
g, 0.357 mmol), TBTU (0.172 g, 0.535 mmol) and DIEA (0.249 mL, 1.43
mmol) in DMF (5.0 mL) was stirred at rt for about 5 min, followed
by addition of 2-aminoacetonitrile, hydrochloric acid (0.040 g,
0.43 mmol). The reaction mixture was stirred at the same
temperature overnight. Water was added and the aqueous phase was
extracted with EtOAc. Organic layer was washed with brine, dried
over magnesium sulfate and filtered. The filtrate was dried and the
crude was purified by prep HPLC (Table 1, Method i) to give
cyanomethyl)carbamoyl)phenyl)-1H-indole-7-carboxamide (0.065 g,
57%) as a solid. LC/MS (Table 1, Method g) R.sub.t=1.30 min; MS m/z
319 (M+H).sup.+ (Btk IC.sub.50=C) Example #16:
4-(3-Amino-2-methylphenyl)-1H-indole-7-carboxamide
##STR00670##
[1274] A mixture of 4-bromo-1H-indole-7-carboxamide (1.28 g, 5.35
mmol, Preparation #2),
2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline
(1.37 g, 5.89 mmol, Combi-Blocks), Na.sub.2CO.sub.3 (1.70 g, 16.06
mmol) and
[1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.392
g, 0.535 mmol) in THF (41.8 mL), MeOH (5.86 Ll), and water (5.86
mL) was stirred at about 70.degree. C. for about 16 h under a
nitrogen atmosphere. The mixture was filtered through Celite.RTM.
and concentrated under reduced pressure. The crude product was
purified by silica gel column with 0-10% MeOH in DCM to provide the
crude product. The residue was triturated with DCM (2.times. with
sonication for about 5 min), filtered, was washed with DCM and
dried under reduced pressure to provide
4-(3-amino-2-methylphenyl)-1H-indole-7-carboxamide (0.86 g, 61%):
LC/MS (Table 1, Method g) R.sub.t=1.03 min; MS m/z: 266
(M+H).sup.+. (Btk IC.sub.50=C)
Example #17:
4-(3-Acrylamido-2-methylphenyl)-1H-pyrrolo[2,3-c]pyridine-7-carboxamide
##STR00671##
[1276] To a solution of
4-(3-amino-2-methylphenyl)-1H-pyrrolo[2,3-c]pyridine-7-carboxamide
(3.0 g, 11.3 mmol, Example #2) and TEA (3.14 mL, 22.5 mmol) in THF
(113 mL) was slowly added acryloyl chloride (1.01 mL, 12.4 mmol) at
0.degree. C. The reaction was stirred at about 0.degree. C. for
about 20 min. The mixture was concentrated under reduced pressure
and water (100 mL) was added and the suspension was sonicated for
30 min, filtered, washed with water (100 mL), ether (100 mL) and
dried to give
4-(3-acrylamido-2-methylphenyl)-1H-pyrrolo[2,3-c]pyridine-7-carboxamide
(3.05 g, 85%): LC/MS (Table 1, Method f) R.sub.t=1.27 min; MS m/z:
321 (M+H).sup.+. (Btk IC.sub.50=A)
Example #18: 4-(3-Acrylamidophenyl)-1H-indazole-7-carboxamide
##STR00672##
[1277] Step A: Methyl 2-amino-4-chloro-3-methylbenzoate
##STR00673##
[1279] To a mixture of 2-amino-4-chloro-3-methylbenzoic acid (5.0
g, 26.9 mmol, Enamine) and cesium carbonate (13.2 g, 40.4 mmol) in
DMF (100 mL) was added iodomethane (1.77 mL, 28.3 mmol). The
mixture was then stirred at rt for about 16 h. Water was added and
extracted with EtOAc. The organic layer was washed with brine,
dried over magnesium sulfate and filtered. The filtrate was
concentrated and purified by chromatography on silica gel (5-60%
EtOAc in heptane) to provide methyl
2-amino-4-chloro-3-methylbenzoate (4.48 g) as a solid. LC/MS (Table
1, Method g) R.sub.t=1.74 min; MS m/z 200 (M+H).sup.+.
Step B: Methyl 4-chloro-1H-indazole-7-carboxylate
##STR00674##
[1281] To a solution of methyl 2-amino-4-chloro-3-methylbenzoate
(4.5 g, 22.5 mmol) in CHCl.sub.3 (100 mL) was added acetic
anhydride (4.89 mL, 51.8 mmol). The mixture was then stirred at rt
for about 2 h, followed by addition of isopentyl nitrite (6.68 mL,
49.6 mmol) and potassium acetate (0.664 g, 6.76 mmol). The reaction
mixture was heated at refluxed for about 18 h. The reaction was
diluted with DCM and washed with saturated sodium bicarbonate and
dried over magnesium sulfate. The filtrate is concentrate to
provide crude methyl 4-chloro-1H-indazole-7-carboxylate (4.46 g):
LC/MS (Table 1, Method g) R.sub.t=1.47 min; MS m/z 211
(M+H).sup.+.
Step C: 4-Chloro-1H-indazole-7-carboxamide
##STR00675##
[1283] To a suspension of methyl 4-chloro-1H-indazole-7-carboxylate
(4.3 g, 20.4 mmol) in 1,4-dioxane (75 mL) was added a solution of
KOH (1.69 g, 26.5 mmol) in water (75 mL). The reaction mixture was
then stirred at rt for about 16 h to give a clear solution. Solvent
was removed and the residue was treated with 1N HCl to precipitate
the crude acid, which was used without further purification. A
mixture of this crude acid (0.5 g, 2.54 mmol),
N-((ethylimino)methylene)-N3,N3-dimethylpropane-1,3-diamine
hydrochloride (0.731 g, 3.82 mmol) and HOBt (0.584 g, 3.82 mmol) in
DMF (15 mL) was stirred at rt for about 60 min, then ammonia (0.5 N
solution in 1,4-dioxane, 50.9 mL, 25.4 mmol) was added. The
reaction mixture was stirred at rt for about 6 h. The suspension
was filtered and washed with EtOAc. The filtrate was concentrated
and treated with water. The precipitate was filtered, washed with
water and air-dried to provide 4-chloro-1H-indazole-7-carboxamide
(0.43 g) as a solid; LC/MS (Table 1, Method g) R.sub.t=1.00 min; MS
m/z 196 (M+H).sup.+.
Step D: 4-(3-Aminophenyl)-1H-indazole-7-carboxamide
##STR00676##
[1285] A suspension of 4-chloro-1H-indazole-7-carboxamide (0.15 g,
0.767 mmol), tert-butyl
(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)carbamate
(0.367 g, 1.15 mmol), cesium carbonate (0.75 g, 2.3 mmol) in DME
(4.0 mL) and water (2.0 mL) was degassed and purged with nitrogen
for 5 min. Then tris(dibenzylideneacetone)dipalladium(0) (0.07 g,
0.077 mmol) and
2-(dicyclohexylphosphino)-2',4',6'-triisopropylbiphenyl (0.037 g,
0.077 mmol) were added. The reaction vessel was sealed and heated
using Biotage Initiator at about 140.degree. C. for about 30 min.
The mixture was cooled to rt and filtered through a pad of
Celite.RTM.. The filtrate was partitioned between water and EtOAc.
Organic layer was washed with brine, dried over magnesium sulfate
and filtered. The filtrate was concentrated and purified by
chromatography on silica gel (30-100% EtOAc/heptane). This product
was then dissolved in DCM (2 mL) and treated with TFA (5 mL, 64.9
mmol). The reaction mixture was stirred at rt overnight. Excess TFA
and solvent were removed to provide crude
4-(3-aminophenyl)-1H-indazole-7-carboxamide, trifluoroacetic acid
(0.195 g) as a solid. LC/MS (Table 1, Method g) R.sub.t=0.25 min;
MS m/z 253 (M+H).sup.+.
Step E: 4-(3-Acrylamidophenyl)-1H-indazole-7-carboxamide
##STR00677##
[1287] A suspension of 4-(3-aminophenyl)-1H-indazole-7-carboxamide,
TFA (0.1 g, 0.27 mmol), DIEA (0.143 mL, 0.819 mmol) in THF (2.5 mL)
was cooled in an ice bath and acryloyl chloride (0.026 mL, 0.31
mmol) is added slowly. After 30 min, the reaction was treated with
MeOH and stirred for about 5 min. Solvent was then removed under
vacuum and the residue was triturated with DCM to provide
4-(3-acrylamidophenyl)-1H-indazole-7-carboxamide (56 mg) as a
solid: .sup.1H NMR (d-DMSO-d6) .delta. 13.17 (s, 1H) 10.34 (s, 1H)
8.28 (s, 1H) 8.21 (s, 1H) 8.17 (s, 1H) 8.00 (d, J=7.48 Hz, 1H) 7.73
(d, J=7.70 Hz, 1H)7.40-7.59 (m, 3H)7.30 (d, J=7.59 Hz, 1H)6.39-6.58
((m, 1H)6.17-6.36 ((m, 1H) 5.60-5.97 (m, 1H). (Btk IC.sub.50=A)
Example #19: 4-(3-Acrylamidophenyl)-1H-indazole-7-carboxamide
##STR00678##
[1288] Step A: Methyl
4-bromo-2-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-7-carboxy-
late
##STR00679##
[1290] To a solution of diisopropylamine (1.45 mL 10.1 mmol) and
anhydrous THF (30 mL), a solution of t-BuLi (11 mL, 11.7 mmol) in
pentane was added at about -78.degree. C. under nitrogen atmosphere
reaction mixture was stirred for about 30 min. Then a solution of
methyl
4-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-7-carboxylate
(3 g, 7.81 mmol, Preparation #10, step A) in anhydrous THF (10 mL)
was added at about -78.degree. C. After about 2 h, a solution of
iodomethane (2.216 g, 15.61 mmol) in anhydrous THF (10 mL) was
added at about -78.degree. C. The mixture continued to stir for
about 2 h at about -78.degree. C. The reaction mixture was quenched
with aqueous NH.sub.4Cl, extracted with EtOAc (500 mL.times.3). The
organic phase was dried over Na.sub.2SO.sub.4, concentrated under
reduced pressure, and the residue was purified by prep-HPLC (Table
1, Method ao) to provide methyl
4-bromo-2-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-7-carboxy-
late (1 g, 32%) as a solid: .sup.1H NMR (CDCl.sub.3) .delta.
7.51-7.49 (d, J=8.0, 1H), 7.39-7.37 (d, J=8, 1H), 6.55 (s, 1H),
5.77 (s, 2H), 4.06 (s, 3H), 3.31-3.27 (m, 2H), 2.60 (s, 3H),
0.87-0.83 (m, 2H), 0.00 (s, 9H).
Step B:
4-Bromo-2-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-7--
carboxylicacid
##STR00680##
[1292] To a solution of methyl
4-bromo-2-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-7-carboxy-
late (0.6 g, 1.5 mmol) in MeOH (3 mL), THF (6 mL) and water (3 mL),
LiOH (0.361 g, 15.1 mmol) was added and the reaction mixture was
heated to about 45.degree. C. for about 3 h. The reaction mixture
was adjusted to pH<3 by the addition of 1N HCl, then extracted
with EtOAc (300 mL.times.3), and the organic phase was concentrated
under reduced pressure to provide
4-bromo-2-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-7-carboxy-
lic acid (0.5 g, 86%) as a solid: .sup.1H NMR (DMSO-d6) .delta.
13.32 (s, 1H), 7.53-7.42 (m, 2H), 6.56 (s, 1H), 5.86 (s, 2H),
3.36-3.32 (m, 2H), 2.63 (s, 3H), 0.90-0.82 (m, 2H), 0.00 (s,
9H).
Step C:
4-Bromo-2-methyl-1-((2-(trimethysilyl)ethoxy)methyl)-1H-indole-7-c-
arboxamide
##STR00681##
[1294] To a solution of
4-bromo-2-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-7-carboxy-
lic acid (0.5 g, 1.30 mmol) in THF (10 mL) and DCM (12 mL), HOBt
(0.299 g, 1.95 mmol) and EDCI (0.374 g, 1.95 mmol) were added at
about 0.degree. C. Then the reaction mixture was stirred for about
1 hour at rt, then bubbled with NH.sub.3 gas for about 20 min, and
stirring continued overnight at rt. Aqueous NaHCO.sub.3 was added
and the mixture was extracted with EtOAc (200 mL.times.3), and the
organic phase was dried over Na.sub.2SO.sub.4, concentrated under
reduced pressure to provide
4-bromo-2-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-7-carboxa-
mide (0.45 g, 90%) as a solid: .sup.1H NMR (DMSO-d6) .delta. 8.10
(s, 1H), 7.67 (s, 1H), 7.36-7.34 (d, J=8, 1H), 7.20-7.18 (d, J=8,
1H), 6.46 (s, 1H), 5.74 (s, 2H), 3.46-3.38 (m, 2H), 2.56 (s, 3H),
0.90-0.83 (m, 2H), 0.00 (s, 9H).
Step D: 4-Bromo-2-methyl-1H-indole-7-carboxamide
##STR00682##
[1296] To a solution of
4-bromo-2-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-7-carboxa-
mide (350 mg, 0.913 mmol) in THF (15 mL) was added TBAF (2.4 g,
9.13 mmol) and ethane-1,2-diamine (1.1 g, 18.3 mmol). The mixture
was refluxed overnight. The reaction mixture was concentrated under
reduced pressure and the residue was purified by silica gel column
to provide 4-bromo-2-methyl-1H-indole-7-carboxamide (180 mg, 78%)
as a solid: .sup.1H NMR (DMSO-d6) .delta. 11.18 (s, 1H), 8.05 (s,
1H), 7.48-7.42 (m, 2H), 7.20-7.18 (d, J=8, 1H), 6.14 (s, 1H), 2.41
(s, 3H).
Step E: 4-(3-Aminophenyl)-2-methyl-1H-indole-7-carboxamide
##STR00683##
[1298] To a solution of 4-bromo-2-methyl-1H-indole-7-carboxamide
(180 mg, 0.711 mmol) in THF (8 mL) and water (4 mL) and MeOH (4 mL)
was added 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline
(187 mg, 0.853 mmol), Pd(dppf)Cl.sub.2 (104 mg, 0.142 mmol) and
Na.sub.2CO.sub.3 (226 mg, 2.13 mmol), and the solution was heated
at about 90.degree. C. for about 2 h. The reaction mixture was
concentrated under reduced pressure and purified by silica gel
column to provide
4-(3-aminophenyl)-2-methyl-1H-indole-7-carboxamide (80 mg, 42%) as
a solid: .sup.1H NMR (MeOD) .delta. 10.92 (s, 1H), 7.99 (s, 1H),
7.66-7.63 (d, J=12, 2H), 7.61 (s, 1H), 7.13-7.09 (m, 1H), 6.99-6.97
(d, J=8, 1H), 6.88 (s, 1H), 6.78-6.73 (m, 2H), 6.58-6.56 (d, J=8,
1H), 6.29 (s, 1H), 2.42 (s, 3H).
Step F: 4-(3-Acrylamidophenyl)-2-methyl-1H-indole-7-carboxamide
##STR00684##
[1300] To a solution of
4-(3-aminophenyl)-2-methyl-1H-indole-7-carboxamide (80 mg, 0.302
mmol) in DCM (6 mL), acryloyl chloride (40.9 mg, 0.452 mmol) and
DIEA (0.105 mL, 0.603 mmol) were added at about 0.degree. C. The
mixture was stirred for about 1 hour at rt. The reaction mixture
was concentrated under reduced pressure and the residue was
purified by prep-HPLC (Table 1, Method an) to give
4-(3-acrylamidophenyl)-2-methyl-1H-indole-7-carboxamide (10 mg,
11%) as a solid: LC/MS (Table 1, Method j) R.sub.t=2.07 min; MS
m/z: 320 (M+H).sup.+. (Btk IC.sub.50=A) Example #20:
4-(3-Acrylamidophenyl)-2-ethyl-1H-indole-7-carboxamide
##STR00685##
Step A: 4-Bromo-2-iodo-1H-indole-7-carboxamide
##STR00686##
[1302] To a solution of
4-bromo-2-iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-7-carboxami-
de ((1.5 g, 3.03 mmol, Preparation #24) in THF (20 mL), TBAF (15.84
g, 60.6 mmol) and ethane-1,2-diamine (1.82 g, 30.3 mmol) were
added, and the solution was heated at reflux overnight. The
solution was concentrated under reduced pressure and water (30 mL)
and EtOAc (30 mL) were added, and the organic phase was dried and
concentrated under reduced pressure. The residue was purified by
column chromatography (Pet ether:EtOAc=10: 1 to 1:1) to provide
4-bromo-2-iodo-1H-indole-7-carboxamide (700 mg, 63%): LC/MS (Table
1, Method k) R.sub.t=1.91 min; MS m/z: 367 (M+H).sup.+.
Step B: 4-Bromo-2-vinyl-1H-indole-7-carboxamide
##STR00687##
[1304] To a solution of 4-bromo-2-iodo-1H-indole-7-carboxamide
(0.630 g, 1.726 mmol) in 1.4-dioxane (4.5 mL) and water (0.5 mL),
CsF (0.787 g, 5.18 mmol), Pd(PPh.sub.3).sub.2C.sub.12 (0.242 g,
0.345 mmol) and potassium trifluoro(vinyl)borate (254 mg, 1.899
mmol) were added. The reaction mixture was heated to about
90.degree. C. for about 2 h under N.sub.2 atmosphere. The mixture
was concentrated under reduced pressure, and the residue was
purified by column chromatography to provide
4-bromo-2-vinyl-1H-indole-7-carboxamide (0.140 g, 31%): .sup.1H NMR
(CDCl3) .delta. 10.36 (s, 1H), 7.2-7.12 (m, 2H), 6.72-6.65 (m, 1H),
6.50 (s, 1H), 6.25-5.78 (m, 2H), 5.69 (d, J=17.6, 1H), 5.33 (d,
J=10.8, 1H).
Step C: 4-(3-Aminophenyl)-2-vinyl-1H-indole-7-carboxamide
##STR00688##
[1306] To a solution of 4-bromo-2-vinyl-1H-indole-7-carboxamide
(0.12 g, 0.45 mmol) in THF (10 mL), water (5 mL) and MeOH (5 mL),
3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (119 mg,
0.543 mmol), PdCl.sub.2(dppf) (66.2 mg, 0.091 mmol) and
Na.sub.2CO.sub.3 (144 mg, 1.358 mmol) were added. The reaction
mixture was heated at about 90.degree. C. for about 2 h. The
mixture was concentrated under reduced pressure and the residue was
purified by column chromatography on silica gel to provide
4-(3-aminophenyl)-2-vinyl-1H-indole-7-carboxamide (80 mg, 75%):
LC/MS (Table 1, Method 1) R.sub.t=1.06 min; MS m/z: 278
(M+H).sup.+.
Step C: 4-(3-Aminophenyl)-2-ethyl-1H-indole-7-carboxamide
##STR00689##
[1308] To a solution of
4-(3-aminophenyl)-2-vinyl-1H-indole-7-carboxamide (46 mg, 0.116
mmol) in THF (10 mL), Pd/C (10 mg, 0.094 mmol) was added. The
mixture was stirred for about 1.5 h at rt. The mixture was filtered
through a pad of Celite.COPYRGT., and the filtrate was concentrated
under reduced pressure to provide
4-(3-aminophenyl)-2-ethyl-1H-indole-7-carboxamide (40 mg, 70%),
which was used to next step directly: LC/MS (Table 1, Method 1)
R.sub.t=1.21 min; MS m/z: 280 (M+H).sup.+.
Step D:4-(3-Acrylamidophenyl)-2-ethyl-1H-indole-7-carboxamide
##STR00690##
[1310] To a solution of
4-(3-aminophenyl)-2-ethyl-1H-indole-7-carboxamide (20 mg, 0.072
mmol) in DCM (15 mL), TEA (29 mg, 0.288 mmol) and acryloyl chloride
(13.05 mg, 0.144 mmol) were added at about 0.degree. C. The
solution was stirred overnight at rt. The solution was concentrated
under reduced pressure, and the residue was purified by pre-HPLC
(Table 1, Method am) to provide
4-(3-acrylamidophenyl)-2-ethyl-1H-indole-7-carboxamide (9 mg, 38%):
LC/MS (Table 1, Method d) R.sub.t=2.91 min; MS m/z: 334
(M+H).sup.+. (Btk IC.sub.50=A)
Example #21:
4-(3-Amino-2-methylphenyl)-2-(4,4-difluorocyclohex-1-enyl)-1H-indole-7-ca-
rboxamide
##STR00691##
[1311] Step A:
4-Bromo-2-(4,4-difluorocyclohex-1-en-1-yl)-1H-indole-7-carboxamide
##STR00692##
[1313] A mixture of
2-(4,4-difluorocyclohex-1-en-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolan-
e (0.267 g, 1.09 mmol, Syngene),
4-bromo-2-iodo-1H-indole-7-carboxamide (0.363 g, 0.995 mmol,
Preparation #1), Na.sub.2CO.sub.3 (0.316 g, 2.98 mmol) in THF (7
mL), MeOH (0.98 mL), and water (0.98 mL) was added
[1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.073
g, 0.099 mmol). The mixture was bubbled with nitrogen and the
vessel was sealed and heated at about 80.degree. C. for about 4 h.
The reaction was cooled to rt, filtered through Celite.RTM. and
concentrated under reduced pressure. The residue was purified by
silica gel column with EtOAc/hexanes (30-100%) to provide crude
product which was further purified by silica gel column eluting
with a gradient of 30-70% EtOAc/hexanes to provide
4-bromo-2-(4,4-difluorocyclohex-1-en-1-yl)-1H-indole-7-carboxamide
(0.25 g, 71%): LC/MS (Table 1, Method f) R.sub.t=1.82 min; MS m/z:
357 (M+H).sup.+.
Step B:
4-(3-Amino-2-methylphenyl)-2-(4,4-difluorocyclohex-1-enyl)-1H-indo-
le-7-carboxamide
##STR00693##
[1315] A mixture of
4-bromo-2-(4,4-difluorocyclohex-1-enyl)-1H-indole-7-carboxamide
(0.48 g, 0.622 mmol),
2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline
(0.203 g, 0.870 mmol, Combi-Blocks), Na.sub.2CO.sub.3 (0.198 g,
1.865 mmol) and
[1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.045
g, 0.062 mmol) in THF (5 mL), MeOH (0.700 mL), and water (0.700 mL)
was stirred at about 70.degree. C. for about 16 h under a nitrogen
atmosphere. The mixture was filtered through Celite.RTM. and
concentrated under reduced pressure. The residue was passed through
a silica gel column with EtOAc/heptane (50-75%) to provide the
crude product. The crude product was triturated with DCM (2.times.
with sonication for about 5 min), filtered, washed with DCM and
dried under reduced pressure to provide
4-(3-amino-2-methylphenyl)-2-(4,4-difluorocyclohex-1-enyl)-1H-ind-
ole-7-carboxamide (134 mg, 57%): LC/MS (Table 1, Method f)
R.sub.t=1.36 min; MS m/z: 382 (M+H).sup.+. (Btk IC.sub.50=A)
Example #22:
4-(3-Acrylamidophenyl)-2-(2-ethoxyethyl)-1H-indole-7-carboxamide
##STR00694##
[1316] Step A:
(E)-4-Bromo-2-(2-ethoxyvinyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-ind-
ole-7-carboxamide
##STR00695##
[1318] Five reaction vessels were charged with a solution of
4-bromo-2-iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-7-carboxami-
de (1 g, 2.02 mmol, Preparation #24) in toluene (100 mL) was added
(E)-tributyl(2-ethoxyvinyl)stannane (1.09 g, 3.03 mmol),
Pd(PPh.sub.3).sub.2Cl.sub.2 (0.142 g, 0.202 mmol) and LiCl (0.428
g, 10.1 mmol). The mixtures were heated at about 90.degree. C.
overnight under N.sub.2 atmosphere. All five reaction mixtures were
combined, concentrated under reduced pressure, and the residue was
purified by silica gel column to provide
(E)-4-bromo-2-(2-ethoxyvinyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-ind-
ole-7-carboxamide (2 g, 45%) as a yellow solid: .sup.1H NMR
(DMSO-d6) .delta. 8.11 (s, 1H), 7.69 (s, 1H), 7.37-7.35 (d, J=8,
1H), 7.17-7.15 (d, J=8, 1H), 6.96 (s, 1H), 6.78-6.76 (d, J=8, 1H),
5.80-5.78 (d, J=8, 2H), 5.69-5.68 (d, J=4, 1H), 4.24-4.08 (m, 2H),
3.42-3.36 (m, 2H), 1.43-1.34 (m, 3H), 0.86-0.82 (m, 2H), 0.00 (s,
9H).
Step B:
(E)-4-(3-Aminophenyl)-2-(2-ethoxyvinyl)-1-((2-(trimethylsilyl)etho-
xy)methyl)-1H-indole-7-carboxamide
##STR00696##
[1320] To a solution of
(E)-4-bromo-2-(2-ethoxyvinyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-ind-
ole-7-carboxamide (1.5 g, 3.41 mmol) in THF (20 mL), water (10 mL)
and MeOH (10 mL) was added
3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (0.897 g,
4.10 mmol), Pd(dppf)Cl.sub.2 (0.5 g, 0.683 mmol) and
Na.sub.2CO.sub.3 (1.085 g, 10.24 mmol). The solution was heated at
about 90.degree. C. for about 2 h. The reaction mixture was
concentrated under reduced pressure and purified by silica gel
column to provide
(E)-4-(3-aminophenyl)-2-(2-ethoxyvinyl)-1-((2-(trimethylsilyl)ethoxy)meth-
yl)-1H-indole-7-carboxamide (0.80 g, 52%): .sup.1H NMR (DMSO-d6)
.delta. 8.06 (s, 1H), 7.62 (s, 1H), 7.30-7.22 (m, 2H), 7.15 (s,
1H), 7.10-7.08 (d, J=8, 1H), 6.93 (s, 1H), 6.83-6.81 (d, J=8, 1H),
6.68-6.65 (m, 2H), 5.82-5.80 (d, J=8, 2H), 5.67-5.66 (d, J=4, 1H),
5.28 (s, 2H), 4.18-4.06 (m, 2H), 3.43-3.37 (m, 2H), 1.39-1.33 (m,
3H), 0.86-0.82 (m, 2H), 0.00 (s, 9H).
Step C:
4-(3-Aminophenyl)-2-(2-ethoxyethyl)-1-((2-(trimethylsilyl)ethoxy)m-
ethyl)-1H-indole-7-carboxamide
##STR00697##
[1322] Two reaction vessels were charged with a solution of
(E)-4-(3-aminophenyl)-2-(2-ethoxyvinyl)-1-((2-(trimethylsilyl)ethoxy)meth-
yl)-1H-indole-7-carboxamide (400 mg, 0.886 mmol) in MeOH (60 mL),
and Pd/C (400 mg, 10%). The mixtures were stirred for about 1 h at
rt under H.sub.2 (14 psi) atmosphere. The two reaction mixtures
were combined, filtered and concentrated under reduced pressure to
provide
4-(3-aminophenyl)-2-(2-ethoxyethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)--
1H-indole-7-carboxamide (600 mg, 75%) as a solid, which was used
directly for the next step: .sup.1H NMR (DMSO-d6) .delta. 8.05 (s,
1H), 7.61 (s, 1H), 7.32-7.31 (d, J=4, 1H), 7.23-7.09 (m, 2H), 6.90
(s, 1H), 6.81-6.79 (d, J=8, 1H), 6.68-6.66 (d, J=8, 1H), 6.58 (s,
1H), 5.78 (s, 2H), 5.26 (s, 2H), 3.79-3.76 (m, 2H), 3.55-3.52 (m,
2H), 3.45-3.41 (m, 2H), 3.15-3.12 (m, 2H), 1.26-1.15 (m, 3H),
0.87-0.83 (m, 2H), 0.01 (s, 9H).
Step D:
4-(3-Aminophenyl)-2-(2-ethoxyethyl)-1H-indole-7-carboxamide
##STR00698##
[1324] To a solution of
4-(3-aminophenyl)-2-(2-ethoxyethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)--
1H-indole-7-carboxamide (500 mg, 1.10 mmol) in THF (20 mL) was
added TBAF (2.88 g, 11.0 mmol) and ethane-1,2-diamine (1.33 g, 22.0
mmol). The mixture was stirred for about 5 h at about 80.degree. C.
The reaction mixture was concentrated under reduced pressure, and
the residue was purified by silica gel column to provide
4-(3-aminophenyl)-2-(2-ethoxyethyl)-1H-indole-7-carboxamide (267
mg, 75%) as a solid: .sup.1H NMR (DMSO-d6) .delta. 11.09 (s, 1H),
8.12 (s, 1H), 7.76-7.74 (d, J=8, 1H), 7.46-7.44 (d, J=8, 1H),
7.24-7.19 (m, 1H), 7.09-7.07 (d, J=8, 1H), 6.96 (s, 1H), 6.87-6.85
(d, J=8, 1H), 6.67-6.66 (d, J=4, 1H), 6.45 (s, 1H), 5.25 (s, 2H),
3.76-3.73 (m, 2H), 3.59-3.54 (m, 2H), 3.13-3.09 (m, 2H), 1.27-1.23
(m, 3H).
Step E:
4-(3-Acrylamidophenyl)-2-(2-ethoxyethyl)-1H-indole-7-carboxamide
##STR00699##
[1326] Two reaction vessels were charged with a solution of
4-(3-aminophenyl)-2-(2-ethoxyethyl)-1H-indole-7-carboxamide (60 mg,
0.186 mmol) in DCM (2 mL). DIEA (0.065 mL, 0.371 mmol) and acryloyl
chloride (25.2 mg, 0.278 mmol) were added and the mixtures were
stirred for about 1 h at rt. The two reaction mixtures were
combined, concentrated under reduced pressure, and the residue was
purified by prep-HPLC (Table 1, Method w) to provide
4-(3-acrylamidophenyl)-2-(2-ethoxyethyl)-1H-indole-7-carboxamide
(21.6 mg, 26.4%) as a solid: LC/MS (Table 1, Method d) R.sub.t=2.95
min; MS m/z: 378 (M-H).sup.-. (Btk IC.sub.50=A)
Example #23:
4-(3-Acrylamidophenyl)-2-(2-hydroxyethyl)-1H-indole-7-carboxamide
##STR00700##
[1327] Step A:
4-(3-Aminophenyl)-2-(2-hydroxyethyl)-1H-indole-7-carboxamide
##STR00701##
[1329] Two reaction vessels were charged with a solution of
4-(3-aminophenyl)-2-(2-ethoxyethyl)-1H-indole-7-carboxamide (100
mg, 0.309 mmol, Example #22, Step D) in DCM (10 mL) was added
dropwise tribromoborane (387 mg, 1.55 mmol) at about -78.degree. C.
The mixtures were stirred for about 2 h at about 0.degree. C. The
two reaction mixtures were combined and aqueous NaHCO.sub.3 was
added and the mixture was extracted with DCM (100 mL.times.3). The
organic phase was dried over Na.sub.2SO.sub.4, concentrated under
reduced pressure to give
4-(3-aminophenyl)-2-(2-hydroxyethyl)-1H-indole-7-carboxamide (160
mg, 88%) as a yellow solid: .sup.1H NMR (DMSO-d6) .delta. 10.96 (s,
1H), 8.04 (s, 1H), 7.67-7.65 (d, J=8, 1H), 7.38-7.34 (d, J=16, 1H),
7.16-7.12 (m, 1H), 7.01-6.99 (d, J=8, 1H), 6.91 (s, 1H), 6.81-6.80
(d, J=4, 1H), 6.62-6.59 (d, J=12, 1H), 6.36 (s, 1H), 5.33 (s, 2H),
4.87 (s, 1H), 3.73-3.70 (m, 2H), 2.96-2.93 (m, 2H).
Step B:
4-(3-Aminophenyl)-2-(2-hydroxyethyl)-1H-indole-7-carboxamide
##STR00702##
[1331] To a solution of
4-(3-aminophenyl)-2-(2-hydroxyethyl)-1H-indole-7-carboxamide (40
mg, 0.135 mmol) in pyridine (4 mL) was added EDCI (31 mg, 0.163
mmol) and acrylic acid (9.8 mg, 0.135 mmol). The mixture was
stirred for about 3 h at about 110.degree. C. The reaction mixture
was concentrated under reduced pressure and the residue was
purified by prep-HPLC (Table 1, Method al) to provide
4-(3-acrylamidophenyl)-2-(2-hydroxyethyl)-1H-indole-7-carboxamide
(4.5 mg, 10%) as a solid: LC/MS (Table 1, Method j) R.sub.t=2.46
min; MS m/z: 350 (M+H).sup.+. (Btk IC.sub.50=A)
Example #24:
4-((1-Acryloylazetidin-3-yl)(methyl)amino)-1H-indole-7-carboxamide
##STR00703##
[1332] Step A:
tert-Butyl-3-((7-cyano-1H-indol-4-yl)amino)azetidine-1-carboxylate
##STR00704##
[1334] In a 4 mL reaction vial, 4-bromo-1H-indole-7-carbonitrile
(200 mg, 0.905 mmol, Sinova),
chloro[2-(dicyclohexylphosphino)-3,6-dimethoxy-2',4',6'-triisopropyl-1,1'-
-biphenyl][2-(2-amino-ethyl)phenyl]palladium(II) (9.03 mg, 0.011
mmol), and
dicyclohexyl(2',4',6'-triisopropyl-3,6-dimethoxy-[1,1'-biphenyl]-2-yl-
)phosphine (6.07 mg, 0.011 mmol) were added. The solid mixture was
evacuated and backfilled with nitrogen. Lithium
bis(trimethylsilyl)amide (2.17 mL, 2.17 mmol) was added followed by
tert-butyl-3-aminoazetidine-1-carboxylate (170 .mu.l, 1.09 mmol).
The reaction mixture was heated at about 65.degree. C. for about
2.5 h. The reaction mixture was quenched with a few drops of 1N HCl
and diluted with EtOAc (10 mL). The EtOAc layer was washed with a
saturated aqueous solution of NaHCO.sub.3 and dried over
MgSO.sub.4, filtered and concentrated under vacuum. The crude
material was purified via flash chromatography, using a gradient of
5-40% EtOAc in heptane to give
tert-butyl-3-((7-cyano-1H-indol-4-yl)amino)azetidine-1-carboxylate
(160 mg, 57%); LC/MS (Table 1, Method as) R.sub.t=2.13 min.; MS
m/z: 311 (M-H).sup.-.
Step B: tert-Butyl
4-((1-(tert-butoxycarbonyl)azetidin-3-yl)amino)-7-cyano-1H-indole-1-carbo-
xylate
##STR00705##
[1336] In a 100 mL round-bottomed flask, tert-butyl
3-((7-cyano-1H-indol-4-yl)amino)azetidine-1-carboxylate (200 mg,
0.640 mmol) in MeCN (5 mL) was added to give a brown solution. DMAP
(15.6 mg, 0.128 mmol) and BOC.sub.2O (419 mg, 1.92 mmol) were
added. Reaction mixture was stirred for about 18 h at rt. Reaction
mixture was diluted with water (2 mL) and EtOAC (3 mL). The entire
suspension was filtered and washed with EtOAc (5 mL). The white
precipitate collected was dried in a vacuum oven at about
70.degree. C. for about 2 h to give tert-Butyl
4-((1-(tert-butoxycarbonyl)azetidin-3-yl)amino)-7-cyano-1H-indole-1-carbo-
xylate (154 mg, 58.3%). LC/MS (Table 1, Method as) R.sub.t=2.54
min.; MS m/z: 411 (M-H).sup.-.
Step C:
tert-Butyl-4-((1-(tert-butoxycarbonyl)azetidin-3-yl)(methyl)amino)-
-7-cyano-1H-indole-1-carboxylate
##STR00706##
[1338] In a 4 mL reaction vial, sodium hydride (23.9 mg, 0.598
mmol, 60% disp in mineral oil) in DMF (1 mL) was added to give a
white suspension. Reaction mixture was cooled to about 0.degree. C.
and tert-butyl
4-((1-(tert-butoxycarbonyl)azetidin-3-yl)amino)-7-cyano-1H-indole-1-carbo-
xylate (145 mg, 0.352 mmol) was added as a solution in DMF (4 mL).
After about 30 min, iodomethane (33 .mu.l, 0.528 mmol) was added.
Stirring was continued at 0.degree. C. for about 1 h. The reaction
was quenched with water (15 mL) and extracted with EtOAc (20 mL).
The organic layer was dried over MgSO4, filtered and concentrated.
The material was purified via flash chromatography using a gradient
of 0-25% EtOAc/heptane over 5 min, then held at 25% EtOAc/heptane
for 5 min, to give crude
tert-Butyl-4-((1-(tert-butoxycarbonyl)azetidin-3-yl)(methyl)amino)-7-cyan-
o-1H-indole-1-carboxylate (148 mg, 71.1%); LC/MS (Table 1, Method
as) R.sub.t=2.71 min.; MS m/z: 427 (M+H).sup.+.
Step D: tert-Butyl
3-((7-carbamoyl-1H-indol-4-yl)(methyl)amino)azetidine-1-carboxylate
##STR00707##
[1340] To a solution of tert-butyl
4-((1-(tert-butoxycarbonyl)azetidin-3-yl)(methyl)amino)-7-cyano-1H-indole-
-1-carboxylate (148 mg, 0.250 mmol) in ethanol (2 mL)/DMSO (0.500
mL) was added hydrogen peroxide (0.515 mL, 5.04 mmol) and NaOH (1M,
0.515 mL, 0.515 mmol). The reaction mixture was stirred at rt for
about 2 h. To the reaction mixture was added water (5 mL) and the
precipitate was collected via filtration, washed with water (5 mL)
and dried in a vacuum oven at about 70.degree. C. for about 2 h to
give tert-Butyl
3-((7-carbamoyl-1H-indol-4-yl)(methyl)amino)azetidine-1-carboxylate
(60 mg, 52%); LC/MS (Table 1, Method as) R.sub.t=1.97 min.; MS m/z:
345 (M+H).sup.+.
Step E: 4-(Azetidin-3-yl(methyl)amino)-1H-indole-7-carboxamide
##STR00708##
[1342] In a 4 mL reaction vial, tert-butyl
3-((7-carbamoyl-1H-indol-4-yl)(methyl)amino)azetidine-1-carboxylate
(60 mg, 0.129 mmol) in 1,4-dioxane (2 mL) was added to give an
off-white solution. 4M HCl in dioxane (0.129 mL, 0.516 mmol) was
added. Reaction was stirred at rt for about 2 h. It was the warmed
to about 50.degree. C. for about 2 h. Additional 4M HCl in dioxane
(0.129 mL, 0.516 mmol) was added and stirring was continued at
about 50.degree. C. for about 45 min. Reaction mixture was filtered
and washed with DCM to give a precipitate. The precipitate was
dissolved in water (2 mL) and basified with a few drops of 5N
aqueous NaOH solution. The aqueous layer was then extracted with
DCM (2.times.7 mL) and EtOAC (2.times.8 mL). The organic layers
were combined and dried over MgSO.sub.4, filtered and concentrated
to give 4-(azetidin-3-yl(methyl)amino)-1H-indole-7-carboxamide (29
mg, 66%); LC/MS (Table 1, Method as) R.sub.t=0.73 min.; MS m/z: 245
(M+H).sup.+.
Step F:
4-((1-Acryloylazetidin-3-yl)(methyl)amino)-1H-indole-7-carboxamide
##STR00709##
[1344] A flask was charged with
4-(azetidin-3-yl(methyl)amino)-1H-indole-7-carboxamide (28 mg,
0.083 mmol) and N-ethyl-N-isopropylpropan-2-amine (65 .mu.l, 0.373
mmol) in DCM (5 mL). The mixture was cooled to 0.degree. C. on an
ice-bath. Acryloyl chloride (7.38 .mu.l, 0.091 mmol) was added and
the mixture stirred to about 20 min. Reaction mixture was
concentrated. The material was purified via flash chromatography
using a gradient of 1.0-3.3% MeOH/DCM over 7 min then held at 3.3%
for 5 min to give
4-((1-Acryloylazetidin-3-yl)(methyl)amino)-1H-indole-7-carboxamide
(10.5 mg, 43%); LC/MS (Table 1, Method a) R.sub.t=1.31 min.; MS
m/z: 299 (M+H).sup.+. (Btk IC.sub.50=A)
Example #25:
4-(1-Acryloylpiperidin-3-yl)-1H-indole-7-carboxamide
##STR00710##
[1345] Step A: tert-Butyl
3-(7-carbamoyl-1H-indol-4-yl)-5,6-dihydropyridine-1(2H)-carboxylate
##STR00711##
[1347] A 20 mL vial was charged with
4-bromo-1H-indole-7-carboxamide (300 mg, 1.255 mmol), tert-butyl
3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-
-carboxylate (466 mg, 1.506 mmol),
(1,1-bis(diphenylphosphino)ferrocene)dichloropalladium (92 mg,
0.125 mmol) and sodium carbonate (399 mg, 3.76 mmol). To the solid
mixture was added THF (6 mL):MeOH (0.840 mL):Water (0.840 mL). The
suspension was sparged with nitrogen for about 5 min. The reaction
mixture was heated at about 70.degree. C. overnight. Reaction
mixture was filtered over a pad of Celite.RTM., concentrated and
purified by silica gel column (30-60% EtOAc/heptane) to give
tert-butyl
3-(7-carbamoyl-1H-indol-4-yl)-5,6-dihydropyridine-1(2H)-carboxylate
(355 mg, 83%); LC/MS (Table 1, Method as) R.sub.t=2.14 min.; MS
m/z: 340 (M-H).sup.-.
Step B: tert-Butyl
3-(7-carbamoyl-1H-indol-4-yl)piperidine-1-carboxylate
##STR00712##
[1349] A flask was charged tert-butyl
3-(7-carbamoyl-1H-indol-4-yl)-5,6-dihydropyridine-1(2H)-carboxylate
(355 mg, 1.04 mmol) and palladium (55.3 mg, 0.520 mmol). Ethyl
acetate (10 mL) was added under vacuum and the mixture was stirred
under H.sub.2 balloon at rt for about 5 h. The reaction mixture was
filtered over a pad of Celite.RTM. and washed with MeOH (20 mL) and
EtOAc (30 mL). The filtrate was concentrated under reduced pressure
to give tert-Butyl
3-(7-carbamoyl-1H-indol-4-yl)piperidine-1-carboxylate (357 mg,
100%); LC/MS (Table 1, Method as) R.sub.t=2.14 min.; MS m/z: 342
(M-H).sup.-.
Step C: 4-(Piperidin-3-yl)-1H-indole-7-carboxamide
##STR00713##
[1351] A flask was charged with Methanol (5 mL) and cooled to
0.degree. C. Acetyl chloride (0.828 mL, 11.6 mmol) was added drop
wise, and the ice bath was removed. The mixture was stirred at rt
for about 25 min. The solution was then added to tert-butyl
3-(7-carbamoyl-1H-indol-4-yl)piperidine-1-carboxylate (100 mg,
0.291 mmol) and the reaction mixture was stirred at rt for about 4
h. The mixture was concentrated under vacuum. The residue was
dissolved in water (10 mL) and washed with EtOAc (7 mL). The
aqueous layer was basified with a few of drops of 50% w/w NaOH
solution and extracted with EtOAC (12 mL). The EtOAc layer was
dried over MgSO4, filtered and concentrated to give
4-(Piperidin-3-yl)-1H-indole-7-carboxamide (40 mg, 56%); the
material was used crude in the next step without further
characterization.
Step D: 4-(1-Acryloylpiperidin-3-yl)-1H-indole-7-carboxamide
##STR00714##
[1353] A flask was charged with
4-(piperidin-3-yl)-1H-indole-7-carboxamide (40 mg, 0.164 mmol) and
N-ethyl-N-isopropylpropan-2-amine (43 .mu.L, 0.247 mmol) in DCM (5
mL). The mixture was cooled to 0.degree. C. Acryloyl chloride
(14.69 .mu.L, 0.181 mmol) was added and the mixture stirred for
about 20 min. Reaction mixture was concentrated. The material was
purified by silica gel column using a gradient of 1.0-5.5%
MeOH/CH.sub.2Cl2 over 10 min; to give
4-(1-Acryloylpiperidin-3-yl)-1H-indole-7-carboxamide (41 mg, 84%);
LC/MS (Table 1, Method a) R.sub.t=1.53 min.; MS m/z: 298
(M+H).sup.+. (Btk IC.sub.50=B)
Example
#26:4-(1-Acryloylpiperidin3-yl)-2-(1-methyl-1H-pyrazol-4-yl)-1H-in-
dole-7-carboxamide
##STR00715##
[1354] Step A: tert-Butyl
3-(7-carbamoyl-2-(1-methyl-1H-pyrazol-4-yl)-1H-indol-4-yl)-5,6-dihydropyr-
idine-1(2H)-carboxylate
##STR00716##
[1356] A 20 mL vial was charged with
4-bromo-2-(1-methyl-1H-pyrazol-4-yl)-1H-indole-7-carboxamide (216
mg, 0.677 mmol, Preparation #10), tert-butyl
3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-
-carboxylate (251 mg, 0.812 mmol),
(1,1-Bis(diphenylphosphino)ferrocene)dichloropalladium(1:1) complex
with DCM (55.3 mg, 0.068 mmol) and sodium carbonate (215 mg, 2.03
mmol). To the solid mixture was added THF (3 mL):MeOH (0.420
mL):Water (0.420 mL). The suspension was sparged with N.sub.2 for
about 5 min. The reaction mixture was heated at about 70.degree. C.
overnight. Reaction mixture was filtered over a pad of celite,
concentrated and was purified by silica gel column (0-2% MeOH/DCM)
to give tert-butyl
3-(7-carbamoyl-2-(1-methyl-1H-pyrazol-4-yl)-1H-indol-4-yl)-5,6-dihydropyr-
idine-1(2H)-carboxylate (227 mg, 80%); LC/MS (Table 1, Method as)
R.sub.t=2.09 min.; MS m/z: 422 (M+H).sup.+.
Step B: tert-butyl
3-(7-carbamoyl-2-(1-methyl-1H-pyrazol-4-yl)-1H-indol-4-yl)piperidine-1-ca-
rboxylate
##STR00717##
[1358] A flask was charged with tert-butyl
3-(7-carbamoyl-2-(1-methyl-1H-pyrazol-4-yl)-1H-indol-4-yl)-5,6-dihydropyr-
idine-1(2H)-carboxylate (227 mg, 0.539 mmol) and 10% palladium on
carbon (28.7 mg, 0.027 mmol). Ethyl acetate (5 mL) was added under
vacuum and the mixture was stirred under H.sub.2 balloon at rt for
about 5 h. The reaction mixture was filtered over a pad of
Celite.COPYRGT. and washed with MeOH (20 mL) and EtOAc (30 mL). The
filtrate was concentrated under reduced pressure to give the title
compound (177 mg, 78%); LC/MS (Method as) R.sub.t=2.08 min.; MS
m/z: 424 (M+H).sup.+.
Step C:
2-(1-Methyl-1H-pyrazol-4-yl)-4-(piperidin-3-yl)-1H-indole-7-carbox-
amide
##STR00718##
[1360] A flask was charged with MeOH (2 mL) and cooled to 0.degree.
C. Acetyl chloride (0.151 mL, 2.12 mmol) was added drop wise, and
the ice bath was removed. The mixture was stirred at rt for about
25 min. The solution was then added to tert-butyl
3-(7-carbamoyl-2-(1-methyl-1H-pyrazol-4-yl)-1H-indol-4-yl)piperidine-1-ca-
rboxylate (30 mg, 0.071 mmol) and the reaction mixture was stirred
at rt overnight. The mixture was concentrated under vacuum. The
residue was dissolved in water (3 mL) and washed with DCM (3 mL).
The aqueous layer was basified with a few drops of 5N NaOH to give
a suspension, to which was added DCM. The DCM layer was separated.
The aqueous layer formed a precipitate which was collected via
filtration and washed with a mixture of DCM/EtOAC/MeOH (1:1:1) (6
mL). This filtrate was combined with the DCM layer and concentrated
under vacuum to give
2-(1-methyl-1H-pyrazol-4-yl)-4-(piperidin-3-yl)-1H-indole-7-carboxamide
(18 mg, 79%); LC/MS (Table 1, Method as) R.sub.t=1.03 min.; MS m/z:
324 (M+H).sup.+.
Step D: 4-(1-Acryloylpiperidin
3-yl)-2-(1-methyl-1H-pyrazol-4-yl)-1H-indole-7-carboxamide
##STR00719##
[1362] A flask was charged with
2-(1-methyl-1H-pyrazol-4-yl)-4-(piperidin-3-yl)-1H-indole-7-carboxamide
(18 mg, 0.056 mmol) and N-ethyl-N-isopropylpropan-2-amine (0.044
mL, 0.250 mmol) in DCM (5 mL). The mixture was cooled to 0.degree.
C. on an ice-bath. Acryloyl chloride (4.97 .mu.l, 0.061 mmol) was
added and the mixture stirred for about 20 min. Reaction mixture
was concentrated. The material was purified by silica gel column
(2.0-6.5% MeOH/DCM) to give 4-(1-acryloylpiperidin
3-yl)-2-(1-methyl-1H-pyrazol-4-yl)-1H-indole-7-carboxamide (9 mg,
43%); LC/MS (Table 1, Method a) R.sub.t=1.56 min.; MS m/z: 378
(M+H).sup.+. (Btk IC.sub.50=A)
Example #27:
4-((1-Acryloylazetidin-3-yl)oxy)-1H-indole-7-carboxamide
##STR00720##
[1363] Step A: tert-butyl
3-(4-bromo-3-nitrophenoxy)azetidine-1-carboxylate
##STR00721##
[1365] Cesium carbonate (2.038 g, 6.26 mmol) was added in DMF (12
mL) to give a white suspension. Molecular sieves (4 .ANG., 8-12
mesh, beads, 100 mg) 4-bromo-3-nitrophenol (1 g, 4.59 mmol) and
tert-butyl 3-((methylsulfonyl)oxy)azetidine-1-carboxylate (1.048 g,
4.17 mmol) were added, and the mixture was heated at about
85.degree. C. for about 18 h. The crude mixture was partitioned
between EtOAc (50 mL) and saturated aqueous ammonium chloride
solution (30 mL). The organic layer was washed by brine (30 mL),
dried over sodium sulfate, filtered and concentrated to afford
tert-butyl 3-(4-bromo-3-nitrophenoxy)azetidine-1-carboxylate (0.799
g, 2.14 mmol, 46.7% yield): LC/MS (Table 1, Method a) R.sub.t=2.62
min; MS m/z 373, 375 (M+H).sup.+.
Step B: tert-butyl
3-((7-bromo-1H-indol-4-yl)oxy)azetidine-1-carboxylate
##STR00722##
[1367] A 100 mL round-bottom flask was degassed with nitrogen and
cooled to about -70.degree. C. in a dry-ice/acetone bath. A
solution of vinylmagnesium bromide in THF (1.0 M, 21.59 mL, 21.59
mmol) was added into the flask. Then a solution of tert-butyl
3-(4-bromo-3-nitrophenoxy)azetidine-1-carboxylate (2.65 g, 5.40
mmol) in 2-methyl-THF (18 mL) was added dropwise over 8 min, the
mixture was stirred at about -70.degree. C. for about 1 h, and the
reaction mixture was quenched by saturated aqueous ammonium
chloride solution (22 mL) at about -60.degree. C. The resulting
mixture was warmed to rt and EtOAc (50 mL) and water (40 mL) were
added. The layers were separated, the aqueous layer was extracted
with EtOAc (50 mL), the combined organic layers were washed with
brine (50 mL), dried over sodium sulfate, filtered and concentrated
to afford an orange oil, which was purified by silica gel
chromatography eluting with a gradient of 0 to 40% EtOAc/heptane to
afford tert-butyl
3-((7-bromo-1H-indol-4-yl)oxy)azetidine-1-carboxylate (0.87 g, 2.37
mmol, 43.9% yield): LC/MS (Table 1, Method a) R.sub.t=2.52 min; MS
m/z 367, 369 (M+H).sup.+.
Step C: tert-butyl
3-((7-cyano-1H-indol-4-yl)oxy)azetidine-1-carboxylate
##STR00723##
[1369] In a 20 mL microwave reaction vial, tert-butyl
3-((7-bromo-1H-indol-4-yl)oxy)azetidine-1-carboxylate (0.8 g, 2.178
mmol), zinc cyanide (0.512 g, 4.36 mmol) and DMF (12 mL) were added
to give a yellow suspension. The vial was degassed with nitrogen,
tetrakis(triphenylphosphine)palladium(0) (0.755 g, 0.654 mmol) was
added. The mixture was degassed with nitrogen, and then the
reaction mixture was heated in a Biotage.RTM. microwave reactor at
about 160.degree. C. for about 30 min (2 psi maximum pressure, 235
max watts). The resulting orange suspension was filtered through
Celite.RTM., washed with DMF (10 mL) and 2-methyl-THF (3.times.10
mL), the filtrate was concentrated in vacuo to remove most DMF,
then it was partitioned between 2-methyl-THF (50 mL) and saturated
aqueous ammonium chloride solution (50 mL). The organic layer was
washed with water (30 mL) and brine (30 mL), dried over sodium
sulfate, filtered and concentrated to afford an orange oil, which
was purified by silica gel chromatography eluting with a gradient
of 0 to 50% EtOAc/heptane to afford tert-butyl
3-((7-cyano-1H-indol-4-yl)oxy)azetidine-1-carboxylate (0.28 g,
0.894 mmol, 41.0% yield): LC/MS (Table 1, Method a) R.sub.t=2.29
min; MS m/z 314 (M+H).sup.+.
Step D:4-((1-acryloylazetidin-3-yl)oxy)-1H-indole-7-carboxamide
##STR00724##
[1371] A mixture of tert-butyl
3-((7-cyano-1H-indol-4-yl)oxy)azetidine-1-carboxylate (0.28 g,
0.894 mmol) and potassium carbonate (0.309 g, 2.234 mmol) in DMSO
(2.98 mL) was cooled to about 10.degree. C. by ice-cold water bath,
then hydrogen peroxide (0.091 ml, 0.894 mmol) was added dropwise.
The reaction mixture was stirred at rt for about 18 h, hydrogen
peroxide (0.023 mL, 0.225 mmol) was added. The reaction mixture was
stirred at rt for about an additional 9 h. Water (30 mL) was added
to the reaction mixture and the mixture was extracted with EtOAc
(2.times.30 mL) and the combined organic layers were dried over
sodium sulfate, filtered and concentrated to afford the crude
tert-butyl
3-((7-carbamoyl-1H-indol-4-yl)oxy)azetidine-1-carboxylate, which
was used directly in the next step. To a suspension of tert-butyl
3-((7-carbamoyl-1H-indol-4-yl)oxy)azetidine-1-carboxylate (0.27 g,
0.815 mmol) in MeOH (4.45 mL) was added hydrogen chloride (4.0 M in
dioxane, 4.07 mL, 16.30 mmol) dropwise, the mixture was stirred at
rt for about 30 min, then the mixture was concentrated in vacuo to
afford the crude 4-(azetidin-3-yloxy)-1H-indole-7-carboxamide
hydrochloride, which was used directly in the next step.
[1372] The suspension of
4-(azetidin-3-yloxy)-1H-indole-7-carboxamide hydrochloride (0.218
g, 0.815 mmol) in DCM (13.0 mL) was cooled to about -10.degree. C.
in an ice/sodium chloride bath, TEA (0.568 mL, 4.08 mmol) was added
dropwise; then a solution of acryloyl chloride (0.075 mL, 0.897
mmol) in DCM (3.26 mL) was added dropwise via syringe and the
reaction mixture was stirred for about 30 min. The reaction mixture
was concentrated in vacuo, the crude material was purified by
silica gel chromatography eluting with a gradient of 0 to 10%
MeOH/DCM to afford
4-((1-acryloylazetidin-3-yl)oxy)-1H-indole-7-carboxamide (0.16 g,
0.555 mmol, 68.1% yield): LC/MS (Table 1, Method a) R.sub.t=1.37
min; MS m/z 286 (M+H).sup.+. (Btk IC.sub.50=A)
Example #28*:
(S)-4-(1-(1-Acryloylazetidin-3-yl)ethyl)-1H-indole-7-carboxamide
and
(R)-4-(1-(1-acryloylazetidin-3-yl)ethyl)-1H-indole-7-carboxamide
##STR00725##
[1373] Step A: tert-butyl
3-(1-(((trifluoromethyl)sulfonyl)oxy)vinyl)azetidine-1-carboxylate
and tert-butyl
3-(1-(((trifluoromethyl)sulfonyl)oxy)ethylidene)azetidine-1-carboxylate
##STR00726##
[1375] To a solution of diisopropylamine (0.646 mL, 4.57 mmol) in
THF (3.8 mL) at about 0.degree. C. was added a solution of
n-butyllithium (2 M in hexanes) (2.28 mL, 4.57 mmol) dropwise
(internal temperature maintained below about 3.degree. C.). The
reaction mixture was stirred at about 0.degree. C. for about 30
min, and was cooled down to about -78.degree. C. A solution of
tert-butyl 3-acetylazetidine-1-carboxylate (0.758 g, 3.81 mmol) in
THF (7.6 mL) was added dropwise (keeping the internal temperature
below about -70.degree. C.), and reaction mixture was then stirred
at about -78.degree. C. for about 30 min. A solution of
1,1,1-trifluoro-N-phenyl-N-((trifluoromethyl)sulfonyl)methanesulfonamide
(1.42 g, 4.00 mmol) in THF (7.6 mL) was added dropwise (keeping the
internal temperature below about -70.degree. C.). After addition,
the mixture was allowed to warm to about 0.degree. C. over about 4
h, and the reaction mixture was quenched with saturated NH.sub.4Cl
and extracted with EtOAc (3.times.50 mL), concentrated and purified
by silica gel chromatography eluting with a gradient of 0-15%
EtOAc/heptane to afford a mixture of tert-butyl
3-(1-(((trifluoromethyl)sulfonyl)oxy)vinyl)azetidine-1-carboxylate
and tert-butyl
3-(1-(((trifluoromethyl)sulfonyl)oxy)ethylidene)azetidine-1-carboxylate
as a yellow oil (0.398 g, 31%): .sup.1H NMR (400 MHz, CDCl.sub.3)
tert-butyl
3-(1-(((trifluoromethyl)sulfonyl)oxy)vinyl)azetidine-1-carboxylate:
.delta. 5.32 (d, J=4.2 Hz, 1H), 5.16 (dd, J=4.2, 1.0 Hz, 1H), 4.15
(t, J=8.8 Hz, 2H), 3.93 (dd, J=8.8, 6.1 Hz, 2H), 3.49-3.37 (m, 1H),
1.44 (s, 9H); tert-butyl
3-(1-(((trifluoromethyl)sulfonyl)oxy)ethylidene)azetidine-1-carboxylate:
.delta. 4.58-4.53 (m, 2H), 4.52-4.49 (m, 2H), 1.98-1.94 (m, 3H),
1.45 (s, 9H)
Step B: tert-butyl
3-(1-(7-carbamoyl-1H-indol-4-yl)vinyl)azetidine-1-carboxylate and
tert-butyl
3-(1-(7-carbamoyl-1H-indol-4-yl)ethylidene)azetidine-1-carboxylate
##STR00727##
[1377] To a vial charged with a mixture of tert-butyl
3-(1-(((trifluoromethyl)sulfonyl)oxy)vinyl)azetidine-1-carboxylate
and tert-butyl
3-(1-(((trifluoromethyl)sulfonyl)oxy)ethylidene)azetidine-1-carboxylate
(0.388 g, 1.17 mmol),
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-7-carboxamide
(0.279 g, 0.975 mmol), Pd(dppf)Cl.sub.2(0.043 g, 0.059 mmol) and
sodium carbonate (0.31 g, 2.93 mmol) was added 1,4-dioxane (3 mL)
and water (1 mL). The reaction mixture was evacuated and filled
with nitrogen (repeated 3 times). The mixture was then heated at
about 80.degree. C. for about 1 h. The reaction mixture was
concentrated and diluted with MeOH/DCM. The mixture was filtered
and washed with MeOH/DCM and the filtrate was concentrated to
dryness. The crude product was purified by silica gel
chromatography eluting with a gradient of 0-3% MeOH/DCM to give a
mixture of tert-butyl
3-(1-(7-carbamoyl-1H-indol-4-yl)vinyl)azetidine-1-carboxylate and
tert-butyl
3-(1-(7-carbamoyl-1H-indol-4-yl)ethylidene)azetidine-1-carboxylate
(0.277 g, 83%) as a yellow oil: LC/MS (Table 1, Method a)
R.sub.t=2.08, 2.13 min.; MS m/z: 340 (M-H).sup.-.
Step C: tert-butyl
3-(1-(7-carbamoyl-1H-indol-4-yl)ethyl)azetidine-1-carboxylate
##STR00728##
[1379] To a flask charged with 10 wt % Pd/C (0.026 g, 0.024 mmol)
was added a solution of tert-butyl
3-(1-(7-carbamoyl-1H-indol-4-yl)vinyl)azetidine-1-carboxylate and
tert-butyl
3-(1-(7-carbamoyl-1H-indol-4-yl)ethylidene)azetidine-1-carboxylate
(0.26 g, 0.76 mmol) in EtOAc (10 mL) and about 2 drops of MeOH. The
mixture was hydrogenated with a hydrogen balloon at about rt for
about 2 h. The reaction mixture was filtered through a pad of
Celite.RTM. and washed with EtOAc. The filtrate was concentrated to
dryness to give tert-butyl
3-(1-(7-carbamoyl-1H-indol-4-yl)ethyl)azetidine-1-carboxylate
(0.212 g, 81%) as a light yellow foam: LC/MS (Table 1, Method a)
R.sub.t=2.08 min.; MS m/z: 342 (M-H).sup.-.
Step D:
(S)-4-(1-(1-acryloylazetidin-3-yl)ethyl)-1H-indole-7-carboxamide
and
(R)-4-(1-(1-acryloylazetidin-3-yl)ethyl)-1H-indole-7-carboxamide
##STR00729##
[1381] tert-Butyl
3-(1-(7-carbamoyl-1H-indol-4-yl)ethyl)azetidine-1-carboxylate (0.17
g, 0.495 mmol) was purified by preparative chiral HPLC (Table 2,
Method 1) to give
(S)-4-(1-(1-acryloylazetidin-3-yl)ethyl)-1H-indole-7-carboxamide
(0.063 g, 37%) (R.sub.t=12.339 min, or =positive) and
(R)-4-(1-(1-acryloylazetidin-3-yl)ethyl)-1H-indole-7-carboxamide
(0.066 g, 39%) (R.sub.t=18.959 min, or =negative).
Step E.1:
(S)-4-(1-(1-acryloylazetidin-3-yl)ethyl)-1H-indole-7-carboxamide
##STR00730##
[1383] To a vial charged with (S)-tert-butyl
3-(1-(7-carbamoyl-1H-indol-4-yl)ethyl)azetidine-1-carboxylate
(0.063 g, 0.183 mmol) and MeOH (1 mL) was added hydrogen chloride
(4 M in dioxane, 0.92 mL, 3.67 mmol) at about rt. The mixture was
stirred for about 30 min, then the mixture was concentrated in
vacuo to afford the crude (S)-tert-butyl
3-(1-(7-carbamoyl-1H-indol-4-yl)ethyl)azetidine-1-carboxylate
hydrochloride that was used without additional purification.
[1384] To a suspension of
(S)-4-(1-(azetidin-3-yl)ethyl)-1H-indole-7-carboxamide
hydrochloride (0.051, 0.183 mmol) in THF (2 mL) and DCM (1 mL) at
about 0.degree. C. was added N-ethyl-N-isopropylpropan-2-amine
(0.096 mL, 0.550 mmol) followed by acryloyl chloride (0.017 mL,
0.202 mmol). The mixture was stirred at about 0.degree. C. for
about 30 min. The mixture was quenched with MeOH, and the volatiles
were removed under reduced pressure. The residue was partitioned
between DCM and saturated aqueous NaHCO.sub.3. The organic layer
was concentrated, and the crude product was purified by silica gel
chromatography eluting with a gradient of 0-5% MeOH/DCM to afford
(S)-4-(1-(1-acryloylazetidin-3-yl)ethyl)-1H-indole-7-carboxamide
(0.039 g, 69.9%) as a white solid: LC/MS (Table 1, Method a)
R.sub.t=1.50 min.; MS m/z: 298 (M+H).sup.+. (Btk IC.sub.50=B)
Step E.2:
(R)-4-(1-(1-acryloylazetidin-3-yl)ethyl)-1H-indole-7-carboxamide
##STR00731##
[1386] To a vial charged with (R)-tert-butyl
3-(1-(7-carbamoyl-1H-indol-4-yl)ethyl)azetidine-1-carboxylate
(0.066 g, 0.192 mmol) and MeOH (1 mL) was added hydrogen chloride
(4 M in dioxane, 0.96 mL, 3.84 mmol) at about rt. The mixture was
stirred at rt for about 1 h, then the mixture was concentrated in
vacuo to afford the crude (R)-tert-butyl
3-(1-(7-carbamoyl-1H-indol-4-yl)ethyl)azetidine-1-carboxylate
hydrochloride that was used without additional purification.
[1387] To a suspension of
(R)-4-(1-(azetidin-3-yl)ethyl)-1H-indole-7-carboxamide
hydrochloride (0.054 g, 0.192 mmol) in THF (2 mL) and DCM (1 mL) at
about 0.degree. C. was added N-ethyl-N-isopropylpropan-2-amine (0.1
mL, 0.577 mmol) followed by dropwise addition of acryloyl chloride
(0.018 mL, 0.212 mmol). The mixture was stirred at about 0.degree.
C. for about 30 min. The mixture was quenched with MeOH, and the
volatiles were removed under reduce pressure. The residue was
partitioned between DCM and saturated aqueous NaHCO.sub.3. The
organic layer was concentrated, and the crude product was purified
by silica gel chromatography eluting with a gradient of 0-5%
MeOH/DCM to afford
(R)-4-(1-(1-acryloylazetidin-3-yl)ethyl)-1H-indole-7-carboxamide
(0.042 g, 73.2%) as a white solid. LC/MS (Table 1, Method a)
R.sub.t=1.50 min.; MS m/z: 298 (M+H).sup.+. (Btk IC.sub.50=A)
Example #29:
4-((1-Acryloylazetidin-3-yl)(methyl)amino)-1H-pyrrolo[2,3-c]pyridine-7-ca-
rboxamide
Step A: 4-bromo-1H-pyrrolo[2,3-c]pyridine-7-carbonitrile
##STR00732##
[1389] To a solution of 4-bromo-1H-pyrrolo[2,3-c]pyridine [ChemTec]
(10.4 g, 52.8 mmol) in DCM (66.0 mL) and DME (66.0 mL) was added
3-chlorobenzoperoxoic acid (21.29 g, 95 mmol, 77% by weight) in one
portion and the mixture was allowed to stir for about 16 h. The
organic solvents were removed under reduced pressure, the solid
triturated with DCM and the solid filtered to yield a mixture of
both product and benzoic acid. The filtrate still contained
additional product and it was concentrated further under reduced
pressure to enable a second filtration. The combined filtercakes
were dried and transferred to a 1 L round bottom flask containing a
magnetic stir bar. MeCN (264 mL) and TEA (14.8 mL, 106 mmol) were
added to give an off-white slurry. Trimethylsilyl cyanide (24.64
mL, 185 mmol) was added in one portion via syringe and the mixture
was heated to reflux. After about 2 h of heating the mixture was
allowed to cool to rt. The reaction was quenched by the addition of
100 mL of 1 M NaOH, diluted with 100 mL of EtOAc, transferred to a
separatory funnel and further diluted with 100 mL of 1 M NaOH and
100 mL of EtOAc. The layers were separated and the aqueous phase
was extracted with EtOAc (3.times.150 mL). The combined organic
extracts were washed with at 1:1 mixture of brine and 1 M NaOH
(2.times.50 mL), dried over Na.sub.2SO.sub.4, filtered and the
solvent was removed to afford
4-bromo-1H-pyrrolo[2,3-c]pyridine-7-carbonitrile as a brown-yellow
solid (10.28 g, 80%). .sup.1H NMR (400 MHz, DMSO) .delta. 8.44 (s,
1H), 7.96 (d, J=3.1 Hz, 1H), 6.71 (d, J=3.1 Hz, 1H).
Step B:4-bromo-1H-pyrrolo[2,3-c]pyridine-7-carboxamide
##STR00733##
[1391] To a solution of
4-bromo-1H-pyrrolo[2,3-c]pyridine-7-carbonitrile (10.2 g, 45.9
mmol) in EtOH (104 mL) were added a 1 M aqueous solution of NaOH
(115 mL, 115 mmol) and 30% hydrogen peroxide (80 mL, 781 mmol) and
the reaction mixture was heated to about 45.degree. C. and stirred
for about 30 min. The organic solvent was removed under reduced
pressure. The mixture was diluted with 30 mL of water and filtered
to afford 4-bromo-1H-pyrrolo[2,3-c]pyridine-7-carboxamide as a
light yellow solid (9.87 g, 83%). LC/MS (Table 1, Method as):
R.sub.t=1.81 min; MS m/z: 240, 242 (M+H).sup.+.
Step C: tert-butyl
3-((7-carbamoyl-1H-pyrrolo[2,3-c]pyridin-4-yl)(methyl)amino)azetidine-1-c-
arboxylate
##STR00734##
[1393] 4-Bromo-1H-pyrrolo[2,3-c]pyridine-7-carboxamide (580 mg,
2.416 mmol) was dissolved in 12 mL of anhydrous dioxane and dried
for about 1 h over Na.sub.2SO.sub.4. The solution was then filtered
into an oven-dried 75 mL pressure vessel and the drying agent
washed using 3 mL of dioxane. The solution was degassed using a
stream of argon and tert-butyl
3-(methylamino)azetidine-1-carboxylate hydrochloride (0.969 g, 4.35
mmol, Synthonix) was added followed by
chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2--
aminoethyl)phenyl)]palladium(II) (0.089 g, 0.12 mmol) and X-Phos
(0.057 g, 0.12 mmol). The mixture was degassed for about 10 min and
LiHMDS (1 M in THF, 10.87 mL, 10.87 mmol) was added dropwise via
syringe, the vial sealed and heated to about 90.degree. C. for
about 19 h. The reaction was cooled to rt and quenched by addition
of aqueous NaHCO.sub.3 (20 mL) and diluted with EtOAc (50 mL).
Further dilution using water (10 mL) and brine (10 mL) led to
complete dissolution and the layers were separated. The aqueous
phase was extracted with EtOAc (3.times.20 mL). The combined
organic extracts were washed with 1:1 brine and aqueous NaHCO.sub.3
(20 mL), dried over Na.sub.2SO.sub.4, filtered and the solvent was
removed under reduced pressure. The crude material was deposited
onto silica and purified using a silica column (40 g), eluting with
0-5% of MeOH/DCM. The fractions containing product were
concentrated under reduced pressure to afford tert-butyl
3-((7-carbamoyl-1H-pyrrolo[2,3-c]pyridin-4-yl)(methyl)amino)azetidine-1-c-
arboxylate as a light-yellow solid (0.61 g, 69%). .sup.1H NMR (400
MHz, DMSO) .delta. 11.41 (bs, 1H), 7.90 (bs, 1H), 7.48-7.43 (m,
1H), 7.43-7.39 (m, 2H), 6.60 (dd, J=3.1, 2.0 Hz, 1H), 4.61-4.51 (m,
1H), 4.23-4.14 (m, 2H), 3.86 (dd, J=8.9, 5.2 Hz, 2H), 3.06 (s, 3H),
1.38 (s, 9H).
Step D:
4-(azetidin-3-yl(methyl)amino)-1H-pyrrolo[2,3-c]pyridine-7-carboxa-
mide hydrochloride
##STR00735##
[1395] To a 50 mL round bottom flask containing a magnetic stir bar
and MeOH (1.97 mL) was added acetyl chloride (1307 .mu.l, 18.38
mmol) at about 0.degree. C. via syringe. After about 10 min, the
mixture was warmed to rt and stirred for about 1 h. Then, a
solution of tert-butyl
3-((7-carbamoyl-1H-pyrrolo[2,3-c]pyridin-4-yl)(methyl)amino)azetidine-1-c-
arboxylate (127 mg, 0.368 mmol) in MeOH (1970 .mu.L) and DCM (657
.mu.L) was added dropwise via syringe and the reaction stirred for
about 5 h at rt. The solvents were removed under reduced pressure
to afford
4-(azetidin-3-yl(methyl)amino)-1H-pyrrolo[2,3-c]pyridine-7-carboxamide
hydrochloride (128 mg, 99%).LC/MS (Table 1, Method at):
R.sub.t=0.93 min.; MS m/z: 246 (M+H).sup.+.
##STR00736##
Step
E:4-((1-acryloylazetidin-3-yl)(methyl)amino)-1H-pyrrolo[2,3-c]pyridi-
ne-7-carboxamide
[1396] To a cooled solution of the
4-(azetidin-3-yl(methyl)amino)-1H-pyrrolo[2,3-c]pyridine-7-carboxamide
hydrochloride (101 mg, 0.36 mL) in DCM (5760 .mu.L) and
ethyldiisopropylamine (258 .mu.L, 1.440 mmol) was added a solution
of acryloyl chloride (50 mg, 0.552 mmol) in DCM (1440 .mu.L)
dropwise via syringe keeping the internal temperature at or below
at -4.degree. C. The mixture was allowed to stir for 15 min. The
reaction was quenched by addition of 0.3 mL of water, the solvent
volume reduced to 1.5 mL and the mixture loaded onto 4 g of silica.
The material was purified using a 24 g silica column, 0-10%
MeOH/DCM. The fractions containing product were concentrated under
reduced pressure to afford
4-((I-acryloylazetidin-3-yl)(methyl)amino)-1H-pyrrolo[2,3-c]pyridine-7-ca-
rboxamide as a white solid (89 mg, 78%). .sup.1H NMR (400 MHz,
DMSO) .delta. 11.43 (bs, 1H), 7.98-7.88 (m, 1H), 7.49-7.44 (m, 2H),
7.42 (s, 1H), 6.64-6.58 (m, 1H), 6.40-6.29 (m, 1H), 6.11 (dd,
J=17.0, 2.2 Hz, 1H), 5.68 (dd, J=10.2, 2.2 Hz, 1H), 4.72-4.62 (m,
1H), 4.60-4.52 (m, 1H), 4.31-4.18 (m, 2H), 3.97 (dd, J=10.5, 5.2
Hz, 1H), 3.08 (s, 3H); MS m/z: 300 (M+H).sup.+. (Btk
IC.sub.50=A)
Example #30*:
(R)-4-(1-Acryloylpiperidin-3-yl)-1H-indole-7-carboxamide and
(S)-4-(1-acryloylpiperidin-3-yl)-1H-indole-7-carboxamide
##STR00737##
[1398] A sample of
4-(1-acryloylpiperidin-3-yl)-1H-indole-7-carboxamide (0.03 g, 0.10
mmol) was purified via preparative chiral HPLC (Table 2, Method 2)
to give (R)-4-(1-acryloylpiperidin-3-yl)-1H-indole-7-carboxamide
(0.012 g, 40%)(R.sub.t=17.14 min, or =positive) (Btk IC.sub.50=B)
and (S)-4-(1-acryloylpiperidin-3-yl)-1H-indole-7-carboxamide (0.013
g, 43%)(R.sub.t=20.46 min, or =negative) (Btk IC.sub.50=A): LC/MS
(Table 1, Method a) R.sub.t=1.47 min.; MS mz: 298 (M+H).sup.+.
TABLE-US-00051 TABLE 3 Examples prepared from an acryloyl amide
using chiral method: Table 2, Method 4 R.sub.t min m/z (Table 1,
ESI+ Btk Acryloyl Amide Product Example # Method) (M + H).sup.+
IC.sub.50 4-(Azetidin-3- yl)(methyl)amino)-2-
(tetrahydrofuran-3-yl)-1H- indole-7-carboxamide (Example #E.9.21)
##STR00738## 5.1 1.37 (ax) 369 A 4-(Azetidin-3-
yl)(methyl)amino)-2- (tetrahydrofuran-3-yl)-1H-
indole-7-carboxamide (Example #E.9.21) ##STR00739## 5.2 1.37 (ax)
369 A
TABLE-US-00052 TABLE 4 Examples prepared from an acryloyl amide
using chiral method: Table 2, Method 15 R.sub.t min m/z (Table 1,
ESI+ Btk Acryloyl Amide Product Example # Method) (M + H).sup.+
IC.sub.50 4-(1,4-Oxazepan-6-yl)-1H- pyrrolo[2,3-c]pyridine-7-
carboxamide (Prepared using L with Preparation #49 and
Pd(OH).sub.2, G with HCl and E with acryloyl chloride) ##STR00740##
3.1 1.27 (as) 315 B 4-(1,4-Oxazepan-6-yl)-1H-
pyrrolo[2,3-c]pyridine-7- carboxamide (Prepared using L with
Preparation #49 and Pd(OH).sub.2, G with HCl and E with acryloyl
chloride) ##STR00741## 3.2 1.26 (as) 315 B
TABLE-US-00053 TABLE 5 Examples prepared from an acryloyl amide
using chiral method: Table 2, Method 16 R.sub.t min m/z (Table 1,
ESI+ Btk Acryloyl Amide Product Example # Method) (M + H).sup.+
IC.sub.50 2-(1-Methyl-1H-pyrazol-4- yl)-4-(piperidin-3-yl)-1H-
indole-7-carboxamide hydrochloride (Prepared using A from
Preparation #10 with tert-butyl 5-(4,4,5,5- tetramethyl-1,3,2-
dioxaborolan-2-yl)-3,4- dihydropyridine-1(2H)- carboxylate
[Anisyn], L with Pd/C, G with acetyl chloride, E with acryloyl
chloride) ##STR00742## 4.1 1.54 (ba) 378 A
2-(1-Methyl-1H-pyrazol-4- yl)-4-(piperidin-3-yl)-1H-
indole-7-carboxamide hydrochloride (Prepared using A from
Preparation #10 with tert-butyl 5-(4,4,5,5- tetramethyl-1,3,2-
dioxaborolan-2-yl)-3,4- dihydropyridine-1(2H)- carboxylate
[Anisyn], L with Pd/C, G with acetyl chloride, E with acryloyl
chloride) ##STR00743## 4.2 1.58 (ba) 378 A
* * * * *